Principal Investigator Finder

Discover recently funded principal investigators in your research area

Search Principal Investigators

Find PIs who have received recent NIH funding in your area of interest

Search Results

Found 280 principal investigators from 200 displayed projects for "GLP-1" (2021–2026)

Note: 268,895 projects matched but only the first 200 were analyzed. Try narrowing your search with a more specific term or selecting "Project title only".

Opportunity Digest

Heuristic scoring to help trainees and job seekers prioritize which labs to inspect first.

53

High-opportunity leads

202

Likely hiring signals

33

Training-friendly awards

58

Average opportunity score

Prioritize records with strong opportunity signals, then validate fit using abstracts, institution pages, and lab websites.

Filter for opportunity type

Neil Alan Shneider

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

High-opportunity lead · 88/100
Likely hiring
Large award
Very recent
Active award
$5,151,818
FY 2026

Project Title

Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS

Grant Number:

5U01NS134684-03

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2024

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ALS is a progressive neurodegenerative disease that affects tens of thousands of Americans. Therapeutic options for ALS patients remain severely limited, but for the ~15% of ALS patients with a disease-causing mutation, gene-based therapeutics, including antisense oligonucleotides (ASOs), provide a ...

Research Terms

<ALS patients><ASO therapeutics><ASO therapy><ASO treatment><Acceleration><Access to Care><Affect><Alleles><Allelomorphs><Amendment><American><Amyotrophic Lateral Sclerosis patients><Antimorphic mutation><Antisense Agent><Antisense Oligonucleotide Therapy><Antisense Oligonucleotides><Award><C9ORF72><Cell model><Cellular model><Clinical><Clinical Evaluation><Clinical Protocols><Clinical Research><Clinical Study><Clinical Testing><Clinical assessments><Communities><DNA Therapy><DNA mutation><Data><Degenerative Neurologic Disorders><Development><Disease><Disorder><Dominant Negative><Dominant-Negative Mutant><Dominant-Negative Mutation><Dose><Engineering><Enrollment><Ensure><FTD dementia><Family><Fibroblasts><Foundations><Frontal Temporal Dementia><Frontotemporal Dementia><Future><Gene Alteration><Gene Inactivation><Gene Mutation><Gene Silencing><Gene Transfer Clinical><Generations><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Goals><Guidelines><Haplotypes><Health Services Accessibility><IRB><IRBs><In Vitro><In vivo analysis><Individual><Industrialization><Industry><Institutional Review Boards><Investigational Drugs><Investigational New Drugs><Investigators><Knowledge><Medicine><Messenger RNA><Mission><Modality><Modeling><Molecular Target><Mutate><Mutation><NINDS><National Institute of Neurological Diseases and Stroke><National Institute of Neurological Disorders and Stroke><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Orphan Disease><Pathogenicity><Patient Recruitments><Patients><Phase><Precision Medicine Initiative><Preparedness><Protocol><Protocols documentation><Rare Diseases><Rare Disorder><Readiness><Regulatory Pathway><Regulatory approval><Research Infrastructure><Research Personnel><Research Resources><Researchers><Resources><Risk><SOD-1><SOD-1 protein><SOD1><SOD1 gene><SOD1 gene product><Savings><Series><TAR DNA-binding protein 43><TDP-43><TDP43><Technology><Therapeutic><Time><Toxic effect><Toxicities><Transcript><Translational Research><Translational Science><Treatment Protocols><Treatment Regimen><Treatment Schedule><Universities><Variant><Variation><Work><access to health services><access to services><access to treatment><accessibility to health services><anti-sense oligonucleotide drug><anti-sense oligonucleotide therapy><anti-sense oligonucleotide treatment><anti-sense therapy><antisense drug><antisense oligo><antisense oligonucleotide therapeutic><antisense therapeutics><antisense therapy><availability of services><care access><chromosome 9 open reading frame 72><clinic ready><clinical development><clinical infrastructure><clinical ready><clinical test><clinical trial protocol><cohort><customized therapy><customized treatment><de novo mutation><de novo variant><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><develop therapy><developmental><disease causing variant><disease-causing allele><disease-causing mutation><drug clearance><enroll><experience><first in man><first-in-human><front temporal dementia><frontal lobe dementia><frontotemporal lobar degeneration dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><gain of function><gene defect><gene function><gene repair therapy><gene testing><gene therapeutics><gene therapy><gene-based testing><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic testing><genetic therapy><genome mutation><genomic therapy><health service access><health services availability><iPS><iPSC><iPSCs><in vivo><in vivo evaluation><in vivo testing><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><intervention development><lead candidate><long read seq><long-read sequencing><long-read transcript sequencing><low-frequency mutation><mRNA><meeting><meetings><mutant><mutant allele><neurodegenerative illness><orphan disorder><participant recruitment><pathogenic allele><pathogenic variant><patient population><patient specific therapies><patient specific treatment><pre-clinical study><precision medicine><precision-based medicine><preclinical study><preservation><programs><protein TDP-43><protein TDP43><protocol development><rare allele><rare mutation><rare variant><regulatory authorization><regulatory certification><regulatory clearance><research clinical testing><screening><screenings><service availability><success><superoxide dismutase 1><tailored medical treatment><tailored therapy><tailored treatment><therapeutic agent development><therapeutic development><therapeutic gene><therapy development><transcriptional silencing><translation research><translational investigation><treatment access><treatment development><treatment planning><unique treatment>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGE M SHAW

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

High-opportunity lead · 88/100
Likely hiring
Large award
Very recent
Active award
$4,028,522
FY 2026

Project Title

SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design

Grant Number:

5P01AI131251-10

Activity Code:

P01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2017

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The development of an effective HIV-1 vaccine has proven to be a daunting scientific challenge. Despite decades of research, there are no examples of immunogens that consistently elicit potent broadly neutralizing antibodies (bNAbs). Our scientific premise is that there are three pri...

Research Terms

<AIDS vaccine development><Address><Affinity><Amino Acid Substitution><Animals><Antibodies><Antibody Affinity><Antibody Response><Antigen Receptors><Antigenic Determinants><Antigens><Apical><Autologous><Award><B blood cells><B cell><B cell differentiation><B cell receptor><B cells><B lymphocyte differentiation><B-Cell Antigen Receptor><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><Bioinformatics><Biological><Biophysics><Blood Plasma Cell><Cell Lineage><Chemicals><Chronic><Clinical Treatment Moab><Combining Site><D-Mannose><Development><Env trimer><Envelope Protein><Epitopes><Event><Exposure to><Foundations><Gametes><Genes><Genetics-Mutagenesis><Germ Cells><Germ Lines><Germ-Line Cells><Germinal Center><Glycans><Goals><Grant><HIV Env><HIV Infections><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine development><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 vaccine><HIV-1 vaccine development><HIV-I><HIV1><HIV1 vaccine><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Humoral Immunities><Immunization><Immunochemical Immunologic><Immunogenetics><Immunologic><Immunological><Immunologically><Immunologics><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><KI mice><Knock-in Mouse><Laboratories><Lineage Tracing><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Mannopyranose><Mannopyranoside><Mannose><Memory B Cell><Memory B-Lymphocyte><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Monkeys><Monoclonal Antibodies><Murine><Mus><Mutagenesis><Mutagenesis Molecular Biology><Pathway interactions><Pattern><Peptides><Plasma Cells><Plasmacytes><Polysaccharides><Prevalence><Primates><Primates Mammals><Process><R-Series Research Projects><R01 Mechanism><R01 Program><Reactive Site><Regimen><Reproducibility><Reproductive Cells><Research><Research Grants><Research Project Grants><Research Projects><Rhesus Macaque><Rhesus Monkey><Role><SHIV><SOSIP><Science><Scientific Advances and Accomplishments><Sex Cell><Specificity><Structure of germinal center of lymph node><Testing><Time><Transmission><Vaccination><Vaccine Design><Vaccine Research><Vaccines><Viral><Virus><antibody-based immunity><antigen antibody affinity><biologic><biophysical foundation><biophysical principles><biophysical sciences><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cellular lineage mapping><cellular lineage tracking><challenge in rhesus macaques><clinical relevance><clinically relevant><design><designing><develop AIDS vaccine><develop HIV vaccine><develop HIV-1 vaccine><develop a HIV vaccine><develop a HIV-1 vaccine><development of a HIV vaccine><developmental><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><human immunodeficiency virus infection><immunogen><indel><infected rhesus macaques><infected rhesus monkey><infected with HIV><infected with human immunodeficiency virus><infection in rhesus macaques><infection of rhesus macaques><initial cell><insertion/deletion><insertion/deletion mutation><knockin mice><mAbs><monoclonal Abs><neutralizing antibody><novel><pathway><plasmocyte><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><scientific accomplishments><scientific advances><sexual cell><simian HIV><simian human immunodeficiency virus><social role><statistics><transmission process><vaccine against HIV-1><vaccine effectiveness><vaccine-related research>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Theodore M Kamenecka

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 88/100
Likely hiring
Large award
Very recent
Active award
$1,781,729
FY 2026

Project Title

Preclinical development of a precision therapy for a monogenic mental health disorder

Grant Number:

5U01MH136567-03

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY In this project, we propose to develop primary and secondary lead small molecules into preclinical drug candidates for a precision SYNGAP1-DEE therapy. This research is consistent with the mission of NIMH because this genetic disorder impacts mental health and behavior through impair...

Research Terms

<ASD><Adverse effects><Affect><Animal Model><Animal Models and Related Studies><Autism><Autistic Disorder><Automation><Automobile Driving><Behavior><Behavioral><Biological Agent><Biological Products><Biology><Brain><Brain Nervous System><CNS Nervous System><Care Givers><Caregivers><Central Nervous System><Chemical Agents><Chemical Structure><Chemicals><Clinical Research><Clinical Study><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><DNA mutation><Development><Diagnosis><Disease><Disorder><Distress><Disturbance in cognition><Dose><Drug Kinetics><Drugs><Early Infantile Autism><Encephalon><Ensure><Epilepsy><Epileptic Seizures><Epileptics><Escalante syndrome><Exhibits><Family><Formulation><Fragile X><Fragile X Syndrome><Funding><Gene Expression><Gene Targeting><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic defect><Genetic mutation><Goals><Human><Impaired cognition><Impairment><In Vitro><Infantile Autism><Intellectual disability><Intellectual functioning disability><Intellectual limitation><Kanner's Syndrome><Knowledge><Lead><Link><Live Birth><Martin-Bell Syndrome><Martin-Bell-Renpenning syndrome><Medication><Medicinal Chemistry><Mental Health><Mental Hygiene><Mental disorders><Mental health disorders><Mice><Mice Mammals><Microsomes><Mission><Modern Man><Murine><Mus><Mutation><NIMH><National Institute of Mental Health><Nerve Cells><Nerve Unit><Nervous System Physiology><Neural Cell><Neuraxis><Neurocyte><Neurodevelopmental Disorder><Neurologic function><Neurological Development Disorder><Neurological function><Neurons><Oral><Outcome><PK/PD><Pathogenicity><Pathway interactions><Patients><Pb element><Penetrance><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phenotype><Pre-clinical Drug Testing/Development><Precision therapeutics><Preclinical Drug Development><Preclinical Drug Testing/Development><Prevalence><Property><Proteins><Psychiatric Disease><Psychiatric Disorder><Psychological Health><QOL improvement><R-Series Research Projects><R01 Mechanism><R01 Program><Renpenning syndrome 2><Reporting><Research><Research Grants><Research Project Grants><Research Projects><Risk><SYNGAP1><Safety><Seizure Disorder><Seizures><Solubility><Spinal Column><Spine><Synaptic Ras GTPase Activating Protein 1><Technology><Testing><Variant><Variation><Vertebral column><Work><X-linked mental deficiency-megalotestes syndrome><X-linked mental retardation with fragile X syndrome><X-linked mental retardation-fragile site 1 syndrome><autism spectral disorder><autism spectrum disorder><autism-fragile X (AFRAX) syndrome><autistic spectrum disorder><backbone><biologics><biopharmaceutical><biotherapeutic agent><brain cell><brain tissue><chemical library><cognitive dysfunction><cognitive enhancement><cognitive loss><design><designing><determine efficacy><developmental><driving><drug candidate><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epilepsia><epileptogenic><evaluate efficacy><examine efficacy><fra(X) syndrome><fra(X)(28) syndrome><fra(X)(q27) syndrome><fra(X)(q27-28) syndrome><fragile X-mental retardation syndrome><fragile Xq syndrome><fragile site mental retardation 1><genetic approach><genetic condition><genetic disorder><genetic strategy><genome mutation><heavy metal Pb><heavy metal lead><improved><improvements in QOL><improvements in quality of life><in vivo><individual patient><intellectual and developmental disability><lead optimization><lead series><limited intellectual functioning><macro-orchidism-marker X (MOMX) syndrome><macro-orchidism-marker X syndrome><mar(X) syndrome><marker X syndrome><mental illness><mental retardation-macroorchidism syndrome><model of animal><mouse genetics><nervous system function><neurodevelopmental disease><neuronal><novel><pathway><patient population><pharmacokinetics and pharmacodynamics><pre-clinical><pre-clinical development><pre-clinical drug development><precision therapies><precision treatment><preclinical><preclinical development><protein expression><psychiatric illness><psychological disorder><quality of life improvement><rare genetic disease><rare genetic disorder><scaffold><scaffolding><scale up><screening><screenings><small molecule><small molecule libraries><social>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Courtney A Miller

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 88/100
Likely hiring
Large award
Very recent
Active award
$1,781,729
FY 2026

Project Title

Preclinical development of a precision therapy for a monogenic mental health disorder

Grant Number:

5U01MH136567-03

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY In this project, we propose to develop primary and secondary lead small molecules into preclinical drug candidates for a precision SYNGAP1-DEE therapy. This research is consistent with the mission of NIMH because this genetic disorder impacts mental health and behavior through impair...

Research Terms

<ASD><Adverse effects><Affect><Animal Model><Animal Models and Related Studies><Autism><Autistic Disorder><Automation><Automobile Driving><Behavior><Behavioral><Biological Agent><Biological Products><Biology><Brain><Brain Nervous System><CNS Nervous System><Care Givers><Caregivers><Central Nervous System><Chemical Agents><Chemical Structure><Chemicals><Clinical Research><Clinical Study><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><DNA mutation><Development><Diagnosis><Disease><Disorder><Distress><Disturbance in cognition><Dose><Drug Kinetics><Drugs><Early Infantile Autism><Encephalon><Ensure><Epilepsy><Epileptic Seizures><Epileptics><Escalante syndrome><Exhibits><Family><Formulation><Fragile X><Fragile X Syndrome><Funding><Gene Expression><Gene Targeting><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic defect><Genetic mutation><Goals><Human><Impaired cognition><Impairment><In Vitro><Infantile Autism><Intellectual disability><Intellectual functioning disability><Intellectual limitation><Kanner's Syndrome><Knowledge><Lead><Link><Live Birth><Martin-Bell Syndrome><Martin-Bell-Renpenning syndrome><Medication><Medicinal Chemistry><Mental Health><Mental Hygiene><Mental disorders><Mental health disorders><Mice><Mice Mammals><Microsomes><Mission><Modern Man><Murine><Mus><Mutation><NIMH><National Institute of Mental Health><Nerve Cells><Nerve Unit><Nervous System Physiology><Neural Cell><Neuraxis><Neurocyte><Neurodevelopmental Disorder><Neurologic function><Neurological Development Disorder><Neurological function><Neurons><Oral><Outcome><PK/PD><Pathogenicity><Pathway interactions><Patients><Pb element><Penetrance><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phenotype><Pre-clinical Drug Testing/Development><Precision therapeutics><Preclinical Drug Development><Preclinical Drug Testing/Development><Prevalence><Property><Proteins><Psychiatric Disease><Psychiatric Disorder><Psychological Health><QOL improvement><R-Series Research Projects><R01 Mechanism><R01 Program><Renpenning syndrome 2><Reporting><Research><Research Grants><Research Project Grants><Research Projects><Risk><SYNGAP1><Safety><Seizure Disorder><Seizures><Solubility><Spinal Column><Spine><Synaptic Ras GTPase Activating Protein 1><Technology><Testing><Variant><Variation><Vertebral column><Work><X-linked mental deficiency-megalotestes syndrome><X-linked mental retardation with fragile X syndrome><X-linked mental retardation-fragile site 1 syndrome><autism spectral disorder><autism spectrum disorder><autism-fragile X (AFRAX) syndrome><autistic spectrum disorder><backbone><biologics><biopharmaceutical><biotherapeutic agent><brain cell><brain tissue><chemical library><cognitive dysfunction><cognitive enhancement><cognitive loss><design><designing><determine efficacy><developmental><driving><drug candidate><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epilepsia><epileptogenic><evaluate efficacy><examine efficacy><fra(X) syndrome><fra(X)(28) syndrome><fra(X)(q27) syndrome><fra(X)(q27-28) syndrome><fragile X-mental retardation syndrome><fragile Xq syndrome><fragile site mental retardation 1><genetic approach><genetic condition><genetic disorder><genetic strategy><genome mutation><heavy metal Pb><heavy metal lead><improved><improvements in QOL><improvements in quality of life><in vivo><individual patient><intellectual and developmental disability><lead optimization><lead series><limited intellectual functioning><macro-orchidism-marker X (MOMX) syndrome><macro-orchidism-marker X syndrome><mar(X) syndrome><marker X syndrome><mental illness><mental retardation-macroorchidism syndrome><model of animal><mouse genetics><nervous system function><neurodevelopmental disease><neuronal><novel><pathway><patient population><pharmacokinetics and pharmacodynamics><pre-clinical><pre-clinical development><pre-clinical drug development><precision therapies><precision treatment><preclinical><preclinical development><protein expression><psychiatric illness><psychological disorder><quality of life improvement><rare genetic disease><rare genetic disorder><scaffold><scaffolding><scale up><screening><screenings><small molecule><small molecule libraries><social>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GAVIN R RUMBAUGH

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 88/100
Likely hiring
Large award
Very recent
Active award
$1,781,729
FY 2026

Project Title

Preclinical development of a precision therapy for a monogenic mental health disorder

Grant Number:

5U01MH136567-03

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY In this project, we propose to develop primary and secondary lead small molecules into preclinical drug candidates for a precision SYNGAP1-DEE therapy. This research is consistent with the mission of NIMH because this genetic disorder impacts mental health and behavior through impair...

Research Terms

<ASD><Adverse effects><Affect><Animal Model><Animal Models and Related Studies><Autism><Autistic Disorder><Automation><Automobile Driving><Behavior><Behavioral><Biological Agent><Biological Products><Biology><Brain><Brain Nervous System><CNS Nervous System><Care Givers><Caregivers><Central Nervous System><Chemical Agents><Chemical Structure><Chemicals><Clinical Research><Clinical Study><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><DNA mutation><Development><Diagnosis><Disease><Disorder><Distress><Disturbance in cognition><Dose><Drug Kinetics><Drugs><Early Infantile Autism><Encephalon><Ensure><Epilepsy><Epileptic Seizures><Epileptics><Escalante syndrome><Exhibits><Family><Formulation><Fragile X><Fragile X Syndrome><Funding><Gene Expression><Gene Targeting><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic defect><Genetic mutation><Goals><Human><Impaired cognition><Impairment><In Vitro><Infantile Autism><Intellectual disability><Intellectual functioning disability><Intellectual limitation><Kanner's Syndrome><Knowledge><Lead><Link><Live Birth><Martin-Bell Syndrome><Martin-Bell-Renpenning syndrome><Medication><Medicinal Chemistry><Mental Health><Mental Hygiene><Mental disorders><Mental health disorders><Mice><Mice Mammals><Microsomes><Mission><Modern Man><Murine><Mus><Mutation><NIMH><National Institute of Mental Health><Nerve Cells><Nerve Unit><Nervous System Physiology><Neural Cell><Neuraxis><Neurocyte><Neurodevelopmental Disorder><Neurologic function><Neurological Development Disorder><Neurological function><Neurons><Oral><Outcome><PK/PD><Pathogenicity><Pathway interactions><Patients><Pb element><Penetrance><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phenotype><Pre-clinical Drug Testing/Development><Precision therapeutics><Preclinical Drug Development><Preclinical Drug Testing/Development><Prevalence><Property><Proteins><Psychiatric Disease><Psychiatric Disorder><Psychological Health><QOL improvement><R-Series Research Projects><R01 Mechanism><R01 Program><Renpenning syndrome 2><Reporting><Research><Research Grants><Research Project Grants><Research Projects><Risk><SYNGAP1><Safety><Seizure Disorder><Seizures><Solubility><Spinal Column><Spine><Synaptic Ras GTPase Activating Protein 1><Technology><Testing><Variant><Variation><Vertebral column><Work><X-linked mental deficiency-megalotestes syndrome><X-linked mental retardation with fragile X syndrome><X-linked mental retardation-fragile site 1 syndrome><autism spectral disorder><autism spectrum disorder><autism-fragile X (AFRAX) syndrome><autistic spectrum disorder><backbone><biologics><biopharmaceutical><biotherapeutic agent><brain cell><brain tissue><chemical library><cognitive dysfunction><cognitive enhancement><cognitive loss><design><designing><determine efficacy><developmental><driving><drug candidate><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epilepsia><epileptogenic><evaluate efficacy><examine efficacy><fra(X) syndrome><fra(X)(28) syndrome><fra(X)(q27) syndrome><fra(X)(q27-28) syndrome><fragile X-mental retardation syndrome><fragile Xq syndrome><fragile site mental retardation 1><genetic approach><genetic condition><genetic disorder><genetic strategy><genome mutation><heavy metal Pb><heavy metal lead><improved><improvements in QOL><improvements in quality of life><in vivo><individual patient><intellectual and developmental disability><lead optimization><lead series><limited intellectual functioning><macro-orchidism-marker X (MOMX) syndrome><macro-orchidism-marker X syndrome><mar(X) syndrome><marker X syndrome><mental illness><mental retardation-macroorchidism syndrome><model of animal><mouse genetics><nervous system function><neurodevelopmental disease><neuronal><novel><pathway><patient population><pharmacokinetics and pharmacodynamics><pre-clinical><pre-clinical development><pre-clinical drug development><precision therapies><precision treatment><preclinical><preclinical development><protein expression><psychiatric illness><psychological disorder><quality of life improvement><rare genetic disease><rare genetic disorder><scaffold><scaffolding><scale up><screening><screenings><small molecule><small molecule libraries><social>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KEVIN O SAUNDERS

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$4,755,401
FY 2026

Project Title

Conjugate nanoparticle platform development for HIV-1 envelope immunogens

Grant Number:

5U19AI160546-05

Activity Code:

U19

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/17/2021

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

ABSTRACT – OVERALL HIV-1 broadly neutralizing antibodies (bnAbs) are protective in animal models of HIV-1 infection, but are not elicited in humans by current vaccine regimens. To elicit bnAbs, the B cell lineage vaccine design approach aims to administer multiple immunogens in a specific sequence t...

Research Terms

<2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><AICDA><AICDA protein><AID gene><AID protein><AIDS Vaccines><AIDS vaccine><Affinity><Amino Acids><Animal Model><Animal Models and Related Studies><Antibodies><Antigens><Avidity><B blood cells><B cell><B cell receptor><B cells><B-Cell Antigen Receptor><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Sites><Biomanufacturing><Blood Serum><C pylori><C. pylori><CDA2 protein><COVID-19 S protein><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><Campylobacter pylori><Cell Line><Cell Lineage><CellLine><Chimera Protein><Chimeric Proteins><Clinical Trials><Combining Site><Complex><Consumption><DNA mutation><Data><Development><Doctor of Philosophy><Documentation><Drugs><Early-Stage Clinical Trials><Electron Microscopy><Ensure><Env trimer><Enzyme Activation><Enzyme Gene><Enzymes><Ferritin><Food and Drug Administration><Frequencies><Fusion Protein><Future><Gene Fusion><Generations><Genetic Change><Genetic defect><Genetic mutation><Germinal Center><Goals><Good Manufacturing Process><Good manufacturing practice><H pylori><H pylory><H. pylori><H. pylory><HIV Env><HIV Infections><HIV Vaccine Trials Network><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 vaccine><HIV-I><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><HVTN><Helicobacter pylori><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><IND Filing><IND application><IND package><IND submission><Immune system><Immunization><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunology><Industry><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Influenza HA><Influenza Hemagglutinin><Investigational New Drug Application><KI mice><Knock-in Mouse><Lead><Link><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Medication><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Mutation><Nature><Negative Staining><Outcome><Pb element><Ph.D.><PhD><Pharmaceutical Preparations><Phase 1 Clinical Trials><Phase I Clinical Trials><Process><Production><Qualifying><Reaction><Reactive Site><Regimen><Rhesus Macaque><Rhesus Monkey><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><Series><Serum><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Site><Somatic Mutation><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Strains Cell Lines><Structure><Structure of germinal center of lymph node><Testing><Time><Toxic effect><Toxicities><USFDA><United States Food and Drug Administration><Vaccine Design><Vaccines><Viral><Virion><Virus Particle><activation-induced cytidine deaminase><activation-induced deaminase><aminoacid><booster dose><booster shot><booster vaccine><conformation><conformational><conformational state><conformationally><conformations><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><cross reactivity><cultured cell line><design><designing><developmental><drug/agent><evaluate vaccines><experience><flu HA><flu hemagglutinin><genome mutation><heavy metal Pb><heavy metal lead><human immunodeficiency virus infection><human immunodeficiency virus vaccine><humanized mice><humanized mouse><immunization strategy><immunogen><immunogenic><immunogenicity><improved><infected with HIV><infected with human immunodeficiency virus><influenza viral HA><influenza viral hemagglutinin><influenza virus HA><influenza virus hemagglutinin><innovate><innovation><innovative><knockin mice><manufacture><model of animal><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><non-human primate><nonhuman primate><pandemic><pandemic disease><phase 1 trial><phase I protocol><phase I trial><process optimization><programs><quality assurance><somatic variant><sortase><spike proteins on SARS-CoV-2><srtA gene product><statistical analysis><trafficking><transpeptidation><trial planning><vaccination strategy><vaccination study><vaccination trial><vaccine against HIV><vaccine against HIV-1><vaccine antibodies><vaccine boost><vaccine evaluation><vaccine induced antibodies><vaccine platform><vaccine screening><vaccine study><vaccine testing><vaccine trial><vaccine-induced antibodies>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Pamela J Bjorkman

CALIFORNIA INSTITUTE OF TECHNOLOGY, PASADENA, CA

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$4,147,848
FY 2026

Project Title

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

Grant Number:

5P01AI100148-13

Activity Code:

P01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2013

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). During the previous funding period, the Bjorkman lab used novel design strategies to develop HIV-1 envelope (Env) trimer-based immunogens to elicit bNAbs against single and mult...

Research Terms

<AIDS><AIDS Vaccines><AIDS vaccine><AIDS/HIV><Ab response><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Advanced HIV><Affect><Affinity><Animal Model><Animal Models and Related Studies><Animals><Anti-Retroviral Agents><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigenic Determinants><Antigens><Antisera><Assay><Attenuated><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Binding Sites><Bioassay><Bioinformatics><Biological Assay><Clinical Treatment Moab><Collaborations><Combining Site><DNA mutation><Data><Development><Domestic Rabbit><Drugs><ELISA><Electron Microscopy><Engineering><Env trimer><Enzyme-Linked Immunosorbent Assay><Epitope Mapping><Epitopes><Event><Evolution><Failure><Feedback><Funding><Genetic Change><Genetic defect><Genetic mutation><Germ Lines><Germinal Center><Glycans><Goals><HIV Env><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 vaccine><HIV-I><HIV/AIDS><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune Sera><Immunization><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Impairment><Inducer Cells><Inducer T-Lymphocytes><Laboratories><Left><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Medication><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Monoclonal Antibodies><Murine><Mus><Mutation><Oryctolagus cuniculus><Outcome><Pathway interactions><Persons><Pharmaceutical Preparations><Phylogenetic Analysis><Phylogenetics><Polysaccharides><Primates><Primates Mammals><Proteins><Public Health><Publications><RNA vaccine><RNA-based vaccine><Rabbits><Rabbits Mammals><Reactive Site><Regimen><Research><Rhesus Macaque><Rhesus Monkey><SHIV><SOSIP><Scientific Advances and Accomplishments><Scientific Publication><Severe HIV Disease><Structure of germinal center of lymph node><Testing><Transgenic Mice><Vaccination><Vaccine Design><Vaccine Research><Vaccines><Viral><Virus><anti-retroviral><antibody biosynthesis><attenuate><attenuates><biophysical analysis><biophysical studies><booster dose><booster shot><booster vaccine><challenge in rhesus macaques><design><designing><developmental><drug/agent><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><genome mutation><human immunodeficiency virus vaccine><immune serum><immunogen><immunogenicity><immunoglobulin biosynthesis><improved><infected rhesus macaques><infected rhesus monkey><infection in rhesus macaques><infection of rhesus macaques><mAbs><mRNA><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><membrane structure><model of animal><monoclonal Abs><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><next generation><novel><pathway><pressure><prevent><preventing><protection pathway><protective pathway><protein expression><recruit><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><scaffold><scaffolding><scientific accomplishments><scientific advances><screening><screenings><simian HIV><simian human immunodeficiency virus><synergism><tool><vaccine against HIV><vaccine against HIV-1><vaccine boost><vaccine platform><vaccine-related research>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Beatrice H Hahn

CALIFORNIA INSTITUTE OF TECHNOLOGY, PASADENA, CA

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$4,147,848
FY 2026

Project Title

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

Grant Number:

5P01AI100148-13

Activity Code:

P01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2013

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). During the previous funding period, the Bjorkman lab used novel design strategies to develop HIV-1 envelope (Env) trimer-based immunogens to elicit bNAbs against single and mult...

Research Terms

<AIDS><AIDS Vaccines><AIDS vaccine><AIDS/HIV><Ab response><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Advanced HIV><Affect><Affinity><Animal Model><Animal Models and Related Studies><Animals><Anti-Retroviral Agents><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigenic Determinants><Antigens><Antisera><Assay><Attenuated><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Binding Sites><Bioassay><Bioinformatics><Biological Assay><Clinical Treatment Moab><Collaborations><Combining Site><DNA mutation><Data><Development><Domestic Rabbit><Drugs><ELISA><Electron Microscopy><Engineering><Env trimer><Enzyme-Linked Immunosorbent Assay><Epitope Mapping><Epitopes><Event><Evolution><Failure><Feedback><Funding><Genetic Change><Genetic defect><Genetic mutation><Germ Lines><Germinal Center><Glycans><Goals><HIV Env><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 vaccine><HIV-I><HIV/AIDS><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune Sera><Immunization><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Impairment><Inducer Cells><Inducer T-Lymphocytes><Laboratories><Left><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Medication><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Monoclonal Antibodies><Murine><Mus><Mutation><Oryctolagus cuniculus><Outcome><Pathway interactions><Persons><Pharmaceutical Preparations><Phylogenetic Analysis><Phylogenetics><Polysaccharides><Primates><Primates Mammals><Proteins><Public Health><Publications><RNA vaccine><RNA-based vaccine><Rabbits><Rabbits Mammals><Reactive Site><Regimen><Research><Rhesus Macaque><Rhesus Monkey><SHIV><SOSIP><Scientific Advances and Accomplishments><Scientific Publication><Severe HIV Disease><Structure of germinal center of lymph node><Testing><Transgenic Mice><Vaccination><Vaccine Design><Vaccine Research><Vaccines><Viral><Virus><anti-retroviral><antibody biosynthesis><attenuate><attenuates><biophysical analysis><biophysical studies><booster dose><booster shot><booster vaccine><challenge in rhesus macaques><design><designing><developmental><drug/agent><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><genome mutation><human immunodeficiency virus vaccine><immune serum><immunogen><immunogenicity><immunoglobulin biosynthesis><improved><infected rhesus macaques><infected rhesus monkey><infection in rhesus macaques><infection of rhesus macaques><mAbs><mRNA><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><membrane structure><model of animal><monoclonal Abs><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><next generation><novel><pathway><pressure><prevent><preventing><protection pathway><protective pathway><protein expression><recruit><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><scaffold><scaffolding><scientific accomplishments><scientific advances><screening><screenings><simian HIV><simian human immunodeficiency virus><synergism><tool><vaccine against HIV><vaccine against HIV-1><vaccine boost><vaccine platform><vaccine-related research>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michel C Nussenzweig

CALIFORNIA INSTITUTE OF TECHNOLOGY, PASADENA, CA

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$4,147,848
FY 2026

Project Title

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

Grant Number:

5P01AI100148-13

Activity Code:

P01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2013

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). During the previous funding period, the Bjorkman lab used novel design strategies to develop HIV-1 envelope (Env) trimer-based immunogens to elicit bNAbs against single and mult...

Research Terms

<AIDS><AIDS Vaccines><AIDS vaccine><AIDS/HIV><Ab response><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Advanced HIV><Affect><Affinity><Animal Model><Animal Models and Related Studies><Animals><Anti-Retroviral Agents><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigenic Determinants><Antigens><Antisera><Assay><Attenuated><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Binding Sites><Bioassay><Bioinformatics><Biological Assay><Clinical Treatment Moab><Collaborations><Combining Site><DNA mutation><Data><Development><Domestic Rabbit><Drugs><ELISA><Electron Microscopy><Engineering><Env trimer><Enzyme-Linked Immunosorbent Assay><Epitope Mapping><Epitopes><Event><Evolution><Failure><Feedback><Funding><Genetic Change><Genetic defect><Genetic mutation><Germ Lines><Germinal Center><Glycans><Goals><HIV Env><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 vaccine><HIV-I><HIV/AIDS><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune Sera><Immunization><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Impairment><Inducer Cells><Inducer T-Lymphocytes><Laboratories><Left><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Medication><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Monoclonal Antibodies><Murine><Mus><Mutation><Oryctolagus cuniculus><Outcome><Pathway interactions><Persons><Pharmaceutical Preparations><Phylogenetic Analysis><Phylogenetics><Polysaccharides><Primates><Primates Mammals><Proteins><Public Health><Publications><RNA vaccine><RNA-based vaccine><Rabbits><Rabbits Mammals><Reactive Site><Regimen><Research><Rhesus Macaque><Rhesus Monkey><SHIV><SOSIP><Scientific Advances and Accomplishments><Scientific Publication><Severe HIV Disease><Structure of germinal center of lymph node><Testing><Transgenic Mice><Vaccination><Vaccine Design><Vaccine Research><Vaccines><Viral><Virus><anti-retroviral><antibody biosynthesis><attenuate><attenuates><biophysical analysis><biophysical studies><booster dose><booster shot><booster vaccine><challenge in rhesus macaques><design><designing><developmental><drug/agent><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><genome mutation><human immunodeficiency virus vaccine><immune serum><immunogen><immunogenicity><immunoglobulin biosynthesis><improved><infected rhesus macaques><infected rhesus monkey><infection in rhesus macaques><infection of rhesus macaques><mAbs><mRNA><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><membrane structure><model of animal><monoclonal Abs><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><next generation><novel><pathway><pressure><prevent><preventing><protection pathway><protective pathway><protein expression><recruit><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><scaffold><scaffolding><scientific accomplishments><scientific advances><screening><screenings><simian HIV><simian human immunodeficiency virus><synergism><tool><vaccine against HIV><vaccine against HIV-1><vaccine boost><vaccine platform><vaccine-related research>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tony Yuen

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$2,321,095
FY 2026

Project Title

A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease

Grant Number:

3U01AG073148-05S1

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/30/2021

End Date:

8/31/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY Thanks to the ongoing parent U01 AG073148, we are currently moving our humanized follicle–stimulating hormone– (FSH–) blocking antibody, Hu6, through early phase development for future use not only in Alzheimer’s disease (AD), but also in osteoporosis, obesity, and dyslipidemia. The...

Research Terms

<3xTg><3xTg-AD mice><3xTg-AD mouse><AD dementia><AD model><AD pathology><APP-PS1><APP/PS1><Ab response><Acceleration><Acute><Admission><Admission activity><Adverse effects><African Green Monkey><Age><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimer's disease pathology><Alzheimer's pathology><Alzheimers Dementia><Amentia><Ammon Horn><Antibodies><Antibody Formation><Antibody Production><Antigenic Determinants><Binding><Binding Determinants><Biodistribution><Bioreactors><Blocking Antibodies><Blood><Blood Chemical Analyses><Blood Chemical Analysis><Blood Reticuloendothelial System><Blood Serum><Body fat><Bypass><Cell Line><Cell Therapy><CellLine><Cercopithecus aethiops><Chlorocebus aethiops><Cholesterol><Clinical><Clinical Research><Clinical Study><Code><Coding System><Cognition><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Complex><Computer Models><Computerized Models><Contracting Opportunities><Contracts><Cornu Ammonis><Data><Dementia><Dentate Fascia><Development><Disease><Disorder><Disturbance in cognition><Dose><Drug Kinetics><Dyslipidemias><Energy Expenditure><Energy Metabolism><Entorhinal Area><Epitopes><Estrogen Replacement Therapy><Estrogens><FSH Receptors><Fascia Dentata><Fees><Follicle Stimulating Hormone><Follicle Stimulating Hormone Receptor><Follitropin><Food and Drug Administration><Formulation><Funding><Future><Generations><Goals><Gonadal structure><Good Manufacturing Process><Good manufacturing practice><Grivet Monkey><Gyrus Dentatus><Health Hazards><Hippocampus><Hormone use><Human><Hypercholesteremia><Hypophysis><Hypophysis Cerebri><IND Filing><IND application><IND package><IND submission><Impaired cognition><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Laboratories><Lead><Life><Mammalia><Mammals><Medical><Memory Loss><Menopause><Mice><Mice Mammals><Modern Man><Molecular Interaction><Monkeys><Murine><Mus><Nerve Degeneration><Neuron Degeneration><Obesity><Oophorectomy><Organ><Osteoporosis><Ovariectomy><Parents><Pathogenesis><Pb element><Perimenopausal><Perimenopause><Persons><Pharmacokinetics><Phase><Physiology><Pituitary><Pituitary Gland><Pituitary Hormones><Pituitary Nervous System><Post-Menopause><Post-menopausal Period><Postmenopausal Period><Postmenopause><Primary Senile Degenerative Dementia><Process><Public Health><Receptor Protein><Recombinant TSH><Recombinant Thyroid-Stimulating Hormone><Regulation><Rest><Risk><Running><Safety><Scientist><Serum><Severities><Strains Cell Lines><Structure><Symptom Burden><Testing><Textbooks><Therapeutic><Therapeutic Estrogen><Therapeutic antibodies><Thyreotropin><Thyroid><Thyroid Gland><Thyroid Head and Neck><Thyroid Stimulating Hormone><Thyroid-Stimulating Hormone><Thyrotropin><Time><Toxicology><Transgenic Organisms><USFDA><United States Food and Drug Administration><VAC-TX><Vaccine Therapy><Visceral><Woman><Work><adiposity><after menopause><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><ages><aging associated disease><aging associated disorders><aging population><aging related disease><aging related disorders><alzheimer model><antibody biosynthesis><blood chemistry><bone><bone loss><cell bank><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><clinic ready><clinical ready><cognitive dysfunction><cognitive loss><commercialization><computational modeling><computational models><computer based models><computerized modeling><corpulence><cultured cell line><dentate gyrus><design><designing><developmental><disease associated with aging><disease of aging><disorder of aging><disorders associated with aging><disorders related to aging><efficacy study><entorhinal cortex><experience><female gonadectomy><first in man><first-in-human><following menopause><gender difference><gender-associated difference><gonad><gonads><good laboratory practice><heavy metal Pb><heavy metal lead><high blood cholesterol><hippocampal><humanized monoclonal antibodies><hypercholesterolemia><immunoglobulin biosynthesis><knock-down><knockdown><manufacture><manufacturing organization><memory decline><men><menopause transition><microbioreactor><mild cognitive decline><mild cognitive disorder><mild cognitive dysfunction><mild cognitive impairment><mild cognitive loss><mild neurocognitive impairment><monomer><mouse model><murine model><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal degeneration><parent><past menopause><peri-menopausal><peri-menopause><pharmacologic><population aging><post-menopausal><postmenopausal><postmenopausal status><prevent><preventing><primary degenerative dementia><programs><quality assurance><receptor><senile dementia of the Alzheimer type><shRNA><short hairpin RNA><small hairpin RNA><stable cell line><therapeutic candidate><therapeutic vaccination><transgenic><transition to menopause><transitional menopause>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mone Zaidi

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100
Likely hiring
Large award
Active award
Team-scale grant
$2,321,095
FY 2026

Project Title

A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease

Grant Number:

3U01AG073148-05S1

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/30/2021

End Date:

8/31/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Large budget suggests more room for personnel or project growth.

Project Abstract

PROJECT SUMMARY Thanks to the ongoing parent U01 AG073148, we are currently moving our humanized follicle–stimulating hormone– (FSH–) blocking antibody, Hu6, through early phase development for future use not only in Alzheimer’s disease (AD), but also in osteoporosis, obesity, and dyslipidemia. The...

Research Terms

<3xTg><3xTg-AD mice><3xTg-AD mouse><AD dementia><AD model><AD pathology><APP-PS1><APP/PS1><Ab response><Acceleration><Acute><Admission><Admission activity><Adverse effects><African Green Monkey><Age><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimer's disease pathology><Alzheimer's pathology><Alzheimers Dementia><Amentia><Ammon Horn><Antibodies><Antibody Formation><Antibody Production><Antigenic Determinants><Binding><Binding Determinants><Biodistribution><Bioreactors><Blocking Antibodies><Blood><Blood Chemical Analyses><Blood Chemical Analysis><Blood Reticuloendothelial System><Blood Serum><Body fat><Bypass><Cell Line><Cell Therapy><CellLine><Cercopithecus aethiops><Chlorocebus aethiops><Cholesterol><Clinical><Clinical Research><Clinical Study><Code><Coding System><Cognition><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Complex><Computer Models><Computerized Models><Contracting Opportunities><Contracts><Cornu Ammonis><Data><Dementia><Dentate Fascia><Development><Disease><Disorder><Disturbance in cognition><Dose><Drug Kinetics><Dyslipidemias><Energy Expenditure><Energy Metabolism><Entorhinal Area><Epitopes><Estrogen Replacement Therapy><Estrogens><FSH Receptors><Fascia Dentata><Fees><Follicle Stimulating Hormone><Follicle Stimulating Hormone Receptor><Follitropin><Food and Drug Administration><Formulation><Funding><Future><Generations><Goals><Gonadal structure><Good Manufacturing Process><Good manufacturing practice><Grivet Monkey><Gyrus Dentatus><Health Hazards><Hippocampus><Hormone use><Human><Hypercholesteremia><Hypophysis><Hypophysis Cerebri><IND Filing><IND application><IND package><IND submission><Impaired cognition><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Laboratories><Lead><Life><Mammalia><Mammals><Medical><Memory Loss><Menopause><Mice><Mice Mammals><Modern Man><Molecular Interaction><Monkeys><Murine><Mus><Nerve Degeneration><Neuron Degeneration><Obesity><Oophorectomy><Organ><Osteoporosis><Ovariectomy><Parents><Pathogenesis><Pb element><Perimenopausal><Perimenopause><Persons><Pharmacokinetics><Phase><Physiology><Pituitary><Pituitary Gland><Pituitary Hormones><Pituitary Nervous System><Post-Menopause><Post-menopausal Period><Postmenopausal Period><Postmenopause><Primary Senile Degenerative Dementia><Process><Public Health><Receptor Protein><Recombinant TSH><Recombinant Thyroid-Stimulating Hormone><Regulation><Rest><Risk><Running><Safety><Scientist><Serum><Severities><Strains Cell Lines><Structure><Symptom Burden><Testing><Textbooks><Therapeutic><Therapeutic Estrogen><Therapeutic antibodies><Thyreotropin><Thyroid><Thyroid Gland><Thyroid Head and Neck><Thyroid Stimulating Hormone><Thyroid-Stimulating Hormone><Thyrotropin><Time><Toxicology><Transgenic Organisms><USFDA><United States Food and Drug Administration><VAC-TX><Vaccine Therapy><Visceral><Woman><Work><adiposity><after menopause><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><ages><aging associated disease><aging associated disorders><aging population><aging related disease><aging related disorders><alzheimer model><antibody biosynthesis><blood chemistry><bone><bone loss><cell bank><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><clinic ready><clinical ready><cognitive dysfunction><cognitive loss><commercialization><computational modeling><computational models><computer based models><computerized modeling><corpulence><cultured cell line><dentate gyrus><design><designing><developmental><disease associated with aging><disease of aging><disorder of aging><disorders associated with aging><disorders related to aging><efficacy study><entorhinal cortex><experience><female gonadectomy><first in man><first-in-human><following menopause><gender difference><gender-associated difference><gonad><gonads><good laboratory practice><heavy metal Pb><heavy metal lead><high blood cholesterol><hippocampal><humanized monoclonal antibodies><hypercholesterolemia><immunoglobulin biosynthesis><knock-down><knockdown><manufacture><manufacturing organization><memory decline><men><menopause transition><microbioreactor><mild cognitive decline><mild cognitive disorder><mild cognitive dysfunction><mild cognitive impairment><mild cognitive loss><mild neurocognitive impairment><monomer><mouse model><murine model><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal degeneration><parent><past menopause><peri-menopausal><peri-menopause><pharmacologic><population aging><post-menopausal><postmenopausal><postmenopausal status><prevent><preventing><primary degenerative dementia><programs><quality assurance><receptor><senile dementia of the Alzheimer type><shRNA><short hairpin RNA><small hairpin RNA><stable cell line><therapeutic candidate><therapeutic vaccination><transgenic><transition to menopause><transitional menopause>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jingyi Qian

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$894,808
FY 2026

Project Title

Sex differences in adverse metabolic effects of shift work

Grant Number:

1R01DK146265-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract The overarching goal of this project is to elucidate the role of biological sex in modulating the adverse metabolic effects of circadian misalignment, with the ultimate aim of designing sex-specific interventions to mitigate health risks associated with night shift work. Night shift work, p...

Research Terms

<Acute><Address><Adverse effects><Animals><Appetite><Appetite Regulation><Appetite stimulated><Automobile Driving><Behavioral><Beta Cell><Caloric Intake><Carbohydrates><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Circadian desynchrony><Consumption><Data><Desire for food><Diabetes Mellitus><Dietary intake><Differences between sexes><Differs between sexes><Eating><Endocrine Gland Secretion><Energy Intake><Exhibits><Experimental Designs><Female><Food><Food Intake><Foundations><GLP-1><Glp-1><Glucose Intolerance><Glycemic Index><Glycemic Index Number><Goals><Health><Healthy diet><Hormones><Hour><Human><Hunger><Impairment><Impulsivity><Increased food appetite><Insulin Cell><Insulin Secreting Cell><Intermediary Metabolism><Intervention><L-tyrosyl-L-tyrosine><Laboratories><Laboratory Study><Leptin><Measurement><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolism><Modeling><Modern Man><Motivation><Na element><Neurocognitive><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Protein><Obesity><Observational Study><Oral><PYY Peptide><Participant><Patient Self-Report><Pattern><Peptide YY><Personal Satisfaction><Physical activity><Physiologic><Physiological><Physiology><Precision Health><Predisposition><Protocol><Protocols documentation><Randomized><Research><Research Design><Risk><Role><Satiation><Schedule><Self-Report><Sex Differences><Sexual differences><Sodium><Study Type><Subcellular Process><Susceptibility><System><Testing><Therapeutic Hormone><Thesaurismosis><Tyr-Tyr><Variant><Variation><Woman><Work><adiposity><balanced diet><biological sex><blood glucose regulation><caloric dietary content><circadian><circadian desynchronization><circadian misalignment><clinical care><clinical practice><comparing females and males><comparing women and men><corpulence><craving><day shift><design><designing><diabetes><disparities in sex><driving><energy balance><experiences among men><experiment><experimental research><experimental study><experiments><exposure to light><exposure to visible light><females compared to males><females compared with males><females versus males><females vs. males><food quality><ghrelin><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose metabolism><glucose regulation><good diet><hedonic><human data><impaired glucose tolerance><improved><increased appetite><increased hunger><indexing><innovate><innovation><innovative><insight><insulin secretion><insulin sensitivity><light exposure><light pollution exposure><male><male experience><men><men's experience><metabolism disorder><night shift><night work><novel><observational research study><observational survey><peptide tyrosine-tyrosine><personalized health intervention><personalized intervention><precision interventions><randomisation><randomization><randomly assigned><satiety><saturated dietary fat><saturated dietary lipid><saturated fat><saturated lipid><sex><sex based differences><sex disparity><sex-dependent differences><sex-related differences><sex-specific differences><shift work><shiftwork><social role><stem><study design><tyrosyltyrosine><well-being><wellbeing><women compared to men><women compared with men><women versus men><women vs. men><β-cell><β-cells><βCell><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael R. Farzan

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$889,519
FY 2026

Project Title

A multi-biologic, AAV-deliverable HIV-1 functional cure

Grant Number:

1R01AI197972-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Broadly neutralizing antibodies (bnAbs) and the antibody-like biologic eCD4-Ig (eCD4) can suppress established HIV-1 and SHIV infections when they are present at sufficient concentrations. BnAbs and eCD4 can be delivered passively or expressed from a recombinant adeno-associated viru...

Research Terms

<21+ years old><AAV delivered><AAV delivery><AAV vector><AAV-based delivery><AAV-based vector><AAV-based viral delivery><AAV-mediated delivery><AIDS Virus><Ab-dependent cellular cytotoxicity><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adeno-Associated Viruses><Adeno-associated-virus-based delivery><Adult><Adult Human><Affinity><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Affinity><Antibody Binding Sites><Assay><Autoantibody binding><Autoantibody reactivity><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Sites><Bioassay><Bioavailability><Biological><Biological Agent><Biological Assay><Biological Availability><Biological Products><Blood Serum><Bypass><Class II Genes><Clinical Trials><Clinical Trials Design><Combining Site><Complement><Complement Proteins><DNA mutation><Data><Dependoparvovirus><Dependovirus><Development><Directed Molecular Evolution><Dose><Drug Kinetics><Drugs><Ensure><Envelope Protein><Exhibits><FcRn><FcRn neonatal transfer protein><Framework Regions><Future><Genetic Change><Genetic defect><Genetic mutation><Germ Lines><Glycans><Goals><HIV><HIV Infections><HIV cure><HIV functional cure><HIV viral infection><HIV virus infection><HIV-1><HIV-1 cure><HIV-1 functional cure><HIV-1 infection><HIV-I><HIV/AIDS cure><HIV1><HLA Class II Genes><Half-Life><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Ig Somatic Hypermutation><IgG1><IgG2><Immune><Immune system><Immunes><Immunoglobulin Somatic Hypermutation><Impairment><Individual><Infant><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infusion><Infusion procedures><Injections><Intramuscular Injections><Knowledge><LAV-HTLV-III><Lymphadenopathy-Associated Virus><M mulatta><M. mulatta><MHC Class II><MHC Class II Genes><Macaca><Macaca mulatta><Macaca rhesus><Macaque><Mediating><Medication><Modeling><Modern Man><Mutate><Mutation><Paratopes><Patients><Peptides><Periodicals><Persons><Pharmaceutical Preparations><Pharmacokinetics><Physiologic Availability><Polysaccharides><Predisposition><Property><Protocol><Protocols documentation><Reactive Site><Reagent><Receptor Protein><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Recombinants><Resistance><Rhesus><Rhesus Macaque><Rhesus Monkey><Risk><Rodent><Rodentia><Rodents Mammals><SHIV><SIV><Serial Passage><Serum><Simian Immunodeficiency Viruses><Site><Susceptibility><System><Techniques><Technology><Testing><Transgenes><Transgenic Mice><Translating><Vaccines><Variant><Variation><Viral><Virus><Virus-HIV><Virus-like particle><Wild Type Mouse><Work><adeno associated virus group><adeno-associated viral vector><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adeno-associated virus vector><adenovirus mediated delivery><adult youth><adulthood><antibody combining site><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><antigen antibody affinity><antiretroviral therapy><antiretroviral treatment><arm><biologic><biologics><biopharmaceutical><biotherapeutic agent><cell engineering><cellular engineering><challenge in rhesus macaques><complementation><computer based prediction><cost><cross reactivity><delivered with AAV><delivery with AAV><developmental><directed evolution><drug/agent><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><fitness><genome mutation><human immunodeficiency virus cure><human immunodeficiency virus infection><human model><immunogenic><immunogenicity><improved><in vivo><infected rhesus macaques><infected rhesus monkey><infected with HIV><infected with human immunodeficiency virus><infection in rhesus macaques><infection of rhesus macaques><infusions><insight><intramuscular drug administration><invention><mimetics><model of animal><model of human><mutant><neonatal Fc receptor><neutralizing antibody><novel><periodic><periodical><predictive modeling><rAAV><receptor><recombinant AAV><resistant><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><safety testing><side effect><simian HIV><simian human immunodeficiency virus><somatic hypermutation><success><transgene><vector><virus-like nanoparticles><viruslike particle><wildtype mouse><young adult><young adult age><young adulthood>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Manish Sagar

BOSTON MEDICAL CENTER, BOSTON, MA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$872,596
FY 2026

Project Title

HIV-1 antibodies in the presence of tuberculosis and other coinfections

Grant Number:

1R01AI197970-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Worldwide, tuberculosis (TB) is the most common disease in people living with HIV (PWH). Although, studies have conclusively demonstrated that HIV-1 enhances the development and progression of TB, there is limited understanding about TB effects on HIV-1 pathogenesis. We have observed...

Research Terms

<Ab response><Ab-dependent cellular cytotoxicity><Acceleration><Affect><After Care><After-Treatment><Aftercare><Anatomic Sites><Anatomic structures><Anatomy><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antibody Therapy><Antigenic Determinants><Antigens><Binding Determinants><Blood Plasma><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Clinical Treatment Moab><Cryptococcosis><Development><Disease><Disease Outcome><Disease remission><Disorder><Effector Cell><Env trimer><Epitopes><Fc domain><Frequencies><Future><Germinal Center><HIV Env><HIV disease transmission><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection transmission><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV transmission><HIV viral transmission><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 spread><HIV-1 transmission><HIV-1 vaccine><HIV-1 virus transmission><HIV-I><HIV/AIDS transmission><HIV/Mtb><HIV/TB><HIV/mycobacterium tuberculosis><HIV/tuberculosis><HIV1><HIV1 vaccine><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Histoplasmosis><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Ig Somatic Hypermutation><Immune response><Immunity><Immunoglobulin Somatic Hypermutation><Individual><Inducer Cells><Inducer T-Lymphocytes><Infection><Inflammatory><Inflammatory Response><Infusion><Infusion procedures><Knowledge><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M. tuberculosis/HIV><M.tb infection><M.tuberculosis infection><MTB infection><Mediating><Memory><Monoclonal Antibodies><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Opportunistic Infections><Outcome><PLWH><PWH><Pathogenesis><Pathway interactions><Persons><Plasma><Plasma Serum><Predisposition><Prevention><Remission><Resistance><Reticuloendothelial System, Serum, Plasma><Structure of germinal center of lymph node><Subcellular Process><Susceptibility><T cell response><T4 Cells><T4 Lymphocytes><TB infection><Torulosis><Transmission><Tuberculosis><VAC-TX><Vaccination><Vaccine Therapy><Vaccines><Variant><Variation><Virus><Work><antibody based therapies><antibody biosynthesis><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody treatment><antibody-based therapeutics><antibody-based treatment><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><antiretroviral therapy><antiretroviral treatment><co-infection><coinfection><developmental><disseminated TB><disseminated tuberculosis><host response><human immunodeficiency virus transmission><immune system response><immunogen><immunoglobulin biosynthesis><immunoresponse><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infection due to Mycobacterium tuberculosis><infusions><insight><lymph gland><lymph nodes><lymphnodes><mAbs><microbial antigen><microorganism antigen><monoclonal Abs><mtb><neutralizing antibody><non-tuberculosis mycobacteria><non-tuberculosis mycobacterial><non-tuberculous mycobacteria><non-tuberculous mycobacterial><nontuberculosis mycobacterial><nontuberculous mycobacteria><nontuberculous mycobacterial><novel><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><post treatment><pressure><prevent><preventing><programs><resistance strain><resistant><resistant strain><response><somatic hypermutation><spread of human immunodeficiency virus><syndemic><synergistic epidemic><systemic inflammation><systemic inflammatory response><therapeutic vaccination><transmission process><tuberculosis infection><tuberculous spondyloarthropathy><vaccine against HIV-1><vaccine strategy><virus characteristic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yong Xiong

YALE UNIVERSITY, NEW HAVEN, CT

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$844,711
FY 2026

Project Title

Molecular investigations of HIV-1 maturation pathways and inhibitor actions in situ

Grant Number:

5R01AI192025-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/24/2025

End Date:

3/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY: The HIV-1 life cycle critically depends on a maturation process that transforms the viral core from a spherical to a conical shape, a crucial step for productive infection of host cells. This process is driven by the proteolytic cleavage of Gag and Gag-Pol polyproteins, resulting in...

Research Terms

<AIDS><Acceleration><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Advanced HIV><Affect><Assay><Binding><Binding Sites><Bioassay><Biochemical><Biochemistry><Biological Assay><Biological Chemistry><C perfringens pfoA gene product><C perfringens theta-toxin><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Capsid><Capsid Proteins><Cell Body><Cell Line><Cell surface><CellLine><Cells><Clinical><Clostridium perfringens theta-toxin><Coat Proteins><Combining Site><Communities><Complex><Computer Models><Computerized Models><Cryo-electron Microscopy><Cryo-electron tomography><Cryoelectron Microscopy><Data><Development><Drugs><Electron Cryomicroscopy><Environment><Enzyme Gene><Enzymes><Foundations><Genetics-Mutagenesis><HIV-1><HIV-I><HIV1><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Hybrids><Imaging Procedures><Imaging Technics><Imaging Techniques><In Situ><In Vitro><Infection><Integration Host Factors><Investigation><Laboratories><Life Cycle><Life Cycle Stages><Medication><Methodology><Modern Man><Molecular><Molecular Interaction><Mutagenesis><Mutagenesis Molecular Biology><Pathway interactions><Perfringolysin O><Permeability><Pharmaceutical Preparations><Process><Productivity><Reactive Site><Research><Research Resources><Resolution><Resources><Role><Series><Severe HIV Disease><Shapes><Site><Strains Cell Lines><Structure><System><T4 Cells><T4 Lymphocytes><Testing><Toxin><Validation><Viral><Viral Coat Proteins><Viral Gene Products><Viral Gene Proteins><Viral Outer Coat Protein><Viral Proteins><Viral Structural Proteins><Virion><Virus><Virus Particle><Virus-like particle><Visualization><Work><antiretroviral therapy><antiretroviral treatment><cofactor><computational modeling><computational models><computer based models><computerized modeling><cryo-EM><cryo-EM tomography><cryoEM><cryoEM tomography><cryoelectron tomography><cryogenic electron microscopy><cultured cell line><developmental><drug/agent><electron cryo-tomography><experiment><experimental research><experimental study><experiments><improved><inhibitor><innovate><innovation><innovative><insight><life course><multidisciplinary><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><particle><pathway><pol Gene Products><pol Polyproteins><pol Protein><prevent><preventing><resolutions><small molecule><social role><structural biology><success><theta hemolysin><tool><validations><virus host interaction><virus protein><virus-like nanoparticles><viruslike particle>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Chitra Upadhyay

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$828,695
FY 2026

Project Title

Harnessing native glycosylation to improve immunogenicity of HIV-1 Env immunogens

Grant Number:

5R01AI179427-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Developing an effective HIV vaccine to curb HIV infections is a global urgency. Env is the sole target for broadly neutralizing antibodies (bNAbs), and is the focus of vaccination strategies. One barrier to a protective HIV vaccine is the dense array of glycans that covers the surfac...

Research Terms

<AIDS Vaccines><AIDS Virus><AIDS vaccine><Ab response><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affect><Alteplase><Amino Acids><Animal Model><Animal Models and Related Studies><Antibody Formation><Antibody Production><Antigenic Determinants><Antigens><Binding><Binding Determinants><Biogenesis><Biology><Cell Body><Cells><Chaperone><Chronic><Complex><D-Galactose><D-Mannose><Data><Development><Endoplasmic Reticulum><Engineering><Env trimer><Environment><Epidemic><Epitopes><Ergastoplasm><Exposure to><Galactopyranose><Galactopyranoside><Galactose><Genetic Polymorphism><Glycans><Glycoproteins><Goals><Golgi><Golgi Apparatus><Golgi Complex><HIV><HIV Env><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV Infections><HIV env Protein gp120><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 vaccine><HIV-I><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><HTLV-III gp120><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hybrids><Immune response><Immunization><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigators><Knowledge><LAV-HTLV-III><Link><Lymphadenopathy-Associated Virus><Mannopyranose><Mannopyranoside><Mannose><Measures><Mediating><Metabolic Glycosylation><Modern Man><Molecular Chaperones><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Origin of Life><Pathway interactions><Pattern><Peptide Signal Sequences><Phenotype><Play><Polysaccharides><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Property><Protein Biosynthesis><Protein Modification><Proteins><Publishing><Recombinant Tissue Plasminogen Activator><Research Personnel><Researchers><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Role><SOSIP><Shapes><Signal Peptide><Signal Sequences><Site><Structure><Surface><T-Plasminogen Activator><Time><Tissue Activator D-44><Tissue Plasminogen Activator><Tissue-Type Plasminogen Activator><Translations><Vaccination><Vaccine Design><Vaccines><Variant><Variation><Viral><Viral Antigens><Virion><Virus><Virus Particle><Virus-HIV><aminoacid><antibody biosynthesis><clinical relevance><clinically relevant><conformation><conformational><conformational state><conformationally><conformations><cross reactivity><design><designing><developmental><flexibility><flexible><glycosylation><gp120><gp120 ENV Glycoprotein><gp120(HIV)><gp160><host response><human immunodeficiency virus infection><human immunodeficiency virus vaccine><immune system response><immunization strategy><immunogen><immunogenicity><immunoglobulin biosynthesis><immunoresponse><imprint><improved><in vivo><infected with HIV><infected with human immunodeficiency virus><innovative technologies><model of animal><neutralizing antibody><pathway><polymorphism><prevent><preventing><prophylactic><protein folding><protein signal sequence><protein synthesis><response><social role><t-PA><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tool><translation><vaccination strategy><vaccination study><vaccination trial><vaccine against HIV><vaccine against HIV-1><vaccine candidate><vaccine study><vaccine trial><virus antigen>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Petter Bjornstad

UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, SAN ANTONIO, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$825,255
FY 2026

Project Title

Metabolite Markers of Diabetic Kidney Disease

Grant Number:

1R01DK143234-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT: Diabetic kidney disease (DKD) threatens roughly 40 % of individuals living with type 1 diabetes (T1D), driving kidney failure and cardiovascular death even in the era of continuous glucose monitoring and automated insulin delivery. Hypoxia, obesity and insulin resistance,...

Research Terms

<1-Phosphatidylinositol 3-Kinase><1H-Purin-6-amine><21+ years old><Acceleration><Adenine><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Agonist><Albuminuria><Automobile Driving><Binding><Biological Markers><Biopsy><Blood Plasma><Brittle Diabetes Mellitus><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Causality><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cessation of life><Clinical><Continuous Glucose Monitor><Data><Death><Diabetes Mellitus><Diabetic Kidney Disease><Diabetic Nephropathy><Diabetic mouse><Disease Management><Disease Progression><Disorder Management><Dissection><Docking><Dose><Dysfunction><Enzyme Gene><Enzymes><Epithelial Cells><Etiology><Event><Exclusion><Fibrosis><Functional disorder><GLP-1 receptor><GLP-I receptor><Genetic><Glomerular Filtration Rate><Glucan Phosphorylase><Heart Vascular><Human><Humulin R><Hyperglycemia><Hypoxia><Hypoxic><IDDM><Individual><Inflammatory><Injury><Injury to Kidney><Insulin><Insulin Receptor><Insulin Receptor Protein-Tyrosine Kinase><Insulin Resistance><Insulin-Dependent Diabetes Mellitus><Insulin-Dependent Tyrosine Protein Kinase><Intermediary Metabolism><Intervention><Intracellular Communication and Signaling><Intracellular Second Messenger><Juvenile-Onset Diabetes Mellitus><KO mice><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Failure><Kidney Insufficiency><Kidney Urinary System><Kinases><Knock-out Mice><Knockout Mice><Length><Link><Maps><Maturity-Onset Diabetes Mellitus><Measures><Mediating><Metabolic><Metabolic Processes><Metabolic stress><Metabolism><Mice><Mice Mammals><Modeling><Modern Man><Modernization><Molecular><Molecular Interaction><Murine><Mus><NIDDM><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Null Mouse><Obesity><Outcome><Oxygen Deficiency><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pathogenicity><Pathway interactions><Patients><Persons><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Phosphorylases><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Placebo Control><Placebos><Plasma><Plasma Serum><Predictive Value><Production><Prognostic Marker><PtdIns 3-Kinase><Receptor Signaling><Regular Insulin><Renal Disease><Renal Failure><Renal Insufficiency><Renal function><Reticuloendothelial System, Serum, Plasma><Role><SGLT 2 inhibitor><SGLT2i><STZ><Second Messenger Systems><Second Messengers><Sham Treatment><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Source><Stable Diabetes Mellitus><Streptozocin><Streptozotocin><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Technology><Testing><Therapeutic><Transphosphorylases><Tubular><Tubular formation><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type I Phosphatidylinositol Kinase><Type II Diabetes Mellitus><Type II diabetes><Type III Phosphoinositide 3-Kinase><Urine><Vitamin B4><Work><Zanosar><adiposity><adult onset diabetes><adult youth><adulthood><alpha-Glucan Phosphorylases><bio-markers><biologic marker><biological signal transduction><biomarker><causation><circulatory system><cohort><continuous blood glucose monitor><continuous blood sugar monitor><continuous glucose measurement><continuous sugar monitor><corpulence><decline in function><decline in functional status><diabetes><diabetes management><diabetes mellitus management><diabetes mouse model><diabetic management><dietary><disease causation><disease model><disorder model><driving><early biomarkers><early detection biomarkers><early detection markers><experiment><experimental research><experimental study><experiments><functional decline><functional improvement><functional status decline><glucagon-like peptide-1 receptor><high risk><human tissue><hyperglycemic><improve function><improved functional outcomes><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><injured><injuries><insulin dependent diabetes><insulin dependent type 1><insulin resistant><insulin tolerance><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><kidney biopsy><kidney disorder><kidney fibrosis><kidney function><kidney injury><maturity onset diabetes><metabolism measurement><metabolomics><metabonomics><mitochondrial metabolism><mouse genetics><mouse model><multiomics><multiple omics><murine model><mutant><panomics><pathophysiology><pathway><pharmacologic><placebo controlled><pre-clinical><preclinical><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><premature><prematurity><prevent><preventing><prognostic biomarker><prognostic indicator><reconstitute><reconstitution><renal><renal biopsy><renal disorder><renal fibrosis><renal injury><response><risk stratification><scRNA sequencing><scRNA-seq><sham therapy><signal transduction second messengers><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial multiomics><spatial omics><spatial relationship><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatial tri-omics><spatially resolved transcriptomics><spatio transcriptomics><stable isotope><stratify risk><targeted biomarker><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic biomarker><therapeutic marker><therapeutic target><trial enrollment><type 1 and type 2 diabetes><type 2 DM><type I and type II diabetes><type I diabetes><type II DM><type one diabetes><type two diabetes><young adult><young adult age><young adulthood>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kumar Sharma

UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, SAN ANTONIO, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$825,255
FY 2026

Project Title

Metabolite Markers of Diabetic Kidney Disease

Grant Number:

1R01DK143234-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT: Diabetic kidney disease (DKD) threatens roughly 40 % of individuals living with type 1 diabetes (T1D), driving kidney failure and cardiovascular death even in the era of continuous glucose monitoring and automated insulin delivery. Hypoxia, obesity and insulin resistance,...

Research Terms

<1-Phosphatidylinositol 3-Kinase><1H-Purin-6-amine><21+ years old><Acceleration><Adenine><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Agonist><Albuminuria><Automobile Driving><Binding><Biological Markers><Biopsy><Blood Plasma><Brittle Diabetes Mellitus><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Causality><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cessation of life><Clinical><Continuous Glucose Monitor><Data><Death><Diabetes Mellitus><Diabetic Kidney Disease><Diabetic Nephropathy><Diabetic mouse><Disease Management><Disease Progression><Disorder Management><Dissection><Docking><Dose><Dysfunction><Enzyme Gene><Enzymes><Epithelial Cells><Etiology><Event><Exclusion><Fibrosis><Functional disorder><GLP-1 receptor><GLP-I receptor><Genetic><Glomerular Filtration Rate><Glucan Phosphorylase><Heart Vascular><Human><Humulin R><Hyperglycemia><Hypoxia><Hypoxic><IDDM><Individual><Inflammatory><Injury><Injury to Kidney><Insulin><Insulin Receptor><Insulin Receptor Protein-Tyrosine Kinase><Insulin Resistance><Insulin-Dependent Diabetes Mellitus><Insulin-Dependent Tyrosine Protein Kinase><Intermediary Metabolism><Intervention><Intracellular Communication and Signaling><Intracellular Second Messenger><Juvenile-Onset Diabetes Mellitus><KO mice><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Failure><Kidney Insufficiency><Kidney Urinary System><Kinases><Knock-out Mice><Knockout Mice><Length><Link><Maps><Maturity-Onset Diabetes Mellitus><Measures><Mediating><Metabolic><Metabolic Processes><Metabolic stress><Metabolism><Mice><Mice Mammals><Modeling><Modern Man><Modernization><Molecular><Molecular Interaction><Murine><Mus><NIDDM><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Null Mouse><Obesity><Outcome><Oxygen Deficiency><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pathogenicity><Pathway interactions><Patients><Persons><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Phosphorylases><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Placebo Control><Placebos><Plasma><Plasma Serum><Predictive Value><Production><Prognostic Marker><PtdIns 3-Kinase><Receptor Signaling><Regular Insulin><Renal Disease><Renal Failure><Renal Insufficiency><Renal function><Reticuloendothelial System, Serum, Plasma><Role><SGLT 2 inhibitor><SGLT2i><STZ><Second Messenger Systems><Second Messengers><Sham Treatment><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Source><Stable Diabetes Mellitus><Streptozocin><Streptozotocin><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Technology><Testing><Therapeutic><Transphosphorylases><Tubular><Tubular formation><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type I Phosphatidylinositol Kinase><Type II Diabetes Mellitus><Type II diabetes><Type III Phosphoinositide 3-Kinase><Urine><Vitamin B4><Work><Zanosar><adiposity><adult onset diabetes><adult youth><adulthood><alpha-Glucan Phosphorylases><bio-markers><biologic marker><biological signal transduction><biomarker><causation><circulatory system><cohort><continuous blood glucose monitor><continuous blood sugar monitor><continuous glucose measurement><continuous sugar monitor><corpulence><decline in function><decline in functional status><diabetes><diabetes management><diabetes mellitus management><diabetes mouse model><diabetic management><dietary><disease causation><disease model><disorder model><driving><early biomarkers><early detection biomarkers><early detection markers><experiment><experimental research><experimental study><experiments><functional decline><functional improvement><functional status decline><glucagon-like peptide-1 receptor><high risk><human tissue><hyperglycemic><improve function><improved functional outcomes><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><injured><injuries><insulin dependent diabetes><insulin dependent type 1><insulin resistant><insulin tolerance><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><kidney biopsy><kidney disorder><kidney fibrosis><kidney function><kidney injury><maturity onset diabetes><metabolism measurement><metabolomics><metabonomics><mitochondrial metabolism><mouse genetics><mouse model><multiomics><multiple omics><murine model><mutant><panomics><pathophysiology><pathway><pharmacologic><placebo controlled><pre-clinical><preclinical><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><premature><prematurity><prevent><preventing><prognostic biomarker><prognostic indicator><reconstitute><reconstitution><renal><renal biopsy><renal disorder><renal fibrosis><renal injury><response><risk stratification><scRNA sequencing><scRNA-seq><sham therapy><signal transduction second messengers><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial multiomics><spatial omics><spatial relationship><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatial tri-omics><spatially resolved transcriptomics><spatio transcriptomics><stable isotope><stratify risk><targeted biomarker><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic biomarker><therapeutic marker><therapeutic target><trial enrollment><type 1 and type 2 diabetes><type 2 DM><type I and type II diabetes><type I diabetes><type II DM><type one diabetes><type two diabetes><young adult><young adult age><young adulthood>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Deborah Persaud

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$779,616
FY 2026

Project Title

Defective HIV-1 proviral abundance and their immune effects in children and adolescents living with perinatal HIV-1

Grant Number:

1R01AI198053-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

During suppressive antiretroviral therapy (ART), HIV-1 persists in long-lived resting memory CD4+ T cells of children and young adults with perinatal HIV-1 as both intact and defective proviral genomes. The intact, replication-competent proviruses contribute to the latent reservoir and are a lifelon...

Research Terms

<0-11 years old><12-20 years old><15 year old><15 years of age><21+ years old><7S Gamma Globulin><Address><Adolescence><Adolescent><Adolescent Youth><Adult><Adult Human><Age><Antibodies><Antigens><Assay><Autologous><Binding><Bioassay><Biological Assay><Blood Plasma><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Caring><Cell Body><Cells><Child><Child Youth><Childhood><Children (0-21)><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><DNA><Data><Defect><Deoxyribonucleic Acid><Disease remission><Enrollment><Frequencies><Funding><Future><Gene Transcription><Genetic Transcription><Genome><Goals><HIV Infections><HIV infection persistence><HIV persistence><HIV viral infection><HIV viral persistence><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 persistence><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><HPV Vaccine><Health><Health Care Costs><Health Costs><History><Hour><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Papilloma Virus Vaccine><Human immunodeficiency virus 1><Human papillomavirus Vaccine><IgG><Immune><Immune Cell Activation><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune Markers><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune mediated therapy><Immune response><Immunes><Immunochemical Immunologic><Immunoglobulin G><Immunologic><Immunologic Diseases><Immunologic Factors><Immunologic Markers><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological Factors><Immunological System Dysfunction><Immunologically><Immunologically Directed Therapy><Immunologics><Immunotherapeutic agent><Immunotherapy><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Intervention><Length><Life><Link><Low Prevalence><Measures><Messenger RNA><Molecular><Molecular Immunology><Molecular Interaction><Molecular Virology><NIH><National Institutes of Health><Nature><Non-Polyadenylated RNA><Outcome><PBMC><Participant><Perinatal><Perinatal Infection><Peripartum><Peripheral Blood Mononuclear Cell><Persons><Plasma><Plasma Serum><Production><Proteins><Proviruses><RNA><RNA Expression><RNA Gene Products><Recording of previous events><Remission><Research Specimen><Residual><Residual state><Rest><Reticuloendothelial System, Serum, Plasma><Ribonucleic Acid><Role><Sampling><Shapes><Source><Specimen><T4 Cells><T4 Lymphocytes><Transcript><Transcription><United States National Institutes of Health><Viral><Viral Burden><Viral Gene Products><Viral Gene Proteins><Viral Load><Viral Load result><Viral Proteins><Viremia><Virus><Work><Youth><Youth 10-21><acute infection><adolescence (12-20)><adult youth><adulthood><age 15><age 15 years><age associated><age correlated><age dependent><age group><age linked><age related><age specific><ages><antiretroviral therapy><antiretroviral treatment><biobank><biorepository><clinical relevance><clinically relevant><co-morbid><co-morbidity><cohort><comorbidity><cost effective><demographics><design><designing><enroll><exhaustion><fifteen year old><fifteen years of age><genome sequencing><histories><host response><human immunodeficiency virus infection><human immunodeficiency virus persistence><immune activation><immune drugs><immune health><immune system health><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic substance><immunologic therapeutics><immunological biomarkers><immunological markers><immunological substance><immunoresponse><immunotherapeutics><immunotherapy agent><improved><in utero><infancy><infantile><infected with HIV><infected with human immunodeficiency virus><insight><juvenile><juvenile human><kids><mRNA><memory CD4 T cell><memory CD4 T lymphocyte><neonate><neutralizing antibody><novel><pediatric><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><prevent><preventing><response to therapy><response to treatment><social role><therapeutic response><therapy duration><therapy response><treatment response><treatment responsiveness><vaccine against HIV-1><viraemia><viral RNA><viral sepsis><virus RNA><virus protein><virusemia><young adult><young adult age><young adulthood><youngster><youth age>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BARBARA L HEMPSTEAD

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$776,035
FY 2026

Project Title

Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration

Grant Number:

4R01AG078613-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The aging brain is characterized by a slow deterioration of homeostatic balance between pro- and anti-inflam- matory cytokines, resulting in a proinflammatory state. Resident CNS immune cells are normally present in a resting state, but exhibit heightened vulnerability to secondary insults with agin...

Research Terms

<21+ years old><AD dementia><AD model><Acute><Address><Adult><Adult Human><Affect><Affinity><Aging><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimers Dementia><Ammon Horn><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antibodies><Antigen-Presenting Cells><Antigenic Determinants><Apoplexy><Atrophic><Atrophy><B-Cell Activation Antigen><B-lymphocyte Activation Antigen B7-1><B7 Antigen><B7-1><B7-1 Costimulatory Molecule><B7-1 Protein><B71 Antigen><BB-1><BB1><BDNF><Binding><Binding Determinants><Biochemical><Biological><Biophysics><Blocking Antibodies><Brain Trauma><Brain Vascular Accident><Brain-Derived Neurotrophic Factor><CD152><CD152 Antigen><CD152 Gene><CD28><CD28 Antigen Ligand 1><CD28 gene><CD28LG><CD28LG1><CD80><CD80 Antigens><CD80 gene><CNS Diseases><CNS disorder><CTL A4-Ig B7 Inhibitor><CTLA 4><CTLA-4 Gene><CTLA-4-Ig><CTLA4><CTLA4 gene><CTLA4-Fc><CTLA4-Ig><CTLA4-Ig immunoconjugate><CTLA4-TM><Cachectin Receptors><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Proteins><Cell surface><Cells><Central Nervous System Diseases><Central Nervous System Disorders><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Clinical Treatment Moab><Complex><Cornu Ammonis><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DLG4><DLG4 gene><Data><Degenerative Neurologic Disorders><Dendritic Spines><Deterioration><Dorsal><Effectiveness><Epitopes><Equilibrium><Evaluation><Exhibits><External Domain><Extracellular Domain><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><GP80-LNGFR><Gene Modified><Glia><Glial Cells><Goals><Hippocampus><Hortega cell><Human><IDEC-114 Monoclonal Antibody><Imaging Device><Imaging Instrument><Imaging Tool><Immune><Immunes><Immunomodulation><Impairment><In Vitro><Infiltration><Inflammation><Inflammatory><Injections><Injury><Intracellular Communication and Signaling><KI mice><Knock-in Mouse><Kolliker's reticulum><LAB7><Lead><Ligands><Low-Affinity Nerve Growth Factor Receptor><Macrophage><Mammalia><Mammals><Maps><Memory><Mice><Mice Mammals><Micro-tubule><Microglia><Microtubules><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><Morphology><Murine><Mus><Mφ><NGF Receptor><NGF Receptors><NGFR Protein><Nerve Cells><Nerve Degeneration><Nerve Growth Factor Receptor><Nerve Growth Factor Receptor p75><Nerve Growth Factor Receptors><Nerve Unit><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neuroglia><Neuroglial Cells><Neurologic Degenerative Conditions><Neurologic Disorders><Neurological Disorders><Neuron Degeneration><Neurons><Neurotrophic Factor Receptor><Neurotrophin Receptors><Neurotropin Receptor p75><Non-neuronal cell><Nonneuronal cell><PSD95><Pb element><Phenotype><Population><Prevention><Primary Senile Degenerative Dementia><Primates><Primates Mammals><Process><Proteins><Pyramidal neuron><Reagent><Receptor Protein><Rest><Retrieval><Role><SAP90><Secondary to><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spinal Column><Spine><Stroke><Surface><Synapses><Synaptic><T44><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNFR><Techniques><Testing><Therapeutic><Time><Traumatic Brain Injury><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Validation><Vertebral column><accessory cell><adulthood><aged brain><aging brain><alzheimer model><anti-B7-1><anti-CD80><backbone><balance><balance function><basal forebrain cholinergic neurons><behavior study><behavioral impairment><behavioral study><biologic><biological signal transduction><biophysical characteristics><biophysical characterization><biophysical foundation><biophysical measurement><biophysical parameters><biophysical principles><biophysical properties><biophysical sciences><brain attack><brain-derived neurotrophic factor precursor><cerebral vascular accident><cerebrovascular accident><cytokine><cytotoxic T lymphocyte-associated antigen 4-immunoglobulin><cytotoxic T-lymphocyte antigen 4><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><dendrite spine><density><gene modification><genetically modified><gitter cell><gp75 NGFR><heavy metal Pb><heavy metal lead><hippocampal><hippocampal pyramidal neuron><humanized mice><humanized mouse><imaging study><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><impaired behavior><in vitro testing><in vivo><injuries><insight><knockin mice><mAbs><member><mesoglia><microglial cell><microgliocyte><monoclonal Abs><mouse model><murine model><native protein drug><nerve cement><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroinflammation><neuroinflammatory><neurological degeneration><neurological disease><neuronal><neuronal degeneration><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><p75><p75 neurotrophin receptor><p75 transcription factor><p75NTR><perivascular glial cell><pharmaceutical protein><postsynaptic><pre-clinical><preclinical><prevent><preventing><primary degenerative dementia><pro-BDNF><protein drug agent><protein protein interaction><protein-based drug><receptor><response><senile dementia of the Alzheimer type><social role><stroked><strokes><synapse><therapeutic protein><tool><transcriptional coactivator p75><traumatic brain damage><validations>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Francis Sang Yong Lee

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$776,035
FY 2026

Project Title

Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration

Grant Number:

4R01AG078613-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The aging brain is characterized by a slow deterioration of homeostatic balance between pro- and anti-inflam- matory cytokines, resulting in a proinflammatory state. Resident CNS immune cells are normally present in a resting state, but exhibit heightened vulnerability to secondary insults with agin...

Research Terms

<21+ years old><AD dementia><AD model><Acute><Address><Adult><Adult Human><Affect><Affinity><Aging><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimers Dementia><Ammon Horn><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antibodies><Antigen-Presenting Cells><Antigenic Determinants><Apoplexy><Atrophic><Atrophy><B-Cell Activation Antigen><B-lymphocyte Activation Antigen B7-1><B7 Antigen><B7-1><B7-1 Costimulatory Molecule><B7-1 Protein><B71 Antigen><BB-1><BB1><BDNF><Binding><Binding Determinants><Biochemical><Biological><Biophysics><Blocking Antibodies><Brain Trauma><Brain Vascular Accident><Brain-Derived Neurotrophic Factor><CD152><CD152 Antigen><CD152 Gene><CD28><CD28 Antigen Ligand 1><CD28 gene><CD28LG><CD28LG1><CD80><CD80 Antigens><CD80 gene><CNS Diseases><CNS disorder><CTL A4-Ig B7 Inhibitor><CTLA 4><CTLA-4 Gene><CTLA-4-Ig><CTLA4><CTLA4 gene><CTLA4-Fc><CTLA4-Ig><CTLA4-Ig immunoconjugate><CTLA4-TM><Cachectin Receptors><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Proteins><Cell surface><Cells><Central Nervous System Diseases><Central Nervous System Disorders><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Clinical Treatment Moab><Complex><Cornu Ammonis><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DLG4><DLG4 gene><Data><Degenerative Neurologic Disorders><Dendritic Spines><Deterioration><Dorsal><Effectiveness><Epitopes><Equilibrium><Evaluation><Exhibits><External Domain><Extracellular Domain><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><GP80-LNGFR><Gene Modified><Glia><Glial Cells><Goals><Hippocampus><Hortega cell><Human><IDEC-114 Monoclonal Antibody><Imaging Device><Imaging Instrument><Imaging Tool><Immune><Immunes><Immunomodulation><Impairment><In Vitro><Infiltration><Inflammation><Inflammatory><Injections><Injury><Intracellular Communication and Signaling><KI mice><Knock-in Mouse><Kolliker's reticulum><LAB7><Lead><Ligands><Low-Affinity Nerve Growth Factor Receptor><Macrophage><Mammalia><Mammals><Maps><Memory><Mice><Mice Mammals><Micro-tubule><Microglia><Microtubules><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><Morphology><Murine><Mus><Mφ><NGF Receptor><NGF Receptors><NGFR Protein><Nerve Cells><Nerve Degeneration><Nerve Growth Factor Receptor><Nerve Growth Factor Receptor p75><Nerve Growth Factor Receptors><Nerve Unit><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neuroglia><Neuroglial Cells><Neurologic Degenerative Conditions><Neurologic Disorders><Neurological Disorders><Neuron Degeneration><Neurons><Neurotrophic Factor Receptor><Neurotrophin Receptors><Neurotropin Receptor p75><Non-neuronal cell><Nonneuronal cell><PSD95><Pb element><Phenotype><Population><Prevention><Primary Senile Degenerative Dementia><Primates><Primates Mammals><Process><Proteins><Pyramidal neuron><Reagent><Receptor Protein><Rest><Retrieval><Role><SAP90><Secondary to><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spinal Column><Spine><Stroke><Surface><Synapses><Synaptic><T44><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNFR><Techniques><Testing><Therapeutic><Time><Traumatic Brain Injury><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Validation><Vertebral column><accessory cell><adulthood><aged brain><aging brain><alzheimer model><anti-B7-1><anti-CD80><backbone><balance><balance function><basal forebrain cholinergic neurons><behavior study><behavioral impairment><behavioral study><biologic><biological signal transduction><biophysical characteristics><biophysical characterization><biophysical foundation><biophysical measurement><biophysical parameters><biophysical principles><biophysical properties><biophysical sciences><brain attack><brain-derived neurotrophic factor precursor><cerebral vascular accident><cerebrovascular accident><cytokine><cytotoxic T lymphocyte-associated antigen 4-immunoglobulin><cytotoxic T-lymphocyte antigen 4><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><dendrite spine><density><gene modification><genetically modified><gitter cell><gp75 NGFR><heavy metal Pb><heavy metal lead><hippocampal><hippocampal pyramidal neuron><humanized mice><humanized mouse><imaging study><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><impaired behavior><in vitro testing><in vivo><injuries><insight><knockin mice><mAbs><member><mesoglia><microglial cell><microgliocyte><monoclonal Abs><mouse model><murine model><native protein drug><nerve cement><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroinflammation><neuroinflammatory><neurological degeneration><neurological disease><neuronal><neuronal degeneration><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><p75><p75 neurotrophin receptor><p75 transcription factor><p75NTR><perivascular glial cell><pharmaceutical protein><postsynaptic><pre-clinical><preclinical><prevent><preventing><primary degenerative dementia><pro-BDNF><protein drug agent><protein protein interaction><protein-based drug><receptor><response><senile dementia of the Alzheimer type><social role><stroked><strokes><synapse><therapeutic protein><tool><transcriptional coactivator p75><traumatic brain damage><validations>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alison Bloom Kohan

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$773,140
FY 2026

Project Title

Impact of a Glucagon-Like Peptide-1 Receptor Agonist administration on SIV/HIV pathogenesis and ART

Grant Number:

5R01DK140931-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2025

End Date:

3/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Antiretroviral therapy (ART) administration to people living with HIV (PWH) associates significant weight gain and dramatic (>30%) increase in visceral and abdominal adipose tissue (AdT). Obesity and AdT hypertrophy are accompanied with inflammation, type 2 diabetes and cardiovascular disease. Since...

Research Terms

<AIDS Virus><AIDS/HIV><Abdomen><Achievement><Achievement Attainment><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adipose tissue><Adult-Onset Diabetes Mellitus><Adverse effects><Age><Agonist><Animal Model><Animal Models and Related Studies><Autopsy><Autoregulation><Blood><Blood Plasma><Blood Reticuloendothelial System><Body Tissues><Body Weight><Body Weight decreased><Cardiovascular Diseases><Cell Body><Cell Function><Cell Isolation><Cell Physiology><Cell Process><Cell Segregation><Cell Separation><Cell Separation Technology><Cells><Cellular Function><Cellular Immune Function><Cellular Metabolic Process><Cellular Physiology><Cellular Process><Cholesterol><Chronic><Clinical><Clinical Management><Data><Defect><Deposit><Deposition><Development><Diabetes Mellitus><Diagnosis><Diet><Drugs><Dysfunction><Elements><Environment><Event><Exhibits><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Fat necrosis><Fats><Fatty Tissue><Fatty acid glycerol esters><Feedback><Fibrosis><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Free Fatty Acids><Frequencies><Functional disorder><GLP-1><GLP-1 receptor><GLP-I receptor><General Population><General Public><Generalized Growth><Glp-1><Growth><HDL><HDL Lipoproteins><HIV><HIV Infections><HIV cure><HIV functional cure><HIV in patients><HIV incidence><HIV individuals><HIV infected individuals><HIV infected persons><HIV patient><HIV people><HIV positive individuals><HIV positive patient><HIV positive people><HIV viral infection><HIV virus infection><HIV-1 cure><HIV-1 functional cure><HIV-1 incidence><HIV-1 infection><HIV-1 infection incidence><HIV/AIDS><HIV/AIDS cure><HIV/AIDS incidence><Health Care Costs><Health Costs><Heavy Lipoproteins><High Density Lipoproteins><Homeostasis><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Viruses><Human immunodeficiency virus infected patients><Human immunodeficiency virus positive patients><Hypercholesteremia><Hyperglyceridemia><Hyperlipemia><Hyperlipidemia><Hypertriglyceridemia><Hypertrophy><Immune><Immune Cell Activation><Immune infiltrates><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Incidence><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infiltration><Inflammation><Inflammatory><Inflammatory Infiltrate><Integration Host Factors><Intermediary Metabolism><Intervention><Ketosis-Resistant Diabetes Mellitus><LAV-HTLV-III><Lead><Lipids><Liver><Lymphadenopathy-Associated Virus><M nemestrina><M. nemestrina><Macaca nemestrina><Macrophage><Maintenance><Maturity-Onset Diabetes Mellitus><Measures><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolic dysfunction><Metabolism><Modeling><Modern Man><Mφ><NAFLD><NHP models><NIDDM><Natural History><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Nonesterified Fatty Acids><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Obesity Epidemic><Operative Procedures><Operative Surgical Procedures><Organ><PLWH><PWH><Pathogenesis><Patients living with HIV><Patients suffering from HIV><Pb element><Pharmaceutical Preparations><Phenotype><Physiological Homeostasis><Physiopathology><Pigtail Macaque><Pigtail Monkey><Plasma><Plasma Serum><Prevention><Proliferating><QOL improvement><Raised TG><Raised triglycerides><Residual><Residual state><Reticuloendothelial System, Serum, Plasma><Risk><SIV><Simian Immunodeficiency Viruses><Site><Slow-Onset Diabetes Mellitus><Source><Stable Diabetes Mellitus><Steatonecrosis><Subcellular Process><Surgical><Surgical Interventions><Surgical Procedure><T cell infiltration><T-Cells><T-Lymphocyte><T2 DM><T2D><T2DM><Testing><Thesaurismosis><Time><Tissue Growth><Tissues><Triacylglycerol><Triglycerides><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Unhealthy Diet><Vascularization><Viral><Viral reservoir><Virus><Virus reservoir><Virus-HIV><Visceral><Wasting Disease><Wasting Syndrome><Weight Gain><Weight Increase><Weight Loss><Weight Loss Agents><Weight Reduction><Weight-Loss Drugs><adipose><adiposity><adult onset diabetes><ages><alpha-Lipoproteins><antiretroviral therapy><antiretroviral treatment><body weight gain><body weight increase><body weight loss><cardiovascular disorder><cell metabolism><cell sorting><cellular metabaolism><co-morbid><co-morbidity><comorbidity><corpulence><cytokine><developmental><diabetes><diets><drug/agent><elevated tg><elevated triglyceride><experience><functional improvement><glucagon-like peptide 1><glucagon-like peptide-1 receptor><heavy metal Pb><heavy metal lead><hepatic body system><hepatic organ system><high blood cholesterol><high triglycerides><host response><human immunodeficiency virus cure><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus patient><hypercholesterolemia><immune activation><immune cell infiltrate><immune function><immune system response><immunoresponse><improve function><improved><improved functional outcomes><improvements in QOL><improvements in quality of life><increased triglycerides><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><ketosis resistant diabetes><life span><lifespan><maturity onset diabetes><metabolic profile><metabolism disorder><model of animal><mortality><necropsy><non-alcohol fatty liver disease><non-alcoholic fatty liver disease><non-alcoholic liver disease><nonalcoholic fatty liver disease><nonhuman primate models><ontogeny><pathophysiology><patient infected with HIV><patient with HIV><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacologic><pig-tailed macaque><poor diet><postmortem><pre-clinical><preclinical><prevent><preventing><prognostic><promoter><promotor><quality of life improvement><restoration><surgery><systemic inflammation><systemic inflammatory response><thymus derived lymphocyte><type 2 DM><type II DM><type two diabetes><viral DNA><virtual><virus DNA><wasting condition><wasting disorder><western diet><western-style diet><western-type diet><white adipose tissue><wt gain><wt-loss><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ivona Vasile Pandrea

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$773,140
FY 2026

Project Title

Impact of a Glucagon-Like Peptide-1 Receptor Agonist administration on SIV/HIV pathogenesis and ART

Grant Number:

5R01DK140931-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/10/2025

End Date:

3/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Antiretroviral therapy (ART) administration to people living with HIV (PWH) associates significant weight gain and dramatic (>30%) increase in visceral and abdominal adipose tissue (AdT). Obesity and AdT hypertrophy are accompanied with inflammation, type 2 diabetes and cardiovascular disease. Since...

Research Terms

<AIDS Virus><AIDS/HIV><Abdomen><Achievement><Achievement Attainment><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adipose tissue><Adult-Onset Diabetes Mellitus><Adverse effects><Age><Agonist><Animal Model><Animal Models and Related Studies><Autopsy><Autoregulation><Blood><Blood Plasma><Blood Reticuloendothelial System><Body Tissues><Body Weight><Body Weight decreased><Cardiovascular Diseases><Cell Body><Cell Function><Cell Isolation><Cell Physiology><Cell Process><Cell Segregation><Cell Separation><Cell Separation Technology><Cells><Cellular Function><Cellular Immune Function><Cellular Metabolic Process><Cellular Physiology><Cellular Process><Cholesterol><Chronic><Clinical><Clinical Management><Data><Defect><Deposit><Deposition><Development><Diabetes Mellitus><Diagnosis><Diet><Drugs><Dysfunction><Elements><Environment><Event><Exhibits><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Fat necrosis><Fats><Fatty Tissue><Fatty acid glycerol esters><Feedback><Fibrosis><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Free Fatty Acids><Frequencies><Functional disorder><GLP-1><GLP-1 receptor><GLP-I receptor><General Population><General Public><Generalized Growth><Glp-1><Growth><HDL><HDL Lipoproteins><HIV><HIV Infections><HIV cure><HIV functional cure><HIV in patients><HIV incidence><HIV individuals><HIV infected individuals><HIV infected persons><HIV patient><HIV people><HIV positive individuals><HIV positive patient><HIV positive people><HIV viral infection><HIV virus infection><HIV-1 cure><HIV-1 functional cure><HIV-1 incidence><HIV-1 infection><HIV-1 infection incidence><HIV/AIDS><HIV/AIDS cure><HIV/AIDS incidence><Health Care Costs><Health Costs><Heavy Lipoproteins><High Density Lipoproteins><Homeostasis><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Viruses><Human immunodeficiency virus infected patients><Human immunodeficiency virus positive patients><Hypercholesteremia><Hyperglyceridemia><Hyperlipemia><Hyperlipidemia><Hypertriglyceridemia><Hypertrophy><Immune><Immune Cell Activation><Immune infiltrates><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Incidence><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infiltration><Inflammation><Inflammatory><Inflammatory Infiltrate><Integration Host Factors><Intermediary Metabolism><Intervention><Ketosis-Resistant Diabetes Mellitus><LAV-HTLV-III><Lead><Lipids><Liver><Lymphadenopathy-Associated Virus><M nemestrina><M. nemestrina><Macaca nemestrina><Macrophage><Maintenance><Maturity-Onset Diabetes Mellitus><Measures><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolic dysfunction><Metabolism><Modeling><Modern Man><Mφ><NAFLD><NHP models><NIDDM><Natural History><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Nonesterified Fatty Acids><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Obesity Epidemic><Operative Procedures><Operative Surgical Procedures><Organ><PLWH><PWH><Pathogenesis><Patients living with HIV><Patients suffering from HIV><Pb element><Pharmaceutical Preparations><Phenotype><Physiological Homeostasis><Physiopathology><Pigtail Macaque><Pigtail Monkey><Plasma><Plasma Serum><Prevention><Proliferating><QOL improvement><Raised TG><Raised triglycerides><Residual><Residual state><Reticuloendothelial System, Serum, Plasma><Risk><SIV><Simian Immunodeficiency Viruses><Site><Slow-Onset Diabetes Mellitus><Source><Stable Diabetes Mellitus><Steatonecrosis><Subcellular Process><Surgical><Surgical Interventions><Surgical Procedure><T cell infiltration><T-Cells><T-Lymphocyte><T2 DM><T2D><T2DM><Testing><Thesaurismosis><Time><Tissue Growth><Tissues><Triacylglycerol><Triglycerides><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Unhealthy Diet><Vascularization><Viral><Viral reservoir><Virus><Virus reservoir><Virus-HIV><Visceral><Wasting Disease><Wasting Syndrome><Weight Gain><Weight Increase><Weight Loss><Weight Loss Agents><Weight Reduction><Weight-Loss Drugs><adipose><adiposity><adult onset diabetes><ages><alpha-Lipoproteins><antiretroviral therapy><antiretroviral treatment><body weight gain><body weight increase><body weight loss><cardiovascular disorder><cell metabolism><cell sorting><cellular metabaolism><co-morbid><co-morbidity><comorbidity><corpulence><cytokine><developmental><diabetes><diets><drug/agent><elevated tg><elevated triglyceride><experience><functional improvement><glucagon-like peptide 1><glucagon-like peptide-1 receptor><heavy metal Pb><heavy metal lead><hepatic body system><hepatic organ system><high blood cholesterol><high triglycerides><host response><human immunodeficiency virus cure><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus patient><hypercholesterolemia><immune activation><immune cell infiltrate><immune function><immune system response><immunoresponse><improve function><improved><improved functional outcomes><improvements in QOL><improvements in quality of life><increased triglycerides><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><ketosis resistant diabetes><life span><lifespan><maturity onset diabetes><metabolic profile><metabolism disorder><model of animal><mortality><necropsy><non-alcohol fatty liver disease><non-alcoholic fatty liver disease><non-alcoholic liver disease><nonalcoholic fatty liver disease><nonhuman primate models><ontogeny><pathophysiology><patient infected with HIV><patient with HIV><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacologic><pig-tailed macaque><poor diet><postmortem><pre-clinical><preclinical><prevent><preventing><prognostic><promoter><promotor><quality of life improvement><restoration><surgery><systemic inflammation><systemic inflammatory response><thymus derived lymphocyte><type 2 DM><type II DM><type two diabetes><viral DNA><virtual><virus DNA><wasting condition><wasting disorder><western diet><western-style diet><western-type diet><white adipose tissue><wt gain><wt-loss><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bing Chen

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$752,675
FY 2026

Project Title

HIV-1 membrane fusion and inhibition

Grant Number:

5R01AI181618-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/20/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Summary Virus entry begins with the first encounter between the virus and the cell surface and ends with delivery of the contents of the virus into the host cell. HIV-1 membrane fusion is the first key delivery step, mediated by the virus-encoded envelope glycoprotein [Env; trimeric (gp160)3 cleaved...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Address><Antibodies><Binding><Binding Sites><C-C CKR-5><C-C CKR-5 Gene><C-C Chemokine Receptor Type 5><C-C Chemokine Receptor Type 5 Gene><CC Chemokine Receptor 5><CC-CKR-5><CC-CKR-5 Gene><CC-CKR5><CCCKR5><CCCKR5 Gene><CCR-5><CCR-5 Gene><CCR5><CCR5 Protein><CCR5 Receptors><CCR5 gene><CD195 Antigen><CD195 Antigen Gene><CD4 Antigens><CD4 Molecule><CD4 Protein><CD4 Receptors><CHEMR13><CHEMR13 Gene><CKR-5><CKR-5 Gene><CKR5><CKR5 Gene><CKR5 Receptors><CMKBR5><CMKBR5 Gene><COVID-19 S protein><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19 virus><CXC-R4><CXCR-4><CXCR4><CXCR4 gene><Cell Body><Cell surface><Cells><Chemokine (C-C Motif) Receptor 5><Chemokine (C-C) Receptor 5><Chemokine (C-C) Receptor 5 Gene><Chemokine Receptor Gene><Clinical Treatment Moab><CoV-2><CoV2><Combining Site><Complex><Cryo-electron Microscopy><Cryo-electron tomography><Cryoelectron Microscopy><Cytoplasmic Domain><Cytoplasmic Tail><D2S201E><Detergents><Development><Ebola><Electron Cryomicroscopy><Electron Microscopy><Env trimer><Envelope Protein><FB22><FDA approved><Future><Glycoproteins><Goals><HIV Env><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV Infections><HIV env Protein gp120><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV intervention><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 Fusion Co-Receptor><HIV-1 Fusion Co-Receptor Gene><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 intervention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV1><HM89><HSY3RR><HTLV-III gp120><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infection prevention><Influenza HA><Influenza Hemagglutinin><Intervention Strategies><LAP3><LCR1><LESTR><Length><Lipid Bilayers><Lipids><Mediating><Membrane><Membrane Fusion><Metabolic Glycosylation><Micelles><Modern Man><Molecular><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Mechanisms of Action><Molecular Stereochemistry><Monoclonal Antibodies><NPY3R><NPYR><NPYRL><NPYY3R><OKT4 antigen><Pilot Projects><Prevent infection><Process><Property><Reaction><Reactive Site><Receptor Protein><Resolution><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Structure><Surface><Surface CD4 Receptors><System><T4 molecule><TM Domain><Technology><Therapeutic><Therapeutic Agents><Transmembrane Domain><Transmembrane Region><Viral><Viral Fusion Proteins><Viral Vaccines><Virion><Virus><Virus Inhibitors><Virus Particle><Visualization><Wuhan coronavirus><chemokine receptor><conformation><conformational><conformational state><conformationally><conformations><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease-19 virus><cryo-EM><cryo-EM tomography><cryoEM><cryoEM tomography><cryoelectron tomography><cryogenic electron microscopy><design><designing><develop a vaccine><develop therapy><develop vaccines><development of a vaccine><developmental><electron cryo-tomography><electron tomography><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><flu HA><flu hemagglutinin><glycosylation><gp120><gp120 ENV Glycoprotein><gp120(HIV)><gp160><hCoV19><helper T lymphocyte marker><human immunodeficiency virus infection><improved><infected with HIV><infected with human immunodeficiency virus><influenza viral HA><influenza viral hemagglutinin><influenza virus HA><influenza virus hemagglutinin><inhibitor><insight><intervention development><lipid bilayer membrane><mAbs><membrane assembly><membrane structure><monoclonal Abs><movie><nCoV2><nanodisk><neutralizing antibody><novel><particle><pilot study><receptor><receptor binding><receptor bound><reconstitute><reconstitution><resolutions><small molecule><social role><spike proteins on SARS-CoV-2><structural biology><therapy development><treat HIV><treat Human Immunodeficiency Virus><treatment development><vaccine development><viral inhibitor>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael R Rickels

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Recent
Active award
$731,968
FY 2026

Project Title

Restoring awareness of hypoglycemia in type 1 diabetes

Grant Number:

5U01DK135120-04

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/25/2022

End Date:

12/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY / ABSTRACT This application “Restoring awareness of hypoglycemia in type 1 diabetes” proposes to elucidate the heterogeneity of impaired awareness of hypoglycemia (IAH) in type 1 diabetes through completion of a 24-month Sequential Multiple Assignment Randomized Trial (SMART) designe...

Research Terms

<21+ years old><Achievement><Achievement Attainment><Adrenaline><Adult><Adult Human><Age><Antidiabetic Hormone><Awareness><Blood Glucose><Blood Sugar><Brittle Diabetes Mellitus><Carbohydrates><Clampings><Clinical><Clinical Research><Clinical Study><Clinical Trials Design><Closure by clamp><Continuous Glucose Monitor><Defect><Defense Mechanisms><Development><Diabetes Mellitus><Disease><Disorder><Dose><Drug Therapy><Education><Education for Intervention><Educational Intervention><Educational aspects><Epinephrine><Event><Exposure to><Failure><Generations><Glucagon><Glukagon><HG-Factor><Hepatic><Heterogeneity><Humulin R><Hybrids><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><Hyperinsulinemia><Hyperinsulinism><Hypoglycemia><IDDM><Impairment><Individual><Ingestion><Instruction Intervention><Insulin><Insulin-Dependent Diabetes Mellitus><Interacinar Cell Pancreatic Polypeptide><Intervention><Islands of Langerhans Transplantation><Islands of Pancreas Transplantation><Islets of Langerhans Grafting><Islets of Langerhans Transplantation><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Life Experience><Measurement><Measures><Morbidity><Novolin R><Outcome><Pancreatic Islets Transplantation><Pancreatic Polypeptide><Participant><Patient Self-Report><Peripheral><Personalized medical approach><Pharmacological Treatment><Pharmacology><Pharmacotherapy><Physiologic><Physiological><Questionnaires><Randomized><Recommendation><Regular Insulin><Reporting><Research Design><Risk><Self-Report><Sequential Multiple Assignment Randomized Trial><Standardization><Study Type><Sudden-Onset Diabetes Mellitus><Symptoms><Syndrome><System><T1 DM><T1 diabetes><T1D><T1DM><Technology><Testing><Therapeutic><Therapeutic Epinephrine><Time><Training Intervention><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Work><adulthood><ages><autologous islet transplantation><clinical practice><continuous blood glucose monitor><continuous blood sugar monitor><continuous glucose measurement><continuous sugar monitor><counterregulation><developmental><diabetes><disease duration><disease length><drug intervention><drug treatment><experience><falls><glucose RA><glucose disposal><glucose production><glucose rate of appearance><glycemic control><hyperglycemic><hypoglycemic><hypoglycemic episodes><illness length><improved><individualized approach><ingest><instructional intervention><insulin dependent diabetes><insulin dependent type 1><insulin secretion><insulin stimulated glucose disposal><islet auto transplantation><islet beta cell transplantation><islet cell transplant><islet cell transplantation><islet transplantation><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><mortality><novel><permissiveness><personalized approach><personalized health intervention><personalized intervention><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><post-transplant><post-transplantation><posttransplant><posttransplantation><precision approach><precision interventions><psychological defense mechanism><randomisation><randomization><randomized, clinical trials><randomly assigned><response><restoration><standard of care><study design><tailored approach><technology intervention><technology platform><technology system><technology-based interventions><technology-enabled interventions><technology-focused interventions><theories><trial design><type I diabetes><type one diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sushant Bhatnagar

UNIVERSITY OF ALABAMA AT BIRMINGHAM, BIRMINGHAM, AL

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$727,752
FY 2026

Project Title

The Role of Tomosyn-1 in Regulating Insulin Secretion from Pancreatic beta-cells

Grant Number:

2R01DK120684-06A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2019

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Type 2 diabetes (T2D) affects ~10% of the US adult population, and another 84.1 million have prediabetes. The β-cell dysfunction is an early and essential event in an impaired glucose tolerant state (IGT) that leads to diabetes, including obesity-linked T2D. The formation of SNARE complexes is rate-...

Research Terms

<21+ years old><3'5'-cyclic ester of AMP><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Assay><Beta Cell><Binding><Binding Proteins><Bioassay><Biochemical><Biological Assay><Blood Glucose><Blood Plasma><Blood Sugar><Cell Communication and Signaling><Cell Function><Cell Line><Cell Physiology><Cell Process><Cell Signaling><Cell membrane><CellLine><Cellular Function><Cellular Physiology><Cellular Process><Competence><Complex><Coupled><Cues><Cyclic AMP><Cyclic AMP-Dependent Protein Kinases><Cytoplasmic Membrane><D-Glucose><Dextrose><Diabetes Mellitus><Disease><Disorder><Dysfunction><E3 Ligase><E3 Ubiquitin Ligase><Event><Exhibits><Exocytosis><Functional disorder><GLP-1><Genetics-Mutagenesis><Glp-1><Glucose><Goals><High Fat Diet><Human><Humulin R><Image><Impairment><Insulin><Insulin Antagonists><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out Mice><Knockout Mice><Knowledge><Leanness><Ligand Binding Protein><Ligand Binding Protein Gene><Link><Maturity-Onset Diabetes Mellitus><Mediating><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metabolic><Metabolic Clearance Rate><Metabolic Protein Degradation><Methods><Mice><Mice Mammals><Mission><Modern Man><Molecular><Molecular Interaction><Molecular Target><Murine><Mus><Mutagenesis><Mutagenesis Molecular Biology><NIDDM><NIH><NSF attachment protein><NSF attachment protein receptor><National Institutes of Health><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Null Mouse><Nutritional><Obese Mice><Obesity><Outcome><PKA><Pancreatic beta Cell><Pancreatic β-Cell><Persons><Phase><Phosphorylation><Phosphorylation Site><Physiologic><Physiological><Physiology><Physiopathology><Plasma><Plasma Membrane><Plasma Serum><Population><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Pre-DM><Prediabetes><Prediabetes syndrome><Prediabetic State><Predisposition><Protein Binding><Protein Kinase A><Protein Modification><Protein Phosphorylation><Protein Turnover><Proteins><Public Health><Regular Insulin><Regulation><Regulatory Protein Degradation><Reticuloendothelial System, Serum, Plasma><Role><SNAP receptor><SNARE><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulus><Strains Cell Lines><Structure of beta Cell of islet><Subcellular Process><Surface Proteins><Susceptibility><T2 DM><T2D><T2DM><Testing><Therapeutic><Thinness><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><United States><United States National Institutes of Health><adenosine 3'5' monophosphate><adiposity><adult onset diabetes><adulthood><attenuated insulin secretion><biological signal transduction><blood glucose regulation><blunted insulin secretion><bound protein><cAMP><cAMP-Dependent Protein Kinases><clearance rate><compare to control><comparison control><corpulence><cultured cell line><decreased insulin release><decreased insulin secretion><defective insulin secretion><diabetes><diet-associated obesity><diet-induced obesity><diet-related obesity><diminished insulin release><diminished insulin secretion><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose regulation><glucose tolerance><hormonal regulation><hormone regulation><imaging><impaired glucose tolerance><impaired insulin release><impaired insulin secretion><improved><inadequate insulin release><inadequate insulin secretion><inhibitor><insight><insulin granule><insulin inhibitor><insulin secretion><insulin sensitivity><islet><ketosis resistant diabetes><knock-down><knockdown><lowered insulin secretion><maturity onset diabetes><mouse model><murine model><non-diabetic><nondiabetic><nutritious><ob/ob mouse><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathophysiology><plasmalemma><pre-diabetes><pre-diabetic><prediabetic><prevent><preventing><protein degradation><recruit><reduced insulin release><response><secretion process><social role><soluble N-ethylmaleimide-sensitive factor attachment protein><soluble N-ethylmaleimide-sensitive fusion attachment protein><soluble N-ethylmaleimide-sensitive-factor attachment protein receptor><soluble NSF attachment protein><suppressed insulin release><suppressed insulin secretion><synaptotagmin><syntaxin><type 2 DM><type II DM><type two diabetes><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amy Christine Arnold

PENNSYLVANIA STATE UNIV HERSHEY MED CTR, HERSHEY, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$706,467
FY 2026

Project Title

Angiotensin-(1-7) and Cardiovascular Derangements in Obesity Hypertension

Grant Number:

5R01HL170140-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Obesity is a global epidemic that is associated with sympathetic overactivation, endothelial dysfunction, and insulin resistance; all of which can contribute to hypertension development. Despite well-established clinical associations, the mechanisms connecting obesity with hypertensi...

Research Terms

<Acute><Address><Ang I (1-7)><Angiotensins><Animal Model><Animal Models and Related Studies><Anti-Hypertensive Agents><Anti-Hypertensive Drugs><Anti-Hypertensives><Area><BP reduction><Blood Pressure><Blood Vessels><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Catecholamines><Causality><Chronic><Clampings><Clinical><Clinical Data><Closure by clamp><Cross-Over Studies><Crossover Studies><Data><Development><Diameter><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Echography><Echotomography><Endocrine Gland Secretion><Endogenous Nitrate Vasodilator><Endothelium><Endothelium-Derived Nitric Oxide><Epidemic><Etiology><Euglycemic Clamping><Euglycemic-hyperinsulinemic Clamp><Glucose Clamp><Health><Heart Vascular><Hormones><Human><Humulin R><Hyperinsulinemic Clamp><Hypertension><Hypotensive Agent><Hypotensive Drugs><Individual><Infusion><Infusion procedures><Insulin><Insulin Resistance><Intravenous><Knowledge><Laboratories><Measures><Mediating><Medical Ultrasound><Metabolic><Methods><Modeling><Modern Man><Mononitrogen Monoxide><Muscle><Muscle Tissue><Nerve><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><Novolin R><Obese Mice><Obesity><Obesity Related Hypertension><Organ><Outcome><Patients><Physiologic><Physiological><Placebo Control><Pure Autonomic Failures><Randomized><Regular Insulin><Renin-Angiotensin System><Research><Risk><Rodent Model><Role><Sympathins><Testing><Therapeutic><Therapeutic Hormone><Ultrasonic Imaging><Ultrasonogram><Ultrasonography><Ultrasound Diagnosis><Ultrasound Medical Imaging><Ultrasound Test><Vascular Endothelium><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Vasodilatation><Vasodilation><Vasorelaxation><adiposity><angiotensin I (1-7)><angiotensin-(1-7)><anti-hypertension><blood pressure elevation><blood pressure reduction><brachial artery><cardiovascular disorder><causation><circulatory system><contrast enhanced><corpulence><developmental><diagnostic ultrasound><disease causation><elevated blood pressure><endothelial cell derived relaxing factor><endothelial dysfunction><glucose RA><glucose production><glucose rate of appearance><glucose uptake><high blood pressure><hyperpiesia><hyperpiesis><hypertensive><hypertensive disease><hypertensive disorder><improved><increase in blood pressure><increased blood pressure><infusions><innovate><innovation><innovative><insulin resistant><insulin sensitivity><insulin tolerance><lower BP><lower blood pressure><lowers blood pressure><metabolic profile><model of animal><mouse model><multidisciplinary><murine model><muscular><novel><ob/ob mouse><obesity intervention><obesity therapy><obesity treatment><patient population><pharmacologic><placebo controlled><randomisation><randomization><randomly assigned><recruit><reduce BP><reduce blood pressure><reduction in BP><reduction in blood pressure><response><shear stress><social role><sonogram><sonography><sound measurement><stable isotope><tool><ultrasound imaging><ultrasound scanning><vascular>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alfredo Gamboa

PENNSYLVANIA STATE UNIV HERSHEY MED CTR, HERSHEY, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$706,467
FY 2026

Project Title

Angiotensin-(1-7) and Cardiovascular Derangements in Obesity Hypertension

Grant Number:

5R01HL170140-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Obesity is a global epidemic that is associated with sympathetic overactivation, endothelial dysfunction, and insulin resistance; all of which can contribute to hypertension development. Despite well-established clinical associations, the mechanisms connecting obesity with hypertensi...

Research Terms

<Acute><Address><Ang I (1-7)><Angiotensins><Animal Model><Animal Models and Related Studies><Anti-Hypertensive Agents><Anti-Hypertensive Drugs><Anti-Hypertensives><Area><BP reduction><Blood Pressure><Blood Vessels><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Catecholamines><Causality><Chronic><Clampings><Clinical><Clinical Data><Closure by clamp><Cross-Over Studies><Crossover Studies><Data><Development><Diameter><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Echography><Echotomography><Endocrine Gland Secretion><Endogenous Nitrate Vasodilator><Endothelium><Endothelium-Derived Nitric Oxide><Epidemic><Etiology><Euglycemic Clamping><Euglycemic-hyperinsulinemic Clamp><Glucose Clamp><Health><Heart Vascular><Hormones><Human><Humulin R><Hyperinsulinemic Clamp><Hypertension><Hypotensive Agent><Hypotensive Drugs><Individual><Infusion><Infusion procedures><Insulin><Insulin Resistance><Intravenous><Knowledge><Laboratories><Measures><Mediating><Medical Ultrasound><Metabolic><Methods><Modeling><Modern Man><Mononitrogen Monoxide><Muscle><Muscle Tissue><Nerve><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><Novolin R><Obese Mice><Obesity><Obesity Related Hypertension><Organ><Outcome><Patients><Physiologic><Physiological><Placebo Control><Pure Autonomic Failures><Randomized><Regular Insulin><Renin-Angiotensin System><Research><Risk><Rodent Model><Role><Sympathins><Testing><Therapeutic><Therapeutic Hormone><Ultrasonic Imaging><Ultrasonogram><Ultrasonography><Ultrasound Diagnosis><Ultrasound Medical Imaging><Ultrasound Test><Vascular Endothelium><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Vasodilatation><Vasodilation><Vasorelaxation><adiposity><angiotensin I (1-7)><angiotensin-(1-7)><anti-hypertension><blood pressure elevation><blood pressure reduction><brachial artery><cardiovascular disorder><causation><circulatory system><contrast enhanced><corpulence><developmental><diagnostic ultrasound><disease causation><elevated blood pressure><endothelial cell derived relaxing factor><endothelial dysfunction><glucose RA><glucose production><glucose rate of appearance><glucose uptake><high blood pressure><hyperpiesia><hyperpiesis><hypertensive><hypertensive disease><hypertensive disorder><improved><increase in blood pressure><increased blood pressure><infusions><innovate><innovation><innovative><insulin resistant><insulin sensitivity><insulin tolerance><lower BP><lower blood pressure><lowers blood pressure><metabolic profile><model of animal><mouse model><multidisciplinary><murine model><muscular><novel><ob/ob mouse><obesity intervention><obesity therapy><obesity treatment><patient population><pharmacologic><placebo controlled><randomisation><randomization><randomly assigned><recruit><reduce BP><reduce blood pressure><reduction in BP><reduction in blood pressure><response><shear stress><social role><sonogram><sonography><sound measurement><stable isotope><tool><ultrasound imaging><ultrasound scanning><vascular>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Naykky Singh Ospina

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$694,122
FY 2026

Project Title

Navigating the Uncertainties of Thyroid Cancer Risk in GLP-1RA Users

Grant Number:

1R01CA299220-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/23/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become pivotal in managing diabetes and obesity, with a prescription surge of 300% from 2020-2022, with more than half of the U.S. adult population eligible for therapy, reflecting their potential to impact patient important outcomes. Despite...

Research Terms

<21+ years old><AI based method><Address><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Adverse Experience><Adverse event><Agonist><Bayesian Analysis><Bayesian Method><Bayesian Methodology><Bayesian Statistical Method><Bayesian approaches><Bayesian classification method><Bayesian classification procedure><Bayesian computation><Bayesian inference><Bayesian network analysis><Bayesian posterior distribution><Bayesian spatial analysis><Bayesian statistical analysis><Bayesian statistical inference><Bayesian statistics><Benefits and Risks><Body Weight decreased><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Data><Data Bases><Data Set><Databases><Detection><Development><Diabetes Mellitus><Electronic Health Record><Eligibility><Eligibility Determination><Evaluation><Event><Evidence based treatment><Exposure to><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Goals><Health Benefit><Heart Vascular><Hybrids><Incidence><Individual><Investigation><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Urinary System><Knowledge><Literature><Machine Learning><Malignant Thyroid Gland Neoplasm><Malignant Tumor of the Thyroid><Malignant Tumor of the Thyroid Gland><Malignant neoplasm of thyroid><Maturity-Onset Diabetes Mellitus><Metabolic><Methodology><Methods><Modeling><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Observational Study><Outcome><Patients><Policy Maker><Population><Population Heterogeneity><Probability><Protocol Screening><Randomization trial><Randomized, Controlled Trials><Relative Risks><Reporting><Research><Residual><Residual state><Risk><Risk Estimate><Risk-Benefit Assessment><Sample Size><Series><Slow-Onset Diabetes Mellitus><Specific qualifier value><Specified><Stable Diabetes Mellitus><Statistical Methods><Structural Models><Subgroup><T2 DM><T2D><T2DM><Techniques><Thyroid Cancer><Translating><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Uncertainty><Variant><Variation><Weight><Weight Loss><Weight Reduction><active comparator><active comparison control><adiposity><adult onset diabetes><adulthood><alternative treatment><artificial intelligence method><beneficiary><body weight loss><cancer diagnosis><cancer risk><cardiovascular disorder><circulatory system><clinical care><corpulence><data base><data collected in real world><design><designing><developmental><diabetes><diabetes management><diabetes mellitus management><diabetic management><diverse populations><doubt><effective therapy><effective treatment><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><evidence base><experiment><experimental research><experimental study><experiments><glucagon-like peptide 1><glucagon-like peptide-1 receptor><heterogeneous population><high dimensionality><high risk><high risk group><high risk individual><high risk people><high risk population><insight><ketosis resistant diabetes><machine based learning><maturity onset diabetes><model-based simulation><models and simulation><multidisciplinary><novel><observational research study><observational survey><population diversity><post-market><prevent><preventing><public health relevance><randomized control trial><randomized trial><real world data><renal><simulation><statistic methods><trend><type 2 DM><type II DM><type two diabetes><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Muhammad Abdul-Ghani

UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, SAN ANTONIO, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$684,914
FY 2026

Project Title

Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes

Grant Number:

5R01DK097554-13

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/21/2012

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract The current ADA/EASD recommendation for glucose control in newly diagnosed T2DM patients who are free from CVD and renal disease is to start on metformin and sequentially add other glucose lowering agents upon metformin failure to maintain HbA1c <7.0%. The recently completed...

Research Terms

<Active Follow-up><Adipocytes><Adipose Cell><Adult-Onset Diabetes Mellitus><Agonist><Applications Grants><Benchmarking><Best Practice Analysis><Beta Cell><Body Weight decreased><Body fat><Bone Density><Bone Mineral Density><Causality><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Chemosensitization><Chemosensitization/Potentiation><Clinical><Combined Modality Therapy><Complex><D-Glucose><Data><Defect><Development><Dextrose><Diabetes Mellitus><Dimethylbiguanidine><Dimethylguanylguanidine><Drugs><Etiology><Ex4 peptide><Exendin 4><Failure><Fat Cells><Fats><Fatty acid glycerol esters><GIP receptor><GLP-1><Glimepiride><Glp-1><Glucose><Glucose Plasma Concentration><Glucose-Dependent Insulinotropic Polypeptide><Glycohemoglobin A><Glycosylated hemoglobin A><Goals><Grant Proposals><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Hemoglobin A(1)><Humulin R><Hyperglycemia><Insulin><Insulin Cell><Insulin Secreting Cell><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Urinary System><Lipocytes><Liver><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Medication><Metabolic><Metformin><Methods><Microvascular Dysfunction><Multimodal Therapy><Multimodal Treatment><Muscle><Muscle Tissue><Myocardial><N,N-dimethyl-imidodicarbonimidic diamide><NIDDM><Nephropathy><Newly Diagnosed><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Outcome Study><Patients><Pharmaceutical Preparations><Pioglitazone><Post-Menopause><Post-menopausal Period><Postmenopausal Period><Postmenopause><Potentiation><Randomized><Receptor Gene><Recommendation><Regimen><Regular Insulin><Renal Disease><Risk><Risk Reduction><Role><Skeletal Muscle><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Subcellular Process><Sulfonylurea Compounds><T2 DM><T2D><T2DM><Testing><Therapeutic><Time><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Voluntary Muscle><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Woman><active followup><adult onset diabetes><after menopause><benchmark><blood glucose regulation><body weight gain><body weight increase><body weight loss><causation><combination therapy><combined modality treatment><combined treatment><comparable efficacy><comparative effectiveness><comparative effectiveness study><comparative efficacy><compare efficacy><conventional therapy><conventional treatment><determine efficacy><developmental><diabetes><diabetic patient><disease causation><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy study><efficacy testing><evaluate efficacy><examine efficacy><exenatide><follow up><follow-up><followed up><following menopause><followup><gastric inhibitory polypeptide receptor><glargine><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose regulation><glucose-dependent insulinotropic polypeptide receptor><hemoglobin A1c><hepatic body system><hepatic organ system><hyperglycemic><improved><insulin secretion><insulin sensitivity><intervention algorithm><ketosis resistant diabetes><kidney disorder><liraglutide><maturity onset diabetes><microvascular complications><microvascular disease><multi-modal therapy><multi-modal treatment><muscular><past menopause><post-menopausal><postmenopausal><postmenopausal status><prevent><preventing><primary outcome><protective effect><randomisation><randomization><randomly assigned><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><renal><renal disorder><risk-reducing><secondary outcome><small vessel disease><social role><standard of care><sulfonylurea><therapeutic algorithm><therapy algorithm><treatment algorithm><type 2 DM><type II DM><type two diabetes><wt gain><wt-loss><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Isin Cakir

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$664,240
FY 2026

Project Title

Epigenetic Regulation of Hypothalamic Energy Homeostasis

Grant Number:

1R01DK145725-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/18/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The regulation of body weight and food intake are under tight control by the hypothalamic circuits in the central nervous system. Perturbations leading to weight gain or loss is usually countered by these circuits to keep body weight within homeostatic limits, a process that is dysregulated in diet ...

Research Terms

<Agonist><Arcuate Nucleus><Area><Autoregulation><Biology><Body Tissues><Body Weight><Body Weight decreased><Brain><Brain Nervous System><CNS Nervous System><Caloric Restriction><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Central Nervous System><Chemicals><Collaborations><Cues><Data><EC 2.1.1><ESET><Eating><Encephalon><Endocrine Gland Secretion><Energy Expenditure><Energy Metabolism><Enzyme Gene><Enzyme Tests><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Expression Signature><Fasting><Feeding behaviors><Food Intake><GLP-1><Gene Expression Profile><Gene Pool><Gene Transcription><Genes><Genetic Transcription><Genome><Glia><Glial Cells><Glp-1><Glutamates><Health><Histone H3><Histones><History><Homeostasis><Hormonal><Hormones><Human><Hunger><Hypothalamic structure><Hypothalamus><Infundibular Nucleus><Ingestive Behavior><Intracellular Communication and Signaling><Joints><KG1T><KIAA0067><Kolliker's reticulum><L-Glutamate><L-Lysine><Leanness><Leptin><Lysine><Maintenance><Maps><Mediating><Memory><Metabolic><Methods><Methylation><Methyltransferase><Mice><Mice Mammals><Modern Man><Modification><Molecular><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuraxis><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroglia><Neuroglial Cells><Neurons><Non-neuronal cell><Nonneuronal cell><Nutrient><Nutritional><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Mice><Obese Protein><Obesity><Physiological Homeostasis><Population><Process><RNA Expression><Recording of previous events><Regulation><Resolution><Risk><Rodent><Rodentia><Rodents Mammals><Role><SETDB1><SETDB1 gene><Signal Transduction><Signal Transduction Systems><Signaling><Structure of nucleus infundibularis hypothalami><Target Populations><Testing><Therapeutic Hormone><Thinness><Tissues><Transcription><Weight><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Weight maintenance regimen><adiposity><biological signal transduction><body weight gain><body weight increase><body weight loss><calorie restriction><cell type><chromatin modification><co-morbid><co-morbidity><comorbidity><corpulence><design><designing><diet-associated obesity><diet-induced obesity><diet-related obesity><energy balance><epigenetic biomarker><epigenetic marker><epigenetic regulation><epigenetically><epigenome><experience><fasted><fasts><feeding><feeding-related behaviors><gene expression pattern><gene expression signature><genetic approach><genetic strategy><ghrelin><global gene expression><global transcription profile><glucagon-like peptide 1><glutamatergic><histone H3 methyltransferase><histone demethylase><histone methylase><histone methylation><histone methyltransferase><histories><hypothalamic><knock-down><knockdown><member><methylase><nerve cement><neuronal><novel><nutrient intake activity><nutritious><ob/ob mouse><obesigenic><obesity management><obesogenic><public health relevance><resolutions><response><social role><transcriptional profile><transcriptional signature><transcriptome><transcriptome profiling><transcriptomic profiling><transcriptomics><transmethylase><weight control><weight maintenance><weight management><weights><wt gain><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hongyan Guo

LOUISIANA STATE UNIV HSC SHREVEPORT, SHREVEPORT, LA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$660,723
FY 2026

Project Title

The role of ZBP1 in controlling HSV-1 pathogenesis

Grant Number:

1R01AI189875-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Herpes simplex virus type 1 (HSV-1) is a highly prevalent human pathogen with worldwide prevalence levels of about 67%. The outcome of infection with HSV-1 can be asymptomatic, mild, or life-threatening. Our previous work has shown that HSV-1 activates Z-form nucleic acid Binding Pro...

Research Terms

<(TNF)-α><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Gene Caspase 8><Apoptotic Cysteine Protease Gene><Apoptotic Protease MCH-5 Gene><Biology><Body Tissues><Brain Inflammation><CAP4><CAP4 protease><CASP8><CASP8 Protein><CASP8 gene><Cachectin><Cachectin Receptors><Caspase-8 Gene><Caspase-8/Flice><Cell Body><Cell Communication and Signaling><Cell Death><Cell Death Signaling><Cell Death Signaling Process><Cell Signaling><Cells><Cessation of life><Cold Sore><DKFZp547I0610><DKFZp564I0682><Death><Dermatitis><Disease><Disorder><Double-Stranded DNA><Double-Stranded RNA><Eczema Herpeticum><Encephalitis><FADD-Homologous ICE/CED3-Like Protease Gene><FADD-Like ICE><FADD-Like ICE Gene><FADD-homologous ICE/CED3-Like Protease><FLICE><FLICE protein><Fever Blister><Gene Transcription><Generations><Genetic Transcription><Glues><HSV><HSV encephalitis><HSV stromal keratitis><HSV-1><HSV1><Herpes Labialis><Herpes Simplex Encephalitis><Herpes Simplex Type 1><Herpes Simplex Virus><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes encephalitis><Herpes labialis Virus><Herpes stromal keratitis><Herpesvirus 1><Herpetic Encephalitis><Herpetic Stomatitis><Host Defense><Human><ICE-Like Apoptotic Protease 5 Gene><Infection><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><Innate Immune Response><Intracellular Communication and Signaling><KIAA0012><Kinases><Labial Herpes Simplex><Laboratories><Left><Left-Handed DNA><Life><Ligands><MACH protein><MACH-Alpha-1/2/3 Protein Gene><MACH-Beta-1/2/3/4 Protein Gene><MCH5><MCH5 Isoform Alpha Gene><MORT1-Associated CED-3 Homolog Gene><MORT1-Associated CED3 Homolog Gene><Macrophage-Derived TNF><Maps><Mch5 protease><Mediating><Meningitis><Mice><Mice Mammals><Modeling><Modern Man><Monocyte-Derived TNF><Murine><Mus><Nature><Non-Polyadenylated RNA><Nucleic Acids><Oral Herpes Simplex><Organoids><Orthomyxovirus Type A><Outcome><Pathogenesis><Pathology><Pathway interactions><Phosphotransferase Gene><Phosphotransferases><Prevalence><Process><Production><Programmed Cell Death><Protein Kinase Interaction><Proteins><RIP1><RIPK1><RIPK1 gene><RNA><RNA Expression><RNA Gene Products><Receptor Protein><Receptor-Interacting Protein><Receptor-Interacting Serine/Threonine Kinase 1><Regulation><Reporting><Ribonucleic Acid><Role><Route><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Simplexvirus><Skin><Source><TLR1><TLR1 gene><TLR1 protein><TLR1 receptor><TLR3><TLR3 gene><TNF><TNF A><TNF Alpha><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNF gene><TNF-α><TNFA><TNFR><TNFα><Testing><Tissues><Toll-Like Receptor 1><Toll-Like Receptor 3><Toll/Interleukin-1 Receptor-Like><Transcription><Transphosphorylases><Tumor Necrosis Factor><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Tumor Necrosis Factor-alpha><Type A Influenza><Vaccines><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Pathogenesis><Viral Proteins><Virus><Virus Diseases><Work><Z-DNA><Z-Form DNA><adapter protein><adaptive immune response><biological signal transduction><caspase-8><cell type><combat><ds-DNA><dsDNA><dsRNA><herpes febrilis><herpes simplex i><herpes simplex virus 1 encephalitis><herpes simplex virus encephalitis><herpes simplex-1><herpetic stromal keratitis><human pathogen><in vivo><insight><intraoral herpes simplex infection><intraoral hsv infection><mouse model><murine model><necrocytosis><neonate><nucleic acid binding protein><oral HSV><oral herpes><oral mucosal herpes><pathway><receptor><recruit><rsc786><social role><viral infection><virus infection><virus pathogenesis><virus protein><virus-induced disease><zDNA>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michelle E Kimple

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$648,973
FY 2026

Project Title

The role of G protein-dependent and -independent EP3 signaling in beta-cell compensation and diabetes

Grant Number:

5R01DK137505-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/18/2024

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

SUMMARY/ABSTRACT: Diabetes is a costly and complex chronic illness and a serious public health problem. The number of individuals with diabetes, particularly obesity-linked type 2 diabetes (T2D), is certain to increase over the next decades. Shockingly, the children of today have an estimated overal...

Research Terms

<0-11 years old><3'5'-cyclic ester of AMP><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adult-Onset Diabetes Mellitus><Agonist><Arachidonic Acids><Area><Assay><Beta Cell><Binding><Bioassay><Biochemical><Biological Assay><Blood Circulation><Blood Glucose><Blood Sugar><Bloodstream><Body Tissues><Caring><Cell Body><Cell Communication and Signaling><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Cellular biology><Child><Child Youth><Children (0-21)><Chronic><Chronic Disease><Chronic Illness><Clinical><Compensation><Complex><Confocal Microscopy><Critical Paths><Critical Pathways><Cyclic AMP><D-Glucose><Data><Dextrose><Diabetes Mellitus><Diabetes prevention><Diabetic mouse><Dinoprostone><Drugs><Dysfunction><Endocrine Gland Secretion><Enzyme Gene><Enzymes><Failure><Foundations><Functional disorder><Future><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein alpha Subunit><G-Protein α Subunit><G-Protein-Coupled Receptors><G-Proteins><GDP Dissociation Factor><GDP Dissociation Stimulators><GDP Exchange Factors><GDP-GTP Exchange Protein><GDP-GTP Reversing Factors><GLP-1><GLP-1 receptor><GLP-I receptor><GPCR><GTP GDP exchange factor><GTP-Binding Protein alpha Subunits><GTP-Binding Protein α Subunits><GTP-Binding Proteins><GTP-Regulatory Proteins><Glp-1><Glucose><Goals><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Exchange Factors><Guanine Nucleotide Exchange Protein><Guanine Nucleotide Regulatory Proteins><Guanine Nucleotide Releasing Factors><Guanyl-Nucleotide Exchange Factor><Guanyl-Nucleotide Releasing Factor><Health><Hormones><Human><Humulin R><Image><Individual><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Leanness><Link><Maturity-Onset Diabetes Mellitus><Measurement><Medication><Membrane><Metabolic><Methods><Mice><Mice Mammals><Microscopy><Modern Man><Molecular><Molecular Interaction><Monomeric G-Proteins><Monomeric GTP-Binding Proteins><Murine><Mus><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Obese Mice><Obesity><Organ Donor><PGE2><PGE2 alpha><PGE2alpha><Pancreas><Pancreatic><Pancreatic beta Cell><Pancreatic β-Cell><Pathway interactions><Patients><Pharmaceutical Preparations><Phosphorylation><Physiopathology><Play><Preventive><Production><Proliferating><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Prostaglandins><Prostanoids><Protein Phosphorylation><Proteomics><Public Health><Publishing><Qualifying><Receptor Protein><Regular Insulin><Research><Rodent><Rodentia><Rodents Mammals><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Slow-Onset Diabetes Mellitus><Small G-Proteins><Small GTPases><Stable Diabetes Mellitus><Structure of beta Cell of islet><Subcellular Process><T2 DM><T2D><T2DM><Techniques><Testing><Therapeutic><Therapeutic Hormone><Thinness><Time><Tissues><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Variant><Variation><Visualization><Work><adenosine 3'5' monophosphate><adiposity><adult onset diabetes><biological signal transduction><cAMP><cell biology><cell imaging><cellular imaging><cellular targeting><chronic disorder><corpulence><cost><diabetes><diabetes mellitus therapy><diabetes mouse model><diabetes therapy><drug/agent><exchange factor><functional loss><glucagon-like peptide 1><glucagon-like peptide-1 receptor><healthspan><healthy life span><imaging><improved><innovate><innovation><innovative><insulin secretion><islet><ketosis resistant diabetes><kids><life-time risk><lifetime risk><maturity onset diabetes><membrane structure><metabolism measurement><metabolome><metabolomics><metabonome><metabonomics><mutant><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><non-diabetic><nondiabetic><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapy target><ob/ob mouse><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathophysiology><pathway><preservation><prevent><preventing><programs><receptor><response><sensor><social role><type 2 DM><type II DM><type two diabetes><youngster><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bart C DE JONGHE

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$639,550
FY 2026

Project Title

Neural Mechanisms of Nausea, Vomiting, and Energy Dysregulation

Grant Number:

5R01DK112812-09

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2017

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Nausea and vomiting promote mammalian survival. Paradoxically, emetic “side effects” are ubiquitously reported for FDA-approved pharmacotherapeutics for obesity, diabetes, and cancer pharmacotherapies and present alongside polymorbidities that contribute to detrimental life-threateni...

Research Terms

<Address><Adverse Experience><Adverse event><Agonist><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Animals><Anti-emetics><Antiemetic Effect><Area Postrema><Attenuated><Award><Behavior><Behavioral><Body Weight decreased><CDDP><Cachectic><Cachexia><Cancers><Cell Body><Cell Nucleus><Cells><Chronic><Chronic Disease><Chronic Illness><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Clinical Trials><Common Rat Strains><Complex><Cysplatyna><D-Glucose><Data><Dextrose><Diabetes Mellitus><Dichlorodiammineplatinum><Dorsal><Drug Side Effects><Drug Therapy><Drugs><Emesis><Emetic Agents><Emetic Drugs><Emetics><Ensure><Exhibits><FDA approved><Feeding behaviors><Ferrets><GABA Receptor><GIP receptor><GLP-1><Gastric Inhibitory Polypeptide><Gene Transcription><Genetic Transcription><Glp-1><Glucose><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Glucose-Dependent Insulinotropic Polypeptide><Health Care><Heterogeneity><Hind Brain><Ingestive Behavior><Intestinal><Intestines><Investigation><Life><Ligands><Malaise><Malignant Neoplasms><Malignant Tumor><Mediating><Medical><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Mice><Mice Mammals><Modernization><Molecular><Murine><Mus><NK-1 Receptors><NK1R><NKIR><Nausea><Nausea and Vomiting><Nausea and Vomiting Therapy><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroendocrine><Neuroendocrine System><Neurokinin-1 Receptors><Neurons><Neurosecretory Systems><Nucleus><Nutrition><Obesity><Outcome><Pancreatic beta Cell><Pancreatic β-Cell><Patients><Peyrone's Chloride><Peyrone's Salt><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiology><Platinum Diamminodichloride><Play><Population><Pre-Clinical Model><Preclinical Models><Publications><Publishing><QOL><Quality of life><RNA Expression><Rat><Rats Mammals><Rattus><Receptor Activation><Receptor Signaling><Reporting><Rhombencephalon><Role><SP-P Receptors><Scientific Publication><Shrews><Stimulus><Structure of area postrema><Structure of beta Cell of islet><Substance P Receptor><System><TAC1R><TACR1><TACR1 gene><Tachykinin Receptor 1><Testing><Therapeutic><Thesaurismosis><Transcription><Vomiting><Weight Loss><Weight Reduction><Work><adiposity><analog><antagonism><antagonist><anti-emetic agents><anti-emetic drugs><anti-emetic effect><anti-emetic support><antiemetic support><attenuate><attenuates><attenuation><behavioral pharmacology><body weight loss><bowel><chemotherapy><chronic disorder><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><clinical relevance><clinically relevant><co-morbid><co-morbidity><comorbidity><comparative><corpulence><debilitating symptom><diabetes><drug intervention><drug treatment><drug/agent><feeding-related behaviors><gamma-Aminobutyric Acid Receptors><gastric inhibitory peptide><gastric inhibitory polypeptide receptor><gastrointestinal><glucagon-like peptide 1><glucose-dependent insulinotropic polypeptide receptor><glycemic control><hindbrain><improved><malignancy><metabolism disorder><model of animal><neoplasm/cancer><neural><neural mechanism><neurogenetics><neuromechanism><neuronal><novel><nutrient intake activity><pancreas beta cell><pancreas β cell><pancreatic b-cell><patient prognosis><pharmaceutical intervention><pharmacobehavioral><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><prevent><preventing><response><side effect><social role><transcriptomics><virtual><vomiting and nausea management><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MATTHEW R HAYES

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$639,550
FY 2026

Project Title

Neural Mechanisms of Nausea, Vomiting, and Energy Dysregulation

Grant Number:

5R01DK112812-09

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2017

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Nausea and vomiting promote mammalian survival. Paradoxically, emetic “side effects” are ubiquitously reported for FDA-approved pharmacotherapeutics for obesity, diabetes, and cancer pharmacotherapies and present alongside polymorbidities that contribute to detrimental life-threateni...

Research Terms

<Address><Adverse Experience><Adverse event><Agonist><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Animals><Anti-emetics><Antiemetic Effect><Area Postrema><Attenuated><Award><Behavior><Behavioral><Body Weight decreased><CDDP><Cachectic><Cachexia><Cancers><Cell Body><Cell Nucleus><Cells><Chronic><Chronic Disease><Chronic Illness><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Clinical Trials><Common Rat Strains><Complex><Cysplatyna><D-Glucose><Data><Dextrose><Diabetes Mellitus><Dichlorodiammineplatinum><Dorsal><Drug Side Effects><Drug Therapy><Drugs><Emesis><Emetic Agents><Emetic Drugs><Emetics><Ensure><Exhibits><FDA approved><Feeding behaviors><Ferrets><GABA Receptor><GIP receptor><GLP-1><Gastric Inhibitory Polypeptide><Gene Transcription><Genetic Transcription><Glp-1><Glucose><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Glucose-Dependent Insulinotropic Polypeptide><Health Care><Heterogeneity><Hind Brain><Ingestive Behavior><Intestinal><Intestines><Investigation><Life><Ligands><Malaise><Malignant Neoplasms><Malignant Tumor><Mediating><Medical><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Mice><Mice Mammals><Modernization><Molecular><Murine><Mus><NK-1 Receptors><NK1R><NKIR><Nausea><Nausea and Vomiting><Nausea and Vomiting Therapy><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neuroendocrine><Neuroendocrine System><Neurokinin-1 Receptors><Neurons><Neurosecretory Systems><Nucleus><Nutrition><Obesity><Outcome><Pancreatic beta Cell><Pancreatic β-Cell><Patients><Peyrone's Chloride><Peyrone's Salt><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiology><Platinum Diamminodichloride><Play><Population><Pre-Clinical Model><Preclinical Models><Publications><Publishing><QOL><Quality of life><RNA Expression><Rat><Rats Mammals><Rattus><Receptor Activation><Receptor Signaling><Reporting><Rhombencephalon><Role><SP-P Receptors><Scientific Publication><Shrews><Stimulus><Structure of area postrema><Structure of beta Cell of islet><Substance P Receptor><System><TAC1R><TACR1><TACR1 gene><Tachykinin Receptor 1><Testing><Therapeutic><Thesaurismosis><Transcription><Vomiting><Weight Loss><Weight Reduction><Work><adiposity><analog><antagonism><antagonist><anti-emetic agents><anti-emetic drugs><anti-emetic effect><anti-emetic support><antiemetic support><attenuate><attenuates><attenuation><behavioral pharmacology><body weight loss><bowel><chemotherapy><chronic disorder><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><clinical relevance><clinically relevant><co-morbid><co-morbidity><comorbidity><comparative><corpulence><debilitating symptom><diabetes><drug intervention><drug treatment><drug/agent><feeding-related behaviors><gamma-Aminobutyric Acid Receptors><gastric inhibitory peptide><gastric inhibitory polypeptide receptor><gastrointestinal><glucagon-like peptide 1><glucose-dependent insulinotropic polypeptide receptor><glycemic control><hindbrain><improved><malignancy><metabolism disorder><model of animal><neoplasm/cancer><neural><neural mechanism><neurogenetics><neuromechanism><neuronal><novel><nutrient intake activity><pancreas beta cell><pancreas β cell><pancreatic b-cell><patient prognosis><pharmaceutical intervention><pharmacobehavioral><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><prevent><preventing><response><side effect><social role><transcriptomics><virtual><vomiting and nausea management><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Diego V Bohorquez

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$637,471
FY 2026

Project Title

A gut sense for dietary lysine

Grant Number:

1R01DK143462-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

1/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

SUMMARY As an essential amino acid, lysine is necessary for life. Accordingly, when exposed to a lysine-deficient diet, animals will seek out dietary lysine1. However, when animals are lysine-replete, lysine administration is a powerful inhibitor of overall food intake2. Despite this fine-tuned regu...

Research Terms

<5-HT><5-Hydroxytryptamine><5HT><Affect><Affinity><Amino Acids><Animals><Autoregulation><Basic Amino Acid Transport Proteins><Basic Amino Acid Transport Systems><Basic Fibroblast Growth Factor><Basic Fibroblast Growth Factor Gene><Behavior><Biology><Brain><Brain Nervous System><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Carrier Proteins><Cas nuclease technology><Cationic Amino Acid Transport Proteins><Cationic Amino Acid Transport Systems><Cationic Amino Acid Transporters><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cessation of life><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Consumption><Cranial Nerve X><Data><Death><Detection><Diet><Dietary Proteins><Duodenum><Eating><Eating Behavior><Encephalon><Enteramine><Equilibrium><Essential Amino Acids><Esthesia><Exposure to><FGF-2><FGF2><FGF2 gene><FGFB><Feeding behaviors><Fibroblast Growth Factor 2><Fibroblast Growth Factor 2 Gene><Food Intake><Food Preferences><Foundations><Future><GLP-1><Generalized Growth><Genes><Gestation><Glp-1><Glutamates><Goals><Growth><Gut Epithelium><HBGF-2><Heparin-Binding Growth Factor 2><Heparin-Binding Growth Factor Class II><Hippophaine><Homeostasis><Impairment><Ingestion><Ingestive Behavior><Intestinal><Intestines><Intracellular Communication and Signaling><KO mice><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Knowledge><L-Glutamate><L-Lysine><Laboratories><Lesion><Life><Link><Lysine><Macronutrients><Macronutrients Nutrition><Malnutrition><Mediating><Membrane Transport Proteins><Membrane Transporters><Metabolic><Mice><Mice Mammals><Modeling><Murine><Mus><Nerve><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Neuroendocrine><Neuroendocrine System><Neuronal Transmission><Neurosecretory Systems><Neurotransmitters><Null Mouse><Nutrient><Nutritional><Nutritional Deficiency><Obesity><Organoids><Partner in relationship><Physiologic><Physiological><Physiological Homeostasis><Pneumogastric Nerve><Pregnancy><Prostate Epithelial Cell Growth Factor><Protein Biosynthesis><Protein Deficiency><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><Receptor Protein><Regulation><Research><Research Grants><Research Project Grants><Research Projects><Rewards><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Sensation><Sensory><Serotonin><Signal Pathway><Signal Transduction><Signal Transduction Pathway><Signal Transduction Systems><Signaling><Site><Specialized Epithelial Cell><Strains Cell Lines><Synapses><Synaptic><Taste Buds><Tenth Cranial Nerve><Testing><Therapeutic><Tissue Growth><Transcript><Transport Protein Gene><Transport Proteins><Transporter Protein><Undernutrition><Vagus Nerve><Vagus nerve structure><Weaning><Wild Type Mouse><Work><adiposity><afferent nerve><aminoacid><axon signaling><axon-glial signaling><axonal signaling><bFGF><balance><balance function><behavior change><behavior phenotype><behavioral phenotyping><biological signal transduction><body sense><bowel><corpulence><cultured cell line><deficiency of protein><diet choice><diet preference><dietary><dietary choice><dietary deficiency><dietary preferences><diets><experience><experiment><experimental research><experimental study><experiments><feeding-related behaviors><food Ingestion><food choice><food consumption><gastrointestinal epithelium><glia signaling><glial signaling><glucagon-like peptide 1><glutamatergic><gut to brain axis><gut-brain axis><gut-brain communication><gut-brain interactions><gut-brain relationship><gut-brain signaling><ingest><inhibitor><intestinal epithelium><malnourished><mate><nerve signaling><neural circuit><neural circuitry><neural signaling><neurocircuitry><neuronal signaling><neurotransmission><new approaches><novel approaches><novel strategies><novel strategy><nutrient intake activity><nutrition deficiency><nutrition deficiency disorder><nutritional deficiency disorder><nutritious><ontogeny><optogenetics><preference><preservation><prevent><preventing><protein intake><protein synthesis><receptor><response><sensory nerve><sugar><synapse><synaptic circuit><synaptic circuitry><taste receptor><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Samuel Klein

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$627,620
FY 2026

Project Title

EFFICACY AND SAFETY OF A KETOGENIC DIET IN TYPE 1 DIABETES

Grant Number:

5R01DK137837-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells that causes dependence on exogenous insulin. Despite remarkable advances in diabetes device technology, less than 25% of adults with T1D achieve the recommended HbA1c target of <7.0%. Moreover, subcutaneous deliver...

Research Terms

<(TNF)-α><0-11 years old><21+ years old><Acute><Address><Adherence><Adipose tissue><Adult><Adult Human><Affect><American><Antidiabetic Hormone><Apo-B><ApoB><Apolipoproteins B><Artificial Pancreas><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Behavioral><Biochemistry><Biological Chemistry><Blood Glucose><Blood Plasma><Blood Serum><Blood Sugar><Body Composition><Body Weight><Bone 4-Carboxyglutamic Protein><Bone Density><Bone Gla Protein><Bone Mineral Density><Bone gamma-Carboxyglutamic Acid Protein><Brittle Diabetes Mellitus><C-terminal type I collagen telopeptide><CO2><CTX><CYCLO-cell><Cachectin><Calcium><Carbohydrates><Carbon Dioxide><Carbonic Anhydride><Carloxan><Case Series><Cause of Death><Child><Child Youth><Children (0-21)><Cholesterol><Chronic><Ciclofosfamida><Ciclofosfamide><Cicloxal><Clafen><Claphene><Complications of Diabetes Mellitus><Consumption><Coxa><Creatinine><Cycloblastin><Cycloblastine><Cyclophospham><Cyclophosphamide><Cyclophosphamidum><Cyclophosphan><Cyclophosphane><Cyclophosphanum><Cyclostin><Cyclostine><Cytophosphan><Cytophosphane><Cytoxan><D-Glucose><DEXA><DXA><Dependence><Development><Devices><Dextrose><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Acidosis><Diabetic Complications><Diabetic Ketoacidosis><Diabetic Ketosis><Diet therapy><Dietary Carbohydrates><Dietitian><Dual-Energy X-Ray Absorptiometry><Dual-Energy Xray Absorptiometry><Dyslipidemias><Eating Behavior><Education><Educational aspects><Electrolytes><Endoxan><Endoxana><Enduxan><Euglycemic Clamping><Euglycemic-hyperinsulinemic Clamp><Event><Evidence based practice guidelines><Fats><Fatty Tissue><Fatty acid glycerol esters><Femur><Food><Fosfaseron><Genoxal><Genuxal><Glomerular Filtration Rate><Glucagon><Glucose><Glucose Clamp><Glukagon><Glycohemoglobin A><Glycosylated hemoglobin A><HDL><HDL Lipoproteins><HG-Factor><HPGF><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Health><Heavy Lipoproteins><Hemoglobin A(1)><Hepatic><Hepatocyte-Stimulating Factor><High Density Lipoproteins><Hip><Hip region structure><Hour><Humulin R><Hybridoma Growth Factor><Hybrids><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><Hyperinsulinemia><Hyperinsulinemic Clamp><Hyperinsulinism><Hypoglycemia><IDDM><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Iatrogenesis><Impairment><Incidence><Insulin><Insulin Resistance><Insulin-Dependent Diabetes Mellitus><Intake><Interleukin-6><Interview><Intra-abdominal><Isocaloric><Juvenile-Onset Diabetes Mellitus><Ketone Bodies><Ketones><Ketosis><Ketosis-Prone Diabetes Mellitus><Knowledge><LDL><LDL Lipoproteins><Leanness><Ledoxina><Life Expectancy><Life Style><Lifestyle><Lipids><Lipoproteins><Liver><Low-Density Lipoproteins><MGI-2><Macrophage-Derived TNF><Measures><Metabolic><Methods><Mitoxan><Monitor><Monocyte-Derived TNF><Myeloid Differentiation-Inducing Protein><N-terminal><NH2-terminal><Neck><Neosar><Novolin R><Nutrition><Observational Study><Osteocalcin><PAI-1><PAI1><PLANH1><Patients><Peripheral><Persons><Plasma><Plasma Serum><Plasmacytoma Growth Factor><Plasminogen Activator Inhibitor 1><Preparation><Prevalence><Procedures><Procollagen><Procytox><QOL><Quality of life><Questionnaires><Randomized, Controlled Trials><Recommendation><Records><Regular Insulin><Renal function><Research Institute><Reticuloendothelial System, Serum, Plasma><Risk><Risk Reduction><Safety><Sendoxan><Serine or Cysteine Proteinase Inhibitor Clade E Member 1><Serum><Site><Social Behavior><Spinal Column><Spine><Sudden-Onset Diabetes Mellitus><Survey Instrument><Surveys><Syklofosfamid><System><T1 DM><T1 diabetes><T1D><T1DM><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Testing><Thinness><Time><Triacylglycerol><Triglycerides><Trioxopurine><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Type 1 Diabetes Mellitus><Type 1 Plasminogen Activator Inhibitor><Type 1 diabetes><Type I Diabetes Mellitus><United States><Universities><Uric Acid><Urine><Vertebral column><Vitamin K-Dependent Bone Protein><Vitamin K-Dependent Calcium-Binding Protein><Washington><Zytoxan><adipogenesis><adipose><adulthood><alpha-Lipoproteins><autoimmune beta cell destruction><autoimmune islet destruction><backbone><beta cell autoimmunity><beta-Lipoproteins><bone health><bone turnover><cardiometabolic><cardiometabolic risk><cardiometabolism><cardiovascular risk><cardiovascular risk factor><clinical efficacy><cost><cystatin C><determine efficacy><developmental><diabetes><diabetes distress><diabetes-related distress><diabetes-specific distress><diabetic ketoacidotic><diet adherence><diet control><dietary adherence><dietary control><dietary therapy><distress related to diabetes><distress specific to diabetes><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><evidence based guidelines><evidence based recommendations><examine efficacy><food craving><glycemic control><hemoglobin A1c><hepatic body system><hepatic organ system><hyperglycemic><hypoglycemic><hypoglycemic episodes><iatrogenic><iatrogenically><iatrogenicity><implementation outcomes><improved><improved outcome><inflammation marker><inflammatory marker><insulin dependent diabetes><insulin dependent type 1><insulin resistant><insulin sensitivity><insulin tolerance><interest><interferon beta 2><intrahepatic><islet autoimmunity><islet cell autoimmunity><juvenile diabetes><juvenile diabetes mellitus><keto diet><ketogenic diet><ketosis prone diabetes><kidney function><kids><life span><lifespan><lipid biosynthesis><lipogenesis><medical attention><medical college><medical schools><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><observational research study><observational survey><particle><post gamma-globulins><post-gamma-protein><preparations><primary outcome><randomized control trial><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><risk-reducing><safety assessment><school of medicine><social><social determinants><socio-demographic factors><sociobehavior><sociobehavioral><sociodemographic factors><sociodeterminant><subcutaneous><subdermal><type I diabetes><type one diabetes><white adipose tissue><yellow adipose tissue><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Antonio Abbate

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$626,076
FY 2026

Project Title

Prevention of heart failure with IL-1 blockade: a mechanistic study

Grant Number:

5R01AG076360-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary This application is for a Mechanistic Clinical Study (R01) entitled “Prevention of HF with IL-1 blockade: a mechanistic study” submitted by Antonio Abbate MD, PhD and Benjamin Van Tassell, PharmD. Despite improvements in early diagnosis and treatment, ST-segment elevation myocardial ...

Research Terms

<Acute><Acute myocardial infarct><Acute myocardial infarction><Affect><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Approaches to prevention><Biological Markers><Body Tissues><Boston><C-reactive protein><Cardiac><Cardiac Output><Cardiac infarction><Cardiopulmonary><Cessation of life><Clinical><Clinical Data><Clinical Research><Clinical Study><Clinical Trials><Coupled><Death><Doctor of Pharmacy><Doctor of Philosophy><Doppler Echocardiography><Doppler Study><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Dysfunction><Early Diagnosis><Early treatment><Echocardiogram><Echocardiography><Event><Exercise><Exercise Test><Fever><Functional disorder><Heart failure><Hospital Admission><Hospitalization><Hospitals><IL-1><IL-1ra><IL1><IL1 febrile inhibitor><IL1RN><Image><Impairment><Incidence><Infarction><Inflammation><Inflammation Mediators><Inflammatory><Inflammatory Response><Interleukin I><Interleukin-1><Interleukin-1 Receptor Antagonist><Intervention><Ischemia><LVEF><Left><Left Ventricular Ejection Fraction><Link><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Magnetic Resonance><Measures><Mediator><Morbidity><Muscle><Muscle Tissue><Myocardial Infarct><Myocardial Infarction><Myocardial depression><Myocardial dysfunction><Myocardium><Outcome><Oxygen Consumption><Patients><Ph.D.><PhD><Pharm.D.><PharmD><Phase 2 Clinical Trials><Phase II Clinical Trials><Physiopathology><Placebo Control><Placebos><Prevention><Prevention approach><Process><Proteins, specific or class, C-reactive><Pyrexia><QOL><Quality of Life Assessment><Quality of life><ROC Analyses><ROC Curve><Randomized><Recombinant Interleukin-1><Reperfusion Therapy><Risk><Risk Factors><Role><Sensitivity and Specificity><Sham Treatment><T Helper Factor><Testing><Time><Tissues><Translating><Transthoracic Echocardiography><Ventricular><Woman><adjudication><adjudicative process and procedure><anakinra><bio-markers><biologic marker><biomarker><cardiac depression><cardiac dysfunction><cardiac failure><cardiac function><cardiac imaging><cardiac infarct><cardiac muscle><cardiac preservation><cardiac scanning><cardiodepression><cardiorespiratory fitness><cardiorespiratory health><coronary attack><coronary infarct><coronary infarction><cytokine><early detection><early therapy><febrile><febris><function of the heart><healing><heart attack><heart dysfunction><heart function><heart imaging><heart infarct><heart infarction><heart muscle><heart output><heart preservation><heart scanning><heart sonography><imaging><improved><infarct><inflammatory mediator><injury response><insight><interleukin 1 receptor antagonist protein><lymphocyte activating factor><mortality><multidisciplinary><muscular><myocardial damage><new approaches><novel><novel approaches><novel strategies><novel strategy><pathophysiology><phase 2 study><phase II protocol><phase II study><placebo controlled><preservation><prevent><preventing><primary end point><primary endpoint><randomisation><randomization><randomly assigned><receiver operating characteristic analyses><receiver operating characteristic curve><reperfusion><response to injury><sham therapy><social role><systemic inflammation><systemic inflammatory response><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Benjamin W Van Tassell

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$626,076
FY 2026

Project Title

Prevention of heart failure with IL-1 blockade: a mechanistic study

Grant Number:

5R01AG076360-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary This application is for a Mechanistic Clinical Study (R01) entitled “Prevention of HF with IL-1 blockade: a mechanistic study” submitted by Antonio Abbate MD, PhD and Benjamin Van Tassell, PharmD. Despite improvements in early diagnosis and treatment, ST-segment elevation myocardial ...

Research Terms

<Acute><Acute myocardial infarct><Acute myocardial infarction><Affect><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Approaches to prevention><Biological Markers><Body Tissues><Boston><C-reactive protein><Cardiac><Cardiac Output><Cardiac infarction><Cardiopulmonary><Cessation of life><Clinical><Clinical Data><Clinical Research><Clinical Study><Clinical Trials><Coupled><Death><Doctor of Pharmacy><Doctor of Philosophy><Doppler Echocardiography><Doppler Study><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Dysfunction><Early Diagnosis><Early treatment><Echocardiogram><Echocardiography><Event><Exercise><Exercise Test><Fever><Functional disorder><Heart failure><Hospital Admission><Hospitalization><Hospitals><IL-1><IL-1ra><IL1><IL1 febrile inhibitor><IL1RN><Image><Impairment><Incidence><Infarction><Inflammation><Inflammation Mediators><Inflammatory><Inflammatory Response><Interleukin I><Interleukin-1><Interleukin-1 Receptor Antagonist><Intervention><Ischemia><LVEF><Left><Left Ventricular Ejection Fraction><Link><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Magnetic Resonance><Measures><Mediator><Morbidity><Muscle><Muscle Tissue><Myocardial Infarct><Myocardial Infarction><Myocardial depression><Myocardial dysfunction><Myocardium><Outcome><Oxygen Consumption><Patients><Ph.D.><PhD><Pharm.D.><PharmD><Phase 2 Clinical Trials><Phase II Clinical Trials><Physiopathology><Placebo Control><Placebos><Prevention><Prevention approach><Process><Proteins, specific or class, C-reactive><Pyrexia><QOL><Quality of Life Assessment><Quality of life><ROC Analyses><ROC Curve><Randomized><Recombinant Interleukin-1><Reperfusion Therapy><Risk><Risk Factors><Role><Sensitivity and Specificity><Sham Treatment><T Helper Factor><Testing><Time><Tissues><Translating><Transthoracic Echocardiography><Ventricular><Woman><adjudication><adjudicative process and procedure><anakinra><bio-markers><biologic marker><biomarker><cardiac depression><cardiac dysfunction><cardiac failure><cardiac function><cardiac imaging><cardiac infarct><cardiac muscle><cardiac preservation><cardiac scanning><cardiodepression><cardiorespiratory fitness><cardiorespiratory health><coronary attack><coronary infarct><coronary infarction><cytokine><early detection><early therapy><febrile><febris><function of the heart><healing><heart attack><heart dysfunction><heart function><heart imaging><heart infarct><heart infarction><heart muscle><heart output><heart preservation><heart scanning><heart sonography><imaging><improved><infarct><inflammatory mediator><injury response><insight><interleukin 1 receptor antagonist protein><lymphocyte activating factor><mortality><multidisciplinary><muscular><myocardial damage><new approaches><novel><novel approaches><novel strategies><novel strategy><pathophysiology><phase 2 study><phase II protocol><phase II study><placebo controlled><preservation><prevent><preventing><primary end point><primary endpoint><randomisation><randomization><randomly assigned><receiver operating characteristic analyses><receiver operating characteristic curve><reperfusion><response to injury><sham therapy><social role><systemic inflammation><systemic inflammatory response><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAUL W. SPEARMAN

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$609,012
FY 2026

Project Title

Viral and Cellular Determinants of HIV-1 Assembly

Grant Number:

5R01AI186611-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/20/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The major goal of this application is to define viral interactions with host pathways that are essential for the assembly of infectious HIV-1 particles. We previously identified Rab11-FIP1C (FIP1C) as a key adaptor protein required for HIV-1 envelope protein (Env) trafficking and particle incorporat...

Research Terms

<AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Assay><Binding><Bioassay><Biochemical><Biological><Biological Assay><Cell Body><Cell fusion><Cells><Cytoplasm><Cytoplasmic Domain><Cytoplasmic Tail><Data><Dependence><Endosomes><Env trimer><Envelope Protein><Event><Generations><Genetic Technics><Genetic Techniques><Goals><Granular Endoplasmic Reticulum><HIV><HIV Env><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV replication><HIV viral replication><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV1><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Integration Host Factors><Investigation><Knock-out><Knockout><Knowledge><LAV-HTLV-III><Label><Laboratories><Link><Lymphadenopathy-Associated Virus><Macrophage><Measurement><Mediating><Membrane><Modeling><Molecular Interaction><Mφ><N-terminal><NH2-terminal><Pathway interactions><Peptides><Process><Productivity><Protein Biosynthesis><Protein Trafficking><Proteins><Receptosomes><Recycling><Retroviral Antigen gag Protein><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Ribosomes><Role><Rough ER><Rough endoplasmic reticulum><Rough-Surfaced Endoplasmic Reticulum><Scaffolding Protein><Site><T-Cells><T-Lymphocyte><Techniques><Travel><Tubular><Tubular formation><Viral><Viral gag Proteins><Virus Replication><Virus-HIV><Visualization><Work><adapter protein><antiretroviral therapy><antiretroviral treatment><biologic><cell type><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><experiment><experimental research><experimental study><experiments><gag Antigens><gag Gene Products><gag Polyproteins><gag Protein><group specific antigen><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><imaging approach><imaging based approach><intervention effect><live cell microscopy><membrane structure><mutant><novel><particle><pathway><permissiveness><protein synthesis><protein transport><quantitative imaging><recruit><social role><thymus derived lymphocyte><trafficking><viral multiplication><viral replication><virus multiplication>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Linda M Rinaman

FLORIDA STATE UNIVERSITY, TALLAHASSEE, FL

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$592,841
FY 2026

Project Title

Impact of Perinatal Western Diet on Offspring GLP1 Circuits

Grant Number:

1R01DK143059-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract In humans, rodents, and other mammals, the perinatal period of offspring development (i.e., gestational and lactational) is marked by significant neurodevelopment and plasticity. During this period, maternal nutrition strongly shapes the developmental assembly and later func...

Research Terms

<21+ years old><ARHGEF5><ARHGEF5 gene><Adolescent><Adolescent Youth><Adult><Adult Children><Adult Daughters><Adult Human><Adult Offspring><Adult Sons><Affect><Agonist><Antidiabetic Hormone><Appearance><Assay><Axon><Behavior><Behavior assessment><Behavioral><Bioassay><Bioavailability><Biological Assay><Biological Availability><Biological Markers><Blood><Blood - brain barrier anatomy><Blood Reticuloendothelial System><Blood-Brain Barrier><Body Composition><Brain><Brain Nervous System><Brain region><Cell Communication and Signaling><Cell Signaling><Characteristics><Clinical><Clinical effectiveness><Common Rat Strains><Consumption><Corpus Striatum><Corpus striatum structure><Cre driver><Data><Development><Diet><Diet rich in fats and sugars><Differences between sexes><Differs between sexes><Dose><Drug Receptors><Eating><Electrophysiology><Electrophysiology (science)><Encephalon><Environment><Exposure to><FISH Technic><FISH Technique><FISH analysis><FISH assay><Female><Fiber><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Food><Food Intake><Food Preferences><Foundations><GEF5><GLP-1 receptor><GLP-I receptor><Gestation><Glucagon><Glucose tolerance test><Glukagon><HG-Factor><Health><Hemato-Encephalic Barrier><Hind Brain><Human><Hyperglycemic-Glycogenolytic Factor><Hypothalamic structure><Hypothalamus><IPGTT><Injections><Intake><Intracellular Communication and Signaling><Label><Lactation><Link><Literature><Maintenance><Mammalia><Mammals><Maternal Nutrition><Maternal diet><Measures><Membrane><Metabolic><Modeling><Modern Man><Motivation><Nature><Nerve Cells><Nerve Unit><Neural Cell><Neural Development><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurons><Neurophysiology / Electrophysiology><Nucleus Accumbens><Nutritional><Obesity><Outcome><P60><Paraventricular Nucleus of Thalamus><Paraventricular Thalamic Nucleus><Perinatal><Perinatal Exposure><Peripartum><Physiologic><Physiologic Availability><Physiological><Physiology><Predisposition><Pregnancy><Protocol><Protocols documentation><Publishing><Rat><Rats Mammals><Rattus><Receptor Signaling><Reducing diet><Reporter><Rewards><Rhombencephalon><Risk><Rodent><Rodent Model><Rodentia><Rodents Mammals><Sex Differences><Sexual differences><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Slice><Solid><Striate Body><Striatum><Structure><Structure of paraventricular nucleus of thalamus><Susceptibility><Synapses><Synaptic><System><TIM1><Testing><Time><Viral><Weaning><adiposity><adult youth><adulthood><analog><behavioral assessment><bio-markers><biologic marker><biological signal transduction><biomarker><bloodbrain barrier><clinical relevance><clinically relevant><combat><corpulence><density><developmental><developmental plasticity><diet choice><diet high in fat and sugar><diet preference><dietary choice><dietary preferences><diets><early life exposure><electrophysiological><experiment><experimental research><experimental study><experiments><food choice><glucagon-like peptide-1 receptor><glucose tolerance><high-fat/sugar diet><hindbrain><hypothalamic><impaired glucose tolerance><improved><insight><intraperitoneal glucose tolerance test><juvenile><juvenile human><lactating><lactational><life span><lifespan><mRNA Expression><male><maternal nutrition during pregnancy><membrane structure><mesolimbic dopamine system><mesolimbic system><mother nutrition><neural circuit><neural circuitry><neurocircuitry><neurodevelopment><neuronal><novel><nutritious><offspring><optogenetics><perinatal period><perinatal phase><postnatal><postsynaptic><pre-clinical><preclinical><preference><presynaptic><pup><receptor function><response><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><striatal><synapse><synaptic circuit><synaptic circuitry><western diet><western-style diet><western-type diet><young adult><young adult age><young adulthood><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vishwajeet Puri

OHIO UNIVERSITY ATHENS, ATHENS, OH

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$589,326
FY 2026

Project Title

Identifying a novel player in skeletal muscle performance and metabolism

Grant Number:

5R01DK138635-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Abstract Skeletal muscle (SkM) function and strength, and intrinsic muscle quality are closely linked to the pathogenesis and pathophysiology of metabolic disease. However, the regulatory molecular mechanisms in SkM performance remain elusive. The current proposal will focus on identifying n...

Research Terms

<Ablation><Adipocytes><Adipose Cell><Adipose tissue><Adult-Onset Diabetes Mellitus><Aerobic><Agonist><Animals><Attenuated><Autoregulation><Basic Research><Basic Science><Biology><Biopsy><Body Tissues><Cell Communication and Signaling><Cell Signaling><Cellular Matrix><Characteristics><Chemicals><Contracting Opportunities><Contracts><Cytoskeletal Gene><Cytoskeletal Proteins><Cytoskeletal System><Cytoskeleton><D-Glucose><Data><Dextrose><Disease><Disorder><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Dysfunction><Fat Cells><Fats><Fatty Tissue><Fatty acid glycerol esters><Functional disorder><GLP-1 receptor><GLP-I receptor><Glucose><Glycogen><Glycogen (Starch) Synthase><Glycogen Phosphorylase><Glycogen Synthase><Glycogen Synthetase><Health><High Fat Diet><Homeostasis><Human><Humulin R><Impairment><Insulin><Insulin Resistance><Intermediary Metabolism><Intracellular Communication and Signaling><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out Mice><Knockout Mice><Link><Lipids><Lipocytes><Locomotor Activity><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Mediating><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolism><Mice><Mice Mammals><Micro-tubule><Microtubules><Modeling><Modern Man><Molecular><Motility><Motor><Motor Activity><Movement><Murine><Mus><Muscle><Muscle Atrophy><Muscle Cells><Muscle Tissue><Muscle function><Muscular Atrophy><Myocytes><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Null Mouse><Obesity><Organelles><Pathogenesis><Pathogenicity><Pathway interactions><Performance><Phenotype><Phosphorylase ab><Phosphorylation><Physical Function><Physiologic><Physiological><Physiological Homeostasis><Physiopathology><Play><Process><Protein Phosphorylation><Proteins><Radial><Radius><Receptor Signaling><Regular Insulin><Regulation><Regulatory Protein><Role><Signal Transduction><Signal Transduction Systems><Signaling><Site><Skeletal Muscle><Slow-Onset Diabetes Mellitus><Source><Stable Diabetes Mellitus><T2 DM><T2D><T2DM><Testing><Thesaurismosis><Tissues><Transgenes><Transgenic Mice><Translational Research><Translational Science><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><UDP-Glucose Glycogen Glucosyl Transferase><Vimentin><Voluntary Muscle><Work><adipose><adiposity><adult onset diabetes><adult youth><attenuate><attenuates><biological signal transduction><blood glucose regulation><body movement><clinical relevance><clinically relevant><corpulence><decreased muscle strength><design><designing><dynapenia><endurance exercise><exercise training><fat metabolism><gain of function><genetic regulatory protein><glucagon-like peptide-1 receptor><glucose control><glucose disposal><glucose homeostasis><glucose regulation><glucose uptake><glycemic control><indexing><innovate><innovation><innovative><insulin resistant><insulin sensitivity><insulin signaling><insulin stimulated glucose disposal><insulin tolerance><interdisciplinary collaboration><intracellular skeleton><ketosis resistant diabetes><lipid metabolism><loss of function><low muscle strength><maturity onset diabetes><mechanical energy><metabolism disorder><mouse model><murine model><muscle breakdown><muscle degradation><muscle deterioration><muscle loss><muscle physiology><muscle strength><muscle strength decline><muscle wasting><muscular><novel><pathophysiology><pathway><protein expression><recruit><reduced muscle strength><regulatory gene product><skeletal muscle metabolism><skeletal muscle protein metabolism><social role><therapeutic target><transcriptomics><transdisciplinary collaboration><transgene><translation research><translational investigation><type 2 DM><type II DM><type two diabetes><white adipose tissue><yellow adipose tissue><young adult><young adult age><young adulthood>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Deok-Ho Kim

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$579,729
FY 2026

Project Title

High-throughput neurovascular-unit-on-a-chip with OASIS for modeling Parkinson's disease

Grant Number:

5R01NS133965-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, affecting nearly one million people in the United States as of 2020. The core etiopathology comprises intracellular accumulation of Lewy body-like α-synuclein (α-syn), followed by progressive loss of m...

Research Terms

<3-D><3-Dimensional><3D><Address><Affect><Agonist><Amentia><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Architecture><Automobile Driving><Autonomic Dysfunction><Autonomic nervous system><BBB penetration><BBB permeabilization><BBB permeable><Biologic Models><Biological Models><Blood><Blood - brain barrier anatomy><Blood Circulation><Blood Reticuloendothelial System><Blood Vessels><Blood-Brain Barrier><Bloodstream><Body Tissues><Brain><Brain Nervous System><Caring><Cell Body><Cells><Cerebral endothelium><Cerebrovascular system><Characteristics><Circulation><Clinical><Clinical Evaluation><Clinical Testing><Complex><DA Neuron><Data><Degenerative Neurologic Disorders><Dementia><Development><Development and Research><Devices><Disease><Disease Management><Disease Progression><Disorder><Disorder Management><Dopamine><Dopamine neuron><Drug Delivery><Drug Delivery Systems><Drugs><Dysfunction><Dyskinesia Syndromes><Encephalon><Engineering><Engineering / Architecture><Ensure><Ex4 peptide><Exendin 4><Experimental Models><Fe element><Ferritin><Functional disorder><GLP-1 receptor><GLP-I receptor><Hemato-Encephalic Barrier><Human><Human Engineering><Human Figure><Human body><Hydroxytyramine><Illumination><In Vitro><Iron><Lewy Bodies><Light><Lighting><Mediating><Medication><Mesencephalon><Methods><Mice><Mice Mammals><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Mid-brain><Midbrain><Midbrain structure><Model System><Modeling><Modern Man><Movement Disorder Syndromes><Movement Disorders><Murine><Mus><NAC precursor><Nerve Cells><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurology><Neurons><PARK1 protein><PARK4 protein><Paralysis Agitans><Parkinson><Parkinson Disease><Parkinsonian><Parkinsonian Condition><Parkinsonian Diseases><Parkinsonian Disorders><Parkinsonian Syndrome><Parkinsonism><Pathogenicity><Pathologic><Pathology><Patients><Perfusion><Persons><Pharmaceutical Preparations><Phenotype><Phosphorylation><Photoradiation><Physiology><Physiopathology><Primary Parkinsonism><Prior Therapy><Protein Phosphorylation><Proteins><R & D><R&D><Reporting><Research><SNCA><SNCA protein><Site><Structure><Substantia Nigra><Substantia nigra structure><Symptoms><Syndrome><System><Therapeutic><Tissue Engineering><Tissues><Toxin><Treatment Efficacy><Tyrosine><United States><a-syn><a-synuclein><alpha synuclein><alpha synuclein gene><alphaSP22><assay development><asyn><bioengineered tissue><blood vessels in the brain><blood-brain barrier penetration><blood-brain barrier permeabilization><blood-brain barrier permeable><bloodbrain barrier><bloodbrain barrier penetration><bloodbrain barrier permeabilization><bloodbrain barrier permeable><brain blood vessels><brain endothelium><brain vasculature><cell type><cerebral blood vessel><cerebral vasculature><cerebrovascular vessels><cerebrovasculature><chip model><chip system><clinical relevance><clinical test><clinically relevant><cortical endothelium><cost effective><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><determine efficacy><develop therapy><developmental><disease model><disorder model><dopaminergic neuron><driving><drug candidate><drug efficacy><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><engineered tissue><evaluate efficacy><examine efficacy><exenatide><glucagon-like peptide-1 receptor><hiPSC><human disease><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><iPSC technology><in vivo><induced human pluripotent stem cells><induced pluripotent stem cell technology><insoluble aggregate><intervention development><intervention efficacy><manage symptom><microfluidic chip><microphysiologic model><microphysiologic platform><microphysiologic system><microphysiology model><microphysiology platform><microphysiology system><model of animal><motor control><nano cage><nano medicinal><nano medicine><nanocage><nanomedicinal><nanomedicine><nerve cell death><nerve cell loss><neural><neural inflammation><neuro-vascular><neuro-vascular unit><neurodegenerative illness><neuroinflammation><neuroinflammatory><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal loss><neuroprotection><neuroprotective><neurovascular><neurovascular unit><non A-beta component of AD amyloid><non A4 component of amyloid precursor><novel><on a chip><on chip><optogenetics><pars compacta><pathophysiology><peripheral blood><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phenotypic biomarker><phenotypic marker><pre-formed fibril><prevent><preventing><progenitor biology><progenitor cell biology><protein aggregate><protein aggregation><research and development><research clinical testing><screening><screenings><shear stress><spatial and temporal><spatial temporal><spatiotemporal><standard of care><stem and progenitor biology><stem cell biology><symptom management><therapeutic efficacy><therapy development><therapy efficacy><three dimensional><treatment development><vascular><µfluidic><α synuclein gene><α-syn><α-synuclein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gabsang Lee

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$579,729
FY 2026

Project Title

High-throughput neurovascular-unit-on-a-chip with OASIS for modeling Parkinson's disease

Grant Number:

5R01NS133965-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, affecting nearly one million people in the United States as of 2020. The core etiopathology comprises intracellular accumulation of Lewy body-like α-synuclein (α-syn), followed by progressive loss of m...

Research Terms

<3-D><3-Dimensional><3D><Address><Affect><Agonist><Amentia><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Architecture><Automobile Driving><Autonomic Dysfunction><Autonomic nervous system><BBB penetration><BBB permeabilization><BBB permeable><Biologic Models><Biological Models><Blood><Blood - brain barrier anatomy><Blood Circulation><Blood Reticuloendothelial System><Blood Vessels><Blood-Brain Barrier><Bloodstream><Body Tissues><Brain><Brain Nervous System><Caring><Cell Body><Cells><Cerebral endothelium><Cerebrovascular system><Characteristics><Circulation><Clinical><Clinical Evaluation><Clinical Testing><Complex><DA Neuron><Data><Degenerative Neurologic Disorders><Dementia><Development><Development and Research><Devices><Disease><Disease Management><Disease Progression><Disorder><Disorder Management><Dopamine><Dopamine neuron><Drug Delivery><Drug Delivery Systems><Drugs><Dysfunction><Dyskinesia Syndromes><Encephalon><Engineering><Engineering / Architecture><Ensure><Ex4 peptide><Exendin 4><Experimental Models><Fe element><Ferritin><Functional disorder><GLP-1 receptor><GLP-I receptor><Hemato-Encephalic Barrier><Human><Human Engineering><Human Figure><Human body><Hydroxytyramine><Illumination><In Vitro><Iron><Lewy Bodies><Light><Lighting><Mediating><Medication><Mesencephalon><Methods><Mice><Mice Mammals><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Mid-brain><Midbrain><Midbrain structure><Model System><Modeling><Modern Man><Movement Disorder Syndromes><Movement Disorders><Murine><Mus><NAC precursor><Nerve Cells><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurology><Neurons><PARK1 protein><PARK4 protein><Paralysis Agitans><Parkinson><Parkinson Disease><Parkinsonian><Parkinsonian Condition><Parkinsonian Diseases><Parkinsonian Disorders><Parkinsonian Syndrome><Parkinsonism><Pathogenicity><Pathologic><Pathology><Patients><Perfusion><Persons><Pharmaceutical Preparations><Phenotype><Phosphorylation><Photoradiation><Physiology><Physiopathology><Primary Parkinsonism><Prior Therapy><Protein Phosphorylation><Proteins><R & D><R&D><Reporting><Research><SNCA><SNCA protein><Site><Structure><Substantia Nigra><Substantia nigra structure><Symptoms><Syndrome><System><Therapeutic><Tissue Engineering><Tissues><Toxin><Treatment Efficacy><Tyrosine><United States><a-syn><a-synuclein><alpha synuclein><alpha synuclein gene><alphaSP22><assay development><asyn><bioengineered tissue><blood vessels in the brain><blood-brain barrier penetration><blood-brain barrier permeabilization><blood-brain barrier permeable><bloodbrain barrier><bloodbrain barrier penetration><bloodbrain barrier permeabilization><bloodbrain barrier permeable><brain blood vessels><brain endothelium><brain vasculature><cell type><cerebral blood vessel><cerebral vasculature><cerebrovascular vessels><cerebrovasculature><chip model><chip system><clinical relevance><clinical test><clinically relevant><cortical endothelium><cost effective><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><determine efficacy><develop therapy><developmental><disease model><disorder model><dopaminergic neuron><driving><drug candidate><drug efficacy><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><engineered tissue><evaluate efficacy><examine efficacy><exenatide><glucagon-like peptide-1 receptor><hiPSC><human disease><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><iPSC technology><in vivo><induced human pluripotent stem cells><induced pluripotent stem cell technology><insoluble aggregate><intervention development><intervention efficacy><manage symptom><microfluidic chip><microphysiologic model><microphysiologic platform><microphysiologic system><microphysiology model><microphysiology platform><microphysiology system><model of animal><motor control><nano cage><nano medicinal><nano medicine><nanocage><nanomedicinal><nanomedicine><nerve cell death><nerve cell loss><neural><neural inflammation><neuro-vascular><neuro-vascular unit><neurodegenerative illness><neuroinflammation><neuroinflammatory><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal loss><neuroprotection><neuroprotective><neurovascular><neurovascular unit><non A-beta component of AD amyloid><non A4 component of amyloid precursor><novel><on a chip><on chip><optogenetics><pars compacta><pathophysiology><peripheral blood><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phenotypic biomarker><phenotypic marker><pre-formed fibril><prevent><preventing><progenitor biology><progenitor cell biology><protein aggregate><protein aggregation><research and development><research clinical testing><screening><screenings><shear stress><spatial and temporal><spatial temporal><spatiotemporal><standard of care><stem and progenitor biology><stem cell biology><symptom management><therapeutic efficacy><therapy development><therapy efficacy><three dimensional><treatment development><vascular><µfluidic><α synuclein gene><α-syn><α-synuclein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ryang Hwa Lee

TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, COLLEGE STATION, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$575,221
FY 2026

Project Title

Engineered extracellular vesicles derived from mesenchymal stem cells for the treatment of type 1 diabetes

Grant Number:

5R01DK136890-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Type 1 diabetes (T1D) is an autoimmune disease wherein a loss in immune tolerance leads to the initiation and progressive destruction of insulin-producing β cells. Numerous immune interventions have been reported to delay β-cell loss, but a few clinical trials have demonstrated safety and ...

Research Terms

<7S Gamma Globulin><Ablation><Acceleration><Adherent Culture><Adoptive Transfer><Antibodies><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Azides><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Beta Cell><Biodistribution><Bone-Derived Transforming Growth Factor><Brittle Diabetes Mellitus><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cells><Clinical><Clinical Treatment Moab><Clinical Trials><Data><Data Engineering><Development><Diabetes Mellitus><Disease remission><Dose><Engineering><Engraftment><Fc Receptor><Genes><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Goals><Humulin R><Hyperglycemia><IDDM><IgG><Immune><Immune Tolerance><Immune mediated therapy><Immunes><Immunoglobulin G><Immunologic Tolerance><Immunologically Directed Therapy><Immunomodulation><Immunotherapy><In Vitro><Inbred NOD Mice><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Label><Ligands><Literature><Mediating><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Metabolic><MicroRNAs><Milk Growth Factor><Monitor><Monoclonal Antibodies><Monolayer culture><NOD Mouse><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><OKT3 antigen><Outcome><PD 1><PD-1><PD1><Particle Size><Patients><Plasmids><Platelet Transforming Growth Factor><Play><Pre-Clinical Model><Pre-DM><Preclinical Models><Preclinical data><Prediabetes><Prediabetes syndrome><Prediabetic State><Prevention><Proteins><Recombinant DNA Technology><Regular Insulin><Regulatory T-Lymphocyte><Remission><Remission Induction><Reporting><Research><Role><Safety><Sudden-Onset Diabetes Mellitus><System><T-Cells><T-Lymphocyte><T1 DM><T1 diabetes><T1D><T1DM><T3 Antigens><T3 Complex><T3 molecule><T4 Cells><T4 Lymphocytes><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Testing><Therapeutic><Therapeutic Effect><Toxic effect><Toxicities><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Treg><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Viral><antibody receptor><autoimmune condition><autoimmune disorder><autoimmunity disease><autoreactive T cell><clinical applicability><clinical application><compare to control><comparison control><developmental><diabetes><diabetic><extracellular vesicles><functional group><genetically engineered><genotoxicity><high risk><hyperglycemic><immune modulation><immune modulatory intervention><immune regulation><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapies><immune-based treatments><immuno therapy><immunointervention><immunologic reactivity control><immunological intervention><immunological paralysis><immunomodulatory><immunoregulation><immunoregulatory><improved><in vivo Model><insight><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><mAbs><mesenchymal stromal cell><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><miRNA><monoclonal Abs><monolayer><mouse model><murine model><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><non-diabetic><non-obese diabetic (NOD) mice><nondiabetic><nonobese diabetic (NOD) mice><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><overexpress><overexpression><polypeptide><pre-diabetes><pre-diabetic><preclinical findings><preclinical information><prediabetic><programmed cell death 1><programmed cell death protein 1><programmed death 1><rational design><regulatory T-cells><response><self-reactive T cell><side effect><sle2><social role><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><type 1 diabetes onset><type I diabetes><type one diabetes><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aditi Gupta

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$549,412
FY 2026

Project Title

Personalized risk assessment in Neurofibromatosis Type 1

Grant Number:

5R01NS131112-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Neurofibromatosis (NF) encompasses a set of complex genetic disorders that affect almost every organ system and increase risk for the development of benign and malignant central and peripheral nervous system tumors. Of the three types of NF, Neurofibromatosis Type 1 (NF1) is...

Research Terms

<0-11 years old><21+ years old><AD/HD><ADHD><AI based><AI based method><AI system><Adult><Adult Human><Affect><Algorithms><Artificial Intelligence><Attention deficit hyperactivity disorder><Automobile Driving><Behavioral><Benign><Biologic Models><Biological Markers><Biological Models><Birth><Body System><CNS Nervous System><Caring><Central Nervous System><Characteristics><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Data><Clinical Markers><Collaborations><Complex><Computer Reasoning><Data><Data Set><Development><Diagnosis><Disease><Disease Management><Disease Surveillance><Disorder><Disorder Management><Electronic Health Record><Environment><Ethnic Origin><Ethnicity><Family><Family member><Genetic Diseases><Germ-Line Mutation><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioma><Health Care Systems><Hereditary><Hereditary Mutation><Individual><Informatics><Inherited><Institution><Knowledge><Machine Intelligence><Machine Learning><Malignant><Malignant - descriptor><Manuals><Measurable><Measures><Methods><Model System><Modeling><Morbidity><Multiple Neurofibromas><NF-1><NF-1 Protein><NF-1 encoded protein><NF1><NF1 GRP><NF1 Protein><NF1 gene><NF1-GAP-Related Protein><Neuraxis><Neurofibromatoses><Neurofibromatosis><Neurofibromatosis 1><Neurofibromatosis 1 Genes><Neurofibromatosis I><Neurofibromatosis Syndrome><Neurofibromatosis Type 1 Gene Product><Neurofibromatosis Type 1 Protein><Neurofibromin><Neurofibromin 1><Neuroglial Neoplasm><Neuroglial Tumor><Optics><Organ System><Outcome><PNS Neoplasm><PNS Tumor><Parturition><Pathway interactions><Patients><Pattern><Pediatric Hospitals><Performance><Peripheral Nerve Neoplasms><Peripheral Nerve Tumors><Peripheral Nervous System Neoplasms><Peripheral Nervous System Tumor><Peripheral Neurofibromatosis><Phenotype><Physicians><Population><Predisposition><Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder><Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder><Preventative measure><Preventive measure><Prognostic Marker><Psychometrics><QOL><QOL improvement><Quality of life><Race><Races><Recklinghausen Disease of Nerve><Recklinghausen's disease><Recklinghausen's neurofibromatosis><Registries><Reproducibility><Research><Risk><Risk Assessment><Safety><Site><Structure><Susceptibility><Symptoms><Syndrome><Techniques><Time><Type 1 Neurofibromatosis><Type I Neurofibromatosis><Universities><Washington><adulthood><artificial intelligence based><artificial intelligence method><autosome><behavior phenotype><behavioral phenotyping><bio-markers><biologic marker><biomarker><burden of disease><burden of illness><care outcomes><care providers><clinical biomarkers><clinical database><clinical decision support><clinical decision-making><clinical heterogeneity><clinical phenotype><clinical research site><clinical site><clinical validation><clinically actionable><clinically useful biomarkers><comparative><computer based prediction><cost><data harmonization><deep learning><deep learning method><deep learning strategy><developmental><discovery mining><disease burden><disease phenotype><disease prognosis><disease prognostication><disease risk><disorder risk><driving><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><electronic structure><gene interaction><genetic condition><genetic disorder><germ-line defect><germline variant><glial-derived tumor><harmonized data><health care outcomes><improved><improvements in QOL><improvements in quality of life><individual patient><insight><inter-individual variability><inter-individual variation><interest><kids><life span><lifespan><literature mining><literature searching><machine based learning><machine learning based model><machine learning model><multi-scale data><multiple data sources><multiscale data><neurofibromatosis type 1 gene><neurofibromatosis type 1 protein/gene><neuroglia neoplasm><neuroglia tumor><nf 1 Genes><novel><optical><pathway><phenotyping algorithm><point of care><precision medicine><precision-based medicine><predictive modeling><predictive tools><prognostic><prognostic biomarker><prognostic indicator><quality of life improvement><racial><racial background><racial origin><response><risk stratification><scoliosis><sex><stratify risk><structured data><success><support tools><text mining><text searching><tool><tumor><verification and validation><von Recklinghausen Disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PHILIP R.O. PAYNE

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$549,412
FY 2026

Project Title

Personalized risk assessment in Neurofibromatosis Type 1

Grant Number:

5R01NS131112-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Neurofibromatosis (NF) encompasses a set of complex genetic disorders that affect almost every organ system and increase risk for the development of benign and malignant central and peripheral nervous system tumors. Of the three types of NF, Neurofibromatosis Type 1 (NF1) is...

Research Terms

<0-11 years old><21+ years old><AD/HD><ADHD><AI based><AI based method><AI system><Adult><Adult Human><Affect><Algorithms><Artificial Intelligence><Attention deficit hyperactivity disorder><Automobile Driving><Behavioral><Benign><Biologic Models><Biological Markers><Biological Models><Birth><Body System><CNS Nervous System><Caring><Central Nervous System><Characteristics><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Clinical Data><Clinical Markers><Collaborations><Complex><Computer Reasoning><Data><Data Set><Development><Diagnosis><Disease><Disease Management><Disease Surveillance><Disorder><Disorder Management><Electronic Health Record><Environment><Ethnic Origin><Ethnicity><Family><Family member><Genetic Diseases><Germ-Line Mutation><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioma><Health Care Systems><Hereditary><Hereditary Mutation><Individual><Informatics><Inherited><Institution><Knowledge><Machine Intelligence><Machine Learning><Malignant><Malignant - descriptor><Manuals><Measurable><Measures><Methods><Model System><Modeling><Morbidity><Multiple Neurofibromas><NF-1><NF-1 Protein><NF-1 encoded protein><NF1><NF1 GRP><NF1 Protein><NF1 gene><NF1-GAP-Related Protein><Neuraxis><Neurofibromatoses><Neurofibromatosis><Neurofibromatosis 1><Neurofibromatosis 1 Genes><Neurofibromatosis I><Neurofibromatosis Syndrome><Neurofibromatosis Type 1 Gene Product><Neurofibromatosis Type 1 Protein><Neurofibromin><Neurofibromin 1><Neuroglial Neoplasm><Neuroglial Tumor><Optics><Organ System><Outcome><PNS Neoplasm><PNS Tumor><Parturition><Pathway interactions><Patients><Pattern><Pediatric Hospitals><Performance><Peripheral Nerve Neoplasms><Peripheral Nerve Tumors><Peripheral Nervous System Neoplasms><Peripheral Nervous System Tumor><Peripheral Neurofibromatosis><Phenotype><Physicians><Population><Predisposition><Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder><Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder><Preventative measure><Preventive measure><Prognostic Marker><Psychometrics><QOL><QOL improvement><Quality of life><Race><Races><Recklinghausen Disease of Nerve><Recklinghausen's disease><Recklinghausen's neurofibromatosis><Registries><Reproducibility><Research><Risk><Risk Assessment><Safety><Site><Structure><Susceptibility><Symptoms><Syndrome><Techniques><Time><Type 1 Neurofibromatosis><Type I Neurofibromatosis><Universities><Washington><adulthood><artificial intelligence based><artificial intelligence method><autosome><behavior phenotype><behavioral phenotyping><bio-markers><biologic marker><biomarker><burden of disease><burden of illness><care outcomes><care providers><clinical biomarkers><clinical database><clinical decision support><clinical decision-making><clinical heterogeneity><clinical phenotype><clinical research site><clinical site><clinical validation><clinically actionable><clinically useful biomarkers><comparative><computer based prediction><cost><data harmonization><deep learning><deep learning method><deep learning strategy><developmental><discovery mining><disease burden><disease phenotype><disease prognosis><disease prognostication><disease risk><disorder risk><driving><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><electronic structure><gene interaction><genetic condition><genetic disorder><germ-line defect><germline variant><glial-derived tumor><harmonized data><health care outcomes><improved><improvements in QOL><improvements in quality of life><individual patient><insight><inter-individual variability><inter-individual variation><interest><kids><life span><lifespan><literature mining><literature searching><machine based learning><machine learning based model><machine learning model><multi-scale data><multiple data sources><multiscale data><neurofibromatosis type 1 gene><neurofibromatosis type 1 protein/gene><neuroglia neoplasm><neuroglia tumor><nf 1 Genes><novel><optical><pathway><phenotyping algorithm><point of care><precision medicine><precision-based medicine><predictive modeling><predictive tools><prognostic><prognostic biomarker><prognostic indicator><quality of life improvement><racial><racial background><racial origin><response><risk stratification><scoliosis><sex><stratify risk><structured data><success><support tools><text mining><text searching><tool><tumor><verification and validation><von Recklinghausen Disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mario Stevenson

UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, CORAL GABLES, FL

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,967
FY 2026

Project Title

Revealing HIV-1 persistence in myeloid cell reservoirs

Grant Number:

5R01MH116701-09

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/1/2018

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract. HIV-1 persistence in ART is maintained predominantly by tissue reservoirs. However, due to challenges in sampling anatomic sites, particularly in living subjects, most of the information on viral reservoir composition and dynamics has been gleaned from studies with circulating CD4+ T cells...

Research Terms

<AIDS focused research><AIDS related research><AIDS research><AIDS science><AIDS specific research><AIDS/HIV><Affinity><Anatomic Sites><Anatomic structures><Anatomy><Area><Binding><Blood Plasma><Blood Plasma Cell><Body Tissues><CD4 Antigens><CD4 Cells><CD4 Molecule><CD4 Positive T Lymphocytes><CD4 Protein><CD4 Receptors><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Mediated Immunology><Cell Protection><Cell membrane><Cell-Mediated Immunity><Cells><Cellular Immunity><Chronic><Clinical><Cytoplasmic Membrane><Cytoprotection><Evolution><Frequencies><Funding><Glean><Glycoproteins><HIV Genome><HIV Infections><HIV cure><HIV focused research><HIV functional cure><HIV infection persistence><HIV investigation><HIV persistence><HIV related research><HIV research><HIV science><HIV specific research><HIV viral infection><HIV viral persistence><HIV virus infection><HIV-1><HIV-1 cure><HIV-1 functional cure><HIV-1 genome><HIV-1 infection><HIV-1 persistence><HIV-I><HIV/AIDS><HIV/AIDS cure><HIV1><HIV1 genome><Hortega cell><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune Surveillance><Immunity><Immunologic Surveillance><Immunosurveillance><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Interruption><Investigation on HIV><Kinetics><Length of Life><Ligands><Location><Longevity><Lymphoid><Macrophage><Male Genital Organs><Male Genital System><Male Genitalia><Mediating><Membrane><Methods><Microglia><Molecular Interaction><Myelogenous><Myeloid><Myeloid Cells><Mφ><Nature><OKT4 antigen><Plasma><Plasma Cells><Plasma Membrane><Plasma Serum><Plasmacytes><Play><Population><Proteomics><Research><Reticuloendothelial System, Serum, Plasma><Role><Sampling><Source><Surface CD4 Receptors><T-Cell Epitopes><T-Cells><T-Lymphocyte><T-Lymphocyte Epitopes><T4 Cells><T4 Lymphocytes><T4 molecule><Tissues><Variant><Variation><Viral><Viral reservoir><Viremia><Virion><Virus><Virus Particle><Virus reservoir><acute infection><antiretroviral therapy><antiretroviral treatment><cell mediated immune response><cohort><cytoprotective><defined contribution><design><designing><genital tract><gitter cell><helper T lymphocyte marker><high risk group><high risk individual><high risk people><high risk population><high throughput analysis><human immunodeficiency virus cure><human immunodeficiency virus infection><human immunodeficiency virus persistence><human immunodeficiency virus research><infected with HIV><infected with human immunodeficiency virus><insight><male reproductive body system><male reproductive organ system><male reproductive system><membrane structure><mesoglia><microglial cell><microgliocyte><molecular clock><new approaches><novel><novel approaches><novel strategies><novel strategy><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><plasmalemma><plasmocyte><pressure><reproductive tract><research addressing HIV><research in HIV><research into HIV><research on HIV><research on human immunodeficiency virus><research to address HIV><science on HIV><science to address HIV><social role><studies on HIV><thymus derived lymphocyte><tool><viraemia><viral rebound><viral sepsis><virus rebound><virusemia>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Heikki Hyöty

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,242
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S2

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard E Lloyd

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,242
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S2

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kristian F Lynch

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,242
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S2

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eoin McKinney

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,242
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S2

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joseph Frank Petrosino

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

High-opportunity lead · 74/100
Likely hiring
Above-average budget
Very recent
Active award
$524,242
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S2

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Min-Jeong Kim

STATE UNIVERSITY NEW YORK STONY BROOK, STONY BROOK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$921,020
FY 2026

Project Title

The utility of cyclooxygenase-1 PET imaging as a novel neuroinflammatory biomarker for Alzheimer's disease

Grant Number:

1R01AG093678-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Epidemiological evidence has suggested that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) can protect against Alzheimer’s disease (AD); however, results from large-scale trials investigating the ability of NSAIDs to prevent AD have been disappointing, in part becaus...

Research Terms

<AD biological marker><AD biomarker><AD dementia><AD pathology><AD patients><AD related biomarker><AD therapy><AD treatment><Active Follow-up><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's biomarker><Alzheimer's disease biological marker><Alzheimer's disease biomarker><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease related biomarker><Alzheimer's disease therapy><Alzheimer's pathology><Alzheimer's patient><Alzheimer's related biomarker><Alzheimer's therapy><Alzheimers Dementia><Alzheimer’s biological marker><Amyloid><Amyloid (Aβ) plaques><Amyloid Plaques><Amyloid Substance><Arachidonic Acid Cyclooxygenase><Arteries><Binding><Biological Markers><Blood Plasma><Blood Sample><Blood specimen><Brain><Brain Nervous System><COX-1><COX-1 protein><Cell Communication and Signaling><Cell Signaling><Clinical Trials><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Cyclo-Oxygenase><Cyclo-Oxygenase-1><Cyclooxygenase><Cyclooxygenase 3><Development><Diagnosis><Diagnostic><Disease><Disease Progression><Disorder><Disturbance in cognition><Dose><Drug Monitoring><Drug Targeting><Drug Therapy><Drugs><Encephalon><Enrollment><Epidemiology><Failure><Fatty Acid Cyclo-Oxygenase><Fatty Acid Cyclooxygenase><Future><Goals><Health><Health Care><Hortega cell><Human><Hydroperoxide Cyclase><Image><Impaired cognition><Individual><Inflammation><Inflammatory><Inflammatory Response><Intracellular Communication and Signaling><MR Imaging><MR Tomography><MRI><MRIs><MT-bound tau><Magnetic Resonance Imaging><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medication><Methods><Microglia><Mission><Modern Man><Molecular Interaction><Monkeys><NMR Imaging><NMR Tomography><NSAIDs><Neuritic Plaques><Noise><Non-Steroidal Anti-Inflammatory Agents><Nuclear Magnetic Resonance Imaging><PET><PET Scan><PET imaging><PETSCAN><PETT><PGH Synthase><PGH Synthase 1><PGH2 Synthetase><Participant><Personal Satisfaction><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacological Treatment><Pharmacotherapy><Phlebotomy><Plasma><Plasma Serum><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Prevention><Primary Senile Degenerative Dementia><Prostaglandin Cyclo-Oxygenase><Prostaglandin Cyclooxygenase><Prostaglandin Endoperoxide Synthetase><Prostaglandin G-H Synthase><Prostaglandin G/H Synthase 1><Prostaglandin H Synthase><Prostaglandin H2 Synthase><Prostaglandin H2 Synthase 1><Prostaglandin H2 Synthetase><Prostaglandin Synthase><Prostaglandin Synthetase><Prostaglandin-Endoperoxide Synthase><Prostaglandin-Endoperoxide Synthase 1><Public Health><Rad.-PET><Research><Reticuloendothelial System, Serum, Plasma><Scanning><Senile Plaques><Severities><Severity of illness><Signal Transduction><Signal Transduction Systems><Signaling><Testing><Therapeutic Trials><Thick><Thickness><Time><Venous blood sampling><Work><Zeugmatography><active followup><amyloid beta plaque><amyloid-b plaque><assess effectiveness><aβ plaques><bio-markers><biologic marker><biological signal transduction><biomarker><biomarker in AD><biomarker in Alzheimer's><biomarker in Alzheimer's disease><brain MR imaging><brain MRI><brain magnetic resonance imaging><cerebral MR imaging><cerebral MRI><cerebral magnetic resonance imaging><cognitive dysfunction><cognitive function><cognitive loss><cored plaque><cyclo-oxygenase I><cyclooxygenase 1><determine effectiveness><determine efficacy><developmental><diffuse plaque><disease severity><drug intervention><drug treatment><drug/agent><effectiveness assessment><effectiveness evaluation><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><enroll><epidemiologic><epidemiological><epidemiology research study><epidemiology study><epidemiology survey><evaluate effectiveness><evaluate efficacy><examine effectiveness><examine efficacy><follow up><follow-up><followed up><followup><gitter cell><imaging><imaging biomarker><imaging marker><imaging-based biological marker><imaging-based biomarker><imaging-based marker><improved><inhibitor><innovate><innovation><innovative><investigate longitudinal><longitudinal investigation><longitudinal research><mesoglia><microglial cell><microgliocyte><microtubule bound tau><microtubule-bound tau><mild cognitive decline><mild cognitive disorder><mild cognitive dysfunction><mild cognitive impairment><mild cognitive loss><mild neurocognitive impairment><neural inflammation><neuroinflammation><neuroinflammatory><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-steroidal anti-inflammatory drugs><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><older adult><older adulthood><patient living with Alzheimer's disease><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><perivascular glial cell><pharmaceutical><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical><preclinical><prevent><preventing><primary degenerative dementia><programs><prostaglandin H synthase-1><radioligand><repurposing><senile dementia of the Alzheimer type><specific biomarkers><study longitudinal><survey longitudinal><tau><tau Proteins><tau factor><therapeutic target><well-being><wellbeing><τ Proteins>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Adolfo Garcia-Ocana

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$868,670
FY 2026

Project Title

DYRK1A inhibitors, GLP1 Receptor Agonists and Immunomodulation for Beta Cell Regeneration Therapy in Type 1 Diabetes

Grant Number:

1R01DK141874-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Type 1 diabetes (T1D) affects ~2 million people in the US, including children. T1D is a major burden to society in terms of health costs, loss of productivity; it reduces quality of life and expectancy and causes loss of life due to acute and chronic complications. Its incidence is rising wo...

Research Terms

<0-11 years old><21+ years old><Acute><Address><Adult><Adult Human><Affect><Agonist><Anti-CD3 Antibody><Antigens><Autoimmune Mechanism><Autoimmune Process><Autoimmune Status><Autoimmunity><B9 endocrine pancreas><Beta Cell><Brittle Diabetes Mellitus><CD25><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><Cell Body><Cell Death><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Survival><Cell Viability><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chronic><Clinical><Clinical Trials><Co-Stimulator><Combined Modality Therapy><Costimulator><Data><Diabetes Mellitus><Diagnosis><Disease><Disease remission><Disorder><Dose><Dysfunction><Endocrine Pancreas><Epidermal Thymocyte Activating Factor><Ex4 peptide><Exendin 4><Expectancy><Experimental Models><Foundations><Functional disorder><Fusion Protein><Future><GLP-1 receptor><GLP-I receptor><Health><Health Care Costs><Health Costs><Heterogeneity><HuM291><Human><Humulin R><Hyperglycemia><IDDM><IL-2><IL2 Protein><IL2R><IL2RA><IL2RA gene><Immune><Immune Regulators><Immune Targeting><Immune Tolerance><Immune mediated therapy><Immune system><Immunes><Immunochemical Immunologic><Immunodeficient Mouse><Immunologic><Immunologic Tolerance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunomodulators><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Inbred NOD Mice><Incidence><Inflammation><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin deficiency><Insulin-Dependent Diabetes Mellitus><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intervention><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Kinases><Life><Life Expectancy><Lymphocyte Mitogenic Factor><Mediating><Mitogenic Factor><MoAb HuM291><Modeling><Modern Man><Molecular><Monoclonal Antibody HuM291><Multimodal Therapy><Multimodal Treatment><NOD Mouse><Natural regeneration><Nesidioblasts><Newly Diagnosed><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><OKT3 antigen><Onset of illness><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Patients><Persons><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Prevention><QOL><Quality of life><Receptor Protein><Recovery><Regeneration><Regimen><Regular Insulin><Regulatory T-Lymphocyte><Remission><Replacement Therapy><Residual><Residual state><Societies><Specificity><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><T cell growth factor><T-Cell Growth Factor><T-Cell Stimulating Factor><T1 DM><T1 diabetes><T1D><T1DM><T3 Antigens><T3 Complex><T3 molecule><TCGFR><Testing><Therapeutic><Therapeutic Effect><Thymocyte Stimulating Factor><Time><Transphosphorylases><Transplantation><Treg><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Tyrosine Phosphorylation><Work><Youth><Youth 10-21><adulthood><autoimmune beta cell destruction><autoimmune islet destruction><autoreactive T cell><beta cell autoimmunity><cell regeneration><cellular regeneration><combination therapy><combinatorial><combined modality treatment><combined treatment><cytokine><design><designing><diabetes><diabetes mellitus therapy><diabetes therapy><disease onset><disorder onset><early onset><empowerment><exenatide><glucagon-like peptide-1 receptor><glycemic control><high risk group><high risk individual><high risk people><high risk population><hyperglycemic><immune modulation><immune modulators><immune modulatory intervention><immune regulation><immune self tolerance><immune suppression><immune suppressive activity><immune suppressive function><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapies><immune-based treatments><immuno therapy><immunodeficient mouse model><immunogen><immunogenicity><immunointervention><immunologic reactivity control><immunological intervention><immunological paralysis><immunomodulatory><immunomodulatory molecules><immunoregulation><immunoregulator><immunoregulatory><immunoregulatory molecules><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><inhibitor><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulin secretion><insulitis><islet><islet autoimmunity><islet cell autoimmunity><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><multi-modal therapy><multi-modal treatment><necrocytosis><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathophysiology><pleiotropic effect><pleiotropism><pleiotropy><preservation><productivity loss><receptor><regenerate><regeneration based therapy><regeneration therapy><regenerative therapeutics><regenerative therapy><regulatory T-cells><self-reactive T cell><therapy optimization><transplant><treatment effect><treatment optimization><type 1 diabetes onset><type I diabetes><type one diabetes><youngster><youth age><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Thomas R Malek

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$868,670
FY 2026

Project Title

DYRK1A inhibitors, GLP1 Receptor Agonists and Immunomodulation for Beta Cell Regeneration Therapy in Type 1 Diabetes

Grant Number:

1R01DK141874-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Type 1 diabetes (T1D) affects ~2 million people in the US, including children. T1D is a major burden to society in terms of health costs, loss of productivity; it reduces quality of life and expectancy and causes loss of life due to acute and chronic complications. Its incidence is rising wo...

Research Terms

<0-11 years old><21+ years old><Acute><Address><Adult><Adult Human><Affect><Agonist><Anti-CD3 Antibody><Antigens><Autoimmune Mechanism><Autoimmune Process><Autoimmune Status><Autoimmunity><B9 endocrine pancreas><Beta Cell><Brittle Diabetes Mellitus><CD25><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><Cell Body><Cell Death><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Survival><Cell Viability><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chronic><Clinical><Clinical Trials><Co-Stimulator><Combined Modality Therapy><Costimulator><Data><Diabetes Mellitus><Diagnosis><Disease><Disease remission><Disorder><Dose><Dysfunction><Endocrine Pancreas><Epidermal Thymocyte Activating Factor><Ex4 peptide><Exendin 4><Expectancy><Experimental Models><Foundations><Functional disorder><Fusion Protein><Future><GLP-1 receptor><GLP-I receptor><Health><Health Care Costs><Health Costs><Heterogeneity><HuM291><Human><Humulin R><Hyperglycemia><IDDM><IL-2><IL2 Protein><IL2R><IL2RA><IL2RA gene><Immune><Immune Regulators><Immune Targeting><Immune Tolerance><Immune mediated therapy><Immune system><Immunes><Immunochemical Immunologic><Immunodeficient Mouse><Immunologic><Immunologic Tolerance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunomodulators><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Inbred NOD Mice><Incidence><Inflammation><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin deficiency><Insulin-Dependent Diabetes Mellitus><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intervention><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Kinases><Life><Life Expectancy><Lymphocyte Mitogenic Factor><Mediating><Mitogenic Factor><MoAb HuM291><Modeling><Modern Man><Molecular><Monoclonal Antibody HuM291><Multimodal Therapy><Multimodal Treatment><NOD Mouse><Natural regeneration><Nesidioblasts><Newly Diagnosed><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><OKT3 antigen><Onset of illness><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Patients><Persons><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Prevention><QOL><Quality of life><Receptor Protein><Recovery><Regeneration><Regimen><Regular Insulin><Regulatory T-Lymphocyte><Remission><Replacement Therapy><Residual><Residual state><Societies><Specificity><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><T cell growth factor><T-Cell Growth Factor><T-Cell Stimulating Factor><T1 DM><T1 diabetes><T1D><T1DM><T3 Antigens><T3 Complex><T3 molecule><TCGFR><Testing><Therapeutic><Therapeutic Effect><Thymocyte Stimulating Factor><Time><Transphosphorylases><Transplantation><Treg><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Tyrosine Phosphorylation><Work><Youth><Youth 10-21><adulthood><autoimmune beta cell destruction><autoimmune islet destruction><autoreactive T cell><beta cell autoimmunity><cell regeneration><cellular regeneration><combination therapy><combinatorial><combined modality treatment><combined treatment><cytokine><design><designing><diabetes><diabetes mellitus therapy><diabetes therapy><disease onset><disorder onset><early onset><empowerment><exenatide><glucagon-like peptide-1 receptor><glycemic control><high risk group><high risk individual><high risk people><high risk population><hyperglycemic><immune modulation><immune modulators><immune modulatory intervention><immune regulation><immune self tolerance><immune suppression><immune suppressive activity><immune suppressive function><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapies><immune-based treatments><immuno therapy><immunodeficient mouse model><immunogen><immunogenicity><immunointervention><immunologic reactivity control><immunological intervention><immunological paralysis><immunomodulatory><immunomodulatory molecules><immunoregulation><immunoregulator><immunoregulatory><immunoregulatory molecules><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><inhibitor><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulin secretion><insulitis><islet><islet autoimmunity><islet cell autoimmunity><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><multi-modal therapy><multi-modal treatment><necrocytosis><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathophysiology><pleiotropic effect><pleiotropism><pleiotropy><preservation><productivity loss><receptor><regenerate><regeneration based therapy><regeneration therapy><regenerative therapeutics><regenerative therapy><regulatory T-cells><self-reactive T cell><therapy optimization><transplant><treatment effect><treatment optimization><type 1 diabetes onset><type I diabetes><type one diabetes><youngster><youth age><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALBERTO PUGLIESE

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$868,670
FY 2026

Project Title

DYRK1A inhibitors, GLP1 Receptor Agonists and Immunomodulation for Beta Cell Regeneration Therapy in Type 1 Diabetes

Grant Number:

1R01DK141874-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Type 1 diabetes (T1D) affects ~2 million people in the US, including children. T1D is a major burden to society in terms of health costs, loss of productivity; it reduces quality of life and expectancy and causes loss of life due to acute and chronic complications. Its incidence is rising wo...

Research Terms

<0-11 years old><21+ years old><Acute><Address><Adult><Adult Human><Affect><Agonist><Anti-CD3 Antibody><Antigens><Autoimmune Mechanism><Autoimmune Process><Autoimmune Status><Autoimmunity><B9 endocrine pancreas><Beta Cell><Brittle Diabetes Mellitus><CD25><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><Cell Body><Cell Death><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Survival><Cell Viability><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chronic><Clinical><Clinical Trials><Co-Stimulator><Combined Modality Therapy><Costimulator><Data><Diabetes Mellitus><Diagnosis><Disease><Disease remission><Disorder><Dose><Dysfunction><Endocrine Pancreas><Epidermal Thymocyte Activating Factor><Ex4 peptide><Exendin 4><Expectancy><Experimental Models><Foundations><Functional disorder><Fusion Protein><Future><GLP-1 receptor><GLP-I receptor><Health><Health Care Costs><Health Costs><Heterogeneity><HuM291><Human><Humulin R><Hyperglycemia><IDDM><IL-2><IL2 Protein><IL2R><IL2RA><IL2RA gene><Immune><Immune Regulators><Immune Targeting><Immune Tolerance><Immune mediated therapy><Immune system><Immunes><Immunochemical Immunologic><Immunodeficient Mouse><Immunologic><Immunologic Tolerance><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunomodulators><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><In Vitro><Inbred NOD Mice><Incidence><Inflammation><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin deficiency><Insulin-Dependent Diabetes Mellitus><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Intervention><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Kinases><Life><Life Expectancy><Lymphocyte Mitogenic Factor><Mediating><Mitogenic Factor><MoAb HuM291><Modeling><Modern Man><Molecular><Monoclonal Antibody HuM291><Multimodal Therapy><Multimodal Treatment><NOD Mouse><Natural regeneration><Nesidioblasts><Newly Diagnosed><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><OKT3 antigen><Onset of illness><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Patients><Persons><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Prevention><QOL><Quality of life><Receptor Protein><Recovery><Regeneration><Regimen><Regular Insulin><Regulatory T-Lymphocyte><Remission><Replacement Therapy><Residual><Residual state><Societies><Specificity><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><T cell growth factor><T-Cell Growth Factor><T-Cell Stimulating Factor><T1 DM><T1 diabetes><T1D><T1DM><T3 Antigens><T3 Complex><T3 molecule><TCGFR><Testing><Therapeutic><Therapeutic Effect><Thymocyte Stimulating Factor><Time><Transphosphorylases><Transplantation><Treg><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Tyrosine Phosphorylation><Work><Youth><Youth 10-21><adulthood><autoimmune beta cell destruction><autoimmune islet destruction><autoreactive T cell><beta cell autoimmunity><cell regeneration><cellular regeneration><combination therapy><combinatorial><combined modality treatment><combined treatment><cytokine><design><designing><diabetes><diabetes mellitus therapy><diabetes therapy><disease onset><disorder onset><early onset><empowerment><exenatide><glucagon-like peptide-1 receptor><glycemic control><high risk group><high risk individual><high risk people><high risk population><hyperglycemic><immune modulation><immune modulators><immune modulatory intervention><immune regulation><immune self tolerance><immune suppression><immune suppressive activity><immune suppressive function><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapies><immune-based treatments><immuno therapy><immunodeficient mouse model><immunogen><immunogenicity><immunointervention><immunologic reactivity control><immunological intervention><immunological paralysis><immunomodulatory><immunomodulatory molecules><immunoregulation><immunoregulator><immunoregulatory><immunoregulatory molecules><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><inhibitor><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulin secretion><insulitis><islet><islet autoimmunity><islet cell autoimmunity><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><multi-modal therapy><multi-modal treatment><necrocytosis><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathophysiology><pleiotropic effect><pleiotropism><pleiotropy><preservation><productivity loss><receptor><regenerate><regeneration based therapy><regeneration therapy><regenerative therapeutics><regenerative therapy><regulatory T-cells><self-reactive T cell><therapy optimization><transplant><treatment effect><treatment optimization><type 1 diabetes onset><type I diabetes><type one diabetes><youngster><youth age><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William Edward Balch

SCRIPPS RESEARCH INSTITUTE, THE, LA JOLLA, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$855,694
FY 2026

Project Title

Managing Alpha-1-Antitrypsin Deficiency (AATD) through Proteostasis Signaling Pathways

Grant Number:

5R01HL169631-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract: Alpha-1-antitrypsin (AAT) deficiency (AATD) is the most common, underdiagnosed inherited genetic condition (1:1500) and the primary modifier for chronic obstructive pulmonary disease (COPD) (300 million patients world- wide- 3 million deaths annually). AATD is an aging and ...

Research Terms

<70-kD Heat-Shock Protein><A1PI><AAT deficiency><ATF6><ATF6 gene><Activating Transcription Factor 6><Address><Affect><Age Years><Aging><Alleles><Allelomorphs><Amyloidosis><Antiproteases><Automobile Driving><BiP gene><BiP protein><Biology><Blood Plasma><Blood Serum><Bronchiectasis><COPD><Causality><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular Stress><Cellular Stress Response><Cessation of life><Chaperone><Chemicals><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><Clinic><Clinical><Clinical Paths><Clinical Pathways><Clinical Treatment><Collaborations><Collection><DNA mutation><Data><Death><Diagnosis><Disease><Disease Management><Disease Progression><Disorder><Disorder Management><Dysfunction><ER stress><Effectiveness><Endopeptidase Inhibitors><Endoplasmic Reticulum><Equilibrium><Ergastoplasm><Etiology><FDA approved><Functional disorder><GRP78><GRP78 gene><Gene variant><Genetic><Genetic Change><Genetic Diseases><Genetic defect><Genetic mutation><Genome><Genotype><Glucose-Regulated Protein, 78-kD><Granulocyte Elastase><HSP 70><HSP70><HSPA5><Health><Heat-Shock 70-kD Protein 5><Heat-Shock Proteins 70><Hepatic Cells><Hepatic Disorder><Hepatic Failure><Hepatic Parenchymal Cell><Hepatocyte><Hereditary><Hereditary Disease><Human><Inborn Genetic Diseases><Individual><Infusion><Infusion procedures><Inherited><Inherited disorder><Intracellular Communication and Signaling><Investigators><Leukocyte Elastase><Life><Link><Liver><Liver Cells><Liver Failure><Liver diseases><Lung><Lung Diseases><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Lysosomal Elastase><Machine Learning><Maps><Medicine><Missense Mutation><Modeling><Modern Man><Molecular Chaperones><Mutation><Neutrophil Elastase><Output><PMN Elastase><Pathology><Patients><Peptidase Inhibitors><Peptide Hydrolase Inhibitors><Peptide Peptidohydrolase Inhibitors><Phenotype><Physiopathology><Plasma><Plasma Serum><Polymers><Polymorphonuclear Leukocyte Elastase><Population><Prize><Process><Property><Protease Antagonists><Protease Inhibitor><Proteinase Inhibitors><Proteins><Publications><Pulmonary Diseases><Pulmonary Disorder><Research><Research Personnel><Researchers><Resolution><Reticuloendothelial System, Serum, Plasma><Role><Scientific Publication><Serum><Severity of illness><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid><Stress><Structure of parenchyma of lung><System><Testing><Therapeutic><Therapeutic Intervention><Time><Training><Transplantation><Tripcellim><Trypsin><Variant><Variation><XBP1><XBP1 gene><a1-antitrypsin deficiency><aberrant protein folding><abnormal protein folding><allelic variant><alpha 1 Antiprotease><alpha 1-Antiproteinase><alpha 1-Antitrypsin><alpha 1-Antitrypsin Deficiency><alpha 1-Antitrypsin Trypsin Inhibitor><alpha 1-Protease Inhibitor><alpha 1-Proteinase Inhibitor><alpha-1-anti-trypsin deficiency><alpha1-antitrypsin deficiency><amyloid disease><balance><balance function><biological signal transduction><causation><cell stress><chronic obstructive pulmonary disorder><clinical intervention><clinical therapy><cost><design><designing><disease causation><disease of the lung><disease severity><disorder of the lung><driving><drug development><effective therapy><effective treatment><end stage disease><endoplasmic reticulum stress><experiment><experimental research><experimental study><experiments><gain of function><genetic condition><genetic diagnosis><genetic disorder><genetic disorder diagnosis><genetic variant><genome mutation><genomic variant><hepatic body system><hepatic disease><hepatic organ system><hepatopathy><hereditary disorder><heritable disorder><hsp70 Family><immunoglobulin heavy chain-binding protein><improved><inborn error><individual responsibility><infusions><inherited diseases><inherited genetic disease><inherited genetic disorder><innovate><innovation><innovative><insight><intervention therapy><liver disorder><loss of function><lung disorder><lung failure><lung health><machine based learning><missense single nucleotide polymorphism><missense single nucleotide variant><missense variant><mutant><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><paralog><paralogous gene><pathologic protein folding><pathophysiology><patient population><polymer><polymeric><polymerization><programs><protein folding><protein homeostasis><protein misfolding><proteostasis><pulmonary failure><pulmonary health><resolutions><response><sensor><small molecule><social role><tool><transplant><trial regimen><trial treatment><α-1 anti-trypsin deficiency><α-1-antitrypsin deficiency><α1-Antitrypsin><α1-Antitrypsin Deficiency><α1-Proteinase Inhibitor>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kathleen Alanna Page

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$845,922
FY 2026

Project Title

The Role of Gut-Brain Pathways on Childhood Obesity and Type 2 Diabetes Development

Grant Number:

1R01DK145940-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Childhood obesity and youth-onset type 2 diabetes (T2D) are increasing at an alarming rate, yet the underlying mechanisms remain poorly understood. Gut-derived hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), peptide YY...

Research Terms

<0-11 years old><12-20 years old><21+ years old><7 year old><7 years of age><Address><Adolescence><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Ammon Horn><Appetite><Appetite Regulation><BMI><BMI percentile><BMI z-score><Beta Cell><Body mass index><Brain><Brain Nervous System><Brain imaging><Brain region><Caloric Intake><Caring><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cellular Function><Cellular Physiology><Cellular Process><Central Lobe><Child><Child Youth><Childhood><Children (0-21)><Cornu Ammonis><Corpus Striatum><Corpus striatum structure><D-Glucose><Data><Desire for food><Development><Dextrose><Diabetes Mellitus><Diet><Dysfunction><Early Intervention><Encephalon><Endocrine Gland Secretion><Energy Intake><Exposure to><Female><Foundations><Functional disorder><Funding><GIP receptor><GLP-1><Gestational Diabetes><Gestational Diabetes Mellitus><Glp-1><Glucose><Glucose-Dependent Insulinotropic Polypeptide><Goals><Health><Hippocampus><Hormone secretion><Hormones><Hypothalamic structure><Hypothalamus><Impairment><Insula><Insula of Reil><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Intervention><Intracellular Communication and Signaling><Island of Reil><Ketosis-Resistant Diabetes Mellitus><L-tyrosyl-L-tyrosine><Life Style><Lifestyle><Link><Long-term cohort><Longitudinal Studies><Longitudinal Surveys><Longitudinal cohort><Maturity-Onset Diabetes Mellitus><Measures><Metabolic><Metabolic Diseases><Metabolic Disorder><Modeling><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nutrient><OGTT><Obesity><Oral><Oral Glucose Tolerance Test><Outcome><PYY Peptide><Participant><Pathway interactions><Peptide YY><Physical activity><Physiopathology><Play><Pregnancy-Induced Diabetes><Process><Quetelet index><Research><Research Design><Rewards><Risk><Risk Factors><Role><Satiation><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Sleep><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Striate Body><Striatum><Study Type><Subcellular Process><T2 DM><T2D><T2DM><Testing><Therapeutic Hormone><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Tyr-Tyr><Weight Gain><Weight Increase><Work><Youth><Youth 10-21><adiposity><adolescence (12-20)><adult onset diabetes><adulthood><age 7><age 7 years><behavior influence><behavioral influence><biological signal transduction><body weight gain><body weight increase><brain pathway><brain visualization><caloric dietary content><child adiposity><child obesity><childhood adiposity><childhood obesity><cohort><corpulence><critical period><cue reactivity><developmental><developmental plasticity><diabetes><diabetes risk><diets><eating cues><exposed in utero><fetal exposure><food cues><gastric inhibitory polypeptide receptor><ghrelin><glucagon-like peptide 1><glucose metabolism><glucose-dependent insulinotropic polypeptide receptor><gut to brain axis><gut-brain axis><gut-brain communication><gut-brain interactions><gut-brain relationship><gut-brain signaling><hippocampal><hormonal secretion><hunger cues><hypothalamic><in utero exposure><insight><insulin resistant><insulin tolerance><intergenerational><intra-uterine environmental exposure><intrauterine environmental exposure><ketosis resistant diabetes><kids><life-style data><life-style factor><lifestyle data><lifestyle factors><long-term study><longitudinal outcome studies><longitudinal research study><maturity onset diabetes><metabolism disorder><modifiable lifestyle factors><neural><neural imaging><neural mechanism><neuro-imaging><neuroimaging><neurological imaging><neuromechanism><novel><obese children><obesity during childhood><obesity in children><obesity prevention><obesity risk><offspring><pathophysiology><pathway><pediatric><pediatric obesity><peptide tyrosine-tyrosine><precision medicine><precision-based medicine><pregnancy diabetes><prenatal><prenatal exposure><prenatal influence><prenatally exposed><prepregnancy><prevent obesity><recruit><response><risk for obesity><risk of obesity><satiety><seven year old><seven years of age><social role><striatal><study design><type 2 DM><type II DM><type two diabetes><tyrosyltyrosine><unborn><wt gain><youngster><youth age><β-cell><β-cells><βCell><♀>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ANNY H XIANG

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$845,922
FY 2026

Project Title

The Role of Gut-Brain Pathways on Childhood Obesity and Type 2 Diabetes Development

Grant Number:

1R01DK145940-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Childhood obesity and youth-onset type 2 diabetes (T2D) are increasing at an alarming rate, yet the underlying mechanisms remain poorly understood. Gut-derived hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), peptide YY...

Research Terms

<0-11 years old><12-20 years old><21+ years old><7 year old><7 years of age><Address><Adolescence><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Ammon Horn><Appetite><Appetite Regulation><BMI><BMI percentile><BMI z-score><Beta Cell><Body mass index><Brain><Brain Nervous System><Brain imaging><Brain region><Caloric Intake><Caring><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cellular Function><Cellular Physiology><Cellular Process><Central Lobe><Child><Child Youth><Childhood><Children (0-21)><Cornu Ammonis><Corpus Striatum><Corpus striatum structure><D-Glucose><Data><Desire for food><Development><Dextrose><Diabetes Mellitus><Diet><Dysfunction><Early Intervention><Encephalon><Endocrine Gland Secretion><Energy Intake><Exposure to><Female><Foundations><Functional disorder><Funding><GIP receptor><GLP-1><Gestational Diabetes><Gestational Diabetes Mellitus><Glp-1><Glucose><Glucose-Dependent Insulinotropic Polypeptide><Goals><Health><Hippocampus><Hormone secretion><Hormones><Hypothalamic structure><Hypothalamus><Impairment><Insula><Insula of Reil><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Intervention><Intracellular Communication and Signaling><Island of Reil><Ketosis-Resistant Diabetes Mellitus><L-tyrosyl-L-tyrosine><Life Style><Lifestyle><Link><Long-term cohort><Longitudinal Studies><Longitudinal Surveys><Longitudinal cohort><Maturity-Onset Diabetes Mellitus><Measures><Metabolic><Metabolic Diseases><Metabolic Disorder><Modeling><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nutrient><OGTT><Obesity><Oral><Oral Glucose Tolerance Test><Outcome><PYY Peptide><Participant><Pathway interactions><Peptide YY><Physical activity><Physiopathology><Play><Pregnancy-Induced Diabetes><Process><Quetelet index><Research><Research Design><Rewards><Risk><Risk Factors><Role><Satiation><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Sleep><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Striate Body><Striatum><Study Type><Subcellular Process><T2 DM><T2D><T2DM><Testing><Therapeutic Hormone><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Tyr-Tyr><Weight Gain><Weight Increase><Work><Youth><Youth 10-21><adiposity><adolescence (12-20)><adult onset diabetes><adulthood><age 7><age 7 years><behavior influence><behavioral influence><biological signal transduction><body weight gain><body weight increase><brain pathway><brain visualization><caloric dietary content><child adiposity><child obesity><childhood adiposity><childhood obesity><cohort><corpulence><critical period><cue reactivity><developmental><developmental plasticity><diabetes><diabetes risk><diets><eating cues><exposed in utero><fetal exposure><food cues><gastric inhibitory polypeptide receptor><ghrelin><glucagon-like peptide 1><glucose metabolism><glucose-dependent insulinotropic polypeptide receptor><gut to brain axis><gut-brain axis><gut-brain communication><gut-brain interactions><gut-brain relationship><gut-brain signaling><hippocampal><hormonal secretion><hunger cues><hypothalamic><in utero exposure><insight><insulin resistant><insulin tolerance><intergenerational><intra-uterine environmental exposure><intrauterine environmental exposure><ketosis resistant diabetes><kids><life-style data><life-style factor><lifestyle data><lifestyle factors><long-term study><longitudinal outcome studies><longitudinal research study><maturity onset diabetes><metabolism disorder><modifiable lifestyle factors><neural><neural imaging><neural mechanism><neuro-imaging><neuroimaging><neurological imaging><neuromechanism><novel><obese children><obesity during childhood><obesity in children><obesity prevention><obesity risk><offspring><pathophysiology><pathway><pediatric><pediatric obesity><peptide tyrosine-tyrosine><precision medicine><precision-based medicine><pregnancy diabetes><prenatal><prenatal exposure><prenatal influence><prenatally exposed><prepregnancy><prevent obesity><recruit><response><risk for obesity><risk of obesity><satiety><seven year old><seven years of age><social role><striatal><study design><type 2 DM><type II DM><type two diabetes><tyrosyltyrosine><unborn><wt gain><youngster><youth age><β-cell><β-cells><βCell><♀>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yoann Aldon

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$841,429
FY 2026

Project Title

Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting

Grant Number:

5R01AI183406-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/16/2024

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT This research proposal aims to develop new immunogens for an HIV-1 vaccine by utilizing advanced protein design techniques and deep learning methods. Conventional structure-guided approaches have limitations in achieving desired structural characteristics. Therefore, this st...

Research Terms

<AIDS vaccine development><Address><Adjuvant><Animals><Antibodies><Antibody Response><Antigen Presentation><Antigenic Determinants><Antigens><Attention><B blood cells><B cell><B cell repertoire><B cells><B-Cell Activation><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><C4 b><C4b><Cell Body><Cell Ontogeny><Cells><Characteristics><Clinical Treatment Moab><Clinical Trials><Combining Site><Complement 4b><Complement C4b><Complex><Core Protein><Data><Development><Elements><Engineering><Env trimer><Envelope Protein><Epitopes><Evaluation><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fostering><Germ Lines><Germinal Center><HIV 1 Envelope Protein gp120><HIV Env><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV Infections><HIV env Protein gp120><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine development><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 vaccine><HIV-1 vaccine development><HIV-I><HIV1><HIV1 vaccine><HTLV-III gp120><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune response><Immunization><Immunize><In Vitro><Incidence><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation><KI mice><Kinetics><Knock-in Mouse><Light><Mammalian Cell><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Modern Man><Molecular Interaction><Monoclonal Antibodies><Pathway interactions><Photoradiation><Polishes><Prevention><Process><Property><Protein Engineering><Proteins><Reactive Site><Regimen><Research><Research Proposals><Role><Shapes><Spinal Column><Spine><Structure><Structure of germinal center of lymph node><Techniques><Testing><Transgenic Mice><Vaccinee><Vaccines><Vertebral column><activated B cells><alpha helix><backbone><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><deep learning><deep learning method><deep learning strategy><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><develop AIDS vaccine><develop HIV vaccine><develop HIV-1 vaccine><develop a HIV vaccine><develop a HIV-1 vaccine><development of a HIV vaccine><developmental><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><flow cytophotometry><genetic protein engineering><gp120><gp120 ENV Glycoprotein><gp120(HIV)><host response><human immunodeficiency virus infection><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><improved><in vivo><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><insight><knockin mice><mAbs><mRNA><mRNA delivery><membrane structure><messenger RNA delivery><monoclonal Abs><mouse model><murine model><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neutralizing antibody><novel><pathway><preservation><protein design><response><screening><screenings><social role><tool><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine against HIV-1><vaccine strategy><α-helix>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Marie Pancera

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$841,429
FY 2026

Project Title

Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting

Grant Number:

5R01AI183406-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/16/2024

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT This research proposal aims to develop new immunogens for an HIV-1 vaccine by utilizing advanced protein design techniques and deep learning methods. Conventional structure-guided approaches have limitations in achieving desired structural characteristics. Therefore, this st...

Research Terms

<AIDS vaccine development><Address><Adjuvant><Animals><Antibodies><Antibody Response><Antigen Presentation><Antigenic Determinants><Antigens><Attention><B blood cells><B cell><B cell repertoire><B cells><B-Cell Activation><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><C4 b><C4b><Cell Body><Cell Ontogeny><Cells><Characteristics><Clinical Treatment Moab><Clinical Trials><Combining Site><Complement 4b><Complement C4b><Complex><Core Protein><Data><Development><Elements><Engineering><Env trimer><Envelope Protein><Epitopes><Evaluation><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fostering><Germ Lines><Germinal Center><HIV 1 Envelope Protein gp120><HIV Env><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV Infections><HIV env Protein gp120><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine development><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 vaccine><HIV-1 vaccine development><HIV-I><HIV1><HIV1 vaccine><HTLV-III gp120><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune response><Immunization><Immunize><In Vitro><Incidence><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation><KI mice><Kinetics><Knock-in Mouse><Light><Mammalian Cell><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Modern Man><Molecular Interaction><Monoclonal Antibodies><Pathway interactions><Photoradiation><Polishes><Prevention><Process><Property><Protein Engineering><Proteins><Reactive Site><Regimen><Research><Research Proposals><Role><Shapes><Spinal Column><Spine><Structure><Structure of germinal center of lymph node><Techniques><Testing><Transgenic Mice><Vaccinee><Vaccines><Vertebral column><activated B cells><alpha helix><backbone><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><deep learning><deep learning method><deep learning strategy><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><develop AIDS vaccine><develop HIV vaccine><develop HIV-1 vaccine><develop a HIV vaccine><develop a HIV-1 vaccine><development of a HIV vaccine><developmental><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><flow cytophotometry><genetic protein engineering><gp120><gp120 ENV Glycoprotein><gp120(HIV)><host response><human immunodeficiency virus infection><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><improved><in vivo><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><insight><knockin mice><mAbs><mRNA><mRNA delivery><membrane structure><messenger RNA delivery><monoclonal Abs><mouse model><murine model><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neutralizing antibody><novel><pathway><preservation><protein design><response><screening><screenings><social role><tool><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine against HIV-1><vaccine strategy><α-helix>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ivan D'Orso

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$828,340
FY 2026

Project Title

Regulation of HIV-1 transcription reactivation potential by transcription factor density and composition

Grant Number:

1R01AI198076-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/6/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Although HIV-1 infection can be controlled through long-term treatment with anti-retroviral therapy (ART), a true cure has been elusive. Reservoir cells persist over time and support latent HIV-1 reactivation upon therapy cessation, yet little is known about the underlying molecular...

Research Terms

<Applications Grants><Basal Transcription Factor><Basal transcription factor genes><Basic Research><Basic Science><Binding><Biology><Cell Body><Cell model><Cells><Cellular model><Chromatin><DNA-Dependent RNA Polymerase II><Data><Epidemic><Future><Gametes><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic Transcription><Genome><Genomic approach><Germ Cells><Germ-Line Cells><Goals><Grant Proposals><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Knowledge><Ligands><Link><Location><Maintenance><Measures><Mission><Modeling><Molecular><Molecular Interaction><NIAID><National Institute of Allergy and Infectious Disease><Nature><Participant><Phase><Polymerase><Program Efficiency><Proviruses><RNA Expression><RNA Polymerase B><RNA Polymerase II><Regulation><Reproductive Cells><Resolution><Role><Sampling><Sex Cell><Site><Time><Transcription><Transcription Factor Proto-Oncogene><Transcription Initiation><Transcription factor genes><Viral><Viral Latency><Virus Integration><Virus Latency><antiretroviral therapy><antiretroviral treatment><cell immortalization><density><genetic approach><genetic strategy><genomic effort><genomic strategy><human immunodeficiency virus infection><infected with HIV><infected with human immunodeficiency virus><initial cell><insight><integration site><latency/reactivation><new approaches><novel approaches><novel strategies><novel strategy><pharmacologic><programs><rational design><reactivation from latency><recruit><resolutions><response><sexual cell><social role><transcription factor><viral genome integration><viral integration><virus genome integration>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGE M SHAW

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$807,628
FY 2026

Project Title

SHIV-guided design of novel HIV-1 fusion peptide immunogens

Grant Number:

5R01AI183332-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/21/2024

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract. SHIV-infected rhesus macaques (RMs) develop HIV-1 broadly neutralizing antibodies (bNAbs) via Env-Ab coevolutionary pathways that recapitulate events in HIV-1 infected humans (Science 371:eabd2638, 2021). We hypothesize that SHIV-infected RMs can thus serve as a novel “molecular guide” for...

Research Terms

<AIDS Vaccines><AIDS Virus><AIDS vaccine><Ab-mediated immunity><Ab-mediated protection><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Affinity><Antibody Response><Antibody immunity><Antibody protection><Antibody-mediated protection><Antigenic Determinants><Antigens><Apical><Autologous><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><Biologic Models><Biological Models><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Lineage><Cells><Combining Site><DNA mutation><Development><Dose><Env trimer><Epitope Mapping><Epitopes><Event><Frequencies><Genetic Change><Genetic defect><Genetic mutation><Germ Lines><Glycans><HIV><HIV Env><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV vaccine><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 vaccine><HIV-I><HIV/AIDS Vaccines><HIV1><HIV1 vaccine><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immunization><Infection><Investigators><KI mice><Knock-in Mouse><Knock-out><Knockout><LAV-HTLV-III><Link><Lymphadenopathy-Associated Virus><M mulatta><M. mulatta><Macaca><Macaca mulatta><Macaca rhesus><Macaque><Metabolic Glycosylation><Model System><Modern Man><Molecular><Molecular Interaction><Monkeys><Mutation><Pathway interactions><Pattern><Peptides><Polysaccharides><Process><Proteins><Reactive Site><Rectum><Regimen><Reproducibility><Research Personnel><Researchers><Reverse engineering><Rhesus><Rhesus Macaque><Rhesus Monkey><SHIV><SOSIP><Scheme><Science><Site><Structure><T4 Cells><T4 Lymphocytes><Testing><Transmission><Vaccination><Vaccines><Virus-HIV><antibody-mediated immunity><antigen antibody affinity><challenge in rhesus macaques><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><discover vaccines><evaluate vaccines><genome mutation><glycosylation><human immunodeficiency virus vaccine><immunogen><infected rhesus macaques><infected rhesus monkey><infection in rhesus macaques><infection of rhesus macaques><innovate><innovation><innovative><knockin mice><model of animal><neutralizing antibody><next generation><novel><pathway><pre-clinical><preclinical><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><simian HIV><simian human immunodeficiency virus><transmission process><vaccination study><vaccination trial><vaccine against HIV><vaccine against HIV-1><vaccine candidate><vaccine development><vaccine discovery><vaccine evaluation><vaccine screening><vaccine study><vaccine testing><vaccine trial>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GEORGE M SHAW

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$803,591
FY 2026

Project Title

SHIV-infected rhesus macaques as a model for HIV-1 bNAb development

Grant Number:

1R01AI197997-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/3/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY A major roadblock to the development of rational HIV-1 prevention strategies is the lack of a suitable primate model in which broadly neutralizing antibodies (bNAbs) can be commonly induced and the molecular, biological and immunological mechanisms responsible for eliciting such resp...

Research Terms

<AIDS prevention><Acceleration><Affinity><Amino Acid Substitution><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Affinity><Antibody Response><Antigenic Determinants><Antigens><Apical><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Binding Sites><Biological><Chemicals><Chronic><Clinical><Clinical Treatment Moab><Combining Site><D-Mannose><Development><Dose><Env trimer><Epitopes><Event><Exhibits><Face><Frequencies><Germ Lines><Glycans><HIV Env><HIV Prevention><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 prevention><HIV-I><HIV/AIDS prevention><HIV1><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune><Immunes><Immunochemical Immunologic><Immunogenetics><Immunologic><Immunological><Immunologically><Immunologics><Infection><Kinetics><Laboratories><Lead><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Mannopyranose><Mannopyranoside><Mannose><Modeling><Modern Man><Molecular><Molecular Interaction><Monkeys><Monoclonal Antibodies><NHP models><Pathway interactions><Pattern><Pb element><Peptides><Polysaccharides><Prevalence><Prevent HIV><Preventative strategy><Prevention strategy><Preventive strategy><Primates><Primates Mammals><Progress Reports><Reactive Site><Rectum><Reproducibility><Rhesus><Rhesus Macaque><Rhesus Monkey><SHIV><Science><Testing><Time><Translating><Transmission><Virus><Work><antigen antibody affinity><biologic><candidate identification><challenge in rhesus macaques><design><designing><developmental><faces><facial><heavy metal Pb><heavy metal lead><immunogen><immunogenicity><indel><infected rhesus macaques><infected rhesus monkey><infection in rhesus macaques><infection of rhesus macaques><innovate><innovation><innovative><insertion/deletion><insertion/deletion mutation><mAbs><model of animal><monoclonal Abs><neutralizing antibody><new approaches><nonhuman primate models><novel><novel approaches><novel strategies><novel strategy><pathway><prevent AIDS><prevent human immunodeficiency virus><response><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><simian HIV><simian human immunodeficiency virus><transmission process>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zandrea Ambrose

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$790,847
FY 2026

Project Title

Deciphering HIV-1 Resistance Pathways against Capsid Inhibitors in vitro and in Humanized Mice

Grant Number:

1R01AI195459-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The HIV-1 capsid, a cone-shaped protein shell, is a promising target for antiviral interventions, with lenacapavir (LEN), a potent capsid inhibitor, demonstrating efficacy in treatment and prevention. However, resistance to LEN has been reported in both in vitro and clinical contexts...

Research Terms

<Acceleration><Address><Affect><Animal Model><Animal Models and Related Studies><Anti-viral Agents><Anti-viral Therapy><Assay><Bar Codes><Bioassay><Biological Assay><Capsid><Cell Culture Techniques><Characteristics><Clinical><Clinical Trials><Cone><Conserved Sequence><Correlation Studies><DNA mutation><Data><Development><Dose><Drug resistance><Drug resistance pathway><Evolution><Future><Generations><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Grant><HIV intervention><HIV therapeutic><HIV therapy><HIV treatment><HIV-1><HIV-1 intervention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><In Vitro><Infection><Interferon Type I><Interphase Cell><Intervention><Investigation><Knowledge><Laboratories><Libraries><Link><Maps><Modeling><Mucosa><Mucosal Tissue><Mucous Membrane><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mutagenesis><Mutagenesis Molecular Biology><Mutation><Non-dividing Cell><Nondividing Cell><Nucleotides><Pathway interactions><Phenotype><PrEP><Preventative strategy><Prevention><Prevention strategy><Prevention trial><Preventive strategy><Proteins><Public Health><Reporting><Research><Resistance><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistant to Multiple Drug><Resistant to multi-drug><Resistant to multidrug><Resting Cell><Scanning><Shapes><Site><Statistical Correlation><Therapeutic><Transmission><Validation><Variant><Variation><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><barcode><base><bases><cell culture><cell cultures><combinatorial><cost><de novo mutation><de novo variant><design><designing><developmental><drug resistant><drug resistant pathway><effective intervention><effective therapy><effective treatment><experiment><experimental research><experimental study><experiments><fitness><genome mutation><humanized mice><humanized mouse><improved><in vivo><in vivo Model><inhibitor><insight><large data sets><large datasets><large scale data><large scale data sets><large scale datasets><model of animal><mouse model><multi-drug resistant><multidrug resistant><murine model><mutant><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathway><pre-exposure prophylaxis><pressure><rational design><resistance mutation><resistance to Drug><resistant><resistant mutation><resistant to Drug><therapeutic target><transmission process><treat HIV><treat Human Immunodeficiency Virus><treatment strategy><validations><viral fitness><viral infectious disease treatment><viral transmission><virus protein><virus transmission>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Masahiro Yamashita

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$790,847
FY 2026

Project Title

Deciphering HIV-1 Resistance Pathways against Capsid Inhibitors in vitro and in Humanized Mice

Grant Number:

1R01AI195459-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The HIV-1 capsid, a cone-shaped protein shell, is a promising target for antiviral interventions, with lenacapavir (LEN), a potent capsid inhibitor, demonstrating efficacy in treatment and prevention. However, resistance to LEN has been reported in both in vitro and clinical contexts...

Research Terms

<Acceleration><Address><Affect><Animal Model><Animal Models and Related Studies><Anti-viral Agents><Anti-viral Therapy><Assay><Bar Codes><Bioassay><Biological Assay><Capsid><Cell Culture Techniques><Characteristics><Clinical><Clinical Trials><Cone><Conserved Sequence><Correlation Studies><DNA mutation><Data><Development><Dose><Drug resistance><Drug resistance pathway><Evolution><Future><Generations><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Grant><HIV intervention><HIV therapeutic><HIV therapy><HIV treatment><HIV-1><HIV-1 intervention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><In Vitro><Infection><Interferon Type I><Interphase Cell><Intervention><Investigation><Knowledge><Laboratories><Libraries><Link><Maps><Modeling><Mucosa><Mucosal Tissue><Mucous Membrane><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mutagenesis><Mutagenesis Molecular Biology><Mutation><Non-dividing Cell><Nondividing Cell><Nucleotides><Pathway interactions><Phenotype><PrEP><Preventative strategy><Prevention><Prevention strategy><Prevention trial><Preventive strategy><Proteins><Public Health><Reporting><Research><Resistance><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistant to Multiple Drug><Resistant to multi-drug><Resistant to multidrug><Resting Cell><Scanning><Shapes><Site><Statistical Correlation><Therapeutic><Transmission><Validation><Variant><Variation><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><barcode><base><bases><cell culture><cell cultures><combinatorial><cost><de novo mutation><de novo variant><design><designing><developmental><drug resistant><drug resistant pathway><effective intervention><effective therapy><effective treatment><experiment><experimental research><experimental study><experiments><fitness><genome mutation><humanized mice><humanized mouse><improved><in vivo><in vivo Model><inhibitor><insight><large data sets><large datasets><large scale data><large scale data sets><large scale datasets><model of animal><mouse model><multi-drug resistant><multidrug resistant><murine model><mutant><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathway><pre-exposure prophylaxis><pressure><rational design><resistance mutation><resistance to Drug><resistant><resistant mutation><resistant to Drug><therapeutic target><transmission process><treat HIV><treat Human Immunodeficiency Virus><treatment strategy><validations><viral fitness><viral infectious disease treatment><viral transmission><virus protein><virus transmission>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Isabelle G De Plaen

LURIE CHILDREN'S HOSPITAL OF CHICAGO, CHICAGO, IL

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$786,725
FY 2026

Project Title

Role of Flt-1 in necrotizing enterocolitis development

Grant Number:

1R01DK146174-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

1/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT: Necrotizing enterocolitis (NEC) is a major cause of morbidity and mortality among premature infants that commonly leads to overwhelming sepsis and extensive intestinal tissue necrosis requiring surgery. NEC pathogenesis is not completely understood, and no specific therapies currently exis...

Research Terms

<(TNF)-α><21+ years old><6-Phosphogluconate Dehydrogenase><Adult><Adult Human><Adverse effects><Affect><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiostatic Agents><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Bacteria><Binding><Blood Serum><Blood Vessels><Blood monocyte><Body Tissues><Cachectin><Cell Body><Cell Communication and Signaling><Cell Cycle Progression><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Signaling><Cells><Cellular Proliferation><DNA Replication><DNA Synthesis><DNA biosynthesis><Data><Development><Disease><Disorder><Endothelial Cells><Enteral Feeding><Enzyme Gene><Enzymes><FLK1><FLT VEGF Receptor><FLT1 RTK><FLT1 Receptor Tyrosine Kinase><Flt-1><Foundations><Future><Gene Delivery><Genes><Goals><Human><Immune><Immune system><Immunes><Impairment><Incidence><Infant><Inflammatory><Injury><Intestinal><Intestinal Diseases><Intestinal Disorder><Intestines><Intracellular Communication and Signaling><Ischemia><KDR gene><Ligands><Macrophage><Macrophage-Derived TNF><Marrow monocyte><Mediating><Membrane><Metabolic><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Monocyte-Derived TNF><Morbidity><Murine><Mus><Myeloid Cells><Mφ><Necrosis><Necrotic><Necrotizing Enterocolitis><Neonatal><Neovascularization Inhibitors><Operative Procedures><Operative Surgical Procedures><Pathogenesis><Phosphogluconate Dehydrogenase><Play><Predisposition><Premature Infant><Proliferating><Proteins><Proto-Oncogene Protein flt><Public Health><RNA chemical synthesis><RNA synthesis><Receptor Protein><Receptor Tyrosine Kinase,Class V><Recombinants><Research><Role><Sepsis><Serum><Short Bowel Syndrome><Signal Transduction><Signal Transduction Systems><Signaling><Solid><Stress><Surgical><Surgical Interventions><Surgical Procedure><Susceptibility><System><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Testing><Therapeutic><Tissues><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tyrosine Protein Kinase FRT><Tyrosine Protein Kinase Receptor FLT><VEGF><VEGF Receptor flt-1 Protein><VEGF Receptors><VEGF Trap><VEGF Trap R1R2><VEGFA><VEGFA gene><VEGFR><VEGFR-1><VEGFR-2><VEGFR1><VEGFR2><VEGFs><VPF Receptor><Vascular Endothelial Cell><Vascular Endothelial Cell Growth Factor Receptor><Vascular Endothelial Growth Factor A><Vascular Endothelial Growth Factor Receptor 2><Vascular Endothelial Growth Factor Receptor-1><Vascular Endothelial Growth Factor Trap><Vascular Endothelial Growth Factors><Vascular Permeability Factor Receptor><Vasculotropin><adulthood><angiogenesis><antiangiogenic><biological signal transduction><bowel><clinical relevance><clinically relevant><coping><density><developmental><enteric feeding><feeding tube><fms-Like Tyrosine Kinase><gastric feeding><improved><in vivo><infancy><infantile><infants born premature><infants born prematurely><injuries><injury to the intestines><intestinal barrier><intestinal injury><intestinal mucosal barrier><intestine disease><intestine disorder><membrane structure><monocyte><mortality><nano particle><nano-sized particle><nanoparticle><nanosized particle><necrotic tissue><neonatal human><new approaches><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel approaches><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><overexpress><overexpression><postnatal><premature baby><premature infant human><premature neonates><premature newborn><preservation><preterm baby><preterm infant><preterm infant human><preterm neonate><preterm newborn><prevent><preventing><pup><receptor><recruit><short gut syndrome><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><surgery><tissue necrosis><tube feeding><vascular>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laura C Alonso

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$770,603
FY 2026

Project Title

GIP receptor signaling mechanisms

Grant Number:

1R01DK142926-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract The incretin hormones, GIP and GLP-1, have fundamental roles in the control of whole-body metabolic tone (e.g., insulin secretion and insulin sensitivity). Therapeutics targeting GIP and GLP-1 receptors have several positive health impacts, including but not limited to improved insulin sens...

Research Terms

<3'5'-cyclic ester of AMP><ARRB2><Actins><Acute><Address><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adipocytes><Adipose Cell><Adult-Onset Diabetes Mellitus><Affect><Alleles><Allelomorphs><Arrestins><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Bioassay><Biological><Biological Assay><Biology><Body Tissues><Body Weight decreased><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancer Treatment><Cardiac Diseases><Cardiac Disorders><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cartoons><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular biology><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computing Methodologies><Cyclic AMP><D-Glucose><Data><Degenerative Neurologic Disorders><Development><Dextrose><Diabetes Mellitus><Disease><Disease Progression><Disorder><Drugs><Endocrine Gland Secretion><Endocrine Therapy><Engineering><Fat Cells><Fats><Fatty acid glycerol esters><Female><Future><GIP receptor><GLP-1><GLP-1 receptor><GLP-I receptor><GLUT 4 protein><GLUT4><GLUT4 gene><GLUT4 protein><Gene Frequency><Gene Transcription><Genetic Transcription><Genotype><Glp-1><Glucose><Glucose tolerance test><Glucose-Dependent Insulinotropic Polypeptide><Health><Heart Diseases><Heart Vascular><Heterogeneity><Hormonal Therapy><Hormone secretion><Hormones><Human><IPGTT><Intermediary Metabolism><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Urinary System><Knock-out><Knockout><Knowledge><Learning><Link><Lipocytes><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Medication><Metabolic><Metabolic Control><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolism><Methods><Mice><Mice Mammals><Microscopy><Modern Man><Molecular><Molecular Interaction><Murine><Mus><NIDDM><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Pancreatic beta Cell><Pancreatic β-Cell><Paralysis Agitans><Parkinson><Parkinson Disease><Pathway interactions><Persons><Pharmaceutical Preparations><Phenotype><Physiologic><Physiological><Physiology><Primary Parkinsonism><Quantitative Microscopy><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Receptor Activation><Receptor Signaling><Retinal S-Antigen><Role><Sampling><Signal Transduction><Signal Transduction Pathway><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Structure of beta Cell of islet><T2 DM><T2D><T2DM><Testing><Therapeutic><Therapeutic Hormone><Thesaurismosis><Tissues><Tracer><Transcription><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Variant><Variation><Weight Loss><Weight Reduction><Work><adenosine 3'5' monophosphate><adult onset diabetes><allelic frequency><antagonism><antagonist><anti-cancer therapy><arrestin B><beta cell development><beta-arrestin><beta-arrestin 2><biologic><biological signal transduction><body weight loss><cAMP><cancer therapy><cancer-directed therapy><cardiovascular health><cell biology><cell community><cell type><cellular community><circulatory system><computational methodology><computational methods><computer based method><computer methods><computing method><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><diabetes><drug/agent><endocrine pancreas development><expectation><experiment><experimental research><experimental study><experiments><gastric inhibitory polypeptide receptor><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose disposal><glucose metabolism><glucose tolerance><glucose uptake><glucose-dependent insulinotropic polypeptide receptor><heart disorder><hormonal secretion><hormone therapy><improved><in vivo><incretin hormone><insulin secretion><insulin sensitivity><insulin stimulated glucose disposal><insulin-responsive glucose transporter><intraperitoneal><intraperitoneal glucose tolerance test><islet><islet development><ketosis resistant diabetes><male><maturity onset diabetes><metabolism disorder><mouse model><murine model><neurodegenerative illness><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathway><programs><receptor function><renal><response><scRNA sequencing><scRNA-seq><sex><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><success><synergism><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transcriptome sequencing><transcriptomic sequencing><type 2 DM><type II DM><type two diabetes><validation studies><wt-loss><β-arrestin><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TIMOTHY E MCGRAW

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$770,603
FY 2026

Project Title

GIP receptor signaling mechanisms

Grant Number:

1R01DK142926-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract The incretin hormones, GIP and GLP-1, have fundamental roles in the control of whole-body metabolic tone (e.g., insulin secretion and insulin sensitivity). Therapeutics targeting GIP and GLP-1 receptors have several positive health impacts, including but not limited to improved insulin sens...

Research Terms

<3'5'-cyclic ester of AMP><ARRB2><Actins><Acute><Address><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adipocytes><Adipose Cell><Adult-Onset Diabetes Mellitus><Affect><Alleles><Allelomorphs><Arrestins><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Bioassay><Biological><Biological Assay><Biology><Body Tissues><Body Weight decreased><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancer Treatment><Cardiac Diseases><Cardiac Disorders><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cartoons><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular biology><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computing Methodologies><Cyclic AMP><D-Glucose><Data><Degenerative Neurologic Disorders><Development><Dextrose><Diabetes Mellitus><Disease><Disease Progression><Disorder><Drugs><Endocrine Gland Secretion><Endocrine Therapy><Engineering><Fat Cells><Fats><Fatty acid glycerol esters><Female><Future><GIP receptor><GLP-1><GLP-1 receptor><GLP-I receptor><GLUT 4 protein><GLUT4><GLUT4 gene><GLUT4 protein><Gene Frequency><Gene Transcription><Genetic Transcription><Genotype><Glp-1><Glucose><Glucose tolerance test><Glucose-Dependent Insulinotropic Polypeptide><Health><Heart Diseases><Heart Vascular><Heterogeneity><Hormonal Therapy><Hormone secretion><Hormones><Human><IPGTT><Intermediary Metabolism><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Urinary System><Knock-out><Knockout><Knowledge><Learning><Link><Lipocytes><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Medication><Metabolic><Metabolic Control><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolism><Methods><Mice><Mice Mammals><Microscopy><Modern Man><Molecular><Molecular Interaction><Murine><Mus><NIDDM><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Pancreatic beta Cell><Pancreatic β-Cell><Paralysis Agitans><Parkinson><Parkinson Disease><Pathway interactions><Persons><Pharmaceutical Preparations><Phenotype><Physiologic><Physiological><Physiology><Primary Parkinsonism><Quantitative Microscopy><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Receptor Activation><Receptor Signaling><Retinal S-Antigen><Role><Sampling><Signal Transduction><Signal Transduction Pathway><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Structure of beta Cell of islet><T2 DM><T2D><T2DM><Testing><Therapeutic><Therapeutic Hormone><Thesaurismosis><Tissues><Tracer><Transcription><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Variant><Variation><Weight Loss><Weight Reduction><Work><adenosine 3'5' monophosphate><adult onset diabetes><allelic frequency><antagonism><antagonist><anti-cancer therapy><arrestin B><beta cell development><beta-arrestin><beta-arrestin 2><biologic><biological signal transduction><body weight loss><cAMP><cancer therapy><cancer-directed therapy><cardiovascular health><cell biology><cell community><cell type><cellular community><circulatory system><computational methodology><computational methods><computer based method><computer methods><computing method><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><diabetes><drug/agent><endocrine pancreas development><expectation><experiment><experimental research><experimental study><experiments><gastric inhibitory polypeptide receptor><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose disposal><glucose metabolism><glucose tolerance><glucose uptake><glucose-dependent insulinotropic polypeptide receptor><heart disorder><hormonal secretion><hormone therapy><improved><in vivo><incretin hormone><insulin secretion><insulin sensitivity><insulin stimulated glucose disposal><insulin-responsive glucose transporter><intraperitoneal><intraperitoneal glucose tolerance test><islet><islet development><ketosis resistant diabetes><male><maturity onset diabetes><metabolism disorder><mouse model><murine model><neurodegenerative illness><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathway><programs><receptor function><renal><response><scRNA sequencing><scRNA-seq><sex><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><success><synergism><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transcriptome sequencing><transcriptomic sequencing><type 2 DM><type II DM><type two diabetes><validation studies><wt-loss><β-arrestin><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Elisabetta Patorno

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$767,671
FY 2026

Project Title

Novel approaches to improve comparative effectiveness research of medical and surgical weight reduction strategies in clinical practice

Grant Number:

5R01DK138036-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

The obesity epidemic will affect 1 in 2 adults in the US by 2030. While several medical and surgical weight reduction strategies are available, with newer, transformative medications recently approved, little is known about their safety and effectiveness in clinical practice. Real-world evidence (RW...

Research Terms

<2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate><21+ years old><Address><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Adverse Experience><Adverse event><Affect><Agonist><Algorithms><Amfebutamone><BMI><BMI percentile><BMI z-score><Body Measures><Body Weight decreased><Body mass index><Body measure procedure><Bupropion><Calibration><Cancers><Cardiometabolic Disease><Cardiometabolic Disorder><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Categories><Cessation of life><Clinical><Clinical Management><Comparative Effectiveness Research><Complement><Complement Proteins><Data><Data Bases><Databases><Death><Dietary Practices><Drugs><Effectiveness><Epidemiology><Event><Follow-Up Studies><Future><GLP-1><GLP-1 receptor><GLP-I receptor><Gastric Bypass><Glp-1><Goals><Head><Health Care Professional><Health Insurance><Health Professional><Heart Vascular><Infrastructure><Ketosis-Resistant Diabetes Mellitus><Knowledge><Life Style><Lifestyle><Link><Long-Term Effects><Long-term cohort study><Longitudinal cohort study><Malignant Neoplasms><Malignant Tumor><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Medical><Medical Research><Medication><Methodology><Modification><NIDDM><Nalorex><Naltrexone><Nemexin><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nurses' Health Study><Obesity><Obesity Epidemic><Operative Procedures><Operative Surgical Procedures><Outcome><Outcome Measure><Participant><Patient Representative><Patients><Pharmaceutical Epidemiology><Pharmaceutical Preparations><Pharmacoepidemiology><Phentermine><Population Research><Population-based research><Population-level research><Production><Quetelet index><Randomized, Controlled Trials><ReVia><Residual><Residual state><Risk><Safety><Slow-Onset Diabetes Mellitus><Specificity><Stable Diabetes Mellitus><Standardization><Statistical Methods><Surgical><Surgical Interventions><Surgical Procedure><T2 DM><T2D><T2DM><Testing><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Validation><Vivitrol><Weight Loss><Weight Reduction><Wellbutrin><Woman><Work><adiposity><adult onset diabetes><adulthood><alpha,alpha-dimethyl-benzeneethanamine><bariatric surgery><body weight loss><buproprion><cardiometabolic><cardiometabolism><cardiovascular disorder><circulatory system><clinical practice><comparative effectiveness><comparative safety><complementation><corpulence><data base><data collected in real world><data infrastructure><dietary><dietary pattern><drug epidemiology><drug/agent><epidemiologic><epidemiological><follow-up research study><follow-up survey><gastric banding><gastric bypass surgery><glucagon-like peptide 1><glucagon-like peptide-1 receptor><health insurance plan><implantable gastric stimulation banding><improved><insight><insurance claims><investigate population><ketosis resistant diabetes><machine learning based prediction model><machine learning based predictive model><machine learning prediction><machine learning prediction model><malignancy><maturity onset diabetes><measurable outcome><men><neoplasm/cancer><new approaches><novel approaches><novel strategies><novel strategy><obese patients><obesity surgery><outcome measurement><patients with obesity><pharmacoepidemiologic><pharmacoepidemiological><population investigation><population level investigation><population specific research><prediction algorithm><premature><prematurity><randomized control trial><real world data><real world evidence><statistic methods><stomach bypass><stomach stapling><studies of populations><study of the population><study population><study with follow-up><success><surgery><survey population><topiramate><type 2 DM><type II DM><type two diabetes><validations><waist circumference><weight loss intervention><weight loss surgery><weight loss therapy><weight loss treatment><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Schahram Akbarian

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$758,730
FY 2026

Project Title

Nicotine and NLRP3 Inflammasome in HIV-1-Associated CNS Inflammation

Grant Number:

5R01DA059876-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/15/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Human immunodeficiency virus type 1 (HIV-1) infection remains incurable, with over 38 million people affected worldwide. While HIV-1 is known to enter the brain within the first two weeks of infection, it is estimated that 20- 50% of people with HIV-1 will develop HIV-associated neur...

Research Terms

<AIDS Virus><AIDS dementia><AIDS with dementia><AIDS-related dementia><Acquired Immune Deficiency Syndrome Virus><Acquired Immune Deficiency Syndrome related dementia><Acquired Immunodeficiency Syndrome Virus><Acute><Address><Affect><Autopsy><Biological Markers><Biology><Brain><Brain Inflammation><Brain Nervous System><Brain region><CNS Nervous System><Cell Body><Cell Communication><Cell Interaction><Cell-to-Cell Interaction><Cells><Central Nervous System><Chronic><Cigarette Smoker><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Collaborations><Data><Dementia Due to HIV Disease><Dementia associated with AIDS><Dementia in human immunodeficiency virus (HIV) disease><Development><Disease><Disorder><Disturbance in cognition><Encephalitis><Encephalon><Future><Genes><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Dementia><HIV Infections><HIV associated dementia><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV cure><HIV disease><HIV functional cure><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection persistence><HIV latency><HIV neurocognitive impairment><HIV people><HIV persistence><HIV positive individuals><HIV positive people><HIV replication><HIV viral infection><HIV viral persistence><HIV viral replication><HIV virus infection><HIV-1><HIV-1 associated dementia><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 cure><HIV-1 dementia><HIV-1 disease><HIV-1 functional cure><HIV-1 infection><HIV-1 persistence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-2><HIV-I><HIV-II><HIV-associated neurocognitive disorder><HIV-related dementia><HIV/AIDS cure><HIV/AIDS disease><HIV1><HIV2><HTLV-IV><Heterograft><Heterologous Transplantation><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 2><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type IV><Human immunodeficiency virus 1><Human immunodeficiency virus 2><IQ Deficit><Immune><Immune response><Immunes><Impaired cognition><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammasome><Inflammation><Inflammatory><Inflammatory Response><LAV-2><LAV-HTLV-III><Lineage Tracing><Literature><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Microglia><Modeling><Modern Man><Morbidity><Myeloid Cells><NIDA><National Institute of Drug Abuse><National Institute on Drug Abuse><Neuraxis><Neurocognitive><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurologic Manifestations><Neurologic Signs and Symptoms><Neurologic Symptoms><Neurological Manifestations><Neurological Signs and Symptoms><Nicotine><Nicotinic Acetylcholine Receptors><Nicotinic Receptors><Outcome><PLWH><PWH><Pathway interactions><Persons><Play><Population><Productivity><RNA Seq><RNA sequencing><RNAseq><Research><Role><Sampling><Signal Pathway><Site><Smoke><Smoker><Smoking><Substance Use Disorder><System><Testing><Therapeutic Intervention><Time><Tissue Model><Tobacco smoke><Tobacco smoking><Tobacco smoking behavior><Tonsil><United States><Upregulation><Viral reservoir><Virus><Virus reservoir><Virus-HIV><Work><Xenograft><Xenograft procedure><Xenotransplantation><asymptomatic HIV infection><bio-markers><biologic marker><biomarker><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cell type><cellular lineage mapping><cellular lineage tracking><chronic HIV infection><clinical relevance><clinically relevant><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><cohort><comorbidity><developmental><differential expression><differentially expressed><direct application><experience><exposure to nicotine><gitter cell><host response><human immunodeficiency virus cure><human immunodeficiency virus disease><human immunodeficiency virus infection><human immunodeficiency virus persistence><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><humanized mice><humanized mouse><iPS><iPSC><iPSCs><immune system response><immunoresponse><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><insight><intelligence quotient deficit><intervention therapy><latent HIV infection><mesoglia><microglial cell><microgliocyte><mouse model><multidisciplinary><murine model><necropsy><neural inflammation><neural manifestation><neurocognitive decline><neurocognitive impairment><neuroinflammation><neuroinflammatory><new technology><nicotine consumption><nicotine exposure><nicotine use><non-smoker><nonsmoker><novel><novel technologies><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><postmortem><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><substance use and disorder><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic target><tonsillar><transcriptional differences><transcriptome sequencing><transcriptomic sequencing><virology><xeno-transplant><xeno-transplantation>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BENJAMIN K CHEN

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$758,730
FY 2026

Project Title

Nicotine and NLRP3 Inflammasome in HIV-1-Associated CNS Inflammation

Grant Number:

5R01DA059876-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/15/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Human immunodeficiency virus type 1 (HIV-1) infection remains incurable, with over 38 million people affected worldwide. While HIV-1 is known to enter the brain within the first two weeks of infection, it is estimated that 20- 50% of people with HIV-1 will develop HIV-associated neur...

Research Terms

<AIDS Virus><AIDS dementia><AIDS with dementia><AIDS-related dementia><Acquired Immune Deficiency Syndrome Virus><Acquired Immune Deficiency Syndrome related dementia><Acquired Immunodeficiency Syndrome Virus><Acute><Address><Affect><Autopsy><Biological Markers><Biology><Brain><Brain Inflammation><Brain Nervous System><Brain region><CNS Nervous System><Cell Body><Cell Communication><Cell Interaction><Cell-to-Cell Interaction><Cells><Central Nervous System><Chronic><Cigarette Smoker><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Collaborations><Data><Dementia Due to HIV Disease><Dementia associated with AIDS><Dementia in human immunodeficiency virus (HIV) disease><Development><Disease><Disorder><Disturbance in cognition><Encephalitis><Encephalon><Future><Genes><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Dementia><HIV Infections><HIV associated dementia><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV cure><HIV disease><HIV functional cure><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection persistence><HIV latency><HIV neurocognitive impairment><HIV people><HIV persistence><HIV positive individuals><HIV positive people><HIV replication><HIV viral infection><HIV viral persistence><HIV viral replication><HIV virus infection><HIV-1><HIV-1 associated dementia><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 cure><HIV-1 dementia><HIV-1 disease><HIV-1 functional cure><HIV-1 infection><HIV-1 persistence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-2><HIV-I><HIV-II><HIV-associated neurocognitive disorder><HIV-related dementia><HIV/AIDS cure><HIV/AIDS disease><HIV1><HIV2><HTLV-IV><Heterograft><Heterologous Transplantation><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 2><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type IV><Human immunodeficiency virus 1><Human immunodeficiency virus 2><IQ Deficit><Immune><Immune response><Immunes><Impaired cognition><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammasome><Inflammation><Inflammatory><Inflammatory Response><LAV-2><LAV-HTLV-III><Lineage Tracing><Literature><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Microglia><Modeling><Modern Man><Morbidity><Myeloid Cells><NIDA><National Institute of Drug Abuse><National Institute on Drug Abuse><Neuraxis><Neurocognitive><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurologic Manifestations><Neurologic Signs and Symptoms><Neurologic Symptoms><Neurological Manifestations><Neurological Signs and Symptoms><Nicotine><Nicotinic Acetylcholine Receptors><Nicotinic Receptors><Outcome><PLWH><PWH><Pathway interactions><Persons><Play><Population><Productivity><RNA Seq><RNA sequencing><RNAseq><Research><Role><Sampling><Signal Pathway><Site><Smoke><Smoker><Smoking><Substance Use Disorder><System><Testing><Therapeutic Intervention><Time><Tissue Model><Tobacco smoke><Tobacco smoking><Tobacco smoking behavior><Tonsil><United States><Upregulation><Viral reservoir><Virus><Virus reservoir><Virus-HIV><Work><Xenograft><Xenograft procedure><Xenotransplantation><asymptomatic HIV infection><bio-markers><biologic marker><biomarker><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cell type><cellular lineage mapping><cellular lineage tracking><chronic HIV infection><clinical relevance><clinically relevant><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><cohort><comorbidity><developmental><differential expression><differentially expressed><direct application><experience><exposure to nicotine><gitter cell><host response><human immunodeficiency virus cure><human immunodeficiency virus disease><human immunodeficiency virus infection><human immunodeficiency virus persistence><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><humanized mice><humanized mouse><iPS><iPSC><iPSCs><immune system response><immunoresponse><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><insight><intelligence quotient deficit><intervention therapy><latent HIV infection><mesoglia><microglial cell><microgliocyte><mouse model><multidisciplinary><murine model><necropsy><neural inflammation><neural manifestation><neurocognitive decline><neurocognitive impairment><neuroinflammation><neuroinflammatory><new technology><nicotine consumption><nicotine exposure><nicotine use><non-smoker><nonsmoker><novel><novel technologies><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><postmortem><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><substance use and disorder><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic target><tonsillar><transcriptional differences><transcriptome sequencing><transcriptomic sequencing><virology><xeno-transplant><xeno-transplantation>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Talia H Swartz

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$758,730
FY 2026

Project Title

Nicotine and NLRP3 Inflammasome in HIV-1-Associated CNS Inflammation

Grant Number:

5R01DA059876-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/15/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Human immunodeficiency virus type 1 (HIV-1) infection remains incurable, with over 38 million people affected worldwide. While HIV-1 is known to enter the brain within the first two weeks of infection, it is estimated that 20- 50% of people with HIV-1 will develop HIV-associated neur...

Research Terms

<AIDS Virus><AIDS dementia><AIDS with dementia><AIDS-related dementia><Acquired Immune Deficiency Syndrome Virus><Acquired Immune Deficiency Syndrome related dementia><Acquired Immunodeficiency Syndrome Virus><Acute><Address><Affect><Autopsy><Biological Markers><Biology><Brain><Brain Inflammation><Brain Nervous System><Brain region><CNS Nervous System><Cell Body><Cell Communication><Cell Interaction><Cell-to-Cell Interaction><Cells><Central Nervous System><Chronic><Cigarette Smoker><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Collaborations><Data><Dementia Due to HIV Disease><Dementia associated with AIDS><Dementia in human immunodeficiency virus (HIV) disease><Development><Disease><Disorder><Disturbance in cognition><Encephalitis><Encephalon><Future><Genes><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Dementia><HIV Infections><HIV associated dementia><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV cure><HIV disease><HIV functional cure><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection persistence><HIV latency><HIV neurocognitive impairment><HIV people><HIV persistence><HIV positive individuals><HIV positive people><HIV replication><HIV viral infection><HIV viral persistence><HIV viral replication><HIV virus infection><HIV-1><HIV-1 associated dementia><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 cure><HIV-1 dementia><HIV-1 disease><HIV-1 functional cure><HIV-1 infection><HIV-1 persistence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-2><HIV-I><HIV-II><HIV-associated neurocognitive disorder><HIV-related dementia><HIV/AIDS cure><HIV/AIDS disease><HIV1><HIV2><HTLV-IV><Heterograft><Heterologous Transplantation><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 2><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type IV><Human immunodeficiency virus 1><Human immunodeficiency virus 2><IQ Deficit><Immune><Immune response><Immunes><Impaired cognition><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammasome><Inflammation><Inflammatory><Inflammatory Response><LAV-2><LAV-HTLV-III><Lineage Tracing><Literature><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Microglia><Modeling><Modern Man><Morbidity><Myeloid Cells><NIDA><National Institute of Drug Abuse><National Institute on Drug Abuse><Neuraxis><Neurocognitive><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurologic Manifestations><Neurologic Signs and Symptoms><Neurologic Symptoms><Neurological Manifestations><Neurological Signs and Symptoms><Nicotine><Nicotinic Acetylcholine Receptors><Nicotinic Receptors><Outcome><PLWH><PWH><Pathway interactions><Persons><Play><Population><Productivity><RNA Seq><RNA sequencing><RNAseq><Research><Role><Sampling><Signal Pathway><Site><Smoke><Smoker><Smoking><Substance Use Disorder><System><Testing><Therapeutic Intervention><Time><Tissue Model><Tobacco smoke><Tobacco smoking><Tobacco smoking behavior><Tonsil><United States><Upregulation><Viral reservoir><Virus><Virus reservoir><Virus-HIV><Work><Xenograft><Xenograft procedure><Xenotransplantation><asymptomatic HIV infection><bio-markers><biologic marker><biomarker><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cell type><cellular lineage mapping><cellular lineage tracking><chronic HIV infection><clinical relevance><clinically relevant><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><cohort><comorbidity><developmental><differential expression><differentially expressed><direct application><experience><exposure to nicotine><gitter cell><host response><human immunodeficiency virus cure><human immunodeficiency virus disease><human immunodeficiency virus infection><human immunodeficiency virus persistence><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><humanized mice><humanized mouse><iPS><iPSC><iPSCs><immune system response><immunoresponse><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><insight><intelligence quotient deficit><intervention therapy><latent HIV infection><mesoglia><microglial cell><microgliocyte><mouse model><multidisciplinary><murine model><necropsy><neural inflammation><neural manifestation><neurocognitive decline><neurocognitive impairment><neuroinflammation><neuroinflammatory><new technology><nicotine consumption><nicotine exposure><nicotine use><non-smoker><nonsmoker><novel><novel technologies><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><postmortem><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><substance use and disorder><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic target><tonsillar><transcriptional differences><transcriptome sequencing><transcriptomic sequencing><virology><xeno-transplant><xeno-transplantation>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mingnan Chen

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$756,078
FY 2026

Project Title

Deciphering the Interplay of Depleting Anti-PD-1 Antibodies and Autoimmune Environments in Type-1 Diabetes: Towards Better Utility of Therapeutic Antibody

Grant Number:

1R01AI187812-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/19/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY This project aims to investigate the interactions and impacts between a depleting antibody (D-aPD-1) that targets programmed death-1-expressing (PD-1+) cells and the autoimmune environment in type 1 diabetes (T1D). PD- 1+ cells are primarily effector lymphocytes that are diabetogenic...

Research Terms

<Ab-mediated immunity><Ab-mediated protection><Acceleration><Address><Adverse effects><Affect><Affinotoxins><After Care><After-Treatment><Aftercare><Age><Albumins><Amendment><Antibodies><Antibody Therapy><Antibody immunity><Antibody protection><Antibody-drug conjugates><Antibody-mediated protection><Autoimmune><Autoimmune Diseases><Autoimmune Responses><Autoimmune Status><Autoimmunity><Automobile Driving><B9 endocrine pancreas><Brittle Diabetes Mellitus><Cell Body><Cells><Characteristics><Chronic Disease><Chronic Illness><Clinical><Cytotoxin-Antibody Conjugates><Development><Diabetes Mellitus><Disease><Disease Management><Disorder><Disorder Management><Endocrine Pancreas><Environment><Family><Fc Receptor><Female><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Foundations><Gene Expression><Hyperglycemia><Hyperglycemic Mice><IDDM><Immune><Immune response><Immunes><Immunotoxins><Inbred NOD Mice><Individual><Insulin-Dependent Diabetes Mellitus><Islands of Langerhans><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Lymphatic cell><Lymphocyte><Lymphocytic><Mediating><Mediator><Mice><Mice Mammals><Monoclonal Antibody-Toxin Conjugates><Murine><Mus><NOD Mouse><Nesidioblasts><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Outcome><PD 1><PD-1><PD-1 antibody><PD1><PD1 antibody><Pancreatic Islets><Pars endocrina pancreatis><Pathway interactions><Patients><Persons><Play><Population><Pre-Clinical Model><Preclinical Models><Public Health><R-Series Research Projects><R01 Mechanism><R01 Program><Research><Research Grants><Research Project Grants><Research Projects><Role><Shapes><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><Testing><Therapeutic><Therapeutic antibodies><Toxin-Antibody Conjugates><Toxin-Antibody Hybrids><Treatment outcome><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><aPD-1><aPD1><ages><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><antibody based therapies><antibody receptor><antibody treatment><antibody-based therapeutics><antibody-based treatment><antibody-mediated immunity><autoimmune condition><autoimmune disorder><autoimmunity disease><bi-specific killer engagers><bispecific killer cell engager><bispecific killer engagers><bispecific natural killer engager><cell type><chronic disorder><clinical development><combinatorial><comparative><cytotoxic><design><designing><develop therapy><developmental><diabetes><diabetogenic><driving><effective therapy><effective treatment><flow cytophotometry><host response><hyperglycemic><immune system response><immunoresponse><improved><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><insulitis><intervention development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><lymph cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathway><post treatment><preservation><programmed cell death 1><programmed cell death protein 1><programmed death 1><protective effect><public health relevance><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><social role><systemic lupus erythematosus susceptibility 2><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapy development><treatment development><type I diabetes><type one diabetes><αPD-1><αPD1><♀>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Julie Paik

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$745,846
FY 2026

Project Title

Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease

Grant Number:

5R01DK135706-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/19/2024

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP- 1RA) are rapidly changing the therapeutic landscape for patients with diabetes and kidney disease, but are underutilized in high-risk populations. Randomized controlled trials (RCTs) have robustly ...

Research Terms

<Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Address><Adverse Experience><Adverse event><Affect><Age><Agonist><Amputation><Anticoagulant Agents><Anticoagulant Drugs><Anticoagulants><Benzodiazepine Compounds><Benzodiazepines><Calibration><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cell Communication and Signaling><Cell Signaling><Clinical><Clinical Management><Complex><D-Glucose><Data><Data Bases><Databases><Dextrose><Diabetes Mellitus><Diabetic Acidosis><Diabetic Ketoacidosis><Diabetic Ketosis><Diabetic Kidney Disease><Diabetic Nephropathy><Dipeptidyl Aminopeptidases><Dipeptidyl Peptidases><Dipeptidylpeptide Hydrolases><Disease Progression><Drug Interactions><Drug Prescribing><Drug Prescriptions><Drugs><Education><Educational aspects><Effectiveness><Electronic Health Record><Ethnic Origin><Ethnicity><Event><Exclusion><Fracture><GLP-1 receptor><GLP-I receptor><Glucose><Goals><Health Care><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Heart Vascular><Humulin R><Hyperpotassemia><Hypoglycemia><Impairment><Incentives><Individual><Insulin><Intracellular Communication and Signaling><Kidney><Kidney Diseases><Kidney Urinary System><Knowledge><Link><Medicaid><Medicare><Medication><Methodology><Monitor><Nephropathy><Novolin R><Older Population><Patient Care><Patient Care Delivery><Patients><Pharmaceutical Preparations><Polypharmacy><Population><Race><Races><Randomized, Controlled Trials><Regular Insulin><Renal Disease><Renal function><Residual><Residual state><Risk><SGLT 2 inhibitor><SGLT2i><Safety><Sample Size><Scanning><Signal Transduction><Signal Transduction Systems><Signaling><Sodium glucose co-transporter 2 inhibitor><Subgroup><Sulfonylurea Compounds><Surveillance Methods><Therapeutic><Time><Title 18><Trees><Update><Urinary tract infection><Urinary tract infectious disease><active comparator><active comparison control><acute kidney injury><adverse event risk><ages><biological signal transduction><blood thinner><bone fracture><care for patients><care of patients><caring for patients><circulatory system><clinical care><clinical practice><clinical relevance><clinically relevant><cohort><data base><data mining><datamining><diabetes><diabetic ketoacidotic><drug safety><drug/agent><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><falls><frailty><genital infection><glucagon-like peptide-1 receptor><health insurance for disabled><high reward><high risk><high risk group><high risk individual><high risk people><high risk population><hyperkalemia><hypoglycemic><hypoglycemic episodes><implementation efforts><inhibitor><insight><kidney disorder><kidney function><medication prescription><medication safety><multimorbidity><multiple chronic conditions><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><older groups><older individuals><older person><pharmaceutical safety><prescribed medication><programs><prospective><racial><racial background><racial origin><randomized control trial><renal><renal disorder><safety outcomes><screening><screenings><sex><statistics><sulfonylurea><thrombopoiesis inhibitor><urinary infection>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Raimund Ingo Herzog

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$742,174
FY 2026

Project Title

Mechanism of ultrasound neuromodulation effects on glucose homeostasis and diabetes

Grant Number:

5R01DK131127-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary The dominant and increasingly evident role of the central nervous system in glucose metabolism regulation remains an attractive therapeutic target for diabetes. Brain stem and hypothalamic coordinating centers of feeding and glucose homeostasis have been well characterized over the ...

Research Terms

<Abdomen><Acute><Address><Adult-Onset Diabetes Mellitus><Affect><Afferent Neurons><Alimentary Canal><Animal Model><Animal Models and Related Studies><Animals><Antidiabetic Hormone><Area><Autonomic Pathways><Autonomic nervous system><Autoregulation><Brain><Brain Nervous System><Brain Stem><Brainstem><CNS Nervous System><Carbon><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cells><Central Nervous System><Circulation><Clinical><Clinical Data><Clinical Research><Clinical Study><D-Glucose><Denervation><Development><Dextrose><Diabetes Mellitus><Diagnosis><Digestive Tract><Distal><Encephalon><Endocrine Gland Secretion><Euglycemic Clamping><Euglycemic-hyperinsulinemic Clamp><Focused Ultrasound><Focused Ultrasound Ablation><Focused Ultrasound Therapy><Focused Ultrasound Treatment><GI Tract><GLP-1><Gastrointestinal Tract><Gastrointestinal tract structure><Genetic><Glp-1><Glucagon><Glucose><Glucose Clamp><Glukagon><Glycogen><HG-Factor><Hepatic><Hepatic Glycogen><Hepatology><High Power Focused Ultrasound><High-intensity focused ultrasound><Homeostasis><Hormones><Human><Humulin R><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><Hyperinsulinemic Clamp><Hypothalamic structure><Hypothalamus><Individual><Ingestion><Insulin><Insulin Resistance><Intracellular Communication and Signaling><Investigation><Ion Channel><Ionic Channels><Ketosis-Resistant Diabetes Mellitus><Link><Liver Glycogen><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Mediating><Mediator><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Membrane Channels><Mesenteric><Mesentery><Metabolic><Methods><Mice><Mice Mammals><Microelectrodes><Miniaturized Electrodes><Modality><Modeling><Modern Man><Molecular><Murine><Mus><NIDDM><NMR Imaging><NMR Spectrometer><NMR Spectroscopy><NMR Tomography><Nerve><Nerve Cells><Nerve Fibers><Nerve Plexus><Nerve Unit><Nervous System><Neural Cell><Neuraxis><Neurocyte><Neuroendocrinology><Neurologic Body System><Neurologic Organ System><Neurons><Newly Diagnosed><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Non-pharmacologic Therapy><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nonpharmacologic Intervention><Nonpharmacologic Therapy><Nonpharmacologic approach><Nonpharmacologic treatment><Novolin R><Nuclear Magnetic Resonance Imaging><Nucleus><Nutrient><OGTT><Oral Glucose Tolerance Test><Patients><Peripheral><Physiologic pulse><Physiological Homeostasis><Pilot Projects><Play><Portal Vein><Portal vein structure><Pre-Clinical Model><Preclinical Models><Preclinical data><Pulse><Reflex><Reflex action><Reflex control><Regular Insulin><Regulation><Resistance><Rodent Model><Role><Scientist><Sensory><Sensory Neurons><Signal Transduction><Signal Transduction Systems><Signaling><Site><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><T2 DM><T2D><T2DM><Testing><Therapeutic Effect><Therapeutic Hormone><Time><Tracer><Transgenic Organisms><Type 2 Diabetes Mellitus><Type 2 diabetes><Type 2 diabetic><Type II Diabetes Mellitus><Type II diabetes><Type II diabetic><Ultrasonic Therapy><Uncertainty><Validation><Work><Zeugmatography><adult onset diabetes><alimentary tract><alternative treatment><biological signal transduction><blood glucose regulation><cell type><clinical translation><clinically translatable><design><designing><developmental><diabetes><diabetic><diabetic patient><digestive canal><doubt><euglycemia><experiment><experimental research><experimental study><experiments><feeding><gastrointestinal><ghrelin><glucagon-like peptide 1><glucose control><glucose disposal><glucose homeostasis><glucose metabolism><glucose regulation><glucose sensor><glucose tolerance><glycemic control><human subject><hyperglycemic><hypothalamic><image-based method><imaging method><imaging modality><ingest><innovate><innovation><innovative><insulin resistant><insulin sensitivity><insulin stimulated glucose disposal><insulin tolerance><ketosis resistant diabetes><maturity onset diabetes><model of animal><neural circuit><neural circuitry><neural control><neural regulation><neurocircuitry><neuromodulation><neuromodulatory><neuronal><neuroregulation><non-drug therapy><non-drug treatment><nondrug therapy><nondrug treatment><novel><nuclear magnetic resonance spectroscopy><optogenetics><pilot study><pre-clinical><pre-clinical study><preclinical><preclinical findings><preclinical information><preclinical study><resistant><response><sensor><skills><social role><stable isotope><synaptic circuit><synaptic circuitry><synergism><therapeutic target><therapeutic ultrasound><tool><transgenic><translational study><treatment site><type 2 DM><type II DM><type two diabetes><ultrasonic treatment><ultrasound><ultrasound based therapy><ultrasound guided therapy><ultrasound therapy><ultrasound treatment><validations>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Maureen A Gannon

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$735,808
FY 2026

Project Title

Nrf2 and the expansion and preservation of beta cell mass

Grant Number:

5R01DK139631-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary All major forms of diabetes result from a deficit of functional β-cells. Thus, it is critically important to develop therapies to preserve and expand β-cell mass. We have demonstrated that Nrf2, the master transcriptional regulator of antioxidant enzymes, plays a significant role in modulati...

Research Terms

<3'5'-cyclic ester of AMP><ATAC sequencing><ATAC-seq><ATACseq><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Age><Aging><Agonist><Antioxidants><Assay for Transposase-Accessible Chromatin using sequencing><Beta Cell><Biologic Models><Biological Models><Cell Body><Cell Communication and Signaling><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Protection><Cell Signaling><Cells><Cellular Proliferation><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Cues><Cyclic AMP><Cytoprotection><D-Glucose><Data><Development><Dextrose><Diabetes Mellitus><Diabetic mouse><Diet><Dinoprostone><Disease><Disorder><EP4><Eicosanoids><Epididymal Secretory Protein E4><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GLP-1 receptor><GLP-I receptor><GPCR><Gene Targeting><Gene Transcription><Genes><Genetic Transcription><Glucose><Glucose Intolerance><HE4><Human><Humulin R><Immunodeficient Mouse><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Investigators><Knowledge><Lead><Link><Major Epididymis-Specific Protein E4><Mediating><Metabolic stress><Model System><Modeling><Modern Man><Molecular><Novolin R><Oxidative Stress><PGE2><PGE2 alpha><PGE2alpha><Pathway interactions><Patients><Pb element><Phenotype><Play><Position><Positioning Attribute><Proliferating><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Protective Agents><Protective Drugs><Publishing><Putative Protease Inhibitor WAP5><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Receptor Activation><Receptor Protein><Regular Insulin><Research Personnel><Researchers><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Testing><Therapeutic><Toxic effect><Toxicities><Transcription><Transplantation><Treatment Efficacy><WAP Four-Disulfide Core Domain Protein 2><WAP5><WFDC2><WFDC2 gene><Work><adenosine 3'5' monophosphate><ages><antagonism><antagonist><anti-oxidant enzyme><antioxidant enzyme><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><biological signal transduction><cAMP><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><cytokine><cytoprotective><dJ461P17.6><db/db mouse><develop therapy><developmental><diabetes><diabetes mouse model><diets><experience><gain of function><global gene expression><global transcription profile><glucagon-like peptide-1 receptor><glucose tolerance><heavy metal Pb><heavy metal lead><improved><in vivo><innovate><innovation><innovative><intervention development><intervention efficacy><islet><loss of function><mouse model><murine model><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><preservation><prevent><preventing><receptor><social role><therapeutic efficacy><therapeutic evaluation><therapeutic testing><therapy development><therapy efficacy><transcriptome><transcriptome sequencing><transcriptomic sequencing><transplant><treatment development><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Adolfo Garcia-Ocana

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$735,808
FY 2026

Project Title

Nrf2 and the expansion and preservation of beta cell mass

Grant Number:

5R01DK139631-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary All major forms of diabetes result from a deficit of functional β-cells. Thus, it is critically important to develop therapies to preserve and expand β-cell mass. We have demonstrated that Nrf2, the master transcriptional regulator of antioxidant enzymes, plays a significant role in modulati...

Research Terms

<3'5'-cyclic ester of AMP><ATAC sequencing><ATAC-seq><ATACseq><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Age><Aging><Agonist><Antioxidants><Assay for Transposase-Accessible Chromatin using sequencing><Beta Cell><Biologic Models><Biological Models><Cell Body><Cell Communication and Signaling><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Protection><Cell Signaling><Cells><Cellular Proliferation><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Cues><Cyclic AMP><Cytoprotection><D-Glucose><Data><Development><Dextrose><Diabetes Mellitus><Diabetic mouse><Diet><Dinoprostone><Disease><Disorder><EP4><Eicosanoids><Epididymal Secretory Protein E4><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GLP-1 receptor><GLP-I receptor><GPCR><Gene Targeting><Gene Transcription><Genes><Genetic Transcription><Glucose><Glucose Intolerance><HE4><Human><Humulin R><Immunodeficient Mouse><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Investigators><Knowledge><Lead><Link><Major Epididymis-Specific Protein E4><Mediating><Metabolic stress><Model System><Modeling><Modern Man><Molecular><Novolin R><Oxidative Stress><PGE2><PGE2 alpha><PGE2alpha><Pathway interactions><Patients><Pb element><Phenotype><Play><Position><Positioning Attribute><Proliferating><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Protective Agents><Protective Drugs><Publishing><Putative Protease Inhibitor WAP5><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Receptor Activation><Receptor Protein><Regular Insulin><Research Personnel><Researchers><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Testing><Therapeutic><Toxic effect><Toxicities><Transcription><Transplantation><Treatment Efficacy><WAP Four-Disulfide Core Domain Protein 2><WAP5><WFDC2><WFDC2 gene><Work><adenosine 3'5' monophosphate><ages><antagonism><antagonist><anti-oxidant enzyme><antioxidant enzyme><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><biological signal transduction><cAMP><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><cytokine><cytoprotective><dJ461P17.6><db/db mouse><develop therapy><developmental><diabetes><diabetes mouse model><diets><experience><gain of function><global gene expression><global transcription profile><glucagon-like peptide-1 receptor><glucose tolerance><heavy metal Pb><heavy metal lead><improved><in vivo><innovate><innovation><innovative><intervention development><intervention efficacy><islet><loss of function><mouse model><murine model><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><preservation><prevent><preventing><receptor><social role><therapeutic efficacy><therapeutic evaluation><therapeutic testing><therapy development><therapy efficacy><transcriptome><transcriptome sequencing><transcriptomic sequencing><transplant><treatment development><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DONALD K. SCOTT

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$735,808
FY 2026

Project Title

Nrf2 and the expansion and preservation of beta cell mass

Grant Number:

5R01DK139631-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary All major forms of diabetes result from a deficit of functional β-cells. Thus, it is critically important to develop therapies to preserve and expand β-cell mass. We have demonstrated that Nrf2, the master transcriptional regulator of antioxidant enzymes, plays a significant role in modulati...

Research Terms

<3'5'-cyclic ester of AMP><ATAC sequencing><ATAC-seq><ATACseq><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Age><Aging><Agonist><Antioxidants><Assay for Transposase-Accessible Chromatin using sequencing><Beta Cell><Biologic Models><Biological Models><Cell Body><Cell Communication and Signaling><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Protection><Cell Signaling><Cells><Cellular Proliferation><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Cues><Cyclic AMP><Cytoprotection><D-Glucose><Data><Development><Dextrose><Diabetes Mellitus><Diabetic mouse><Diet><Dinoprostone><Disease><Disorder><EP4><Eicosanoids><Epididymal Secretory Protein E4><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GLP-1 receptor><GLP-I receptor><GPCR><Gene Targeting><Gene Transcription><Genes><Genetic Transcription><Glucose><Glucose Intolerance><HE4><Human><Humulin R><Immunodeficient Mouse><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Investigators><Knowledge><Lead><Link><Major Epididymis-Specific Protein E4><Mediating><Metabolic stress><Model System><Modeling><Modern Man><Molecular><Novolin R><Oxidative Stress><PGE2><PGE2 alpha><PGE2alpha><Pathway interactions><Patients><Pb element><Phenotype><Play><Position><Positioning Attribute><Proliferating><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Protective Agents><Protective Drugs><Publishing><Putative Protease Inhibitor WAP5><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Receptor Activation><Receptor Protein><Regular Insulin><Research Personnel><Researchers><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Testing><Therapeutic><Toxic effect><Toxicities><Transcription><Transplantation><Treatment Efficacy><WAP Four-Disulfide Core Domain Protein 2><WAP5><WFDC2><WFDC2 gene><Work><adenosine 3'5' monophosphate><ages><antagonism><antagonist><anti-oxidant enzyme><antioxidant enzyme><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><biological signal transduction><cAMP><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><cytokine><cytoprotective><dJ461P17.6><db/db mouse><develop therapy><developmental><diabetes><diabetes mouse model><diets><experience><gain of function><global gene expression><global transcription profile><glucagon-like peptide-1 receptor><glucose tolerance><heavy metal Pb><heavy metal lead><improved><in vivo><innovate><innovation><innovative><intervention development><intervention efficacy><islet><loss of function><mouse model><murine model><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><preservation><prevent><preventing><receptor><social role><therapeutic efficacy><therapeutic evaluation><therapeutic testing><therapy development><therapy efficacy><transcriptome><transcriptome sequencing><transcriptomic sequencing><transplant><treatment development><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mojgan Hosseini Naghavi

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$734,072
FY 2026

Project Title

+TIPs as novel host capsid-binding co-factors in early HIV-1 infection

Grant Number:

5R01AI172818-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/9/2023

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Several aspects of early HIV-1 infection are both unusual and still poorly understood. In particular, HIV-1's cone-shaped viral core consists of pentamers and hexamers of capsid (CA) protein and is known to be metastable, undergoing restructuring and CA loss that is driven b...

Research Terms

<4-3 Hydrophobic Repeat><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Amino Acids><Area><Automobile Driving><Binding><Binding Sites><Biochemical><Biochemistry><Biological Chemistry><CLIP-170><CLIP-170 gene><Capsid><Capsid Proteins><Cell Nucleus><Charge><Coat Proteins><Coiled-Coil Domain><Combining Site><Complex><Cone><Conflict><Conflict (Psychology)><Cryo-electron Microscopy><Cryoelectron Microscopy><Cyclophilin A><Cytoplasmic Protein><Cytosol><Data><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Electron Cryomicroscopy><Elongation Factor><GeneHomolog><Goals><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><Homolog><Homologous Gene><Homologue><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Image><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Integration Host Factors><Intracellular Transport><Kinesin><Left><Left-Handed Twist><Mediating><Micro-tubule><Microtubules><Modeling><Molecular Interaction><Motor><Movement><Nucleus><Peptide Domain><Process><Protein Domains><Proteins><Reactive Site><Regulatory Protein><Research><Shapes><Structure><Tertiary Protein Structure><Testing><Tubular><Tubular formation><Viral><Viral Coat Proteins><Viral Genome><Viral Outer Coat Protein><Viral Reverse Transcription><Work><adapter protein><aminoacid><body movement><cofactor><cryo-EM><cryoEM><cryogenic electron microscopy><cytoplasmic linker protein 170><driving><dynactin><dynactin 1><dynein activator protein><genetic regulatory protein><human immunodeficiency virus infection><imaging><infected with HIV><infected with human immunodeficiency virus><insight><mutant><novel><particle><recruit><regulatory gene product><virus genome>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Owen Pornillos

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$734,072
FY 2026

Project Title

+TIPs as novel host capsid-binding co-factors in early HIV-1 infection

Grant Number:

5R01AI172818-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/9/2023

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Several aspects of early HIV-1 infection are both unusual and still poorly understood. In particular, HIV-1's cone-shaped viral core consists of pentamers and hexamers of capsid (CA) protein and is known to be metastable, undergoing restructuring and CA loss that is driven b...

Research Terms

<4-3 Hydrophobic Repeat><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Amino Acids><Area><Automobile Driving><Binding><Binding Sites><Biochemical><Biochemistry><Biological Chemistry><CLIP-170><CLIP-170 gene><Capsid><Capsid Proteins><Cell Nucleus><Charge><Coat Proteins><Coiled-Coil Domain><Combining Site><Complex><Cone><Conflict><Conflict (Psychology)><Cryo-electron Microscopy><Cryoelectron Microscopy><Cyclophilin A><Cytoplasmic Protein><Cytosol><Data><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Electron Cryomicroscopy><Elongation Factor><GeneHomolog><Goals><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><Homolog><Homologous Gene><Homologue><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Image><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Integration Host Factors><Intracellular Transport><Kinesin><Left><Left-Handed Twist><Mediating><Micro-tubule><Microtubules><Modeling><Molecular Interaction><Motor><Movement><Nucleus><Peptide Domain><Process><Protein Domains><Proteins><Reactive Site><Regulatory Protein><Research><Shapes><Structure><Tertiary Protein Structure><Testing><Tubular><Tubular formation><Viral><Viral Coat Proteins><Viral Genome><Viral Outer Coat Protein><Viral Reverse Transcription><Work><adapter protein><aminoacid><body movement><cofactor><cryo-EM><cryoEM><cryogenic electron microscopy><cytoplasmic linker protein 170><driving><dynactin><dynactin 1><dynein activator protein><genetic regulatory protein><human immunodeficiency virus infection><imaging><infected with HIV><infected with human immunodeficiency virus><insight><mutant><novel><particle><recruit><regulatory gene product><virus genome>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MICHAEL Ilya BUKRINSKY

STATE UNIVERSITY NEW YORK STONY BROOK, STONY BROOK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$733,977
FY 2026

Project Title

The effects of cART and HIV-1 infection on neural circuitry

Grant Number:

5R01MH134776-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT A significant proportion of individuals receiving antiretroviral therapy (ART) for HIV-1 infection develop cognitive deficits. This may be due solely to the HIV-1 infection; however, this may also indicate that prolonged ART itself may contribute to the impairments, particularly in the cont...

Research Terms

<3-D><3-D Imaging><3-Dimensional><3D><3D imaging><AIDS><AIDS Virus><AIDS drugs><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advanced HIV><Affect><Animal Model><Animal Models and Related Studies><Animals><Anti-AIDS Agents><Anti-AIDS Drugs><Anti-HIV Agents><Anti-HIV Drugs><Anti-Human Immunodeficiency Virus Agents><Anti-Retroviral Agents><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Brain><Brain Mapping><Brain Nervous System><Brain region><Cell Body><Cells><Clinical><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Complement><Complement Proteins><Complex><Conditioning Therapy><Conflict><Conflict (Psychology)><Data><Data Set><Disease><Disorder><Disturbance in cognition><Drug Side Effects><Drug Therapy><Drugs><Elements><Encephalon><Exposure to><FBJ osteosarcoma oncogene><FOS gene><Future><G0S7><Genetic><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV disease transmission><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection transmission><HIV intervention><HIV neurocognitive impairment><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-I><HIV-associated neurocognitive disorder><HIV/AIDS transmission><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Impaired cognition><Impairment><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Maps><Medication><Memory><Mice><Mice Mammals><Microscopic><Molecular><Monitor><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurocyte><Neurons><PLWH><PWH><Pathogenesis><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Population><PrEP><Prophylactic treatment><Prophylaxis><Protooncogene FOS><Proxy><Regimen><Research><Risk><Severe HIV Disease><Tenofovir><Testing><Therapeutic><Three-Dimensional Imaging><Time><Viread><Virus-HIV><anti-retroviral><antiAIDS agent><antiretroviral therapy><antiretroviral treatment><behavior intervention><behavioral intervention><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><brain circuitry><c fos><c-fos Gene><c-fos Proto-Oncogenes><candidate validation><clinical relevance><clinically relevant><cognitive defects><cognitive dysfunction><cognitive function><cognitive loss><cognitive process><complementation><drug intervention><drug treatment><drug/agent><emtricitabine><experience><experiment><experimental research><experimental study><experiments><full scale manufacturing><human immunodeficiency virus infection><human immunodeficiency virus transmission><in silico><in vivo><in vivo monitoring><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><large scale manufacturing><large scale production><mass production><model of animal><mortality><mouse model><murine model><neural circuit><neural circuitry><neural network><neurocircuitry><neuronal><neuronal patterning><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapeutics><new therapy><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapeutics><novel therapy><novel therapy approach><novel therapy target><optogenetics><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-exposure prophylaxis><prevent><preventing><response to therapy><response to treatment><side effect><social><spread of human immunodeficiency virus><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><therapeutic response><therapy response><three dimensional><time measurement><tool><treat HIV><treat Human Immunodeficiency Virus><treatment effect><treatment response><treatment responsiveness><v-FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GRIGORI N ENIKOLOPOV

STATE UNIVERSITY NEW YORK STONY BROOK, STONY BROOK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$733,977
FY 2026

Project Title

The effects of cART and HIV-1 infection on neural circuitry

Grant Number:

5R01MH134776-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT A significant proportion of individuals receiving antiretroviral therapy (ART) for HIV-1 infection develop cognitive deficits. This may be due solely to the HIV-1 infection; however, this may also indicate that prolonged ART itself may contribute to the impairments, particularly in the cont...

Research Terms

<3-D><3-D Imaging><3-Dimensional><3D><3D imaging><AIDS><AIDS Virus><AIDS drugs><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advanced HIV><Affect><Animal Model><Animal Models and Related Studies><Animals><Anti-AIDS Agents><Anti-AIDS Drugs><Anti-HIV Agents><Anti-HIV Drugs><Anti-Human Immunodeficiency Virus Agents><Anti-Retroviral Agents><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Brain><Brain Mapping><Brain Nervous System><Brain region><Cell Body><Cells><Clinical><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Complement><Complement Proteins><Complex><Conditioning Therapy><Conflict><Conflict (Psychology)><Data><Data Set><Disease><Disorder><Disturbance in cognition><Drug Side Effects><Drug Therapy><Drugs><Elements><Encephalon><Exposure to><FBJ osteosarcoma oncogene><FOS gene><Future><G0S7><Genetic><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV disease transmission><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection transmission><HIV intervention><HIV neurocognitive impairment><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-I><HIV-associated neurocognitive disorder><HIV/AIDS transmission><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Impaired cognition><Impairment><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Maps><Medication><Memory><Mice><Mice Mammals><Microscopic><Molecular><Monitor><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurocyte><Neurons><PLWH><PWH><Pathogenesis><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Population><PrEP><Prophylactic treatment><Prophylaxis><Protooncogene FOS><Proxy><Regimen><Research><Risk><Severe HIV Disease><Tenofovir><Testing><Therapeutic><Three-Dimensional Imaging><Time><Viread><Virus-HIV><anti-retroviral><antiAIDS agent><antiretroviral therapy><antiretroviral treatment><behavior intervention><behavioral intervention><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><brain circuitry><c fos><c-fos Gene><c-fos Proto-Oncogenes><candidate validation><clinical relevance><clinically relevant><cognitive defects><cognitive dysfunction><cognitive function><cognitive loss><cognitive process><complementation><drug intervention><drug treatment><drug/agent><emtricitabine><experience><experiment><experimental research><experimental study><experiments><full scale manufacturing><human immunodeficiency virus infection><human immunodeficiency virus transmission><in silico><in vivo><in vivo monitoring><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><large scale manufacturing><large scale production><mass production><model of animal><mortality><mouse model><murine model><neural circuit><neural circuitry><neural network><neurocircuitry><neuronal><neuronal patterning><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapeutics><new therapy><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapeutics><novel therapy><novel therapy approach><novel therapy target><optogenetics><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-exposure prophylaxis><prevent><preventing><response to therapy><response to treatment><side effect><social><spread of human immunodeficiency virus><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><therapeutic response><therapy response><three dimensional><time measurement><tool><treat HIV><treat Human Immunodeficiency Virus><treatment effect><treatment response><treatment responsiveness><v-FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALEXEI KOULAKOV

STATE UNIVERSITY NEW YORK STONY BROOK, STONY BROOK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$733,977
FY 2026

Project Title

The effects of cART and HIV-1 infection on neural circuitry

Grant Number:

5R01MH134776-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT A significant proportion of individuals receiving antiretroviral therapy (ART) for HIV-1 infection develop cognitive deficits. This may be due solely to the HIV-1 infection; however, this may also indicate that prolonged ART itself may contribute to the impairments, particularly in the cont...

Research Terms

<3-D><3-D Imaging><3-Dimensional><3D><3D imaging><AIDS><AIDS Virus><AIDS drugs><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advanced HIV><Affect><Animal Model><Animal Models and Related Studies><Animals><Anti-AIDS Agents><Anti-AIDS Drugs><Anti-HIV Agents><Anti-HIV Drugs><Anti-Human Immunodeficiency Virus Agents><Anti-Retroviral Agents><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Brain><Brain Mapping><Brain Nervous System><Brain region><Cell Body><Cells><Clinical><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Complement><Complement Proteins><Complex><Conditioning Therapy><Conflict><Conflict (Psychology)><Data><Data Set><Disease><Disorder><Disturbance in cognition><Drug Side Effects><Drug Therapy><Drugs><Elements><Encephalon><Exposure to><FBJ osteosarcoma oncogene><FOS gene><Future><G0S7><Genetic><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV disease transmission><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection transmission><HIV intervention><HIV neurocognitive impairment><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-I><HIV-associated neurocognitive disorder><HIV/AIDS transmission><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Impaired cognition><Impairment><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Maps><Medication><Memory><Mice><Mice Mammals><Microscopic><Molecular><Monitor><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurocyte><Neurons><PLWH><PWH><Pathogenesis><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Population><PrEP><Prophylactic treatment><Prophylaxis><Protooncogene FOS><Proxy><Regimen><Research><Risk><Severe HIV Disease><Tenofovir><Testing><Therapeutic><Three-Dimensional Imaging><Time><Viread><Virus-HIV><anti-retroviral><antiAIDS agent><antiretroviral therapy><antiretroviral treatment><behavior intervention><behavioral intervention><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><brain circuitry><c fos><c-fos Gene><c-fos Proto-Oncogenes><candidate validation><clinical relevance><clinically relevant><cognitive defects><cognitive dysfunction><cognitive function><cognitive loss><cognitive process><complementation><drug intervention><drug treatment><drug/agent><emtricitabine><experience><experiment><experimental research><experimental study><experiments><full scale manufacturing><human immunodeficiency virus infection><human immunodeficiency virus transmission><in silico><in vivo><in vivo monitoring><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><large scale manufacturing><large scale production><mass production><model of animal><mortality><mouse model><murine model><neural circuit><neural circuitry><neural network><neurocircuitry><neuronal><neuronal patterning><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapeutics><new therapy><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapeutics><novel therapy><novel therapy approach><novel therapy target><optogenetics><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-exposure prophylaxis><prevent><preventing><response to therapy><response to treatment><side effect><social><spread of human immunodeficiency virus><synaptic circuit><synaptic circuitry><temporal measurement><temporal resolution><therapeutic response><therapy response><three dimensional><time measurement><tool><treat HIV><treat Human Immunodeficiency Virus><treatment effect><treatment response><treatment responsiveness><v-FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yingchang Lu

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$728,959
FY 2026

Project Title

Virtual systemic identification of drug targets of obesity candidate genes

Grant Number:

5R01DK135938-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Over 40% of adults are obese in the US. Although reducing caloric intake and/or increasing physical activity can lead to weight loss in the short to medium term in some people, they lose efficacy in the long term. Bariatric surgeries are currently the most durable and effective treatment for obesity...

Research Terms

<Action Potentials><Adverse effects><Agonist><Amygdala><Amygdaloid Body><Amygdaloid Nucleus><Amygdaloid structure><Anti-Obesity Agents><Anti-Obesity Drugs><Anxiety><Appetite><Arcuate Nucleus><BMI><BMI percentile><BMI z-score><Behavior><Behavioral><Bipolar Affective Psychosis><Bipolar Disorder><Blood Plasma><Body Weight decreased><Body fat><Body mass index><Brain><Brain Nervous System><Brain Stem><Brainstem><CNS Nervous System><CRISPR><CRISPR/Cas system><Caloric Intake><Candidate Disease Gene><Candidate Gene><Central Nervous System><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><DNA mutation><Data><Desire for food><Digestion><Dopamine Antagonists><Dopamine Receptor Antagonists><Dopaminergic Antagonists><Drug Targeting><Drug usage><Eating><Electronic Health Record><Encephalon><Endocannabinoids><Endogenous Cannabinoids><Energy Intake><Esthesia><FDA approved><Feeling suicidal><Food Intake><GLP-1 receptor><GLP-I receptor><GWA study><GWAS><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetic study><Health system><Hypothalamic structure><Hypothalamus><In Vitro><Individual><Induced pluripotent stem cell derived neurons><Infundibular Nucleus><Insulinoma amyloid peptide><Intermediary Metabolism><Investigation><LEPR><LEPR gene><Length><Leptin><Limbic System><Link><Major Depressive Disorder><Manic-Depressive Psychosis><Mendelian randomization><Mental Depression><Metabolic Processes><Metabolism><Methodology><Molecular><Moods><Mutation><Nerve Cells><Nerve Unit><Neural Cell><Neuraxis><Neurites><Neurocyte><Neuron from iPSC><Neuron from induced pluripotent stem cells><Neurons><Neuropeptides><Nucleus Accumbens><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Protein><Obesity><Obesity Epidemic><Obsessive-Compulsive Disorder><Obsessive-Compulsive Neurosis><Participant><Pathogenicity><Pathway interactions><Patients><Peripheral><Persons><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Physical activity><Plasma><Plasma Serum><Prevention><Production><Proteins><Proteome><Quetelet index><Receptor Protein><Reporting><Research Resources><Resources><Reticuloendothelial System, Serum, Plasma><Rewards><Risk Behaviors><Risky Behavior><Safety><Satiation><Sensation><Smoking><Structure of nucleus infundibularis hypothalami><Suicidal thoughts><TOPMed><Trans-Omics for Precision Medicine><Transcript><Veterans><Waist-Hip Ratio><Weight Loss><Weight Reduction><Work><acomplia><adipogenesis><adiposity><adult adiposity><adult obesity><adults with obesity><amlintide><amygdaloid nuclear complex><amylin><analog><antagonism><antagonist><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><at risk behavior><bariatric surgery><biobank><biorepository><bipolar affective disorder><bipolar disease><bipolar illness><bipolar mood disorder><body weight loss><caloric dietary content><cardiometabolic><cardiometabolism><clinical depression><co-morbid><co-morbidity><cohort><comorbidity><compound repositioning><compound repurposing><corpulence><depression><diabetes associated peptide><differentiation of pluripotent stem cells><differentiation protocol><drinking><drug action><drug repositioning><drug repurposing><drug use><effective therapy><effective treatment><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><exome><exome sequencing><exome-seq><functional genomics><gastric banding><gastric bypass surgery><gene signatures><genetic resource><genetic signature><genome mutation><genome wide association><genome wide association scan><genome wide association study><genomewide association scan><genomewide association study><global gene expression><global transcription profile><glucagon-like peptide-1 receptor><hiPSC><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><hypothalamic><iPS neurons><iPSC derived-neurons><implantable gastric stimulation banding><induced human pluripotent stem cells><induced pluripotent stem cell neurons><innovate><innovation><innovative><insulin signaling><insulinoma amyloid polypeptide><islet amyloid polypeptide><lipid biosynthesis><lipogenesis><liraglutide><major depression><major depression disorder><manic depressive disorder><manic depressive illness><neural circuit><neural circuitry><neurocircuitry><neuronal><neurons derived from induced pluripotent stem cells><neurons differentiated from induced pluripotent stem cells><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapeutic uses for existing drugs><new therapy target><new use of drug><new uses for an approved drug><new uses for existing drugs><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><obesity intervention><obesity risk><obesity surgery><obesity therapy><obesity treatment><pancreatic amylin><pathway><pharmaceutical><pharmacologic><pharmacological repurposing><phenome><pluripotent stem cell differentiation><programs><receptor><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><rimonabant><risk for obesity><risk of obesity><satiety><screening><screenings><stomach stapling><substance use><substance using><success><suicidal ideation><suicidal thinking><suicide ideation><synaptic circuit><synaptic circuitry><therapeutic repositioning><therapeutic repurposing><therapeutic target><thoughts about suicide><trait><transcriptome><virtual><waist-to-hip ratio><weight loss surgery><whole genome association analysis><whole genome association study><wt-loss><zimulti>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alon Herschhorn

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$713,107
FY 2026

Project Title

Molecular determinants and vulnerabilities of HIV-1 spread by cell-to-cell transmission

Grant Number:

1R01AI195206-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/20/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract. HIV-1 replicates in host cells to produce new virions by two alternative routes. As free virus, HIV-1 buds from infected cells and circulates in the host until encountering a new permissive target cell. In addition, HIV-1 can efficiently spread by direct transmission from infected to uninf...

Research Terms

<(IFN) α><(IFN)-α><(IFN)α><AIDS Virus><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Alferon><Antibody Response><Assay><Bioassay><Biological Assay><Biology><Body Tissues><C-C CKR-5><C-C CKR-5 Gene><C-C Chemokine Receptor Type 5><C-C Chemokine Receptor Type 5 Gene><C-X-C Chemokine Receptor Type 4><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CC Chemokine Receptor 5><CC-CKR-5><CC-CKR-5 Gene><CC-CKR5><CCCKR5><CCCKR5 Gene><CCR-5><CCR-5 Gene><CCR5><CCR5 Protein><CCR5 Receptors><CCR5 gene><CD184 Antigen><CD195 Antigen><CD195 Antigen Gene><CD4 Antigens><CD4 Cells><CD4 Molecule><CD4 Positive T Lymphocytes><CD4 Protein><CD4 Receptors><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD94 Antigen><CHEMR13><CHEMR13 Gene><CKR-5><CKR-5 Gene><CKR5><CKR5 Gene><CKR5 Receptors><CMKBR5><CMKBR5 Gene><CXCR4 Receptors><Cell Body><Cell Junctions><Cell Line><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><CellLine><Cells><Cellular Cytotoxicity><Chemokine (C-C Motif) Receptor 5><Chemokine (C-C) Receptor 5><Chemokine (C-C) Receptor 5 Gene><Chemokine (C-X-C Motif) Receptor 4><Chemokine, CXC Motif, Receptor 4><Clinical><Cryo-electron Microscopy><Cryoelectron Microscopy><Development><Drugs><Electron Cryomicroscopy><Elements><Endogenous Interferon Beta><Event><Exhibits><Fibroblast Interferon><Foundations><Fusin><Generalized Growth><Genes><Glycoproteins><Growth><HIV><HIV disease transmission><HIV infection spread><HIV infection transmission><HIV replication><HIV spread><HIV transmission><HIV viral replication><HIV viral transmission><HIV-1 Fusion Co-Receptor><HIV-1 Fusion Co-Receptor Gene><HIV-1 replication><HIV-1 spread><HIV-1 transmission><HIV-1 viral replication><HIV-1 virus replication><HIV-1 virus transmission><HIV/AIDS transmission><Host Factor><Host Factor Protein><Human><Human Biology><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Viruses><IFN><IFN Alpha><IFN α><IFN-α><IFN-β><IFNa><IFNb><IFNα><IgG Receptors><Imaging technology><Immune><Immune Evasion><Immunes><Immunoglobulin G Receptor><In Situ Hybridization><In Vitro><Integration Host Factors><Intercellular Junctions><Interferon Alfa-n3><Interferon Type I><Interferon-α><Interferon-β><Interferons><Interruption><KLRD1 Protein><Killer Cell Lectin-Like Receptor Subfamily D, Member 1><Killer Cell Lectin-Like Receptor Subfamily D, Member 1 Isoforms 1, 2><Killer Cell Lectin-Like Receptor Subfamily D, Member 1 Protein><Knowledge><Kp43 antigen><LAV-HTLV-III><LESTR Receptor><LPS-Associated Protein 3><Leukocyte Interferon><Leukocyte-Derived Seven-Transmembrane Domain Receptor><Link><Lipopolysaccharide-Associated Protein 3><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphadenopathy-Associated Virus><Lymphatic nodes><Lymphoblast Interferon><Lymphoblastoid Interferon><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Lytotoxicity><Measures><Mediating><Medication><Membrane><Modality><Modern Man><Molecular><NHP models><NK Cell Receptor><NK receptor><Natural Interferon Beta><Natural Killer Cells Antigen CD94><Natural human interferon beta><Neuropeptide Y Receptor Y3><OKT4 antigen><Pathogenesis><Patients><Pattern><Persons><Pharmaceutical Preparations><Population><Prevention><Productivity><Proteins><Recrudescences><Resistance><Resolution><Route><SDF-1 Receptor><SDF1/PBSF Receptor CXCR4><Site><Specificity><Spleen Seven-Transmembrane-Segment Receptor><Staining method><Stains><Strains Cell Lines><Stromal Cell-Derived Factor 1 Receptor><Structure><Surface CD4 Receptors><T cells for CAR><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T4 molecule><Therapeutic><Therapeutic Agents><Time><Tissue Growth><Tissues><Transmission><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Pathogenesis><Viral Physiology><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus-HIV><Visualization><antiretroviral therapy><antiretroviral treatment><cell mediated cytotoxicity><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cryo-EM><cryoEM><cryogenic electron microscopy><cultured cell line><cytotoxicity><design><designing><developmental><drug/agent><engineered NK cell><engineered natural killer cell><gamma Fc Receptors><helper T lymphocyte marker><high resolution imaging><human immunodeficiency virus replication><human immunodeficiency virus transmission><human immunodeficiency virus-1 replication><human model><humanized mice><humanized mouse><image-based method><imaging method><imaging modality><immune evasive><improved><in situ Hybridization Genetics><in situ Hybridization Staining Method><in vivo><insight><latency/reactivation><lymph gland><lymph nodes><lymphnodes><membrane structure><model of human><mouse model><murine model><neutralizing antibody><nonhuman primate models><ontogeny><permissiveness><reactivation from latency><resistant><resolutions><small molecule><spread of human immunodeficiency virus><thymus derived lymphocyte><tool><transmission process><viral infection><viral multiplication><viral replication><viral transmission><virological synapse><virus infection><virus multiplication><virus pathogenesis><virus transmission><virus-induced disease><work group><working group>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zandrea Ambrose

BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), BOSTON, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$703,756
FY 2026

Project Title

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis

Grant Number:

5R01AI175068-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2023

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Antiretroviral pre-exposure prophylaxis (PrEP) is an important tool for preventing transmission to virus naïve individuals and plays an important role in current efforts to end the HIV epidemic. If taken daily current oral PrEP strategies reliably block HIV transmission. However, the require...

Research Terms

<AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Anti-Retroviral Agents><Binding><Biological Mimetics><Biomimetics><Body Tissues><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cells><Clinical Research><Clinical Study><Collection><Communities><Dendrimers><Dendritic Cells><Dendritic Compounds><Dendrons><Development><Diagnosis><Drug Delivery><Drug Delivery Systems><Drug Formulations><Drug Precursors><Drugs><Encapsulated><Engineering><Ensure><Epidemic><Exhibits><Fatigue><Federal Government><Food and Drug Administration><Formulation><Fumarates><Future><G(M3) Ganglioside><Ganglioside GM3><HIV><HIV Infections><HIV disease transmission><HIV incidence><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection in mucosa><HIV infection spread><HIV infection transmission><HIV mucosal challenge><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 incidence><HIV-1 infection><HIV-1 infection in mucosa><HIV-1 infection incidence><HIV-1 mucosal challenge><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS incidence><HIV/AIDS transmission><HIV1><Hematoside><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrophobicity><II3NeuAcLacCer><In Vitro><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammatory Response><Injectable><Injections><Institution><Intake><Integrase><LAV-HTLV-III><Lack of Energy><Length><Link><Lipids><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Macrophage><Maintenance><Mediating><Medication><Membrane><Mice><Mice Mammals><Micelles><Modern Man><Molecular Interaction><Mucosa><Mucosal Inflammation><Mucosal Tissue><Mucositis><Mucous Membrane><Murine><Mus><Myeloid Cells><Mφ><NIH><NNRTI><National Government><National Institutes of Health><Nucleosides><Oral><PLWH><PWH><Pharmaceutical Preparations><Physiologic><Physiological><Play><Polymers><PrEP><Preventative strategy><Prevention strategy><Preventive strategy><Primary Prevention><Pro-Drugs><Prodrugs><Property><Public Health><Randomized, Controlled Trials><Rectum><Reverse Transcriptase Inhibitors><Risk><Role><Sexual Transmission><Sialyl Lactosylceramide><Sialyllactosylceramide><Site><Surface><System><T4 Cells><T4 Lymphocytes><Temperature><Tenofovir><Testing><Time><Tissues><Transmission><USFDA><United States><United States Food and Drug Administration><United States National Institutes of Health><Vagina><Veiled Cells><Viral Diseases><Viread><Virus><Virus Diseases><Virus-HIV><Work><anti-retroviral><antiretroviral therapy><antiretroviral treatment><aqueous><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><copolymer><crosslink><design><designing><determine efficacy><developmental><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><emtricitabine><evaluate efficacy><examine efficacy><extracellular vesicles><female genital tract><female reproductive tract><high risk><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus transmission><humanized mice><humanized mouse><hydrophilicity><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><interest><interstitial><membrane structure><mouse model><mucosal HIV infection><mucosal HIV-1 infection><murine model><nano particle><nano polymer><nano-sized particle><nanoparticle><nanopolymer><nanosized particle><non-human primate><non-nucleoside RT inhibitors><non-nucleoside reverse transcriptase inhibitors><nonhuman primate><nonnucleoside reverse transcriptase inhibitors><open label><open label study><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pill><polymer><polymeric><pre-exposure prophylaxis><prevent><preventing><randomized control trial><sexually transmitted><site targeted delivery><social role><spread of human immunodeficiency virus><targeted delivery><technology platform><technology system><tool><transmission process><uptake><viral infection><virus infection><virus-induced disease><women's genital tract><women's reproductive tract>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SURYARAM GUMMULURU

BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), BOSTON, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$703,756
FY 2026

Project Title

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis

Grant Number:

5R01AI175068-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2023

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Antiretroviral pre-exposure prophylaxis (PrEP) is an important tool for preventing transmission to virus naïve individuals and plays an important role in current efforts to end the HIV epidemic. If taken daily current oral PrEP strategies reliably block HIV transmission. However, the require...

Research Terms

<AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Anti-Retroviral Agents><Binding><Biological Mimetics><Biomimetics><Body Tissues><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cells><Clinical Research><Clinical Study><Collection><Communities><Dendrimers><Dendritic Cells><Dendritic Compounds><Dendrons><Development><Diagnosis><Drug Delivery><Drug Delivery Systems><Drug Formulations><Drug Precursors><Drugs><Encapsulated><Engineering><Ensure><Epidemic><Exhibits><Fatigue><Federal Government><Food and Drug Administration><Formulation><Fumarates><Future><G(M3) Ganglioside><Ganglioside GM3><HIV><HIV Infections><HIV disease transmission><HIV incidence><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection in mucosa><HIV infection spread><HIV infection transmission><HIV mucosal challenge><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 incidence><HIV-1 infection><HIV-1 infection in mucosa><HIV-1 infection incidence><HIV-1 mucosal challenge><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS incidence><HIV/AIDS transmission><HIV1><Hematoside><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrophobicity><II3NeuAcLacCer><In Vitro><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammatory Response><Injectable><Injections><Institution><Intake><Integrase><LAV-HTLV-III><Lack of Energy><Length><Link><Lipids><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Macrophage><Maintenance><Mediating><Medication><Membrane><Mice><Mice Mammals><Micelles><Modern Man><Molecular Interaction><Mucosa><Mucosal Inflammation><Mucosal Tissue><Mucositis><Mucous Membrane><Murine><Mus><Myeloid Cells><Mφ><NIH><NNRTI><National Government><National Institutes of Health><Nucleosides><Oral><PLWH><PWH><Pharmaceutical Preparations><Physiologic><Physiological><Play><Polymers><PrEP><Preventative strategy><Prevention strategy><Preventive strategy><Primary Prevention><Pro-Drugs><Prodrugs><Property><Public Health><Randomized, Controlled Trials><Rectum><Reverse Transcriptase Inhibitors><Risk><Role><Sexual Transmission><Sialyl Lactosylceramide><Sialyllactosylceramide><Site><Surface><System><T4 Cells><T4 Lymphocytes><Temperature><Tenofovir><Testing><Time><Tissues><Transmission><USFDA><United States><United States Food and Drug Administration><United States National Institutes of Health><Vagina><Veiled Cells><Viral Diseases><Viread><Virus><Virus Diseases><Virus-HIV><Work><anti-retroviral><antiretroviral therapy><antiretroviral treatment><aqueous><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><copolymer><crosslink><design><designing><determine efficacy><developmental><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><emtricitabine><evaluate efficacy><examine efficacy><extracellular vesicles><female genital tract><female reproductive tract><high risk><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus transmission><humanized mice><humanized mouse><hydrophilicity><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><interest><interstitial><membrane structure><mouse model><mucosal HIV infection><mucosal HIV-1 infection><murine model><nano particle><nano polymer><nano-sized particle><nanoparticle><nanopolymer><nanosized particle><non-human primate><non-nucleoside RT inhibitors><non-nucleoside reverse transcriptase inhibitors><nonhuman primate><nonnucleoside reverse transcriptase inhibitors><open label><open label study><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pill><polymer><polymeric><pre-exposure prophylaxis><prevent><preventing><randomized control trial><sexually transmitted><site targeted delivery><social role><spread of human immunodeficiency virus><targeted delivery><technology platform><technology system><tool><transmission process><uptake><viral infection><virus infection><virus-induced disease><women's genital tract><women's reproductive tract>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bjoern Markus Reinhard

BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), BOSTON, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$703,756
FY 2026

Project Title

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis

Grant Number:

5R01AI175068-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2023

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary Antiretroviral pre-exposure prophylaxis (PrEP) is an important tool for preventing transmission to virus naïve individuals and plays an important role in current efforts to end the HIV epidemic. If taken daily current oral PrEP strategies reliably block HIV transmission. However, the require...

Research Terms

<AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Anti-Retroviral Agents><Binding><Biological Mimetics><Biomimetics><Body Tissues><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cells><Clinical Research><Clinical Study><Collection><Communities><Dendrimers><Dendritic Cells><Dendritic Compounds><Dendrons><Development><Diagnosis><Drug Delivery><Drug Delivery Systems><Drug Formulations><Drug Precursors><Drugs><Encapsulated><Engineering><Ensure><Epidemic><Exhibits><Fatigue><Federal Government><Food and Drug Administration><Formulation><Fumarates><Future><G(M3) Ganglioside><Ganglioside GM3><HIV><HIV Infections><HIV disease transmission><HIV incidence><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection in mucosa><HIV infection spread><HIV infection transmission><HIV mucosal challenge><HIV people><HIV positive individuals><HIV positive people><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 incidence><HIV-1 infection><HIV-1 infection in mucosa><HIV-1 infection incidence><HIV-1 mucosal challenge><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS incidence><HIV/AIDS transmission><HIV1><Hematoside><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrophobicity><II3NeuAcLacCer><In Vitro><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammatory Response><Injectable><Injections><Institution><Intake><Integrase><LAV-HTLV-III><Lack of Energy><Length><Link><Lipids><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid Tissue><Macrophage><Maintenance><Mediating><Medication><Membrane><Mice><Mice Mammals><Micelles><Modern Man><Molecular Interaction><Mucosa><Mucosal Inflammation><Mucosal Tissue><Mucositis><Mucous Membrane><Murine><Mus><Myeloid Cells><Mφ><NIH><NNRTI><National Government><National Institutes of Health><Nucleosides><Oral><PLWH><PWH><Pharmaceutical Preparations><Physiologic><Physiological><Play><Polymers><PrEP><Preventative strategy><Prevention strategy><Preventive strategy><Primary Prevention><Pro-Drugs><Prodrugs><Property><Public Health><Randomized, Controlled Trials><Rectum><Reverse Transcriptase Inhibitors><Risk><Role><Sexual Transmission><Sialyl Lactosylceramide><Sialyllactosylceramide><Site><Surface><System><T4 Cells><T4 Lymphocytes><Temperature><Tenofovir><Testing><Time><Tissues><Transmission><USFDA><United States><United States Food and Drug Administration><United States National Institutes of Health><Vagina><Veiled Cells><Viral Diseases><Viread><Virus><Virus Diseases><Virus-HIV><Work><anti-retroviral><antiretroviral therapy><antiretroviral treatment><aqueous><beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine><copolymer><crosslink><design><designing><determine efficacy><developmental><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><emtricitabine><evaluate efficacy><examine efficacy><extracellular vesicles><female genital tract><female reproductive tract><high risk><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus transmission><humanized mice><humanized mouse><hydrophilicity><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><interest><interstitial><membrane structure><mouse model><mucosal HIV infection><mucosal HIV-1 infection><murine model><nano particle><nano polymer><nano-sized particle><nanoparticle><nanopolymer><nanosized particle><non-human primate><non-nucleoside RT inhibitors><non-nucleoside reverse transcriptase inhibitors><nonhuman primate><nonnucleoside reverse transcriptase inhibitors><open label><open label study><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pill><polymer><polymeric><pre-exposure prophylaxis><prevent><preventing><randomized control trial><sexually transmitted><site targeted delivery><social role><spread of human immunodeficiency virus><targeted delivery><technology platform><technology system><tool><transmission process><uptake><viral infection><virus infection><virus-induced disease><women's genital tract><women's reproductive tract>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel A Lawrence

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$692,404
FY 2026

Project Title

A Novel PAI-1 Function Drives Lung Fibrosis

Grant Number:

5R01HL163870-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2022

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Progressive scarring of the lung interstitium is a common feature of many systemic and primary lung diseases including Idiopathic Pulmonary Fibrosis (IPF). IPF is a common disorder, and patients diagnosed with this disorder experience substantial morbidity and a median survival of 3...

Research Terms

<AD dementia><ASCVD><Afibrinogenemia><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Animal Model><Animal Models and Related Studies><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Attenuated><Binding><Biology><Biotin><Bleo><Bleomycin><Body Tissues><Bone-Derived Transforming Growth Factor><Cell Body><Cell Line><Cell Surface Receptors><CellLine><Cells><Cessation of life><Chimera Protein><Chimeric Proteins><Cicatrix><Complement S-Protein><Confocal Microscopy><Congenital afibrinogenemia><Congenital hypofibrinogenemia><Cytoplasm><DNA mutation><Data><Death><Diagnosis><Disease><Disease Pathway><Disease Progression><Disorder><Drugs><Endocytosis><Epibolin><Epithelial Cells><Essential Amino Acids><Factor I Deficiency><Fibrinogen Deficiency><Fibrinolyses><Fibrinolysis><Fibroblasts><Fibrosing Alveolitis><Fibrosis><Fibrotic lesions in lung><Foundations><Fusion Protein><Gene Deletion><Genetic Change><Genetic defect><Genetic mutation><Heart><Hereditary factor I deficiency disease><Hereditary hypofibrinogenemia><Human><In Vitro><Incidence><KI mice><Kidney><Kidney Urinary System><Knock-in Mouse><Label><Lesion><Ligands><Ligase><Ligase Gene><Liver><Lung><Lung Alveolar Epithelia><Lung Diseases><Lung Respiratory System><Lung Tissue Fibrosis><Lung damage><Lung scar><Lung tissue scar><Mediating><Mediator><Medication><Mice><Mice Mammals><Milk Growth Factor><Modeling><Modern Man><Molecular Biology Techniques><Molecular Interaction><Morbidity><Murine><Mus><Mutation><Organ><PAI-1><PAI1><PLANH1><Pathway interactions><Patients><Phage Display><Pharmaceutical Preparations><Phenotype><Plasminogen Activator><Plasminogen Activator Inhibitor 1><Plasminogen Activator Interaction><Platelet Transforming Growth Factor><Primary Senile Degenerative Dementia><Profibrotic factor><Profibrotic signal><Protein Sortings><Proteins><Proteomics><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary Scar><Pulmonary Tissue fibrosis><Receptor Protein><Regulation><Role><Scarring at the lung><Scarring in the lung><Scars><Serine or Cysteine Proteinase Inhibitor Clade E Member 1><Serum Spreading Factor><Severities><Shortness of Breath><Skin><Stimulus><Strains Cell Lines><Surface Plasmon Resonance><Synthetases><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Testing><Therapeutic><Tissues><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Transgenic Mice><Type 1 Plasminogen Activator Inhibitor><U-PA><U-Plasminogen Activator><Urinary Plasminogen Activator><Urokinase><Urokinase Plasminogen Activator><Urokinase-Type Plasminogen Activator><Vitamin H><Vitronectin><Wound Repair><aging associated disease><aging associated disorders><aging related disease><aging related disorders><alveolar epithelium><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><attenuate><attenuates><coenzyme R><cultured cell line><design><designing><diffuse interstitial pulmonary fibrosis><disease associated with aging><disease of aging><disease of the lung><disorder of aging><disorder of the lung><disorders associated with aging><disorders related to aging><drug/agent><efficacious intervention><efficacious therapy><efficacious treatment><experience><experiment><experimental research><experimental study><experiments><fibrogenesis><fibrosis in the lung><fibrotic lung><gene deletion mutation><genome mutation><hepatic body system><hepatic organ system><idiopathic pulmonary fibrosis><in vivo><inhibitor><knockin mice><lung development><lung disorder><lung fibrosis><lung injury><model of animal><mortality><mosaic><mouse model><murine model><mutant><mutation scanning><mutation screening><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><pathway><prevent><preventing><primary degenerative dementia><protein reconstitution><prototype><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><receptor><renal><senile dementia of the Alzheimer type><small molecule><social role><sortilin><therapeutic target><uptake><validation studies><wound healing><wound recovery><wound resolution>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

THOMAS H SISSON

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$692,404
FY 2026

Project Title

A Novel PAI-1 Function Drives Lung Fibrosis

Grant Number:

5R01HL163870-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2022

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Progressive scarring of the lung interstitium is a common feature of many systemic and primary lung diseases including Idiopathic Pulmonary Fibrosis (IPF). IPF is a common disorder, and patients diagnosed with this disorder experience substantial morbidity and a median survival of 3...

Research Terms

<AD dementia><ASCVD><Afibrinogenemia><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Animal Model><Animal Models and Related Studies><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Attenuated><Binding><Biology><Biotin><Bleo><Bleomycin><Body Tissues><Bone-Derived Transforming Growth Factor><Cell Body><Cell Line><Cell Surface Receptors><CellLine><Cells><Cessation of life><Chimera Protein><Chimeric Proteins><Cicatrix><Complement S-Protein><Confocal Microscopy><Congenital afibrinogenemia><Congenital hypofibrinogenemia><Cytoplasm><DNA mutation><Data><Death><Diagnosis><Disease><Disease Pathway><Disease Progression><Disorder><Drugs><Endocytosis><Epibolin><Epithelial Cells><Essential Amino Acids><Factor I Deficiency><Fibrinogen Deficiency><Fibrinolyses><Fibrinolysis><Fibroblasts><Fibrosing Alveolitis><Fibrosis><Fibrotic lesions in lung><Foundations><Fusion Protein><Gene Deletion><Genetic Change><Genetic defect><Genetic mutation><Heart><Hereditary factor I deficiency disease><Hereditary hypofibrinogenemia><Human><In Vitro><Incidence><KI mice><Kidney><Kidney Urinary System><Knock-in Mouse><Label><Lesion><Ligands><Ligase><Ligase Gene><Liver><Lung><Lung Alveolar Epithelia><Lung Diseases><Lung Respiratory System><Lung Tissue Fibrosis><Lung damage><Lung scar><Lung tissue scar><Mediating><Mediator><Medication><Mice><Mice Mammals><Milk Growth Factor><Modeling><Modern Man><Molecular Biology Techniques><Molecular Interaction><Morbidity><Murine><Mus><Mutation><Organ><PAI-1><PAI1><PLANH1><Pathway interactions><Patients><Phage Display><Pharmaceutical Preparations><Phenotype><Plasminogen Activator><Plasminogen Activator Inhibitor 1><Plasminogen Activator Interaction><Platelet Transforming Growth Factor><Primary Senile Degenerative Dementia><Profibrotic factor><Profibrotic signal><Protein Sortings><Proteins><Proteomics><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary Scar><Pulmonary Tissue fibrosis><Receptor Protein><Regulation><Role><Scarring at the lung><Scarring in the lung><Scars><Serine or Cysteine Proteinase Inhibitor Clade E Member 1><Serum Spreading Factor><Severities><Shortness of Breath><Skin><Stimulus><Strains Cell Lines><Surface Plasmon Resonance><Synthetases><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Testing><Therapeutic><Tissues><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Transgenic Mice><Type 1 Plasminogen Activator Inhibitor><U-PA><U-Plasminogen Activator><Urinary Plasminogen Activator><Urokinase><Urokinase Plasminogen Activator><Urokinase-Type Plasminogen Activator><Vitamin H><Vitronectin><Wound Repair><aging associated disease><aging associated disorders><aging related disease><aging related disorders><alveolar epithelium><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><attenuate><attenuates><coenzyme R><cultured cell line><design><designing><diffuse interstitial pulmonary fibrosis><disease associated with aging><disease of aging><disease of the lung><disorder of aging><disorder of the lung><disorders associated with aging><disorders related to aging><drug/agent><efficacious intervention><efficacious therapy><efficacious treatment><experience><experiment><experimental research><experimental study><experiments><fibrogenesis><fibrosis in the lung><fibrotic lung><gene deletion mutation><genome mutation><hepatic body system><hepatic organ system><idiopathic pulmonary fibrosis><in vivo><inhibitor><knockin mice><lung development><lung disorder><lung fibrosis><lung injury><model of animal><mortality><mosaic><mouse model><murine model><mutant><mutation scanning><mutation screening><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><pathway><prevent><preventing><primary degenerative dementia><protein reconstitution><prototype><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><receptor><renal><senile dementia of the Alzheimer type><small molecule><social role><sortilin><therapeutic target><uptake><validation studies><wound healing><wound recovery><wound resolution>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DARA L KRAITCHMAN

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$690,951
FY 2026

Project Title

Image-guided Bariatric Arterial Embolization (BAE) for the Treatment of Obesity

Grant Number:

5R01DK135399-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2013

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Over 40% of Americans are obese, with the prevalence of obesity continuing to rise. Obesity negatively affects general health and has been attributed to an increasing incidence of diabetes, heart disease, vascular disease, joint stress, lumbar spine disorders, liver and biliary disease, and various ...

Research Terms

<90Y><Address><Affect><American><Animal Model><Animal Models and Related Studies><Animals><Appetite><Appetite stimulated><Arterial Embolization><Arteries><Attenuated><BMI><BMI percentile><BMI z-score><Bariatrics><Biliary><Blood Vessels><Body Weight decreased><Body mass index><Brain><Brain Nervous System><Cancer Treatment><Cancers><Canine Species><Canis familiaris><Cardiac Diseases><Cardiac Disorders><Catheters><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Client><Clinical><Clinical Trials><Complex><Cranial Nerve X><Cryoablation><Cryosurgery><Data><Desire for food><Diabetes Mellitus><Diameter><Disease><Disorder><Dogs><Dogs Mammals><Early-Stage Clinical Trials><Embolism><Embolization Therapy><Embolotherapy><Embolus><Encapsulated><Encephalon><Endocrine><Endocrine Gland Secretion><Equipment><Esophagogastric Junction><Family suidae><Feeling><Funding><Fundus><GLP-1><Gastric Inflammation><Gastric ulcer><Gastrins><Gastritis><Gastroesophageal Junction><Glp-1><Goals><Grant><Health><Heart Diseases><Hormonal><Hormones><Human><Hunger><Hyperthermia><Image><Imaging Device><Imaging Instrument><Imaging Procedures><Imaging Technics><Imaging Techniques><Imaging Tool><Incidence><Increased food appetite><Injury><Intervention><Intestinal><Intestines><Intracellular Communication and Signaling><Ischemia><Label><Liver><Location><Magnetism><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Medical Care Costs><Microbeads><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Microspheres><Modeling><Modern Man><Morbid Obesity><Obesity><Operative Procedures><Operative Surgical Procedures><Organ><Overweight><Pancreas><Pancreatic><Patients><Perforation><Persons><Phase 1 Clinical Trials><Phase I Clinical Trials><Pigs><Pneumogastric Nerve><Prevalence><Procedures><Production><Progress Reports><Quetelet index><Radioactive><Radioembolization><Radiolabeled><Reflux><Risk><Safety><Satiation><Serious Adverse Event><Severe Adverse Event><Severe obesity><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Diseases><Spleen><Spleen Reticuloendothelial System><Stomach><Stomach Ulcer><Structure><Suidae><Surgical><Surgical Interventions><Surgical Procedure><Swine><Techniques><Tenth Cranial Nerve><Testing><Therapeutic Embolization><Therapeutic Hormone><Translating><Translations><Ulcer><Ulceration><United States><Vagus Nerve><Vagus nerve structure><Vascular Diseases><Vascular Disorder><Vascular blood supply><Weight><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Y-90><Yttrium 90><adiposity><anti-cancer therapy><appetite loss><attenuate><attenuates><bariatric surgery><biological signal transduction><blood supply><blood vessel disorder><body weight gain><body weight increase><body weight loss><bowel><cancer therapy><cancer-directed therapy><canine><canine animal model><canine model><clinical hyperthermia><clinical relevance><clinically relevant><cone-beam CT><cone-beam computed tomography><corpulence><cost><diabetes><dog model><domestic dog><embolization><esophagogastric sphincter><extreme obesity><feelings><gastric><gastric artery><gastric banding><gastric bypass surgery><gastric fundus><ghrelin><glucagon-like peptide 1><heart disorder><heat injury><hepatic body system><hepatic organ system><hyperthermia therapy><hyperthermia treatment><image guidance><image guided><image guided therapy><imaging><implantable gastric stimulation banding><improved><increased appetite><increased hunger><injuries><iron oxide nano particle><iron oxide nanoparticle><joint stress><magnetic><malignancy><medical costs><medical expenses><meter><microfluidic chip><minimally invasive><model of animal><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><obese patients><obesity intervention><obesity surgery><obesity therapy><obesity treatment><patients with obesity><phase I protocol><porcine><radiolabeling><radiologically labeled><reconstruction><satiety><serious adverse experience><serious adverse reaction><site targeted delivery><soft tissue><spine disorder><stomach fundus><stomach stapling><success><suid><surgery><targeted delivery><thermal injury><translation><translation to humans><tumor><vascular><vascular dysfunction><vascular supply><vasculopathy><volume CT><volume computed tomography><volumetric computed tomography><weight loss surgery><weights><wt gain><wt-loss><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Clifford Raabe Weiss

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$690,951
FY 2026

Project Title

Image-guided Bariatric Arterial Embolization (BAE) for the Treatment of Obesity

Grant Number:

5R01DK135399-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2013

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Over 40% of Americans are obese, with the prevalence of obesity continuing to rise. Obesity negatively affects general health and has been attributed to an increasing incidence of diabetes, heart disease, vascular disease, joint stress, lumbar spine disorders, liver and biliary disease, and various ...

Research Terms

<90Y><Address><Affect><American><Animal Model><Animal Models and Related Studies><Animals><Appetite><Appetite stimulated><Arterial Embolization><Arteries><Attenuated><BMI><BMI percentile><BMI z-score><Bariatrics><Biliary><Blood Vessels><Body Weight decreased><Body mass index><Brain><Brain Nervous System><Cancer Treatment><Cancers><Canine Species><Canis familiaris><Cardiac Diseases><Cardiac Disorders><Catheters><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Client><Clinical><Clinical Trials><Complex><Cranial Nerve X><Cryoablation><Cryosurgery><Data><Desire for food><Diabetes Mellitus><Diameter><Disease><Disorder><Dogs><Dogs Mammals><Early-Stage Clinical Trials><Embolism><Embolization Therapy><Embolotherapy><Embolus><Encapsulated><Encephalon><Endocrine><Endocrine Gland Secretion><Equipment><Esophagogastric Junction><Family suidae><Feeling><Funding><Fundus><GLP-1><Gastric Inflammation><Gastric ulcer><Gastrins><Gastritis><Gastroesophageal Junction><Glp-1><Goals><Grant><Health><Heart Diseases><Hormonal><Hormones><Human><Hunger><Hyperthermia><Image><Imaging Device><Imaging Instrument><Imaging Procedures><Imaging Technics><Imaging Techniques><Imaging Tool><Incidence><Increased food appetite><Injury><Intervention><Intestinal><Intestines><Intracellular Communication and Signaling><Ischemia><Label><Liver><Location><Magnetism><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Medical Care Costs><Microbeads><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Microspheres><Modeling><Modern Man><Morbid Obesity><Obesity><Operative Procedures><Operative Surgical Procedures><Organ><Overweight><Pancreas><Pancreatic><Patients><Perforation><Persons><Phase 1 Clinical Trials><Phase I Clinical Trials><Pigs><Pneumogastric Nerve><Prevalence><Procedures><Production><Progress Reports><Quetelet index><Radioactive><Radioembolization><Radiolabeled><Reflux><Risk><Safety><Satiation><Serious Adverse Event><Severe Adverse Event><Severe obesity><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Diseases><Spleen><Spleen Reticuloendothelial System><Stomach><Stomach Ulcer><Structure><Suidae><Surgical><Surgical Interventions><Surgical Procedure><Swine><Techniques><Tenth Cranial Nerve><Testing><Therapeutic Embolization><Therapeutic Hormone><Translating><Translations><Ulcer><Ulceration><United States><Vagus Nerve><Vagus nerve structure><Vascular Diseases><Vascular Disorder><Vascular blood supply><Weight><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Y-90><Yttrium 90><adiposity><anti-cancer therapy><appetite loss><attenuate><attenuates><bariatric surgery><biological signal transduction><blood supply><blood vessel disorder><body weight gain><body weight increase><body weight loss><bowel><cancer therapy><cancer-directed therapy><canine><canine animal model><canine model><clinical hyperthermia><clinical relevance><clinically relevant><cone-beam CT><cone-beam computed tomography><corpulence><cost><diabetes><dog model><domestic dog><embolization><esophagogastric sphincter><extreme obesity><feelings><gastric><gastric artery><gastric banding><gastric bypass surgery><gastric fundus><ghrelin><glucagon-like peptide 1><heart disorder><heat injury><hepatic body system><hepatic organ system><hyperthermia therapy><hyperthermia treatment><image guidance><image guided><image guided therapy><imaging><implantable gastric stimulation banding><improved><increased appetite><increased hunger><injuries><iron oxide nano particle><iron oxide nanoparticle><joint stress><magnetic><malignancy><medical costs><medical expenses><meter><microfluidic chip><minimally invasive><model of animal><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><obese patients><obesity intervention><obesity surgery><obesity therapy><obesity treatment><patients with obesity><phase I protocol><porcine><radiolabeling><radiologically labeled><reconstruction><satiety><serious adverse experience><serious adverse reaction><site targeted delivery><soft tissue><spine disorder><stomach fundus><stomach stapling><success><suid><surgery><targeted delivery><thermal injury><translation><translation to humans><tumor><vascular><vascular dysfunction><vascular supply><vasculopathy><volume CT><volume computed tomography><volumetric computed tomography><weight loss surgery><weights><wt gain><wt-loss><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TRACEY MCLAUGHLIN

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$681,391
FY 2026

Project Title

Rapid Gastric Emptying: A Modifiable Risk Factor for Postbariatric Hypoglycemia

Grant Number:

1R01DK143214-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/12/2026

End Date:

2/28/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT: Bariatric surgery provides substantial health benefits, including diabetes remission, but up to 38% of cases are complicated by symptomatic and disabling postprandial hypoglycemia which occurs multiple times per day, with glucose concentrations low enough to cause seizures, loss of conscio...

Research Terms

<Accidents><Active Follow-up><Affect><Agonist><Amentia><Anxiety><Arrhythmia><Bariatrics><Beta Cell><Blood Glucose><Blood Sugar><Cardiac Arrhythmia><Case Study><Case-Base Studies><Cell secretion><Cellular Secretion><Cessation of life><Child Care><Clinical><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><D-Glucose><Data><Death><Dementia><Development><Dextrose><Diabetes Mellitus><Dietary Fats><Disabling><Disease remission><Distal><Disturbance in cognition><Eating><Evaluation><Event><Exposure to><Familiarity><Fats><Fatty acid glycerol esters><Fear><Food Intake><Fright><GLP-1><Gamma Camera Imaging><Gastrectomy><Gastric Bypass><Gastric Emptying><Gastric Remnant><Gastric Stump><Gastrostomy><Glp-1><Glucose><Health><Health Benefit><Heart Arrhythmias><Hindgut><Humulin R><Hyperinsulinemia><Hyperinsulinism><Hypertrophy><Hypoglycemia><Impaired cognition><Individual><Injury><Insulin><Insulin Cell><Insulin Secreting Cell><Intermediary Metabolism><Intervention><Malnutrition><Medical><Metabolic><Metabolic Marker><Metabolic Processes><Metabolism><Modality><Novolin R><Nutrient><Nutritional Deficiency><Operative Procedures><Operative Surgical Procedures><Oral><Oral Ingestion><Patients><Physical Function><Physiologic><Physiological><Physiology><Population><Postprandial Hypoglycemia><Prevention><Prospective Studies><Puericulture><QOL><Quality of life><Radioisotope Scanning><Radionuclide Imaging><Reactive hypoglycemia><Regular Insulin><Remission><Remnant Stomach><Residual Stomach><Rest><Risk><Risk Factors><Role><Safety><Scintigraphy><Seizures><Small Intestines><Standardization><Stomach><Surgeon><Surgical><Surgical Interventions><Surgical Procedure><Testing><Time><Unconscious><Unconscious State><Unconsciousness><Undernutrition><Work><active followup><analog><antagonism><antagonist><bariatric surgery><case report><cognitive dysfunction><cognitive function><cognitive loss><consciousness loss><developmental><diabetes><dietary><dietary deficiency><dietary lipid><disability><efficacy testing><experience><follow up><follow-up><followed up><followup><gastric><gastric banding><gastric bypass surgery><glucagon-like peptide 1><hypoglycemia unawareness><hypoglycemic><hypoglycemic episodes><hypoglycemic reaction><ileum><implantable gastric stimulation banding><incretin hormone><injuries><insulin secretion><insulin sensitivity><malleable risk><malnourished><modifiable risk><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><nutrition deficiency><nutrition deficiency disorder><nutritional deficiency disorder><obesity surgery><off-label application><off-label prescribing><off-label use><prospective><prospective research study><prospective survey><psychosocial><radionuclide imaging/scanning><radionuclide scanning><repurposing><small bowel><social role><stomach bypass><stomach emptying><stomach stapling><surgery><weight loss surgery><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JOY Marie SCHMITZ

UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, HOUSTON, TX

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$679,454
FY 2026

Project Title

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study

Grant Number:

5R01DA062720-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/15/2025

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The United States is experiencing a resurgence in cocaine use and cocaine related mortality. In 2021, approximately 1.4 million Americans met criteria for cocaine use disorder (CUD) with cocaine involved in nearly 25,000 overdose deaths, a 22% increase since 2020. No FDA-approved ph...

Research Terms

<Adult-Onset Diabetes Mellitus><Agonist><Alcohol Chemical Class><Alcohol Drinking><Alcohol consumption><Alcohols><American><Animals><Area><Attenuated><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Blood Glucose><Blood Sugar><Brain><Brain Nervous System><Brain region><Cannabis><Clinical><Clinical Trials><Cocaine><Cocaine use disorder><Cognition Therapy><Cognitive Psychotherapy><Cognitive Therapy><Cognitive treatment><Conditioning Therapy><Consumption><Cues><Development><Dopamine><Dose><Drug Screening><Drug Therapy><Drugs><Effectiveness><Encephalon><EtOH drinking><EtOH use><Event-Related Potentials><Ex4 peptide><Exendin 4><Exhibits><Experimental Therapies><FDA approved><Feedback><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Goals><Human><Hydroxytyramine><Hyperphagia><Incentives><Intermediary Metabolism><Investigational Therapies><Investigational Treatments><Ketosis-Resistant Diabetes Mellitus><Literature><Marijuana><Maturity-Onset Diabetes Mellitus><Measures><Medication><Metabolic><Metabolic Processes><Metabolism><Modern Man><Motivation><NIDA><NIDDM><National Institute of Drug Abuse><National Institute on Drug Abuse><Neural Pathways><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nucleus Accumbens><Obesity><Outcome><Overeating><Pathway interactions><Patient Self-Report><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Placebos><Psychometrics><Questionnaires><Rewards><Satiation><Schedule><Self-Report><Sham Treatment><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulus><Strategic Planning><System><T2 DM><T2D><T2DM><Testing><Titrations><Tobacco><Tobacco smoking><Tobacco smoking behavior><Treatment outcome><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Urine><adiposity><adult onset diabetes><alcohol ingestion><alcohol intake><alcohol product use><alcohol use><alcoholic beverage consumption><alcoholic drink intake><attenuate><attenuates><behavior intervention><behavior measurement><behavioral economics><behavioral intervention><behavioral measure><behavioral measurement><clinical practice><cocaine craving><cocaine cue><cocaine self-administration><cocaine use><cognitive behavior intervention><cognitive behavior modification><cognitive behavior therapy><cognitive behavioral intervention><cognitive behavioral modification><cognitive behavioral therapy><cognitive behavioral treatment><compound repositioning><compound repurposing><conditioned place preference><corpulence><craving><design><designing><developmental><drug intervention><drug repositioning><drug repurposing><drug treatment><drug/agent><effective therapy><effective treatment><efficacy trial><ethanol consumption><ethanol drinking><ethanol ingestion><ethanol intake><ethanol product use><ethanol use><event related potential><evidence base><exenatide><experience><experimental therapeutic agents><experimental therapeutics><glucagon-like peptide 1><glucagon-like peptide receptor><glucagon-like peptide-1 receptor><hedonic><improved><incretin hormone><indexing><ketosis resistant diabetes><marihuana><maturity onset diabetes><mortality><multi-modality><multimodality><neurophysiological><neurophysiology><new therapeutic uses for existing drugs><new use of drug><new uses for an approved drug><new uses for existing drugs><novel><overdose death><overdose fatalities><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological repurposing><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><place conditioning><polyphagia><pre-clinical><preclinical><randomized, clinical trials><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><response><response to therapy><response to treatment><satiety><self-administer cocaine><sham therapy><subcutaneous><subdermal><therapeutic repositioning><therapeutic repurposing><therapeutic response><therapy response><treatment effect><treatment response><treatment responsiveness><trial comparing><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Francesco Versace

UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, HOUSTON, TX

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$679,454
FY 2026

Project Title

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study

Grant Number:

5R01DA062720-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/15/2025

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The United States is experiencing a resurgence in cocaine use and cocaine related mortality. In 2021, approximately 1.4 million Americans met criteria for cocaine use disorder (CUD) with cocaine involved in nearly 25,000 overdose deaths, a 22% increase since 2020. No FDA-approved ph...

Research Terms

<Adult-Onset Diabetes Mellitus><Agonist><Alcohol Chemical Class><Alcohol Drinking><Alcohol consumption><Alcohols><American><Animals><Area><Attenuated><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Blood Glucose><Blood Sugar><Brain><Brain Nervous System><Brain region><Cannabis><Clinical><Clinical Trials><Cocaine><Cocaine use disorder><Cognition Therapy><Cognitive Psychotherapy><Cognitive Therapy><Cognitive treatment><Conditioning Therapy><Consumption><Cues><Development><Dopamine><Dose><Drug Screening><Drug Therapy><Drugs><Effectiveness><Encephalon><EtOH drinking><EtOH use><Event-Related Potentials><Ex4 peptide><Exendin 4><Exhibits><Experimental Therapies><FDA approved><Feedback><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Goals><Human><Hydroxytyramine><Hyperphagia><Incentives><Intermediary Metabolism><Investigational Therapies><Investigational Treatments><Ketosis-Resistant Diabetes Mellitus><Literature><Marijuana><Maturity-Onset Diabetes Mellitus><Measures><Medication><Metabolic><Metabolic Processes><Metabolism><Modern Man><Motivation><NIDA><NIDDM><National Institute of Drug Abuse><National Institute on Drug Abuse><Neural Pathways><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nucleus Accumbens><Obesity><Outcome><Overeating><Pathway interactions><Patient Self-Report><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Placebos><Psychometrics><Questionnaires><Rewards><Satiation><Schedule><Self-Report><Sham Treatment><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulus><Strategic Planning><System><T2 DM><T2D><T2DM><Testing><Titrations><Tobacco><Tobacco smoking><Tobacco smoking behavior><Treatment outcome><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Urine><adiposity><adult onset diabetes><alcohol ingestion><alcohol intake><alcohol product use><alcohol use><alcoholic beverage consumption><alcoholic drink intake><attenuate><attenuates><behavior intervention><behavior measurement><behavioral economics><behavioral intervention><behavioral measure><behavioral measurement><clinical practice><cocaine craving><cocaine cue><cocaine self-administration><cocaine use><cognitive behavior intervention><cognitive behavior modification><cognitive behavior therapy><cognitive behavioral intervention><cognitive behavioral modification><cognitive behavioral therapy><cognitive behavioral treatment><compound repositioning><compound repurposing><conditioned place preference><corpulence><craving><design><designing><developmental><drug intervention><drug repositioning><drug repurposing><drug treatment><drug/agent><effective therapy><effective treatment><efficacy trial><ethanol consumption><ethanol drinking><ethanol ingestion><ethanol intake><ethanol product use><ethanol use><event related potential><evidence base><exenatide><experience><experimental therapeutic agents><experimental therapeutics><glucagon-like peptide 1><glucagon-like peptide receptor><glucagon-like peptide-1 receptor><hedonic><improved><incretin hormone><indexing><ketosis resistant diabetes><marihuana><maturity onset diabetes><mortality><multi-modality><multimodality><neurophysiological><neurophysiology><new therapeutic uses for existing drugs><new use of drug><new uses for an approved drug><new uses for existing drugs><novel><overdose death><overdose fatalities><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological repurposing><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><place conditioning><polyphagia><pre-clinical><preclinical><randomized, clinical trials><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><response><response to therapy><response to treatment><satiety><self-administer cocaine><sham therapy><subcutaneous><subdermal><therapeutic repositioning><therapeutic repurposing><therapeutic response><therapy response><treatment effect><treatment response><treatment responsiveness><trial comparing><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Luba Yammine

UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, HOUSTON, TX

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$679,454
FY 2026

Project Title

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study

Grant Number:

5R01DA062720-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/15/2025

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The United States is experiencing a resurgence in cocaine use and cocaine related mortality. In 2021, approximately 1.4 million Americans met criteria for cocaine use disorder (CUD) with cocaine involved in nearly 25,000 overdose deaths, a 22% increase since 2020. No FDA-approved ph...

Research Terms

<Adult-Onset Diabetes Mellitus><Agonist><Alcohol Chemical Class><Alcohol Drinking><Alcohol consumption><Alcohols><American><Animals><Area><Attenuated><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Blood Glucose><Blood Sugar><Brain><Brain Nervous System><Brain region><Cannabis><Clinical><Clinical Trials><Cocaine><Cocaine use disorder><Cognition Therapy><Cognitive Psychotherapy><Cognitive Therapy><Cognitive treatment><Conditioning Therapy><Consumption><Cues><Development><Dopamine><Dose><Drug Screening><Drug Therapy><Drugs><Effectiveness><Encephalon><EtOH drinking><EtOH use><Event-Related Potentials><Ex4 peptide><Exendin 4><Exhibits><Experimental Therapies><FDA approved><Feedback><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Goals><Human><Hydroxytyramine><Hyperphagia><Incentives><Intermediary Metabolism><Investigational Therapies><Investigational Treatments><Ketosis-Resistant Diabetes Mellitus><Literature><Marijuana><Maturity-Onset Diabetes Mellitus><Measures><Medication><Metabolic><Metabolic Processes><Metabolism><Modern Man><Motivation><NIDA><NIDDM><National Institute of Drug Abuse><National Institute on Drug Abuse><Neural Pathways><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nucleus Accumbens><Obesity><Outcome><Overeating><Pathway interactions><Patient Self-Report><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Placebos><Psychometrics><Questionnaires><Rewards><Satiation><Schedule><Self-Report><Sham Treatment><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulus><Strategic Planning><System><T2 DM><T2D><T2DM><Testing><Titrations><Tobacco><Tobacco smoking><Tobacco smoking behavior><Treatment outcome><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Urine><adiposity><adult onset diabetes><alcohol ingestion><alcohol intake><alcohol product use><alcohol use><alcoholic beverage consumption><alcoholic drink intake><attenuate><attenuates><behavior intervention><behavior measurement><behavioral economics><behavioral intervention><behavioral measure><behavioral measurement><clinical practice><cocaine craving><cocaine cue><cocaine self-administration><cocaine use><cognitive behavior intervention><cognitive behavior modification><cognitive behavior therapy><cognitive behavioral intervention><cognitive behavioral modification><cognitive behavioral therapy><cognitive behavioral treatment><compound repositioning><compound repurposing><conditioned place preference><corpulence><craving><design><designing><developmental><drug intervention><drug repositioning><drug repurposing><drug treatment><drug/agent><effective therapy><effective treatment><efficacy trial><ethanol consumption><ethanol drinking><ethanol ingestion><ethanol intake><ethanol product use><ethanol use><event related potential><evidence base><exenatide><experience><experimental therapeutic agents><experimental therapeutics><glucagon-like peptide 1><glucagon-like peptide receptor><glucagon-like peptide-1 receptor><hedonic><improved><incretin hormone><indexing><ketosis resistant diabetes><marihuana><maturity onset diabetes><mortality><multi-modality><multimodality><neurophysiological><neurophysiology><new therapeutic uses for existing drugs><new use of drug><new uses for an approved drug><new uses for existing drugs><novel><overdose death><overdose fatalities><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological repurposing><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><place conditioning><polyphagia><pre-clinical><preclinical><randomized, clinical trials><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><response><response to therapy><response to treatment><satiety><self-administer cocaine><sham therapy><subcutaneous><subdermal><therapeutic repositioning><therapeutic repurposing><therapeutic response><therapy response><treatment effect><treatment response><treatment responsiveness><trial comparing><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kristina H Lewis

HARVARD PILGRIM HEALTH CARE, INC., Canton, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$670,441
FY 2026

Project Title

Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use

Grant Number:

5R01HL171293-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2023

End Date:

11/30/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Over 40% of US adults have obesity, many with weight-related complications such as hypertension and diabetes. Current clinical guidelines suggest lifestyle change as the first-line obesity treatment approach, but this does not produce sustained clinically-significant weight ...

Research Terms

<2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate><21+ years old><Active Follow-up><Address><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Age><Agonist><American><Amfebutamone><Anti-Obesity Agents><Anti-Obesity Drugs><Apoplexy><Arrhythmia><BMI><BMI percentile><BMI z-score><Bariatrics><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Body Weight><Body Weight decreased><Body mass index><Brain Vascular Accident><Bupropion><Cardiac Arrhythmia><Cardiac infarction><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Characteristics><Chronic Disease><Chronic Illness><Clinical><Clinical Research><Clinical Services><Clinical Study><Clinical Trials><Comparative Effectiveness Research><Complication><Conditioning Therapy><Data><Data Set><Development><Diabetes Mellitus><Drug Prescribing><Drug Prescriptions><Drug Therapy><Drugs><Dyslipidemias><ED visit><ER visit><Economics><Effectiveness><Eligibility><Eligibility Determination><Emergencies><Emergency Situation><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room visit><Epidemiology><Event><FDA approved><GLP-1><Glp-1><Guidelines><Head><Health><Health Care><Health Care Costs><Health Care Utilization><Health Costs><Health Insurance><Health Services><Heart Arrhythmias><Heart Vascular><Heart failure><Hospital Admission><Hospitalization><Hypertension><Incidence><Individual><Intention><Intervention><Ketosis-Resistant Diabetes Mellitus><Lead><Length of Stay><Life Style><Lifestyle><Maturity-Onset Diabetes Mellitus><Measures><Medical Care Costs><Medication><Medicine><Morbid Obesity><Myocardial Infarct><Myocardial Infarction><NIDDM><Nalorex><Naltrexone><Nemexin><New Agents><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Number of Days in Hospital><Obesity><Obesity Epidemic><Out-patients><Outcome><Outpatients><Patients><Pb element><Pharmaceutical Preparations><Pharmacies><Pharmacological Treatment><Pharmacotherapy><Pharmacy facility><Phentermine><Physicians><Policies><Procedures><Protocol Screening><Provider><Qualifying><Quetelet index><ReVia><Recommendation><Research><Risk><Safety><Severe obesity><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stroke><T2 DM><T2D><T2DM><Techniques><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Update><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Visit><Vivitrol><Weight><Weight Loss><Weight Reduction><Wellbutrin><active followup><adiposity><adult onset diabetes><adulthood><ages><alpha,alpha-dimethyl-benzeneethanamine><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><bariatric surgery><behavior intervention><behavioral intervention><body weight loss><brain attack><buproprion><cardiac failure><cardiac infarct><cardiometabolic><cardiometabolism><cerebral vascular accident><cerebrovascular accident><chronic disorder><circulatory system><clinical practice><clinical significance><clinically significant><co-morbid><co-morbidity><cohort><comorbidity><comparative><comparative effectiveness><comparative effectiveness study><coronary attack><coronary infarct><coronary infarction><corpulence><cost><customized therapy><customized treatment><design><designing><developmental><diabetes><drug intervention><drug treatment><drug/agent><economic><epidemiologic><epidemiological><extreme obesity><follow up><follow-up><followed up><followup><gastric banding><gastric bypass surgery><glucagon-like peptide 1><health care service use><health care service utilization><health insurance plan><health service use><health service utilization><heart attack><heart infarct><heart infarction><heavy metal Pb><heavy metal lead><high blood pressure><hospital days><hospital length of stay><hospital stay><hyperpiesia><hyperpiesis><hypertensive><hypertensive disease><hypertensive disorder><implantable gastric stimulation banding><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><insurance claims><ketosis resistant diabetes><life style intervention><lifestyle intervention><liraglutide><maturity onset diabetes><medical costs><medical expenses><medication prescription><obese patients><obesity intervention><obesity surgery><obesity therapy><obesity treatment><patient specific therapies><patient specific treatment><patients with obesity><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pharmacy benefit><prescribed medication><programs><revascularization><sex><stomach stapling><stroked><strokes><tailored medical treatment><tailored therapy><tailored treatment><topiramate><treatment choice><type 2 DM><type II DM><type two diabetes><unique treatment><weight loss surgery><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Darren Toh

HARVARD PILGRIM HEALTH CARE, INC., Canton, MA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$670,441
FY 2026

Project Title

Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use

Grant Number:

5R01HL171293-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2023

End Date:

11/30/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Over 40% of US adults have obesity, many with weight-related complications such as hypertension and diabetes. Current clinical guidelines suggest lifestyle change as the first-line obesity treatment approach, but this does not produce sustained clinically-significant weight ...

Research Terms

<2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate><21+ years old><Active Follow-up><Address><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Age><Agonist><American><Amfebutamone><Anti-Obesity Agents><Anti-Obesity Drugs><Apoplexy><Arrhythmia><BMI><BMI percentile><BMI z-score><Bariatrics><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Body Weight><Body Weight decreased><Body mass index><Brain Vascular Accident><Bupropion><Cardiac Arrhythmia><Cardiac infarction><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Characteristics><Chronic Disease><Chronic Illness><Clinical><Clinical Research><Clinical Services><Clinical Study><Clinical Trials><Comparative Effectiveness Research><Complication><Conditioning Therapy><Data><Data Set><Development><Diabetes Mellitus><Drug Prescribing><Drug Prescriptions><Drug Therapy><Drugs><Dyslipidemias><ED visit><ER visit><Economics><Effectiveness><Eligibility><Eligibility Determination><Emergencies><Emergency Situation><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room visit><Epidemiology><Event><FDA approved><GLP-1><Glp-1><Guidelines><Head><Health><Health Care><Health Care Costs><Health Care Utilization><Health Costs><Health Insurance><Health Services><Heart Arrhythmias><Heart Vascular><Heart failure><Hospital Admission><Hospitalization><Hypertension><Incidence><Individual><Intention><Intervention><Ketosis-Resistant Diabetes Mellitus><Lead><Length of Stay><Life Style><Lifestyle><Maturity-Onset Diabetes Mellitus><Measures><Medical Care Costs><Medication><Medicine><Morbid Obesity><Myocardial Infarct><Myocardial Infarction><NIDDM><Nalorex><Naltrexone><Nemexin><New Agents><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Number of Days in Hospital><Obesity><Obesity Epidemic><Out-patients><Outcome><Outpatients><Patients><Pb element><Pharmaceutical Preparations><Pharmacies><Pharmacological Treatment><Pharmacotherapy><Pharmacy facility><Phentermine><Physicians><Policies><Procedures><Protocol Screening><Provider><Qualifying><Quetelet index><ReVia><Recommendation><Research><Risk><Safety><Severe obesity><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stroke><T2 DM><T2D><T2DM><Techniques><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Update><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Visit><Vivitrol><Weight><Weight Loss><Weight Reduction><Wellbutrin><active followup><adiposity><adult onset diabetes><adulthood><ages><alpha,alpha-dimethyl-benzeneethanamine><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><bariatric surgery><behavior intervention><behavioral intervention><body weight loss><brain attack><buproprion><cardiac failure><cardiac infarct><cardiometabolic><cardiometabolism><cerebral vascular accident><cerebrovascular accident><chronic disorder><circulatory system><clinical practice><clinical significance><clinically significant><co-morbid><co-morbidity><cohort><comorbidity><comparative><comparative effectiveness><comparative effectiveness study><coronary attack><coronary infarct><coronary infarction><corpulence><cost><customized therapy><customized treatment><design><designing><developmental><diabetes><drug intervention><drug treatment><drug/agent><economic><epidemiologic><epidemiological><extreme obesity><follow up><follow-up><followed up><followup><gastric banding><gastric bypass surgery><glucagon-like peptide 1><health care service use><health care service utilization><health insurance plan><health service use><health service utilization><heart attack><heart infarct><heart infarction><heavy metal Pb><heavy metal lead><high blood pressure><hospital days><hospital length of stay><hospital stay><hyperpiesia><hyperpiesis><hypertensive><hypertensive disease><hypertensive disorder><implantable gastric stimulation banding><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><insurance claims><ketosis resistant diabetes><life style intervention><lifestyle intervention><liraglutide><maturity onset diabetes><medical costs><medical expenses><medication prescription><obese patients><obesity intervention><obesity surgery><obesity therapy><obesity treatment><patient specific therapies><patient specific treatment><patients with obesity><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pharmacy benefit><prescribed medication><programs><revascularization><sex><stomach stapling><stroked><strokes><tailored medical treatment><tailored therapy><tailored treatment><topiramate><treatment choice><type 2 DM><type II DM><type two diabetes><unique treatment><weight loss surgery><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia Sue Grigson

PENNSYLVANIA STATE UNIV HERSHEY MED CTR, HERSHEY, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$667,063
FY 2026

Project Title

Cocaine Addition and the Need-State Hypothesis

Grant Number:

5R01DA060250-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2025

End Date:

2/28/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary. The Problem. In a recent paper entitled “Preaddiction - A Missing Concept for Treating Substance Use Disorders”, McLellan, Koob and Volkow [7] argue that intervention need not be limited to the final stage of the disease and likely would be more successful if administered early in t...

Research Terms

<1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide><3-D><3-Dimensional><3D><Actiq><Agonist><Animal Model><Animal Models and Related Studies><Appetite><Behavior><Behavioral><Bilateral><Brain><Brain Nervous System><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 years><Cessation of life><Cocaine><Common Rat Strains><Conditioned Reflex><Cues><Data Reporting><Death><Desire for food><Development><Disease><Disorder><Dopamine><Drug Delivery><Drug Delivery Systems><Drug Modelings><Drugs><Duragesic><Early Intervention><Early identification><Early treatment><Encephalon><Ex4 peptide><Exendin 4><Exhibits><FBJ osteosarcoma oncogene><FOS gene><Female><Fentanest><Fentanyl><Fentyl><Fiber><G0S7><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Gustation><Human><Hydroxytyramine><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Infusion><Infusion procedures><Intervention><Light><Locus Coeruleus><Measures><Mediating><Medication><Microscopy><Modeling><Modern Man><Nature><Nucleus Accumbens><Nucleus Pigmentosus Pontis><Oral Administration><Oral Drug Administration><Organism><Paper><Pattern><Pharmaceutical Preparations><Phentanyl><Photometry><Photoradiation><Physiologic><Physiological><Protooncogene FOS><Rat><Rats Mammals><Rattus><Reporting><Resistance><Rewards><Risk><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Saccharin><Satiation><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severities><Site><Sprague-Dawley Rats><Stimulant overdose><Substance Use Disorder><Taste><Taste Perception><Telemetries><Telemetry><Testing><Time><United States><Vulnerable Populations><Withdrawal><addiction><addictive disorder><antagonism><antagonist><blue nucleus><c fos><c-fos Gene><c-fos Proto-Oncogenes><cocaine seeking><conditioned response><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><data representation><data representations><developmental><drug/agent><early therapy><exenatide><glucagon-like peptide 1><glucagon-like peptide-1 receptor><gustatory perception><gustatory processing><gustatory response><infusions><innovate><innovation><innovative><intraoral drug delivery><living system><locus ceruleus structure><male><model of animal><neural circuit><neural circuitry><neurocircuitry><novel><overdose death><overdose fatalities><protective effect><psychostimulant overdose><psychostimulant use><resilience><resilient><resistant><response><satiety><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><stimulant use><substance use and disorder><synaptic circuit><synaptic circuitry><synthetic opiate><synthetic opioid><taste processing><taste response><telemetric><three dimensional><tool><use of stimulants><v-FOS FBJ Murine Osteosarcoma Viral Oncogene Homolog><vulnerable group><vulnerable individual><vulnerable people><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHANG-GUO ZHAN

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$662,881
FY 2026

Project Title

Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse

Grant Number:

7R01DA057866-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY More than 38 million people are living with Human Immunodeficiency Virus (HIV) infection worldwide which continues to be a global public health problem. Despite the widespread use of efficacious combination of antiretroviral therapy (cART), up to 70% of HIV-positive individuals suff...

Research Terms

<AIDS Virus><AIDS prevention><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Assay><Attenuated><Automobile Driving><Autoregulation><Axon Terminals><Behavioral><Binding><Binding Sites><Bioassay><Biological><Biological Assay><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Chemicals><Cocaine><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Combining Site><Computer Models><Computerized Models><Crystal Meth><Crystal methamphetamine><Cyclicity><DAT dopamine transporter><DNA mutation><Deoxyephedrine><Desoxyephedrine><Development><Disturbance in cognition><Dopamine><Doxycycline><Drug abuse><Drug usage><Dysfunction><Encephalon><Exhibits><Expression Signature><Functional disorder><Gene Expression Profile><Gene Transcription><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV Prevention><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV associated neurological disease><HIV associated neurological disorder><HIV in patients><HIV incidence><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV intervention><HIV neurocognitive impairment><HIV patient><HIV people><HIV positive individuals><HIV positive patient><HIV positive people><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 incidence><HIV-1 infection><HIV-1 infection incidence><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV-associated neurocognitive disorder><HIV/AIDS incidence><HIV/AIDS prevention><HIV1><Homeostasis><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Human immunodeficiency virus infected patients><Human immunodeficiency virus positive patients><Hybrids><Hydroxytyramine><IQ Deficit><Impaired cognition><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Intracellular Communication and Signaling><Investigation><K element><KI mice><Knock-in><Knock-in Mouse><LAV-HTLV-III><Life><Link><Lymphadenopathy-Associated Virus><METH effect><Mediating><Methamphetamine><Methamphetamine prevention><Methylamphetamine><Modern Man><Molecular><Molecular Dynamics Simulation><Molecular Interaction><Mutation><N-Methylamphetamine><Nervous System Injuries><Nervous System Trauma><Nervous System damage><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurological Damage><Neurological Injury><Neurological trauma><Nucleus Accumbens><PC-12><PC12 Cells><PLWH><PWH><Patients living with HIV><Patients suffering from HIV><Periodicity><Peripheral><Persons><Pheochromocytoma Cell Line><Physiological Homeostasis><Physiopathology><Play><Potassium><Prefrontal Cortex><Presynaptic Nerve Endings><Presynaptic Terminals><Prevalence><Prevent HIV><Proteins><Public Health><Publishing><RNA Expression><Rat Transgene><Reactive Site><Rewards><Rhythmicity><Risk><Role><Scanning><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Site-Directed Mutagenesis><Site-Specific Mutagenesis><Slice><Strains Cell Lines><Substance abuse problem><Synaptic Boutons><Synaptic Terminals><Synaptic Vesicles><Targeted DNA Modification><Targeted Modification><Therapeutic><Trans-Acting Factors><Trans-Activators><Transactivators><Transcription><Transcription Activator><Transcription Coactivator><Transcription Factor Coactivator><Transcriptional Activator/Coactivator><Transgenic Mice><Transgenic Organisms><Transmission><VMAT2 Protein><Validation><Vesicle><Vibramycin><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus Replication><Virus-HIV><Work><abuse of drugs><abuse of substances><abused drug><abused drugs><abuses drugs><alpha-6-Deoxyoxytetracycline><antiretroviral therapy><antiretroviral treatment><attenuate><attenuates><attenuation><biologic><biological signal transduction><cognitive defects><cognitive dysfunction><cognitive loss><computational modeling><computational models><computer based models><computerized modeling><conditioned place preference><cultured cell line><developmental><dopamine system><dopamine transporter><driving><drug abused><drug of abuse><drug use><drugs abused><drugs of abuse><extracellular><gene expression pattern><gene expression signature><genetic approach><genetic strategy><genome mutation><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus patient><improved><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><intelligence quotient deficit><knockin><knockin mice><meth><meth abuse><meth prevention><meth user><methamphetamine abuse><methamphetamine effect><methamphetamine use prevention><methamphetamine user><molecular dynamics><monoamine vesicular transport proteins><mouse model><murine model><mutant><neuro-AIDS><neuro-HIV><neuroAIDS><neuroHIV><neuroblastoma cell><neurocognitive decline><neurocognitive impairment><neuropsychiatric><neuropsychiatry><neurotrauma><novel><pathophysiology><patient infected with HIV><patient with HIV><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacologic><pheochromocytoma 12 cell line><place conditioning><prevent><prevent AIDS><prevent human immunodeficiency virus><preventing><putamen><social role><substance abuse><transcriptional profile><transcriptional signature><transgenic><transmission process><treat HIV><treat Human Immunodeficiency Virus><uptake><validations><vesicular monoamine transporter><vesicular monoamine transporter 2><viral multiplication><viral replication><virus multiplication><virus protein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jun Zhu

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$662,881
FY 2026

Project Title

Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse

Grant Number:

7R01DA057866-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY More than 38 million people are living with Human Immunodeficiency Virus (HIV) infection worldwide which continues to be a global public health problem. Despite the widespread use of efficacious combination of antiretroviral therapy (cART), up to 70% of HIV-positive individuals suff...

Research Terms

<AIDS Virus><AIDS prevention><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Assay><Attenuated><Automobile Driving><Autoregulation><Axon Terminals><Behavioral><Binding><Binding Sites><Bioassay><Biological><Biological Assay><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Chemicals><Cocaine><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Combining Site><Computer Models><Computerized Models><Crystal Meth><Crystal methamphetamine><Cyclicity><DAT dopamine transporter><DNA mutation><Deoxyephedrine><Desoxyephedrine><Development><Disturbance in cognition><Dopamine><Doxycycline><Drug abuse><Drug usage><Dysfunction><Encephalon><Exhibits><Expression Signature><Functional disorder><Gene Expression Profile><Gene Transcription><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Goals><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV Prevention><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV associated neurological disease><HIV associated neurological disorder><HIV in patients><HIV incidence><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV intervention><HIV neurocognitive impairment><HIV patient><HIV people><HIV positive individuals><HIV positive patient><HIV positive people><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 incidence><HIV-1 infection><HIV-1 infection incidence><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV-associated neurocognitive disorder><HIV/AIDS incidence><HIV/AIDS prevention><HIV1><Homeostasis><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Human immunodeficiency virus infected patients><Human immunodeficiency virus positive patients><Hybrids><Hydroxytyramine><IQ Deficit><Impaired cognition><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Intracellular Communication and Signaling><Investigation><K element><KI mice><Knock-in><Knock-in Mouse><LAV-HTLV-III><Life><Link><Lymphadenopathy-Associated Virus><METH effect><Mediating><Methamphetamine><Methamphetamine prevention><Methylamphetamine><Modern Man><Molecular><Molecular Dynamics Simulation><Molecular Interaction><Mutation><N-Methylamphetamine><Nervous System Injuries><Nervous System Trauma><Nervous System damage><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurological Damage><Neurological Injury><Neurological trauma><Nucleus Accumbens><PC-12><PC12 Cells><PLWH><PWH><Patients living with HIV><Patients suffering from HIV><Periodicity><Peripheral><Persons><Pheochromocytoma Cell Line><Physiological Homeostasis><Physiopathology><Play><Potassium><Prefrontal Cortex><Presynaptic Nerve Endings><Presynaptic Terminals><Prevalence><Prevent HIV><Proteins><Public Health><Publishing><RNA Expression><Rat Transgene><Reactive Site><Rewards><Rhythmicity><Risk><Role><Scanning><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Site-Directed Mutagenesis><Site-Specific Mutagenesis><Slice><Strains Cell Lines><Substance abuse problem><Synaptic Boutons><Synaptic Terminals><Synaptic Vesicles><Targeted DNA Modification><Targeted Modification><Therapeutic><Trans-Acting Factors><Trans-Activators><Transactivators><Transcription><Transcription Activator><Transcription Coactivator><Transcription Factor Coactivator><Transcriptional Activator/Coactivator><Transgenic Mice><Transgenic Organisms><Transmission><VMAT2 Protein><Validation><Vesicle><Vibramycin><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus Replication><Virus-HIV><Work><abuse of drugs><abuse of substances><abused drug><abused drugs><abuses drugs><alpha-6-Deoxyoxytetracycline><antiretroviral therapy><antiretroviral treatment><attenuate><attenuates><attenuation><biologic><biological signal transduction><cognitive defects><cognitive dysfunction><cognitive loss><computational modeling><computational models><computer based models><computerized modeling><conditioned place preference><cultured cell line><developmental><dopamine system><dopamine transporter><driving><drug abused><drug of abuse><drug use><drugs abused><drugs of abuse><extracellular><gene expression pattern><gene expression signature><genetic approach><genetic strategy><genome mutation><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus patient><improved><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><intelligence quotient deficit><knockin><knockin mice><meth><meth abuse><meth prevention><meth user><methamphetamine abuse><methamphetamine effect><methamphetamine use prevention><methamphetamine user><molecular dynamics><monoamine vesicular transport proteins><mouse model><murine model><mutant><neuro-AIDS><neuro-HIV><neuroAIDS><neuroHIV><neuroblastoma cell><neurocognitive decline><neurocognitive impairment><neuropsychiatric><neuropsychiatry><neurotrauma><novel><pathophysiology><patient infected with HIV><patient with HIV><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacologic><pheochromocytoma 12 cell line><place conditioning><prevent><prevent AIDS><prevent human immunodeficiency virus><preventing><putamen><social role><substance abuse><transcriptional profile><transcriptional signature><transgenic><transmission process><treat HIV><treat Human Immunodeficiency Virus><uptake><validations><vesicular monoamine transporter><vesicular monoamine transporter 2><viral multiplication><viral replication><virus multiplication><virus protein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Long-Sheng Song

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$650,691
FY 2026

Project Title

Junctophilin-1 in the heart

Grant Number:

5R01HL176940-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/10/2025

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY / ABSTRACT Heart failure (HF) is a leading cause of morbidity and mortality worldwide. HF is associated with high risk of fatal ventricular arrhythmias and sudden cardiac death. The pathophysiological basis of systolic HF includes the impaired function of existing cardiomyocytes and ...

Research Terms

<21+ years old><Ablation><Adult><Adult Human><Age Months><Area><Arrhythmia><Assay><Autoregulation><Binding><Bioassay><Biological Assay><Body Tissues><Ca2+-Activated Protease><Calcium-Activated Neutral Protease><Calcium-Activated Neutral Proteinase><Calcium-Activated Protease><Calcium-Dependent Neutral Protease><Calcium-Dependent Neutral Proteinase><Calpain><Cardiac><Cardiac Arrhythmia><Cardiac Diseases><Cardiac Disorders><Cardiac Muscle Cells><Cardiac Muscle Contraction><Cardiac Myocytes><Cardiac development><Cardiocyte><Cell Communication and Signaling><Cell Signaling><Cell membrane><Cessation of life><Co-Immunoprecipitations><Compensation><Complex><Coupling><Cytoplasmic Membrane><Data><Death><Defect><Desminase><Development><Disease><Disorder><Dysfunction><Functional disorder><Future><Genes><Genetic><Goals><Heart><Heart Arrhythmias><Heart Diseases><Heart Muscle Cells><Heart failure><Heart myocyte><Homeostasis><Human><Hypertrophy><Impairment><In Vitro><Intracellular Communication and Signaling><Isoforms><KI mice><KO mice><Knock-in><Knock-in Mouse><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Laboratories><Link><Maintenance><Mechanics><Mediating><Mediator><Membrane><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Molecular Target><Morbidity><Murine><Mus><Myocardial depression><Myocardial dysfunction><Myocardium><Natural regeneration><Null Mouse><Organ><Outcome><Papain-Like Cysteine Protease><Pathogenesis><Physiologic><Physiological><Physiological Homeostasis><Physiology><Physiopathology><Plasma Membrane><Process><Protein Cleavage><Protein Family><Protein Isoforms><Proteins><Proteolysis><Proteomics><RNA Seq><RNA sequencing><RNAseq><Regeneration><Regulation><Resolution><Role><RyR2><Sarcoplasmic Reticulum><Signal Transduction><Signal Transduction Systems><Signaling><Site><Skeletal Muscle><Stress><Structure><Systolic heart failure><Testing><Therapeutic><Tissues><Translating><Variant><Variation><Ventricular Arrhythmia><Voluntary Muscle><adulthood><biological signal transduction><cardiac dysfunction><cardiac failure><cardiac function><cardiac muscle><cardiac regeneration><cardiogenesis><cardiomyocyte><confocal imaging><developmental><differential expression><differentially expressed><experiment><experimental research><experimental study><experiments><function of the heart><heart development><heart disorder><heart dysfunction><heart failure and reduced ejection fraction><heart failure with reduced ejection fraction><heart formation><heart function><heart muscle><heart regeneration><high resolution imaging><high risk><human disease><improved><in vivo><insight><interdisciplinary approach><junctophilin><junctophilin-1><junctophilin-2><junctophilin-3><knockin><knockin mice><life span><lifespan><loss of function><mechanic><mechanical><membrane structure><mortality><mouse model><multidisciplinary approach><murine model><nano><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathophysiology><plasmalemma><premature><prematurity><preservation><pressure><protein expression><protein protein interaction><regenerate><resolutions><social role><sudden cardiac death><tandem mass spectrometry><transcriptional differences><transcriptome sequencing><transcriptomic sequencing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David Eric Arterburn

KAISER FOUNDATION RESEARCH INSTITUTE, Oakland, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$649,786
FY 2026

Project Title

Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes

Grant Number:

5R01DK135515-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/6/2024

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY More than 12 million Americans currently live with both obesity and type 2 diabetes (T2D), putting them in one of the highest risk groups for developing serious microvascular and macrovascular complications. The Ameri- can Diabetes Association’s clinical practice guidelines recommend...

Research Terms

<Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Adult-Onset Diabetes Mellitus><Affect><Age><Agonist><American><Asian><Benefits and Risks><Black><Black race><Blood Pressure><Blood Vessels><Body Weight decreased><Cessation of life><Clinical><Clinical Practice Guideline><Clinical Trials><Comparative Effectiveness Research><Complications of Diabetes Mellitus><D-Glucose><Data><Data Bases><Databases><Death><Dextrose><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Acidosis><Diabetic Complications><Diabetic Ketoacidosis><Diabetic Ketosis><Disease Progression><Drug Therapy><Drugs><ED care><ER care><Effectiveness><Electronic Health Record><Eligibility><Eligibility Determination><Emergency Care><Emergency Department care><Emergency Room care><Emergency health care><Emergency medical care><Enrollment><Ethnic Origin><Ethnicity><Event><Fee-for-Service Plans><Fees for Service><GLP-1><GLP-1 receptor><GLP-I receptor><GU Infection><Gastrectomy><Gastric Bypass><Gender><Genitourinary System Infection><Genitourinary infection><Glp-1><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Head><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Hemoglobin A(1)><Hispanic><Hospital Admission><Hospitalization><Hyperglycemia><Hypoglycemia><Incidence><Insurance Coverage><Insurance Status><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Urinary System><Knowledge><Life Style><Lifestyle><Link><Longitudinal Studies><Longitudinal Surveys><Maturity-Onset Diabetes Mellitus><Medical><Medicare><Medication><Metabolic><Microvascular Dysfunction><NIDDM><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Operative Procedures><Operative Surgical Procedures><Outcome><Patients><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacological Treatment><Pharmacotherapy><Protocol Screening><Race><Races><Randomization trial><Randomized, Controlled Trials><Recommendation><Renal Disease><Reoperation><Repeat Surgery><Research><Research Design><Risk><SGLT 2 inhibitor><SGLT2i><Safety><Sample Size><Sampling><Selection for Treatments><Severities><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Stable Diabetes Mellitus><Study Type><Subgroup><Surgical><Surgical Interventions><Surgical Procedure><T2 DM><T2D><T2DM><Therapeutic><Title 18><Treatment Cost><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><Weight Loss><Weight Reduction><Weight maintenance regimen><Work><acute kidney injury><adiposity><adult adiposity><adult obesity><adult onset diabetes><adults with obesity><ages><alternative treatment><bariatric surgery><blood glucose regulation><body weight loss><clinical practice and guidelines><co-morbid><co-morbidity><cohort><comorbidity><comparative effectiveness><comparative effectiveness study><comparative safety><compare effectiveness><corpulence><cost><data base><data collected in real world><diabetes><diabetes mellitus therapy><diabetes therapy><diabetic ketoacidotic><drug intervention><drug treatment><drug/agent><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><enroll><ethnic minority><ethnic minority group><ethnic minority individual><ethnic minority people><ethnic minority population><gastric banding><gastric bypass surgery><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose control><glucose homeostasis><glucose regulation><glycemic control><hazard><health insurance for disabled><hemoglobin A1c><high risk group><high risk individual><high risk people><high risk population><hospitalization rates><hyperglycemic><hypoglycemic><hypoglycemic episodes><implantable gastric stimulation banding><improved><infectious disease of genitourinary system><ketosis resistant diabetes><kidney disorder><long-term study><longitudinal outcome studies><longitudinal research study><macrovascular complication><macrovascular disease><maturity onset diabetes><microvascular complications><microvascular disease><mortality><obese patients><obesity intervention><obesity management><obesity surgery><obesity therapy><obesity treatment><patient population><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><patients with obesity><pharmaceutical><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><prevent><preventing><prospective><racial><racial background><racial minority><racial minority group><racial minority individual><racial minority people><racial minority population><racial origin><randomized control trial><randomized trial><real world data><renal><renal disorder><research study><rural dwellers><rural resident><safety outcomes><safety study><selection of treatment><small vessel disease><stomach bypass><stomach stapling><study design><surgery><surgery risk><surgical risk><therapy selection><treatment selection><type 2 DM><type II DM><type two diabetes><uptake><urogenital infection><vascular><weight control><weight loss surgery><weight management><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rozalina Grubina McCoy

KAISER FOUNDATION RESEARCH INSTITUTE, Oakland, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$649,786
FY 2026

Project Title

Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes

Grant Number:

5R01DK135515-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/6/2024

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY More than 12 million Americans currently live with both obesity and type 2 diabetes (T2D), putting them in one of the highest risk groups for developing serious microvascular and macrovascular complications. The Ameri- can Diabetes Association’s clinical practice guidelines recommend...

Research Terms

<Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Adult-Onset Diabetes Mellitus><Affect><Age><Agonist><American><Asian><Benefits and Risks><Black><Black race><Blood Pressure><Blood Vessels><Body Weight decreased><Cessation of life><Clinical><Clinical Practice Guideline><Clinical Trials><Comparative Effectiveness Research><Complications of Diabetes Mellitus><D-Glucose><Data><Data Bases><Databases><Death><Dextrose><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Acidosis><Diabetic Complications><Diabetic Ketoacidosis><Diabetic Ketosis><Disease Progression><Drug Therapy><Drugs><ED care><ER care><Effectiveness><Electronic Health Record><Eligibility><Eligibility Determination><Emergency Care><Emergency Department care><Emergency Room care><Emergency health care><Emergency medical care><Enrollment><Ethnic Origin><Ethnicity><Event><Fee-for-Service Plans><Fees for Service><GLP-1><GLP-1 receptor><GLP-I receptor><GU Infection><Gastrectomy><Gastric Bypass><Gender><Genitourinary System Infection><Genitourinary infection><Glp-1><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Head><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Hemoglobin A(1)><Hispanic><Hospital Admission><Hospitalization><Hyperglycemia><Hypoglycemia><Incidence><Insurance Coverage><Insurance Status><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Urinary System><Knowledge><Life Style><Lifestyle><Link><Longitudinal Studies><Longitudinal Surveys><Maturity-Onset Diabetes Mellitus><Medical><Medicare><Medication><Metabolic><Microvascular Dysfunction><NIDDM><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Operative Procedures><Operative Surgical Procedures><Outcome><Patients><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacological Treatment><Pharmacotherapy><Protocol Screening><Race><Races><Randomization trial><Randomized, Controlled Trials><Recommendation><Renal Disease><Reoperation><Repeat Surgery><Research><Research Design><Risk><SGLT 2 inhibitor><SGLT2i><Safety><Sample Size><Sampling><Selection for Treatments><Severities><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Stable Diabetes Mellitus><Study Type><Subgroup><Surgical><Surgical Interventions><Surgical Procedure><T2 DM><T2D><T2DM><Therapeutic><Title 18><Treatment Cost><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><Weight Loss><Weight Reduction><Weight maintenance regimen><Work><acute kidney injury><adiposity><adult adiposity><adult obesity><adult onset diabetes><adults with obesity><ages><alternative treatment><bariatric surgery><blood glucose regulation><body weight loss><clinical practice and guidelines><co-morbid><co-morbidity><cohort><comorbidity><comparative effectiveness><comparative effectiveness study><comparative safety><compare effectiveness><corpulence><cost><data base><data collected in real world><diabetes><diabetes mellitus therapy><diabetes therapy><diabetic ketoacidotic><drug intervention><drug treatment><drug/agent><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><enroll><ethnic minority><ethnic minority group><ethnic minority individual><ethnic minority people><ethnic minority population><gastric banding><gastric bypass surgery><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose control><glucose homeostasis><glucose regulation><glycemic control><hazard><health insurance for disabled><hemoglobin A1c><high risk group><high risk individual><high risk people><high risk population><hospitalization rates><hyperglycemic><hypoglycemic><hypoglycemic episodes><implantable gastric stimulation banding><improved><infectious disease of genitourinary system><ketosis resistant diabetes><kidney disorder><long-term study><longitudinal outcome studies><longitudinal research study><macrovascular complication><macrovascular disease><maturity onset diabetes><microvascular complications><microvascular disease><mortality><obese patients><obesity intervention><obesity management><obesity surgery><obesity therapy><obesity treatment><patient population><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><patients with obesity><pharmaceutical><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><prevent><preventing><prospective><racial><racial background><racial minority><racial minority group><racial minority individual><racial minority people><racial minority population><racial origin><randomized control trial><randomized trial><real world data><renal><renal disorder><research study><rural dwellers><rural resident><safety outcomes><safety study><selection of treatment><small vessel disease><stomach bypass><stomach stapling><study design><surgery><surgery risk><surgical risk><therapy selection><treatment selection><type 2 DM><type II DM><type two diabetes><uptake><urogenital infection><vascular><weight control><weight loss surgery><weight management><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Riyaz Mohamed

AUGUSTA UNIVERSITY, AUGUSTA, GA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$645,382
FY 2026

Project Title

Role of Netrin-1 in Polycystic Kidney Disease

Grant Number:

1R01DK142863-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in the polycystic kidney disease 1 (PKD1) gene, leading to the development of numerous fluid-filled cysts originating from tubular epithelial cells. These cystic epithelial cells exhibit a hyperproliferative ...

Research Terms

<ADPKD><Acceleration><Address><Adult Polycystic Kidney Disease><Antibodies><Automobile Driving><Autosomal Dominant Polycystic Kidney><Autosomal Dominant Polycystic Kidney Disease><Binding><Calcium><Cancers><Cell Body><Cell Communication and Signaling><Cell Culture Techniques><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Signaling><Cells><Cellular Proliferation><Clinical Treatment Moab><Clinical Trials><Complement><Complement Proteins><Coupled><Cyst><Cystic Kidney Diseases><Cystic Renal Diseases><Cystic kidney><DNA mutation><Data><Development><Dialysis><Dialysis procedure><Disease><Disease Progression><Disorder><Dominant Polycystic Kidney Disease><Drug Therapy><ESKD><ESRD><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Environment><Epithelial Cell Proliferation><Epithelial Cells><Epithelium><Equilibrium><Exhibits><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Female><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Foundations><Generalized Growth><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Glycoprotein GP-2><Goals><Growth><Health><Hereditary><Human><Immune><Immunes><In Vitro><Infiltration><Infusion><Infusion procedures><Inherited><Injury to Kidney><Intracellular Communication and Signaling><Invaded><Kidney><Kidney Cyst><Kidney Diseases><Kidney Grafting><Kidney Replacement Therapy><Kidney Transplantation><Kidney Transplants><Kidney Tubules><Kidney Urinary System><Knock-out><Knockout><Knowledge><Laminin><Liquid substance><Macrophage><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Monoclonal Antibodies><Mouse Homolog of NETRIN 1><Murine><Mus><Mutation><Mφ><NETRIN 1-Like><NTN1><NTN1 gene><NTN1 gene product><NTN1L><Nephropathy><Outcome><Pathology><Pathway interactions><Patients><Persons><Pharmacological Treatment><Pharmacotherapy><Phenotype><Play><Polycystic Kidney><Polycystic Kidney Diseases><Production><Proliferating><Proteins><Publishing><Receptor Protein><Renal Cyst><Renal Disease><Renal Grafting><Renal Replacement Therapy><Renal Transplantation><Renal Transplants><Renal function><Renal tubule structure><Rodent Model><Role><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Testing><Tissue Growth><Transgenic Mice><Tubular><Tubular formation><United States><Upregulation><Vasopressin Receptor><antagonism><antagonist><balance><balance function><biological signal transduction><cancer cell><cell culture><cell cultures><complementation><conditional knock-out><conditional knockout><developmental><dialysis therapy><driving><drug intervention><drug treatment><effective therapy><effective treatment><efficacy testing><fluid><genome mutation><improved><infusions><insight><interdisciplinary approach><kidney disorder><kidney function><kidney injury><kidney tx><liquid><mAbs><male><malignancy><monoclonal Abs><mouse model><multidisciplinary approach><murine model><neoplasm/cancer><netrin receptor><netrin-1><netrin-1 receptors><neutralizing antibody><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><ontogeny><overexpress><overexpression><paracrine><pathway><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><prevent><preventing><receptor><renal><renal disorder><renal injury><renal tubule><side effect><social role><therapeutic target><tolvaptan><translational opportunities><translational potential><tumor growth><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mojgan Hosseini Naghavi

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$627,317
FY 2026

Project Title

The interplay between HIV-1 and amyloid precursor protein in infection and neurotoxicity

Grant Number:

5R01NS131094-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Human Immunodeficiency Virus type 1 (HIV-1) infects a number of different immune cell types with diverse replication strategies and clinical outcomes. Amongst these, we have a good understanding of infection in T- Cells, depletion of which results in Acquired Immune Deficiency Syndro...

Research Terms

<AD dementia><ADAM10 protein><AIDS><APP processing><Acceleration><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Advanced HIV><Affect><Alzheimer Type Dementia><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimer's precursor protein><Alzheimers Dementia><Amentia><Amyloid><Amyloid A4 Protein Precursor><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Protein A4><Amyloid Protein Precursor><Amyloid Proteins><Amyloid Substance><Amyloid beta-Protein><Amyloid beta-Protein Precursor><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Amyloid β-Protein Precursor><Aβ><Brain><Brain Nervous System><C-terminal><CNS Nervous System><Cell Body><Cell Line><Cell membrane><CellLine><Cells><Central Nervous System><Clinical><Co-culture><Cocultivation><Coculture><Coculture Techniques><Complex><Complex Mixtures><Conflict><Conflict (Psychology)><Cytoplasmic Membrane><Darkness><Data><Degenerative Neurologic Disorders><Dementia><Development><Drug Design><Encephalon><Environment><Future><Genetic><HIV 1 associated neurocognitive disorder><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV intervention><HIV neurocognitive impairment><HIV therapeutic><HIV therapy><HIV treatment><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 intervention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV-associated neurocognitive disorder><HIV1><Hortega cell><Host Factor><Host Factor Protein><Human Amyloid Precursor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune><Immunes><Infection><Integral Membrane Protein><Integration Host Factors><Intrinsic Membrane Protein><Left><Light><Lysosomes><Macrophage><Mediating><Microglia><Modeling><Multivesicular Body><Mφ><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neuraxis><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neuron Degeneration><Neurons><Neurotoxins><Outcome><Pathway interactions><Patients><Persons><Photoradiation><Plasma Membrane><Play><Primary Senile Degenerative Dementia><Process><Production><Protein C><Protein Cleavage><Proteins><Proteolysis><QOL><Quality of life><Research><Research Proposals><Retroviral Antigen gag Protein><Role><Severe HIV Disease><Sorting><Strains Cell Lines><T-Cells><T-Lymphocyte><Tail><Testing><Text><Therapeutic><Transmembrane Protein><Transmembrane Protein Gene><Vacuolar Protein Sorting><Viral><Viral Activity><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Physiology><Viral Proteins><Viral gag Proteins><Virion><Virus><Virus Assembly><Virus Particle><Virus Replication><Work><a beta peptide><abeta><amyloid beta><amyloid precursor protein><amyloid precursor protein processing><amyloid-b protein><antiretroviral therapy><antiretroviral treatment><beta amyloid fibril><beta secretase><cell type><cultured cell line><cytokine><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><gag Antigens><gag Gene Products><gag Polyproteins><gag Protein><gamma secretase><gamma secretase complex><genetic approach><genetic strategy><gitter cell><group specific antigen><hiPSC><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><induced human pluripotent stem cells><inhibitor><insight><insoluble aggregate><mesoglia><microglial cell><microgliocyte><neural degeneration><neurocognitive disorder><neurodegeneration><neurodegenerative><neurodegenerative illness><neurological degeneration><neuron toxicity><neuronal><neuronal degeneration><neuronal toxicity><neuroprotection><neuroprotective><neurotoxic><neurotoxicant><neurotoxicity><novel><pathway><perivascular glial cell><plasmalemma><preservation><prevent><preventing><primary degenerative dementia><protein aggregate><protein aggregation><senile dementia of the Alzheimer type><social role><soluble amyloid precursor protein><thymus derived lymphocyte><treat HIV><treat Human Immunodeficiency Virus><viral assembly><viral multiplication><viral replication><virus multiplication><virus protein><β-secretase><γ-secretase>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Meenakshi G Hegde

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$627,253
FY 2026

Project Title

Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma

Grant Number:

5R01CA276684-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2023

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Immunotherapy has shown limited efficacy against pediatric sarcoma. In our recently completed phase I study, infusion of HER2-targeted chimeric antigen receptor T cells (CAR-T) was safe and showed encouraging indicators of antitumor activity, including three durable complete...

Research Terms

<0-11 years old><21+ years old><Address><Adoptive Transfer><Adult><Adult Human><Antigen Targeting><Antigens><Antitumor Response><Autologous><B7-H1><Biology><Blood Serum><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD19><CD19 gene><CD274><CD8><CD8B><CD8B1><CD8B1 gene><CTX><CYCLO-cell><Cancers><Carloxan><Cell Body><Cell Communication and Signaling><Cell Isolation><Cell Line><Cell Segregation><Cell Separation><Cell Separation Technology><Cell Signaling><Cell Therapy><CellLine><Cells><Checkpoint inhibitor><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Child><Child Youth><Children (0-21)><Ciclofosfamida><Ciclofosfamide><Cicloxal><Clafen><Claphene><Clinic><Clinical><Clinical Evaluation><Clinical Research><Clinical Study><Clinical Testing><Clinical Trials><Combination Chemotherapy Regimen><Combination immunotherapy><Cycloblastin><Cycloblastine><Cyclophospham><Cyclophosphamide><Cyclophosphamidum><Cyclophosphan><Cyclophosphane><Cyclophosphanum><Cyclostin><Cyclostine><Cytophosphan><Cytophosphane><Cytoxan><Data><Development><Disease><Disorder><Dose><Down-Regulation><Drugs><Dysfunction><ERBB2><ERBB2 gene><Early-Stage Clinical Trials><Endoxan><Endoxana><Enduxan><Engineering><Event><Fosfaseron><Functional disorder><Future><Genoxal><Genuxal><Goals><HER -2><HER-2><HER2><HER2 Genes><HER2/neu><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><IND Filing><IND application><IND package><IND submission><Immune><Immune Markers><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immune signaling><Immunes><Immunologic Markers><Immunologically Directed Therapy><Immunotherapy><In complete remission><Infusion><Infusion procedures><Intervention><Intracellular Communication and Signaling><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Investigators><Kinetics><Knowledge><LYT3><Ledoxina><Literature><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Soft Tissue Neoplasm><Malignant Tumor><Medication><Mitoxan><NEU Oncogene><NEU protein><NTRKR1><Neosar><Neurotrophic Tyrosine Kinase Receptor-Related 1><Oncogene ErbB2><Outcome><PD 1><PD-1><PD-1 antibody><PD-1 blockade><PD-1/PD-L1><PD-1/PDL1><PD-L1><PD1><PD1 antibody><PD1 blockade><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL-1><Patient Selection><Patients><Pharmaceutical Preparations><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Phase I Study><Physiopathology><Predisposition><Procytox><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><Public Health><Quimioterapia><ROR1><ROR1 gene><Receptor Protein><Receptor Tyrosine Kinase-Like Orphan Receptor 1><Recurrence><Recurrent><Recurrent disease><Refractory><Relapse><Relapsed Disease><Reporting><Research><Research Personnel><Researchers><Rhabdomyosarcoma><Safety><Sarcoma><Sendoxan><Serum><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Susceptibility><Syklofosfamid><T cell response><T cells for CAR><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><TKR1><Testing><Therapeutic><Toxic effect><Toxicities><Transgenes><Treatment outcome><Tumor Antigens><Tumor Escape><Tumor Immune Escape><Tumor Promotion><Tumor Tissue><Tumor-Associated Antigen><Upregulation><Zytoxan><aPD-1><aPD1><adult youth><adulthood><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><anti-tumor effect><anti-tumor response><antiPD-1><antitumor effect><biological signal transduction><biomarker identification><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><cancer antigens><cancer chemotherapy><cancer evasion><cancer immune escape><cancer immune evasion><cancer microenvironment><cell based intervention><cell mediated immune response><cell mediated intervention><cell mediated therapies><cell sorting><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><childhood sarcoma><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical efficacy><clinical predictors><clinical test><cohort><combinatorial immunotherapy><complete response><cultured cell line><design><designing><developmental><drug/agent><dual immunotherapy><erbB-2 Genes><fludarabine><herstatin><identification of biomarkers><identification of new biomarkers><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogen><immunological biomarkers><immunological markers><improved><infusions><innovate><innovation><innovative><kids><life year loss><malignancy><malignant soft tissue tumor><marker identification><neoplasm/cancer><neu Genes><new approaches><novel approaches><novel strategies><novel strategy><pathophysiology><pediatric sarcoma><peripheral blood><phase 1 study><phase 1 trial><phase I protocol><phase I trial><pre-clinical study><preclinical study><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><prospective><protein death-ligand 1><rational design><receptor><research clinical testing><response><response to therapy><response to treatment><sle2><success><systemic lupus erythematosus susceptibility 2><therapeutic response><therapy response><thymus derived lymphocyte><transgene><treatment response><treatment responsiveness><tumor><tumor evasion><tumor immune evasion><tumor microenvironment><tumor-specific antigen><years of life lost><young adult><young adult age><young adulthood><youngster><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Konstantinos Drosatos

UNIVERSITY OF CINCINNATI, CINCINNATI, OH

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$623,928
FY 2026

Project Title

Role of GLUT1 in diabetic cardiomyopathy

Grant Number:

5R01HL175251-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2025

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Diabetic cardiomyopathy (DbCM), which occurs in either Type-1 Diabetes (T1D) or Type-2 Diabetes (T2D), defines heart failure (HF) that occurs in the absence of coronary artery disease, hypertension, and valvular disease. Our research has discovered in human myocardial samples and mouse dia...

Research Terms

<2,4-thiazolidinedione><2-oxo-propanal><Ablation><Acetylformaldehyde><Address><Adult-Onset Diabetes Mellitus><Advanced Glycation End Products><Advanced Glycosylation End Products><Affect><Agonist><Anabolism><Atlases><Attenuated><Basal Transcription Factor><Basal transcription factor genes><Blood Glucose><Blood Sugar><Brittle Diabetes Mellitus><Cardiac><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac Toxicity><Cardiocyte><Cardiotoxic><Cardiotoxicity><Cell Communication and Signaling><Cell Signaling><Clinical Research><Clinical Study><Co-Transporters><Complications of Diabetes Mellitus><Coronary Arteriosclerosis><Coronary Artery Disease><Coronary Artery Disorder><Coronary Atherosclerosis><D-Glucose><Data><Deacetylation><Death Rate><Development><Dextrose><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Complications><Diabetic mouse><Dimethylbiguanidine><Dimethylguanylguanidine><Disease><Disorder><Drugs><Elements><Erythrocyte/Hepatoma Glucose Transporter><Event><Exclusion><FKHR><FOXO1><FOXO1A><FOXO1A gene><Fibrosis><Forkhead Box O1A><Forkhead in Rhabdomyosarcoma><GLP-1 receptor><GLP-I receptor><GLUT><GLUT 4 protein><GLUT1><GLUT4><GLUT4 gene><GLUT4 protein><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Transcription><Glitazones><Glucose><Glucose Binding Protein><Glucose Transport Protein><Glucose Transporter><Glucose Transporter 1><Heart><Heart Muscle Cells><Heart failure><Heart myocyte><Hexosamines><Human><Humulin R><Hyperglycemia><Hyperphagia><Hypertension><IDDM><Impairment><Insulin><Insulin Resistance><Insulin deficiency><Insulin-Dependent Diabetes Mellitus><Intracellular Communication and Signaling><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Kruppel-like transcription factors><Lead><Link><Maps><Maturity-Onset Diabetes Mellitus><Mediating><Medication><Metabolic><Metabolic Pathway><Metformin><Methylglyoxal><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Myocardial><N,N-dimethyl-imidodicarbonimidic diamide><NIDDM><Na element><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><O-GlcNAc Transferase gene><O-GlcNAc transferase><Overeating><Oxidative Stress><Pathologic><Pathway interactions><Patients><Pb element><Pharmaceutical Preparations><Population><Proteins><Proteome><Pyruvaldehyde><Pyruvic Aldehyde><RNA Expression><Regular Insulin><Research><Role><Route><SGLT 2 inhibitor><SGLT2i><SIRT1><SIRT1 gene><SLC2A1><SLC2A1 gene><Sampling><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Sirtuin 1><Slow-Onset Diabetes Mellitus><Sodium><Sodium glucose co-transporter 2 inhibitor><Solute Carrier Family 2, Facilitated Glucose Transporter, Member 1><Stable Diabetes Mellitus><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Therapeutic><Thiazolidinediones><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><Upregulation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><adult onset diabetes><advanced glycation endproduct><advanced glycosylation endproduct><atherosclerotic coronary disease><attenuate><attenuates><biological signal transduction><biosynthesis><cardiac failure><cardiac function><cardiomyocyte><cardioprotectant><cardioprotection><cardioprotective><coronary arterial disease><db/db mouse><developmental><diabetes><diabetes mouse model><diabetic><diabetic cardiomyopathy><diabetic cardiopathy><diabetic cardiopathy disease><diabetic cardiopathy disorder><diabetic cardiovascular disease><diabetic cardiovascular disorder><diabetic patient><drug/agent><function of the heart><global gene expression><global transcription profile><glucagon-like peptide-1 receptor><glucose uptake><heart function><heavy metal Pb><heavy metal lead><high blood pressure><hyperglycemic><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><improved><in vivo><inhibitor><insulin dependent diabetes><insulin dependent type 1><insulin resistant><insulin signaling><insulin tolerance><insulin-responsive glucose transporter><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><lipidome><maturity onset diabetes><metabolome><metabonome><mitochondrial dysfunction><mortality rate><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><pathway><pharmacologic><polyphagia><prevent><preventing><social role><symporter><therapeutic target><thiazolidinedione><transcription factor><transcriptome><type 1 and type 2 diabetes><type 2 DM><type I and type II diabetes><type I diabetes><type II DM><type one diabetes><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAMELA U FREDA

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$612,928
FY 2026

Project Title

Central Mediation of Growth Hormone Effects in Humans

Grant Number:

5R01DK133392-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/25/2023

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY GH and IGF-1 are well known to act on peripheral tissues to importantly influence growth, metabolism and body composition. Recently, however, our preliminary work and other data in mice have suggested that central effects of GH on the orexigenic hypothalamic neuropeptide AgRP (agouti...

Research Terms

<AGRP protein><ART protein><Acromegaly><Affect><Agonist><Appetite Stimulants><Appetite-Stimulating Drugs><Attenuated><Autoregulation><Blood Plasma><Body Composition><Body Tissues><Body Weight><Brain><Brain Nervous System><Cell Communication and Signaling><Cell Signaling><Clinical><Clinical Treatment><Data><Development><Disease><Disorder><Drugs><Encephalon><Endocrine Gland Secretion><Energy Expenditure><Energy Metabolism><GLP-1 receptor><GLP-I receptor><Generalized Growth><Growth><Growth Hormone><Growth Hormone 1><Homeostasis><Hormones><HuB219><Human><Hypothalamic structure><Hypothalamus><IGF-1><IGF-I><IGF-I-SmC><Impairment><Inappropriate GH Secretion Syndrome (Acromegaly)><Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)><Infusion><Infusion procedures><Insulin Resistance><Insulin-Like Growth Factor 1><Insulin-Like Growth Factor I><Insulin-Like Somatomedin Peptide I><Intermediary Metabolism><Intracellular Communication and Signaling><Investigation><LEP-R><LEPR Protein><Leptin><Level of Evidence><Link><Mediation><Mediator><Medication><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Modern Man><Murine><Mus><Negotiating><Negotiation><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Neuropeptides><Nutrient><Nutrition><Nutritional><OB Receptor><OB-R><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Protein><Obesity><Operative Procedures><Operative Surgical Procedures><Patients><Peptides><Peripheral><Pharmaceutical Preparations><Phase><Physiological Homeostasis><Pituitary Growth Hormone><Placebos><Plasma><Plasma Serum><Process><Protein Overexpression><Receptor Protein><Rest><Reticuloendothelial System, Serum, Plasma><Role><Sham Treatment><Signal Transduction><Signal Transduction Systems><Signaling><Somatomedin C><Somatotropin><Somatotropin Hypersecretion Syndrome (Acromegaly)><Surgical><Surgical Interventions><Surgical Procedure><Testing><Therapeutic Hormone><Time><Tissue Growth><Tissues><Weight><Work><acromegalic features><adiposity><agouti-related protein><antagonism><antagonist><attenuate><attenuates><biological signal transduction><clinical intervention><clinical therapy><corpulence><developmental><drug/agent><falls><glucagon-like peptide-1 receptor><glucose metabolism><human model><hypothalamic><infusions><innovate><innovation><innovative><insight><insulin resistant><insulin tolerance><leptin receptor><leptin-binding protein><life span><lifespan><liraglutide><model of human><mortality><neuronal><novel><nutrient deprivation><nutritional deprivation><nutritious><ontogeny><orexigenic><pegvisomant><randomized placebo controlled study><receptor><response><sham therapy><social role><somatotropic hormone><stem><surgery><trial regimen><trial treatment><weights>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Venkatram Reddy Atigadda

UNIVERSITY OF ALABAMA AT BIRMINGHAM, BIRMINGHAM, AL

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$610,112
FY 2026

Project Title

Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer

Grant Number:

5R01CA276683-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2023

End Date:

2/29/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract: Non-melanoma skin cancer (NMSC), which include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) is one of the most common types of cancers in the US. Due to compromised immunity, solid organ transplant recipients (SOTRs) are at a much higher risk for NMSC and it often becomes t...

Research Terms

<13 cis retinoate><13-cRA><13-cis-Retinoic Acid><13-cis-Vitamin A Acid><3-methyl TTNEB><9-cRA><9-cis-Retinoic Acid><9-cis-Retinoic Acid Receptor><ATRA><Acidity><Adverse effects><Agonist><American Cancer Society><Animals><Apoptosis><Apoptosis Pathway><Basal Cell Epithelioma><Basal cell carcinoma><Basiloma><Bexarotene><Binding><Bioavailability><Biological Availability><Biological Markers><Blood Serum><Calorimetry><Cancer Biology><Cancer Model><CancerModel><Cancers><Carbon><Carboxylic Acids><Carcinoma Cell><Cause of Death><Cell Respiration><Cellular Respiration><Chemopreventive><Chemopreventive Agent><Chronic><Clinical><Complex><Cutaneous Lymphoproliferative Disorder><Data><Development><Disease><Disorder><Dose><Drug Kinetics><Drugs><Economic Burden><Emotional><Epidermoid Carcinoma><Evaluation><F element><FDA approved><Fluorine><Gene Transcription><Genetic Transcription><Grant><Group 17 Elements><H element><Half-Life><Halogens><Homo><Human><Hydrogen><Hyperlipemia><Hyperlipidemia><Immune><Immunes><Immunity><In Vitro><Individual><Inflammation><Inflammatory><Investigation><Investigators><Isotretinoin><Isotretinoinum><Keratinocyte carcinoma><Laboratories><Ligand Binding><Lipids><Liver X Receptor><Lymphoproliferative Disorder of the Skin><Malignant Epithelial Cell><Malignant Neoplasms><Malignant Tumor><Measures><Medication><Metabolic><Modeling><Modern Man><Modification><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Nitrogen><Non-Melanoma Skin Cancer><Nuclear Receptors><Oral><Parents><Peptides><Pharmaceutical Preparations><Pharmacokinetics><Phase I Study><Physiologic Availability><Planocellular Carcinoma><Play><Polyenes><Population><Prevent skin cancer><Preventative strategy><Prevention><Prevention strategy><Preventive><Preventive strategy><Programmed Cell Death><Proliferating><Property><Proteins><RNA Expression><RXR><RXR Protein><Receptor Protein><Research Personnel><Researchers><Retinoic Acid><Retinoic Acid Agent><Retinoic Acid Receptor><Retinoic Acid Receptor RXR><Retinoic Acid and Derivatives><Retinoicacid-13-cis><Retinoicacid-9-cis><Retinoid X Receptors><Retinoids><Rodent Ulcer><Roentgen Rays><Role><Safety><Serum><Single Crystal Diffraction><Skin><Skin Carcinogenesis><Skin Carcinoma><Solid><Squamous Carcinoma><Squamous Cell Epithelioma><Squamous cell carcinoma><Structure><Surface><Targretin><Tetralones><Titrations><Toxic effect><Toxicities><Trans Vitamin A Acid><Transcription><Translating><Translations><Tretinoin><Tretinoinum><UVB induced><Vitamin A Acid><X Ray Crystallographies><X-Radiation><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray Radiation><X-Ray/Neutron Crystallography><X-ray><Xray><Xray Crystallography><aerobic metabolism><aerobic respiration><alitretinoin><all-trans-Retinoic Acid><all-trans-Vitamin A acid><analog><anti-carcinogenic><basal cell carcinoma of skin><bio-markers><biologic marker><biomarker><biophysical analysis><biophysical studies><cancer chemoprevention><cancer diagnosis><cancer type><chemoprevention agent><cis-Retinoic Acid><clinical candidate><clinical development><combat><conformation><conformational><conformational state><conformationally><conformations><cutaneous carcinogenesis><cutaneous lesions><dermal lesion><design><designing><developmental><drug/agent><experiment><experimental research><experimental study><experiments><high risk><human model><improved><innovate><innovation><innovative><lipophilicity><malignancy><member><metabolic profile><model of human><mouse model><murine model><neoplasm/cancer><non-compliance><non-compliant><noncompliance><noncompliant><nonmelanoma skin cancer><novel><organ transplant patient><organ transplant recipient><oxidative metabolism><parent><pharmacologic><phase 1 study><pre-clinical><pre-clinical development><pre-clinical evaluation><preclinical><preclinical development><preclinical evaluation><prevent><preventing><prospective><receptor><recruit><side effect><skin cancer prevention><skin lesion><small molecule><social role><time interval><tissue biomarkers><trans-Retinoic Acid><translation><ultraviolet B induced><ultraviolet b radiation induced><ultraviolet light b induced><water solubility>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joann Trejo

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$591,032
FY 2026

Project Title

Endothelial Cytoprotective Signaling by Activated Protein C/Protease-activated Receptor-1

Grant Number:

5R01HL163931-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract There are currently limited treatment options for improving endothelial dysfunction in vascular diseases such as sepsis, resulting in high morbidity and mortality. Endothelial dysfunction results in endothelial cell activation, disruption of endothelial barrier function and sensitiv...

Research Terms

<22kD Caveolae Protein><ARB1><ARRB1><ARRB1 gene><ARRB2><Agonist><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Anticoagulant Agents><Anticoagulant Drugs><Anticoagulants><Apoptosis><Apoptosis Pathway><Apoptotic><Arginine><Arr1><Binding><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Caveolae><Caveolas><Caveolin 1, Caveolae Protein, 22kD><Cell Body><Cell Communication and Signaling><Cell Membrane Lipid Rafts><Cell Protection><Cell Signaling><Cell membrane><Cells><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Coagulation Factor II Receptor><Cytoplasmic Membrane><Cytoprotection><Edg Receptors><Endothelial Cells><Endothelium><Esteroproteases><Exhibits><Future><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G Protein-Coupled Receptor Kinase 5><G-Protein-Coupled Receptors><G-Proteins><GPCR><GPRK5><GPRK5 Gene><GRK5><GRK5 gene><GTP-Binding Proteins><GTP-Regulatory Proteins><Goals><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Heterotrimeric G-Proteins><Heterotrimeric GTP-Binding Proteins><Human><In Vitro><Inflammation><Inflammatory Response><Injury><Intracellular Communication and Signaling><Kinases><Knock-out><Knockout><L-Arginine><Ligands><Mediating><Mediator><Membrane><Membrane Microdomains><Modern Man><Molecular Interaction><Morbidity><N-terminal><NH2-terminal><PAR-1 Receptor><PAR1 Receptor><Pathogenesis><Pathologic><Pathway interactions><Peptidases><Peptide Hydrolases><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiologic><Physiological><Plasma Membrane><Programmed Cell Death><Protease Gene><Protease-Activated Receptor 1><Proteases><Protein Phosphorylation><Proteinase-Activated Receptor 1><Proteinases><Proteolytic Enzymes><Receptor Protein><Research><S1P Receptor><SPHK1 enzyme><Sepsis><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><Sphingosine-1-Phosphate Receptor><System><Testing><Therapeutic><Thrombase><Thrombin><Transducers><Transphosphorylases><VIP21><VIP21 protein><Vascular Diseases><Vascular Disorder><activated Protein C><arrestin B><beta-arrestin><beta-arrestin 2><biological signal transduction><blood thinner><blood vessel disorder><caveolin 1><cytoprotective><desensitization><endothelial dysfunction><fibrinogenase><improved><in vivo><injuries><innovate><innovation><innovative><insight><lipid raft><membrane structure><mortality><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathway><pharmacologic><plasmalemma><pre-clinical study><preclinical study><receptor><resilience><resilient><response><sphingosine kinase-1><therapeutic agent development><therapeutic development><thrombopoiesis inhibitor><vascular dysfunction><vasculopathy><vesicular integral membrane protein 21 kDa><β-arrestin>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew J. Merrins

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$583,915
FY 2026

Project Title

Metabolic Functions of Pyruvate Kinase M2 in Pancreatic Beta-cells

Grant Number:

7R01DK113103-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2017

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Over 450 million people suffer from type 2 diabetes (T2D), a disease defined by the failure of pancreatic β-cells. In the first period of support, we showed that pharmacologic activators of pyruvate kinase (PK) potentiate insulin secretion from mouse, rat, and human islets, as well as diabe...

Research Terms

<3'5'-cyclic ester of AMP><3,5 cyclic AMP synthetase><A kinase anchoring protein><AKAP><Acceleration><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adenyl Cyclase><Adenylate Cyclase><Adenylyl Cyclase><Adult-Onset Diabetes Mellitus><Agonist><Alpha Cell><Amino Acids><Anti-diabetic Agents><Anti-diabetic Drugs><Antidiabetic Hormone><Beta Cell><Binding><Biosensor><Calcineurin><Cell Communication and Signaling><Cell Signaling><Cell membrane><Clinical><Common Rat Strains><Compensation><Cues><Cyclic AMP><Cyclic AMP-Dependent Protein Kinases><Cytoplasmic Membrane><D-Glucose><Data><Development><Dextrose><Disease><Disorder><Drug Targeting><Dysfunction><Electric Capacitance><Electrical Capacitance><Endosomes><Enzyme Gene><Enzymes><Exocytosis Induction><Failure><Functional disorder><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G Protein-Coupled Receptor Signaling><G(s), alpha Subunit><G(s), α Subunit><G(s)alpha><G(s)α><G-Protein-Coupled Receptors><GIPR><GIPR gene><GLP-1><GLP-1 receptor><GLP-I receptor><GPCR><GPCR Signaling><GTP-Binding Protein alpha Subunits, Gs><GTP-Binding Protein α Subunits, Gs><Gastric Inhibitory Polypeptide><Generations><Glp-1><Glucagon><Glucagon Cell><Glucagon Secreting Cell><Glucose><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Glukagon><Gs alpha Family G-Protein><Gsα><Gαs><HG-Factor><Human><Humulin R><Hyperglycemic-Glycogenolytic Factor><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Isoforms><KO mice><Ketosis-Resistant Diabetes Mellitus><Kinetics><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Knowledge><Maturity-Onset Diabetes Mellitus><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic stress><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Molecular Interaction><Murine><Mus><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Null Mouse><Nutrient><PKA><PP2B><Pancreatic beta Cell><Pancreatic β-Cell><Paracrine Communication><Paracrine Signaling><Patients><Persons><Phosphoenolpyruvate><Physiopathology><Plasma Membrane><Play><Production><Protein Isoforms><Protein Kinase A><Protein Phosphatase-2B><Publishing><Pyruvate Kinase><Rat><Rat model of diabetes><Rats Mammals><Rattus><Receptor Protein><Receptor Signaling><Receptosomes><Regular Insulin><Regulation><Regulatory Ns Protein><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulatory Gs G-Protein><Structure of beta Cell of islet><T2 DM><T2D><T2DM><Testing><Therapeutic><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Work><adenosine 3'5' monophosphate><adult onset diabetes><alpha Subunit Stimulatory GTP-Binding Protein><alpha-Gs><alpha-cell><aminoacid><anti-diabetic><bariatric surgery><biological sensor><biological signal transduction><cAMP><cAMP-Dependent Protein Kinases><capacitance><detection of nutrient><developmental><diabetic rat><diabetic rat model><gastric banding><gastric bypass surgery><gastric inhibitory peptide><glucagon-like peptide 1><glucagon-like peptide-1 receptor><hormonal signals><hormone signals><implantable gastric stimulation banding><in vivo><incretin hormone><insight><insulin secretion><islet><ketosis resistant diabetes><maturity onset diabetes><metabolism disorder><mimetics><mitochondrial><nano><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><next generation><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><nutrient metabolism><nutrient sensing><obesity surgery><pancreas beta cell><pancreas β cell><pancreatic b-cell><paracrine><pathophysiology><perception of nutrients><pharmacologic><phosphoenol transphosphorylase><phosphoenolpyruvate kinase><plasmalemma><receptor><recruit><response><scaffold><scaffolding><social role><source localization><stomach stapling><therapeutic target><type 2 DM><type II DM><type two diabetes><voltage><weight loss surgery><α-Gs><α-cell><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jingshi Shen

UNIVERSITY OF COLORADO, Boulder, CO

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$551,250
FY 2026

Project Title

Vesicle fusion regulation in metabolism

Grant Number:

1R01DK142287-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/19/2026

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Many metabolic responses involve the trafficking of proteins within the endomembrane system. A major branch of membrane protein trafficking is vesicle fusion, which entails the merging of membrane-enclosed vesicles with their target membranes. Vesicle fusion mediates key metabolic pr...

Research Terms

<Acceleration><Address><Adipocytes><Adipose Cell><Adult-Onset Diabetes Mellitus><Affect><Antidiabetic Hormone><Assay><Binding><Bioassay><Biochemical><Biological Assay><Biological Function><Biological Process><Biophysics><Blood Glucose><Blood Sugar><CRISPR><CRISPR/Cas system><Cell membrane><Cell surface><Chimera Protein><Chimeric Proteins><Clustered Regularly Interspaced Short Palindromic Repeats><Critical Paths><Critical Pathways><Cytoplasmic Membrane><Data><Defect><Development><Disease><Disorder><Exocytosis><Experimental Genetics><Fat Cells><Fusion Protein><GLP-1><GLUT 4 protein><GLUT4><GLUT4 gene><GLUT4 protein><Gene Modified><Genetic><Glp-1><Glucagon><Glucose Binding Protein><Glucose Transport Protein><Glucose Transporter><Glukagon><Grips><HG-Factor><High Fat Diet><Human><Humulin R><Hyperglycemic-Glycogenolytic Factor><Insulin><Insulin Resistance><Intermediary Metabolism><Ketosis-Resistant Diabetes Mellitus><Kinetics><Knowledge><Link><Lipid Bilayers><Lipids><Lipocytes><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Mediating><Mediator><Membrane><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Pathway><Metabolic Processes><Metabolism><Modern Man><Molecular><Molecular Interaction><Mouse Strains><Munc-18 protein><Munc18 protein><Muscle Cells><Myocytes><NIDDM><NSF attachment protein receptor><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Pathogenesis><Pathway interactions><Plasma Membrane><Pluripotent Stem Cells><Process><Progenitor Cells><Protein Trafficking><Proteins><Reaction><Receptor Protein><Regular Insulin><Regulation><Research><Role><SNAP receptor><SNARE><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Surface Proteins><System><T2 DM><T2D><T2DM><Testing><Therapeutic Intervention><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Vesicle><Work><adult onset diabetes><biophysical foundation><biophysical principles><biophysical sciences><blood glucose regulation><developmental><experiment><experimental research><experimental study><experiments><gene modification><genetically modified><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose regulation><glucose uptake><grasp><human derived pluripotent stem cell><human pluripotent stem cell><insight><insulin resistant><insulin secretion><insulin tolerance><insulin-responsive glucose transporter><intervention therapy><ketosis resistant diabetes><lipid bilayer membrane><maturity onset diabetes><membrane structure><metabolism disorder><mouse model><murine model><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><pathway><plasmalemma><pluripotent progenitor><progenitor cell differentiation><progenitor differentiation><protein transport><receptor><reconstitute><reconstitution><response><social role><soluble N-ethylmaleimide-sensitive-factor attachment protein receptor><stem and progenitor differentiation><stem cell differentiation><stem cells><syntaxin binding protein 1><syntaxin binding protein Munc18><therapeutically effective><time use><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Malgorzata Kasztan

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$548,747
FY 2026

Project Title

Endothelin 1 in iron handling in sickle cell disease

Grant Number:

5R01HL173038-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract: Sickle cell disease (SCD) is an inherited chronic hemolytic anemia characterized by vaso-occlusive episodes and end organ damage. Up to 80% of patients with SCD will develop chronic kidney disease (CKD), with 30% mortality ascribed to kidney failure. This devastating health outcome exists ...

Research Terms

<21+ years old><Acute><Adult><Adult Human><Affect><Albuminuria><Amino Acids><Attenuated><B-Cell Activation><Blood Plasma><Blood Transfusion><CD71><Causality><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chronic><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Complex><Data><Deposit><Deposition><EDN1><ESKD><ESRD><ET-1><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Endothelin Receptor><Endothelin Type 1><Endothelin-1><Endothelium-Derived Vasoconstrictor Factor Receptors><Enhancers><Etiology><Excretory function><Exhibits><Fe chelation><Fe element><Fe overload><Ferroprotoporphyrin><HIF 1><HIF-1 protein><HIF1><HIF1 protein><Hb SS disease><HbSS disease><Health><Heme><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hemolysis Induction><Hemolytic Anemia><Hepc peptide><Hereditary><Human><Immunoglobulin Enhancer-Binding Protein><In Vitro><Incubated><Inherited><Injury to Kidney><Intervention Strategies><Intestinal><Intestines><Intracellular Communication and Signaling><Iron><Iron Chelates><Iron Chelating Agents><Iron Chelation><Iron Overload><Iron chelator><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><KO mice><Kidney><Kidney Diseases><Kidney Failure><Kidney Insufficiency><Kidney Urinary System><Knock-out Mice><Knockout Mice><Liver><Macrophage><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><Mφ><NF-kB><NF-kB Signaling Pathway><NF-kappa B><NF-kappaB><NFKB><NFKB Signaling Pathway><Nephropathy><Nephrotoxic><Nuclear><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Null Mouse><Organ><Outcome><Patients><Peptides><Phenotype><Plasma><Plasma Serum><Protoheme><Receptor Activation><Receptor Protein><Recycling><Regulation><Renal Disease><Renal Failure><Renal Insufficiency><Reticuloendothelial System, Serum, Plasma><Role><STAT3><STAT3 gene><Serum Iron Level><Severities><Sickle Cell><Sickle Cell Anemia><Signal Transduction><Signal Transduction Systems><Signaling><TFR gene><TFR protein><TFR1><TFRC><TFRC gene><TRFR><Time><Toxic effect><Toxicities><Transcription Factor NF-kB><Transferrin Receptor><Transferrin Receptor 1><Transfusion><Tyrosine-Protein Kinase JAK2><Upregulation><activated B cells><adulthood><ambrisentan><aminoacid><antagonism><antagonist><attenuate><attenuates><biological signal transduction><bowel><causation><chelation><chronic kidney disease><disease causation><erythrolysis><excretion><ferroheme><ferroportin><ferroportin1 protein><heme 1><hepatic body system><hepatic organ system><hepcidin><hypoxia inducible factor 1><improved><in vivo><kappa B Enhancer Binding Protein><kidney disorder><kidney injury><kidney toxicity><metal transporting protein 1><mortality><mouse model><murine model><nephrotoxicity><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><nuclear factor kappa beta><prevent><preventing><receptor><renal><renal disorder><renal injury><sickle RBC><sickle cell disease><sickle cell disorder><sickle disease><sickle erythrocyte><sickle red blood cell><sicklemia><social role><solute carrier family 40 (iron-regulated transporter), member 1><trafficking><uptake><urinary>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nicolai Doliba

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$544,201
FY 2026

Project Title

Role of Alpha Cells in Pathogenesis of Type 1 Diabetes

Grant Number:

5R01DK136564-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Longitudinal studies have shown that individuals at high genetic risk for type 1 diabetes (T1D) progress through several distinct stages prior to the onset of clinical symptoms. Although the factors causally involved in the rate of progression are poorly understood, the presence of i...

Research Terms

<3'5'-cyclic ester of AMP><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Alpha Cell><Antidiabetic Hormone><Assay><Autoantibodies><B9 endocrine pancreas><Beta Cell><Bioassay><Bioenergetics><Biological Assay><Biological Markers><Biosensor><Brittle Diabetes Mellitus><Cell Aggregation><Cell Body><Cell Communication and Signaling><Cell Function><Cell Membrane Permeability><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Clinical><Complex><Concentration Camps><Custom><Cyclic AMP><Cyclic AMP-Dependent Protein Kinases><D-Glucose><Data><Defect><Development><Dextrose><Diabetes Mellitus><Disease><Disorder><Down-Regulation><Drugs><Dysfunction><Electrophysiology><Electrophysiology (science)><Endocrine Pancreas><Evaluation><Exocytosis><Functional disorder><Future><Genes><Genetic><Genetic Risk><Glucagon><Glucagon Cell><Glucagon Secreting Cell><Glucokinase><Glucose><Glukagon><Glutamate Carboxy-Lyase><Glutamate Decarboxylase><Glutamic Acid Decarboxylase><Glycolysis><HG-Factor><Human><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><IDDM><Immune response><Impairment><Individual><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Intracellular Communication and Signaling><Ion Channel><Ionic Channels><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><L-Glutamate-1-carboxy-lyase><Longitudinal Studies><Longitudinal Surveys><Measurement><Measures><Medication><Membrane Channels><Membrane Potentials><Mitochondria><Modern Man><Modification><Nesidioblasts><Neurophysiology / Electrophysiology><Outcomes Research><Oxidative Phosphorylation><Oxidative Phosphorylation Pathway><PKA><PKA inhibitor><Pancreatic Islets><Pars endocrina pancreatis><Pathogenesis><Pathway interactions><Pharmaceutical Preparations><Phenotype><Physiopathology><Position><Positioning Attribute><Property><Protein Kinase A><Resting Potentials><Role><Signal Transduction><Signal Transduction Systems><Signaling><Spirometry><Subcellular Process><Sudden-Onset Diabetes Mellitus><Symptoms><T1 DM><T1 diabetes><T1D><T1DM><Testing><Transmembrane Potentials><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Viral><adenosine 3'5' monophosphate><alpha-cell><analog><arm><autoimmune antibody><autoreactive antibody><bio-markers><biologic marker><biological sensor><biological signal transduction><biomarker><cAMP><cAMP-Dependent Protein Kinases><customs><developmental><diabetes><drug/agent><electrophysiological><experiment><experimental research><experimental study><experiments><glucose metabolism><host response><hyperglycemic><immune system response><immunoresponse><insulin dependent diabetes><insulin dependent type 1><insulin secretion><islet><islet autoantibody><islet cell antibody><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><lens><lenses><long-term study><longitudinal outcome studies><longitudinal research study><membrane permeability><mitochondrial><multidisciplinary><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><non-diabetic><nondiabetic><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathophysiology><pathway><pharmacologic><prevent><preventing><protein kinase inhibitor><ratiometric><self reactive antibody><social role><transcriptomics><type I diabetes><type one diabetes><α-cell><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DORIS A STOFFERS

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$544,201
FY 2026

Project Title

Role of Alpha Cells in Pathogenesis of Type 1 Diabetes

Grant Number:

5R01DK136564-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Longitudinal studies have shown that individuals at high genetic risk for type 1 diabetes (T1D) progress through several distinct stages prior to the onset of clinical symptoms. Although the factors causally involved in the rate of progression are poorly understood, the presence of i...

Research Terms

<3'5'-cyclic ester of AMP><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Affect><Alpha Cell><Antidiabetic Hormone><Assay><Autoantibodies><B9 endocrine pancreas><Beta Cell><Bioassay><Bioenergetics><Biological Assay><Biological Markers><Biosensor><Brittle Diabetes Mellitus><Cell Aggregation><Cell Body><Cell Communication and Signaling><Cell Function><Cell Membrane Permeability><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Clinical><Complex><Concentration Camps><Custom><Cyclic AMP><Cyclic AMP-Dependent Protein Kinases><D-Glucose><Data><Defect><Development><Dextrose><Diabetes Mellitus><Disease><Disorder><Down-Regulation><Drugs><Dysfunction><Electrophysiology><Electrophysiology (science)><Endocrine Pancreas><Evaluation><Exocytosis><Functional disorder><Future><Genes><Genetic><Genetic Risk><Glucagon><Glucagon Cell><Glucagon Secreting Cell><Glucokinase><Glucose><Glukagon><Glutamate Carboxy-Lyase><Glutamate Decarboxylase><Glutamic Acid Decarboxylase><Glycolysis><HG-Factor><Human><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><IDDM><Immune response><Impairment><Individual><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Intracellular Communication and Signaling><Ion Channel><Ionic Channels><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><L-Glutamate-1-carboxy-lyase><Longitudinal Studies><Longitudinal Surveys><Measurement><Measures><Medication><Membrane Channels><Membrane Potentials><Mitochondria><Modern Man><Modification><Nesidioblasts><Neurophysiology / Electrophysiology><Outcomes Research><Oxidative Phosphorylation><Oxidative Phosphorylation Pathway><PKA><PKA inhibitor><Pancreatic Islets><Pars endocrina pancreatis><Pathogenesis><Pathway interactions><Pharmaceutical Preparations><Phenotype><Physiopathology><Position><Positioning Attribute><Property><Protein Kinase A><Resting Potentials><Role><Signal Transduction><Signal Transduction Systems><Signaling><Spirometry><Subcellular Process><Sudden-Onset Diabetes Mellitus><Symptoms><T1 DM><T1 diabetes><T1D><T1DM><Testing><Transmembrane Potentials><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Viral><adenosine 3'5' monophosphate><alpha-cell><analog><arm><autoimmune antibody><autoreactive antibody><bio-markers><biologic marker><biological sensor><biological signal transduction><biomarker><cAMP><cAMP-Dependent Protein Kinases><customs><developmental><diabetes><drug/agent><electrophysiological><experiment><experimental research><experimental study><experiments><glucose metabolism><host response><hyperglycemic><immune system response><immunoresponse><insulin dependent diabetes><insulin dependent type 1><insulin secretion><islet><islet autoantibody><islet cell antibody><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><lens><lenses><long-term study><longitudinal outcome studies><longitudinal research study><membrane permeability><mitochondrial><multidisciplinary><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><non-diabetic><nondiabetic><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathophysiology><pathway><pharmacologic><prevent><preventing><protein kinase inhibitor><ratiometric><self reactive antibody><social role><transcriptomics><type I diabetes><type one diabetes><α-cell><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Scott Edward Kanoski

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$537,628
FY 2026

Project Title

Interactions between diet and cognition

Grant Number:

5R01DK123423-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/20/2019

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Consumption of an obesity-promoting “Western diet” (WD) is strongly associated with cognitive impairment and dementia risk, even independent of obesity 1-5. The hippocampus (HPC), a brain region classically associated with memory function and more recently with energy balance, is pa...

Research Terms

<0-11 years old><21+ years old><ACh Receptors><AD and related dementia><AD related dementia><ADRD><Acetylcholine><Acetylcholine Receptors><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Alzheimer's Disease and its related dementias><Alzheimer's and related dementias><Alzheimer's dementia and related dementia><Alzheimer's dementia or related dementia><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease and related forms of dementia><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease related dementia><Amentia><Ammon Horn><Autoregulation><Behavioral Mechanisms><Bifidobacterium><Binding><Biological><Brain><Brain Nervous System><Brain region><Caloric Intake><Calories><Cell Communication and Signaling><Cell Signaling><Child><Child Youth><Children (0-21)><Cholinergic Receptors><Cholinoceptive Sites><Cholinoceptors><Cognition><Cognitive Disturbance><Cognitive Impairment><Cognitive Retention Disorders><Cognitive decline><Cognitive function abnormal><Common Rat Strains><Consumption><Cornu Ammonis><Data><Dementia><Development><Diet><Dietary Factors><Dietary Intervention><Disease><Disorder><Disturbance in cognition><Dysfunction><Eating><Eating Behavior><Encephalon><Energy Expenditure><Energy Intake><Energy Metabolism><Environment><Feeding behaviors><Food><Food Intake><Functional disorder><Funding><GI microbiome><GLP-1><Gastrointestinal Process><Glp-1><Healthy diet><Hippocampus><Homeostasis><Hyperphagia><Impaired cognition><Ingestive Behavior><Insulinoma amyloid peptide><Intermediary Metabolism><Intestinal><Intestines><Intracellular Communication and Signaling><Lactococcus><Life><Link><Locomotor Activity><Mechanisms of Behavior and Behavior Change><Mediating><Memory><Memory Deficit><Memory Disorders><Memory impairment><Metabolic><Metabolic Processes><Metabolism><Modeling><Molecular Interaction><Motor Activity><Network Analysis><Neurocognition><Neurocognitive><Nutrition Interventions><Nutritional Interventions><Obesity><Outcome><Overeating><Pancreas><Pancreatic><Pathway Analysis><Performance><Physiologic><Physiological><Physiological Homeostasis><Physiopathology><Population><Probiotics><Process><Publications><Rat><Rats Mammals><Rattus><Risk><Rodent><Rodent Model><Rodentia><Rodents Mammals><Role><Satiation><Scientific Publication><Signal Transduction><Signal Transduction Systems><Signaling><Stomach><Testing><Unhealthy Diet><Visuospatial><Weight Gain><Weight Increase><Work><adiposity><adulthood><amlintide><amylin><bacterial genome sequencing><bacterial whole genome sequencing><balanced diet><behavior mechanism><biologic><biological signal transduction><body weight gain><body weight increase><bowel><caloric dietary content><calorie><cholinergic><cognitive dysfunction><cognitive loss><corpulence><dementia risk><developmental><diabetes associated peptide><diet intervention><dietary><diets><digestive tract microbiome><energy balance><enteric microbiome><experiment><experimental research><experimental study><experiments><feeding-related behaviors><gastric><gastrointestinal microbiome><glucagon-like peptide 1><good diet><gut microbiome><gut-associated microbiome><hippocampal><human model><imaging in vivo><in vivo><in vivo imaging><insulinoma amyloid polypeptide><intestinal biome><intestinal microbiome><islet amyloid polypeptide><juvenile><juvenile human><kids><later in life><later life><life span><lifespan><memory dysfunction><microbial><microbiome><mid life><mid-life><middle age><middle aged><midlife><model of human><neural><neural mechanism><neurobiological mechanism><neuromechanism><novel><nutrient intake activity><pancreatic amylin><pathophysiology><pharmacologic><polyphagia><poor diet><programs><respiratory><response><risk factor for dementia><risk for dementia><satiety><saturated dietary fat><saturated dietary lipid><saturated fat><saturated lipid><social role><sugar><visual spatial><western diet><western-style diet><western-type diet><wt gain><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Benjamin Will Darbro

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$526,144
FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

<Age><Agreement><Animal Model><Animal Models and Related Studies><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Assay><Automobile Driving><Benign><Bioassay><Biological><Biological Assay><Biology><Blood Plasma><CDK4><CDK4 gene><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CRISPR><CRISPR/Cas system><Cancer Drug><Cancers><Cause of Death><Cell Body><Cell Division Kinase 4><Cell model><Cells><Cellular model><Classification><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Cyclin-Dependent Kinase 4><Cyclin-Dependent Kinase Inhibitor 2A Gene><Development><Diagnostic><Disease><Disorder><Drug Targeting><Drug resistance><Drugs><Early Diagnosis><Elephantiasis Neuromatosis><Event><Frequencies><Future><Genes><Genetic><Histologic><Histologically><Human><Hyperactivity><INK4><INK4A><In Vitro><Learning><Lesion><Link><Literature><MEKs><MTS1><MTS1 Genes><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Peripheral Nerve Sheath Tumor><Malignant Schwannoma><Malignant Tumor><Mediator><Medication><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><NF-1><NF-1 Protein><NF-1 encoded protein><NF1><NF1 GRP><NF1 Protein><NF1 gene><NF1-GAP-Related Protein><Neoplasms><Neoplastic Disease Chemotherapeutic Agents><Neurofibromatosis 1><Neurofibromatosis 1 Genes><Neurofibromatosis I><Neurofibromatosis Type 1 Gene Product><Neurofibromatosis Type 1 Protein><Neurofibromin><Neurofibromin 1><Neurofibrosarcoma><Neurogenic Sarcoma><Oncogenic><PSK-J3><Pachydermatocele><Pathogenesis><Pathway interactions><Patients><Peptides><Peripheral Neurofibromatosis><Pharmaceutical Preparations><Physiologic><Physiological><Plasma><Plasma Serum><Plexiform Neurofibroma><Plexiform Neuromas><Prevention><Proteomics><RAS driven tumor><RNA Seq><RNA sequencing><RNAseq><Recklinghausen Disease of Nerve><Recklinghausen's disease><Recklinghausen's neurofibromatosis><Reporting><Research Specimen><Resistance><Reticuloendothelial System, Serum, Plasma><Role><Sampling><Specimen><Systematics><TM-MKR><TP16><TSG9A><Testing><Therapeutic Intervention><Tumor Biology><Tumor Markers><Tumor Royale><Tumor Suppressor Proteins><Tumor-Specific Treatment Agents><Type 1 Neurofibromatosis><Type I Neurofibromatosis><Upregulation><Work><ages><anti-cancer drug><biologic><cancer progression><cell transformation><chemotherapy><circulating tumor DNA assay><circulating tumor DNA assessment><circulating tumor DNA evaluation><circulating tumor DNA monitoring><circulating tumor DNA profiling><circulating tumor DNA screening><circulating tumor DNA testing><clinical significance><clinically significant><ctDNA assay><ctDNA assessment><ctDNA evaluation><ctDNA monitoring><ctDNA profiling><ctDNA screening><ctDNA testing><customized therapy><customized treatment><developmental><driving><drug resistant><drug-sensitive><drug/agent><early detection><gene locus><genetic analysis><genetic locus><genomic location><genomic locus><human model><improved><in vivo><in vivo Model><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><intervention therapy><liquid biopsy><malignancy><model of animal><model of human><mouse model><murine model><neoplasia><neoplasm progression><neoplasm/cancer><neoplastic growth><neoplastic progression><neurofibroma><neurofibromatosis type 1 gene><neurofibromatosis type 1 protein/gene><new combination therapies><nf 1 Genes><overexpress><overexpression><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><pathway><patient specific therapies><patient specific treatment><pharmacologic><pre-clinical><pre-clinical study><precancer><precancerous><preclinical><preclinical study><preemptive intervention><premalignant><prevent><preventing><prognostic ability><prognostic assays><prognostic power><prognostic test><prognostic utility><prognostic value><reconstitute><reconstitution><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><social role><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><transcriptome sequencing><transcriptomic sequencing><transformed cells><treatment resistance><tumor><tumor biomarker><tumor progression><tumor specific biomarker><tumor suppressor><unique treatment><von Recklinghausen Disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rebecca D Dodd

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$526,144
FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

<Age><Agreement><Animal Model><Animal Models and Related Studies><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Assay><Automobile Driving><Benign><Bioassay><Biological><Biological Assay><Biology><Blood Plasma><CDK4><CDK4 gene><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CRISPR><CRISPR/Cas system><Cancer Drug><Cancers><Cause of Death><Cell Body><Cell Division Kinase 4><Cell model><Cells><Cellular model><Classification><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Cyclin-Dependent Kinase 4><Cyclin-Dependent Kinase Inhibitor 2A Gene><Development><Diagnostic><Disease><Disorder><Drug Targeting><Drug resistance><Drugs><Early Diagnosis><Elephantiasis Neuromatosis><Event><Frequencies><Future><Genes><Genetic><Histologic><Histologically><Human><Hyperactivity><INK4><INK4A><In Vitro><Learning><Lesion><Link><Literature><MEKs><MTS1><MTS1 Genes><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Peripheral Nerve Sheath Tumor><Malignant Schwannoma><Malignant Tumor><Mediator><Medication><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><NF-1><NF-1 Protein><NF-1 encoded protein><NF1><NF1 GRP><NF1 Protein><NF1 gene><NF1-GAP-Related Protein><Neoplasms><Neoplastic Disease Chemotherapeutic Agents><Neurofibromatosis 1><Neurofibromatosis 1 Genes><Neurofibromatosis I><Neurofibromatosis Type 1 Gene Product><Neurofibromatosis Type 1 Protein><Neurofibromin><Neurofibromin 1><Neurofibrosarcoma><Neurogenic Sarcoma><Oncogenic><PSK-J3><Pachydermatocele><Pathogenesis><Pathway interactions><Patients><Peptides><Peripheral Neurofibromatosis><Pharmaceutical Preparations><Physiologic><Physiological><Plasma><Plasma Serum><Plexiform Neurofibroma><Plexiform Neuromas><Prevention><Proteomics><RAS driven tumor><RNA Seq><RNA sequencing><RNAseq><Recklinghausen Disease of Nerve><Recklinghausen's disease><Recklinghausen's neurofibromatosis><Reporting><Research Specimen><Resistance><Reticuloendothelial System, Serum, Plasma><Role><Sampling><Specimen><Systematics><TM-MKR><TP16><TSG9A><Testing><Therapeutic Intervention><Tumor Biology><Tumor Markers><Tumor Royale><Tumor Suppressor Proteins><Tumor-Specific Treatment Agents><Type 1 Neurofibromatosis><Type I Neurofibromatosis><Upregulation><Work><ages><anti-cancer drug><biologic><cancer progression><cell transformation><chemotherapy><circulating tumor DNA assay><circulating tumor DNA assessment><circulating tumor DNA evaluation><circulating tumor DNA monitoring><circulating tumor DNA profiling><circulating tumor DNA screening><circulating tumor DNA testing><clinical significance><clinically significant><ctDNA assay><ctDNA assessment><ctDNA evaluation><ctDNA monitoring><ctDNA profiling><ctDNA screening><ctDNA testing><customized therapy><customized treatment><developmental><driving><drug resistant><drug-sensitive><drug/agent><early detection><gene locus><genetic analysis><genetic locus><genomic location><genomic locus><human model><improved><in vivo><in vivo Model><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><intervention therapy><liquid biopsy><malignancy><model of animal><model of human><mouse model><murine model><neoplasia><neoplasm progression><neoplasm/cancer><neoplastic growth><neoplastic progression><neurofibroma><neurofibromatosis type 1 gene><neurofibromatosis type 1 protein/gene><new combination therapies><nf 1 Genes><overexpress><overexpression><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><pathway><patient specific therapies><patient specific treatment><pharmacologic><pre-clinical><pre-clinical study><precancer><precancerous><preclinical><preclinical study><preemptive intervention><premalignant><prevent><preventing><prognostic ability><prognostic assays><prognostic power><prognostic test><prognostic utility><prognostic value><reconstitute><reconstitution><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><social role><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><transcriptome sequencing><transcriptomic sequencing><transformed cells><treatment resistance><tumor><tumor biomarker><tumor progression><tumor specific biomarker><tumor suppressor><unique treatment><von Recklinghausen Disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAWN E QUELLE

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$526,144
FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

<Age><Agreement><Animal Model><Animal Models and Related Studies><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Assay><Automobile Driving><Benign><Bioassay><Biological><Biological Assay><Biology><Blood Plasma><CDK4><CDK4 gene><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CRISPR><CRISPR/Cas system><Cancer Drug><Cancers><Cause of Death><Cell Body><Cell Division Kinase 4><Cell model><Cells><Cellular model><Classification><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Cyclin-Dependent Kinase 4><Cyclin-Dependent Kinase Inhibitor 2A Gene><Development><Diagnostic><Disease><Disorder><Drug Targeting><Drug resistance><Drugs><Early Diagnosis><Elephantiasis Neuromatosis><Event><Frequencies><Future><Genes><Genetic><Histologic><Histologically><Human><Hyperactivity><INK4><INK4A><In Vitro><Learning><Lesion><Link><Literature><MEKs><MTS1><MTS1 Genes><Malignant><Malignant - descriptor><Malignant Neoplasms><Malignant Peripheral Nerve Sheath Tumor><Malignant Schwannoma><Malignant Tumor><Mediator><Medication><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><NF-1><NF-1 Protein><NF-1 encoded protein><NF1><NF1 GRP><NF1 Protein><NF1 gene><NF1-GAP-Related Protein><Neoplasms><Neoplastic Disease Chemotherapeutic Agents><Neurofibromatosis 1><Neurofibromatosis 1 Genes><Neurofibromatosis I><Neurofibromatosis Type 1 Gene Product><Neurofibromatosis Type 1 Protein><Neurofibromin><Neurofibromin 1><Neurofibrosarcoma><Neurogenic Sarcoma><Oncogenic><PSK-J3><Pachydermatocele><Pathogenesis><Pathway interactions><Patients><Peptides><Peripheral Neurofibromatosis><Pharmaceutical Preparations><Physiologic><Physiological><Plasma><Plasma Serum><Plexiform Neurofibroma><Plexiform Neuromas><Prevention><Proteomics><RAS driven tumor><RNA Seq><RNA sequencing><RNAseq><Recklinghausen Disease of Nerve><Recklinghausen's disease><Recklinghausen's neurofibromatosis><Reporting><Research Specimen><Resistance><Reticuloendothelial System, Serum, Plasma><Role><Sampling><Specimen><Systematics><TM-MKR><TP16><TSG9A><Testing><Therapeutic Intervention><Tumor Biology><Tumor Markers><Tumor Royale><Tumor Suppressor Proteins><Tumor-Specific Treatment Agents><Type 1 Neurofibromatosis><Type I Neurofibromatosis><Upregulation><Work><ages><anti-cancer drug><biologic><cancer progression><cell transformation><chemotherapy><circulating tumor DNA assay><circulating tumor DNA assessment><circulating tumor DNA evaluation><circulating tumor DNA monitoring><circulating tumor DNA profiling><circulating tumor DNA screening><circulating tumor DNA testing><clinical significance><clinically significant><ctDNA assay><ctDNA assessment><ctDNA evaluation><ctDNA monitoring><ctDNA profiling><ctDNA screening><ctDNA testing><customized therapy><customized treatment><developmental><driving><drug resistant><drug-sensitive><drug/agent><early detection><gene locus><genetic analysis><genetic locus><genomic location><genomic locus><human model><improved><in vivo><in vivo Model><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><innovate><innovation><innovative><insight><intervention therapy><liquid biopsy><malignancy><model of animal><model of human><mouse model><murine model><neoplasia><neoplasm progression><neoplasm/cancer><neoplastic growth><neoplastic progression><neurofibroma><neurofibromatosis type 1 gene><neurofibromatosis type 1 protein/gene><new combination therapies><nf 1 Genes><overexpress><overexpression><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><pathway><patient specific therapies><patient specific treatment><pharmacologic><pre-clinical><pre-clinical study><precancer><precancerous><preclinical><preclinical study><preemptive intervention><premalignant><prevent><preventing><prognostic ability><prognostic assays><prognostic power><prognostic test><prognostic utility><prognostic value><reconstitute><reconstitution><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><social role><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><transcriptome sequencing><transcriptomic sequencing><transformed cells><treatment resistance><tumor><tumor biomarker><tumor progression><tumor specific biomarker><tumor suppressor><unique treatment><von Recklinghausen Disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yi Tan

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

Good lead · 66/100
Likely hiring
Above-average budget
Recent
Active award
$520,374
FY 2026

Project Title

Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis

Grant Number:

5R01HL160927-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Atherosclerosis is a narrowing of arteries caused by plaque buildup. Dyslipidemia, especially elevated low- density lipoprotein cholesterol, is a major risk factor for atherosclerotic plaque formation. Current therapies for atherosclerosis focus on lowering cholesterol. However, conventional lipid l...

Research Terms

<AFGF><APOE><ASCVD><Acidic Fibroblast Growth Factor><Adipose tissue><Adult-Onset Diabetes Mellitus><Agonist><Alpha Endothelial Cell Growth Factor><Alpha Fibroblast Growth Factor><Animal Model><Animal Models and Related Studies><Apo-E><ApoE protein><Apolipoprotein E><Approaches to prevention><Arterial Fatty Streak><Arteries><Atherogenicity><Atheroma><Atheromatous><Atheromatous degeneration><Atheromatous plaque><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Attenuated><Basal Transcription Factor><Basal transcription factor genes><Beta-Endothelial Cell Growth Factor><Biliary><Binding Sites><Blood><Blood Reticuloendothelial System><Breeding><Cardiovascular Diseases><Cell Body><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cells><Cellular Proliferation><Cholesterol><Cholesterol Homeostasis><Chronic><Class I Heparin-Binding Growth Factor><Clinical Research><Clinical Study><Clotting><Coagulation><Coagulation Process><Combining Site><DNA mutation><Data><Development><Diabetes Mellitus><Dose><Dyslipidemias><ECGF-alpha><ECGF-beta><ECGFA><ECGFB><Engineering><Enterocytes><FGF-1><FGF1><FGF1 gene><FGFA><Fatty Tissue><Feces><Fibroblast Growth Factor 1><Fluorescein><Future><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><HBGF-1><HBGF1><Heparin Binding><Heparin Binding Growth Factor-1><Heparin-Binding Fibroblast Growth Factor Class I><Hepatic><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocyte><Human><Hyperlipemia><Hyperlipidemia><Intestinal><Intestinal Absorption><Intestines><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out Mice><Knockout Mice><LDL Cholesterol><LDL Cholesterol Lipoproteins><Label><Life Style><Lifestyle><Lipids><Liver><Liver Cells><Low Density Lipoprotein Cholesterol><Macrophage><Maturity-Onset Diabetes Mellitus><Mediating><Mediator><Metabolic><Metabolic syndrome><Modern Man><Mutation><Mφ><NAFLD><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nuclear Translocation><Null Mouse><Operative Procedures><Operative Surgical Procedures><Organ><Organoids><Pathogenesis><Pathologic><Patients><Phenotype><Play><Prevention approach><RNA Expression><Radioactive Isotopes><Radioisotopes><Radionuclides><Reactive Site><Recombinants><Regulation><Risk><Risk Factors><Role><Site><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Surgical><Surgical Interventions><Surgical Procedure><T2 DM><T2D><T2DM><Testing><Therapeutic><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Upregulation><Variant><Variation><adipose><adult onset diabetes><angiogenesis><atherogenesis><atheromatosis><atherosclerosis plaque><atherosclerotic disease><atherosclerotic lesions><atherosclerotic plaque><atherosclerotic vascular disease><attenuate><attenuates><beta-Lipoprotein Cholesterol><blood glucose regulation><bowel><cardiovascular disorder><cholesterol absorption><cholesterol biosynthesis><cholesterol metabolism><clinical practice><clinical translation><clinically translatable><db/db mouse><developmental><diabetes><dietary><gastrointestinal absorption><genome mutation><glucose control><glucose homeostasis><glucose regulation><heparin bound><hepatic body system><hepatic organ system><insight><ketosis resistant diabetes><maturity onset diabetes><model of animal><neovascularization><new approaches><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><non-alcohol fatty liver disease><non-alcoholic fatty liver disease><non-alcoholic liver disease><nonalcoholic fatty liver disease><novel><novel approaches><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><overexpress><overexpression><plaques in atherosclerosis><prevent><preventing><proliferation capability><proliferation capacity><proliferation potential><proliferative capability><proliferative capacity><proliferative potential><side effect><social role><stool><surgery><transcription factor><translational opportunities><translational potential><tumorigenic><type 2 DM><type II DM><type two diabetes><white adipose tissue><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Josep Maria Domingo-Domenech

MAYO CLINIC ROCHESTER, ROCHESTER, MN

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$492,046
FY 2026

Project Title

Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer

Grant Number:

5R01CA285345-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Prostate cancer (PCa) is the most commonly diagnosed malignancy and effective treatment of castration- resistant PCa (CRPC) remains the major challenge in clinic. SPOP is a substrate-binding adaptor of the CULLIN3-RBX1 E3 ubiquitin ligase complex and the SPOP gene is mutated in 10-15...

Research Terms

<Agreement><American male><American man><American men><Androgen Antagonists><Androgen Receptor><Anti-Androgen><Anti-Androgen Agents><Anti-Oncogenes><Anti-androgen Therapy><Anti-androgen Treatment><Antioncogenes><Binding><Bromodomain><Cancer Cause><Cancer Etiology><Cancer Patient><Cancer Suppressor Genes><Cancers><Castration><Cell Communication and Signaling><Cell Signaling><Cessation of life><Clinic><Clinical><Complex><DNA><DNA Alteration><DNA Methyltransferase><DNA Modification Methylases><DNA Modification Methyltransferases><DNA Sequence Alteration><DNA mutation><DNA-Methyltransferases><Data><Death><Deoxyribonucleic Acid><Diagnosis><Disease><Disease Progression><Disorder><Dnmt><Down-Regulation><E3 Ligase><E3 Ubiquitin Ligase><ERK 1><ERK1><ERK1 Kinase><Emerogenes><Exhibits><Extracellular Signal-Regulated Kinase 1><Extracellular Signal-Regulated Kinase Gene><GEM model><GEMM model><Generalized Growth><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Growth><Hypermethylation><Induced DNA Alteration><Induced Mutation><Induced Sequence Alteration><Intracellular Communication and Signaling><Lesion><MAP Kinase 3><MAP Kinase Gene><MAPK><MAPK3><MAPK3 Mitogen-Activated Protein Kinase><MAPK3 gene><MEKs><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Metastatic Prostate Cancer><Mice><Mice Mammals><Mitogen-Activated Protein Kinase 3><Mitogen-Activated Protein Kinase 3 Gene><Mitogen-Activated Protein Kinase Gene><Modification Methylases><Molecular><Molecular Interaction><Murine><Mus><Mutate><Mutation><NGS Method><NGS system><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncogenesis><Oncogenic><P44ERK1><PSTkinase p44mpk><Pathway interactions><Patients><Phosphorylation><Prostate><Prostate CA><Prostate CA therapy><Prostate Cancer><Prostate Cancer therapy><Prostate Carcinoma Metastatic><Prostate Gland><Prostate malignancy><Prostatic Gland><Protein Methylation><Protein Phosphorylation><Proteins><RBX1><RBX1 gene><RING-Box 1><ROC1><Ras/Raf><Receptor Protein><Receptor Signaling><Receptor-Interacting Protein><Recessive Oncogenes><Regulator of Cullins 1><Resistance><Sampling><Sequence Alteration><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site-Specific DNA-methyltransferase><Surgical Castration><TCGA><Testing><The Cancer Genome Atlas><Tissue Growth><Tumor Biology><Tumor Suppressing Genes><Tumor Suppressor Genes><U.S. Males><US Men><US male><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Upregulation><Xtandi><abiraterone><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen inhibitor><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><biological signal transduction><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><demethylation><design><designing><effective therapy><effective treatment><enzalutamide><epigenetic gene silencing><epigenetic silencing><expression subtypes><gene locus><genetic locus><genetically engineered mouse model><genetically engineered murine model><genome mutation><genomic alteration><genomic location><genomic locus><hormone refractory prostate cancer><inhibitor><innovate><innovation><innovative><males in America><males in the U.S.><males in the US><males in the USA><males in the United States><malignancy><men in America><men in the U.S.><men in the US><men in the USA><men in the United States><molecular sub-types><molecular subsets><molecular subtypes><mortality><neoplasm/cancer><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next gen sequencing><next generation sequencing><nextgen sequencing><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapy approach><novel therapy target><oncosuppressor gene><ontogeny><p44 MAPK><pathway><pre-clinical><preclinical><prostate cancer cell><prostate cancer progression><prostate cancer resistant to androgen><prostate cancer treatment><prostate tumor cell><receptor><resistance mechanism><resistant><resistant mechanism><therapeutic target><treatment group><tumorigenesis><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zhenkun Lou

MAYO CLINIC ROCHESTER, ROCHESTER, MN

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$492,046
FY 2026

Project Title

Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer

Grant Number:

5R01CA285345-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Prostate cancer (PCa) is the most commonly diagnosed malignancy and effective treatment of castration- resistant PCa (CRPC) remains the major challenge in clinic. SPOP is a substrate-binding adaptor of the CULLIN3-RBX1 E3 ubiquitin ligase complex and the SPOP gene is mutated in 10-15...

Research Terms

<Agreement><American male><American man><American men><Androgen Antagonists><Androgen Receptor><Anti-Androgen><Anti-Androgen Agents><Anti-Oncogenes><Anti-androgen Therapy><Anti-androgen Treatment><Antioncogenes><Binding><Bromodomain><Cancer Cause><Cancer Etiology><Cancer Patient><Cancer Suppressor Genes><Cancers><Castration><Cell Communication and Signaling><Cell Signaling><Cessation of life><Clinic><Clinical><Complex><DNA><DNA Alteration><DNA Methyltransferase><DNA Modification Methylases><DNA Modification Methyltransferases><DNA Sequence Alteration><DNA mutation><DNA-Methyltransferases><Data><Death><Deoxyribonucleic Acid><Diagnosis><Disease><Disease Progression><Disorder><Dnmt><Down-Regulation><E3 Ligase><E3 Ubiquitin Ligase><ERK 1><ERK1><ERK1 Kinase><Emerogenes><Exhibits><Extracellular Signal-Regulated Kinase 1><Extracellular Signal-Regulated Kinase Gene><GEM model><GEMM model><Generalized Growth><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Growth><Hypermethylation><Induced DNA Alteration><Induced Mutation><Induced Sequence Alteration><Intracellular Communication and Signaling><Lesion><MAP Kinase 3><MAP Kinase Gene><MAPK><MAPK3><MAPK3 Mitogen-Activated Protein Kinase><MAPK3 gene><MEKs><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Metastatic Prostate Cancer><Mice><Mice Mammals><Mitogen-Activated Protein Kinase 3><Mitogen-Activated Protein Kinase 3 Gene><Mitogen-Activated Protein Kinase Gene><Modification Methylases><Molecular><Molecular Interaction><Murine><Mus><Mutate><Mutation><NGS Method><NGS system><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncogenesis><Oncogenic><P44ERK1><PSTkinase p44mpk><Pathway interactions><Patients><Phosphorylation><Prostate><Prostate CA><Prostate CA therapy><Prostate Cancer><Prostate Cancer therapy><Prostate Carcinoma Metastatic><Prostate Gland><Prostate malignancy><Prostatic Gland><Protein Methylation><Protein Phosphorylation><Proteins><RBX1><RBX1 gene><RING-Box 1><ROC1><Ras/Raf><Receptor Protein><Receptor Signaling><Receptor-Interacting Protein><Recessive Oncogenes><Regulator of Cullins 1><Resistance><Sampling><Sequence Alteration><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Site-Specific DNA-methyltransferase><Surgical Castration><TCGA><Testing><The Cancer Genome Atlas><Tissue Growth><Tumor Biology><Tumor Suppressing Genes><Tumor Suppressor Genes><U.S. Males><US Men><US male><Ubiquitilation><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Upregulation><Xtandi><abiraterone><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen inhibitor><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><biological signal transduction><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><demethylation><design><designing><effective therapy><effective treatment><enzalutamide><epigenetic gene silencing><epigenetic silencing><expression subtypes><gene locus><genetic locus><genetically engineered mouse model><genetically engineered murine model><genome mutation><genomic alteration><genomic location><genomic locus><hormone refractory prostate cancer><inhibitor><innovate><innovation><innovative><males in America><males in the U.S.><males in the US><males in the USA><males in the United States><malignancy><men in America><men in the U.S.><men in the US><men in the USA><men in the United States><molecular sub-types><molecular subsets><molecular subtypes><mortality><neoplasm/cancer><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next gen sequencing><next generation sequencing><nextgen sequencing><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapy approach><novel therapy target><oncosuppressor gene><ontogeny><p44 MAPK><pathway><pre-clinical><preclinical><prostate cancer cell><prostate cancer progression><prostate cancer resistant to androgen><prostate cancer treatment><prostate tumor cell><receptor><resistance mechanism><resistant><resistant mechanism><therapeutic target><treatment group><tumorigenesis><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID G RUSSELL

CORNELL UNIVERSITY, ITHACA, NY

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$482,843
FY 2026

Project Title

Modulation of epigenetic programming of tissue resident macrophage lineages to impact HIV-1 infection, maintenance, and persistence.

Grant Number:

5R01AI176575-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/6/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract It is only recently that the field became aware that certain tissue resident macrophages, including alveolar macrophages and microglial cells, are fetal stem cell derived lineages that behave markedly differently from blood monocyte derived macrophages. With such knowledge...

Research Terms

<AIDS focused research><AIDS related research><AIDS research><AIDS science><AIDS specific research><Address><Alveolar Macrophages><Antitubercular Drugs><Apoptosis><Apoptosis Pathway><Assay><Automobile Driving><Awareness><Bioassay><Biological><Biological Agent><Biological Assay><Biological Products><Biology><Blood monocyte><Body Tissues><Cell Body><Cell Death><Cell Death Induction><Cell Line><Cell Lineage><Cell Survival><Cell Viability><CellLine><Cells><Chemicals><Collaborations><Collection><Disease><Disorder><Drug Therapy><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><FISH Technic><FISH Technique><FISH analysis><FISH assay><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Functional RNA><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Genes><Genetic Transcription><Goals><HIV Infections><HIV focused research><HIV intervention><HIV investigation><HIV related research><HIV research><HIV science><HIV specific research><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 intervention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV1><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammation><Intervening Sequences><Introns><Investigation on HIV><Knowledge><Kupffer Cells><Langerhans cell><Libraries><Link><Luciferase Immunologic><Luciferases><Lung><Lung Respiratory System><Lung infections><Lymphatic cell><Lymphocyte><Lymphocytic><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Macrophage><Maintenance><Malawi><Marrow monocyte><Mediating><Metabolic><Methods><Mice><Mice Mammals><Microglia><Mitochondria><Modeling><Modern Man><Molecular Fingerprinting><Molecular Profiling><Murine><Mus><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Myelogenous><Myeloid><Myeloid Cells><Mφ><Noncoding RNA><Nontranslated RNA><Nyasaland><Outcome><Output><Pathway interactions><Patients><Pharmacological Treatment><Pharmacotherapy><Phenocopy><Phenotype><Play><Population><Production><Productivity><Programmed Cell Death><Pulmonary Macrophages><RNA Expression><Red Pulp><Regulatory Pathway><Reporter><Respiration><Role><Short interfering RNA><Small Interfering RNA><Sorting><Splenic Red Pulp><Stellate Sinusoidal Macrophage><Strains Cell Lines><TB drugs><TB infection><Therapeutic><Tissues><Traction><Transcript><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Tuberculosis><Untranslated RNA><Viral><Virus><Visit><analyze gene expression><anti-TB drugs><anti-tuberculosis drugs><biologic><biologics><biopharmaceutical><biotherapeutic agent><chemical library><cultured cell line><disseminated TB><disseminated tuberculosis><driving><drug discovery><drug intervention><drug treatment><epigenetically><experience><fetal progenitor><fetal stem cell><flow cytophotometry><gene expression analysis><gene expression assay><gitter cell><human immunodeficiency virus infection><human immunodeficiency virus research><infected with HIV><infected with human immunodeficiency virus><infection due to Mycobacterium tuberculosis><inhibitor><latent infection><liver macrophage><lymph cell><mesoglia><microglial cell><microgliocyte><mitochondrial><molecular profile><molecular signature><monocyte><necrocytosis><nef><nef Gene Products><nef Protein><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><noncoding><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><perivascular glial cell><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><programs><pulmonary infections><recruit><research addressing HIV><research in HIV><research into HIV><research on HIV><research on human immunodeficiency virus><research to address HIV><respiratory mechanism><response><scRNA sequencing><scRNA-seq><science on HIV><science to address HIV><screening><screenings><self-renew><self-renewal><siRNA><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><small molecular inhibitor><small molecule><small molecule inhibitor><small molecule libraries><social role><studies on HIV><transcriptional profiling><treat HIV><treat Human Immunodeficiency Virus><tuberculosis drugs><tuberculosis infection><tuberculous spondyloarthropathy><volunteer>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HOMAYON GHIASI

CEDARS-SINAI MEDICAL CENTER, LOS ANGELES, CA

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$470,543
FY 2026

Project Title

Role of type 1 IFN in eye infection

Grant Number:

5R01EY033574-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2023

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT HSV-1 infection is a leading cause of eye disease and genital herpes but no HSV-1 vaccines have shown efficacy in humans. It elicits only a partially protective immune response and can establish persistent latent infections virus in neurons. Induction of type I interferons (IFNs) is an earl...

Research Terms

<(IFN) α><(IFN)-α><(IFN)α><Affect><Alferon><Apoptotic><Autophagocytosis><Binding><Brain Inflammation><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Code><Coding System><Cold Sore><Complex><Cytokine Receptor Binding><Cytotoxic cell><Data><Development><Disease><Disorder><Down-Regulation><Encephalitis><Environment><Event><Eye Infections><Eye diseases><Family><Fever Blister><Functional RNA><Gasser's Ganglion><Gasserian Ganglion><Genes><Genital Herpes Simplex><HSV><HSV-1><HSV1><Herpes Genitalis><Herpes Labialis><Herpes Simplex Type 1><Herpes Simplex Virus><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes labialis Virus><Herpesvirus 1><Herpetic Stomatitis><Human><IFN><IFN Alpha><IFN α><IFN-α><IFNAR><IFNAR1><IFNAR1 gene><IFNa><IFNα><Immune response><In Vitro><Individual><Induction of Apoptosis><Infection><Infection prevention><Interferon Alfa-n3><Interferon Type I><Interferon-α><Interferons><Intracellular Communication and Signaling><K lymphocyte><LYT3><Labial Herpes Simplex><Latent virus infection phase><Lesion><Leukocyte Interferon><Lymphoblast Interferon><Lymphoblastoid Interferon><Maps><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Murine><Mus><NK Cells><Natural Killer Cells><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Non-Polyadenylated RNA><Noncoding RNA><Nontranslated RNA><Nuclear><Ocular Infections><Oral Herpes Simplex><Pharyngitis><Phenotype><Play><Predisposition><Prevalence><Prevent infection><Preventive><Primary Infection><Process><Production><Proteins><Public Health><Publishing><RNA><RNA Gene Products><Recurrence><Recurrent><Recurrent disease><Regulation><Relapsed Disease><Ribonucleic Acid><Role><Semilunar Ganglion><Signal Transduction><Signal Transduction Systems><Signaling><Simplexvirus><Site><Structure of trigeminal ganglion><Susceptibility><System><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Transcript><Trigeminal Ganglias><Trigeminal Ganglion><Untranslated RNA><Vaccines><Viral Diseases><Viral Latency><Virus><Virus Diseases><Virus Latency><Virus Replication><Virus-Genital Herpes><Wild Type Mouse><autophagy><biological signal transduction><combinatorial><cytokine><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><eye disorder><genital herpes><herpes febrilis><herpes genitalia><herpes simplex i><herpes simplex-1><host response><immune system response><immunoresponse><in vivo><infection recurrence><innovate><innovation><innovative><intraoral herpes simplex infection><intraoral hsv infection><latency associated transcript><latency/reactivation><latent persistent infection><latent viral infection><latent virus infection><member><mortality><mouse model><murine model><nerve cell death><nerve cell loss><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal loss><noncoding><ocular disease><ocular disorder><ophthalmopathy><oral HSV><oral herpes><oral mucosal herpes><pathogenic virus><prevent><preventing><promoter><promotor><protein function><reactivation from latency><recombinant virus><recurrent infection><recurring infection><response><secondary infection><social role><vaccine development><venereal herpes><viral infection><viral multiplication><viral pathogen><viral replication><virus infection><virus multiplication><virus pathogen><virus-induced disease><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Estefania Quesada Masachs

UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, CORAL GABLES, FL

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$460,500
FY 2026

Project Title

Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes

Grant Number:

5R01AI092453-13

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Title: Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes Project Summary Human type 1 diabetes (T1D) is characterized by the immune-mediated destruction of insulin-producing pan- creatic beta cells. CD8 T cells are the most common cell found in insulitis lesions ...

Research Terms

<Agonist><Antigen-Presenting Cells><Antigens><Autoantigens><Autoimmune Diseases><Autologous Antigens><Automobile Driving><B9 endocrine pancreas><Beta Cell><Body Tissues><Brittle Diabetes Mellitus><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cell Body><Cell Communication><Cell Function><Cell Interaction><Cell Physiology><Cell Process><Cell to Cell Communication and Signaling><Cell-Cell Signaling><Cell-Mediated Lympholytic Cells><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular injury><Characteristics><Communication><Complex><Computer software><Coupling><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><D-Glucose><Data><Development><Dextrose><Diabetes Mellitus><Diagnosis><Disease><Disorder><Drugs><Endocrine><Endocrine Pancreas><Environment><Event><Evolution><Exocrine pancreas><Exposure to><Frequencies><Funding><GLP-1 receptor><GLP-I receptor><Glucose><Goals><Grant><Heterogeneity><Human><Humulin R><IDDM><Image Analyses><Image Analysis><Immune><Immune Regulators><Immune destruction><Immune mediated destruction><Immune system><Immunes><Immunomodulators><In Situ><In Vitro><Infiltration><Inflammatory><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Invaded><Investigation><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><LYT3><Lesion><Living Donors><Location><Machine Learning><Macrophage><Maintenance><Medication><Metabolic><Methods><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Mφ><Neighborhoods><Nesidioblasts><Novolin R><Organ Donor><Organoids><Pancreas><Pancreatic><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Pathogenesis><Patients><Peptides><Pharmaceutical Preparations><Phenotype><Pre-DM><Prediabetes><Prediabetes syndrome><Prediabetic State><Probability><Production><Property><Regular Insulin><Research Specimen><Residual><Residual state><Role><Sampling><Self-Antigens><Seminal><Slice><Software><Spatial Distribution><Specificity><Specimen><Staining method><Stains><Stress><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><System><T-Cells><T-Lymphocyte><T1 DM><T1 diabetes><T1D><T1DM><T8 Cells><T8 Lymphocytes><Techniques><Technology><Tissue Donors><Tissues><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Upregulation><Work><accessory cell><autoimmune attack><autoimmune condition><autoimmune destruction><autoimmune disorder><autoimmune pathogenesis><autoimmune reactivity><autoimmunity disease><autoreactive T cell><autoreactivity><cell damage><cell injury><cell type><cellular damage><chronic autoimmune disease><cytokine><damage to cells><design><designing><developmental><diabetes><diabetes pathogenesis><driving><drug/agent><exocrine pancreatic><glucagon-like peptide-1 receptor><human tissue><image evaluation><image interpretation><immune modulators><immunogen><immunomodulatory molecules><immunoregulator><immunoregulatory molecules><improved><in vitro Model><in vivo><injury to cells><innovate><innovation><innovative><insulin dependent diabetes><insulin dependent type 1><insulin secretion><insulitis><intercellular communication><islet><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><killer T cell><machine based learning><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-diabetic><nondiabetic><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><pancreas beta cell><pancreas β cell><pancreatic b-cell><pre-diabetes><pre-diabetic><pre-proinsulin><prediabetic><preproinsulin><preservation><response><restraint><self-reactive T cell><social role><spatial and temporal><spatial temporal><spatiotemporal><spheroids><thymus derived lymphocyte><timeline><tool><type I diabetes><type one diabetes><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Saikat Boliar

STATE UNIVERSITY OF NEW YORK AT BUFFALO, AMHERST, NY

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$450,460
FY 2026

Project Title

Virologic and immunologic impacts of active viral persistence in lung AMs of HIV-1-infected, cART-suppressed individuals

Grant Number:

5R01AI176934-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/17/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract Persistence of HIV-1 in tissue reservoirs of therapy-suppressed, aviremic individuals is a major challenge to HIV-1 cure. The viral reservoir consists of myeloid and lymphoid cells that harbor the virus through long periods of combination anti-retroviral therapy (cART). U...

Research Terms

<Address><Affect><Alveolar Macrophages><Assay><Binding><Bioassay><Biological><Biological Assay><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood monocyte><Body Tissues><Brain><Brain Nervous System><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Death Induction><Cell Survival><Cell Viability><Cells><Cellular Immune Function><Chronic><Clonality><Co-culture><Cocultivation><Coculture><Coculture Techniques><Data><Disease Progression><Disease remission><Dysfunction><Effector Cell><Encephalon><Evolution><FISH Technic><FISH Technique><FISH analysis><FISH assay><Feedback><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Frequencies><Functional disorder><Gene Transcription><Genetic Transcription><HIV cure><HIV functional cure><HIV infection persistence><HIV persistence><HIV replication><HIV viral persistence><HIV viral replication><HIV-1><HIV-1 cure><HIV-1 functional cure><HIV-1 persistence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV/AIDS cure><HIV1><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune><Immune Cell Activation><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Diseases><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunologically><Immunologics><Individual><Interruption><Kinetics><Knowledge><Kupffer Cells><Length><Liver><Lung><Lung Respiratory System><Lymphoid Cell><Macrophage><Macrophage Activation><Marrow monocyte><Methods><Microglia><Modern Man><Molecular><Molecular Interaction><Molecular Target><Myelogenous><Myeloid><Myeloid Cells><Mφ><Nature><Non-Polyadenylated RNA><ORFs><Open Reading Frames><Phagocytosis><Physiopathology><Plasma><Plasma Serum><Population><Production><Productivity><Protein Coding Region><Proviruses><Pulmonary Macrophages><RNA><RNA Expression><RNA Gene Products><RNA Splicing><Relapse><Remission><Reporting><Residual><Residual state><Reticuloendothelial System, Serum, Plasma><Ribonucleic Acid><Role><SIV><Simian Immunodeficiency Viruses><Sorting><Splicing><Stellate Sinusoidal Macrophage><Stimulus><Subgroup><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><Tissues><Transcript><Transcription><Translations><Treatment Period><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral reservoir><Viremia><Virion><Virus><Virus Particle><Virus Replication><Virus reservoir><antiretroviral therapy><antiretroviral treatment><biologic><cell type><co-morbid><co-morbidity><cohort><comorbidity><comparative><cytokine><cytotoxic><exhaustion><genetic make-up><genetic makeup><gitter cell><hepatic body system><hepatic organ system><human immunodeficiency virus cure><human immunodeficiency virus persistence><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><human subject><immune activation><immune function><liver macrophage><loss of function><mesoglia><microglial cell><microgliocyte><monocyte><pathophysiology><peripheral blood><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><prevent><preventing><social role><success><thymus derived lymphocyte><transcriptomics><translation><treatment days><treatment duration><viraemia><viral RNA><viral multiplication><viral rebound><viral replication><viral sepsis><virus RNA><virus multiplication><virus protein><virus rebound><virusemia>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Heikki Hyöty

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$439,396
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

5R01DK138372-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard E Lloyd

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$439,396
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

5R01DK138372-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kristian F Lynch

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$439,396
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

5R01DK138372-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eoin McKinney

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$439,396
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

5R01DK138372-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joseph Frank Petrosino

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$439,396
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

5R01DK138372-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAQING WU

CLARK ATLANTA UNIVERSITY, ATLANTA, GA

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$434,940
FY 2026

Project Title

Targeting chemoresistant prostate cancer with novel EED inhibitors

Grant Number:

5R01CA256058-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Docetaxel is the first-line chemotherapy for metastatic castration-resistant prostate cancer (PCa), the major cause of PCa mortality. Unfortunately, in most cases PCa develops docetaxel resistance and continues to progress, which has no cure. Our recent studies (Theranostics, 2021, May 8; 11: 6873-6...

Research Terms

<ABC20><ABCB1><ABCB1 gene><APRF protein><ATP-protein phosphotransferase><Acute-Phase Response Factor><Apoptosis Inhibitor 4><Apoptosis Inhibitor Survivin><Baculoviral IAP Repeat-Containing Protein 5><Basic Research><Basic Science><Binding><Biological><Biology><Cancer Patient><Cell Communication and Signaling><Cell Signaling><Center for Cancer Research><Characteristics><Chemicals><Chemoresistance><Clinical><Complex><Death Rate><Development><Development and Research><Disease Progression><Dose><Drug Design><Drug Kinetics><Drug Synthesis and Chemistry><Drugs><Ectoderm><Embryo><Embryonic><Enhancers><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Excretory function><GP170><GeneHomolog><Generalized Growth><Goals><Growth><Homolog><Homologous Gene><Homologue><IL6-response factor><In Vitro><In vivo analysis><Intermediary Metabolism><Interruption><Intervention><Intracellular Communication and Signaling><Kinase Family Gene><Knowledge><LIF-response factor><Lead><MDR-1><MDR1><MDR1 Protein><Malignant neoplasm of prostate><Malignant prostatic tumor><Medical><Medication><Metabolic Processes><Metabolism><Mice><Mice Mammals><Molecular Interaction><Multidrug Resistance 1><Multidrug Resistance Gene-1><Multidrug Resistance Gene-1s><Multidrug Resistance Proteins><Multidrug Resistant Proteins><Murine><Mus><NCI Center for Cancer Research><Oncogenic><Outcome><P-GP><P-Glycoprotein><P-Glycoprotein 1 Gene><PGY-1 Protein><PGY1><Pathway interactions><Patient Care><Patient Care Delivery><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phenotype><Polycomb><Pre-Clinical Model><Preclinical Models><Property><Prostate CA><Prostate CA therapy><Prostate Cancer><Prostate Cancer therapy><Prostate malignancy><Protein Kinase><Qualifying><R & D><R&D><Reader><Research><Resistance><S Period><S phase><Safety><Signal Transducer and Activator of Transcription 2><Signal Transducer and Activator of Transcription 3><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Stat2 protein><Stat3 protein><Synthesis Period><Synthesis Phase><Taxotere><Testing><Texas><Therapeutic><Tissue Growth><Toxic effect><Toxicities><Toxicology><Translating><Translational Research><Translational Science><Universities><Work><Xenograft Model><absorption><advanced prostate cancer><analog><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><anticancer activity><biologic><biological signal transduction><care for patients><care of patients><caring for patients><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><clinical development><design><designing><developmental><docetaxel><docetaxol><drug development><drug discovery><drug synthesis><drug/agent><epigenetically><excretion><glycogen synthase a kinase><good laboratory practice><heavy metal Pb><heavy metal lead><hormone refractory prostate cancer><hydroxyalkyl protein kinase><improved><in vivo><in vivo evaluation><in vivo testing><inhibitor><innovate><innovation><innovative><lead optimization><mortality><mortality rate><new approaches><new chemical entity><novel><novel approaches><novel strategies><novel strategy><ontogeny><pathway><pharmacologic><phosphorylase b kinase kinase><pre-clinical><pre-clinical development><pre-clinical efficacy><pre-clinical safety><preclinical><preclinical development><preclinical efficacy><preclinical safety><prostate cancer cell><prostate cancer model><prostate cancer resistant to androgen><prostate cancer treatment><prostate tumor cell><prostate tumor model><rational design><research and development><resistant><screening><screenings><small molecule><standard of care><survivin><theranostics><therapeutic agent development><therapeutic development><translation research><translational investigation><xenograft transplant model><xenotransplant model>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael Lim

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$394,444
FY 2026

Project Title

Targeting Lag-3 and PD -1 in Myeloid Cells of GBM

Grant Number:

5R01NS121404-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumor in adults. GBM has a bleak prognosis of approximately 12-15 months, despite continuing advances to the standard of care. Immunotherapy has demonstrated the significant potential to boost immune responses against many can...

Research Terms

<21+ years old><Ablation><Adoptive Transfer><Adult><Adult Human><Antibodies><Antigen Presentation><Antigen-Presenting Cells><Antitumor Response><Assay><B220><Binding><Bioassay><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Sample><Blood monocyte><Blood specimen><Bone Marrow><Bone Marrow Reticuloendothelial System><Brain Cancer><Brain Neoplasia><Brain Neoplasms><Brain Tumors><CD152><CD152 Antigen><CD152 Gene><CD45><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cell Body><Cells><Checkpoint inhibitor><Clinical><Clone Cells><Co-culture><Cocultivation><Coculture><Coculture Techniques><Congenic Mice><Correlative Study><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DNA mutation><Data><Early-Stage Clinical Trials><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Funding><Future><GP180><Genetic Change><Genetic defect><Genetic mutation><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioblastoma><Glioma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Grawitz Tumor><Histology><Human><Hypernephroid Carcinoma><Hypernephroma><Immune><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immune system><Immunes><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Infiltration><Investigation><Ions><KO mice><Knock-out Mice><Knockout Mice><Knowledge><LY5><Laboratories><Long-Term Survivors><Lytotoxicity><Macrophage><Malignant Melanoma><Malignant Tumor of the Brain><Malignant Tumor of the Lung><Malignant neoplasm of brain><Malignant neoplasm of lung><Marrow monocyte><Measures><Mediating><Melanoma><Metabolic><Mice><Mice Mammals><Modern Man><Molecular Interaction><Murine><Mus><Mutation><Myelogenous><Myeloid><Myeloid Cells><Myeloid Progenitor><Myeloid Progenitor Cells><Myeloid Stem Cells><Myeloid-derived suppressor cells><Mφ><Nephroid Carcinoma><Neuroglial Neoplasm><Neuroglial Tumor><Null Mouse><PD 1><PD-1><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD1><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><PTPRC><PTPRC gene><Patients><Peripheral><Phase 1 Clinical Trials><Phase I Clinical Trials><Phenotype><Preclinical data><Prognosis><Progression-Free Survivals><Proliferating><Pulmonary Cancer><Pulmonary malignant Neoplasm><Radiography><Recurrence><Recurrent><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Resistance><Roentgenography><Role><Sampling><Single cell seq><Site><Solid Neoplasm><Solid Tumor><Sorting><Surface><T cell clonality><T cell response><T-Cell Activation><T-Cells><T-Lymphocyte><T-cell receptor clonality><T-cell receptor repertoire><T200><TCR clonality><TCR repertoire><Teff cell><Testing><Therapeutic><Time><Translating><Tumor Antigens><Tumor Cell><Tumor Expansion><Tumor-Associated Antigen><Wild Type Mouse><aCTLA-4><aCTLA-4 antibodies><aCTLA4><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><accessory cell><activate T cells><adulthood><anti programmed cell death 1><anti-CTLA-4><anti-CTLA-4 antibodies><anti-CTLA4><anti-CTLA4 antibodies><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-cancer><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><anti-tumor immune response><anti-tumor response><antiPD-1><cancer antigens><cancer progression><cancer type><check point blockade><checkpoint blockade><combinatorial><cytotoxic T-lymphocyte antigen 4><cytotoxicity><design><designing><draining lymph node><effector T cell><exhaustion><extracellular><flow cytophotometry><functional improvement><genome mutation><glial-derived tumor><glioblastoma multiforme><host response><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune microenvironment><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive microenvironment><immunosuppressive myeloid cells><immunosuppressive response><immunosuppressive tumor microenvironment><improve function><improved><improved functional outcomes><in vivo><inflammatory environment><inflammatory milieu><insight><kidney adenocarcinoma><lung cancer><monocyte><mouse model><murine model><myeloid precursor><myeloid stem and progenitor cell><myeloid suppressor cells><myeloid-derived suppressive cells><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm progression><neoplastic cell><neoplastic progression><neuroglia neoplasm><neuroglia tumor><novel><peripheral blood><phase 1 trial><phase I protocol><phase I trial><preclinical findings><preclinical information><prevent><preventing><programmed cell death 1><programmed cell death protein 1><programmed cell death protein 1 therapy><programmed death 1><radiological imaging><recruit><regional lymph node><resistant><response><single cell next generation sequencing><single cell sequencing><sle2><social role><spongioblastoma multiforme><standard of care><success><suppressive myeloid cells><synergism><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor immune microenvironment><tumor progression><tumor-immune system interactions><tumor-specific antigen><tumors in the brain><wildtype mouse><α-CTLA-4><α-CTLA4><αCTLA-4><αCTLA4><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amol Suryawanshi

NORTH CAROLINA STATE UNIVERSITY RALEIGH, RALEIGH, NC

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$383,845
FY 2026

Project Title

Il-27-mediated immunoregulation in HSV-1 induced stromal keratitis

Grant Number:

5R01EY034495-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/30/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Among ocular infections, recurrent herpes simplex virus-1 (HSV-1) infection causes immune cell infiltration and opacity in the cornea and triggers a severe immuno-inflammatory condition called herpetic stromal keratitis (HSK). HSK is a painful condition and one of the leading causes ...

Research Terms

<(IFN) α><(IFN)-α><(IFN)α><Adrenal Cortex Hormones><Affect><Alferon><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Anti-viral Agents><Anti-viral Response><Attenuated><Blindness><Chronic><Citrates><Citric Acid Cycle><Clinical><Complement><Complement Proteins><Cornea><Corneal infection><Corticoids><Corticosteroids><Cyclic GMP><Data><Dendritic Cells><Diminished Vision><Double-Stranded DNA><Down-Regulation><ERYF1><Endogenous Interferon Beta><Enzyme Gene><Enzymes><Eye Infections><Fibroblast Interferon><GATA Binding Protein 1><GATA-1><GATA1><GATA1 gene><GATA1 protein><GATA1 transcription factor><GF-1 protein><Genes><Glycolysis><Guanosine Cyclic Monophosphate><HSV stromal keratitis><HSV-1><HSV1><Herpes Simplex Keratitis><Herpes Simplex Type 1><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes stromal keratitis><Herpesvirus 1><Herpetic Keratitis><IFN><IFN Alpha><IFN α><IFN-α><IFN-β><IFNa><IFNb><IFNα><ISG15><ISG15 gene><Immune><Immune Evasion><Immune infiltrates><Immune mediated therapy><Immune response><Immunes><Immunity><Immunologically Directed Therapy><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Impairment><Infection><Inflammation><Inflammatory><Inflammatory Response><Injury><Interferon Alfa-n3><Interferon Type I><Interferon-Induced Protein IFI-15K><Interferon-α><Interferon-β><Interferons><Intermediary Metabolism><KO mice><Keratitis><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Knowledge><Krebs Cycle><Leukocyte Interferon><Low Vision><Lymphoblast Interferon><Lymphoblastoid Interferon><Macrophage><Mediating><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Microbial keratitis><Mitochondria><Molecular><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Murine><Mus><Mφ><NF-E1 erythroid-specific transcription factor><NF-E2 protein><NF-E2 transcription factor><NFE1 protein><NFE2 protein><Natural Interferon Beta><Natural human interferon beta><Null Mouse><Ocular Herpes Simplex><Ocular Herpetic Disease><Ocular Infections><Outcome Study><Pain><Painful><Partial Sight><Pathogenesis><Pathway interactions><Patients><Phagolysosome><Pilot Projects><Play><Predisposition><Production><Receptor Protein><Recurrence><Recurrent><Reduced Vision><Regulation><Resistance><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistant to Multiple Drug><Resistant to multi-drug><Resistant to multidrug><Risk><Role><Severities><Sight><Stimulator of Interferon Genes><Subnormal Vision><Susceptibility><TCA cycle><Testing><Transcription Factor GATA1><Treatment Efficacy><Tricarboxylic Acid Cycle><Tricarboxylic Acids><United States><Veiled Cells><Viral><Viral Diseases><Virus><Virus Diseases><Virus Replication><Vision><Visual impairment><anti-viral compound><anti-viral drugs><anti-viral immunity><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral immunity><attenuate><attenuates><cGAMP STING><cGAMP-STING><cGAMP/STING><cGAS/STING><cGMP><complementation><corneal><corneal herpetic disease><cyclic GMP-AMP synthase/STING><cytokine><ds-DNA><dsDNA><globin transcription factor 1><herpes simplex i><herpes simplex virus keratitis><herpes simplex-1><herpetic stromal keratitis><host response><hsv keratitis><immune cell infiltrate><immune evasive><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><infections in the cornea><infectious keratitis><inhibitor><injuries><interest><intervention efficacy><metabolic phenotype><metabotype><mitochondrial><mouse model><multi-drug resistant><multidrug resistant><murine model><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><nuclear factor-erythroid 1><nuclear factor-erythroid 2><ocular herpes><pathogen><pathway><pharmacologic><pilot study><primary outcome><programs><receptor><resistant><response><side effect><social role><therapeutic efficacy><therapy efficacy><transcription factor NFE-1><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease><vision impairment><vision loss><visual function><visual loss><visually impaired>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BRANT Roger BURKHARDT

UNIVERSITY OF SOUTH FLORIDA, TAMPA, FL

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$367,365
FY 2026

Project Title

C. officinalis induction of Nrf2 inhibiting type 1 diabetes

Grant Number:

5R01AT011907-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

7. Project Summary/Abstract Type 1 diabetes (T1D) is an autoimmune disease initiated by genetic predisposition and environmental influences culminating in the destruction of pancreatic β-cells with irreversible loss of insulin production. Despite strong predictive biomarkers of T1D, there is no cure...

Research Terms

<0-11 years old><21+ years old><Active Oxygen><Address><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Anti-diabetic Agents><Anti-diabetic Drugs><Antioxidants><Appearance><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autophagocytosis><Basal Transcription Factor><Basal transcription factor genes><Beta Cell><Biological><Botanical natural products><Brittle Diabetes Mellitus><Cell Body><Cell Communication and Signaling><Cell Death><Cell Function><Cell Line><Cell Physiology><Cell Process><Cell Signaling><Cell Survival><Cell Viability><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Child><Child Youth><Children (0-21)><Clinical><Cornus><D-Glucose><Dependence><Development><Dextrose><Disease><Disorder><EC 6.3.2.2><ERYF1><Early treatment><Ethnopharmacology><Experimental Designs><Female><GATA Binding Protein 1><GATA-1><GATA1><GATA1 gene><GATA1 protein><GATA1 transcription factor><GF-1 protein><Gamma-Glutamylcysteinyl Synthetase><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic propensity><Glucose><Glutamate-Cysteine Ligase><Glutamylcysteine Synthetase><Glutathione Reductase><HO-1 enzyme><HO1><HO2><HSP32><Herbal Medicine><Human><Humulin R><Hydrogen Oxide><Hyperglycemia><IDDM><IPO-B><In Vitro><Inbred NOD Mice><Incidence><Indophenol Oxidase B><Inherited Predisposition><Inherited Susceptibility><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Intervention Strategies><Intracellular Communication and Signaling><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Literature><MNSOD><Manganese Superoxide Dismutase><Measures><Mediating><Methods><Mice><Mice Mammals><Mitochondrial Superoxide Dismutase><Mn Superoxide Dismutase><Mn-SOD><Modality><Modeling><Modern Man><Molecular><Murine><Mus><NF-E1 erythroid-specific transcription factor><NF-E2 protein><NF-E2 transcription factor><NFE1 protein><NFE2 protein><NOD Mouse><Non obese><Non-Obese Diabetic Mice><Nonobese><Nonobese Diabetic Mouse><Novolin R><Nuclear Translocation><Oral><Oral Examination><Oxidative Stress><Oxygen Radicals><Pancreas><Pancreatic><Pancreatic beta Cell><Pancreatic β-Cell><Pathogenesis><Pathway interactions><Patients><Pharmacologic Actions><Plant natural product><Plant-based Natural Product><Plant-derived natural products><Preventative intervention><Preventative measure><Preventative treatment><Preventive measure><Preventive treatment><Pro-Oxidants><Production><Proteins><Proteomics><Reactive Oxygen Species><Reading><Regular Insulin><Reporting><Research><Research Design><Role><SOD2><SOD2 gene><STZ><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Source><Strains Cell Lines><Streptozocin><Streptozotocin><Structure of beta Cell of islet><Study Type><Subcellular Process><Sudden-Onset Diabetes Mellitus><Superoxide Dismutase 2><Symptoms><T1 DM><T1 diabetes><T1D><T1DM><Technology><Therapeutic><Therapeutic Intervention><Toxic effect><Toxicities><Transcription Factor GATA1><Transcription Factor Proto-Oncogene><Transcription factor genes><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Water><Zanosar><adulthood><anti-diabetic><autoimmune condition><autoimmune disorder><autoimmunity disease><autophagy><biologic><biological signal transduction><clinical efficacy><cultured cell line><cytokine><cytotoxic><design><designing><developmental><diabetes pathogenesis><diabetic><drug development><drug resource><early therapy><gamma-Glutamyl-Cysteine Synthetase><genetic vulnerability><genetically predisposed><globin transcription factor 1><heme oxygenase-1><hemeoxygenase 1><hyperglycemic><in vivo><innovate><innovation><innovative><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulitis><interdisciplinary approach><intervention for prevention><intervention therapy><islet><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><male><model of animal><multidisciplinary approach><necrocytosis><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><nuclear factor-erythroid 1><nuclear factor-erythroid 2><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathway><pharmacologic><pre-clinical><preclinical><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><preservation><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><protein expression><social role><study design><therapeutic candidate><transcription factor><transcription factor NFE-1><treatment group><type 1 diabetes onset><type I diabetes><type one diabetes><youngster><β-cell><β-cells><βCell><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stanley M Stevens

UNIVERSITY OF SOUTH FLORIDA, TAMPA, FL

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$367,365
FY 2026

Project Title

C. officinalis induction of Nrf2 inhibiting type 1 diabetes

Grant Number:

5R01AT011907-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/25/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

7. Project Summary/Abstract Type 1 diabetes (T1D) is an autoimmune disease initiated by genetic predisposition and environmental influences culminating in the destruction of pancreatic β-cells with irreversible loss of insulin production. Despite strong predictive biomarkers of T1D, there is no cure...

Research Terms

<0-11 years old><21+ years old><Active Oxygen><Address><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Anti-diabetic Agents><Anti-diabetic Drugs><Antioxidants><Appearance><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autophagocytosis><Basal Transcription Factor><Basal transcription factor genes><Beta Cell><Biological><Botanical natural products><Brittle Diabetes Mellitus><Cell Body><Cell Communication and Signaling><Cell Death><Cell Function><Cell Line><Cell Physiology><Cell Process><Cell Signaling><Cell Survival><Cell Viability><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Child><Child Youth><Children (0-21)><Clinical><Cornus><D-Glucose><Dependence><Development><Dextrose><Disease><Disorder><EC 6.3.2.2><ERYF1><Early treatment><Ethnopharmacology><Experimental Designs><Female><GATA Binding Protein 1><GATA-1><GATA1><GATA1 gene><GATA1 protein><GATA1 transcription factor><GF-1 protein><Gamma-Glutamylcysteinyl Synthetase><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic propensity><Glucose><Glutamate-Cysteine Ligase><Glutamylcysteine Synthetase><Glutathione Reductase><HO-1 enzyme><HO1><HO2><HSP32><Herbal Medicine><Human><Humulin R><Hydrogen Oxide><Hyperglycemia><IDDM><IPO-B><In Vitro><Inbred NOD Mice><Incidence><Indophenol Oxidase B><Inherited Predisposition><Inherited Susceptibility><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Intervention Strategies><Intracellular Communication and Signaling><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Literature><MNSOD><Manganese Superoxide Dismutase><Measures><Mediating><Methods><Mice><Mice Mammals><Mitochondrial Superoxide Dismutase><Mn Superoxide Dismutase><Mn-SOD><Modality><Modeling><Modern Man><Molecular><Murine><Mus><NF-E1 erythroid-specific transcription factor><NF-E2 protein><NF-E2 transcription factor><NFE1 protein><NFE2 protein><NOD Mouse><Non obese><Non-Obese Diabetic Mice><Nonobese><Nonobese Diabetic Mouse><Novolin R><Nuclear Translocation><Oral><Oral Examination><Oxidative Stress><Oxygen Radicals><Pancreas><Pancreatic><Pancreatic beta Cell><Pancreatic β-Cell><Pathogenesis><Pathway interactions><Patients><Pharmacologic Actions><Plant natural product><Plant-based Natural Product><Plant-derived natural products><Preventative intervention><Preventative measure><Preventative treatment><Preventive measure><Preventive treatment><Pro-Oxidants><Production><Proteins><Proteomics><Reactive Oxygen Species><Reading><Regular Insulin><Reporting><Research><Research Design><Role><SOD2><SOD2 gene><STZ><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Source><Strains Cell Lines><Streptozocin><Streptozotocin><Structure of beta Cell of islet><Study Type><Subcellular Process><Sudden-Onset Diabetes Mellitus><Superoxide Dismutase 2><Symptoms><T1 DM><T1 diabetes><T1D><T1DM><Technology><Therapeutic><Therapeutic Intervention><Toxic effect><Toxicities><Transcription Factor GATA1><Transcription Factor Proto-Oncogene><Transcription factor genes><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Water><Zanosar><adulthood><anti-diabetic><autoimmune condition><autoimmune disorder><autoimmunity disease><autophagy><biologic><biological signal transduction><clinical efficacy><cultured cell line><cytokine><cytotoxic><design><designing><developmental><diabetes pathogenesis><diabetic><drug development><drug resource><early therapy><gamma-Glutamyl-Cysteine Synthetase><genetic vulnerability><genetically predisposed><globin transcription factor 1><heme oxygenase-1><hemeoxygenase 1><hyperglycemic><in vivo><innovate><innovation><innovative><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulitis><interdisciplinary approach><intervention for prevention><intervention therapy><islet><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><male><model of animal><multidisciplinary approach><necrocytosis><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><nuclear factor-erythroid 1><nuclear factor-erythroid 2><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathway><pharmacologic><pre-clinical><preclinical><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><preservation><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><protein expression><social role><study design><therapeutic candidate><transcription factor><transcription factor NFE-1><treatment group><type 1 diabetes onset><type I diabetes><type one diabetes><youngster><β-cell><β-cells><βCell><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SANJAY V. MALHOTRA

OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, OR

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$356,850
FY 2026

Project Title

Targeting YB-1 to overcome chemoresistance in ovarian cancer

Grant Number:

1R01CA299328-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Ovarian cancer is the most lethal gynecological malignancy, with most patients succumbing to recurrent disease due to resistance to available treatments. The primary treatment regimen—surgery followed by platinum- or taxane-based chemotherapy—offers limited long-term success...

Research Terms

<ABC20><ABCB1><ABCB1 gene><Address><Adjuvant><Affect><Anzatax><Apoptosis><Apoptosis Pathway><Asotax><Binding><Binding Proteins><Body Tissues><Bristaxol><CBDCA><CDDP><Cancer Biology><Cancer Model><Cancer Patient><Cancer Treatment><CancerModel><Carboplatin><Carboplatino><Carcinogen-DNA Adducts><Cell Body><Cell Cycle Arrest><Cell Function><Cell Growth in Number><Cell Locomotion><Cell Migration><Cell Movement><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Survival><Cell Viability><Cells><Cellular Function><Cellular Migration><Cellular Motility><Cellular Physiology><Cellular Process><Cellular Proliferation><Chemoresistance><Circulatory Collapse><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinic><Combination Drug Therapy><Cysplatyna><DNA Adducts><DNA Damage><DNA Damage Repair><DNA Injury><DNA Repair><DNA binding protein B><Data><Diagnosis><Dichlorodiammineplatinum><Disease><Disease Resistance><Disorder><Drug Efflux><Drugs><Epithelium><Female Reproductive Cancer><GP170><Gene Transcription><Genetic Transcription><Goals><Gynecologic Cancer><Gynecological Cancer><Health><In Vitro><Inhibition of Cell Proliferation><Ligand Binding Protein><Ligand Binding Protein Gene><MDR-1><MDR1><MDR1 Protein><Malignant Cell><Malignant Female Reproductive System Neoplasm><Malignant Gynecologic Neoplasm><Malignant Gynecologic Tumor><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor of the Female Reproductive System><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Medication><Mesenchymal><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Modeling><Molecular Interaction><Multidrug Resistance 1><Multidrug Resistance Gene-1><Multidrug Resistance Gene-1s><Multidrug Resistance Proteins><Multidrug Resistant Proteins><Negative Control of Cell Proliferation><Negative Regulation of Cell Proliferation><Neoplasm Metastasis><Non-Polyadenylated RNA><Normal Tissue><Normal tissue morphology><Operative Procedures><Operative Surgical Procedures><Outcome><Ovary Cancer><P-GP><P-Glycoprotein><P-Glycoprotein 1 Gene><PARP Inhibitor><PARP-1 inhibitor><PARPi><PGY-1 Protein><PGY1><Paclitaxel><Paclitaxel (Taxol)><Palliative Care><Palliative Therapy><Palliative Treatment><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peyrone's Chloride><Peyrone's Salt><Pharmaceutical Preparations><Platinum><Platinum Black><Platinum Diamminodichloride><Podofilox><Podophyllotoxin><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) polymerase 1 inhibitor><Polychemotherapy><Praxel><Prognosis><Programmed Cell Death><Progression-Free Survivals><Protein Binding><Proteins><Pt element><RNA><RNA Expression><RNA Gene Products><RNA Splicing><RNA Stability><Recurrence><Recurrent><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Recurrent disease><Regimen><Relapsed Disease><Repair Complex><Research><Resistance><Resistance development><Resistant development><Ribonucleic Acid><Role><Secondary Neoplasm><Secondary Tumor><Shock><Splicing><Stress><Subcellular Process><Surgical><Surgical Interventions><Surgical Procedure><Survival Rate><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Tissues><Transcription><Translations><Treatment Efficacy><Treatment Protocols><Treatment Regimen><Treatment Schedule><Unscheduled DNA Synthesis><Upregulation><Y-Box-Binding Protein 1><YB-1 Y box binding protein><YB-1 binding protein><acquired treatment resistance><anti-cancer therapy><bound protein><cancer cell><cancer metastasis><cancer progression><cancer recurrence><cancer therapy><cancer-directed therapy><cartilage link protein><cell motility><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><circulatory shock><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><combat><combination chemotherapy><combination pharmacotherapy><comfort care><curative intervention><curative therapeutic><curative therapy><curative treatments><design><designing><determine efficacy><develop therapy><developing resistance><diagnosis among females><diagnosis among women><diagnosis in females><diagnosis in women><diagnosis within females><diagnosis within women><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efflux pump><evaluate efficacy><examine efficacy><experience><female diagnosis><gynecologic malignancy><gynecological malignancy><immune microenvironment><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved><improved outcome><in vivo><inhibitor><innovate><innovation><innovative><intervention development><intervention efficacy><link protein><mortality><neoplasm progression><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ovarian cancer><overexpress><overexpression><palliative intervention><pathway><patient oriented outcomes><patient population><prevent><preventing><recruit><resistance mechanism><resistance to disease><resistance to therapy><resistant><resistant disease><resistant mechanism><resistant to disease><resistant to therapy><response><restraint><screening><screenings><shocks><small molecular inhibitor><small molecule><small molecule inhibitor><social role><success><surgery><synergism><taxane><therapeutic efficacy><therapeutic resistance><therapeutic target><therapy development><therapy efficacy><therapy resistant><translation><treatment development><treatment resistance><tumor><tumor cell metastasis><tumor growth><tumor immune microenvironment><tumor progression><tumor-immune system interactions><women's diagnosis>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Helena Safavi-Hemami

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$318,584
FY 2026

Project Title

Discovery and design of novel insulin evologs from venomous marine cone snails

Grant Number:

5R01DK139317-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

SUMMARY Insulin is a pancreatic peptide hormone that is of critical importance for glucose homeostasis. Disruption of insulin production or function can result in diabetes mellitus. Insulin therapy is the only effective treatment for type 1 diabetes (T1D) and is used by many people with type 2 diabe...

Research Terms

<AI Augmented><AI assisted><AI driven><AI enhanced><AI integrated><AI powered><Absolute ethanol><Address><Adult-Onset Diabetes Mellitus><Animal Model><Animal Models and Related Studies><Animals><Artificial Intelligence enhanced><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><Binding><Biophysics><Blood Glucose><Blood Sugar><Brittle Diabetes Mellitus><Cell Communication and Signaling><Cell Signaling><Chemicals><Clinical Drug Development><Clinical Drug Testing/Development><Collection><Cone><Cryo-electron Microscopy><Cryoelectron Microscopy><D-Glucose><DNA><Data><Deoxyribonucleic Acid><Development><Dextrose><Diabetes Mellitus><Drug Kinetics><Drugs><ETOH><Electron Cryomicroscopy><Endocrine Gland Secretion><Ethanol><Ethyl Alcohol><Evolution><Ex4 peptide><Exendin 4><Fish Venoms><Fishes><Future><GLP-1><Geography><Gestational Diabetes><Gestational Diabetes Mellitus><Glp-1><Glucose><Grain Alcohol><Hormones><Human><Humulin R><Hybrids><Hypoglycemia><IDDM><In vivo analysis><Individual><Injections><Insulin><Insulin Receptor><Insulin Receptor Protein-Tyrosine Kinase><Insulin-Dependent Diabetes Mellitus><Insulin-Dependent Tyrosine Protein Kinase><Intracellular Communication and Signaling><Investigation><Isoforms><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Lead><Libraries><Licensing><Life><Maturity-Onset Diabetes Mellitus><Medication><Metabolic><Methylcarbinol><Modeling><Modern Man><Molecular><Molecular Interaction><NGS Method><NGS system><NIDDM><Names><Nature><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Pancreas><Pancreatic><Pb element><Peptide Hormone Gene><Peptide Synthesis><Performance><Persons><Pharmaceutical Preparations><Pharmacokinetics><Phase><Pregnancy-Induced Diabetes><Production><Property><Protein Isoforms><Publishing><Receptor Activation><Receptor Protein><Regular Insulin><SEQ-AN><STZ><Sequence Analyses><Sequence Analysis><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Snail Venoms><Snails><Solid><Source><Stable Diabetes Mellitus><Streptozocin><Streptozotocin><Structure><Sudden-Onset Diabetes Mellitus><Survey Instrument><Surveys><System><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Techniques><Therapeutic><Therapeutic Hormone><Tissue Preservation><Toxin><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><Venoms><Work><Zanosar><adult onset diabetes><analog><analytical ultracentrifugation><artificial intelligence assisted><artificial intelligence augmented><artificial intelligence driven><artificial intelligence integrated><artificial intelligence powered><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><blood glucose regulation><clinical drug development/testing><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><diabetes><diabetes management><diabetes mellitus management><diabetes mellitus therapy><diabetes therapy><diabetic management><dimer><drug candidate><drug/agent><effective therapy><effective treatment><enhanced with AI><enhanced with Artificial Intelligence><exenatide><fish poison><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose regulation><glycemic control><heavy metal Pb><heavy metal lead><hypoglycemic><hypoglycemic episodes><improved><in vivo evaluation><in vivo testing><insulin dependent diabetes><insulin dependent type 1><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><marine><marine environment><maturity onset diabetes><model of animal><monomer><name><named><naming><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><peptide hormone><pharmacologic><pre-clinical><preclinical><pregnancy diabetes><prevent><preventing><rational design><receptor><scaffold><scaffolding><simulation><subcutaneous><subdermal><therapeutic agent development><therapeutic development><translational impact><type 2 DM><type I diabetes><type II DM><type one diabetes><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel J. Moore

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 66/100
Likely hiring
Solid budget
Very recent
Active award
$317,999
FY 2026

Project Title

Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab

Grant Number:

5R01DK139322-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

This proposal aims to explore the metabolic advantages and mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1Ra) in individuals with stage 2 type 1 diabetes (T1DM) undergoing treatment with teplizumab, an immunomodulatory therapy. Stage 2 T1DM represents a critical juncture where interve...

Research Terms

<Address><Adult-Onset Diabetes Mellitus><Affect><Agonist><Antidiabetic Hormone><Assay><Beta Cell><Bioassay><Biological Assay><Brittle Diabetes Mellitus><C-Peptide><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Clinic><Clinical><Clinical Treatment Moab><Clinical Trials><Combined Modality Therapy><Compensation><Cross-Over Designs><Cross-Over Studies><Crossover Design><Crossover Studies><D-Glucose><Data><Data Analyses><Data Analysis><Development><Dextrose><Disease><Disease Progression><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Dysfunction><Early treatment><Elements><Endogenous Nitrate Vasodilator><Endoplasmic Reticulum><Endothelial Cells><Endothelium><Endothelium-Derived Nitric Oxide><Ergastoplasm><Ex4 peptide><Exendin 4><Feasibility Studies><Functional disorder><Funding><Future><GLP-1 receptor><GLP-I receptor><Glucagon><Glucose><Glukagon><Goals><HG-Factor><Haplotypes><Humulin R><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><IDDM><Immune Modulation Therapy><Immune mediated therapy><Immunologically Directed Therapy><Immunomodulation><Immunotherapy><Individual><Insulin><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intermediary Metabolism><Intervention><Islet Cell><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Knowledge><Life><Linear Regressions><Maturity-Onset Diabetes Mellitus><Measures><Mediating><Metabolic><Metabolic Processes><Metabolism><Mission><Modeling><Monoclonal Antibodies><Mononitrogen Monoxide><Multimodal Therapy><Multimodal Treatment><NIDDK><NIDDM><National Institute of Diabetes and Digestive and Kidney Diseases><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Oral><Outcome><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Physiopathology><Pilot Projects><Placebo Control><Placebo Effect><Population><Process><Proinsulin><Property><Public Health><QOL><Quality of life><Randomized><Regression Analyses><Regression Analysis><Regression Diagnostics><Regular Insulin><Research><Research Design><Role><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Statistical Regression><Structure><Study Type><Subcellular Process><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Testing><Therapeutic><Treatment outcome><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><Vascular Diseases><Vascular Disorder><Vasodilatation><Vasodilation><Vasorelaxation><adult onset diabetes><attenuated insulin secretion><blood vessel disorder><blunted insulin secretion><cardiometabolic><cardiometabolism><clinical practice><combination therapy><combined modality treatment><combined treatment><connecting peptide><data interpretation><decreased insulin release><decreased insulin secretion><defective insulin secretion><design><designing><developmental><diabetes management><diabetes mellitus management><diabetic management><diminished insulin release><diminished insulin secretion><early therapy><effective therapy><effective treatment><endothelial cell derived relaxing factor><exenatide><expectancy effect><expectation effect><experience><feasibility trial><glucagon-like peptide-1 receptor><hyperglucagonemia><hyperglycemic><immune modulation><immune modulatory therapies><immune modulatory treatment><immune regulation><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunologic reactivity control><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory><immunomodulatory biologics><immunomodulatory therapies><immunomodulatory treatment><immunoregulation><immunoregulatory><immunoregulatory therapy><immunoregulatory treatment><impaired insulin release><impaired insulin secretion><improved><inadequate insulin release><inadequate insulin secretion><indexing><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><insulin resistant><insulin secretion><insulin sensitivity><insulin tolerance><interest><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><lowered insulin secretion><mAbs><maturity onset diabetes><monoclonal Abs><multi-modal therapy><multi-modal treatment><nocebo><novel><pathophysiology><patient oriented outcomes><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pilot study><pilot trial><placebo controlled><placebo response><primary outcome><randomisation><randomization><randomly assigned><recruit><reduced insulin release><repurposing><response><slow potential><social role><stem><study design><suppressed insulin release><suppressed insulin secretion><therapeutic immunomodulation><therapeutic immunoregulation><treatment strategy><type 2 DM><type I diabetes><type II DM><type one diabetes><type two diabetes><ultrasound><vascular dysfunction><vasculopathy><volunteer><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rama Rao Amara

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$907,904
FY 2026

Project Title

Targeting PD-1 Pathway for Functional Cure of AIDS

Grant Number:

5R01AI112787-13

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2014

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

This proposal aims to develop an effective therapy to achieve HIV remission by improving the magnitude, breadth, and function of anti-viral CD8 T cells and reducing viral reservoirs using the SIV/macaque model. Dysfunctional anti-HIV immunity and the persistence of viral reservoirs represent two maj...

Research Terms

<AIDS><AIDS Virus><AIDS/HIV><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Adenoviridae><Adenoviruses><Advanced HIV><Animals><Antigenic Determinants><Antigens><Binding><Binding Determinants><Blood><Blood Reticuloendothelial System><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Chimp><Chimpanzee><Chronic><Class I Genes><Co-Stimulator><Combination Vaccines><Combined Modality Therapy><Combined Vaccines><Costimulator><DNA/MVA vaccine><Data><Detection><Disease remission><Effector Cell><Epidermal Thymocyte Activating Factor><Epitopes><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Frequencies><Germinal Center><Goals><Grant><Granzyme><HIV><HIV cure><HIV functional cure><HIV-1 cure><HIV-1 functional cure><HIV/AIDS><HIV/AIDS cure><Haplotypes><Heterogeneity><Human><Human Immunodeficiency Viruses><IL-2><IL2 Protein><Immune mediated therapy><Immunity><Immunologically Directed Therapy><Immunotherapy><Infection><Interleukin 2><Interleukin 2 Precursor><Interleukin II><Interleukin-2><Interleukine 2><Interleukine 2 Precursor><Interleukine II><Interruption><Investments><LAV-HTLV-III><LCM Viruses><LCMV><LYT3><Laboratories><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphadenopathy-Associated Virus><Lymphatic nodes><Lymphocyte Mitogenic Factor><Lymphocytic choriomeningitis virus><M mulatta><M. mulatta><MHC Class I><MHC Class I Genes><Macaca><Macaca mulatta><Macaca rhesus><Macaque><Mice><Mice Mammals><Mitogenic Factor><Modeling><Modern Man><Molecular Interaction><Monitor><Multimodal Therapy><Multimodal Treatment><Murine><Mus><PD 1><PD-1><PD-1 antibody><PD-1 blockade><PD-1 checkpoint pathway><PD-1 pathway><PD-1 signaling pathway><PD1><PD1 antibody><PD1 blockade><PD1 checkpoint pathway><PD1 pathway><PD1 signaling pathway><Pathway interactions><RNA Seq><RNA sequencing><RNAseq><Remission><Rhesus Macaque><Rhesus Monkey><SIV><Safety><Severe HIV Disease><Simian Immunodeficiency Viruses><Sorting><Structure of germinal center of lymph node><Subcellular Process><T cell growth factor><T cell response><T-Cell Growth Factor><T-Cell Stimulating Factor><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Thymocyte Stimulating Factor><Treatment Efficacy><VAC-TX><Vaccinated><Vaccination><Vaccine Therapy><Vaccines><Viral><Viral reservoir><Viremia><Virus reservoir><Virus-HIV><Work><aPD-1><aPD1><anti programmed cell death 1><anti programmed cell death protein 1 checkpoint pathway><anti programmed cell death protein 1 pathway><anti programmed cell death protein 1 signaling pathway><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><antiretroviral therapy><antiretroviral treatment><combination therapy><combined modality treatment><combined treatment><cytokine based immunotherapy><cytokine based therapy><cytokine immunotherapy><cytokine therapy><cytokine treatment><effective therapy><effective treatment><exhaust><exhaustion><flow cytophotometry><human immunodeficiency virus cure><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><improved><intervention efficacy><lymph gland><lymph nodes><lymphnodes><lymphocyte pore-forming protein><multi-modal therapy><multi-modal treatment><non vaccinated><not vaccinated><pathway><perforin><programmed cell death 1><programmed cell death protein 1><programmed death 1><programs><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><success><synergism><systemic lupus erythematosus susceptibility 2><therapeutic efficacy><therapeutic outcome><therapeutic vaccination><therapeutic vaccine><therapy efficacy><therapy outcome><thymus derived lymphocyte><transcriptome sequencing><transcriptomic sequencing><treatment vaccines><unvaccinated><vaccine for the treatment><vaccine for treatment><viraemia><viral rebound><viral sepsis><virus rebound><virusemia><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CYNTHIA A LEMERE

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$840,721
FY 2026

Project Title

Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease

Grant Number:

5R01AG084531-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT: Recent FDA accelerated approvals of two anti-amyloid antibody treatments, aducanumab and lecanemab, for early-stage Alzheimer’s disease (AD) provide the first disease-modifying treatments to date, albeit with moderate slowing of cognitive decline, and vascular side effects ...

Research Terms

<AD brain><AD dementia><AD model><AD pathology><AD patients><APOE><APOE e4><APOE-ε4><APOEε4><APP-PS1><APP/PS1><Acceleration><Acute><Aducanumab><Adult-Onset Diabetes Mellitus><Age><Aging><Agonist><Alzheimer Type Dementia><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimer's brain><Alzheimer's disease brain><Alzheimer's disease model><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's pathology><Alzheimer's patient><Alzheimers Dementia><Ammon Horn><Amyloid><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Protein A4><Amyloid Substance><Amyloid beta-Protein><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antibodies><Antibody Therapy><Antidiabetic Hormone><Apo-E><ApoE protein><Apolipoprotein E><Attenuated><Aβ><BIIB037><Behavior><Behavior Control><Behavioral Manipulation><Binding><Biochemical><Biochemistry><Biological Chemistry><Bleeding><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood Vessels><Brain><Brain Nervous System><Brain Pathology><Carotid Artery Ulcerating Plaque><Carotid Ulcers><Cell Body><Cells><Cerebrovascular system><Chemotactic Cytokines><Cholesterol><Clinical><Clinical Trials><Cognition><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Combined Modality Therapy><Complement><Complement Proteins><Cornu Ammonis><D-Glucose><Data><Dextrose><Diabetes Mellitus><Disease><Disorder><Disturbance in cognition><Dose><Drainage><Drainage procedure><Dropsy><Drugs><Early treatment><Edema><Electrophysiology><Electrophysiology (science)><Encephalon><Euthanasia><FDA approved><FITC-dextran><Female><GLP-1 receptor><GLP-I receptor><Gliosis><Glucagon><Glucose><Glukagon><Goals><HG-Factor><Health><Hemorrhage><Hippocampus><Homologous Chemotactic Cytokines><Human><Hydrops><Hyperglycemic-Glycogenolytic Factor><IgG2><Image><Immune><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunotherapy><Impaired cognition><Inflammation><Injections><Intercrines><KI mice><Ketosis-Resistant Diabetes Mellitus><Knock-in Mouse><Laboratories><Lead><Maps><Maturity-Onset Diabetes Mellitus><Measures><Mediating><Medication><Mercy Killing><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NIDDM><NIH><National Institutes of Health><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neurocyte><Neuron Degeneration><Neurons><Neurophysiology / Electrophysiology><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Outcome><Pathologic><Pathology><Patients><Pb element><Pharmaceutical Preparations><Phase><Phase 3 Clinical Trials><Phase III Clinical Trials><Phenotype><Physiologic><Physiological><Plasma><Plasma Serum><Population><Prevention><Primary Senile Degenerative Dementia><Proteins><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Reporting><Reticuloendothelial System, Serum, Plasma><SIS cytokines><Safety><Single-Nucleus Sequencing><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Subcutaneous Injections><Synapses><Synaptic><T2 DM><T2D><T2DM><Testing><Therapeutic><Time><Titrations><Toxic effect><Toxicities><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States National Institutes of Health><a beta peptide><abeta><adiposity><aduhelm><adult onset diabetes><aged><aged mice><aged mouse><ages><alzheimer model><amyloid angiopathy><amyloid beta><amyloid-b protein><analog><antibody based therapies><antibody immunotherapy><antibody treatment><antibody-based therapeutics><antibody-based treatment><apo E-4><apo E4><apo epsilon4><apoE epsilon 4><apoE-4><apoE4><apolipoprotein E epsilon 4><apolipoprotein E-4><apolipoprotein E4><attenuate><attenuates><behavior test><behavioral control><behavioral test><beta amyloid fibril><blood loss><blood vessels in the brain><brain blood vessels><brain vasculature><cerebral blood vessel><cerebral vasculature><cerebrovascular vessels><cerebrovasculature><chemoattractant cytokine><chemokine><cognitive dysfunction><cognitive loss><combination therapy><combined modality treatment><combined treatment><comparable efficacy><comparative efficacy><compare efficacy><complementation><corpulence><cytokine><diabetes><dimer><disease model><disorder model><drug/agent><early therapy><efficacy testing><elderly mice><electrophysiological><fluorescein isothiocyanate dextran><fluoresceinthiocarbamoyl dextrans><glucagon-like peptide-1 receptor><heavy metal Pb><heavy metal lead><hippocampal><human data><imaging><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><ketosis resistant diabetes><knockin mice><male><maturity onset diabetes><mouse model><multi-modal therapy><multi-modal treatment><murine model><mutant><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal><neuronal degeneration><neuroprotection><neuroprotective><old mice><overexpress><overexpression><patient living with Alzheimer's disease><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><phase III protocol><primary degenerative dementia><receptor><sNuc-Seq><senile dementia of the Alzheimer type><side effect><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><soluble amyloid precursor protein><stroke model><subdermal injection><synapse><transcriptome sequencing><transcriptomic sequencing><transcriptomics><type 2 DM><type II DM><type two diabetes><vascular><vascular amyloid><vascular amyloid accumulation><vascular amyloid build up><vascular amyloid deposition><vascular amyloid deposits><vascular amyloid pathology><vascular amyloidosis><vascular corrosion plaques><vascular erosion plaques><vascular plaque><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MOSHE LEVI

GEORGETOWN UNIVERSITY, WASHINGTON, DC

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$831,580
FY 2026

Project Title

Role of Glycosphingolipids in Kidney Disease in Diabetes and Obesity

Grant Number:

5R01DK139676-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/20/2025

End Date:

11/30/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Obesity and diabetes continue to be leading causes of chronic kidney disease (CKD). In our models of diabetes and obesity, we have found increased renal glycosphingolipids which are associated with impaired mitochondrial function, increased inflammatory T cells (Th17 cells), and progression of renal...

Research Terms

<ACE Inhibitors><ATAC sequencing><ATAC-seq><ATACseq><Agonist><Aldosterone Receptor><Angiotensin I-Converting Enzyme Inhibitors><Angiotensin II Receptor><Angiotensin-Converting Enzyme Antagonists><Angiotensin-Converting Enzyme Inhibitors><Asialogangliosides><Assay for Transposase-Accessible Chromatin using sequencing><Body Tissues><Cardiovascular Diseases><Cell Body><Cells><Cellular injury><Ceramide glucosyltransferase><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Common Rat Strains><Diabetes Mellitus><Disease><Disorder><Electron Microscopy><FDA approved><Fibrosis><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fluorescence Light Microscopy><Fluorescence Microscopy><GLP-1><Gaucher Disease><Gauchers Disease><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><GlcCer synthase><Glp-1><Glucocerebrosides><Glucosyl Ceramides><Glucosylceramides><Glycosphingolipids><Immune><Immunes><Impairment><Inflammation><Inflammatory><Investigators><Kidney><Kidney Diseases><Kidney Tubules><Kidney Urinary System><Kininase II Antagonists><Kininase II Inhibitors><Knowledge><Label><Lipids><Measurement><Mediating><Mediator><Mice><Mice Mammals><Mineralocorticoid Receptor><Mitochondria><Modeling><Murine><Mus><Nephropathy><Obesity><Oxidative Phosphorylation><Oxidative Phosphorylation Pathway><Pathogenesis><Play><Population><Prevalence><Rat><Rats Mammals><Rattus><Renal Disease><Renal function><Renal tubule structure><Research Personnel><Researchers><Risk><Role><SGLT 2 inhibitor><SGLT2i><Single-Nucleus Sequencing><Sodium glucose co-transporter 2 inhibitor><Sphingoglycolipids><T-Cells><T-Lymphocyte><Techniques><Testing><Tissues><Translating><Tubular><Tubular formation><UDP-glucose-N-acylsphingosine glucosyltransferase><UDP-glucose-ceramide glucosyltransferase><UDPglucose-ceramide glucosyltransferase><Visceral Epithelial Cell><adiposity><adult youth><antagonism><antagonist><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><cardiovascular disorder><cell damage><cell injury><cellular damage><ceramide UDPG glucosyltransferase><cerebroside synthase><chronic kidney disease><corpulence><damage to cells><diabetes><diet-associated obesity><diet-induced obesity><diet-related obesity><extracellular><fatty acid oxidation><flow cytophotometry><glomerular visceral epithelial cell><glucagon-like peptide 1><glucocerebroside synthetase><glucosylceramide synthase><glycosylceramide synthetase><high dimensionality><improved><inhibitor><injury to cells><innovate><innovation><innovative><insight><kidney disorder><kidney function><mitochondrial><mouse model><multiomics><multiple omics><murine model><novel><panomics><podocyte><prevent><preventing><renal><renal disorder><renal tubule><sNuc-Seq><senescence><senescent><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><super high resolution><superresolution><thymus derived lymphocyte><ultra high resolution><young adult><young adult age><young adulthood>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mamuka Kvaratskhelia

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$774,370
FY 2026

Project Title

Roles of HIV-1 capsid-binding FG-motif containing cellular cofactors in infection

Grant Number:

5R01AI162665-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/8/2022

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract Early events in HIV-1 lifecycle, such as post-fusion trafficking of viral cores across the cytoplasm, through the nuclear pore complex (NPC) and into the nucleus, remain poorly understood due to limited information about virus-host interactions. Interactions of the core’s surface, which is ...

Research Terms

<AICDA><AICDA protein><AID gene><AID protein><Affinity><Aminoacetic Acid><Assay><Binding><Binding Proteins><Binding Sites><Bioassay><Biochemistry><Biological Assay><Biological Chemistry><Biology><CDA2 protein><Capsid><Capsid Proteins><Cell Body><Cell Nucleus><Cells><Coat Proteins><Combining Site><Complement><Complement Proteins><Complex><Cone><Coupled><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasm><Cytoplasmic Protein><Dependence><Drug Industry><Electron Cryomicroscopy><Ensure><Event><Foundations><Future><Genetic Code><Glycine><Goals><HAART><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><Highly Active Antiretroviral Therapy><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Hydrophobicity><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Integration Host Factors><Knowledge><Label><Life Cycle><Life Cycle Stages><Ligand Binding Protein><Ligand Binding Protein Gene><Mediating><Molecular><Molecular Interaction><Molecular Mechanisms of Action><Monitor><NPC><Nuclear Import><Nuclear Pore Complex><Nucleus><Peptides><Pharmaceutic Industry><Pharmaceutical Industry><Phase 3 Clinical Trials><Phase III Clinical Trials><Phenylalanine><Productivity><Protein Binding><Proteins><Proteomics><Reactive Site><Recombinants><Reporting><Role><Shapes><Single Crystal Diffraction><Surface><Testing><Time><Tube><Tubular><Tubular formation><Viral><Viral Coat Proteins><Viral Outer Coat Protein><Virus><Work><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><activation-induced cytidine deaminase><activation-induced deaminase><base><bases><bound protein><cofactor><complementation><cryo-EM><cryoEM><cryogenic electron microscopy><experiment><experimental research><experimental study><experiments><frontier><highly active antiretroviral treatment><human immunodeficiency virus infection><improved><infected with HIV><infected with human immunodeficiency virus><inhibitor><insight><integration site><life course><live cell microscopy><next generation><novel><novel virus><phase III protocol><prion-like><recruit><retrograde transport><social role><spatial and temporal><spatial temporal><spatiotemporal><structural biology><structural determinants><structural factors><synergism><therapeutic target><trafficking><virology><virus host interaction>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gregory B Melikian

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$774,370
FY 2026

Project Title

Roles of HIV-1 capsid-binding FG-motif containing cellular cofactors in infection

Grant Number:

5R01AI162665-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/8/2022

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract Early events in HIV-1 lifecycle, such as post-fusion trafficking of viral cores across the cytoplasm, through the nuclear pore complex (NPC) and into the nucleus, remain poorly understood due to limited information about virus-host interactions. Interactions of the core’s surface, which is ...

Research Terms

<AICDA><AICDA protein><AID gene><AID protein><Affinity><Aminoacetic Acid><Assay><Binding><Binding Proteins><Binding Sites><Bioassay><Biochemistry><Biological Assay><Biological Chemistry><Biology><CDA2 protein><Capsid><Capsid Proteins><Cell Body><Cell Nucleus><Cells><Coat Proteins><Combining Site><Complement><Complement Proteins><Complex><Cone><Coupled><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasm><Cytoplasmic Protein><Dependence><Drug Industry><Electron Cryomicroscopy><Ensure><Event><Foundations><Future><Genetic Code><Glycine><Goals><HAART><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><Highly Active Antiretroviral Therapy><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Hydrophobicity><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Integration Host Factors><Knowledge><Label><Life Cycle><Life Cycle Stages><Ligand Binding Protein><Ligand Binding Protein Gene><Mediating><Molecular><Molecular Interaction><Molecular Mechanisms of Action><Monitor><NPC><Nuclear Import><Nuclear Pore Complex><Nucleus><Peptides><Pharmaceutic Industry><Pharmaceutical Industry><Phase 3 Clinical Trials><Phase III Clinical Trials><Phenylalanine><Productivity><Protein Binding><Proteins><Proteomics><Reactive Site><Recombinants><Reporting><Role><Shapes><Single Crystal Diffraction><Surface><Testing><Time><Tube><Tubular><Tubular formation><Viral><Viral Coat Proteins><Viral Outer Coat Protein><Virus><Work><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><activation-induced cytidine deaminase><activation-induced deaminase><base><bases><bound protein><cofactor><complementation><cryo-EM><cryoEM><cryogenic electron microscopy><experiment><experimental research><experimental study><experiments><frontier><highly active antiretroviral treatment><human immunodeficiency virus infection><improved><infected with HIV><infected with human immunodeficiency virus><inhibitor><insight><integration site><life course><live cell microscopy><next generation><novel><novel virus><phase III protocol><prion-like><recruit><retrograde transport><social role><spatial and temporal><spatial temporal><spatiotemporal><structural biology><structural determinants><structural factors><synergism><therapeutic target><trafficking><virology><virus host interaction>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Benson Edagwa

UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$767,498
FY 2026

Project Title

Prodrug Formulations Create Sustained-Release Antiretrovirals

Grant Number:

5R01AI145542-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2019

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract Long acting (LA) therapeutics offer real potential for improved regimen adherence and disease outcomes for chronic infectious diseases. For human immunodeficiency virus (HIV) infections only cabenuva has emerged as a sole complete LA regimen to affect long-term viral suppression. However, t...

Research Terms

<AIDS Virus><AIDS prevention><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Adverse effects><Affect><Animals><Anti-Retroviral Agents><BALB C Mouse><BALB/c><Blood Neutrophil><Blood Plasma><Blood Polymorphonuclear Neutrophil><Blood monocyte><Body Tissues><CD34><CD34 gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Count><Cell Number><Cells><Chemistry><Chronic><Clinic Visits><Clinical><Collaborations><Comment><Commentary><Communicable Diseases><DNA mutation><Data><Data Set><Development><Differences between sexes><Differs between sexes><Diphosphates><Disease Outcome><Dose><Drug Carriers><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drug Precursors><Drugs><Early-Stage Clinical Trials><Editorial Comment><Esters><Evaluation><Excipients><Fatty Acids><Female><Formulation><Foundations><Freeze Drying><Freeze Dryings><Funding><Future><Genetic Change><Genetic defect><Genetic mutation><Goals><Guidelines><HIV><HIV Infections><HIV Integrase><HIV Integration Protein><HIV Prevention><HIV intervention><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV/AIDS prevention><HIV1><HPCA1><Half-Life><Health Care><Heptylcarbinols><History><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrolysis><Hydroxyoctanes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunologist><In Vitro><Inbred BALB C Mice><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Injectable><Injection Site Reaction><Injections><Integrase><Intramuscular Injections><LAV-HTLV-III><Lead><Licensing><Life><Lipids><Lymphadenopathy-Associated Virus><Lymphatic cell><Lymphocyte><Lymphocytic><Lyophilization><Lytotoxicity><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Macrophage><Marrow Neutrophil><Marrow monocyte><Medication><Medicine><Metabolic><Mice><Mice Mammals><Modification><Monitor><Murine><Mus><Mutation><Mφ><Names><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Octadecanoates><Octanols><Octyl Alcohols><Octylic Alcohols><PK/PD><Pb element><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Plasma><Plasma Serum><Polymers><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Powder dose form><Powders><Prevent HIV><Pro-Drugs><Process><Prodrugs><Property><Published Comment><Pyrophosphates><Rapid screening><Recording of previous events><Regimen><Research><Reticuloendothelial System><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Safety><Sampling><Scheme><Science><Selection Criteria><Sex Differences><Sexual differences><Site><Solubility><Sprague-Dawley Rats><Stearates><Suspension substance><Suspensions><Synthesis Chemistry><Synthetic Chemistry><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><Tail><Tenofovir><Test Result><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Toxicology><Treatment outcome><Viewpoint><Viral><Viral Burden><Viral Load><Viral Load result><Viread><Virus-HIV><anti-retroviral><antiretroviral therapy><antiretroviral treatment><aqueous><biocompatibility><biomaterial compatibility><candidate selection><chemical stability><clinical candidate><clinical relevance><clinical translation><clinically relevant><clinically translatable><combinatorial><commercial scale manufacturing><compound optimization><crystallinity><cytotoxicity><design><designing><develop drug resistance><developmental><dimer><drug resistance development><drug/agent><emergent virus><emerging virus><expectation><forgiveness><formulation optimization><genome mutation><heavy metal Pb><heavy metal lead><histories><human immunodeficiency virus infection><humanized mice><humanized mouse><improved><in vivo><infected with HIV><infected with human immunodeficiency virus><inhibitor><intramuscular drug administration><lipophilicity><lymph cell><male><manufacturing ramp-up><manufacturing scale-up><melting><monocyte><monomer><mouse model><murine model><name><named><naming><nano><nanocrystal><neutrophil><next generation><particle><pharmacokinetics and pharmacodynamics><pharmacologic><phase I protocol><phosphonate><polymer><polymeric><prevent AIDS><prevent human immunodeficiency virus><scale up batch><scale up production><screening><screenings><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><side effect><success><surfactant><thymus derived lymphocyte><treat HIV><treat Human Immunodeficiency Virus><upscale manufacturing><uptake><viral emergence><viral transmission><virus transmission><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Howard E Gendelman

UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$767,498
FY 2026

Project Title

Prodrug Formulations Create Sustained-Release Antiretrovirals

Grant Number:

5R01AI145542-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2019

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Abstract Long acting (LA) therapeutics offer real potential for improved regimen adherence and disease outcomes for chronic infectious diseases. For human immunodeficiency virus (HIV) infections only cabenuva has emerged as a sole complete LA regimen to affect long-term viral suppression. However, t...

Research Terms

<AIDS Virus><AIDS prevention><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Adverse effects><Affect><Animals><Anti-Retroviral Agents><BALB C Mouse><BALB/c><Blood Neutrophil><Blood Plasma><Blood Polymorphonuclear Neutrophil><Blood monocyte><Body Tissues><CD34><CD34 gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Count><Cell Number><Cells><Chemistry><Chronic><Clinic Visits><Clinical><Collaborations><Comment><Commentary><Communicable Diseases><DNA mutation><Data><Data Set><Development><Differences between sexes><Differs between sexes><Diphosphates><Disease Outcome><Dose><Drug Carriers><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drug Precursors><Drugs><Early-Stage Clinical Trials><Editorial Comment><Esters><Evaluation><Excipients><Fatty Acids><Female><Formulation><Foundations><Freeze Drying><Freeze Dryings><Funding><Future><Genetic Change><Genetic defect><Genetic mutation><Goals><Guidelines><HIV><HIV Infections><HIV Integrase><HIV Integration Protein><HIV Prevention><HIV intervention><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV/AIDS prevention><HIV1><HPCA1><Half-Life><Health Care><Heptylcarbinols><History><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrolysis><Hydroxyoctanes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunologist><In Vitro><Inbred BALB C Mice><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Injectable><Injection Site Reaction><Injections><Integrase><Intramuscular Injections><LAV-HTLV-III><Lead><Licensing><Life><Lipids><Lymphadenopathy-Associated Virus><Lymphatic cell><Lymphocyte><Lymphocytic><Lyophilization><Lytotoxicity><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Macrophage><Marrow Neutrophil><Marrow monocyte><Medication><Medicine><Metabolic><Mice><Mice Mammals><Modification><Monitor><Murine><Mus><Mutation><Mφ><Names><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Octadecanoates><Octanols><Octyl Alcohols><Octylic Alcohols><PK/PD><Pb element><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Plasma><Plasma Serum><Polymers><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Powder dose form><Powders><Prevent HIV><Pro-Drugs><Process><Prodrugs><Property><Published Comment><Pyrophosphates><Rapid screening><Recording of previous events><Regimen><Research><Reticuloendothelial System><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Safety><Sampling><Scheme><Science><Selection Criteria><Sex Differences><Sexual differences><Site><Solubility><Sprague-Dawley Rats><Stearates><Suspension substance><Suspensions><Synthesis Chemistry><Synthetic Chemistry><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><Tail><Tenofovir><Test Result><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Toxicology><Treatment outcome><Viewpoint><Viral><Viral Burden><Viral Load><Viral Load result><Viread><Virus-HIV><anti-retroviral><antiretroviral therapy><antiretroviral treatment><aqueous><biocompatibility><biomaterial compatibility><candidate selection><chemical stability><clinical candidate><clinical relevance><clinical translation><clinically relevant><clinically translatable><combinatorial><commercial scale manufacturing><compound optimization><crystallinity><cytotoxicity><design><designing><develop drug resistance><developmental><dimer><drug resistance development><drug/agent><emergent virus><emerging virus><expectation><forgiveness><formulation optimization><genome mutation><heavy metal Pb><heavy metal lead><histories><human immunodeficiency virus infection><humanized mice><humanized mouse><improved><in vivo><infected with HIV><infected with human immunodeficiency virus><inhibitor><intramuscular drug administration><lipophilicity><lymph cell><male><manufacturing ramp-up><manufacturing scale-up><melting><monocyte><monomer><mouse model><murine model><name><named><naming><nano><nanocrystal><neutrophil><next generation><particle><pharmacokinetics and pharmacodynamics><pharmacologic><phase I protocol><phosphonate><polymer><polymeric><prevent AIDS><prevent human immunodeficiency virus><scale up batch><scale up production><screening><screenings><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><side effect><success><surfactant><thymus derived lymphocyte><treat HIV><treat Human Immunodeficiency Virus><upscale manufacturing><uptake><viral emergence><viral transmission><virus transmission><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joseph A. Baur

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$752,121
FY 2026

Project Title

Role of Activin Type II Receptor Signaling in Muscle Hypertrophy, Obesity, and Weight Loss

Grant Number:

5R01DK139663-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary GLP-1 receptor agonists and GLP-1/GIP dual agonists profoundly decrease body weight in association with significant cardiometabolic benefits. These therapeutic agents are being widely adopted for obesity treatment in the U.S. Certainly, lowering fat mass is metabolically advantageous...

Research Terms

<Abscission><Activins><Adipocytes><Adipose Cell><Adipose tissue><Adopted><Agonist><Animals><Anorectic Drug><Anorectic agent><Anorectics><Anorexiant><Anorexic Drugs><Anorexient Agent><Anorexient Drug><Anorexigenic Drugs><Anti-Obesity Agents><Anti-Obesity Drugs><Appetite Depressants><Appetite Suppressants><Appetite-Depressing Drugs><Appetite-Suppressant Drugs><Binding><Blocking Antibodies><Body Composition><Body Tissues><Body Weight decreased><Bone-Derived Transforming Growth Factor><Calories><Cell Communication and Signaling><Cell Signaling><Data><Defect><Diet><Dose><EYDF><Eating><Energy Expenditure><Energy Metabolism><Excision><Extirpation><FSH-Releasing Protein><Fat Cells><Fats><Fatty Tissue><Fatty acid glycerol esters><Fiber><Fibrosis><Food Intake><Foundations><Future><GDF-8><GDF8><GDF8 gene><GIP receptor><GLP-1><GLP-1 receptor><GLP-I receptor><Gene Action Regulation><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Generalized Growth><Genetic><Genetic Transcription><Glp-1><Glucose-Dependent Insulinotropic Polypeptide><Goals><Growth><Growth Differentiation Factor 8 Gene><Growth/Differentiation Factor 8><Health><Heat Production><High Fat Diet><Human><Hypertrophy><Inflammation><Intermediary Metabolism><Intracellular Communication and Signaling><Isotopes><Knowledge><Leanness><Ligands><Lipids><Lipocytes><MSTN><Mature Lipocyte><Mature fat cell><Measures><Mediating><Metabolic><Metabolic Processes><Metabolism><Methods><Mice><Mice Mammals><Milk Growth Factor><Mitochondria><Modern Man><Molecular><Molecular Interaction><Morphology><Murine><Mus><Muscle><Muscle Atrophy><Muscle Cells><Muscle Proteins><Muscle Tissue><Muscle function><Muscular Atrophy><Myocytes><Nutrient><Obese Mice><Obesity><Pathway interactions><Physical Performance><Physiology><Platelet Transforming Growth Factor><Predisposition><Proteins><Publishing><RNA Expression><Receptor Inhibition><Receptor Signaling><Regimen><Removal><Rodent><Rodentia><Rodents Mammals><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skeletal Muscle><Structure><Surgical Removal><Susceptibility><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Therapeutic><Therapeutic Agents><Thermogenesis><Thinness><Tissue Growth><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Type II Activin Receptor Like Kinases><Type II Activin Receptors><VO2 max><VO2max><Voluntary Muscle><Weight><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Withholding Treatment><activin A><adipocyte development><adipocyte differentiation><adipose><adiposity><adult adiposity><adult obesity><adults with obesity><analyze gene expression><anorexic agent><antagonism><antagonist><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><bariatric surgery><biological signal transduction><body weight gain><body weight increase><body weight loss><calorie><cardiometabolic><cardiometabolism><cessation of treatment><cohort><corpulence><dieting><diets><energy balance><erythroid differentiation factor><erythroid differentiation protein><experiment><experimental research><experimental study><experiments><gastric banding><gastric bypass surgery><gastric inhibitory polypeptide receptor><gene expression analysis><gene expression assay><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose-dependent insulinotropic polypeptide receptor><growth-differentiation factor 8><homo-activin A><implantable gastric stimulation banding><improved><in vivo><inhibitor><insulin sensitivity><maximal oxygen uptake><mitochondrial><muscle breakdown><muscle bulk><muscle degradation><muscle deterioration><muscle form><muscle hypertrophy><muscle loss><muscle mass><muscle strength><muscle wasting><muscular><myostatin><next generation><ob/ob mouse><obesity intervention><obesity surgery><obesity therapy><obesity treatment><ontogeny><oxidation><pathway><patient population><pharmacologic><phase 2 study><phase II study><poor health outcome><preservation><reduced health outcome><resection><response><skeletal><skeletal preservation><social role><stomach stapling><synergism><transcriptional profiling><treatment cessation><treatment effect><weight loss surgery><weight maintenance><weights><white adipose tissue><worse health outcome><wt gain><wt-loss><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patrick Seale

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$752,121
FY 2026

Project Title

Role of Activin Type II Receptor Signaling in Muscle Hypertrophy, Obesity, and Weight Loss

Grant Number:

5R01DK139663-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary GLP-1 receptor agonists and GLP-1/GIP dual agonists profoundly decrease body weight in association with significant cardiometabolic benefits. These therapeutic agents are being widely adopted for obesity treatment in the U.S. Certainly, lowering fat mass is metabolically advantageous...

Research Terms

<Abscission><Activins><Adipocytes><Adipose Cell><Adipose tissue><Adopted><Agonist><Animals><Anorectic Drug><Anorectic agent><Anorectics><Anorexiant><Anorexic Drugs><Anorexient Agent><Anorexient Drug><Anorexigenic Drugs><Anti-Obesity Agents><Anti-Obesity Drugs><Appetite Depressants><Appetite Suppressants><Appetite-Depressing Drugs><Appetite-Suppressant Drugs><Binding><Blocking Antibodies><Body Composition><Body Tissues><Body Weight decreased><Bone-Derived Transforming Growth Factor><Calories><Cell Communication and Signaling><Cell Signaling><Data><Defect><Diet><Dose><EYDF><Eating><Energy Expenditure><Energy Metabolism><Excision><Extirpation><FSH-Releasing Protein><Fat Cells><Fats><Fatty Tissue><Fatty acid glycerol esters><Fiber><Fibrosis><Food Intake><Foundations><Future><GDF-8><GDF8><GDF8 gene><GIP receptor><GLP-1><GLP-1 receptor><GLP-I receptor><Gene Action Regulation><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Generalized Growth><Genetic><Genetic Transcription><Glp-1><Glucose-Dependent Insulinotropic Polypeptide><Goals><Growth><Growth Differentiation Factor 8 Gene><Growth/Differentiation Factor 8><Health><Heat Production><High Fat Diet><Human><Hypertrophy><Inflammation><Intermediary Metabolism><Intracellular Communication and Signaling><Isotopes><Knowledge><Leanness><Ligands><Lipids><Lipocytes><MSTN><Mature Lipocyte><Mature fat cell><Measures><Mediating><Metabolic><Metabolic Processes><Metabolism><Methods><Mice><Mice Mammals><Milk Growth Factor><Mitochondria><Modern Man><Molecular><Molecular Interaction><Morphology><Murine><Mus><Muscle><Muscle Atrophy><Muscle Cells><Muscle Proteins><Muscle Tissue><Muscle function><Muscular Atrophy><Myocytes><Nutrient><Obese Mice><Obesity><Pathway interactions><Physical Performance><Physiology><Platelet Transforming Growth Factor><Predisposition><Proteins><Publishing><RNA Expression><Receptor Inhibition><Receptor Signaling><Regimen><Removal><Rodent><Rodentia><Rodents Mammals><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skeletal Muscle><Structure><Surgical Removal><Susceptibility><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Therapeutic><Therapeutic Agents><Thermogenesis><Thinness><Tissue Growth><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Type II Activin Receptor Like Kinases><Type II Activin Receptors><VO2 max><VO2max><Voluntary Muscle><Weight><Weight Gain><Weight Increase><Weight Loss><Weight Reduction><Withholding Treatment><activin A><adipocyte development><adipocyte differentiation><adipose><adiposity><adult adiposity><adult obesity><adults with obesity><analyze gene expression><anorexic agent><antagonism><antagonist><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><bariatric surgery><biological signal transduction><body weight gain><body weight increase><body weight loss><calorie><cardiometabolic><cardiometabolism><cessation of treatment><cohort><corpulence><dieting><diets><energy balance><erythroid differentiation factor><erythroid differentiation protein><experiment><experimental research><experimental study><experiments><gastric banding><gastric bypass surgery><gastric inhibitory polypeptide receptor><gene expression analysis><gene expression assay><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose-dependent insulinotropic polypeptide receptor><growth-differentiation factor 8><homo-activin A><implantable gastric stimulation banding><improved><in vivo><inhibitor><insulin sensitivity><maximal oxygen uptake><mitochondrial><muscle breakdown><muscle bulk><muscle degradation><muscle deterioration><muscle form><muscle hypertrophy><muscle loss><muscle mass><muscle strength><muscle wasting><muscular><myostatin><next generation><ob/ob mouse><obesity intervention><obesity surgery><obesity therapy><obesity treatment><ontogeny><oxidation><pathway><patient population><pharmacologic><phase 2 study><phase II study><poor health outcome><preservation><reduced health outcome><resection><response><skeletal><skeletal preservation><social role><stomach stapling><synergism><transcriptional profiling><treatment cessation><treatment effect><weight loss surgery><weight maintenance><weights><white adipose tissue><worse health outcome><wt gain><wt-loss><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Candida Joan Rebello

LSU PENNINGTON BIOMEDICAL RESEARCH CTR, BATON ROUGE, LA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$749,481
FY 2026

Project Title

Lifestyle intervention to improve muscle function in older adults

Grant Number:

1R01AG092725-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2026

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT In the United States, nearly one third of adults over 60 years of age have sarcopenic obesity which encompasses the combined effect of muscle impairment and obesity. Inducing loss of fat mass while slowing or preventing loss of skeletal muscle mass and quality are critical f...

Research Terms

<21+ years old><Adherence><Adult><Adult Human><Aerobic Activity><Aerobic Exercise><Aerobic Training><Aerobic fitness><Aeroseb-HC><Age><Age Years><Aging><Behavioral><Biological><Body Composition><Body Weight><Body Weight decreased><Body fat><Caloric Intake><Caloric Restriction><Calorimetry><Carbohydrates><Cetacort><Conscious><Consciousness><Consumption><Cort-Dome><Cortef><Cortenema><Cortisol><Cortispray><Cortril><Creatine><Dermacort><Diet><Diet Composition><Dietary quality><Drug Therapy><Eating><Eldecort><Endocrine Gland Secretion><Energy Intake><Equation><Equilibrium><Excretory function><Exercise><Fats><Fatty acid glycerol esters><Food><Food Intake><GLP-1><Gastric Inhibitory Polypeptide><Glp-1><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Grip strength><Hand><Hand Strength><Health><Hormones><Hydrocortisone><Hydrocortone><Hytone><Impairment><Incidence><Inpatients><Insulin Resistance><Isokinetic Exercise><Isokinetics><Isometric Exercise><Isometrics><Isotonic Exercise><Isotonics><Knee><Leanness><Leptin><Macronutrients><Macronutrients Nutrition><Measures><Mental Health><Mental Hygiene><Metabolic><Methods><Modeling><Muscle><Muscle Tissue><Muscle function><Muscle-Setting Exercise><Musculoskeletal><Nutracort><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Protein><Obesity><Outcome><Participant><Persons><Pharmacological Treatment><Pharmacotherapy><Physical Performance><Pilot Projects><Proctocort><Proteins><Psychological Health><Randomized><Randomized, Controlled Trials><Research><Roentgen Rays><Role><Skeletal Muscle><Static Exercise><Supervision><Testing><Therapeutic Hormone><Thinness><United States><VO2 max><VO2max><Voluntary Muscle><Walking><Weight><Weight Loss><Weight Reduction><X-Radiation><X-Ray Radiation><X-ray><Xray><adiposity><adult adiposity><adult obesity><adulthood><adults with obesity><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><ages><aging population><balance><balance function><biologic><body weight loss><caloric dietary content><calorie restriction><cardiometabolic><cardiometabolism><cardiorespiratory fitness><cardiorespiratory health><cognitive benefits><corpulence><diet and exercise><diet quality><dietary><dietary composition><diets><doubly-labeled water><drug intervention><drug treatment><energy balance><energy density><excretion><exercise intervention><exercise program><feeding><fitness program><frailty><gastric inhibitory peptide><glucagon-like peptide 1><hands><high risk><improved><insight><insulin resistant><insulin sensitivity><insulin tolerance><lean body mass><life style intervention><lifestyle intervention><maximal oxygen uptake><muscle bulk><muscle form><muscle mass><muscle strength><muscular><neurocognitive disorder><older adult><older adulthood><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><physical activity intervention><physical conditioning><physical health><pilot study><population aging><preservation><prevent><preventing><randomisation><randomization><randomized control trial><randomly assigned><resistance exercise><resistance training><sarcopenic obesity><secondary analysis><skeletal muscle atrophy><skeletal muscle breakdown><skeletal muscle loss><skeletal muscle protein loss><skeletal muscle wasting><social role><trend><week trial><weight loss program><weight loss programming><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mojgan Hosseini Naghavi

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$716,595
FY 2026

Project Title

The Role of FEZ Protein Homologs in Early HIV-1 Infection

Grant Number:

5R01AI189411-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/13/2024

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT A critical yet still poorly understood step in HIV-1 infection is the early post-entry trafficking of viral cores across the cytoplasm to reach the nucleus. This requires directed and controlled transport along microtubule filaments by host motor complexes, but precisely how...

Research Terms

<4-3 Hydrophobic Repeat><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Affect><Affinity><Anti-viral Agents><Assay><Avidity><Binding><Bioassay><Biochemical><Biochemistry><Biological Assay><Biological Chemistry><Buckminsterfullerenes><Buckyballs><CC3><Capsid><Capsid Proteins><Cell Body><Cell Nucleus><Cells><Charge><Coat Proteins><Coiled-Coil Domain><Complex><Cone><Crowding><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasm><Cytosol><DNA mutation><Data><Development><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Electron Cryomicroscopy><Elongation Factor><Exhibits><Family member><Filament><Fullerenes><Future><Genetic><Genetic Change><Genetic defect><Genetic mutation><Growing End of the Microtubule><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><HTATIP2 gene><Homologous Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inositol Hexakisphosphate><Inositol Hexaphosphate><Intracellular Transport><Kinases><Kinesin><L-Serine><Left-Handed Twist><Mediating><Micro-tubule><Microtubules><Modeling><Molecular><Molecular Interaction><Motor><Movement><Mutation><Nucleus><Oranges><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Phytic Acid><Plus End of the Microtubule><Predisposition><Process><Protein Family><Protein Homolog><Protein Phosphorylation><ProteinHomolog><Proteins><Publications><Regulation><Reporting><Role><Scientific Publication><Serine><Shapes><Structure><Susceptibility><TIP30><Testing><Transphosphorylases><Viral><Viral Activity><Viral Coat Proteins><Viral Function><Viral Outer Coat Protein><Viral Physiology><Virion><Virus><Virus Particle><adapter protein><antagonism><antagonist><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><body movement><cell type><cofactor><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><differential expression><differentially expressed><genome mutation><human immunodeficiency virus infection><infected with HIV><infected with human immunodeficiency virus><inhibitor><insight><live cell image><live cell imaging><live cellular image><live cellular imaging><member><novel><paralog><paralogous gene><particle><recruit><social role><trafficking><transcriptional differences>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Owen Pornillos

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$716,595
FY 2026

Project Title

The Role of FEZ Protein Homologs in Early HIV-1 Infection

Grant Number:

5R01AI189411-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/13/2024

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT A critical yet still poorly understood step in HIV-1 infection is the early post-entry trafficking of viral cores across the cytoplasm to reach the nucleus. This requires directed and controlled transport along microtubule filaments by host motor complexes, but precisely how...

Research Terms

<4-3 Hydrophobic Repeat><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Affect><Affinity><Anti-viral Agents><Assay><Avidity><Binding><Bioassay><Biochemical><Biochemistry><Biological Assay><Biological Chemistry><Buckminsterfullerenes><Buckyballs><CC3><Capsid><Capsid Proteins><Cell Body><Cell Nucleus><Cells><Charge><Coat Proteins><Coiled-Coil Domain><Complex><Cone><Crowding><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasm><Cytosol><DNA mutation><Data><Development><Dynein><Dynein ATPase><Dynein Adenosine Triphosphatase><Dynein Adenosinetriphosphatase><Electron Cryomicroscopy><Elongation Factor><Exhibits><Family member><Filament><Fullerenes><Future><Genetic><Genetic Change><Genetic defect><Genetic mutation><Growing End of the Microtubule><HIV Infections><HIV viral infection><HIV virus infection><HIV-1><HIV-1 infection><HIV-I><HIV1><HTATIP2 gene><Homologous Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inositol Hexakisphosphate><Inositol Hexaphosphate><Intracellular Transport><Kinases><Kinesin><L-Serine><Left-Handed Twist><Mediating><Micro-tubule><Microtubules><Modeling><Molecular><Molecular Interaction><Motor><Movement><Mutation><Nucleus><Oranges><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Phytic Acid><Plus End of the Microtubule><Predisposition><Process><Protein Family><Protein Homolog><Protein Phosphorylation><ProteinHomolog><Proteins><Publications><Regulation><Reporting><Role><Scientific Publication><Serine><Shapes><Structure><Susceptibility><TIP30><Testing><Transphosphorylases><Viral><Viral Activity><Viral Coat Proteins><Viral Function><Viral Outer Coat Protein><Viral Physiology><Virion><Virus><Virus Particle><adapter protein><antagonism><antagonist><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><body movement><cell type><cofactor><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><differential expression><differentially expressed><genome mutation><human immunodeficiency virus infection><infected with HIV><infected with human immunodeficiency virus><inhibitor><insight><live cell image><live cell imaging><live cellular image><live cellular imaging><member><novel><paralog><paralogous gene><particle><recruit><social role><trafficking><transcriptional differences>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VASSILIKI A BOUSSIOTIS

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$711,511
FY 2026

Project Title

Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy

Grant Number:

5R01CA257672-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PD-1 blocking agents have achieved significant success as anti-cancer therapeutics. The mechanism(s) of how PD-1 compromises anti-tumor function remain poorly understood. Although in trans engagement of PD-1 expressed in T cells by its ligands expressed on APC or cancer cells inhibits T cell activat...

Research Terms

<Ablation><Affect><Antibodies><Antigen-Presenting Cells><Antitumor Response><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B7-1><B7-H1><BB1><Binding><Biochemical><Biopsy><Blood monocyte><CD274><CD28LG><CD28LG1><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD80><CD80 gene><CD8B><CD8B1><CD8B1 gene><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Clinical Trials><Cytoplasmic Domain><Cytoplasmic Tail><Detection><Development><Genes><Human><Immune><Immune Cell Activation><Immune mediated therapy><Immune system><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Individual><Infiltration><Intracellular Communication and Signaling><Knowledge><LAB7><LYT3><Ligands><Macrophage><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Memory><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Murine><Mus><Mφ><Nerve Transmitter Substances><Neurotransmitters><Outcome><PD 1><PD-1><PD-1 blockade><PD-L1><PD1><PD1 blockade><PDL-1><Pathway interactions><Patients><Pattern><Phosphotyrosine><Physiologic><Physiological><Production><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><Proteins><Receptor Protein><Regulatory T-Lymphocyte><Shapes><Signal Induction><Signal Transduction><Signal Transduction Systems><Signaling><T cell response><T memory cell><T-Cell Activation><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T8 Cells><T8 Lymphocytes><Treg><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Tyrosine><Tyrosine-O-phosphate><Work><accessory cell><activate T cells><anti-PD-1 blockade><anti-PD1 blockade><anti-cancer immunotherapy><anti-cancer therapeutic><anti-cancer therapy><anti-tumor immunity><anti-tumor response><anticancer immunotherapy><antitumor immunity><biological signal transduction><cancer cell><cancer immunity><cancer immunotherapy><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer-directed therapy><cell type><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><developmental><exhaustion><fat metabolism><fatty acid oxidation><immune activation><immune check point therapy><immune checkpoint therapy><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved outcome><inhibitor><lipid metabolism><malignancy><memory T lymphocyte><molecular profile><molecular signature><monocyte><neoplasm/cancer><novel><outcome prediction><pathway><peripheral blood><prognostic significance><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><receptor><regulatory T-cells><response><sle2><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor growth><tumor infiltrating T cells><tumor microenvironment>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ioannis Vlachos

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$711,511
FY 2026

Project Title

Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy

Grant Number:

5R01CA257672-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PD-1 blocking agents have achieved significant success as anti-cancer therapeutics. The mechanism(s) of how PD-1 compromises anti-tumor function remain poorly understood. Although in trans engagement of PD-1 expressed in T cells by its ligands expressed on APC or cancer cells inhibits T cell activat...

Research Terms

<Ablation><Affect><Antibodies><Antigen-Presenting Cells><Antitumor Response><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B7-1><B7-H1><BB1><Binding><Biochemical><Biopsy><Blood monocyte><CD274><CD28LG><CD28LG1><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD80><CD80 gene><CD8B><CD8B1><CD8B1 gene><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Clinical Trials><Cytoplasmic Domain><Cytoplasmic Tail><Detection><Development><Genes><Human><Immune><Immune Cell Activation><Immune mediated therapy><Immune system><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Individual><Infiltration><Intracellular Communication and Signaling><Knowledge><LAB7><LYT3><Ligands><Macrophage><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Memory><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Murine><Mus><Mφ><Nerve Transmitter Substances><Neurotransmitters><Outcome><PD 1><PD-1><PD-1 blockade><PD-L1><PD1><PD1 blockade><PDL-1><Pathway interactions><Patients><Pattern><Phosphotyrosine><Physiologic><Physiological><Production><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><Proteins><Receptor Protein><Regulatory T-Lymphocyte><Shapes><Signal Induction><Signal Transduction><Signal Transduction Systems><Signaling><T cell response><T memory cell><T-Cell Activation><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T8 Cells><T8 Lymphocytes><Treg><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Tyrosine><Tyrosine-O-phosphate><Work><accessory cell><activate T cells><anti-PD-1 blockade><anti-PD1 blockade><anti-cancer immunotherapy><anti-cancer therapeutic><anti-cancer therapy><anti-tumor immunity><anti-tumor response><anticancer immunotherapy><antitumor immunity><biological signal transduction><cancer cell><cancer immunity><cancer immunotherapy><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer-directed therapy><cell type><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><developmental><exhaustion><fat metabolism><fatty acid oxidation><immune activation><immune check point therapy><immune checkpoint therapy><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved outcome><inhibitor><lipid metabolism><malignancy><memory T lymphocyte><molecular profile><molecular signature><monocyte><neoplasm/cancer><novel><outcome prediction><pathway><peripheral blood><prognostic significance><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><receptor><regulatory T-cells><response><sle2><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor growth><tumor infiltrating T cells><tumor microenvironment>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KITT F PETERSEN

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$709,296
FY 2026

Project Title

Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes

Grant Number:

5R01DK135645-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/18/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) are emerging as two of the most critical global health challenges of the 21st century. NAFLD is estimated to affect up to one third of the general population, and NAFLD is nearly universally present in patients with T2D, with 75-100%...

Research Terms

<0-11 years old><Address><Adolescent><Adolescent Youth><Adult-Onset Diabetes Mellitus><Affect><Agonist><Antidiabetic Hormone><Body Weight decreased><Child><Child Youth><Children (0-21)><Chronic><Cirrhosis><Clinical Trials><Data><Development><Diabetes Mellitus><Disease><Disorder><Elderly><Fats><Fatty Liver><Fatty acid glycerol esters><GLP-1><General Population><General Public><Glp-1><Glucagon><Glucagon Receptor><Gluconeogenesis><Glukagon><Grant><HG-Factor><Hepatic><Hepatic Disorder><Hepatic mitochondria><Human><Hyperglycemic-Glycogenolytic Factor><Individual><Infusion><Infusion procedures><Insulin Resistance><Ketosis-Resistant Diabetes Mellitus><Lipids><Liver><Liver Mitochondria><Liver Steatosis><Liver diseases><Maturity-Onset Diabetes Mellitus><Measures><Methods><Mitochondria><Modern Man><Muscle Mitochondria><NAFLD><NASH><NHP models><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Participant><Pathogenesis><Patients><Phase><Physiologic><Physiological><Pyruvate Carboxylase><Resolution><Rodent><Rodent Model><Rodentia><Rodents Mammals><Role><Sarcosomes><Science><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Steatohepatitis><T2 DM><T2D><T2DM><Testing><Tracer><Triacylglycerol><Triglycerides><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><Weight Loss><Weight Reduction><adult onset diabetes><advanced age><awake><body weight loss><cirrhotic><developmental><diabetes><fat metabolism><geriatric><global health><glucagon-like peptide 1><glucose biosynthesis><glucose metabolism><hepatic body system><hepatic disease><hepatic gluconeogenesis><hepatic metabolism><hepatic organ system><hepatic steatosis><hepatopathy><hepatosteatosis><infusions><insight><insulin resistant><insulin sensitivity><insulin tolerance><juvenile><juvenile human><ketogenesis><ketosis resistant diabetes><kids><lipid metabolism><liver disorder><liver metabolism><maturity onset diabetes><mitochondrial><mitochondrial metabolism><non-alcohol fatty liver disease><non-alcohol induced steatohepatitis><non-alcoholic fatty liver disease><non-alcoholic liver disease><non-alcoholic steato-hepatitis><non-alcoholic steatohepatitis><nonalcoholic fatty liver disease><nonalcoholic steato-hepatitis><nonalcoholic steatohepatitis><nonhuman primate models><novel><obesity intervention><obesity therapy><obesity treatment><oxidation><pyruvic carboxylase><resolutions><senior citizen><sex><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><type 2 DM><type II DM><type two diabetes><weights><wt-loss><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GERALD I SHULMAN

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$709,296
FY 2026

Project Title

Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes

Grant Number:

5R01DK135645-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/18/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) are emerging as two of the most critical global health challenges of the 21st century. NAFLD is estimated to affect up to one third of the general population, and NAFLD is nearly universally present in patients with T2D, with 75-100%...

Research Terms

<0-11 years old><Address><Adolescent><Adolescent Youth><Adult-Onset Diabetes Mellitus><Affect><Agonist><Antidiabetic Hormone><Body Weight decreased><Child><Child Youth><Children (0-21)><Chronic><Cirrhosis><Clinical Trials><Data><Development><Diabetes Mellitus><Disease><Disorder><Elderly><Fats><Fatty Liver><Fatty acid glycerol esters><GLP-1><General Population><General Public><Glp-1><Glucagon><Glucagon Receptor><Gluconeogenesis><Glukagon><Grant><HG-Factor><Hepatic><Hepatic Disorder><Hepatic mitochondria><Human><Hyperglycemic-Glycogenolytic Factor><Individual><Infusion><Infusion procedures><Insulin Resistance><Ketosis-Resistant Diabetes Mellitus><Lipids><Liver><Liver Mitochondria><Liver Steatosis><Liver diseases><Maturity-Onset Diabetes Mellitus><Measures><Methods><Mitochondria><Modern Man><Muscle Mitochondria><NAFLD><NASH><NHP models><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Participant><Pathogenesis><Patients><Phase><Physiologic><Physiological><Pyruvate Carboxylase><Resolution><Rodent><Rodent Model><Rodentia><Rodents Mammals><Role><Sarcosomes><Science><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Steatohepatitis><T2 DM><T2D><T2DM><Testing><Tracer><Triacylglycerol><Triglycerides><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><Weight Loss><Weight Reduction><adult onset diabetes><advanced age><awake><body weight loss><cirrhotic><developmental><diabetes><fat metabolism><geriatric><global health><glucagon-like peptide 1><glucose biosynthesis><glucose metabolism><hepatic body system><hepatic disease><hepatic gluconeogenesis><hepatic metabolism><hepatic organ system><hepatic steatosis><hepatopathy><hepatosteatosis><infusions><insight><insulin resistant><insulin sensitivity><insulin tolerance><juvenile><juvenile human><ketogenesis><ketosis resistant diabetes><kids><lipid metabolism><liver disorder><liver metabolism><maturity onset diabetes><mitochondrial><mitochondrial metabolism><non-alcohol fatty liver disease><non-alcohol induced steatohepatitis><non-alcoholic fatty liver disease><non-alcoholic liver disease><non-alcoholic steato-hepatitis><non-alcoholic steatohepatitis><nonalcoholic fatty liver disease><nonalcoholic steato-hepatitis><nonalcoholic steatohepatitis><nonhuman primate models><novel><obesity intervention><obesity therapy><obesity treatment><oxidation><pyruvic carboxylase><resolutions><senior citizen><sex><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><type 2 DM><type II DM><type two diabetes><weights><wt-loss><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jung-Im Shin

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$699,322
FY 2026

Project Title

Challenges to Guideline-Recommended Diabetes Care in the United States

Grant Number:

5R01DK139324-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/17/2025

End Date:

11/30/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Modern guidelines recommend novel, effective therapies such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP1RA), and non-steroidal mineralocorticoid antagonists (MRA) in people with diabetes. However, there are significant gaps in adherence to gu...

Research Terms

<Address><Adherence><Age><Agonist><Albuminuria><Area><Attention><Authorization><Authorization documentation><Cardiology><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Cessation of life><Characteristics><Clinical><Coinsurance><Complex><Data><Data Set><Death><Deductibles><Diabetes Mellitus><Drug Therapy><Drugs><ESKD><ESRD><Eligibility><Eligibility Determination><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Endocrinologist><Endocrinology><Ethnic Group><Ethnic Origin><Ethnic People><Ethnic Population><Ethnic individual><Ethnicity><Ethnicity People><Ethnicity Population><Face><Focus Groups><GLP-1 receptor><GLP-I receptor><Geography><Goals><Guidelines><Health><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Health Priorities><Heart Vascular><Hyperglycemia><Individual><Individual Differences><Insurance><Kidney Diseases><Knowledge><Laboratories><Link><Mediating><Mediation><Medicaid><Medicare><Medication><Metabolism and Endocrinology><Methods><Mineralocorticoids><Modeling><Modernization><Monitor><Negotiating><Negotiation><Neighborhoods><Nephrology><Nephropathy><Outcome><Perception><Permission><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Physicians><Policies><Population><Population Research><Population-based research><Population-level research><Prevention><Primary Care><Protocol Screening><Provider><QOC><Quality of Care><Race><Races><Racial Group><Recommendation><Renal Disease><Renin-Angiotensin System><Research><Risk><Risk Reduction><SGLT 2 inhibitor><SGLT2i><Sampling><Socio-economic status><Socioeconomic Status><Sodium glucose co-transporter 2 inhibitor><Specialty><Survey Instrument><Surveys><Testing><Time><Title 18><United States><Variant><Variation><Work><adverse consequence><adverse outcome><age group><ages><antagonism><antagonist><cardiovascular disorder><care outcomes><circulatory system><cohort><copayment><cost><data collected in real world><data warehouse><deprivation><development policy><diabetes><drug intervention><drug treatment><drug/agent><effective therapy><effective treatment><ethnic subgroup><ethnicity group><evidence base><faces><facial><glucagon-like peptide-1 receptor><health care outcomes><health insurance for disabled><high risk><hyperglycemic><improved><improved outcome><indexing><individual patient><inhibitor><investigate population><kidney disorder><medical specialties><novel><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><population investigation><population level investigation><population specific research><prevent><preventing><prior authorization><racial><racial background><racial origin><racial population><racial subgroup><real world data><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><renal disorder><risk-reducing><screening><screenings><sex><social><socio-demographics><socio-economic><socio-economic position><socio-economically><sociodemographics><socioeconomic position><socioeconomically><socioeconomics><studies of populations><study of the population><study population><survey population><uptake>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mandar Deepak Muzumdar

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$692,948
FY 2026

Project Title

Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics

Grant Number:

5R01CA296916-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Incretin mimetics, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), have revolutionized obesity and diabetes treatment, become first-line anti-obesity medications, and may soon be more widely used for other indications including cardiovascular and renal disease ...

Research Terms

<Ablation><Acinar Cell><Aciner Cells><Adverse Experience><Adverse event><Agonist><Anti-Obesity Agents><Anti-Obesity Drugs><Assay><Automobile Driving><B9 endocrine pancreas><Beta Cell><Bioassay><Biological Assay><Body Weight decreased><CCK><Cancers><Cardiovascular Diseases><Cell Body><Cell Communication and Signaling><Cell Function><Cell Growth in Number><Cell Multiplication><Cell Physiology><Cell Process><Cell Proliferation><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Proliferation><Cholecystokinin><Clinical Trials><Computer Analysis><Data><Development><Diabetes Mellitus><Disease><Disorder><Drugs><Duct><Duct (organ) structure><Dysfunction><Endocrine><Endocrine Gland Secretion><Endocrine Pancreas><Enzyme Gene><Enzymes><Equilibrium><Exocrine pancreas><FDA approved><Functional disorder><GEM model><GEMM model><GLP-1><GLP-1 receptor><GLP-I receptor><Genetic><Genetically Engineered Mouse><Glp-1><Health><High Fat Diet><Histologic><Histologically><Hormones><Human><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><In Vitro><Incidence><Insulin Cell><Insulin Secreting Cell><Intercept><Intracellular Communication and Signaling><Islands of Langerhans><Islets of Langerhans><Kidney Diseases><Knock-out><Knockout><Leanness><Link><LoxP-flanked allele><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mediating><Medical><Medication><Metaplasia><Metaplastic Change><Methods><Mice><Mice Mammals><Modern Man><Modernization><Molecular><Murine><Mus><Nephropathy><Nerve Degeneration><Nesidioblasts><Neuron Degeneration><Obesity><Oncogenesis><PDA model><PDAC Model><Pancreas><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Islets><Pancreatitis><Pancreozymin><Pars endocrina pancreatis><Patients><Persons><Pharmaceutical Preparations><Phenotype><Physiologic><Physiological><Physiopathology><Population><Pre-Clinical Model><Preclinical Models><Production><Proliferating><Publishing><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Renal Disease><Reporting><Risk><Risk Factors><Role><Signal Transduction><Signal Transduction Systems><Signaling><Single cell seq><Subcellular Process><System><Testing><Therapeutic Hormone><Thinness><Uropancreozymin><Weight Loss><Weight Reduction><Work><addiction><addictive disorder><adiposity><antagonism><antagonist><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><balance><balance function><bariatric surgery><biological signal transduction><body weight loss><cancer progression><cancer risk><cardiovascular disorder><computational analyses><computational analysis><computer analyses><corpulence><developmental><diabetes><disease prevention><disorder prevention><driving><drug/agent><effective therapy><effective treatment><exocrine pancreatic><experiment><experimental research><experimental study><experiments><feeding><floxed><floxed allele><gastric banding><gastric bypass surgery><genetically engineered mouse model><genetically engineered murine model><glucagon-like peptide 1><glucagon-like peptide-1 receptor><high risk><implantable gastric stimulation banding><improved><in vivo><in vivo Model><interest><islet><kidney disorder><liraglutide><malignancy><mimetics><multi-modality><multimodality><neoplasm progression><neoplasm/cancer><neoplastic progression><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal degeneration><obesity intervention><obesity risk><obesity surgery><obesity therapy><obesity treatment><pancreatic carcinogenesis><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic oncogenesis><pancreatic tumorigenesis><pathophysiology><pharmacologic><pre-clinical><preclinical><receptor><renal disorder><risk for obesity><risk of obesity><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell next generation sequencing><single cell sequencing><single cell transcriptomic profiling><single-cell RNA sequencing><social role><stomach stapling><transcriptome sequencing><transcriptomic sequencing><tumor><tumor progression><tumorigenesis><tumorigenic><weight loss surgery><wt-loss><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

AMBER L BEITELSHEES

UNIVERSITY OF MARYLAND BALTIMORE, BALTIMORE, MD

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$672,063
FY 2026

Project Title

Pharmacogenetics of the Response to a GLP1R Agonist

Grant Number:

5R01DK130238-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Glucagon-like peptide 1 receptor (GLP1R) agonists are an important class of antidiabetic drugs with an attractive clinical profile – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. While there is substantial variation in the magnitude of i...

Research Terms

<Acceleration><Adult-Onset Diabetes Mellitus><After Care><After-Treatment><Aftercare><Agonist><American><Amish><Amputation><Anti-diabetic Agents><Anti-diabetic Drugs><Biological Markers><Blindness><Blood Plasma><Body Weight decreased><Bolus><Bolus Infusion><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Circulation><Clinical><Clinical Trials><County><D-Glucose><DNA Sequence><Data><Dextrose><Diabetes Mellitus><Diabetic Angiopathies><Diabetic Vascular Complications><Diabetic Vascular Diseases><Diabetic Vascular Disorder><Diet><Dose><Drug Prescribing><Drug Prescriptions><Drugs><ESKD><ESRD><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Environmental Factor><Environmental Risk Factor><European><Evaluation><Event><Exercise><Frequencies><GLP-1 receptor><GLP-I receptor><GWA study><GWAS><Gene variant><General Population><General Public><Genetic><Genetic Anticipation><Genetic Markers><Genetic study><Genotype><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Head><Heart Vascular><Hemoglobin A(1)><IVGTT><Individual><Ketosis-Resistant Diabetes Mellitus><Literature><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Mediating><Mediation><Medication><NHLBI><NIDDM><National Heart, Lung, and Blood Institute><Negotiating><Negotiation><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Outcome><Overweight><Participant><Patients><Pharmaceutical Preparations><Pharmacodynamics><Pharmacogenetics><Pharmacogenomics><Phase><Physicians><Physiologic><Physiological><Plasma><Plasma Serum><Population><Principal Investigator><Property><Publishing><Reporting><Research><Research Subjects><Reticuloendothelial System, Serum, Plasma><Risk><Sampling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><T2 DM><T2D><T2DM><TOPMed><Trans-Omics for Precision Medicine><Type 2 Diabetes Mellitus><Type 2 diabetes><Type 2 diabetic><Type II Diabetes Mellitus><Type II diabetes><Type II diabetic><Variant><Variation><Weight Loss><Weight Reduction><adiposity><adult onset diabetes><allelic variant><anti-diabetic><bio-markers><biologic marker><biomarker><biomarker identification><body weight loss><circulatory system><clinical predictors><clopidogrel><corpulence><cost><density><design><designing><diabetes><diabetic patient><diets><drug/agent><dynamic mutation><entire genome><environmental risk><experience><full genome><gene biomarker><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genome wide association><genome wide association scan><genome wide association study><genomewide association scan><genomewide association study><genomic variant><glucagon-like peptide-1 receptor><glucose metabolism><glycemic control><healthy volunteer><hemoglobin A1c><identification of biomarkers><identification of new biomarkers><improved><individual patient><individual response><individualized response><insulin secretion><intravenous administration><intravenous glucose tolerance><intravenous glucose tolerance test><ketosis resistant diabetes><liraglutide><logarithm><logarithmic><marker identification><maturity onset diabetes><medication prescription><microvascular complications of diabetes><non-diabetic><nondiabetic><optimal therapies><optimal treatments><patient population><patient response><patient specific response><pharmacologic><post treatment><precision medicine><precision-based medicine><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><prescribed medication><primary end point><primary endpoint><programs><recruit><response><responsive patient><side effect><subcutaneous><subdermal><type 2 DM><type II DM><type two diabetes><vision loss><visual loss><volunteer><whole genome><whole genome association analysis><whole genome association study><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SIMEON I. TAYLOR

UNIVERSITY OF MARYLAND BALTIMORE, BALTIMORE, MD

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$672,063
FY 2026

Project Title

Pharmacogenetics of the Response to a GLP1R Agonist

Grant Number:

5R01DK130238-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2021

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Glucagon-like peptide 1 receptor (GLP1R) agonists are an important class of antidiabetic drugs with an attractive clinical profile – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. While there is substantial variation in the magnitude of i...

Research Terms

<Acceleration><Adult-Onset Diabetes Mellitus><After Care><After-Treatment><Aftercare><Agonist><American><Amish><Amputation><Anti-diabetic Agents><Anti-diabetic Drugs><Biological Markers><Blindness><Blood Plasma><Body Weight decreased><Bolus><Bolus Infusion><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Circulation><Clinical><Clinical Trials><County><D-Glucose><DNA Sequence><Data><Dextrose><Diabetes Mellitus><Diabetic Angiopathies><Diabetic Vascular Complications><Diabetic Vascular Diseases><Diabetic Vascular Disorder><Diet><Dose><Drug Prescribing><Drug Prescriptions><Drugs><ESKD><ESRD><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Environmental Factor><Environmental Risk Factor><European><Evaluation><Event><Exercise><Frequencies><GLP-1 receptor><GLP-I receptor><GWA study><GWAS><Gene variant><General Population><General Public><Genetic><Genetic Anticipation><Genetic Markers><Genetic study><Genotype><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Head><Heart Vascular><Hemoglobin A(1)><IVGTT><Individual><Ketosis-Resistant Diabetes Mellitus><Literature><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Mediating><Mediation><Medication><NHLBI><NIDDM><National Heart, Lung, and Blood Institute><Negotiating><Negotiation><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Outcome><Overweight><Participant><Patients><Pharmaceutical Preparations><Pharmacodynamics><Pharmacogenetics><Pharmacogenomics><Phase><Physicians><Physiologic><Physiological><Plasma><Plasma Serum><Population><Principal Investigator><Property><Publishing><Reporting><Research><Research Subjects><Reticuloendothelial System, Serum, Plasma><Risk><Sampling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><T2 DM><T2D><T2DM><TOPMed><Trans-Omics for Precision Medicine><Type 2 Diabetes Mellitus><Type 2 diabetes><Type 2 diabetic><Type II Diabetes Mellitus><Type II diabetes><Type II diabetic><Variant><Variation><Weight Loss><Weight Reduction><adiposity><adult onset diabetes><allelic variant><anti-diabetic><bio-markers><biologic marker><biomarker><biomarker identification><body weight loss><circulatory system><clinical predictors><clopidogrel><corpulence><cost><density><design><designing><diabetes><diabetic patient><diets><drug/agent><dynamic mutation><entire genome><environmental risk><experience><full genome><gene biomarker><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genome wide association><genome wide association scan><genome wide association study><genomewide association scan><genomewide association study><genomic variant><glucagon-like peptide-1 receptor><glucose metabolism><glycemic control><healthy volunteer><hemoglobin A1c><identification of biomarkers><identification of new biomarkers><improved><individual patient><individual response><individualized response><insulin secretion><intravenous administration><intravenous glucose tolerance><intravenous glucose tolerance test><ketosis resistant diabetes><liraglutide><logarithm><logarithmic><marker identification><maturity onset diabetes><medication prescription><microvascular complications of diabetes><non-diabetic><nondiabetic><optimal therapies><optimal treatments><patient population><patient response><patient specific response><pharmacologic><post treatment><precision medicine><precision-based medicine><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><prescribed medication><primary end point><primary endpoint><programs><recruit><response><responsive patient><side effect><subcutaneous><subdermal><type 2 DM><type II DM><type two diabetes><vision loss><visual loss><volunteer><whole genome><whole genome association analysis><whole genome association study><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Megan Horn Orzalli

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$671,097
FY 2026

Project Title

Regulation of the NLRP1 inflammasome by HSV-1

Grant Number:

5R01AI182052-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/12/2024

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary. The goals of this project are to identify how herpes simplex virus 1 (HSV-1) activates and inhibits the NLRP1 inflammasome pathway and to understand the contribution of NLRP1 to antiviral defense in human skin. NLRP1 is a guard protein expressed in human keratinocytes that detects p...

Research Terms

<Agonist><Bacterial Infections><Biology><Cell Body><Cell Communication and Signaling><Cell Death Process><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Stress><Cellular Stress Response><Complex><Cullin Domain Protein><Cullin Family Gene><Cullin Family Protein><Cullin Proteins><Cullins><Cutaneous><Cutaneous viral infections><Cytoplasm><Dermal><Development><E3 Ligase><E3 Ubiquitin Ligase><Economics><Epithelium><Event><Fibroblasts><Goals><HSV-1><HSV1><Herpes Simplex><Herpes Simplex Infections><Herpes Simplex Type 1><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes simplex disease><Herpesvirus 1><Herpesvirus hominis disease><Human><Immediate-Early Proteins><Immune><Immunes><Immunology><Infection><Inflammasome><Inflammatory><Innate Immune Response><Intracellular Communication and Signaling><Knowledge><MAP Kinase Kinase Kinase><MAP kinase><MAP3 Kinases><MAPKKKs><Mediating><Mitogen-Activated Protein Kinase Kinase Kinases><Mitogen-Activated Protein Kinases><Modeling><Modern Man><Molecular><Monitor><N-terminal><NH2-terminal><Organ><Pathogen detection><Pathogenesis><Pathogenicity Factors><Pathway interactions><Phosphorylation><Phosphorylation Site><Population><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Preventative strategy><Prevention strategy><Preventive strategy><Productivity><Protein Modification><Protein Phosphorylation><Protein Region><Proteins><RNA Virus Infections><RNA viral infection><Regulation><Research><Role><Signal Induction><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Stimulus><Subcellular Process><System><Testing><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Viral><Viral Diseases><Viral Skin Diseases><Viral skin infections><Virulence Factors><Virus><Virus Activation><Virus Diseases><Virus Induction><bacteria infection><bacterial disease><biological signal transduction><cell stress><cell type><defined contribution><developmental><economic><herpes simplex i><herpes simplex virus 1 infection><herpes simplex virus infection><herpes simplex-1><human model><human pathogen><innate immune pathways><innovate><innovation><innovative><insight><keratinocyte><model of human><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathogen><pathway><response><restraint><sensor><social role><stress activated protein kinase><success><therapeutic target><treatment strategy><ubiquitin ligase><ubiquitin-protein ligase><viral activation><viral induction><viral infection><virus infection><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Taofeek K Owonikoko

UNIVERSITY OF MARYLAND BALTIMORE, BALTIMORE, MD

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$646,115
FY 2026

Project Title

Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer

Grant Number:

5R01CA273216-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Small cell lung cancer (SCLC) is a significant health problem projected to afflict more than 35,000 new patients in the US in 2021. Less than 20% of newly diagnosed patients survive beyond 2 years. New and effective treatments are urgently needed to improve the poor outcome ...

Research Terms

<AI system><Animal Model><Animal Models and Related Studies><Anti-Oncogenes><Antioncogene Protein p53><Antioncogenes><Apoptotic><Applications Grants><Artificial Intelligence><Avian Myelocytomatosis Viral Oncogene Homolog><B7-H1><Bayesian Method><Bayesian Methodology><Bayesian Statistical Method><Bayesian approaches><Bayesian classification method><Bayesian classification procedure><Bayesian posterior distribution><Biological><Biological Markers><CD274><Cancer Genes><Cancer Patient><Cancer Suppressor Genes><Cancer cell line><Cancer-Promoting Gene><Cancers><Cell Line><CellLine><Cellular Tumor Antigen P53><Characteristics><Clinical Trials><Clinical Trials Design><Collecting Cell><Computer Reasoning><DNA Alteration><DNA Sequence Alteration><DNA mutation><DNA seq><DNA sequencing><DNAseq><Data><Dependence><Development><Disease><Disorder><Drug Targeting><Emerogenes><Enzyme Antagonist><Enzyme Inhibitor><Enzyme Inhibitor Agent><Enzyme Inhibitor Drugs><Frustration><Gene Alteration><Gene Expression><Gene Mutation><Gene Transcription><Genetic><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genomics><Genotype><Grant Proposals><Health><Heterograft><Heterologous Transplantation><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Lytotoxicity><MYC gene><Machine Intelligence><Machine Learning><Malignant Neoplasms><Malignant Tumor><Metabolic><Modeling><Molecular><Mutation><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Neoplasm Circulating Cells><Newly Diagnosed><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Oat cell carcinoma><Onco-Suppressor Genes><Oncogenes><Oncogenes-Tumor Suppressors><Oncoprotein p53><Outcome><P53><PD-1 antibody><PD-L1><PD1 antibody><PDL-1><PDX model><PLK Gene><PLK1><PLK1 gene><Pathway interactions><Patient derived xenograft><Patients><Performance><Phase><Phase 2 Clinical Trials><Phase II Clinical Trials><Phosphoprotein P53><Phosphoprotein pp53><Polo-Like Kinase><Pre-Clinical Model><Preclinical Models><Prognosis><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein TP53><RB1><RB1 gene><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Recurrent disease><Relapse><Relapsed Disease><Reproducibility><Resistance><STPK13><Sampling><Sequence Alteration><Serine/Threonine Protein Kinase 13><Small Cell Lung Cancer><Strains Cell Lines><TP53><TP53 gene><TRP53><Testing><Therapeutic><Tissue Sample><Transcription><Transforming Genes><Treatment Efficacy><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressing Genes><Tumor Suppressor Genes><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><aPD-1><aPD1><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-cancer><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><bio-markers><biologic><biologic marker><biomarker><biomarker validation><check point blockade><checkpoint blockade><chemotherapy><circulating neoplastic cell><circulating tumor cell><clinical efficacy><co-clinical trial><cultured cell line><cytotoxicity><determine efficacy><developmental><drug development><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><gene defect><genome mutation><genomic alteration><genomic data><genomic dataset><genomic profiles><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><in vitro activity><in vivo><inhibitor><innovate><innovation><innovative><insight><intervention efficacy><lung oat cell carcinoma><lung small cell neuroendocrine carcinoma><machine based learning><machine learned algorithm><machine learning algorithm><machine learning based algorithm><malignancy><marker validation><model of animal><mouse model><murine model><mutant><mutant allele><myc Oncogenes><neoplasm/cancer><new approaches><new drug combination><new drug treatments><new drugs><new pharmacological therapeutic><new pharmacotherapy combination><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel approaches><novel drug combination><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy combination><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oat cell cancer><oncosuppressor gene><overexpress><overexpression><p53 Antigen><p53 Genes><p53 Tumor Suppressor><participant enrollment><pathway><patient biomarkers><patient derived xenograft model><patient enrollment><phase II protocol><polo-like kinase 1><pre-clinical><pre-clinical assessment><pre-clinical efficacy><preclinical><preclinical assessment><preclinical efficacy><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><protein expression><protein p53><resistance mechanism><resistant><resistant mechanism><retinoblastoma-1><screening><screenings><small cell lung carcinoma><small cell undifferentiated carcinoma><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapy efficacy><therapy optimization><transcriptome sequencing><transcriptomic sequencing><treatment optimization><tumor><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SAMUEL H. GELLMAN

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$643,125
FY 2026

Project Title

Processes mediated by polypeptides

Grant Number:

5R35GM151985-03

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

SUMMARY The proposed research focuses on processes that are mediated by proteins, that are crucial for cellular physiology and that are dysregulated in human disease. This effort has two components that differ topically but share common themes in experimental design. Fundamental mechanistic insight...

Research Terms

<Address><Adult-Onset Diabetes Mellitus><Agonist><Antidiabetic Hormone><Biopolymers><Cell Body><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cell Surface Receptors><Cells><Cellular Function><Cellular Physiology><Cellular Process><Circulatory Collapse><Degenerative Neurologic Disorders><Diabetes Mellitus><Disease><Disorder><Evaluation><Experimental Designs><Family><Foundations><Future><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GLP-1><GLP-2 receptor><GLP-2R><GPCR><Glp-1><Glucagon><Glucagon Receptor><Glukagon><Goals><HG-Factor><Human><Hyperglycemic-Glycogenolytic Factor><Hypoglycemia><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Liquid substance><Maturity-Onset Diabetes Mellitus><Mediating><Medicine><Membrane><Modeling><Modern Man><Molecular><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><NIDDM><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Non-Polyadenylated RNA><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Organelles><Osteoporosis><Outcome><PTH-PTHrP Receptor><PTH-Related Peptide Receptor><PTH-Related Protein Receptor><PTH1 receptor><PTHLP Receptor><PTHrP Receptor><Parathyroid Hormone Receptor><Parathyroid Hormone Receptor 1><Parathyroid Hormone Receptor Type I><Parathyroid Hormone-Like Peptide Receptor><Parathyroid Hormone-Related Peptide Receptor><Patients><Peptide-based drug><Peptides><Phase><Physiology><Play><Polypeptide Hormones><Process><Proteins><RNA><RNA Gene Products><Receptor Protein><Research><Ribonucleic Acid><Role><Shock><Short Bowel Syndrome><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Subcellular Process><T2 DM><T2D><T2DM><Testing><Therapeutic><Transcend><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Work><adult onset diabetes><alpha helix><biological signal transduction><chemical synthesis><circulatory shock><conformation><conformational><conformational state><conformationally><conformations><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><diabetes><dynamical evolution><fluid><glucagon-like peptide 1><human disease><hypoglycemic><hypoglycemic episodes><insight><ketosis resistant diabetes><liquid><maturity onset diabetes><membrane structure><neurodegenerative illness><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><peptide drug><polypeptide><receptor><receptor binding><receptor bound><shocks><short gut syndrome><social role><therapeutic peptide><type 2 DM><type II DM><type two diabetes><α-helix>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Todd Michael Brusko

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$590,577
FY 2026

Project Title

The CD226 costimulatory axis in type 1 diabetes

Grant Number:

5R01DK106191-09

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2016

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT. Type 1 diabetes (T1D) results from complex interactions between over 150 independent loci imparting disease susceptibility and environmental factors that break immune tolerance, leading to the immune- mediated destruction of insulin-producing pancreatic -cells. Among these exists a small ...

Research Terms

<AKT><ATGAM><Adoptive Cell Transfers><Adoptive Transfer><Akt protein><Animals><Antigen-Presenting Cells><Antigens><Antithymocyte Globulin><Antithymoglobulin><Assay><Atrophic Arthritis><Attenuated><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Beta Cell><Binding><Bioassay><Biological><Biological Assay><Blocking Antibodies><Blood Sample><Blood specimen><Body Tissues><Brittle Diabetes Mellitus><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Candidate Disease Gene><Candidate Gene><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Function><Cell Isolation><Cell Lineage><Cell Physiology><Cell Process><Cell Segregation><Cell Separation><Cell Separation Technology><Cell Signaling><Cells><Cellular Function><Cellular Immune Function><Cellular Physiology><Cellular Process><Chimera Protein><Chimeric Proteins><Class II Antigens><Class II Major Histocompatibility Antigens><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><Complex><Cytokine Signal Transduction><Cytokine Signaling><DNA Molecular Biology><Data><Defect><Development><Diabetes Mellitus><Diabetes prevention><Diathesis><Disease><Disease Progression><Disease susceptibility><Disorder><Disseminated Sclerosis><Dose><Environmental Factor><Environmental Risk Factor><Female><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Frequencies><Fusion Protein><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transfer><Gene Transfer Techniques><Genes><Genetic><Genetic Diseases><Genetic Risk><Genome><Genomics><Genotype><Goals><Grant><HL-A Antigens><HLA Antigens><Histocompatibility Antigens Class II><Histology><Human><Human Leukocyte Antigens><Humulin R><I-A Antigen><IDDM><Ia Antigens><Ia-Like Antigens><Image><Immune><Immune Response Antigens><Immune Tolerance><Immune destruction><Immune mediated destruction><Immune-Response-Associated Antigens><Immunes><Immunologic Tolerance><Immunomodulation><In Situ><In Vitro><Inbred NOD Mice><Incidence><Individual><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Intervention><Intracellular Communication and Signaling><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knock-out><Knockout><Leukocyte Antigens><Link><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic cell><Lymphatic nodes><Lymphocyte><Lymphocyte Function><Lymphocytic><Lytotoxicity><MHC Class II Molecule><MHC Class II Protein><MHC Receptor><MHC class II antigen><Major Histocompatibility Complex Class II><Major Histocompatibility Complex Receptor><Methods><Modeling><Modern Man><Modernization><Molecular><Molecular Biology><Molecular Interaction><Multiple Sclerosis><NOD Mouse><Natural History><Non obese><Non-Obese Diabetic Mice><Nonobese><Nonobese Diabetic Mouse><Novolin R><OKT3 antigen><Organ Donor><Pancreas><Pancreatic><Pathogenesis><Pathway interactions><Peripheral><Phase><Phenotype><Preclinical data><Protein Kinase B><Proteins><Proto-Oncogene Proteins c-akt><Publishing><RAC-PK protein><Regular Insulin><Regulatory T-Lymphocyte><Rheumatoid Arthritis><Risk><Risk-associated variant><Role><Safety><Sampling><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spleen><Spleen Reticuloendothelial System><Subcellular Process><Sudden-Onset Diabetes Mellitus><T-Cell Antigen Receptors><T-Cell Receptor><T-Cell Receptor Genes><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T1 DM><T1 diabetes><T1D><T1DM><T3 Antigens><T3 Complex><T3 molecule><T8 Cells><T8 Lymphocytes><TcR Genes><Teff cell><Testing><Th-1 Cell><Th1 Cells><Therapeutic Intervention><Thymoglobulin><Tissue Donors><Tissue imaging><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Transgenesis><Treg><Type 1 Diabetes Mellitus><Type 1 Helper Cell><Type 1 diabetes><Type I Diabetes Mellitus><Variant><Variation><accessory cell><adoptive cell therapy><adoptive cellular therapy><analyze gene expression><attenuate><attenuates><autoimmune condition><autoimmune disorder><autoimmune reactivity><autoimmunity disease><autoreactive T cell><autoreactivity><biologic><biological signal transduction><c-akt protein><cell killing><cell sorting><conditional knock-out><conditional knockout><cross-sectional investigation><cross-sectional research><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><cytotoxicity><developmental><diabetes><diabetes pathogenesis><diabetic><diabetogenic><draining lymph node><drug mechanism><effector T cell><environmental risk><experiment><experimental research><experimental study><experiments><flow cytophotometry><gene expression analysis><gene expression assay><gene locus><genetic condition><genetic disorder><genetic locus><genomic location><genomic locus><human tissue><imaging><immune check point><immune checkpoint><immune function><immune modulation><immune regulation><immune system tolerance><immune unresponsiveness><immunecheckpoint><immunogen><immunologic reactivity control><immunological paralysis><immunomodulatory><immunoregulation><immunoregulatory><in vivo><in vivo Model><insight><insular sclerosis><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><insulitis><intervention therapy><investigate cross-sectional><islet><islet autoantibody><islet cell antibody><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><knock-out animal><knockout animal><knockout gene><liability to disease><lymph cell><lymph gland><lymph nodes><lymphnodes><mouse model><multiomics><multiple omics><murine model><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><panomics><pathway><peripheral blood><peripheral tolerance><preclinical findings><preclinical information><prevent><preventing><programs><protective allele><protective variant><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><regional lymph node><regulatory T-cells><related to A and C-protein><rheumatic arthritis><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><self-reactive T cell><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><study cross-sectional><survey cross-sectional><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic candidate><therapeutic target><thymus derived lymphocyte><trafficking><transcriptional profiling><translational opportunities><translational potential><type 1 diabetes onset><type I diabetes><type one diabetes><β-cell><β-cells><βCell><♀>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BYRON D. FORD

MOREHOUSE SCHOOL OF MEDICINE, ATLANTA, GA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$555,227
FY 2026

Project Title

Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae

Grant Number:

5R01NS125775-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Human cerebral malaria (HCM) is a severe form of Plasmodium falciparum (P.f.) malaria associated with ~500,000 deaths in children annually and impaired brain function in some survivors. HCM is characterized by sequestration of parasitized red blood cells (pRBCs) in cerebral micro-circulation and ind...

Research Terms

<0-11 years old><3-D><3-Dimensional><3D><AKT><ANG1><ANG1 Gene><ANGPT1><ANGPT1 gene><Acetylcholine Receptor Inducing Activity><Acquired brain injury><After Care><After-Treatment><Aftercare><Akt protein><Algorithms><Ang-2><Ang2><Angiopoietin 1 Gene><Angiopoietin-1><Angiopoietin-2><Animal Model><Animal Models and Related Studies><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antibodies><Apoptosis><Apoptosis Pathway><Apoptotic><Attenuated><Autopsy><B7-H1><BALB C Mouse><BALB/c><Behavioral><Blood - brain barrier anatomy><Blood Serum><Blood brain barrier dysfunction><Blood erythrocyte><Blood monocyte><Blood-Brain Barrier><Body Tissues><Brain><Brain Edema><Brain Inflammation><Brain Injuries><Brain Nervous System><Brain Swelling><Breast Cancer Cell Differentiation Factor P45><CD274><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CRG-2><CXCL10><CXCL10 gene><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cell-Extracellular Matrix><Cellular injury><Cerebral Malaria><Cerebrum><Cessation of life><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Clinical Trials><Cognition><Collaborations><Coma><Comatose><Conscious><Consciousness><Cytolysis><Death><Dendritic Cells><Disease><Disorder><ECM><Encephalitis><Encephalon><Epithelial Cells><ErbB-4><ErbB4><ErbB4 gene><Erythrocytes><Erythrocytic><Ethics><Extracellular Matrix><Falciparum Malaria><Fatal Outcome><Ferroprotoporphyrin><Fusion Protein><Gene Expression><Gene variant><Genes><Goals><HER-4><HER4><HO-1 enzyme><HO1><HO2><HRP-2 protein><HSP32><Heart failure><Hemato-Encephalic Barrier><Heme><Host Factor><Host Factor Protein><Human><Human Experimentation><IFI10><IFN><INP10><IP-10><Impairment><In Vitro><Inbred BALB C Mice><Induction of Apoptosis><Infection><Inflammasome><Inflammation><Inflammation Mediators><Inflammatory><Integration Host Factors><Interferons><Intracellular Communication and Signaling><Intracranial Edema><Intravenous><KIAA0003><LYT3><Lysis><MMPs><MOB-1><MR Imaging><MR Tomography><MRI><MRIs><MT-bound tau><Magnetic Resonance Imaging><Malaria><Marrow erythrocyte><Marrow monocyte><Matrix Metalloproteinases><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Mice><Mice Mammals><Microcirculation><Modeling><Modern Man><Murine><Mus><NDF Protein><NDF/Heregulin Receptor Gene><NMR Imaging><NMR Tomography><NRG1 Gene Product><NRG1 Protein><Neuregulin 1><Neuronal Injury><Neuropeptides><Nuclear Magnetic Resonance Imaging><O-methyldihydroartemisinine><Organoids><P falciparum><P. falciparum><P.falciparum><PD 1><PD-1><PD-1 blockade><PD-1/PD-L1><PD-1/PDL1><PD-L1><PD1><PD1 blockade><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL-1><Paludism><Parasites><Participant><Pathogenesis><Peptides><Peripheral Blood Lymphocyte><Phosphorylation><Plasmodium Infections><Plasmodium berghei><Plasmodium falciparum><Plasmodium falciparum Malaria><Predisposition><Production><Programmed Cell Death><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Kinase B><Protein Phosphorylation><Proto-Oncogene Proteins c-akt><Protoheme><RAC-PK protein><Receptor Protein><Recovery><Red Blood Cells><Red Cell><Regulatory Pathway><Reporting><Resistance><Role><SCYB10><STAT3><STAT3 gene><Sensory And Motor Neuron-Derived Factor><Serum><Severities><Severity of illness><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Survival Rate><Survivors><Susceptibility><T-Cell Activation><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Therapeutic Agents><Tissues><Translating><Urine><Veiled Cells><Zeugmatography><abnormal brain function><activate T cells><allelic variant><anti-PD-1 blockade><anti-PD1 blockade><artemether><assess effectiveness><attenuate><attenuates><attenuation><biological signal transduction><blood corpuscles><bloodbrain barrier><brain damage><brain dysfunction><brain endothelial cell><brain impairment><brain microvascular endothelial cell><brain tissue><brain vascular endothelial cell><brain-injured><c-akt protein><cardiac failure><cell culture><cell cultures><cell damage><cell injury><cellular damage><cerebral><cerebral endothelial cell><cerebral microvascular endothelial cell><cerebral vascular endothelial cell><damage to cells><determine effectiveness><disease prognosis><disease prognostication><disease severity><dysfunctional brain><effectiveness assessment><effectiveness evaluation><ethical><evaluate effectiveness><examine effectiveness><ferroheme><gIP-10><genetic variant><genomic variant><heme oxygenase-1><hemeoxygenase 1><hiPSC><histidine-rich protein 2><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><human progenitor cell derived><human stem cell-derived><human subject><iPS><iPSC><iPSCs><improved><in vitro Model><induced human pluripotent stem cells><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><inflammatory mediator><injury to cells><kids><microtubule bound tau><microtubule-bound tau><model of animal><monocyte><mortality><necropsy><neglect><neuro-vascular unit><neurobehavioral><neuron injury><neurovascular unit><plasmodium histidine-rich protein II><post treatment><postmortem><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><prospective><protein death-ligand 1><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><receptor><recruit><related to A and C-protein><resistant><rodent plasmodia><sle2><social role><systemic lupus erythematosus susceptibility 2><tau><tau Proteins><tau factor><three dimensional><thymus derived lymphocyte><wet brain><youngster><τ Proteins>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jonathan K. Stiles

MOREHOUSE SCHOOL OF MEDICINE, ATLANTA, GA

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$555,227
FY 2026

Project Title

Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae

Grant Number:

5R01NS125775-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Human cerebral malaria (HCM) is a severe form of Plasmodium falciparum (P.f.) malaria associated with ~500,000 deaths in children annually and impaired brain function in some survivors. HCM is characterized by sequestration of parasitized red blood cells (pRBCs) in cerebral micro-circulation and ind...

Research Terms

<0-11 years old><3-D><3-Dimensional><3D><AKT><ANG1><ANG1 Gene><ANGPT1><ANGPT1 gene><Acetylcholine Receptor Inducing Activity><Acquired brain injury><After Care><After-Treatment><Aftercare><Akt protein><Algorithms><Ang-2><Ang2><Angiopoietin 1 Gene><Angiopoietin-1><Angiopoietin-2><Animal Model><Animal Models and Related Studies><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antibodies><Apoptosis><Apoptosis Pathway><Apoptotic><Attenuated><Autopsy><B7-H1><BALB C Mouse><BALB/c><Behavioral><Blood - brain barrier anatomy><Blood Serum><Blood brain barrier dysfunction><Blood erythrocyte><Blood monocyte><Blood-Brain Barrier><Body Tissues><Brain><Brain Edema><Brain Inflammation><Brain Injuries><Brain Nervous System><Brain Swelling><Breast Cancer Cell Differentiation Factor P45><CD274><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CRG-2><CXCL10><CXCL10 gene><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cell-Extracellular Matrix><Cellular injury><Cerebral Malaria><Cerebrum><Cessation of life><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Clinical Trials><Cognition><Collaborations><Coma><Comatose><Conscious><Consciousness><Cytolysis><Death><Dendritic Cells><Disease><Disorder><ECM><Encephalitis><Encephalon><Epithelial Cells><ErbB-4><ErbB4><ErbB4 gene><Erythrocytes><Erythrocytic><Ethics><Extracellular Matrix><Falciparum Malaria><Fatal Outcome><Ferroprotoporphyrin><Fusion Protein><Gene Expression><Gene variant><Genes><Goals><HER-4><HER4><HO-1 enzyme><HO1><HO2><HRP-2 protein><HSP32><Heart failure><Hemato-Encephalic Barrier><Heme><Host Factor><Host Factor Protein><Human><Human Experimentation><IFI10><IFN><INP10><IP-10><Impairment><In Vitro><Inbred BALB C Mice><Induction of Apoptosis><Infection><Inflammasome><Inflammation><Inflammation Mediators><Inflammatory><Integration Host Factors><Interferons><Intracellular Communication and Signaling><Intracranial Edema><Intravenous><KIAA0003><LYT3><Lysis><MMPs><MOB-1><MR Imaging><MR Tomography><MRI><MRIs><MT-bound tau><Magnetic Resonance Imaging><Malaria><Marrow erythrocyte><Marrow monocyte><Matrix Metalloproteinases><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Mice><Mice Mammals><Microcirculation><Modeling><Modern Man><Murine><Mus><NDF Protein><NDF/Heregulin Receptor Gene><NMR Imaging><NMR Tomography><NRG1 Gene Product><NRG1 Protein><Neuregulin 1><Neuronal Injury><Neuropeptides><Nuclear Magnetic Resonance Imaging><O-methyldihydroartemisinine><Organoids><P falciparum><P. falciparum><P.falciparum><PD 1><PD-1><PD-1 blockade><PD-1/PD-L1><PD-1/PDL1><PD-L1><PD1><PD1 blockade><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL-1><Paludism><Parasites><Participant><Pathogenesis><Peptides><Peripheral Blood Lymphocyte><Phosphorylation><Plasmodium Infections><Plasmodium berghei><Plasmodium falciparum><Plasmodium falciparum Malaria><Predisposition><Production><Programmed Cell Death><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Kinase B><Protein Phosphorylation><Proto-Oncogene Proteins c-akt><Protoheme><RAC-PK protein><Receptor Protein><Recovery><Red Blood Cells><Red Cell><Regulatory Pathway><Reporting><Resistance><Role><SCYB10><STAT3><STAT3 gene><Sensory And Motor Neuron-Derived Factor><Serum><Severities><Severity of illness><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Survival Rate><Survivors><Susceptibility><T-Cell Activation><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Therapeutic Agents><Tissues><Translating><Urine><Veiled Cells><Zeugmatography><abnormal brain function><activate T cells><allelic variant><anti-PD-1 blockade><anti-PD1 blockade><artemether><assess effectiveness><attenuate><attenuates><attenuation><biological signal transduction><blood corpuscles><bloodbrain barrier><brain damage><brain dysfunction><brain endothelial cell><brain impairment><brain microvascular endothelial cell><brain tissue><brain vascular endothelial cell><brain-injured><c-akt protein><cardiac failure><cell culture><cell cultures><cell damage><cell injury><cellular damage><cerebral><cerebral endothelial cell><cerebral microvascular endothelial cell><cerebral vascular endothelial cell><damage to cells><determine effectiveness><disease prognosis><disease prognostication><disease severity><dysfunctional brain><effectiveness assessment><effectiveness evaluation><ethical><evaluate effectiveness><examine effectiveness><ferroheme><gIP-10><genetic variant><genomic variant><heme oxygenase-1><hemeoxygenase 1><hiPSC><histidine-rich protein 2><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><human progenitor cell derived><human stem cell-derived><human subject><iPS><iPSC><iPSCs><improved><in vitro Model><induced human pluripotent stem cells><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><inflammatory mediator><injury to cells><kids><microtubule bound tau><microtubule-bound tau><model of animal><monocyte><mortality><necropsy><neglect><neuro-vascular unit><neurobehavioral><neuron injury><neurovascular unit><plasmodium histidine-rich protein II><post treatment><postmortem><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><prospective><protein death-ligand 1><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><receptor><recruit><related to A and C-protein><resistant><rodent plasmodia><sle2><social role><systemic lupus erythematosus susceptibility 2><tau><tau Proteins><tau factor><three dimensional><thymus derived lymphocyte><wet brain><youngster><τ Proteins>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Julio E Ayala

VANDERBILT UNIVERSITY, Nashville, TN

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$532,979
FY 2026

Project Title

Molecular mechanisms mediating metabolic benefits of glucagon-like peptide-1 receptor agonists

Grant Number:

5R01DK132852-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Although the ability of glucagon-like peptide-1 receptor (Glp1r) agonists to stimulate insulin secretion and reduce caloric intake has been recognized for over two decades, surprisingly little is known about the molecular mechanisms behind these effects. We have previously shown that...

Research Terms

<ACTH-beta-Lipotropin Precursor><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adipocytes><Adipose Cell><Adrenergic Receptor><Adrenoceptors><Affect><Agonist><Anorectic Drug><Anorectic agent><Anorectics><Anorexiant><Anorexic Drugs><Anorexient Agent><Anorexient Drug><Anorexigenic Drugs><Appetite Depressants><Appetite Suppressants><Appetite-Depressing Drugs><Appetite-Suppressant Drugs><Assessment instrument><Assessment tool><Autoregulation><Basal Transcription Factor><Basal transcription factor genes><Binding><Blood Glucose><Blood Sugar><Body Weight><Body Weight decreased><Brain><Brain Nervous System><CHO Cells><Caloric Intake><Cell Body><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chinese Hamster Ovary><Chinese Hamster Ovary Cell><Clampings><Closure by clamp><Complex><Corticotropin-beta-Lipotropin Precursor><Coupled><Cyclic AMP-Dependent Protein Kinases><D-Glucose><DNA mutation><Data><Development><Dextrose><Diabetes Mellitus><Dose><Drug Side Effects><Drugs><Effectiveness><Encephalon><Endorphin-ACTH Precursor><Energy Intake><Epinephrine Receptors><Event><FK506 Binding Protein 12-Rapamycin Associated Protein 1><FKBP12 Rapamycin Complex Associated Protein 1><FRAP1><FRAP1 gene><FRAP2><Fat Cells><Future><GLP-1><GLP-1 receptor><GLP-I receptor><General Transcription Factor Gene><General Transcription Factors><Genetic Change><Genetic defect><Genetic mutation><Glp-1><Glucose><Glycolysis><HIF 1><HIF-1 protein><HIF1><HIF1 protein><Homeostasis><Human><Hyperglycemia><Hypothalamic structure><Hypothalamus><Hypoxia Inducible Factor><Impairment><Individual><Intracellular Communication and Signaling><KI mice><Knock-in Mouse><Knowledge><Lipocytes><Mature Lipocyte><Mature fat cell><Measures><Mechanistic Target of Rapamycin><Mediating><Medication><Metabolic><Mice><Mice Mammals><Modern Man><Molecular><Molecular Interaction><Molecular Target><Morphology><Murine><Mus><Mutation><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Nutrient><Obesity><Outcome><PKA><Pancreas><Pancreatic><Pathway interactions><Pharmaceutical Preparations><Phosphorylation><Physiologic><Physiological><Physiological Homeostasis><Physiology><Predisposition><Pro-ACTH-Endorphin><Pro-Opio-Melanocortin><Pro-Opiocortin><Pro-Opiomelanocortin><Proopiocortin><Proopiomelanocortin><Protein Kinase A><Protein Phosphorylation><Proteins><Publishing><RAFT1><Receptor Activation><Receptor Protein><Receptor Signaling><Regulation><Regulatory Protein><Resistance><Role><Signal Transduction><Signal Transduction Systems><Signaling><Subcellular Process><Susceptibility><Test Result><Testing><Therapeutic><Therapeutic Effect><Transcription Factor Proto-Oncogene><Transcription factor genes><Treatment Efficacy><Variant><Variation><Weight><Weight Loss><Weight Reduction><adenoreceptor><adiposity><anorexic agent><biological signal transduction><body weight loss><cAMP-Dependent Protein Kinases><caloric dietary content><cardiometabolic><cardiometabolism><cell type><clinical effect><clinical relevance><clinically relevant><corpulence><design><designing><detection of nutrient><developmental><diabetes><drug action><drug/agent><eat less><energy balance><genetic regulatory protein><genome mutation><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose tolerance><hyperglycemic><hypothalamic><hypoxia inducible factor 1><improved><in vivo><insulin secretion><intervention efficacy><islet><knockin mice><liraglutide><mTOR><mammalian target of rapamycin><metabolic phenotype><metabotype><mouse model><murine model><mutant><neuronal><novel><nutrient sensing><pathway><perception of nutrients><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><protein activation><receptor><reduced eating><reduced food intake><regulatory gene product><resistant><response><sensor><social role><temporal measurement><temporal resolution><therapeutic efficacy><therapy efficacy><time measurement><transcription factor><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

John Christian Tilton

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 60/100
Likely hiring
Above-average budget
Active award
$507,792
FY 2026

Project Title

The role of the precursor HIV-1 protease in drug resistance.

Grant Number:

5R01AI191807-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/2/2025

End Date:

12/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Abstract This project aims to determine whether the precursor HIV-1 protease (PR) plays an important role in the development of drug resistance to protease inhibitors (PIs). The precursor PR dimer is far less susceptible to inhibition by PIs than the mature PR dimer, leading to the hypothesi...

Research Terms

<AIDS Virus><Abscission><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Active Sites><Affect><Anti-Retroviral Agents><Antiproteases><Applications Grants><Assay><Bioassay><Biological Assay><Cell Body><Cells><Complication><DNA mutation><Development><Dimerization><Drug Design><Drug resistance><Drugs><Effectiveness><Endopeptidase Inhibitors><Enzyme Gene><Enzymes><Esteroproteases><Excision><Extirpation><Frequencies><Future><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Grant Proposals><HIV><HIV-1 protease><HIV1 protease><Human Immunodeficiency Viruses><In Vitro><Infection><LAV-HTLV-III><Lead><Lymphadenopathy-Associated Virus><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Medication><Molecular><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><Patients><Pb element><Peptidase Inhibitors><Peptidases><Peptide Hydrolase Inhibitors><Peptide Hydrolases><Peptide Peptidohydrolase Inhibitors><Peptides><Pharmaceutical Preparations><Physiologic><Physiological><Play><Polyproteins><Predisposition><Production><Protease Antagonists><Protease Gene><Protease Inhibitor><Proteases><Protein Dimerization><Proteinase Inhibitors><Proteinases><Proteolytic Enzymes><Removal><Resistance><Resistance development><Resistant development><Role><Site><Surgical Removal><Susceptibility><System><Techniques><Testing><Viral><Virus><Virus Replication><Virus-HIV><anti-retroviral><conformation><conformational><conformational state><conformationally><conformations><develop drug resistance><developing resistance><developmental><dimer><drug resistance development><drug resistant><drug/agent><experiment><experimental research><experimental study><experiments><genome mutation><heavy metal Pb><heavy metal lead><innovate><innovation><innovative><insight><monomer><pressure><resection><resistance mutation><resistance to Drug><resistant><resistant mutation><resistant to Drug><social role><viral multiplication><viral replication><virus multiplication>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Allison G Hays

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$484,874
FY 2026

Project Title

Sex-specific factors, inflammation and vascular health across the lifespan in women living with HIV

Grant Number:

5R35HL172680-03

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/8/2024

End Date:

12/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Cardiovascular disease (CVD) remains the leading cause of mortality in women, with approximately one woman dying per minute in the US. Women living with HIV (WLHIV) are a particularly high-risk group of women with high CVD prevalence who have long been understudied in clinical resea...

Research Terms

<AIDS Virus><ASCVD><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affect><Age><Agonist><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Biological><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Vessels><CVD prevention><Cardiac Diseases><Cardiac Disorders><Cardiac infarction><Cardiology><Cardiometabolic Disease><Cardiometabolic Disorder><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Cessation of life><Chronic><Clinical Research><Clinical Study><Clinical Trials><Coronary><Data><Death><Deposit><Deposition><Development><Differences between sexes><Differs between sexes><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Event><Fats><Fatty acid glycerol esters><Female Groups><Future><GLP-1 receptor><GLP-I receptor><Goals><Guidelines><HIV><HIV in patients><HIV individuals><HIV infected individuals><HIV infected men><HIV infected persons><HIV patient><HIV people><HIV positive individuals><HIV positive men><HIV positive patient><HIV positive people><HIV+ men><Health><Heart Diseases><Heart Vascular><Human Immunodeficiency Viruses><Human immunodeficiency virus infected patients><Human immunodeficiency virus positive patients><Image><Impairment><Inflammation><Intermediary Metabolism><Intervention Studies><Knowledge><LAV-HTLV-III><Link><Lipoproteins><Longitudinal Studies><Longitudinal Surveys><Lymphadenopathy-Associated Virus><Males living with HIV><Mediating><Men with HIV><Metabolic Processes><Metabolism><Mononitrogen Monoxide><Myocardial Infarct><Myocardial Infarction><Nature><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><Outcome><PLWH><PWH><Participant><Pathway interactions><Patients living with HIV><Patients suffering from HIV><Population><Premature Menopause><Prevalence><Proteomics><Public Health><Research><Risk><Risk Assessment><Risk Marker><Role><Sex Differences><Sexual differences><Testing><Time><Translating><Vascular Endothelium><Virus-HIV><Woman><Women's Group><Women's mortality><Work><ages><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><bio-markers><biologic><biologic marker><biomarker><cardiac disease prevention><cardiac disease risk><cardiac disorder risk><cardiac infarct><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><circulatory system><clinical relevance><clinically relevant><comparing females and males><comparing women and men><coronary attack><coronary infarct><coronary infarction><death among females><death among women><death in females><death in women><design><designing><developmental><early menopause><endothelial cell derived relaxing factor><endothelial dysfunction><female death><female mortality><females compared to males><females compared with males><females versus males><females vs. males><glucagon-like peptide-1 receptor><heart attack><heart disease risk><heart disorder><heart disorder risk><heart infarct><heart infarction><high risk group><high risk individual><high risk people><high risk population><human immunodeficiency virus patient><imaging><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><inflammatory environment><inflammatory milieu><intervention research><interventional research><interventional study><interventions research><later in life><later life><life span><lifespan><long-term study><longitudinal outcome studies><longitudinal research study><man living with HIV><men><men diagnosed with HIV><men infected with HIV><men living with HIV><mortality among females><mortality among women><mortality in females><mortality in women><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><patient infected with HIV><patient with HIV><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><premature age of menopause><prevent><preventing><programs><risk predictor><risk predictors><sex><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><social role><systemic inflammation><systemic inflammatory response><vascular><women compared to men><women compared with men><women versus men><women vs. men><women's death>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

LLOYD M SMITH

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$475,681
FY 2026

Project Title

Deciphering HIV-1 alternatively spliced transcript functionality with HyPR-MS

Grant Number:

1R01AI192262-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract The complexity of the HIV-1 transcriptome has been progressively revealed throughout recent decades using increasingly advanced RNA sequencing technologies. However, knowledge of the RNA primary sequence alone has not been sufficient to determine the importance or function o...

Research Terms

<0-11 years old><3' Splice Site><AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Advanced HIV><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Artifacts><Assay><Bioassay><Biological Assay><Cell Body><Cells><Child><Child Youth><Children (0-21)><Classification><Code><Coding System><Complex><DNA><Deoxyribonucleic Acid><Development><FISH Technic><FISH Technique><FISH analysis><FISH assay><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Genes><Genetic Transcription><Glycoproteins><Goals><HIV><HIV Genome><HIV replication><HIV viral replication><HIV-1><HIV-1 genome><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV1><HIV1 genome><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Image><Individual><Integration Host Factors><Intervening Sequences><Introns><Investigation><Knowledge><LAV-HTLV-III><Life Cycle><Life Cycle Stages><Lymphadenopathy-Associated Virus><Maps><Measures><Messenger RNA><Morphologic artifacts><Network Analysis><Non-Polyadenylated RNA><ORFs><Open Reading Frames><Organism><Pathway Analysis><Persons><Polyproteins><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Pre-mRNA><Process><Protein Coding Region><Protein Modification><Proteins><Proteomics><RNA><RNA Expression><RNA Gene Products><RNA Seq><RNA Splicing><RNA Stability><RNA and protein interaction><RNA sequencing><RNA targeting drug><RNA targeting therapeutics><RNA, Messenger, Precursors><RNA-Protein Interaction><RNA-targeting therapy><RNAseq><Regulation><Research><Resolution><Ribonucleic Acid><Severe HIV Disease><Splice Acceptor Sites><Splicing><System><Systematics><Techniques><Technology><Testing><Transcript><Transcription><Translations><Variant><Variation><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Physiology><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus-HIV><Work><cofactor><developmental><gene product><global gene expression><global transcription profile><high resolution imaging><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><imaging><improved><in vivo><interest><kids><knock-down><knockdown><life course><living system><mRNA><mRNA Precursor><multiplex assay><nef><nef Gene Products><nef Protein><new technology><novel technologies><overexpress><overexpression><protein expression><protein function><resolutions><single cell analysis><tool><transcriptome><transcriptome sequencing><transcriptomic sequencing><translation><viral RNA><viral infection><viral multiplication><viral replication><virus RNA><virus infection><virus multiplication><virus protein><virus-induced disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nathan M Sherer

UNIVERSITY OF WISCONSIN-MADISON, MADISON, WI

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$475,681
FY 2026

Project Title

Deciphering HIV-1 alternatively spliced transcript functionality with HyPR-MS

Grant Number:

1R01AI192262-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2026

End Date:

1/31/2031

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract The complexity of the HIV-1 transcriptome has been progressively revealed throughout recent decades using increasingly advanced RNA sequencing technologies. However, knowledge of the RNA primary sequence alone has not been sufficient to determine the importance or function o...

Research Terms

<0-11 years old><3' Splice Site><AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Advanced HIV><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Artifacts><Assay><Bioassay><Biological Assay><Cell Body><Cells><Child><Child Youth><Children (0-21)><Classification><Code><Coding System><Complex><DNA><Deoxyribonucleic Acid><Development><FISH Technic><FISH Technique><FISH analysis><FISH assay><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Genes><Genetic Transcription><Glycoproteins><Goals><HIV><HIV Genome><HIV replication><HIV viral replication><HIV-1><HIV-1 genome><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV1><HIV1 genome><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Image><Individual><Integration Host Factors><Intervening Sequences><Introns><Investigation><Knowledge><LAV-HTLV-III><Life Cycle><Life Cycle Stages><Lymphadenopathy-Associated Virus><Maps><Measures><Messenger RNA><Morphologic artifacts><Network Analysis><Non-Polyadenylated RNA><ORFs><Open Reading Frames><Organism><Pathway Analysis><Persons><Polyproteins><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Pre-mRNA><Process><Protein Coding Region><Protein Modification><Proteins><Proteomics><RNA><RNA Expression><RNA Gene Products><RNA Seq><RNA Splicing><RNA Stability><RNA and protein interaction><RNA sequencing><RNA targeting drug><RNA targeting therapeutics><RNA, Messenger, Precursors><RNA-Protein Interaction><RNA-targeting therapy><RNAseq><Regulation><Research><Resolution><Ribonucleic Acid><Severe HIV Disease><Splice Acceptor Sites><Splicing><System><Systematics><Techniques><Technology><Testing><Transcript><Transcription><Translations><Variant><Variation><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Physiology><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus-HIV><Work><cofactor><developmental><gene product><global gene expression><global transcription profile><high resolution imaging><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><imaging><improved><in vivo><interest><kids><knock-down><knockdown><life course><living system><mRNA><mRNA Precursor><multiplex assay><nef><nef Gene Products><nef Protein><new technology><novel technologies><overexpress><overexpression><protein expression><protein function><resolutions><single cell analysis><tool><transcriptome><transcriptome sequencing><transcriptomic sequencing><translation><viral RNA><viral infection><viral multiplication><viral replication><virus RNA><virus infection><virus multiplication><virus protein><virus-induced disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ben E. Black

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$450,488
FY 2026

Project Title

Tuning PARP-1 retention and release on DNA breaks

Grant Number:

5R01CA259037-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Breaks in the structure of DNA are a persistent stress on the integrity of the genome, and they pose a substantial risk of chromosomal rearrangement and genetic mutation that can challenge the well-being of an organism and promote the development of cancer. There are several cellular mechanisms that...

Research Terms

<ADP Ribose><Acute><Address><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose, homopolymer><Adenosine 5'-Diphosphoribose><Adenosine Diphosphate Ribose><Adenosine Diphosphoribose><Alleles><Allelomorphs><Allosteric Regulation><Apoptotic><Asian group><Asian individual><Asian people><Asian population><Asians><Assay><BRCA 1/2><BRCA1/2><Behavior><Binding><Binding Sites><Bioassay><Biochemical><Biological Assay><Biological Function><Biological Process><Biology><Biophysics><Black><Black race><Breast PDX models><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Communication and Signaling><Cell Death><Cell Death Signaling><Cell Death Signaling Process><Cell Signaling><Cell Survival><Cell Viability><Cells><Cellular biology><Chemicals><Chromosomal Rearrangement><Clinic><Clinical><Collaborations><Combining Site><Communication><Complex><Coupled><Crystallographies><Crystallography><DNA><DNA Binding><DNA Binding Interaction><DNA Damage><DNA Damage Repair><DNA Injury><DNA Repair><DNA Structure><DNA bound><DNA mutation><DNA strand break><Defect><Deoxyribonucleic Acid><Deuterium><Development><Engineering><Enzyme Gene><Enzymes><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene variant><Genetic Change><Genetic defect><Genetic mutation><Genome><Goals><H element><H2 isotope><Health><Histones><Human><Hydrogen><Imaging Procedures><Imaging Technics><Imaging Techniques><Inflammation><Intracellular Communication and Signaling><Investigators><Knowledge><Location><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medicinal Chemistry><Medicine><Methods><Mice><Mice Mammals><Modeling><Modern Man><Modification><Molecular Interaction><Monitor><Murine><Mus><Mutation><Nature><Organism><PARP Inhibitor><PARP Polymerase><PARP protein><PARP-1 inhibitor><PARPi><PARS><Pathway interactions><Patient-derived xenograft models of breast cancer><Personal Satisfaction><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Poly Adenosine Diphosphate Ribose><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) Polymerases><Poly(ADP-ribose) polymerase 1 inhibitor><Poly(ADPribose) Polymerase><Poly-ADPR><Polymers><Position><Positioning Attribute><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Production><Property><Protein Dynamics><Protein Modification><Proteins><Reactive Site><Regulation><Research><Research Personnel><Researchers><Risk><Role><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Stress><Testing><Therapeutic Agents><Time><Transcriptional Control><Transcriptional Regulation><Tumor Cell><Unscheduled DNA Synthesis><Variant><Variation><Work><allelic variant><anti-cancer therapy><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><brca gene><breast cancer PDX><breast cancer patient-derived xenograft><cancer cell><cancer progression><cancer therapy><cancer-directed therapy><cell biology><cell killing><compound optimization><design><designing><developmental><drug market><experiment><experimental research><experimental study><experiments><formulation optimization><genetic variant><genome integrity><genome mutation><genomic integrity><genomic variant><homologous recombination><image translation><imaging approach><imaging based approach><improved><innovate><innovation><innovative><insight><interdisciplinary approach><interest><living system><malignancy><mouse model><multidisciplinary approach><murine model><necrocytosis><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><next generation><novel><pathway><poly (ADP-ribose)><poly ADP polymerase><poly ADP ribose synthetase><polymer><polymeric><programs><recruit><repair><repaired><response><small molecule><social role><success><targeted cancer therapy><tool><tumor><tumor progression><tumor xenograft><virtual><well-being><wellbeing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

John M Pascal

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$450,488
FY 2026

Project Title

Tuning PARP-1 retention and release on DNA breaks

Grant Number:

5R01CA259037-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Breaks in the structure of DNA are a persistent stress on the integrity of the genome, and they pose a substantial risk of chromosomal rearrangement and genetic mutation that can challenge the well-being of an organism and promote the development of cancer. There are several cellular mechanisms that...

Research Terms

<ADP Ribose><Acute><Address><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose, homopolymer><Adenosine 5'-Diphosphoribose><Adenosine Diphosphate Ribose><Adenosine Diphosphoribose><Alleles><Allelomorphs><Allosteric Regulation><Apoptotic><Asian group><Asian individual><Asian people><Asian population><Asians><Assay><BRCA 1/2><BRCA1/2><Behavior><Binding><Binding Sites><Bioassay><Biochemical><Biological Assay><Biological Function><Biological Process><Biology><Biophysics><Black><Black race><Breast PDX models><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Communication and Signaling><Cell Death><Cell Death Signaling><Cell Death Signaling Process><Cell Signaling><Cell Survival><Cell Viability><Cells><Cellular biology><Chemicals><Chromosomal Rearrangement><Clinic><Clinical><Collaborations><Combining Site><Communication><Complex><Coupled><Crystallographies><Crystallography><DNA><DNA Binding><DNA Binding Interaction><DNA Damage><DNA Damage Repair><DNA Injury><DNA Repair><DNA Structure><DNA bound><DNA mutation><DNA strand break><Defect><Deoxyribonucleic Acid><Deuterium><Development><Engineering><Enzyme Gene><Enzymes><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene variant><Genetic Change><Genetic defect><Genetic mutation><Genome><Goals><H element><H2 isotope><Health><Histones><Human><Hydrogen><Imaging Procedures><Imaging Technics><Imaging Techniques><Inflammation><Intracellular Communication and Signaling><Investigators><Knowledge><Location><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medicinal Chemistry><Medicine><Methods><Mice><Mice Mammals><Modeling><Modern Man><Modification><Molecular Interaction><Monitor><Murine><Mus><Mutation><Nature><Organism><PARP Inhibitor><PARP Polymerase><PARP protein><PARP-1 inhibitor><PARPi><PARS><Pathway interactions><Patient-derived xenograft models of breast cancer><Personal Satisfaction><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Poly Adenosine Diphosphate Ribose><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) Polymerases><Poly(ADP-ribose) polymerase 1 inhibitor><Poly(ADPribose) Polymerase><Poly-ADPR><Polymers><Position><Positioning Attribute><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Production><Property><Protein Dynamics><Protein Modification><Proteins><Reactive Site><Regulation><Research><Research Personnel><Researchers><Risk><Role><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Stress><Testing><Therapeutic Agents><Time><Transcriptional Control><Transcriptional Regulation><Tumor Cell><Unscheduled DNA Synthesis><Variant><Variation><Work><allelic variant><anti-cancer therapy><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><brca gene><breast cancer PDX><breast cancer patient-derived xenograft><cancer cell><cancer progression><cancer therapy><cancer-directed therapy><cell biology><cell killing><compound optimization><design><designing><developmental><drug market><experiment><experimental research><experimental study><experiments><formulation optimization><genetic variant><genome integrity><genome mutation><genomic integrity><genomic variant><homologous recombination><image translation><imaging approach><imaging based approach><improved><innovate><innovation><innovative><insight><interdisciplinary approach><interest><living system><malignancy><mouse model><multidisciplinary approach><murine model><necrocytosis><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><next generation><novel><pathway><poly (ADP-ribose)><poly ADP polymerase><poly ADP ribose synthetase><polymer><polymeric><programs><recruit><repair><repaired><response><small molecule><social role><success><targeted cancer therapy><tool><tumor><tumor progression><tumor xenograft><virtual><well-being><wellbeing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David McDermott

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$424,605
FY 2026

Project Title

Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

Grant Number:

5R01CA258442-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2021

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A s...

Research Terms

<Abscission><Address><Adjuvant><Adjuvant Study><Adjuvant Therapy><Adjuvant Trials><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiomyolipoma><Angiostatic Agents><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><BAY 54-9085><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood Sample><Blood Tests><Blood specimen><Case-Comparison Studies><Case-Compeer Studies><Case-Referent Studies><Case-Referrent Studies><Case/Control Studies><Cessation of life><Clear Cell><Clinical><Clinical Trials><Collection><Cyst><Data><Death><Diagnosis><Disease><Disease-Free Survival><Disorder><ECOG><Early Diagnosis><Eastern Cooperative Oncology Group><Enrollment><European><Event-Free Survival><Excision><Expression Signature><Extirpation><Future><Gene Expression Profile><General Prognostic Factor><Goals><Grawitz Tumor><Hematologic Tests><Hematological Tests><Hematology Testing><Histologic><Histologically><Hypernephroid Carcinoma><Hypernephroma><IARC><Immune Globulins><Immune mediated therapy><Immunoglobulins><Immunologically Directed Therapy><Immunomodulation><Immunotherapy><Individual><Injury to Kidney><Integral Membrane Protein><International><International Agency for Research on Cancer><Intrinsic Membrane Protein><Kidney Mass><Kidney Neoplasms><Kidney Tumor><Lead><Localized Disease><Measures><Medical center><Metastatic Renal Cell Cancer><Metastatic Renal Cell Carcinoma><Monitor><Mucins><Mucus Glycoprotein><Neovascularization Inhibitors><Nephrectomy><Nephroid Carcinoma><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Outcome><Papillary><Pathologic><Pathology><Patients><Pb element><Phase><Phase 3 Clinical Trials><Phase III Clinical Trials><Plasma><Plasma Serum><Prediction of Response to Therapy><Prognosis><Prognostic Factor><Prognostic Marker><Prognostic/Survival Factor><RNA><RNA Gene Products><Randomized><Recurrence><Recurrent><Removal><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Renal Mass><Renal Neoplasms><Renal Tumor><Resected><Reticuloendothelial System, Serum, Plasma><Retrospective cohort><Ribonucleic Acid><Risk><Risk Assessment><Sampling><Screening for cancer><Sorafenib><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><T-Cells><T-Lymphocyte><Testing><Time><Transmembrane Protein><Transmembrane Protein Gene><Validation><Work><adjuvant protocol><adjuvant treatment><antiangiogenic><bio-markers><biologic marker><biomarker><blood-based biomarker><blood-based marker><case-control survey><case-controlled studies><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><circulating biomarkers><circulating markers><clinical prognostic><cohort><cohort investigation><cohort research><diagnostic biomarker><diagnostic marker><early cancer detection><early detection><enroll><gene expression pattern><gene expression signature><heavy metal Pb><heavy metal lead><high risk><immune check point><immune check point therapy><immune checkpoint><immune checkpoint therapy><immune modulation><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><improved><investigate cohort><kidney adenocarcinoma><kidney injury><kidney injury molecule 1><mortality><outcome prediction><participant enrollment><patient enrollment><patient population><phase III protocol><predict clinical outcome><predict therapeutic response><predict therapy response><prognostic><prognostic biomarker><prognostic indicator><prospective><randomisation><randomization><randomly assigned><rat KIM-1 protein><relapse prediction><relapse risk><renal KIM-1><renal injury><resection><response to therapy><response to treatment><risk stratification><screening cancer patients><stratify risk><study cohort><surgery><survey cohort><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy prediction><therapy response><thymus derived lymphocyte><transcriptional profile><transcriptional signature><treatment prediction><treatment response><treatment response prediction><treatment responsiveness><tumor><validations>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sean Patrick Ryder

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 58/100
Likely hiring
Solid budget
Recent
Active award
$360,125
FY 2026

Project Title

Unmasking the role of maternal transcript UTRs in reproductive fecundity

Grant Number:

5R01HD111505-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/15/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary: My lab is interested in defining how the maternal load is established during oogenesis and decoded af- ter fertilization. We know the identity of the most important maternal transcripts and maternally supplied RNA- binding proteins. We know which factors are required for germline d...

Research Terms

<0-11 years old><21+ years old><3' Untranslated Regions><3'UTR><Address><Adult><Adult Human><Affect><Animals><Bacteria><Buffers><C elegans><C. elegans><C.elegans><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Caenorhabditis elegans><Cas nuclease technology><Cell Body><Cells><Child><Child Youth><Children (0-21)><Clinic><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cues><Cytoplasm><DNA><DNA mutation><Data><Deoxyribonucleic Acid><Development><Double-Stranded RNA><Embryo><Embryo Development><Embryogenesis><Embryonic><Embryonic Development><Ensure><Environment><Environmental Factor><Environmental Risk Factor><Event><Exposure to><Failure><Fecundability><Fecundity><Female><Fertility><Fertilization><Fertilized Egg><Fertilized Ovum><Fishes><Food Chain><Gametes><Gametogenesis><Gender><Gene Action Regulation><Gene Activation><Gene Deletion><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Targeting><Gene Transcription><Generalized Growth><Generations><Genes><Genetic Change><Genetic Models><Genetic Screening><Genetic Transcription><Genetic defect><Genetic mutation><Genome><Genomics><Germ Cells><Germ Lines><Germ-Line Cells><Gestation><Growth><Health><Heat Stress><Hereditary><High temperature of physical object><Hives><Hornets><Individual><Inherited><Instruction><Invertebrata><Invertebrates><Investigation><Laboratories><Learning><Mammalia><Mammals><Maps><Masked mRNA><Maternal Messenger RNA><Maternal mRNA><Measures><Meiosis><Messenger RNA><Molecular><Molecular Genetics><Mutate><Mutation><Nematoda><Nematodes><Non-Polyadenylated RNA><Oocytes><Oogenesis><Ovocytes><Parents><Pathway interactions><Pattern><Pattern Formation><Phenotype><Physiologic><Physiological><Plants><Play><Position><Positioning Attribute><Post-Transcriptional Control><Post-Transcriptional Gene Silencing><Post-Transcriptional Regulation><Pregnancy><Process><Property><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Interference><RNA Silencing><RNA interference screen><RNA, Messenger, Masked><RNA, Messenger, Stored><RNA-Binding Proteins><RNAi><RNAi screen><RNAi-based screen><Regulation><Reiterated Genes><Reporter><Reproduction><Reproductive Biology><Reproductive Cells><Reptiles><Reptilia><Ribonucleic Acid><Risk><Role><Sequence-Specific Posttranscriptional Gene Silencing><Sex Cell><Sex Ratio><Sexual Reproduction><Sterility><Stored mRNA><Stress><Survey Instrument><Surveys><Temperature><Testing><Time><Tissue Growth><Transcript><Transcription><Translating><Translations><Turtles><UTRs><Untranslated Regions><Urticaria><Visualization><Wing><adulthood><cell fate specification><climate change><climatic changes><defined contribution><developmental><dsRNA><environmental change><environmental risk><experiment><experimental research><experimental study><experiments><feeding><fertilizations><gene deletion mutation><gene redundancy><gene replacement><genome editing><genome mutation><genome scale><genome-wide><genomewide><genomic editing><global climate change><high temperature><initial cell><interdisciplinary approach><interest><kids><mRNA><male><meiotic><model organism><multidisciplinary approach><mutant><notch><notch protein><notch receptors><ontogeny><oocyte maturation><parent><pathway><post-transcriptional gene regulation><reproductive><reproductive success><roundworm><sex determination><sexual cell><social role><spatial and temporal><spatial temporal><spatiotemporal><sterile><success><tool><tortoise><translation><ventilation><youngster><zygote><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ruchira Singh

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Good lead · 56/100
Above-average budget
Very recent
Active award
Team-scale grant
$744,451
FY 2026

Project Title

A small molecule PROTAC for macular degeneration

Grant Number:

1UG3NS142998-01A1

Activity Code:

UG3

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/17/2026

End Date:

2/28/2027

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Age-related macular degeneration (AMD) and related macular dystrophies (MDs) are leading causes of adult blindness with limited treatment options. AMD/MDs can present in two forms, geographic atrophy/GA (dry form) and choroidal neovascularization/CNV (wet form). There is strong evidence lin...

Research Terms

<21+ years old><Adult><Adult Human><Adverse effects><Affect><Age Years><Age related macular degeneration><Age related pathologies><Age-Related Maculopathy><Animals><Area><Atrophic AMD><Atrophic age-related macular degeneration><Automobile Driving><Behavior><Biogenesis><Biological><Blindness><Bruch Membrane><Bruch's basal membrane structure><Bruch's membrane><Bruchs membrane><CaCo2><Caco-2 Cells><Cell Communication and Signaling><Cell Signaling><Choroid Neovascularization><Choroidal Neovascularization><Clinical><Clinical Evaluation><Clinical Testing><Collaborations><Complement Inactivators><Complement Inhibitors><Contractor><Data><Deposit><Deposition><Development><Dinoprostone><Drug Kinetics><Drug Targeting><Drug Therapy><Drugs><Druse><Drusen><Dry AMD><Dryness><EC 3.1.1.4><Enzyme Gene><Enzymes><Epithelial Cells><Excretory function><Eye><Eyeball><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Goals><Health><Human><IND Filing><IND application><IND package><IND submission><In Vitro><Inflammation><Inflammatory><Intermediary Metabolism><Intracellular Communication and Signaling><Investigational New Drug Application><Kinetics><Lamina Basalis Choroideae><Lead><Leanness><Lecithinase A2><Letters><Link><Lipids><MOM1><Macular degeneration><Macular degenerative disease><Medication><Medicinal Chemistry><Metabolic Processes><Metabolism><Mice><Mice Mammals><Microsomes><Modern Man><Molecular><Mouse Homolog of Modifier of MIN-1><Murine><Mus><Non-Rodent Model><Non-exudative age-related macular degeneration><Nonexudative age-related macular degeneration><Origin of Life><Outcome Measure><Outer pigmented layer of retina><PGE2><PGE2 alpha><PGE2alpha><PLA2><PLA2B><PLA2G2A><PLA2G2A gene><PLA2S><PLAS1><Pathogenesis><Pathologic><Pathology><Pathway interactions><Pb element><Permeability><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Pharmacological Treatment><Pharmacotherapy><Phase><Phospholipase A2><Phospholipase A2 Group IIA><Phospholipase A2 Polypeptide B><Phospholipase A2, Synovial><Pigment cell layer of retina><Pigmented layer of retina><Plasma Proteins><Preparation><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Protac><Proteins><Proteolysis targeting chimeric><Publishing><Retinal Pigment Epithelium><Retinal pigment epithelial cells><Rodent><Rodent Model><Rodentia><Rodents Mammals><Series><Sight><Signal Transduction><Signal Transduction Systems><Signaling><Solubility><Sterility><Structure><Structure of retinal pigment epithelium><Structure-Activity Relationship><Surrogate Markers><Testing><Therapeutic><Therapeutic Effect><Thinness><Toxicology><Translational Research><Translational Science><Universities><VEGF><VEGFs><Vascular Endothelial Growth Factors><Vision><Visual><Wild Type Mouse><Work><absorption><adulthood><age associated pathologies><age dependent macular degeneration><age dependent pathologies><age induced macular degeneration><age induced pathologies><age related macular disease><age related macular dystrophy><aging associated pathologies><aging dependent pathologies><aging induced pathologies><aging pathologies><aging related pathologies><analog><biologic><biological signal transduction><chemical structure function><chimera drug><clinical test><clinical translation><clinically translatable><complement pathway><developmental><driving><drug intervention><drug treatment><drug/agent><dry age-related macular degeneration><early biomarkers><early detection biomarkers><early detection markers><efficacy study><excretion><experiment><experimental research><experimental study><experiments><geographic atrophy><heavy metal Pb><heavy metal lead><iPS><iPSC><iPSCs><in vivo><induced pluripotent cell><induced pluripotent stem cell><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><inducible pluripotent cell><inducible pluripotent stem cell><inhibitor><intravitreal injection><lead optimization><lecithinase A><macular dystrophy><measurable outcome><mouse model><murine model><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-invasive imaging><noninvasive imaging><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><outcome measurement><overexpress><overexpression><pathway><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><phosphatidase><phosphatidolipase><phosphatidylcholine 2 acylhydrolase><preparations><prevent><preventing><proteolysis targeting chimaera><proteolysis targeting chimera><public health relevance><research clinical testing><response biomarker><response markers><retinal imaging><senile macular disease><side effect><small molecule><sterile><structure function relationship><surrogate bio-markers><surrogate biomarkers><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><translation research><translational investigation><vision loss><visual function><visual loss><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jesse Chimezie Ikeme

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$190,836
FY 2026

Project Title

Assessing Patient-Centric Factors and Enhancing Risk Communication to Improve Treatment Persistence in Kidney and Cardiovascular Care

Grant Number:

5K23DK144712-02

Activity Code:

K23

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

7/15/2025

End Date:

3/31/2030

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) are two classes of medications poised to revolutionize chronic kidney disease (CKD) care after repeatedly demonstrating their ability to prevent cardiovascular disease (CVD) and CKD pr...

Research Terms

<21+ years old><ASCVD><Acceleration><Adoption><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Agonist><Ambulatory Care Facilities><American Heart Association><Application Context><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Attitude><Benefits and Risks><Biometrics><Biometry><Biostatistics><CVD prevention><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Clinical Data><Clinical Practice Guideline><Clinical Trials><Communication><Communities><Complex><Development><Diagnosis><Disease Progression><Drugs><Elements><Equation><Event><Foundations><GLP-1 receptor><GLP-I receptor><Goals><Health><Health Care Providers><Health Care Systems><Health Personnel><Health Services><Health system><Heart Vascular><Heart failure><Hospital Admission><Hospitalization><Individual><Individualized risk prediction><Integrated Health Care Systems><International><Intervention><Interview><Joints><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Urinary System><Knowledge><Lipids><Maturity-Onset Diabetes Mellitus><Measures><Medical><Medication><Mentors><Metabolic><Metabolic syndrome><Methods><Morbidity><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Organ><Outpatient Clinics><Patient Care><Patient Care Delivery><Patient Compliance><Patients><Persons><Pharmaceutical Preparations><Polypharmacy><Population><Predicting Risk><Preventative treatment><Prevention><Preventive><Preventive treatment><Process><Provider><Publishing><Reporting><Risk><Risk Estimate><Risk Factors><Risk Reduction><SGLT 2 inhibitor><SGLT2i><San Francisco><Slow-Onset Diabetes Mellitus><Socioeconomically disadvantaged><Sodium glucose co-transporter 2 inhibitor><Specialist><Specialty><Stable Diabetes Mellitus><Structure><T2 DM><T2D><T2DM><Therapeutic><Time><Translating><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Veterans><Veterans Health Administration><Veterans Health Affairs><Weight><Work><access to health care><accessibility of health care><accessibility to health care><adult onset diabetes><adulthood><atheromatosis><atherosclerosis risk><atherosclerotic disease><atherosclerotic risk><atherosclerotic vascular disease><cardiac disease prevention><cardiac failure><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><cardiovascular risk><cardiovascular risk factor><care coordination><care delivery><care for patients><care of patients><caring for patients><chronic kidney disease><circulatory system><clinical practice and guidelines><co-morbid><co-morbidity><communication aid><comorbidity><contextual factors><coordinating care><cost><developmental><drug/agent><experience><forecasting risk><frailty><glucagon-like peptide-1 receptor><health and care delivery><health care access><health care availability><health care delivery><health care personnel><health care service access><health care service availability><health care worker><health delivery systems><health provider><health services delivery><health staff><health workers><health workforce><healthcare employees><healthcare staff><healthcare workforce><high risk><high risk group><high risk individual><high risk people><high risk population><implementation framework><implementation research framework><implementation science><implementation science framework><improved><innovate><innovation><innovative><insight><integrated health system><integrated system of care><ketosis resistant diabetes><maturity onset diabetes><medical care providers><medical personnel><medical specialties><mortality><new approaches><novel><novel approaches><novel strategies><novel strategy><old age><participant enrollment><patient adherence><patient clinician engagement><patient clinician interaction><patient clinician relationship><patient cooperation><patient doctor engagement><patient doctor interaction><patient doctor relationship><patient enrollment><patient physician engagement><patient physician interaction><patient physician relationship><patient provider engagement><patient provider interaction><patient provider relationship><personalized risk prediction><predict risk><predict risks><predicted risk><predicted risks><predicting risks><predictive risk><predicts risk><prevent><preventing><primary care clinic><primary care provider><primary care setting><providers from primary care><providers of primary care><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><renal><risk prediction><risk predictions><risk-reducing><side effect><socio-economic disadvantage><socio-economically disadvantaged><socio-economically underprivileged><socioeconomic disadvantage><socioeconomically underprivileged><stakeholder insights><stakeholder perspectives><tool><treatment provider><type 2 DM><type II DM><type two diabetes><weights>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alvin P Chan

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$171,276
FY 2026

Project Title

Role of Bile Acids in Time-Restricted Feeding

Grant Number:

1K08DK146180-01

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2030

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Dr. Alvin Chan is a board-certified pediatric gastroenterologist and physician-scientist dedicated to investigating the regulatory role of bile acids in health and disease. His research focuses on how bile acids shape metabolic processes. His long-term carer goal is to estab...

Research Terms

<0-11 years old><Address><Appetite><Autoregulation><Bile Acid Biosynthesis><Bile Acid Biosynthesis Pathway><Bile Acids><Biomedical Research><Biometrics><Biometry><Biostatistics><Blood Plasma><Board Certification><Body Tissues><Body Weight><CP7A><CRISPR><CRISPR/Cas system><CYP7A1><CYP7A1 gene><Caloric Restriction><Catabolism><Cell Communication and Signaling><Cell Signaling><Cellular Metabolic Process><Child><Child Youth><Childhood><Children (0-21)><Cholesterol><Cholesterol Homeostasis><Circadian Rhythms><Clinical Research><Clinical Sciences><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats><Confocal Microscopy><Data><Dedications><Desire for food><Detergents><Development Plans><Development and Research><Diet><Dietary Cholesterol><Dietary Fats><Disease><Disorder><Diurnal Rhythm><Drugs><Dyslipidemias><Eating><Educational workshop><Endocrine Gland Secretion><Enzyme Gene><Enzymes><Ethics><Exhibits><Fats><Fatty acid glycerol esters><Food Intake><Future><GLP-1><GPBAR1><GPBAR1 gene><Gastroenterologist><Gene Expression><Glp-1><Goals><Grant><Health><Hepatic><High Fat Diet><Homeostasis><Hormone secretion><Hormones><Human><Institution><Instruction><Intermediary Metabolism><Intermittent fasting><Intestinal><Intestines><Intracellular Communication and Signaling><KO mice><Knock-out Mice><Knockout Mice><Link><Lipids><Liver><Manuscripts><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mediating><Mediator><Medication><Mentors><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Pathway><Metabolic Processes><Metabolism><Mice><Mice Mammals><Modern Man><Molecular><Morphology><Murine><Mus><NIH><National Institutes of Health><Null Mouse><Nyctohemeral Rhythm><Paper><Pathway interactions><Pattern><Pharmaceutical Preparations><Phase><Physicians><Physiologic><Physiological><Physiological Homeostasis><Physiology><Plasma><Plasma Serum><Play><Preparation><Procedures><Publishing><R & D><R&D><Receptor Protein><Regulation><Research><Research Resources><Resources><Reticuloendothelial System, Serum, Plasma><Role><Scientist><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Specialty><TGR5><Testing><Therapeutic><Therapeutic Hormone><Thesaurismosis><Time><Time-restricted eating><Time-restricted feeding><Tissues><Training><Translational Research><Translational Science><Twenty-Four Hour Rhythm><United States National Institutes of Health><Work><Workshop><Writing><absorption><bile acid anabolism><bile acid biosynthetic process><bile acid formation><bile acid metabolism><bile acid synthesis><bile metabolism><biological signal transduction><bowel><calorie restriction><career><career development><cell metabolism><cellular metabaolism><cholesterol metabolism><circadian process><circadian rhythmicity><combat><daily biorhythm><diet-associated obesity><diet-induced obesity><diet-related obesity><dietary><dietary lipid><diets><diurnal variation><drug/agent><energy balance><ethical><fat metabolism><feeding><food Ingestion><food consumption><glucagon-like peptide 1><hepatic body system><hepatic organ system><hormonal regulation><hormonal secretion><hormone regulation><improved><innovate><innovation><innovative><insight><insulin sensitivity><kids><lipid metabolism><medical specialties><metabolism disorder><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><pediatric><pre-clinical study><preclinical study><preparations><prevent><preventing><programs><receptor><research and development><response><side effect><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tool><translation research><translational investigation><trend><western diet><western-style diet><western-type diet><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yoseob Joseph Hwang

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$169,927
FY 2026

Project Title

Evaluating Comparative Effectiveness of Glucose-lowering Therapy in People with HIV and Type 2 Diabetes

Grant Number:

1K08DK146757-01

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY In the era of modern antiretroviral therapy (ART), cardiometabolic diseases have become a leading cause of morbidity and mortality among people with HIV (PWH). Type 2 diabetes, a major contributor to cardiovascular and kidney disease, now affects approximately one in five PWH. PWH fa...

Research Terms

<21+ years old><AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Adipose tissue><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Advanced HIV><Affect><Age><Agonist><American><Analgesic Management><Attenuated><Award><Canada><Cardiac infarction><Cardiometabolic Disease><Cardiometabolic Disorder><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Caring><Chronic><Clinical><Cluster Analyses><Cluster Analysis><Collaborations><D-Glucose><Data><Development><Dextrose><Diabetes Mellitus><Dimethylbiguanidine><Dimethylguanylguanidine><Dipeptidyl Aminopeptidases><Dipeptidyl Peptidases><Dipeptidylpeptide Hydrolases><Drug Therapy><Drugs><Dysfunction><ESKD><ESRD><Effectiveness><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Epidemiologic Methodology><Epidemiologic Methods><Epidemiologic research methodology><Epidemiologic research methods><Epidemiological Methods><Epidemiological Techniques><Epidemiology><Exposure to><Face><Fatty Tissue><Functional disorder><GLP-1 receptor><GLP-I receptor><Glomerular Filtration Rate><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Goals><HIV><HIV Infections><HIV individuals><HIV infected individuals><HIV infected persons><HIV people><HIV positive individuals><HIV positive people><HIV viral infection><HIV virus infection><HIV-1 infection><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Heart Vascular><Hemoglobin A(1)><Heterogeneity><Human Immunodeficiency Viruses><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammation><Insurance><Insurance Coverage><Insurance Status><Integrase Inhibitors><Internal Medicine><Investigators><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Urinary System><Knowledge><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><Machine Learning><Maturity-Onset Diabetes Mellitus><Medication><Medication Management><Mentors><Metabolic><Metformin><Methods><Methods Epidemiology><Methods in epidemiology><Modernization><Modification><Morbidity><Myocardial Infarct><Myocardial Infarction><N,N-dimethyl-imidodicarbonimidic diamide><NIDDM><Nephropathy><Nephrotoxic><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Obesity><Outcome><PLWH><PWH><Pattern><Pharmaceutical Epidemiology><Pharmaceutical Preparations><Pharmacoepidemiology><Pharmacologic Management><Pharmacological Treatment><Pharmacotherapy><Physicians><Physiopathology><Population><Race><Races><Regimen><Renal Disease><Renal function><Research><Research Personnel><Researchers><SGLT 2 inhibitor><SGLT2i><Selection for Treatments><Severe HIV Disease><Site><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Stable Diabetes Mellitus><Structural Models><Subgroup><Sulfonylurea Compounds><T2 DM><T2D><T2DM><Time><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Uncertainty><United States><Universities><Virus-HIV><Work><adipose><adiposity><adult onset diabetes><adulthood><ages><antiretroviral therapy><antiretroviral treatment><attenuate><attenuates><cardiac infarct><cardiometabolic><cardiometabolism><cardiovascular disorder><career><circulatory system><clinical care><clinical diagnosis><clinical research site><clinical site><co-exposures><co-morbid><co-morbidity><co-occurring exposure><cohort><combined exposure><comorbidity><comparative effectiveness><compare effectiveness><compare treatment><complex exposure><concurrent exposure><coronary attack><coronary infarct><coronary infarction><corpulence><data collected in real world><demographics><design><designing><developmental><diabetes><diabetes management><diabetes mellitus management><diabetic management><doubt><drug epidemiology><drug intervention><drug treatment><drug/agent><epidemiologic><epidemiological><exposure mixture><faces><facial><fat metabolism><glucagon-like peptide-1 receptor><glucose metabolism><glycemic control><heart attack><heart infarct><heart infarction><hemoglobin A1c><human immunodeficiency virus infection><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><inhibitor><innovate><innovation><innovative><ketosis resistant diabetes><kidney disorder><kidney function><kidney toxicity><lipid metabolism><machine based learning><machine learning based method><machine learning method><machine learning methodologies><maturity onset diabetes><medication therapy management><mixed exposure><mortality><multidisciplinary><nephrotoxicity><pathophysiology><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmaceutical intervention><pharmacoepidemiologic><pharmacoepidemiological><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><racial><racial background><racial origin><real world data><real world evidence><renal><renal disorder><response><selection of treatment><simultaneous exposures><sulfonylurea><therapy selection><time to event><time to occurrence><treatment comparison><treatment selection><type 2 DM><type II DM><type two diabetes><uptake><white adipose tissue><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Amanda Candice Leiter

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$166,002
FY 2026

Project Title

Optimizing diabetes treatment strategies in complex comorbidity

Grant Number:

5K08DK137022-04

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Breast cancer (BC) survivors are the largest cancer survivor group (~4 million in the US) given improvements in screening and long-term BC survival. While BC progression is a concern in this group, many BC survivors die of comorbid illness. Specifically, type 2 diabetes (T2D...

Research Terms

<21+ years old><Address><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Age><Agonist><Big Data><BigData><Biometrics><Biometry><Biostatistics><Breast Cancer><Breast Cancer Treatment><Breast Cancer survivor><Breast Cancer therapy><CVD prevention><Cancer Survivor><Cancer Survivorship><Cancer Treatment><Cancers><Cardiac Toxicity><Cardiotoxic><Cardiotoxicity><Cardiovascular Diseases><Cause of Death><Characteristics><Clinical><Clinical Data><Communication><Complex><Complications of Diabetes Mellitus><Country><Data><Data Set><Development><Development and Research><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Complications><Dimethylbiguanidine><Dimethylguanylguanidine><Drugs><Endocrinologist><Epidemiologic Methodology><Epidemiologic Methods><Epidemiologic research methodology><Epidemiologic research methods><Epidemiological Methods><Epidemiological Techniques><Epidemiology><Exclusion><GLP-1 receptor><GLP-I receptor><Goals><Grant><Guidelines><Hemoglobin><Humulin R><Hypoglycemia><Insulin><Investigators><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Urinary System><Knowledge><Leadership><Life Expectancy><Link><Malignant Breast Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Maturity-Onset Diabetes Mellitus><Medication><Mentorship><Metformin><Methods Epidemiology><Methods in epidemiology><Modeling><Morbidity><N,N-dimethyl-imidodicarbonimidic diamide><NIDDM><Natural History><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Outcome><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pharmaceutical Preparations><Physicians><Population><Prevalence><Prognosis><QALY><QOL><Quality of life><Quality-Adjusted Life Expectancy><Quality-Adjusted Life Years><R & D><R&D><Randomized, Controlled Trials><Recommendation><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Regimen><Regular Insulin><Renal Disease><Research><Research Personnel><Researchers><Risk><SGLT 2 inhibitor><SGLT2i><Safety><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Source><Stable Diabetes Mellitus><Statistical Methods><Survivors><T2 DM><T2D><T2DM><Techniques><Training><Translations><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Uncertainty><Writing><adult onset diabetes><adulthood><ages><anti-cancer therapy><breast cancer progression><breast cancer survival><cancer recurrence><cancer survivor care><cancer survivorship care><cancer therapy><cancer-directed therapy><cardiac disease prevention><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><cardiovascular risk><cardiovascular risk factor><career><career development><chemotherapy><co-morbid><co-morbidity><comorbidity><comparative effectiveness><compare treatment><competing risk><data diversity><data imputation><death risk><developmental><diabetes><diabetes management><diabetes mellitus management><diabetic management><diverse data><doubt><drug/agent><effective therapy><effective treatment><epidemiologic><epidemiological><experience><glucagon-like peptide-1 receptor><glycemic control><hypoglycemic><hypoglycemic episodes><improved><imputation method><in silico><innovate><innovation><innovative><ketosis resistant diabetes><kidney disorder><malignancy><malignant breast tumor><maturity onset diabetes><medical college><medical schools><model-based simulation><models and simulation><mortality><mortality risk><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><over-treatment><overtreatment><patient oriented outcomes><randomized control trial><renal><renal disorder><research and development><school of medicine><screening><screenings><shared decision making><skills><statistic methods><success><translation><treatment comparison><treatment strategy><trial comparing><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Saikat Boliar

STATE UNIVERSITY OF NEW YORK AT BUFFALO, AMHERST, NY

Good lead · 56/100
Likely hiring
Very recent
Active award
$152,468
FY 2026

Project Title

Virologic and immunologic impacts of active viral persistence in lung AMs of HIV-1-infected, cART-suppressed individuals

Grant Number:

3R01AI176934-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/17/2024

End Date:

3/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract Persistence of HIV-1 in tissue reservoirs of therapy-suppressed, aviremic individuals is a major challenge to HIV-1 cure. The viral reservoir consists of myeloid and lymphoid cells that harbor the virus through long periods of combination anti-retroviral therapy (cART). U...

Research Terms

<Address><Affect><Alveolar Macrophages><Assay><Binding><Bioassay><Biological><Biological Assay><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood monocyte><Body Tissues><Brain><Brain Nervous System><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Death Induction><Cell Survival><Cell Viability><Cells><Cellular Immune Function><Chronic><Clonality><Co-culture><Cocultivation><Coculture><Coculture Techniques><Data><Disease Progression><Disease remission><Dysfunction><Effector Cell><Encephalon><Evolution><FISH Technic><FISH Technique><FISH analysis><FISH assay><Feedback><Fluorescence In Situ Hybridization><Fluorescent in Situ Hybridization><Frequencies><Functional disorder><Gene Transcription><Genetic Transcription><HIV cure><HIV functional cure><HIV infection persistence><HIV persistence><HIV replication><HIV viral persistence><HIV viral replication><HIV-1><HIV-1 cure><HIV-1 functional cure><HIV-1 persistence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV/AIDS cure><HIV1><Hortega cell><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune><Immune Cell Activation><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Diseases><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunologically><Immunologics><Individual><Interruption><Kinetics><Knowledge><Kupffer Cells><Length><Liver><Lung><Lung Respiratory System><Lymphoid Cell><Macrophage><Macrophage Activation><Marrow monocyte><Methods><Microglia><Modern Man><Molecular><Molecular Interaction><Molecular Target><Myelogenous><Myeloid><Myeloid Cells><Mφ><Nature><Non-Polyadenylated RNA><ORFs><Open Reading Frames><Phagocytosis><Physiopathology><Plasma><Plasma Serum><Population><Production><Productivity><Protein Coding Region><Proviruses><Pulmonary Macrophages><RNA><RNA Expression><RNA Gene Products><RNA Splicing><Relapse><Remission><Reporting><Residual><Residual state><Reticuloendothelial System, Serum, Plasma><Ribonucleic Acid><Role><SIV><Simian Immunodeficiency Viruses><Sorting><Splicing><Stellate Sinusoidal Macrophage><Stimulus><Subgroup><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><Tissues><Transcript><Transcription><Translations><Treatment Period><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral reservoir><Viremia><Virion><Virus><Virus Particle><Virus Replication><Virus reservoir><antiretroviral therapy><antiretroviral treatment><biologic><cell type><co-morbid><co-morbidity><cohort><comorbidity><comparative><cytokine><cytotoxic><exhaustion><genetic make-up><genetic makeup><gitter cell><hepatic body system><hepatic organ system><human immunodeficiency virus cure><human immunodeficiency virus persistence><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><human subject><immune activation><immune function><liver macrophage><loss of function><mesoglia><microglial cell><microgliocyte><monocyte><pathophysiology><peripheral blood><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><prevent><preventing><social role><success><thymus derived lymphocyte><transcriptomics><translation><treatment days><treatment duration><viraemia><viral RNA><viral multiplication><viral rebound><viral replication><viral sepsis><virus RNA><virus multiplication><virus protein><virus rebound><virusemia>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Heikki Hyöty

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Likely hiring
Very recent
Active award
$145,543
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard E Lloyd

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Likely hiring
Very recent
Active award
$145,543
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kristian F Lynch

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Likely hiring
Very recent
Active award
$145,543
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eoin McKinney

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Likely hiring
Very recent
Active award
$145,543
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joseph Frank Petrosino

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Likely hiring
Very recent
Active award
$145,543
FY 2026

Project Title

Virome and Immune Responses associated with IA and Type 1 Diabetes

Grant Number:

3R01DK138372-03S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

1/31/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The goal of this project is to integrate analysis of viral and immune responses using white blood cells, nasal swabs and plasma from 450 children previously collected from the prospective cohort TEDDY study, to build upon previous TEDDY findings that strongly implicated prolonged infections with Typ...

Research Terms

<0-11 years old><15 year old><15 years of age><3 year old><3 years of age><6 year old><6 years of age><Acute><Adenoviridae Infections><Adenovirus Infections><Age><Age of Onset><Anti-viral Response><Antibodies><Antibody Response><Antigen Receptors><Antigens><Autoantibodies><Autoantigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autologous Antigens><Birth><Blood Plasma><Blood Sample><Blood leukocyte><Blood specimen><Brittle Diabetes Mellitus><CC-1><CC-3><CCL14><CCL14 gene><CKb1><Celiac Disease><Celiac Sprue><Cell Body><Cells><Chemokine (C-C Motif) Ligand 14><Chemokine CC-1><Chemokine CC-1/CC-3><Chemokine CC-3><Child><Child Youth><Childhood diabetes><Children (0-21)><Coeliac Disease><Collection><Complex><Country><Data><Detection><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disorder><Enterovirus><Enterovirus Infections><Exposure to><Feces><Finland><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transcription><Gene variant><Genes><Genetic><Genetic Markers><Genetic Risk><Genetic Transcription><Genomics><Genotype><Germany><Global Change><Gluten Enteropathy><Gluten-Sensitive Enteropathy><Goals><HCC-1><HCC-1/HCC-3><HCC-3><Humoral Immunities><IDDM><Immune><Immune response><Immunes><Immunity><Infection><Infectious Agent><Innate Immunity><Insulin-Dependent Diabetes Mellitus><International><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Leukocytes><Leukocytes Reticuloendothelial System><Link><MCIF><Marrow leukocyte><Maternal antibody><Modeling><Molecular><NCC-2><NCC2><Native Immunity><Natural Immunity><Neighborhoods><Nested Case-Control Study><Non-Specific Immunity><Nonspecific Immunity><Nontropical Sprue><PBMC><Parturition><Pattern><Peripheral Blood Mononuclear Cell><Plasma><Plasma Serum><Population><Preventative intervention><Preventative strategy><Prevention strategy><Preventive strategy><Prospective cohort><Prospective, cohort study><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Recombinants><Reticuloendothelial System, Serum, Plasma><Risk><Role><SCYA14><SCYL2><SEQ-AN><SY14><Sampling><Self-Antigens><Sequence Analyses><Sequence Analysis><Series><Serology><Serology test><Serotyping><Single cell seq><Small Inducible Cytokine A14><Small Inducible Cytokine Subfamily A (Cys-Cys), Member 14><Source><Sudden-Onset Diabetes Mellitus><Sweden><System><T1 DM><T1 diabetes><T1D><T1DM><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><United States><Vaccination><Vaccines><Viral><Viral Antibodies><Viral Diseases><Virus><Virus Diseases><White Blood Cells><White Cell><Whole Blood><Work><acute infection><age 15><age 15 years><age 3><age 3 years><age 6><age 6 years><ages><allelic variant><analyze gene expression><anti-viral antibody><antibody-based immunity><autoimmune antibody><autoimmune beta cell destruction><autoimmune condition><autoimmune disorder><autoimmune islet destruction><autoimmunity disease><autoreactive antibody><beta cell autoimmunity><beta cell development><biomarker identification><case control><case-controlled><clinical center><cohort><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><disease risk><disorder risk><early childhood><endocrine pancreas development><fifteen year old><fifteen years of age><gene biomarker><gene expression analysis><gene expression assay><gene expression biomarker><gene marker><gene signature biomarker><genetic biomarker><genetic variant><genomic data><genomic dataset><genomic variant><host response><identification of biomarkers><identification of new biomarkers><idiopathic steatorrhea><immune system response><immunogen><immunoresponse><infectious organism><innovate><innovation><innovative><insight><insulin dependent diabetes><insulin dependent type 1><intervention for prevention><islet><islet autoimmunity><islet cell autoimmunity><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><marker identification><multiomics><multiple omics><nasal swab><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><panomics><pediatric diabetes><peripheral blood><population based><prevent><preventing><prevention intervention><preventional intervention strategy><preventive intervention><progression biomarker><progression marker><prospective><protein expression><qRTPCR><response><self reactive antibody><seroconversion><serology assay><single cell analysis><single cell next generation sequencing><single cell sequencing><six year old><six years of age><social role><stool><three year old><three years of age><transcriptional profiling><treatment strategy><type I diabetes><type one diabetes><viral infection><viral microbiome><virome><virus infection><virus-induced disease><white blood cell><white blood corpuscle><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Larissa Nitschke

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$124,106
FY 2026

Project Title

Mechanisms of Neurological Manifestations in Myotonic Dystrophy Type 1

Grant Number:

1K99NS146618-01

Activity Code:

K99

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Myotonic Dystrophy Type 1 (DM1) is a progressive neuromuscular disorder affecting 1 in 8,500 individuals. Although primarily characterized by skeletal muscle dysfunction, over 80% of DM1 patients exhibit neurological manifestations, including cognitive impairment, autistic features,...

Research Terms

<3' Untranslated Regions><3'UTR><AD/HD><ADHD><Adeno-Associated Viruses><Affect><Age><Age Months><Alleles><Allelomorphs><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Ammon Horn><Anxiety><Attention deficit hyperactivity disorder><Automobile Driving><Behavior assessment><Behavioral><Behavioral Assay><Body Tissues><Brain><Brain Diseases><Brain Disorders><Brain Nervous System><Brain Pathology><Brain region><CIC-1 protein><CLC-1 channel><CLC-1 protein><CNS Diseases><CNS Nervous System><CNS disorder><CUG repeat><Calcium Channel><Calcium Channel Antagonist Receptor><Calcium Channel Blocker Receptors><Calcium Ion Channels><Central Nervous System><Central Nervous System Diseases><Central Nervous System Disorders><Characteristics><Chloride Channels><Chloride Ion Channels><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Computing Methodologies><Cornu Ammonis><Cytoplasm><Defect><Dependoparvovirus><Dependovirus><Development><Disease><Disease Progression><Disorder><Disturbance in cognition><Doxycycline><Drowsiness><Dysfunction><Dystrophia myotonica type 1><Encephalon><Encephalon Diseases><Excessive Daytime Sleepiness><Excessive daytime somnolence><Exhibits><Family><Functional disorder><Future><Gene Expression><Gene Transcription><Genes><Genetic Transcription><Goals><High Prevalence><Hippocampus><Histologic><Histologically><Hyperactivity><Impaired cognition><Individual><Injections><Interruption><Intervention><Intracranial CNS Disorders><Intracranial Central Nervous System Disorders><Knock-out><Knockout><Learning><Life><Long-Term Effects><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Memory><Memory Deficit><Memory impairment><Mental Depression><Mice><Mice Mammals><Modeling><Molecular><Molecular Analysis><Morphology><Murine><Mus><Muscle Weakness><Muscular Weakness><Myotonia><Myotonic dystrophy type 1><NMR Imaging><NMR Tomography><Nature><Nerve Cells><Nerve Unit><Neural Cell><Neuraxis><Neurocyte><Neurologic><Neurologic Manifestations><Neurologic Signs and Symptoms><Neurologic Symptoms><Neurological><Neurological Manifestations><Neurological Signs and Symptoms><Neuromuscular Diseases><Neurons><Neurosciences><Non-Polyadenylated RNA><Nuclear><Nuclear Magnetic Resonance Imaging><Nuclear RNA><Pathogenesis><Pathology><Patients><Personality Traits><Phenotype><Physiologic><Physiological><Physiopathology><Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder><Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder><Process><Proteins><QOL><Quality of life><RNA><RNA Expression><RNA Gene Products><RNA Processing><RNA Seq><RNA Splicing><RNA sequencing><RNA-Binding Proteins><RNAseq><Recovery><Research><Ribonucleic Acid><Role><Skeletal Muscle><Sleep><Sleep disturbances><Somnolence><Splicing><Symptoms><Testing><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Transcript><Transcription><VDCC><Vibramycin><Voltage-Dependent Calcium Channels><Voluntary Muscle><Weight><Work><Zeugmatography><aberrant sleep><adeno associated virus group><age associated><age correlated><age dependent><age linked><age related><age specific><ages><alpha-6-Deoxyoxytetracycline><autism attributes><autism indicator><autism spectrum disorder features><autism spectrum disorder indicator><autism spectrum disorder symptoms><autism symptomology><autism symptoms><autism-like symptoms><autism-related attributes><autistic features><autistic symptoms><autistic traits><autistic-like symptoms><behavioral assessment><cognitive dysfunction><cognitive loss><computational methodology><computational methods><computer based method><computer methods><computing method><depression><design><designing><developmental><disease phenotype><disrupted sleep><disturbed sleep><driving><experiment><experimental research><experimental study><experiments><feeding><hippocampal><impaired sleep><insight><irregular sleep><loss of function><memory dysfunction><mouse model><murine model><mutant><myoneural disorder><neural manifestation><neuromuscular degenerative disorder><neuromuscular disorder><neuronal><novel><paralog><paralogous gene><pathophysiology><programs><skeletal muscle chloride channel CIC-1><sleep disruption><sleep dysregulation><sleep/wake disruption><sleep/wake disturbance><sleepiness><social role><stem><therapeutic agent development><therapeutic development><transcriptome sequencing><transcriptomic sequencing><weights>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mirza Muhammad Fahd Qadir

TULANE UNIVERSITY OF LOUISIANA, NEW ORLEANS, LA

Good lead · 56/100
Training-friendly
Very recent
Active award
Career award
$88,775
FY 2026

Project Title

Sex chromosomes and beta-cell function

Grant Number:

5K99DK140067-02

Activity Code:

K99

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/9/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary. Although Type 2 diabetes (T2D) has been established as a disease affecting insulin producing pancreatic β-cells, surprisingly little is known on the molecular differences across sex. Recent work demonstrates that sex affects T2D pathogenesis, and therapeutic response. Generally, sex...

Research Terms

<Adult-Onset Diabetes Mellitus><Affect><Agonist><Anabolism><Androgen Receptor><Aquadiol><Architecture><Assay><Automobile Driving><Autoregulation><B9 endocrine pancreas><Beta Cell><Bioassay><Biological Assay><Biology><Brittle Diabetes Mellitus><Calibration><Candidate Disease Gene><Candidate Gene><Cell Body><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular biology><Cytoplasm><DNA Content><DNA Index><DNA Ploidy><Data><Differences between sexes><Differs between sexes><Dimenformon><Diogyn><Diogynets><Disease><Disorder><Disproportionate number of men><Disproportionately impacts males><Disproportionately in men><Dissection><Drugs><Dysfunction><ER stress><ERalpha><ERα><ESR1><ESR1 gene><Electron Transport><Endocrine Gland Secretion><Endocrine Pancreas><Engineering / Architecture><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Estrace><Estradiol><Estradiol Receptor alpha><Estradiol Receptor α><Estradiol-17 beta><Estradiol-17beta><Estraldine><Estrogen Receptor 1><Estrogen Receptor alpha><Estrogen Receptor α><Estrogen Receptors><Estrogens><Exhibits><FDA approved><Faculty><Female><Foundations><Four Core Genotypes><Functional disorder><GLP-1><Gender Bias><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Genes><Genetic Transcription><Genome><Genomics><Glp-1><Goals><Gonadal Steroid Hormones><Gonosomes><Homeostasis><Hormone Receptor><Hormone secretion><Hormones><Human><Humulin R><IDDM><Image><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin deficiency><Insulin-Dependent Diabetes Mellitus><Intermediary Metabolism><Intracellular Communication and Signaling><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Maturity-Onset Diabetes Mellitus><Measurement><Medication><Menopause><Mentors><Metabolic><Metabolic Processes><Metabolic Protein Degradation><Metabolic stress><Metabolism><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Molecular><Murine><Mus><NIDDM><NR3A1><Nesidioblasts><Network Analysis><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Output><Ovocyclin><Ovocylin><Oxidative Stress><Pancreas><Pancreatic><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Pathogenesis><Pathway Analysis><Pathway interactions><Pharmaceutical Preparations><Phase><Physiologic><Physiological><Physiological Homeostasis><Physiology><Physiopathology><Ploidies><Progynon><Protein Turnover><Proxy><RNA Expression><Receptor Signaling><Regular Insulin><Regulatory Protein Degradation><Research><Research Proposals><Role><SERMs><Selective Estrogen Receptor Modulators><Sex Bias><Sex Chromosomes><Sex Differences><Sex Hormones><Sex Steroid Hormones><Sexual differences><Signal Transduction><Signal Transduction Systems><Signaling><Slice><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><System><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><Testosterone><Therapeutic Estradiol><Therapeutic Estrogen><Therapeutic Hormone><Therapeutic Testosterone><Training><Trans-Testosterone><Transcription><Transcriptional Control><Transcriptional Regulation><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><Woman><Work><adult onset diabetes><antagonism><antagonist><beta cell development><biological signal transduction><biosynthesis><calcium flux><calcium mobilization><career development><cell biology><cell resilience><cell resiliency><cellular resilience><cellular resiliency><chromosome complement><declines in circulating testosterone><declining testosterone><decreased levels of testosterone><decreases in testosterone><decreasing testosterone><deficiency in testosterone><diabetes pathogenesis><differential expression><differentially expressed><diminished testosterone><disproportionately affects males><disproportionately affects men><disproportionately concentrated among men><disproportionately distributed among men><disproportionately higher among men><disproportionately impacts men><disproportionately occurs in men><driving><drug/agent><electron transfer><endocrine pancreas development><endoplasmic reticulum stress><epigenetically><experiment><experimental research><experimental study><experiments><flexibility><flexible><genetic architecture><global gene expression><global transcription profile><glucagon-like peptide 1><gonadal steroids><hormonal secretion><imaging><in vivo><innovate><innovation><innovative><insulin dependent diabetes><insulin dependent type 1><islet><islet development><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><low circulating testosterone><low levels of testosterone><lower testosterone><male><male bias><male predominance><maturity onset diabetes><men><men disproportionately diagnosed><men disproportionately experience><men experience disproportionate rates><mitochondrial><molecular resilience><molecular resiliency><mouse model><multiomics><multiple omics><murine model><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><panomics><pathophysiology><pathway><pharmacologic><predominantly affecting men><prevent><preventing><programs><protein degradation><reduced testosterone><reduction in testosterone><release of sequestered calcium ion into cytoplasm><resilience><resilient><response><response to therapy><response to treatment><scRNA sequencing><scRNA-seq><screening><screenings><sex><sex based differences><sex steroid><sex-dependent differences><sex-related differences><sex-specific differences><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><tenure process><tenure track><testosterone decline><testosterone deficiency><testosterone insufficiency><testosterone loss><therapeutic response><therapy response><transcriptional differences><transcriptome><treatment response><treatment responsiveness><type 2 DM><type I diabetes><type II DM><type one diabetes><type two diabetes><β-cell><β-cells><βCell><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven J Shoptaw

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 54/100
Large award
Recent
Active award
Team-scale grant
$5,664,411
FY 2026

Project Title

NIDA Clinical Trials Network: Big South/West Node

Grant Number:

5UG1DA020024-22

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2005

End Date:

2/29/2032

Why this may be worth a closer look

  • • Large budget suggests more room for personnel or project growth.

Project Abstract

The Big South/West Node of the NIDA Clinical Trials Network (CTN) has been a part of the CTN since 2005 (originally as the Texas Node, expanding to the Big South/West Node in 2020). The Node is led by the shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center...

Research Terms

<21+ years old><Acceleration><Accident and Emergency department><Acute><Adanon><Address><Adoption><Adult><Adult Human><Advisory Committees><Affect><Agonist><Althose><Amfebutamone><Area><Basic Research><Basic Science><Biological Markers><Buprenorphine><Bupropion><California><Cannabidiol><Cardiopulmonary><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Caring><Cessation of life><Clinic><Clinical><Clinical Treatment><Clinical Trials><Clinical Trials Network><Cocaine><Cocaine use disorder><Conduct Clinical Trials><Crystal Meth><Crystal methamphetamine><Death><Deoxyephedrine><Desoxyephedrine><Devices><Discipline><Disease><Disorder><Dissemination and Implementation><Doctor of Philosophy><Dolophine><Drug Therapy><Drug abuse><Drugs><Emergency Department><Emergency Medicine><Emergency room><Ensure><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exercise><Florida><Food and Drug Administration><Funding><GLP-1><Genetic><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Glp-1><Hallucinogenic Agents><Hallucinogenic Drugs><Hallucinogenic Substances><Hallucinogens><Hcrt protein><Hcrt/ORX><Hcrts/ORXs><Health><Heart Vascular><Heart failure><Immune><Immunes><Individual><Injectable><Institution><International><Intervention><Investigators><Ketamine><Leadership><Life><Los Angeles><Manuscripts><Measurement><Medical><Medical center><Medication><Mentors><Methadone><Methadose><Methamphetamine><Methamphetamine use disorder><Methods><Methylamphetamine><Midazolam><Mission><Monitor><Morbidity><Multi-Institutional Clinical Trial><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><N-Methylamphetamine><NIDA><Nalorex><Naltrexone><National Institute of Drug Abuse><National Institute on Drug Abuse><Natural History><Nemexin><New York><Oral><Outcome><Outcome Measure><Overdose><Patients><Persons><Ph.D.><PhD><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phase><Policies><Policy Maker><Prevalence><Primary Care><Productivity><Psilocibin><Psilocybin><Psychedelic Agents><Psychedelics><Psychotomimetic Agents><Public Health><Publications><Publishing><Randomized><ReVia><Receptor Protein><Research><Research Design><Research Personnel><Research Priority><Researchers><Science><Scientific Publication><Scientist><Site><Specialty><Stimulant><Study Type><Task Forces><Texas><Training><Translational Research><Translational Science><Trauma><USFDA><United States><United States Food and Drug Administration><Universities><Vivitrol><Washington><Wellbutrin><abuse of drugs><abuses drugs><addiction><addictive disorder><adulthood><advisory team><antagonism><antagonist><bio-markers><biologic marker><biomarker><buprenorphine treatment><buproprion><cardiac failure><cardiovascular health><cardiovascular risk><cardiovascular risk factor><circulatory system><clinical care><clinical intervention><clinical therapy><co-morbid><co-morbidity><comorbidity><compound repositioning><compound repurposing><dissemination science><drug intervention><drug repositioning><drug repurposing><drug treatment><drug/agent><effective therapy><effective treatment><efficacious therapy><efficacious treatment><emergency settings><epigenetically><experience><geographic site><glucagon-like peptide 1><health care settings><hypocretin><hypocretin/orexin><hypocretins/orexins><implementation science><implementation strategy><implementation study><improved><innovate><innovation><innovative><measurable outcome><medical specialties><meth><meth use disorder><mortality><neural control><neural imaging><neural regulation><neuro-imaging><neuroimaging><neurological imaging><neuromodulation><neuromodulatory><neuroregulation><new therapeutic uses for existing drugs><new use of drug><new uses for an approved drug><new uses for existing drugs><next generation><non-medical opioid use><nonmedical opioid use><novel><opiate crisis><opiate misuse><opioid crisis><opioid epidemic><opioid misuse><orexin><outcome measurement><overdose death><overdose fatalities><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological repurposing><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><precision medicine><precision-based medicine><psychedelic drug><psychostimulant use><psychostimulant use disorder><psychotomimetic drug><pulmonary><pulmonary arterial hypertension><pulmonary artery hypertension><randomisation><randomization><randomly assigned><receptor><repetitive transcranial magnetic stimulation><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><response><scale up><screening><screenings><stimulant use><stimulant use disorder><strategies for implementation><study design><substance use><substance using><success><therapeutic repositioning><therapeutic repurposing><translation research><translational investigation><trial regimen><trial treatment><uptake><use of stimulants>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MADHUKAR H. TRIVEDI

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 54/100
Large award
Recent
Active award
Team-scale grant
$5,664,411
FY 2026

Project Title

NIDA Clinical Trials Network: Big South/West Node

Grant Number:

5UG1DA020024-22

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/1/2005

End Date:

2/29/2032

Why this may be worth a closer look

  • • Large budget suggests more room for personnel or project growth.

Project Abstract

The Big South/West Node of the NIDA Clinical Trials Network (CTN) has been a part of the CTN since 2005 (originally as the Texas Node, expanding to the Big South/West Node in 2020). The Node is led by the shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center...

Research Terms

<21+ years old><Acceleration><Accident and Emergency department><Acute><Adanon><Address><Adoption><Adult><Adult Human><Advisory Committees><Affect><Agonist><Althose><Amfebutamone><Area><Basic Research><Basic Science><Biological Markers><Buprenorphine><Bupropion><California><Cannabidiol><Cardiopulmonary><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Caring><Cessation of life><Clinic><Clinical><Clinical Treatment><Clinical Trials><Clinical Trials Network><Cocaine><Cocaine use disorder><Conduct Clinical Trials><Crystal Meth><Crystal methamphetamine><Death><Deoxyephedrine><Desoxyephedrine><Devices><Discipline><Disease><Disorder><Dissemination and Implementation><Doctor of Philosophy><Dolophine><Drug Therapy><Drug abuse><Drugs><Emergency Department><Emergency Medicine><Emergency room><Ensure><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exercise><Florida><Food and Drug Administration><Funding><GLP-1><Genetic><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Glp-1><Hallucinogenic Agents><Hallucinogenic Drugs><Hallucinogenic Substances><Hallucinogens><Hcrt protein><Hcrt/ORX><Hcrts/ORXs><Health><Heart Vascular><Heart failure><Immune><Immunes><Individual><Injectable><Institution><International><Intervention><Investigators><Ketamine><Leadership><Life><Los Angeles><Manuscripts><Measurement><Medical><Medical center><Medication><Mentors><Methadone><Methadose><Methamphetamine><Methamphetamine use disorder><Methods><Methylamphetamine><Midazolam><Mission><Monitor><Morbidity><Multi-Institutional Clinical Trial><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><N-Methylamphetamine><NIDA><Nalorex><Naltrexone><National Institute of Drug Abuse><National Institute on Drug Abuse><Natural History><Nemexin><New York><Oral><Outcome><Outcome Measure><Overdose><Patients><Persons><Ph.D.><PhD><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phase><Policies><Policy Maker><Prevalence><Primary Care><Productivity><Psilocibin><Psilocybin><Psychedelic Agents><Psychedelics><Psychotomimetic Agents><Public Health><Publications><Publishing><Randomized><ReVia><Receptor Protein><Research><Research Design><Research Personnel><Research Priority><Researchers><Science><Scientific Publication><Scientist><Site><Specialty><Stimulant><Study Type><Task Forces><Texas><Training><Translational Research><Translational Science><Trauma><USFDA><United States><United States Food and Drug Administration><Universities><Vivitrol><Washington><Wellbutrin><abuse of drugs><abuses drugs><addiction><addictive disorder><adulthood><advisory team><antagonism><antagonist><bio-markers><biologic marker><biomarker><buprenorphine treatment><buproprion><cardiac failure><cardiovascular health><cardiovascular risk><cardiovascular risk factor><circulatory system><clinical care><clinical intervention><clinical therapy><co-morbid><co-morbidity><comorbidity><compound repositioning><compound repurposing><dissemination science><drug intervention><drug repositioning><drug repurposing><drug treatment><drug/agent><effective therapy><effective treatment><efficacious therapy><efficacious treatment><emergency settings><epigenetically><experience><geographic site><glucagon-like peptide 1><health care settings><hypocretin><hypocretin/orexin><hypocretins/orexins><implementation science><implementation strategy><implementation study><improved><innovate><innovation><innovative><measurable outcome><medical specialties><meth><meth use disorder><mortality><neural control><neural imaging><neural regulation><neuro-imaging><neuroimaging><neurological imaging><neuromodulation><neuromodulatory><neuroregulation><new therapeutic uses for existing drugs><new use of drug><new uses for an approved drug><new uses for existing drugs><next generation><non-medical opioid use><nonmedical opioid use><novel><opiate crisis><opiate misuse><opioid crisis><opioid epidemic><opioid misuse><orexin><outcome measurement><overdose death><overdose fatalities><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological repurposing><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><precision medicine><precision-based medicine><psychedelic drug><psychostimulant use><psychostimulant use disorder><psychotomimetic drug><pulmonary><pulmonary arterial hypertension><pulmonary artery hypertension><randomisation><randomization><randomly assigned><receptor><repetitive transcranial magnetic stimulation><repositioning approved drugs><repositioning existing drugs><repurpose approved drugs><repurpose approved medication><repurpose approved therapeutic><repurpose existing drugs><repurpose existing medication><repurpose existing medicine><repurpose existing therapeutics><repurpose existing therapies><repurpose medicine><repurposing><repurposing a drug><repurposing agent><repurposing candidates><repurposing established drugs><repurposing established medication><repurposing existing pharmacological agents><repurposing medication><repurposing of already existing drugs><repurposing pharmaceuticals><response><scale up><screening><screenings><stimulant use><stimulant use disorder><strategies for implementation><study design><substance use><substance using><success><therapeutic repositioning><therapeutic repurposing><translation research><translational investigation><trial regimen><trial treatment><uptake><use of stimulants>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Paul T Bremer

MCLEAN HOSPITAL, BELMONT, MA

Good lead · 54/100
Large award
Recent
Active award
Team-scale grant
$3,657,445
FY 2026

Project Title

Antibody-based therapy for fentanyl-related opioid use disorder

Grant Number:

4UH3DA058544-02

Activity Code:

UH3

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/30/2023

End Date:

1/31/2029

Why this may be worth a closer look

  • • Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract. Abuse of synthetic opioids is a rapidly intensifying public health problem with more than 70,000 reported US overdose deaths in 2022. Currently available medications to reverse opioid intoxication include an intranasal formulation of the opioid antagonist naloxone, commonly known as Narcan...

Research Terms

<Abstinence><Accounting><Actiq><Adanon><Address><Affinity><Althose><Ambulatory Care Facilities><American><Animal Model><Animal Models and Related Studies><Antibody Therapy><Applications Grants><Behavior><Behavioral><Binding><Biological Agent><Biological Products><Books><Brain><Brain Nervous System><Brain region><Buffers><Buprenorphine><Clinical><Clinical Treatment Moab><Clonidine><Cocaine><Common Rat Strains><Data><Development><Dihydrohydroxycodeinone><Diprenorphine><Dolophine><Dose><Drug Therapy><Drugs><Duragesic><Effectiveness><Encephalon><Excipients><Fentanest><Fentanyl><Fentyl><Food><Food Preferences><Formulation><Functional MRI><Functional Magnetic Resonance Imaging><Future><Grant Proposals><Hu-mABs><IV Infusion><Injectable><Inpatients><Intravenous><Intravenous infusion procedures><Investigational Drugs><Investigational New Drugs><Isokinetic Exercise><Isokinetics><Isotonic Exercise><Isotonics><Klofenil><Licensing><Life><MAb Therapeutics><Measures><Medication><Methadone><Methadose><Mice><Mice Mammals><Mission><Molecular Interaction><Monkeys><Monoclonal Antibodies><Murine><Mus><NIDA><Nalorex><Naloxone><Naltrexone><Narcan><Narcanti><National Institute of Drug Abuse><National Institute on Drug Abuse><Nemexin><Opiate Addiction><Opiate Antagonist><Opiate Dependence><Opiate Receptors><Opiate receptor antagonist><Opiates><Opioid><Opioid Antagonist><Opioid Receptor><Opioid receptor antagonist><Outpatient Clinics><Overdose><Oxycodeinon><Oxycodone><Oxycodone SR><Oxycontin><PET><PET Scan><PET imaging><PETSCAN><PETT><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacology><Pharmacotherapy><Phase><Phentanyl><Play><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Pre-Clinical Model><Preclinical Models><Prevention><Procedures><Production><Public Health><Rad.-PET><Rat><Rats Mammals><Rattus><ReVia><Receptor Protein><Recommendation><Relapse><Reporting><Rodent><Rodentia><Rodents Mammals><Role><Roxicodone><Running><Safety><Self Administered><Self Administration><Severities><Sodium Chloride><Specific qualifier value><Specificity><Specified><Testing><Therapeutic><Therapeutic Monoclonal Antibodies><Time><Toxicology><United States><Vivitrol><Withdrawal><Work><abuse liability><abuse potential><analog><antagonism><antagonist><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antinociception><antinociceptive><apnea caused by fentanyl><biologics><biopharmaceutical><biotherapeutic agent><developmental><diet choice><diet preference><dietary choice><dietary preferences><drug candidate><drug development><drug intervention><drug treatment><drug/agent><effective therapy><effective treatment><fMRI><fentalogs><fentalogues><fentanyl abuse><fentanyl analog><fentanyl evoked respiratory depression><fentanyl induced apnea><fentanyl induced hypoventilation><fentanyl induced respiratory depression><fentanyl induced ventilatory depression><fentanyl mediated respiratory depression><fentanyl overdose><fentanyl respiratory depression><food choice><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><in vivo><intravenous administration><intravenous infusion><mAbs><manufacture><manufacturing run><medication for opioid use disorder><model of animal><monoclonal Abs><monoclonal antibody drugs><neural><neural circuit><neural circuitry><neurocircuitry><non-human primate><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonhuman primate><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><opiate crisis><opiate deaths><opiate mortality><opiate overdose><opiate related overdose><opiate use disorder><opiate withdrawal><opioid addiction><opioid crisis><opioid deaths><opioid dependence><opioid dependent><opioid detox><opioid detoxification><opioid drug overdose><opioid epidemic><opioid induced overdose><opioid intoxication><opioid medication overdose><opioid mortality><opioid overdose><opioid overdose death><opioid poisoning><opioid related death><opioid related overdose><opioid toxicity><opioid use disorder><opioid withdrawal><overdose death><overdose fatalities><peripheral blood><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><prevent><preventing><production run><programs><receptor><respiratory><respiratory depression caused by fentanyl><response><salt><screening><screenings><side effect><social role><stability testing><subcutaneous><subdermal><synaptic circuit><synaptic circuitry><synthetic opiate><synthetic opioid><therapeutic mAbs>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rajeev Indrajit Desai

MCLEAN HOSPITAL, BELMONT, MA

Good lead · 54/100
Large award
Recent
Active award
Team-scale grant
$3,657,445
FY 2026

Project Title

Antibody-based therapy for fentanyl-related opioid use disorder

Grant Number:

4UH3DA058544-02

Activity Code:

UH3

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/30/2023

End Date:

1/31/2029

Why this may be worth a closer look

  • • Large budget suggests more room for personnel or project growth.

Project Abstract

Abstract. Abuse of synthetic opioids is a rapidly intensifying public health problem with more than 70,000 reported US overdose deaths in 2022. Currently available medications to reverse opioid intoxication include an intranasal formulation of the opioid antagonist naloxone, commonly known as Narcan...

Research Terms

<Abstinence><Accounting><Actiq><Adanon><Address><Affinity><Althose><Ambulatory Care Facilities><American><Animal Model><Animal Models and Related Studies><Antibody Therapy><Applications Grants><Behavior><Behavioral><Binding><Biological Agent><Biological Products><Books><Brain><Brain Nervous System><Brain region><Buffers><Buprenorphine><Clinical><Clinical Treatment Moab><Clonidine><Cocaine><Common Rat Strains><Data><Development><Dihydrohydroxycodeinone><Diprenorphine><Dolophine><Dose><Drug Therapy><Drugs><Duragesic><Effectiveness><Encephalon><Excipients><Fentanest><Fentanyl><Fentyl><Food><Food Preferences><Formulation><Functional MRI><Functional Magnetic Resonance Imaging><Future><Grant Proposals><Hu-mABs><IV Infusion><Injectable><Inpatients><Intravenous><Intravenous infusion procedures><Investigational Drugs><Investigational New Drugs><Isokinetic Exercise><Isokinetics><Isotonic Exercise><Isotonics><Klofenil><Licensing><Life><MAb Therapeutics><Measures><Medication><Methadone><Methadose><Mice><Mice Mammals><Mission><Molecular Interaction><Monkeys><Monoclonal Antibodies><Murine><Mus><NIDA><Nalorex><Naloxone><Naltrexone><Narcan><Narcanti><National Institute of Drug Abuse><National Institute on Drug Abuse><Nemexin><Opiate Addiction><Opiate Antagonist><Opiate Dependence><Opiate Receptors><Opiate receptor antagonist><Opiates><Opioid><Opioid Antagonist><Opioid Receptor><Opioid receptor antagonist><Outpatient Clinics><Overdose><Oxycodeinon><Oxycodone><Oxycodone SR><Oxycontin><PET><PET Scan><PET imaging><PETSCAN><PETT><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacology><Pharmacotherapy><Phase><Phentanyl><Play><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Pre-Clinical Model><Preclinical Models><Prevention><Procedures><Production><Public Health><Rad.-PET><Rat><Rats Mammals><Rattus><ReVia><Receptor Protein><Recommendation><Relapse><Reporting><Rodent><Rodentia><Rodents Mammals><Role><Roxicodone><Running><Safety><Self Administered><Self Administration><Severities><Sodium Chloride><Specific qualifier value><Specificity><Specified><Testing><Therapeutic><Therapeutic Monoclonal Antibodies><Time><Toxicology><United States><Vivitrol><Withdrawal><Work><abuse liability><abuse potential><analog><antagonism><antagonist><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antinociception><antinociceptive><apnea caused by fentanyl><biologics><biopharmaceutical><biotherapeutic agent><developmental><diet choice><diet preference><dietary choice><dietary preferences><drug candidate><drug development><drug intervention><drug treatment><drug/agent><effective therapy><effective treatment><fMRI><fentalogs><fentalogues><fentanyl abuse><fentanyl analog><fentanyl evoked respiratory depression><fentanyl induced apnea><fentanyl induced hypoventilation><fentanyl induced respiratory depression><fentanyl induced ventilatory depression><fentanyl mediated respiratory depression><fentanyl overdose><fentanyl respiratory depression><food choice><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><in vivo><intravenous administration><intravenous infusion><mAbs><manufacture><manufacturing run><medication for opioid use disorder><model of animal><monoclonal Abs><monoclonal antibody drugs><neural><neural circuit><neural circuitry><neurocircuitry><non-human primate><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonhuman primate><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><opiate crisis><opiate deaths><opiate mortality><opiate overdose><opiate related overdose><opiate use disorder><opiate withdrawal><opioid addiction><opioid crisis><opioid deaths><opioid dependence><opioid dependent><opioid detox><opioid detoxification><opioid drug overdose><opioid epidemic><opioid induced overdose><opioid intoxication><opioid medication overdose><opioid mortality><opioid overdose><opioid overdose death><opioid poisoning><opioid related death><opioid related overdose><opioid toxicity><opioid use disorder><opioid withdrawal><overdose death><overdose fatalities><peripheral blood><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><prevent><preventing><production run><programs><receptor><respiratory><respiratory depression caused by fentanyl><response><salt><screening><screenings><side effect><social role><stability testing><subcutaneous><subdermal><synaptic circuit><synaptic circuitry><synthetic opiate><synthetic opioid><therapeutic mAbs>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Soumya Rahima Benhabbour

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 54/100
Large award
Very recent
Active award
$1,106,984
FY 2026

Project Title

Ultra-long-acting in-situ forming implant (ISFI) as a subcutaneous injection for prevention of HIV and unplanned pregnancy

Grant Number:

1R61AI197035-01

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/14/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Large budget suggests more room for personnel or project growth.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Globally, over 50% of those infected with HIV are women, and annually, ~50% of all pregnancies are unplanned. Therefore, there is a critical need to promote female-controlled methods of multipurpose prevention technologies (MPTs) and delivery strategies that can be disassociated from the sex act. Lo...

Research Terms

<AIDS Virus><AIDS prevention><Abscission><Accelerated Phase><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adverse Experience><Adverse event><Africa><African><Agreement><Animals><Anti-Retroviral Agents><BALB C Mouse><BALB/c><Characteristics><Clinical><Clinical Research><Clinical Study><Common Rat Strains><Contraception><Contraceptive Agents><Contraceptive Usage><Contraceptive methods><Contraceptives><Contracting Opportunities><Contracts><Copper Intrauterine Devices><Copper Releasing IUD><Corlutina><Corluvite><Corpus Luteum Hormone><Country><Cyclogest><Data><Delta4-pregnene-3,20-dione><Depo-Medroxyprogesterone Acetate><Development><Dose><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drugs><Engineering><Epidemic><Evaluation><Event><Excipients><Excision><Extirpation><FDA approved><Fatigue><Female><Fertility Control><Formulation><Gestagenic Agents><Gestagens><Gestation><Gestiron><Gestone><Goals><Grant><HIV><HIV Infections><HIV Prevention><HIV disease transmission><HIV incidence><HIV infection spread><HIV infection transmission><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1 incidence><HIV-1 infection><HIV-1 infection incidence><HIV-1 prevention><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV/AIDS incidence><HIV/AIDS prevention><HIV/AIDS transmission><Health Benefit><Health protection><Human><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Viruses><IND Filing><IND application><IND package><IND submission><Implant><Implantable Drug Delivery Systems><Implantable Infusion Pumps><Implantable Perfusion Pumps><In Situ><In Vitro><Inbred BALB C Mice><Incidence><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inhibition of Fertilization><Injectable><Injections><Intramuscular Injections><Investigational New Drug Application><Investigators><LAV-HTLV-III><Lack of Energy><Lipo-Lutin><Liquid substance><Luteohormone><Lutocyclin><Lutocylin M><Lutogyl><Lutromone><Lymphadenopathy-Associated Virus><Macaca><Macaque><Medication><Medroxyprogesterone 17-Acetate><Medroxyprogesterone Acetate><Medroxyprogesteroni Acetas><Methods><Methylacetoxyprogesterone><Metipregnone><Mice><Mice Mammals><Modeling><Modern Man><Multipurpose prevention technology><Murine><Mus><NHP models><Ovulation><PK/PD><Patients><Performance><Pharmaceutical Preparations><Pharmacokinetics><Phase><Phase 3 Clinical Trials><Phase III Clinical Trials><Post-vaccination infection><PrEP><Pre IND FDA meeting><Pre-IND mtg><Pregn-4-ene-3,20-dione><Pregnancy><Pregnenedione><Preparation><Prevent HIV><Privacy><Process><Progestagenic Agents><Progestasert><Progestational Agents><Progestational Compounds><Progestational Hormones><Progesterone><Progesterone Agents><Progestins><Progestogel><Progestogens><Progestol><Progeston><Prolidon><Proluton><Property><Prophylactic treatment><Prophylaxis><Public Health><Rat><Rats Mammals><Rattus><Regimen><Removal><Research Personnel><Researchers><Residual><Residual state><Rodent><Rodentia><Rodents Mammals><SHIV><Safety><Science><Sexual Transmission><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Site><Subcutaneous Injections><Surgical Removal><Suspension substance><Suspensions><Syngesterone><System><Tail><Technology><Technology Transfer><Therapeutic Progesterone><Therapeutic Progestin><Time><Toxic effect><Toxicities><Translations><Trocars><Unplanned pregnancy><User Compliance><Utrogestan><Vaginal Ring><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral><Virus-HIV><Woman><Writing><allergen response><allergic response><allergy response><anti-retroviral><biomedical implant><breakthrough infection><clinical translation><clinically translatable><commercial scale manufacturing><comparative><compound optimization><contraceptive use><controlled release><copper IUD><copper intra-uterine contraceptive><copper intra-uterine device><copper intrauterine contraceptive><cost effective><design><designing><developmental><drug/agent><fluid><formulation optimization><global health><high risk><human immunodeficiency virus incidence><human immunodeficiency virus infection><human immunodeficiency virus transmission><implant design><implant device><implantable device><in vivo><indwelling device><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><intramuscular drug administration><intravaginal ring><lead optimization><liquid><manufacture><manufacturing ramp-up><manufacturing scale-up><meeting><meetings><men><multipurpose prevention><nano particle><nano-sized particle><nanoparticle><nanosized particle><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><nonhuman primate models><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><particle><pathogen><pharmacokinetic model><pharmacokinetics and pharmacodynamics><pharmacometrics><phase III protocol><pill><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><pre-clinical><pre-exposure prophylaxis><preclinical><preparations><prevent AIDS><prevent human immunodeficiency virus><prophylactic><rational design><resection><scale up batch><scale up production><sex><sexually acquired infection><sexually transmitted><simian HIV><simian human immunodeficiency virus><spread of human immunodeficiency virus><subdermal injection><translation><unintended pregnancy><upscale manufacturing><♀>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sebla B. Kutluay

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 52/100
Likely hiring
Solid budget
Active award
$466,500
FY 2026

Project Title

Regulation and Targeting of HIV-1 Integrase-RNA Interactions

Grant Number:

5R01AI150497-10

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2017

End Date:

11/30/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract The emergence of drug resistant human immunodeficiency virus type-1 (HIV-1) variants and the lack of an effective vaccine require the development of novel anti-retroviral drugs. The catalytic activity of HIV-1 integrase (IN) has been successfully targeted by several highly effective and we...

Research Terms

<Anti-Retroviral Agents><Anti-viral Agents><Assay><Binding><Bioassay><Biochemical><Biological Assay><C-terminal><CRISPR editing screen><CRISPR screen><CRISPR-based screen><CRISPR/Cas9 screen><Capsid><Cell Body><Cells><Cementation><Clinical><Complement><Complement Proteins><Complex><DNA mutation><Data><Defect><Dependence><Development><Distal><Drug resistance><Drugs><EC 2.7.7.49><Electron Microscopy><Electrostatics><Ensure><Enzyme Gene><Enzymes><Evolution><Funding><Generations><Genetic Change><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Genome><Goals><Guide RNA><HAART><HIV-1><HIV-I><HIV1><Highly Active Antiretroviral Therapy><Human Activities><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><In Vitro><Innate Immune Response><Integrase><Integrase Inhibitors><Kinetics><Knowledge><Life Cycle><Life Cycle Stages><Location><Mediating><Medication><Molecular><Molecular Interaction><Morphogenesis><Mutagenesis><Mutagenesis Molecular Biology><Mutation><Nature><Non-Polyadenylated RNA><Nucleic Acids><Nucleocapsid><Outcome><Pathogenesis><Pathway interactions><Patients><Pharmaceutical Preparations><Play><Publishing><Putative RNA-Binding Region><RNA><RNA Binding><RNA Binding Domain><RNA Degradation><RNA Gene Products><RNA Recognition Motif><RNA Transcriptase><RNA bound><RNA-Dependent DNA Polymerase><RNA-Directed DNA Polymerase><RNP Domain><RNP Motif><RNP-1 Signature><Regulation><Reporting><Resistance><Reverse Transcriptase><Reverse Transcription><Revertase><Ribonucleic Acid><Role><Sampling><Short interfering RNA><Small Interfering RNA><Specificity><Testing><Therapeutic><Vaccines><Variant><Variation><Viral><Viral Genome><Virion><Virus><Virus Particle><Virus Replication><Work><anti-retroviral><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><clustered regularly interspaced short palindromic repeats screen><complementation><developmental><drug resistant><drug/agent><empowerment><experiment><experimental research><experimental study><experiments><gRNA><genome mutation><highly active antiretroviral treatment><inhibitor><life course><morphogenetic process><mutant><novel><particle><pathway><physical separation><premature><prematurity><resistance to Drug><resistant><resistant to Drug><siRNA><social role><therapeutic agent development><therapeutic development><therapeutic target><tool><viral RNA><viral multiplication><viral replication><virus RNA><virus genome><virus multiplication>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gregory B Melikian

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$463,600
FY 2026

Project Title

Imaging protease activation and maturation of single HIV-1 particles

Grant Number:

5R01AI189249-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/18/2024

End Date:

10/31/2029

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

HIV-1 is released from infected cells as an immature particle consisting of Gag and Gag-Pol polyproteins. At some point during/after virus budding from the plasma membrane, the viral protease (PR) autoactivates by cleaving itself off Gag-Pol and proceeds to cleave Gag and Gag-Pol at multiple sites a...

Research Terms

<Address><Assay><Bioassay><Biological Assay><Capsid><Cell Body><Cell Communication and Signaling><Cell Membrane Lipids><Cell Membrane Permeability><Cell Signaling><Cell membrane><Cells><Ceramides><Complex><Cone><Cytoplasm><Cytoplasmic Membrane><DNA mutation><Detection><Dimerization><EC 2.7.7.49><Electron Microscopy><Endosomes><Environment><Enzyme Gene><Enzymes><Esteroproteases><Event><FRET><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fluorescence><Fluorescence Light Microscopy><Fluorescence Microscopy><Fluorescence Resonance Energy Transfer><Fluorescent Probes><Förster Resonance Energy Transfer><Genetic Change><Genetic defect><Genetic mutation><HIV-1><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Image><Immunoblotting><In Vitro><Integrase><Intracellular Communication and Signaling><Investigation><Ions><Knowledge><Label><Light><Link><Lipids><Measures><Membrane><Membrane Lipids><Microscopy><Monitor><Mutation><Nucleocapsid><Peptidases><Peptide Hydrolases><Perfusion><Photoradiation><Plasma Membrane><Position><Positioning Attribute><Process><Property><Protease Gene><Proteases><Protein Dimerization><Proteinases><Proteins><Proteolytic Enzymes><RNA Transcriptase><RNA-Dependent DNA Polymerase><RNA-Directed DNA Polymerase><Receptosomes><Regulation><Reporting><Reverse Transcriptase><Revertase><Role><Scanning Electron Microscopy><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Site><Sorting><Sphingomyelin Cholinephosphohydrolase><Sphingomyelin Cleaving Enzyme><Sphingomyelin Phosphodiesterase><Sphingomyelinase><Sphingomyelinase C><Sphingomyelins><Structural Protein><Techniques><Testing><Viral><Virion><Virus><Virus Assembly><Virus Particle><Visualization><Western Blotting><Western Immunoblotting><biological signal transduction><biophysical approaches><biophysical methodology><biophysical methods><biophysical techniques><dimer><experiment><experimental research><experimental study><experiments><flow cytophotometry><genome mutation><genomic RNA><imaging><imaging approach><imaging based approach><imaging study><innovate><innovation><innovative><insight><membrane permeability><membrane structure><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><particle><plasmalemma><pol Gene Products><pol Polyproteins><pol Protein><premature><prematurity><protein blotting><recruit><sensor><social role><spatial and temporal><spatial temporal><spatiotemporal><therapeutic target><viral assembly><viral genomics><virus genomics>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mansoor M. Amiji

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$442,422
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James E Egan

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$442,422
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward J Kim

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$442,422
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gerardo Guillermo Mackenzie

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$442,422
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

5R01CA269233-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Changmeng Cai

UNIVERSITY OF MASSACHUSETTS BOSTON, BOSTON, MA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$418,610
FY 2026

Project Title

Targeting FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancer

Grant Number:

5R01CA299202-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/21/2025

End Date:

1/31/2030

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Background: Prostate cancer (PCa) can develop resistance to androgen receptor (AR)-targeted therapies and progress to AR-indifferent stages, such as NEPC or DNPC, through lineage plasticity. While several driver transcription factors for AR-indifferent PCa have been identified, the m...

Research Terms

<ACSL1><ACSL1 Gene><AOF2><AP-1><AP-1 Enhancer-Binding Protein><AP1><AP1 protein><ASCL1><ASCL1 gene><ASCL1 protein><ASH1><Achaete-Scute Complex Homolog-Like 1 Protein><Achaete-Scute Complex-Like 1 Protein><Achaete-Scute Homolog 1 Protein><Activator Protein-1><Adenocarcinoma><Adenocarcinoma Cell><Androgen Receptor><Automobile Driving><Basal Transcription Factor><Basal transcription factor genes><Binding><Cancer Patient><Cell Body><Cell Line><CellLine><Cells><Chromatin><Clinical Trials><Collaborations><Combined Modality Therapy><Data><Development><Enhancer-Binding Protein AP1><Enhancers><Event><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic Transcription><Goals><HASH1><HASH1 protein><Histones><Human><JUN><KDM1A><KDM1A gene><LSD1><Lysine-Specific Demethylase 1><Lysine-Specific Demethylase 1A><MASH 1 protein><MASH1><MASH1 protein><Malignant Adenoma><Malignant Glandular Cell><Malignant neoplasm of prostate><Malignant prostatic tumor><Mammalian Achaete-Scute Homolog 1><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Neuroendocrine Prostate Cancer><Nucleosomes><PDX model><Patient derived xenograft><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peptides><Process><Prostate CA><Prostate Cancer><Prostate malignancy><Protein Family><Publishing><RNA Expression><Research><Resistance><Resistance development><Resistant development><Role><Series><Site><Strains Cell Lines><Testing><Therapeutic><Transcription><Transcription Factor AP-1><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Mice><Translating><Tumor Cell><Xenograft Model><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><cell transformation><combination therapy><combined modality treatment><combined treatment><cultured cell line><demethylation><design><designing><determine efficacy><developing resistance><developmental><driving><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><hormone refractory prostate cancer><improved><inhibitor><insight><jun Oncogene><mouse model><multi-modal therapy><multi-modal treatment><murine model><neoplastic cell><overexpress><overexpression><patient derived xenograft model><patient oriented outcomes><pre-clinical><preclinical><programs><prostate cancer cell><prostate cancer cell line><prostate cancer progression><prostate cancer resistant to androgen><prostate tumor cell><resistant><response><small molecular inhibitor><small molecule inhibitor><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcription factor><transcriptional reprogramming><transformed cells><treatment effect><treatment strategy><tumor><xenograft transplant model><xenotransplant model>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Taiyi Diana Kuo

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$402,500
FY 2026

Project Title

Decipher the Function of C2cd4a in Metabolism

Grant Number:

5R01DK132227-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

11/30/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Type 2 diabetes (T2D) is caused by insulin resistance in peripheral tissues and pancreatic beta-cell dysfunction. Insulin resistance precedes beta-cell failure, and the beta-cell’s inability to keep up with the increased demand of insulin production and secretion leads to glucose int...

Research Terms

<3C-based approach><3C-based assay><3C-based method><3C-based strategy><3C-based technique><3C-based technology><Ablation><Adult-Onset Diabetes Mellitus><Affect><Agonist><Aldolase B><Amino Acid Sequence><Assay><Basal Transcription Factor><Basal transcription factor genes><Beta Cell><Binding><Bioassay><Biological><Biological Assay><Blood Plasma><Body Tissues><Cell Body><Cell Function><Cell Maturation><Cell Nucleus><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Clampings><Closure by clamp><Co-Immunoprecipitations><Consensus><Coupled><D-Glucose><DNA Binding Domain><DNA mutation><DNA-Binding Protein Motifs><Data><Dextrose><Diabetes Mellitus><Disease><Disorder><Dysfunction><Enhancers><Ethnic Group><Ethnic People><Ethnic Population><Ethnic individual><Ethnicity People><Ethnicity Population><Ex4 peptide><Exendin 4><Exercise><Exons><FKHR><FOXO1><FOXO1A><FOXO1A gene><Failure><Female><Forkhead Box O1A><Forkhead in Rhabdomyosarcoma><Foundations><Frequencies><Functional RNA><Functional disorder><GLP-1 receptor><GLP-I receptor><GWA study><GWAS><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Glibenclamide><Glucose><Glucose Intolerance><Glybenclamide><Glyburide><High Fat Diet><Human><Human Genetics><Humulin R><Hyperglycemia><Hypoglycemia><Insulin><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Intercistronic Region><Intergenic Regions><Intermediary Metabolism><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out><Knock-out Mice><Knockout><Knockout Mice><LDH-A><LDH-M><Lactate Translocase><Lactate Transport Protein><Lactate Transporter><Link><Maps><Maturity-Onset Diabetes Mellitus><Messenger RNA><Metabolic Processes><Metabolism><Mice><Mice Mammals><Micronase><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Mutation><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noncoding RNA><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nontranslated RNA><Novolin R><Nucleus><Null Mouse><OGTT><Oral Glucose Tolerance Test><Pancreatic beta Cell><Pancreatic β-Cell><Pathogenesis><Pathway interactions><Patients><Peripheral><Phenotype><Physiopathology><Plasma><Plasma Serum><Predisposition><Predisposition gene><Primary Protein Structure><Production><Proteins><PubMed><Publications><Pyruvate><RNA Expression><Regular Insulin><Regulation><Reporter><Reporting><Repression><Reticuloendothelial System, Serum, Plasma><Role><SNP Map><Scientific Publication><Secondary to><Single Base Polymorphism><Single Nucleotide Polymorphism><Single Nucleotide Polymorphism Map><Site><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Strenuous Exercise><Structure of beta Cell of islet><Subcellular Process><Sulfonylurea Compounds><Susceptibility><Susceptibility Gene><T2 DM><T2D><T2DM><Testing><Therapeutic><Tissues><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Untranslated RNA><Work><adult onset diabetes><attenuated insulin secretion><biologic><blunted insulin secretion><cell dedifferentiation><chromatin conformation capture><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><chromosome capture><chromosome conformation capture><cofactor><db/db mouse><decreased insulin release><decreased insulin secretion><defective insulin secretion><derepression><diabetes><diabetes mellitus therapy><diabetes risk><diabetes therapy><diminished insulin release><diminished insulin secretion><ethnic subgroup><ethnicity group><exenatide><experience><experiment><experimental research><experimental study><experiments><gain of function><genome mutation><genome scale><genome wide analysis><genome wide association><genome wide association scan><genome wide association study><genome wide studies><genome-wide><genome-wide analysis><genome-wide identification><genomewide><genomewide association scan><genomewide association study><glucagon-like peptide-1 receptor><hyperglycemic><hypoglycemic><hypoglycemic episodes><impaired insulin release><impaired insulin secretion><in vivo><inadequate insulin release><inadequate insulin secretion><insight><insulin resistant><insulin secretion><insulin tolerance><intense exercise><islet><ketosis resistant diabetes><lactate dehydrogenase A><lowered insulin secretion><mRNA><male><maturity onset diabetes><mouse model><multiomics><multiple omics><murine model><noncoding><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><panomics><pathophysiology><pathway><precision medicine><precision-based medicine><predisposing gene><prevent><preventing><promoter><promotor><protein complex><protein sequence><reduced insulin release><response><single nucleotide variant><social role><strenuous activity><strenuous physical activity><sulfonylurea><suppressed insulin release><suppressed insulin secretion><susceptibility allele><susceptibility locus><susceptibility variant><transcription factor><type 2 DM><type II DM><type two diabetes><vigorous exercise><vigorous physical activity><virtual><whole genome association analysis><whole genome association study><β-cell><β-cells><βCell><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeremy Allen Goettel

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

Good lead · 52/100
Likely hiring
Solid budget
Active award
$400,175
FY 2026

Project Title

Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice

Grant Number:

5R01AI176521-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/21/2023

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY With no universal cure, development of an effective vaccine to prevent HIV-1 infection remains a primary goal. A major hurdle for the development of successful vaccination strategies has been the lack of affordable, accessible, tractable, and relevant preclinical model systems. Inve...

Research Terms

<AICDA><AICDA protein><AID gene><AID protein><AIDS Virus><AIDS focused research><AIDS related research><AIDS research><AIDS science><AIDS specific research><Ab response><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antigen-Presenting Cells><Antigenic Determinants><Antigens><Autologous><B blood cells><B cell><B cell receptor><B cells><B-Cell Antigen Receptor><B-Cells><B-Lymphocytes><B-cell><Basic Research><Basic Science><Binding Determinants><Binding Sites><Biologic Models><Biological Models><Blood Precursor Cell><Body Tissues><CD34><CD34 gene><CDA2 protein><CSF1><CSF1 gene><Cell Communication><Cell Function><Cell Interaction><Cell Isolation><Cell Physiology><Cell Process><Cell Segregation><Cell Separation><Cell Separation Technology><Cell-to-Cell Interaction><Cellular Function><Cellular Physiology><Cellular Process><Class I Antigens><Class I Major Histocompatibility Antigens><Clinical Trials><Combining Site><Complex><Complex Class 1><Cord Blood><Cytotoxic cell><Data><Development><Disease><Disorder><Engraftment><Ensure><Epitopes><Ethics><Evaluation><Exhibits><Future><Generations><Genes><Glycans><Goals><GvHD><HIV><HIV Infections><HIV focused research><HIV immunization><HIV immunize><HIV investigation><HIV related research><HIV research><HIV science><HIV specific research><HIV vaccinated><HIV vaccination><HIV viral infection><HIV virus infection><HIV-1><HIV-1 immunization><HIV-1 infection><HIV-1 vaccination><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><HL-A Antigens><HLA Antigens><HPCA1><Hematopoiesis><Hematopoietic Cellular Control Mechanisms><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Heterograft><Heterologous Transplantation><Histocompatibility Antigens Class I><Histocompatibility Complex><Histocompatibility Complices><Homologous Wasting Disease><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human Leukocyte Antigens><Human immunodeficiency virus 1><Immune><Immune response><Immune system><Immunes><Immunization><Immunodeficient Mouse><Immunologic Subtyping><Immunophenotyping><Implant><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Investigation on HIV><Investigators><K lymphocyte><LAV-HTLV-III><Leukocyte Antigens><Liver><Lymphadenopathy-Associated Virus><Lymphatic cell><Lymphocyte><Lymphocytic><Lymphoid Cell><MCSF><MGC31930><MHC Class I Molecule><MHC Class I Protein><MHC class I antigen><Major Histocompatibility Complex><Major Histocompatibility Complex Class 1><Major Histocompatibility Complices><Mediating><Methods><Mice><Mice Mammals><Model System><Modern Man><Mouse Strains><Murine><Mus><Myelogenous><Myeloid><Myeloid Cells><Myelopoiesis><NK Cells><Natural Killer Cells><Operative Procedures><Operative Surgical Procedures><Pathogenesis><Penetration><Polysaccharides><Pre-Clinical Model><Preclinical Models><Prevention><Protocol><Protocols documentation><Publishing><Reactive Site><Research Personnel><Researchers><Runt Disease><Somatic Mutation><Source><Subcellular Process><Surgical><Surgical Interventions><Surgical Procedure><System><T-Cell Activation><T-Cell Depletion><T-Cell Development><T-Cell Ontogeny><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T-cell depletion therapy><T-lymphocyte depletion therapy><Techniques><Testing><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Tissues><Translating><Translational Research><Translational Science><Transmission><Tropism><Umbilical Cord Blood><Vaccination><Vaccines><Viral Diseases><Virus><Virus Diseases><Virus Replication><Virus-HIV><Work><Xenograft><Xenograft procedure><Xenotransplantation><accessory cell><activate T cells><activation-induced cytidine deaminase><activation-induced deaminase><adaptive immune response><adaptive immunity><antibody biosynthesis><antigen-specific T cells><antiretroviral therapy><antiretroviral treatment><blood cell formation><blood cell progenitor><blood progenitor><blood stem cell><blood-forming stem cell><cell sorting><clinical applicability><clinical application><developmental><ethical><fetal><fetal cord blood><graft versus host disease><graft vs host disease><graft vs. host disease><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><hepatic body system><hepatic organ system><host response><human fetal tissue><human fetus tissue><human immunodeficiency virus infection><human immunodeficiency virus research><humanized mice><humanized mouse><immune system response><immunization against HIV><immunization strategy><immunization with HIV><immunized with HIV><immunogen><immunoglobulin biosynthesis><immunoresponse><improved><infected with HIV><infected with human immunodeficiency virus><insight><interest><life span><lifespan><lymph cell><model of animal><mouse model><murine model><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><next generation><non-human primate><nonhuman primate><novel><pre-clinical><preclinical><prevent><preventing><receptor binding><receptor bound><reconstitute><reconstitution><research addressing HIV><research in HIV><research into HIV><research on HIV><research on human immunodeficiency virus><research to address HIV><response><science on HIV><science to address HIV><somatic variant><studies on HIV><surgery><thymus derived lymphocyte><translation research><translational investigation><translational study><transmission process><universal vaccine><vaccination against HIV><vaccination against HIV-1><vaccination protocol><vaccination strategy><vaccination study><vaccination trial><vaccination with HIV><vaccine against HIV-1><vaccine protocol><vaccine study><vaccine trial><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease><xeno-transplant><xeno-transplantation>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kyuyeon Han

UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, IL

Good lead · 52/100
Likely hiring
Solid budget
Active award
$399,750
FY 2026

Project Title

Identification of a new role of membrane‐type 1 matrix metalloproteinases in corneal neovascularization

Grant Number:

5R01EY033758-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

11/30/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Corneal neovascularization (NV) can be caused by severe corneal injury or infection and is a leading cause of blindness. Balance of pro-angiogenic factors and anti-angiogenic factors are important to maintain avascular corneal tissue. Pro-angiogenic factors such as VEGFA an...

Research Terms

<72-kDa Gelatinase><72-kDa Type IV Collagenase><72kD type IV Collagenase><92-kDa Gelatinase><92-kDa Type IV Collagenase><ADAM-17><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Factor><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Factor><Angiogenic Inhibitors><Angiostatic Agents><Angiostatin><Angiostatins><Animal Model><Animal Models and Related Studies><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Antibodies><Assay><BFR-1><Basic Fibroblast Growth Factor><Basic Fibroblast Growth Factor Gene><Binding><Bioassay><Biological Assay><Biophysics><Blindness><Blood Vessels><Body Tissues><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Extracellular Matrix><Cells><Cellular Infiltration><Chloroiodoquine><Clioquinol><Cornea><Corneal Angiogenesis><Corneal Diseases><Corneal Disorder><Corneal Injury><Corneal Neovascularization><Corneal infection><DNA Synthesis Factor><Drugs><ECM><EPC-1 protein><Effectiveness><Endostatins><Endothelial Cell Growth Factor><Endothelial Cells><Enzyme Gene><Enzymes><Equilibrium><Event><Extracellular Matrix><Extracellular Matrix Degradation><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><FGF><FGF-2><FGF2><FGF2 gene><FGFB><FGFR2><FGFR2 gene><FLK1><FLT VEGF Receptor><FLT1 RTK><FLT1 Receptor Tyrosine Kinase><Fibroblast Growth Factor><Fibroblast Growth Factor 2><Fibroblast Growth Factor 2 Gene><Fibroblast Growth Factor Gene Family><Fibroblast Growth Factor Receptor 2 Gene><Fibroblast Growth Regulatory Factor><Fibroblasts><Flt-1><Folate><Folic Acid><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Gelatinase A><Gelatinase B><Gelatinase Neutrophil><Goals><HBGF-2><Heparin-Binding Growth Factor 2><Heparin-Binding Growth Factor Class II><Immune infiltrates><Impairment><Implant><In Vitro><Infiltration><Inflammation><Inflammatory><Injury><Intracellular Communication and Signaling><Iodochlorhydroxyquin><Iodochloroxyquinoline><KDR gene><KGFR Gene><KO mice><KSAM-1><Keratinocyte Growth Factor Receptor Gene><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Kringles 1-4 of Plasminogen><Lead><Libraries><Lytotoxicity><MMP Inhibitor><MMP-2><MMP-8><MMP-9><MMP-9 Protein><MMP14><MMP14 gene><MMPs><MT1-MMP><Macrophage><Macrophage Gelatinase><Matrix Metalloproteinase Inhibitor><Matrix Metalloproteinase-14><Matrix Metalloproteinase-2><Matrix Metalloproteinase-8><Matrix Metalloproteinase-9><Matrix Metalloproteinases><Measures><Mediating><Medication><Membrane-Type Matrix Metalloproteinase 1><Membrane-Type Matrix Metalloproteinase 14><Mice><Mice Mammals><Microbial keratitis><Molecular Biology Techniques><Molecular Interaction><Murine><Mus><Mφ><Neovascularization Inhibitors><Neutrophil Collagenase><Null Mouse><PEDF><PMNL Collagenase><Pb element><Pharmaceutical Preparations><Prostate Epithelial Cell Growth Factor><Protein Cleavage><Proteins><Proteolysis><Proto-Oncogene Protein flt><Pteroylglutamic Acid><Receptor Protein><Receptor Tyrosine Kinase,Class V><Regulation><Reporting><Role><Sight><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><System><TK14><TNF-alpha converting enzyme><TNF-α converting enzyme><Testing><Therapeutic><Therapeutic Agents><Tissues><Type V Collagenase><Tyrosine Protein Kinase FRT><Tyrosine Protein Kinase Receptor FLT><VEGF><VEGF Receptor flt-1 Protein><VEGF Receptors><VEGFA><VEGFA gene><VEGFR><VEGFR-1><VEGFR-2><VEGFR1><VEGFR2><VEGFs><VPF Receptor><Validation><Vascular Endothelial Cell><Vascular Endothelial Cell Growth Factor Receptor><Vascular Endothelial Growth Factor A><Vascular Endothelial Growth Factor Receptor 2><Vascular Endothelial Growth Factor Receptor-1><Vascular Endothelial Growth Factors><Vascular Permeability Factor Receptor><Vasculotropin><Vision><Vitamin M><Wild Type Mouse><analog><antiangiogenic><bFGF><balance><balance function><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><cell type><conditional knock-out><conditional knockout><cornea disorder><corneal><corneal wound><cytokine><cytotoxicity><drug/agent><early PDL protein><early population doubling level cDNA-1 protein><early population doubling level protein><enzyme activity><experiment><experimental research><experimental study><experiments><fms-Like Tyrosine Kinase><heavy metal Pb><heavy metal lead><immune cell infiltrate><in vivo><infections in the cornea><infectious keratitis><inhibitor><injured><injuries><innovate><innovation><innovative><membrane activity><model of animal><mutant><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pigment epithelium-derived factor><proMMP-2><protein expression><quinoline><quinoline analog><receptor><scaffold><scaffolding><side effect><small molecular inhibitor><small molecule><small molecule inhibitor><social role><tumor necrosis factor alpha convertase><tumor necrosis factor-alpha converting enzyme><validations><vascular><vision loss><visual function><visual loss><vitamin Bc><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SARAH SPIEGEL

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA

Good lead · 52/100
Likely hiring
Solid budget
Active award
$388,125
FY 2026

Project Title

Ins and outs of the bioactive sphingolipid metabolite sphingosine-1-phosphate

Grant Number:

5R35GM152058-03

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

11/30/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY AND RELEVANCE The sphingolipid metabolites, sphingosine-1-phosphate (S1P) and its precursors sphingosine and ceramides, have emerged as pleiotropic signaling molecules that regulate diverse cellular responses. Previously, we have shown that in response to numerous stimuli, S1P produc...

Research Terms

<4-Sphingenine><Address><Area><Auditory><Bioenergetics><Biological Function><Biological Process><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell membrane><Cells><Ceramides><Cholesterol><Cholesterol Homeostasis><Coin><Communication><Cytoplasmic Membrane><Enzyme Gene><Enzymes><Family><GeneHomolog><Goals><Homolog><Homologous Gene><Homologue><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunologic Diseases><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Inflammatory><Intermediary Metabolism><Intracellular Communication and Signaling><Link><Location><Lower Organism><Lysosomes><Membrane><Metabolic><Metabolic Processes><Metabolism><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mitochondria><Movement><Names><Neoplasm Metastasis><Organelles><Organism><Plasma Membrane><Process><Proteins><Receptor Protein><Regulation><Research><Role><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Site><Sphingolipids><Sphingosine><Stimulus><biological signal transduction><blood glucose regulation><body movement><cancer metastasis><cholesterol metabolism><glucose control><glucose homeostasis><glucose regulation><human disease><infancy><infantile><living system><membrane structure><mitochondrial><mitochondrial membrane><name><named><naming><novel><plasmalemma><receptor><response><sensor><social role><sphingosine 1-phosphate><sphingosine kinase><tumor cell metastasis>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brent Allen Hanks

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100
Likely hiring
Solid budget
Active award
$352,827
FY 2026

Project Title

Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities

Grant Number:

5R01CA251136-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/20/2021

End Date:

12/31/2026

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

The recent success and expanded use of the checkpoint inhibitor immunotherapies in clinical oncology has resulted in an increased incidence of a variety of immune-related adverse events (irAEs), some of which can have a lasting impact on the lives of our patients. The continued development of adjuva...

Research Terms

<70-kD Heat-Shock Protein><Address><Adjuvant><Antibody Therapy><Arthritis><B7-H1><Blood Neutrophil><Blood Plasma><Blood Polymorphonuclear Neutrophil><Body Tissues><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CDw128b><CMKAR2><CXCR2><Cancer Patient><Cell Communication and Signaling><Cell Signaling><Checkpoint inhibitor><Chemotactic Cytokines><Chronic><Clinical Management><Clinical Oncology><Clinical Research><Clinical Study><Colitis><Colon><Combination immunotherapy><DNA Alteration><DNA Sequence Alteration><DNA mutation><Data><Development><Distant><Engineering><Foundations><Future><Generations><Genetic><Genetic Alteration><Genetic Change><Genetic Diversity><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic Variation><Genetic defect><Genetic mutation><Germ Lines><HSP 70><HSP70><Heat-Shock Proteins 70><Homolog of Drosophila TOLL><Homologous Chemotactic Cytokines><Human><IL8R2><IL8RB><IL8RB gene><IRB><IRBs><Immune><Immune Modulation Therapy><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunologically Directed Therapy><Immunooncology><Immunotherapeutic agent><Immunotherapy><Incidence><Individual><Inflammasome><Inflammatory><Innate Immune System><Institutional Review Boards><Intercrines><Intracellular Communication and Signaling><Investigation><Knock-out><Knockout><Lamina Propria><Link><Lung><Lung Inflammation><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Malignant Melanoma><Marrow Neutrophil><Mediating><Melanoma><Melanoma patient><Mice><Mice Mammals><Modality><Modeling><Modern Man><Murine><Mus><Mutation><Neutrophil Infiltration><Neutrophil Recruitment><Neutrophilic Granulocyte><Neutrophilic Infiltrate><Neutrophilic Leukocyte><Nivolumab><Opdivo><Organ><Outcome><PD-1 antibody><PD-1 antibody therapy><PD-1 blockade><PD-1 therapy><PD-L1><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 blockade><PDL-1><Pathogenesis><Pathology><Pathway interactions><Patients><Plasma><Plasma Serum><Pneumonitis><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Prediction of Response to Therapy><Prevalence><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protocol><Protocols documentation><Pulmonary Inflammation><QOL><Quality of life><Recombinant DNA Technology><Recurrence><Recurrent><Regimen><Reproducibility><Research Specimen><Reticuloendothelial System, Serum, Plasma><Role><SIS cytokines><Sequence Alteration><Signal Transduction><Signal Transduction Systems><Signaling><Specimen><Steroid Compound><Steroid Resistance><Steroid Resistant><Steroids><Structure of parenchyma of lung><T8 Cells><T8 Lymphocytes><TLR4><TLR4 gene><Therapeutic><Tissue Harvesting><Tissues><Toll Homologue><Toxic effect><Toxicities><Transgenic Model><Transgenic Organisms><Tumor Tissue><Work><Yervoy><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><antiPD-1><antibody based therapies><antibody immunotherapy><antibody treatment><antibody-based therapeutics><antibody-based treatment><arthritic><biological signal transduction><biomarker development><cancer type><candidate biomarker><candidate marker><chemoattractant cytokine><chemokine><combinatorial immunotherapy><design><designing><developmental><dual immunotherapy><genetically engineered><genome mutation><genomic alteration><host response><hsp70 Family><immune check point inhibitor><immune drugs><immune modulatory therapies><immune modulatory treatment><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-modulation treatment><immune-oncology><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immuno oncology><immuno therapy><immunologic therapeutics><immunology oncology><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory biologics><immunomodulatory therapies><immunomodulatory treatment><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunotherapeutics><immunotherapy agent><improved><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><insight><ipilimumab><melanoma cancer model><melanoma model><melanoma tumor model><neutrophil><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><oncoimmunology><pathway><patients suffering from melanoma><patients with melanoma><pharmacologic><predict therapeutic response><predict therapy response><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death ligand 1><programmed cell death protein 1 therapy><programmed cell death protein ligand 1><protein death-ligand 1><response><side effect><small molecular inhibitor><small molecule inhibitor><social role><success><therapeutic immunomodulation><therapeutic immunoregulation><therapy prediction><toll-like receptor 4><transgenic><transgenic trait><treatment prediction><treatment response prediction><treatment strategy><tumor><tumor DNA><tumor ablation><tumor cell DNA><tumor-specific DNA><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anne E Bantle

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100
Likely hiring
Solid budget
Active award
$309,212
FY 2026

Project Title

Personalized Nutrition Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus

Grant Number:

5R01DK139020-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/16/2024

End Date:

11/30/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Medical nutrition therapy can be an accessible, cost effective and powerful tool for treatment of type 2 diabetes mellitus (T2DM), but this potential has not been realized for all patients. A common shortcoming of dietary strategies is failure to provide personalization, despite increasing ...

Research Terms

<21+ years old><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Agonist><BMI><BMI percentile><BMI z-score><Blinded><Blood Glucose><Blood Sugar><Body mass index><Client satisfaction><Clinical Trials><Continuous Glucose Monitor><Counseling><D-Glucose><Data><Dextrose><Diabetes Mellitus><Diet><Dietary Intervention><Dietitian><Disease><Disorder><Dose><Drugs><Eating><Education><Educational aspects><Enrollment><Exclusion><Failure><Fasting><Feedback><Food><Food Intake><Food Preferences><Future><GLP-1 receptor><GLP-I receptor><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Hemoglobin A(1)><Humulin R><Hypoglycemia><Individual><Instruction><Insulin><Intervention><Ketosis-Resistant Diabetes Mellitus><Literature><Maturity-Onset Diabetes Mellitus><Measures><Medical Nutrition Therapy><Medication><Mission><Monitor><Multi-center trial><Multicenter Trials><NIDDK><NIDDM><National Institute of Diabetes and Digestive and Kidney Diseases><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Nutrition><Nutrition Interventions><Nutrition Therapy><Nutritional Interventions><Participant><Patient Satisfaction><Patients><Pattern><Persons><Pharmaceutical Preparations><Questionnaires><Quetelet index><Randomized><Randomized, Controlled Trials><Recommendation><Regular Insulin><Role><Self Efficacy><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Sulfonylurea Compounds><Survey Instrument><Surveys><System><T2 DM><T2D><T2DM><Testing><Time><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><adult onset diabetes><adulthood><compare to control><comparison control><continuous blood glucose monitor><continuous blood sugar monitor><continuous glucose measurement><continuous sugar monitor><cost effective><design><designing><diabetes><diabetes education><diabetes management><diabetes mellitus management><diabetes self-care><diabetes self-management><diabetic management><diet adherence><diet choice><diet education><diet intervention><diet preference><dietary><dietary adherence><dietary choice><dietary guidelines><dietary preferences><diets><dosage><drug/agent><effectiveness testing><effectiveness trial><enroll><fasted><fasting glucose><fasts><food choice><glucagon-like peptide-1 receptor><glycemic control><group intervention><hemoglobin A1c><hypoglycemic><hypoglycemic episodes><improved><improved outcome><individualized nutrition><ketosis resistant diabetes><life style intervention><lifestyle intervention><maturity onset diabetes><new approaches><novel approaches><novel strategies><novel strategy><nutrition education><nutritional guideline><personalization of treatment><personalized medicine><personalized nutrition><personalized therapy><personalized treatment><randomisation><randomization><randomized control trial><randomly assigned><response><satisfaction><sex><social role><sulfonylurea><tool><type 2 DM><type II DM><type two diabetes><virtual health visit><virtual visit>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anil Gupta

SCRIPPS RESEARCH INSTITUTE, THE, LA JOLLA, CA

Good lead · 48/100
Above-average budget
Very recent
Active award
$899,741
FY 2026

Project Title

A Single Long-Acting Injection For HBV Treatment Using Novel Entecavir Prodrugs For PWLH

Grant Number:

1R61AI197037-01

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The long-term objective of this research is to develop a long-acting injectable (LAI) therapy for hepatitis B virus (HBV) in individuals co-infected with human immunodeficiency virus (HIV). This project is of significant health relevance as approximately 10% of the 1.2 million people living...

Research Terms

<AIDS Virus><AIDS prevention><Acceleration><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Agreement><Animal Model><Animal Models and Related Studies><Anti-viral Agents><Anti-viral resistance><Bioavailability><Biological Availability><Blood Plasma><Canine Species><Canis familiaris><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Chronic><Circulation><Clinical><Clinical Trials><Collaborations><Common Rat Strains><Communicable Diseases><Data><Delayed-Action Preparations><Development><Dogs><Dogs Mammals><Domestic Rabbit><Dose><Drug Kinetics><Drug Precursors><Drugs><Early-Stage Clinical Trials><Ensure><Evaluation><Formulation><Funding><Future><Genetic Toxicology><Goals><Good Manufacturing Process><Good manufacturing practice><HBV><HBV infection><HBV therapeutic><HBV therapy><HBV treatment><HIV><HIV Infections><HIV Prevention><HIV and HBV><HIV and hepatitis B><HIV individuals><HIV infected individuals><HIV infected persons><HIV intervention><HIV people><HIV positive individuals><HIV positive people><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1 infection><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-HBV><HIV/AIDS prevention><HIV/HBV><HIV/hepatitis B><HIV/hepatitis B virus><Health><Heart Vascular><Hepatic Cancer><Hepatic Disorder><Hepatitis B Infection><Hepatitis B Therapeutic><Hepatitis B Therapy><Hepatitis B Treatment><Hepatitis B Virus><Hour><Human><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Viruses><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Injectable><Injection Site Reaction><Injections><Injury to Liver><Intramuscular><Investigational Drugs><Investigational New Drugs><LAV-HTLV-III><Lead><Liver><Liver diseases><Lymphadenopathy-Associated Virus><Malaria><Malignant neoplasm of liver><Maximal Tolerated Dose><Maximally Tolerated Dose><Maximum Tolerated Dose><Medication><Mission><Modern Man><Muscle><Muscle Tissue><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Necrosis><Necrotic><Oral><Oryctolagus cuniculus><Outcome><PBPK><PK/PD><PLWH><PWH><Paludism><Parents><Patient Compliance><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Pharmacology><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Physiologic Availability><Placebos><Plasma><Plasma Serum><Plasmodium Infections><Polymorph><Population><Pre IND FDA meeting><Pre-IND mtg><Predisposition><Preparation><Prevent HIV><Pro-Drugs><Process><Prodrugs><Property><Public Health><Pulmonary Body System><Pulmonary Organ System><QOL><Quality of life><Rabbits><Rabbits Mammals><Rat><Rats Mammals><Rattus><Recurrent disease><Regimen><Relapsed Disease><Research><Research Design><Research Methodology><Research Methods><Respiratory System><Respiratory Tracts><Respiratory tract structure><Reticuloendothelial System, Serum, Plasma><Rodent><Rodentia><Rodents Mammals><Route><Safety><Schedule><Sham Treatment><Skin><Study Type><Susceptibility><Testing><Therapeutic><Therapeutic Index><Toxic effect><Toxicities><Toxicogenetics><Toxicology><Toxicology Genetics><Treatment Efficacy><United States><United States National Institutes of Health><Viremia><Virus><Virus-HIV><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral resistant><anti-viral therapeutic><anti-virals><authority><canine><carcinogenicity><circulatory system><co-infection><coinfection><compare to control><comparison control><compound optimization><cost><determine efficacy><developmental><domestic dog><drug adherence><drug clearance><drug compliance><drug production><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><entecavir><evaluate efficacy><examine efficacy><first in man><first-in-human><formulation optimization><genotoxicity><good laboratory practice><healthy volunteer><heavy metal Pb><heavy metal lead><hepatic body system><hepatic damage><hepatic disease><hepatic injury><hepatic organ system><hepatitis B viral infection><hepatitis B virus and human immunodeficiency virus><hepatitis B virus infection><hepatopathy><human immunodeficiency virus infection><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HBV><infected with HIV><infected with hepatitis B><infected with hepatitis B virus><infected with human immunodeficiency virus><infection with HBV><infection with hepatitis B virus><innovate><innovation><innovative><intervention efficacy><lead candidate><liver cancer><liver damage><liver disorder><liver infection><liver injury><liver malignancy><malignant liver tumor><manufacture><medication adherence><medication compliance><model of animal><mouse model><murine model><muscular><novel><parent><patient adherence><patient cooperation><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacokinetic model><pharmacokinetics and pharmacodynamics><pharmacologic><phase I protocol><physiologically based pharmacokinetics><pill><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><pre-clinical><preclinical><preparations><prevent><prevent AIDS><prevent human immunodeficiency virus><preventing><product development><research and methods><safety testing><scale up><sham therapy><slow release drug><study design><subcutaneous><subdermal><success><therapeutic efficacy><therapy efficacy><time release medication><treat HIV><treat Human Immunodeficiency Virus><treatment adherence><treatment compliance><triphosphate><tripolyphosphate><viraemia><viral DNA><viral sepsis><virus DNA><virusemia>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jane M. Liebschutz

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 48/100
Above-average budget
Recent
Active award
Team-scale grant
$868,549
FY 2026

Project Title

Appalachian Node

Grant Number:

5UG1DA049436-07

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

6/15/2019

End Date:

2/29/2032

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.

Project Abstract

The Appalachian Node of NIDA Clinical Trials Network (CTN) is committed to discovering novel strategies, new interventions and conducting clinical trials to improve real-world outcomes for individuals who use drugs and have substance use disorders (SUDs) in central Appalachia and the mid-Atlantic re...

Research Terms

<Academic Medical Centers><Access to Care><Address><Administrator><Appalachia><Appalachian><Appalachian Region><Area><Baltimore><Bioinformatics><Caring><Chicago><Clinical><Clinical Research><Clinical Services><Clinical Study><Clinical Trials Network><Cocaine use disorder><Collaborations><Communities><Community Services><Conduct Clinical Trials><Country><Crystal Meth><Crystal methamphetamine><Data><Data Analyses><Data Analysis><Deoxyephedrine><Desoxyephedrine><Development><Drug usage><Effectiveness><Effectiveness of Interventions><Electronic Health Record><Ensure><Epidemic><Event><Evidence based treatment><Focused Ultrasound><Funding><GLP-1><Generalized Growth><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Glp-1><Grant><Growth><Health Care><Health Care Professional><Health Care Technology><Health Professional><Health Services Accessibility><Health Technology><Health system><Improve Access><Individual><Institution><Intervention><Investigators><Learning><Life Expectancy><Lived experience><Lived experiences><Manuscripts><Maryland><Medical><Medicine><Methamphetamine><Methamphetamine use disorder><Methylamphetamine><Mid-Atlantic Region><Middle Atlantic States><Morbidity><N-Methylamphetamine><NIDA><NIH><National Institute of Drug Abuse><National Institute on Drug Abuse><National Institutes of Health><Outcome><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peptides><Persons><Phase><Philadelphia><Policy Maker><Publications><Publishing><Records><Research><Research Personnel><Research Resources><Researchers><Resources><Rural><Rural Community><Scientific Publication><Services><Shoulder><Site><Stimulant overdose><Substance Use Disorder><Testing><Therapeutic><Tissue Growth><Training><United States><United States National Institutes of Health><Universities><University Medical Centers><Urban Community><West Virginia><Xylaxine><Xylazine><access to health services><access to services><access to treatment><accessibility to health services><addiction><addictive disorder><availability of services><care access><clinical practice><college><collegiate><community advisory board><community advisory committee><community advisory panel><community based treatment><compare intervention><comparison intervention><data harmonization><data interpretation><design><designing><developmental><drug use><economic impact><effective therapy><effective treatment><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><experience><geographic site><glucagon-like peptide 1><harmonized data><health service access><health services availability><improved><improved outcome><innovate><innovation><innovative><long-term recovery><medical complication><meeting><meetings><member><meth><meth use disorder><mortality><multi-site trial><multidisciplinary><multisite trial><new approaches><novel><novel approaches><novel strategies><novel strategy><ontogeny><opiate consumption><opiate crisis><opiate drug use><opiate intake><opiate overdose><opiate related overdose><opiate use><opiate use disorder><opioid consumption><opioid crisis><opioid drug overdose><opioid drug use><opioid epidemic><opioid induced overdose><opioid intake><opioid intoxication><opioid medication overdose><opioid overdose><opioid poisoning><opioid related overdose><opioid toxicity><opioid use><opioid use disorder><overdose death><overdose fatalities><patient oriented outcomes><pragmatic effectiveness trial><pragmatic trial><programs><prospective><psychostimulant overdose><recruit><rural area><rural location><rural region><secondary analysis><service availability><service providers><skills><social stigma><stigma><student training><substance use><substance use and disorder><substance using><success><systems research><tool><treatment access><treatment program><uptake>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Erin L Winstanley

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Good lead · 48/100
Above-average budget
Recent
Active award
Team-scale grant
$868,549
FY 2026

Project Title

Appalachian Node

Grant Number:

5UG1DA049436-07

Activity Code:

UG1

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

6/15/2019

End Date:

2/29/2032

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.

Project Abstract

The Appalachian Node of NIDA Clinical Trials Network (CTN) is committed to discovering novel strategies, new interventions and conducting clinical trials to improve real-world outcomes for individuals who use drugs and have substance use disorders (SUDs) in central Appalachia and the mid-Atlantic re...

Research Terms

<Academic Medical Centers><Access to Care><Address><Administrator><Appalachia><Appalachian><Appalachian Region><Area><Baltimore><Bioinformatics><Caring><Chicago><Clinical><Clinical Research><Clinical Services><Clinical Study><Clinical Trials Network><Cocaine use disorder><Collaborations><Communities><Community Services><Conduct Clinical Trials><Country><Crystal Meth><Crystal methamphetamine><Data><Data Analyses><Data Analysis><Deoxyephedrine><Desoxyephedrine><Development><Drug usage><Effectiveness><Effectiveness of Interventions><Electronic Health Record><Ensure><Epidemic><Event><Evidence based treatment><Focused Ultrasound><Funding><GLP-1><Generalized Growth><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Glp-1><Grant><Growth><Health Care><Health Care Professional><Health Care Technology><Health Professional><Health Services Accessibility><Health Technology><Health system><Improve Access><Individual><Institution><Intervention><Investigators><Learning><Life Expectancy><Lived experience><Lived experiences><Manuscripts><Maryland><Medical><Medicine><Methamphetamine><Methamphetamine use disorder><Methylamphetamine><Mid-Atlantic Region><Middle Atlantic States><Morbidity><N-Methylamphetamine><NIDA><NIH><National Institute of Drug Abuse><National Institute on Drug Abuse><National Institutes of Health><Outcome><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Peptides><Persons><Phase><Philadelphia><Policy Maker><Publications><Publishing><Records><Research><Research Personnel><Research Resources><Researchers><Resources><Rural><Rural Community><Scientific Publication><Services><Shoulder><Site><Stimulant overdose><Substance Use Disorder><Testing><Therapeutic><Tissue Growth><Training><United States><United States National Institutes of Health><Universities><University Medical Centers><Urban Community><West Virginia><Xylaxine><Xylazine><access to health services><access to services><access to treatment><accessibility to health services><addiction><addictive disorder><availability of services><care access><clinical practice><college><collegiate><community advisory board><community advisory committee><community advisory panel><community based treatment><compare intervention><comparison intervention><data harmonization><data interpretation><design><designing><developmental><drug use><economic impact><effective therapy><effective treatment><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><experience><geographic site><glucagon-like peptide 1><harmonized data><health service access><health services availability><improved><improved outcome><innovate><innovation><innovative><long-term recovery><medical complication><meeting><meetings><member><meth><meth use disorder><mortality><multi-site trial><multidisciplinary><multisite trial><new approaches><novel><novel approaches><novel strategies><novel strategy><ontogeny><opiate consumption><opiate crisis><opiate drug use><opiate intake><opiate overdose><opiate related overdose><opiate use><opiate use disorder><opioid consumption><opioid crisis><opioid drug overdose><opioid drug use><opioid epidemic><opioid induced overdose><opioid intake><opioid intoxication><opioid medication overdose><opioid overdose><opioid poisoning><opioid related overdose><opioid toxicity><opioid use><opioid use disorder><overdose death><overdose fatalities><patient oriented outcomes><pragmatic effectiveness trial><pragmatic trial><programs><prospective><psychostimulant overdose><recruit><rural area><rural location><rural region><secondary analysis><service availability><service providers><skills><social stigma><stigma><student training><substance use><substance use and disorder><substance using><success><systems research><tool><treatment access><treatment program><uptake>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Peter B Lillehoj

RICE UNIVERSITY, HOUSTON, TX

Good lead · 48/100
Above-average budget
Very recent
Active award
$769,792
FY 2026

Project Title

CRISPR-Cas13-based rapid HIV-1 test

Grant Number:

4R33AI167037-04

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/24/2023

End Date:

3/31/2028

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

HIV is one of the most deadly infectious diseases in the world. HIV transmission is largely driven by acutely infected individuals who are unaware of their status or those receiving antiretroviral therapy but not virally suppressed. Currently available rapid HIV tests, including fourth-generation HI...

Research Terms

<AIDS Virus><AIDS focused research><AIDS related research><AIDS research><AIDS science><AIDS specific research><AIDS test><AIDS/HIV test><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Android App><Android Application><Antibodies><Architecture><Assay><Bathing><Baths><Bioassay><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><COVID-19 antigen><CRISPR><CRISPR/Cas system><Cell Phone Application><Cell phone App><Cellular Phone App><Cellular Phone Application><Clinical><Clinical Management><Clustered Regularly Interspaced Short Palindromic Repeats><Communicable Diseases><Consumption><Data><Detection><Development><Devices><Diagnosis><Diagnostic><Diagnostic tests><Early Diagnosis><Effectiveness><Engineering><Engineering / Architecture><Enzyme Gene><Enzymes><Evaluation><FDA approved><Freeze Drying><Freeze Dryings><General Population><General Public><Generations><HIV><HIV Antigens><HIV Infections><HIV disease transmission><HIV focused research><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection transmission><HIV investigation><HIV latency><HIV people><HIV positive individuals><HIV positive people><HIV related research><HIV research><HIV science><HIV specific research><HIV spread><HIV test><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 spread><HIV-1 test><HIV-1 transmission><HIV-1 virus transmission><HIV-2 test><HIV-Associated Antigens><HIV-I><HIV/AIDS transmission><HIV1><HTLV-III Antigens><HTLV-III-LAV Antigens><Hand><Health><Home><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Antigens><Human immunodeficiency virus 1><Human immunodeficiency virus test><Hydrogen Oxide><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Investigation on HIV><LAV Antigens><LAV-HTLV-III><Laboratories><Lateral><Life><Lymphadenopathy-Associated Antigens><Lymphadenopathy-Associated Virus><Lyophilization><Measurement><Methods><Mission><Modern Man><Morbidity><NIAID><National Institute of Allergy and Infectious Disease><Non-Polyadenylated RNA><Nucleic Acid Amplification Tests><Nucleic Acid Testing><Nucleic Acids><Outcome><PLWH><PWH><Patient Monitoring><Patients><Performance><Phase><Population Heterogeneity><PrEP><Preparation><Procedures><Public Health><R2 Gene><RNA><RNA Gene Products><RNA amplification><RR2 Gene><RRM2><RRM2 gene><Reaction><Refrigeration><Research><Research Specimen><Ribonucleic Acid><Ribonucleoside-Diphosphate Reductase M2 Chain Gene><Ribonucleotide Reductase M2 Polypeptide Gene><Ribonucleotide Reductase Small Chain Gene><SARS-CoV-2 antigen><Saliva><Sampling><Sensitivity and Specificity><Smart Phone App><Smart Phone Application><Smartphone App><Specimen><Speed><Techniques><Technology><Temperature><Test Result><Testing><Time><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus-HIV><Water><acute infection><antiretroviral therapy><antiretroviral treatment><app on a smartphone><application on a smartphone><assess effectiveness><asymptomatic HIV infection><cell phone based app><chronic HIV infection><comparative><coronavirus disease 2019 antigen><cost><determine effectiveness><developmental><diagnostic ability><diagnostic capability><diagnostic power><diagnostic tool><diagnostic utility><diagnostic value><diverse populations><early detection><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><hands><heterogeneous population><high reward><high risk><homes><human immunodeficiency virus infection><human immunodeficiency virus research><human immunodeficiency virus transmission><iOS app><iOS application><iPhone App><iPhone Application><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><instrument><instrumentation><isothermal amplification><latent HIV infection><lateral flow assay><lateral flow test><lateral line><mobile phone app><mortality><new diagnostics><next generation diagnostics><novel diagnostics><nucleic acid detection><operation><operations><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><phone app><phone application><population diversity><pre-exposure prophylaxis><preparations><prototype><rapid assay><rapid test><rapid tests><research addressing HIV><research in HIV><research into HIV><research on HIV><research on human immunodeficiency virus><research to address HIV><saliva assay><saliva based assay><saliva based test><saliva test><salivary assay><salivary test><science on HIV><science to address HIV><self testing><severe acute respiratory syndrome coronavirus 2 antigen><smartphone application><smartphone based app><smartphone based application><spread of human immunodeficiency virus><studies on HIV><test strip><usability><user-friendly><viral RNA><viral detection><viral rebound><viral transmission><virus RNA><virus detection><virus protein><virus rebound><virus transmission>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

WESLEY I. SUNDQUIST

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Good lead · 48/100
Above-average budget
Very recent
Active award
$557,086
FY 2026

Project Title

Biochemistry of HIV-1 Budding

Grant Number:

5R37AI051174-25

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

HIV-1 assembly is driven by the viral Gag polyprotein, with host factors contributing essential activities. We and others have shown that host machinery of the Endosomal Sorting Complexes Required for Transport (ESCRT) pathway mediates the membrane fission reaction that releases HIV-1 virions (terme...

Research Terms

<AIDS Virus><AMOT><AMOT gene><APF-1><ATP phosphohydrolase><ATP-Dependent Proteolysis Factor 1><ATPase><Abscission><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adenosine Triphosphatase><Affinity><Angiomotin><Assay><Binding><Binding Proteins><Binding Sites><Bioassay><Biochemical><Biochemistry><Biogenesis><Biological Assay><Biological Chemistry><Cell Body><Cells><Collaborations><Combining Site><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><Deposit><Deposition><Diameter><E3 Ligase><E3 Ubiquitin Ligase><E3 ubiquitin-protein ligase NEDD4-like><Electron Cryomicroscopy><Endosomes><Excision><Extirpation><F-Actin><Family><Family member><Filament><Filamentous Actin><Funding><GeneHomolog><Genetic><Goals><HIV><HIV Budding><HIV disease transmission><HIV infection spread><HIV infection transmission><HIV spread><HIV transmission><HIV viral transmission><HIV-1><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS transmission><HIV1><HMG-20><High Mobility Protein 20><Homo><Homolog><Homologous Gene><Homologue><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Image><Impairment><Infection><Innate Immune System><Instruction><Integration Host Factors><LAV-HTLV-III><Ligand Binding Protein><Ligand Binding Protein Gene><Lymphadenopathy-Associated Virus><Mammalia><Mammals><Mediating><Membrane><Modeling><Modern Man><Molecular><Molecular Interaction><Neck><Nedd4-2><Nedd4L><Neural precursor cell expressed developmentally down-regulated gene 4-like><Origin of Life><Pathway interactions><Process><Progress Reports><Protein Binding><Proteins><Reaction><Reactive Site><Receptosomes><Removal><Reporting><Research><Resolution><Retrotransposition><Retroviral Antigen gag Protein><Site><Sorting><Structure><Surgical Removal><System><Testing><Therapeutic Intervention><Toxic effect><Toxicities><Ubiquitin><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Variant><Variation><Viral><Viral gag Proteins><Virion><Virus><Virus Particle><Virus-HIV><Work><analog><bound protein><constriction><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><gag Antigens><gag Gene Products><gag Polyproteins><gag Protein><genetic analysis><group specific antigen><human immunodeficiency virus transmission><imaging><in vitro testing><inhibitor><intervention therapy><member><membrane assembly><membrane model><membrane structure><monomer><pathogen><pathway><protein function><reconstitute><reconstitution><recruit><resection><resolutions><spread of human immunodeficiency virus><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><ubiquitin-protein ligase><virus envelope>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jaime M. Moore

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 48/100
Training-friendly
Recent
Active award
Career award
$185,338
FY 2026

Project Title

Physiologic response to bariatric surgery and the impact of adjunct semaglutide - in adolescents (the PRESSURE trial)

Grant Number:

5K23HL163480-04

Activity Code:

K23

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Metabolic and bariatric surgery (MBS) to treat pediatric severe obesity is increasingly common. MBS at younger ages means decades longer to preserve or enhance its cardiometabolic and other health benefits. While mean weight loss after MBS is substantial, >50% of adolescents...

Research Terms

<12-20 years old><21+ years old><Adherence><Adolescence><Adolescent><Adolescent Youth><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Agonist><Anti-Obesity Agents><Anti-Obesity Drugs><Apoplexy><Appetite><BMI><BMI percentile><BMI z-score><Basal Metabolism><Basal metabolic rate><Behavioral><Biological><Blood Pressure><Blood Pressure Monitors><Body Composition><Body Weight><Body Weight decreased><Body mass index><Brain Vascular Accident><Cardiac><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Cessation of life><Childhood><Clinical><Clinical Treatment><Clinical Trials><Continuous Sphygmomanometers><DEXA><DXA><Data><Death><Desire for food><Development Plans><Disease remission><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Drug Therapy><Dual-Energy X-Ray Absorptiometry><Dual-Energy Xray Absorptiometry><Eating Behavior><Echocardiogram><Echocardiography><Environment><Fasting><Fats><Fatty acid glycerol esters><Funding><Future><GLP-1><GLP-1 receptor><GLP-I receptor><Gastrectomy><Gastric Inhibitory Polypeptide><Glp-1><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Goals><Grant><Health><Health Benefit><Heart Vascular><Hispanic><Hour><Hypertension><Indirect Calorimetry><Individual><Injectable><Intervention><Intervention Trial><Interventional trial><Ketosis-Resistant Diabetes Mellitus><L-tyrosyl-L-tyrosine><Learning><Life Style><Lifestyle><Link><Maturity-Onset Diabetes Mellitus><Measures><Mechanics><Medicine><Mental Health><Mental Hygiene><Metabolic><Methods><Morbid Obesity><Morbidity><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nutrition><Obesity><Operative Procedures><Operative Surgical Procedures><Outcome><PYY Peptide><Peptide YY><Peptides><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiologic><Physiologic pulse><Physiological><Physiology><Placebos><Postoperative><Postoperative Period><Predictive Factor><Prospective Studies><Protocol><Protocols documentation><Psychological Health><Publications><Pulse><Quetelet index><Randomized><Randomized, Controlled Trials><Remission><Reporting><Research><Research Design><Residual><Residual state><Respiration Calorimetry><Risk><Risk Factors><Risk Marker><Risk Reduction><Satiation><Scientific Publication><Severe obesity><Sham Treatment><Slow-Onset Diabetes Mellitus><Social Environment><Solid><Stable Diabetes Mellitus><Stroke><Structure><Study Type><Surgical><Surgical Interventions><Surgical Procedure><T2 DM><T2D><T2DM><Testing><Training><Transthoracic Echocardiography><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Tyr-Tyr><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Weight><Weight Loss><Weight Reduction><Weight maintenance regimen><Youth><Youth 10-21><adiposity><adolescence (12-20)><adult onset diabetes><adulthood><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><arterial stiffening><arterial stiffness><artery stiffening><artery stiffness><bariatric surgery><biologic><body weight loss><brain attack><cardiometabolic><cardiometabolic risk><cardiometabolism><cardiovascular disorder><cardiovascular health><career development><cerebral vascular accident><cerebrovascular accident><child adiposity><child obesity><childhood adiposity><childhood obesity><circulatory system><clinical intervention><clinical therapy><co-morbid><co-morbidity><cohort><comorbidity><corpulence><diagnostic tool><double-blind placebo control trial><double-blind placebo controlled trial><double-masked controlled trial><drug intervention><drug treatment><energy balance><experience><extreme obesity><fasted><fasts><gastric banding><gastric bypass surgery><gastric inhibitory peptide><gastrointestinal><ghrelin><glucagon-like peptide 1><glucagon-like peptide-1 receptor><heart rate variability><heart sonography><high blood pressure><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><implantable gastric stimulation banding><improved><insulin secretion><insulin sensitivity><insulin sensitivity test><insulin tolerance test><insulin-induced hypoglycemia test><intervention design><juvenile><juvenile human><ketosis resistant diabetes><maturity onset diabetes><mechanic><mechanical><obese children><obesity during childhood><obesity in children><obesity surgery><pediatric><pediatric department><pediatric obesity><peptide tyrosine-tyrosine><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><phase 2 designs><phase II designs><physical conditioning><physical health><predict responsiveness><predicting response><premature><prematurity><preservation><professor><prospective><prospective research study><prospective survey><psychologic><psychological><randomisation><randomization><randomized control trial><randomly assigned><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><response><resting metabolic rate><risk predictor><risk predictors><risk stratification><risk-reducing><satiety><sham therapy><social climate><social context><social stigma><socioenvironment><socioenvironmental><standard of care><stigma><stomach stapling><stratify risk><stroked><strokes><study design><success><surgery><therapy design><treatment design><trial regimen><trial treatment><type 2 DM><type II DM><type two diabetes><tyrosyltyrosine><weight control><weight loss surgery><weight management><weights><wt-loss><younger age><youth age>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Molly Thomas

OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, OR

Good lead · 48/100
Training-friendly
Recent
Active award
Career award
$172,800
FY 2026

Project Title

Unraveling the Role of PD-1 in CD8+ Tissue-Resident Memory T Cell Homeostasis and Epithelial Damage in Human Colitis

Grant Number:

5K08DK127246-05

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary Monoclonal antibodies against co-inhibitory immune receptors PD-1 and CTLA-4 [immune checkpoint inhibitors (ICIs)] have revolutionized immuno-oncology by reversing T cell exhaustion and harnessing the power of the immune system to fight solid tumors. Although ICI therapy has improved...

Research Terms

<Alimentary Canal><Antibodies><Apoptosis><Apoptosis Pathway><Aquaporins><Area><Assay><Autoimmune Status><Autoimmunity><Autoregulation><Award><B cell receptor><B-Cell Antigen Receptor><B-Cell Attracting Chemokine 1><B-Lymphocyte Chemoattractant><B7-H1><BCA1><BLC gene><BLC protein><Bioassay><Biological Assay><Blocking Antibodies><Blood><Blood Reticuloendothelial System><Body Tissues><CD127><CD152><CD152 Antigen><CD152 Gene><CD183><CD274><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CDW127><CEACAM7><CEACAM7 gene><CGM2><CKR-L2><CMKAR3><CSIF><CSIF-10><CTLA 4><CTLA-4 Gene><CTLA-4 blockade><CTLA-8><CTLA-8 Gene><CTLA4><CTLA4 blockade><CTLA4 gene><CTLA4-TM><CTLA8><CTLA8 Gene><CXCL11><CXCL11 gene><CXCL13><CXCL13 gene><CXCR3><CXCR3 gene><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Mediated Lympholytic Cells><Cells><Checkpoint inhibitor><Chemokine (C-X-C Motif) Receptor 3><Chemokine, CXC Motif, Ligand 13><Chemotaxis><Chromatin><Circulation><Clinical><Clinical Treatment Moab><Colitis><Colon><Colonic inflammation><Colonoscopy><Complex><Cytokine Synthesis Inhibitory Factor><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Antigen 8><Cytotoxic T-Lymphocyte-Associated Antigen 8 Gene><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase 8><Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 Gene><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><Data><Data Set><Defect><Development><Diagnosis><Digestive Tract><Disease><Disorder><Disseminated Malignant Neoplasm><Down-Regulation><Endothelial Cells><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Epithelial Cells><Epithelium><Expression Signature><G Protein-Coupled Receptor 9><GFRP1><GI Tract><GPR9><Gastroenterology><Gastrointestinal Diseases><Gastrointestinal Tract><Gastrointestinal tract structure><Gene Expression Profile><Gene Transcription><General Hospitals><Genes><Genetic Transcription><Goals><Growth Factor Response Protein 1><Growth Factor-Inducible Nuclear Protein N10><H174><Health><Heterogeneity><Home><Homeostasis><Homing><Human><I-TAC><IFN><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IL-10><IL-17><IL-17 Gene><IL-17A><IL-17A Gene><IL-22><IL-7R alpha chain><IL-7R-alpha><IL-7Ralpha><IL-7Rα><IL10><IL10A><IL17><IL17 Protein><IL17 gene><IL17A><IL17A Gene><IL7R><IL7R gene><IP-9><IP10><IP10 Receptor><IP10-Mig receptor><IP10-R><IP9><Immune><Immune Interferon><Immune Tolerance><Immune checkpoint inhibitor><Immune mediated therapy><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunofluorescence Microscopy><Immunologic><Immunologic Receptors><Immunologic Tolerance><Immunological><Immunological Receptors><Immunologically><Immunologically Directed Therapy><Immunologics><Immunology><Immunomodulation><Immunooncology><Immunotherapy><In Situ><In Vitro><Individual><Inflammation><Inflammatory Bowel Diseases><Inflammatory Bowel Disorder><Interferon Gamma><Interferon Type II><Interferons><Interleukin 10 Precursor><Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)><Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) Gene><Interleukin 17 Precursor><Interleukin 17 Precursor Gene><Interleukin-10><Interleukin-17><Intracellular Communication and Signaling><LYT3><Licensing><Ligands><Lytotoxicity><MGC9485><Malignant Neoplasms><Malignant Tumor><Maps><Massachusetts><Mediating><Medicine><Memory><Mentors><Mesenchymal><Metastatic Cancer><Metastatic Malignant Neoplasm><Mice><Mice Mammals><Microscopy><Mig Receptor><Mig-R><MigR><Modeling><Modern Man><Mollies><Monoclonal Antibodies><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><N10><NAK-1><NAK1><NGFI-B protein><NGFIB><NP10><NR4A1><NR4A1 gene><NUR77><Nr4a1 protein><Nuclear Hormone Receptor TR3><Nuclear Receptor Subfamily 4, Group A, Member 1><Oncology><Oncology Cancer><Organoids><Orphan Nuclear Receptor HMR><PD 1><PD-1><PD-1 antibody><PD-1 blockade><PD-1 inhibitors><PD-L1><PD1><PD1 antibody><PD1 blockade><PD1 inhibitors><PDL-1><Pathologic><Patients><Phenotype><Physicians><Physiological Homeostasis><Play><Population><Position><Positioning Attribute><Program Development><Programmed Cell Death><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Public Health><RNA Expression><Receptor Protein><Reporting><Repression><Research><Role><SCYB11><SCYB13><SCYB9B><Scientist><Signal Transduction><Signal Transduction Systems><Signaling><Small Inducible Cytokine Subfamily B, Member 13><Solid Neoplasm><Solid Tumor><Steroid Receptor TR3><System><T cell receptor repertoire sequencing><T cell receptor sequencing><T-Cell Receptor Interaction><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T-cell receptor repertoire><T8 Cells><T8 Lymphocytes><TCR Activation><TCR Interaction><TCR repertoire><TCR repertoire sequencing><TCR sequencing><TCR-seq><TCRseq><TR3><Teff cell><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Transcription><Upregulation><Water Channel Proteins><Work><aPD-1><aPD1><alimentary tract><alpha chain interleukin-7 receptor><anti programmed cell death 1><anti programmed cell death protein 1 inhibitor><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 inhibitors><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 inhibitors><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><b-R1><biobank><biological signal transduction><biorepository><career development><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><cohort><cytokine><cytotoxic><cytotoxic T-lymphocyte antigen 4><cytotoxicity><developmental><diagnostic development><diagnostic tool><digestive canal><effector T cell><epigenetically><epithelial injury><exhaustion><experiment><experimental research><experimental study><experiments><fighting><gastrointestinal><gastrointestinal disorder><gene expression pattern><gene expression signature><homes><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune modulation><immune receptor><immune regulation><immune system tolerance><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune unresponsiveness><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-oncology><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immuno oncology><immuno therapy><immunologic reactivity control><immunological paralysis><immunology oncology><immunomodulatory><immunoregulation><immunoregulatory><improved><inflamed colon><inflammatory disease of the intestine><inflammatory disorder of the intestine><innovate><innovation><innovative><instructor><interleukin-22><intestinal autoinflammation><killer T cell><lFN-Gamma><mAbs><malignancy><medical college><medical schools><monoclonal Abs><neoplasm/cancer><nerve growth factor-inducible B><oncoimmunology><orphan nuclear receptor NGFI-B><orphan nuclear receptor NR4A1><peripheral blood><prevent><preventing><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><programs><prospective><protein death-ligand 1><receptor><resident memory T cell><response><scATAC sequencing><scATAC-seq><scRNA sequencing><scRNA-seq><school of medicine><side effect><single cell ATAC-seq><single cell ATAC-sequencing><single cell Assay for Transposase Accessible Chromatin sequencing><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell genomics><single cell sequencing assay for transposase accessible chromatin><single cell transcriptomic profiling><single-cell Assay for Transposase-Accessible Chromatin with sequencing><single-cell RNA sequencing><single-cell assay for transposase-accessible chromatin using sequencing><single-cell assay for transposase-accessible chromatin-seq><skills><sle2><social role><systemic lupus erythematosus susceptibility 2><therapeutic target><thymus derived lymphocyte><tissue resident memory T cell><transcriptional profile><transcriptional signature><treatment strategy><water channel><water transporter><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ben E. Black

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 48/100
Likely hiring
Recent
Active award
$123,563
FY 2026

Project Title

Tuning PARP-1 retention and release on DNA breaks

Grant Number:

3R01CA259037-05S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Breaks in the structure of DNA are a persistent stress on the integrity of the genome, and they pose a substantial risk of chromosomal rearrangement and genetic mutation that can challenge the well-being of an organism and promote the development of cancer. There are several cellular mechanisms that...

Research Terms

<ADP Ribose><Acute><Address><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose, homopolymer><Adenosine 5'-Diphosphoribose><Adenosine Diphosphate Ribose><Adenosine Diphosphoribose><Alleles><Allelomorphs><Allosteric Regulation><Apoptotic><Asian group><Asian individual><Asian people><Asian population><Asians><Assay><BRCA 1/2><BRCA1/2><Behavior><Binding><Binding Sites><Bioassay><Biochemical><Biological Assay><Biological Function><Biological Process><Biology><Biophysics><Black><Black race><Breast PDX models><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Communication and Signaling><Cell Death><Cell Death Signaling><Cell Death Signaling Process><Cell Signaling><Cell Survival><Cell Viability><Cells><Cellular biology><Chemicals><Chromosomal Rearrangement><Clinic><Clinical><Collaborations><Combining Site><Communication><Complex><Coupled><Crystallographies><Crystallography><DNA><DNA Binding><DNA Binding Interaction><DNA Damage><DNA Damage Repair><DNA Injury><DNA Repair><DNA Structure><DNA bound><DNA mutation><DNA strand break><Defect><Deoxyribonucleic Acid><Deuterium><Development><Engineering><Enzyme Gene><Enzymes><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene variant><Genetic Change><Genetic defect><Genetic mutation><Genome><Goals><H element><H2 isotope><Health><Histones><Human><Hydrogen><Imaging Procedures><Imaging Technics><Imaging Techniques><Inflammation><Intracellular Communication and Signaling><Investigators><Knowledge><Location><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medicinal Chemistry><Medicine><Methods><Mice><Mice Mammals><Modeling><Modern Man><Modification><Molecular Interaction><Monitor><Murine><Mus><Mutation><Nature><Organism><PARP Inhibitor><PARP Polymerase><PARP protein><PARP-1 inhibitor><PARPi><PARS><Pathway interactions><Patient-derived xenograft models of breast cancer><Personal Satisfaction><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Poly Adenosine Diphosphate Ribose><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) Polymerases><Poly(ADP-ribose) polymerase 1 inhibitor><Poly(ADPribose) Polymerase><Poly-ADPR><Polymers><Position><Positioning Attribute><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Production><Property><Protein Dynamics><Protein Modification><Proteins><Reactive Site><Regulation><Research><Research Personnel><Researchers><Risk><Role><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Stress><Testing><Therapeutic Agents><Time><Transcriptional Control><Transcriptional Regulation><Tumor Cell><Unscheduled DNA Synthesis><Variant><Variation><Work><allelic variant><anti-cancer therapy><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><brca gene><breast cancer PDX><breast cancer patient-derived xenograft><cancer cell><cancer progression><cancer therapy><cancer-directed therapy><cell biology><cell killing><compound optimization><design><designing><developmental><drug market><experiment><experimental research><experimental study><experiments><formulation optimization><genetic variant><genome integrity><genome mutation><genomic integrity><genomic variant><homologous recombination><image translation><imaging approach><imaging based approach><improved><innovate><innovation><innovative><insight><interdisciplinary approach><interest><living system><malignancy><mouse model><multidisciplinary approach><murine model><necrocytosis><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><next generation><novel><pathway><poly (ADP-ribose)><poly ADP polymerase><poly ADP ribose synthetase><polymer><polymeric><programs><recruit><repair><repaired><response><small molecule><social role><success><targeted cancer therapy><tool><tumor><tumor progression><tumor xenograft><virtual><well-being><wellbeing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

John M Pascal

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 48/100
Likely hiring
Recent
Active award
$123,563
FY 2026

Project Title

Tuning PARP-1 retention and release on DNA breaks

Grant Number:

3R01CA259037-05S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Breaks in the structure of DNA are a persistent stress on the integrity of the genome, and they pose a substantial risk of chromosomal rearrangement and genetic mutation that can challenge the well-being of an organism and promote the development of cancer. There are several cellular mechanisms that...

Research Terms

<ADP Ribose><Acute><Address><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose, homopolymer><Adenosine 5'-Diphosphoribose><Adenosine Diphosphate Ribose><Adenosine Diphosphoribose><Alleles><Allelomorphs><Allosteric Regulation><Apoptotic><Asian group><Asian individual><Asian people><Asian population><Asians><Assay><BRCA 1/2><BRCA1/2><Behavior><Binding><Binding Sites><Bioassay><Biochemical><Biological Assay><Biological Function><Biological Process><Biology><Biophysics><Black><Black race><Breast PDX models><Cancer Treatment><Cancers><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Communication and Signaling><Cell Death><Cell Death Signaling><Cell Death Signaling Process><Cell Signaling><Cell Survival><Cell Viability><Cells><Cellular biology><Chemicals><Chromosomal Rearrangement><Clinic><Clinical><Collaborations><Combining Site><Communication><Complex><Coupled><Crystallographies><Crystallography><DNA><DNA Binding><DNA Binding Interaction><DNA Damage><DNA Damage Repair><DNA Injury><DNA Repair><DNA Structure><DNA bound><DNA mutation><DNA strand break><Defect><Deoxyribonucleic Acid><Deuterium><Development><Engineering><Enzyme Gene><Enzymes><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene variant><Genetic Change><Genetic defect><Genetic mutation><Genome><Goals><H element><H2 isotope><Health><Histones><Human><Hydrogen><Imaging Procedures><Imaging Technics><Imaging Techniques><Inflammation><Intracellular Communication and Signaling><Investigators><Knowledge><Location><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Medicinal Chemistry><Medicine><Methods><Mice><Mice Mammals><Modeling><Modern Man><Modification><Molecular Interaction><Monitor><Murine><Mus><Mutation><Nature><Organism><PARP Inhibitor><PARP Polymerase><PARP protein><PARP-1 inhibitor><PARPi><PARS><Pathway interactions><Patient-derived xenograft models of breast cancer><Personal Satisfaction><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Poly Adenosine Diphosphate Ribose><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) Polymerases><Poly(ADP-ribose) polymerase 1 inhibitor><Poly(ADPribose) Polymerase><Poly-ADPR><Polymers><Position><Positioning Attribute><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Production><Property><Protein Dynamics><Protein Modification><Proteins><Reactive Site><Regulation><Research><Research Personnel><Researchers><Risk><Role><Signal Transduction><Signal Transduction Systems><Signaling><Site><Specificity><Stress><Testing><Therapeutic Agents><Time><Transcriptional Control><Transcriptional Regulation><Tumor Cell><Unscheduled DNA Synthesis><Variant><Variation><Work><allelic variant><anti-cancer therapy><biological signal transduction><biophysical foundation><biophysical principles><biophysical sciences><brca gene><breast cancer PDX><breast cancer patient-derived xenograft><cancer cell><cancer progression><cancer therapy><cancer-directed therapy><cell biology><cell killing><compound optimization><design><designing><developmental><drug market><experiment><experimental research><experimental study><experiments><formulation optimization><genetic variant><genome integrity><genome mutation><genomic integrity><genomic variant><homologous recombination><image translation><imaging approach><imaging based approach><improved><innovate><innovation><innovative><insight><interdisciplinary approach><interest><living system><malignancy><mouse model><multidisciplinary approach><murine model><necrocytosis><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><next generation><novel><pathway><poly (ADP-ribose)><poly ADP polymerase><poly ADP ribose synthetase><polymer><polymeric><programs><recruit><repair><repaired><response><small molecule><social role><success><targeted cancer therapy><tool><tumor><tumor progression><tumor xenograft><virtual><well-being><wellbeing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mansoor M. Amiji

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100
Likely hiring
Recent
Active award
$86,583
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James E Egan

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100
Likely hiring
Recent
Active award
$86,583
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Edward J Kim

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100
Likely hiring
Recent
Active award
$86,583
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gerardo Guillermo Mackenzie

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100
Likely hiring
Recent
Active award
$86,583
FY 2026

Project Title

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer

Grant Number:

3R01CA269233-04S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary In this Industry-Academic Partnership R01 application, a multidisciplinary team of investigators from the University of California at Davis, TargaGenix and Northeastern University are proposing to develop a highly innovative combination treatment strategy for refractory tumors, such...

Research Terms

<3-D><3-Dimensional><3D><Abraxane><Acids><Affect><Animal Model><Animal Models and Related Studies><Antibody Therapy><Anzatax><Asotax><Biodistribution><Bristaxol><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><California><Cancers><Canine Species><Canis familiaris><Checkpoint inhibitor><Clinical><Clinical Research><Clinical Study><Clinical Treatment><Clinical Trials><Collaborations><Combined Modality Therapy><Common Rat Strains><Data><Dedications><Development><Diagnosis><Difluorodeoxycytidine><Disease><Disorder><Docosahexaenoate><Docosahexaenoic Acids><Docosahexenoic Acids><Dogs><Dogs Mammals><Dose><Drug Combinations><Drug Kinetics><Drugs><Early-Stage Clinical Trials><Evaluation><Fibrosis><Formulation><Foundations><Future><GEM model><GEMM model><Generalized Growth><Genetically Engineered Mouse><Goals><Growth><Human><Hydrogen Oxide><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><In Vitro><Industry><Investigators><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Lead><Link><Lytotoxicity><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Medication><Mission><Modality><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Nanotechnology><Oils><Organoids><PD-L1 antibody><PD-L1 therapy><PD-L1 treatment><PDA model><PDAC Model><PDL1 therapy><PDL1 treatment><Paclitaxel><Paclitaxel (Taxol)><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Grafting><Pancreas Neoplasms><Pancreas Transplantation><Pancreas Tumor><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patients><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Phase 1 Clinical Trials><Phase I Clinical Trials><Polyunsaturated Fatty Acids><Praxel><Pre-Clinical Model><Preclinical Models><Qualifying><Rat><Rats Mammals><Rattus><Refractory><Research Personnel><Researchers><Safety><Scientist><Stromal Neoplasm><Stromal Tumor><System><T cell infiltration><T8 Cells><T8 Lymphocytes><Taxoids><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Therapeutic Agents><Therapeutic Effect><Time><Tissue Growth><Toxic effect><Toxicities><Toxicology><Treatment Efficacy><Treatment outcome><United States><Universities><Unresectable><Water><aPD-L1><aPD-L1 antibodies><aPD-L1 therapy><aPD-L1 treatment><advanced pancreatic cancer><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 antibodies><anti-PD-L1 monoclonal antibodies><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 antibodies><anti-PDL1 therapy><anti-PDL1 treatment><anti-cancer immunotherapy><anti-cancer therapeutic><antiPD-L1><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><anticancer immunotherapy><cancer immunotherapy><canine><check point blockade><check point inhibition><checkpoint blockade><checkpoint inhibition><chemotherapy><clinical development><clinical intervention><clinical relevance><clinical therapy><clinical translation><clinically relevant><clinically translatable><combination therapy><combined modality treatment><combined treatment><cytotoxicity><dFdC><dFdCyd><density><determine efficacy><developmental><domestic dog><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><experience><gemcitabine><genetically engineered mouse model><genetically engineered murine model><heavy metal Pb><heavy metal lead><immune cell infiltrate><immune check point><immune check point blockade><immune check point inhibition><immune check point inhibitor><immune checkpoint><immune checkpoint blockade><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogenic><immunotherapy for cancer><immunotherapy of cancer><improved><improved outcome><in vivo><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><interest><intervention efficacy><lead candidate><malignancy><model of animal><multi-modal therapy><multi-modal treatment><multi-modality><multidisciplinary><multimodality><nano emulsion><nano medicinal><nano medicine><nano tech><nano technology><nano-technological><nanoemulsion><nanomedicinal><nanomedicine><nanotech><nanotechnological><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ontogeny><pancreatic cancer model><pancreatic cancer patients><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor model><patients with pancreatic cancer><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><phase I protocol><rational design><therapeutic efficacy><therapy efficacy><three dimensional><translatable strategy><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><αPD-L1><αPD-L1 antibodies><αPD-L1 therapy><αPD-L1 treatment><αPDL1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Keanu Davis

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 48/100
Training-friendly
Very recent
Active award
$55,114
FY 2026

Project Title

A deep mutational scan of the HIV-1 capsid core.

Grant Number:

1F30AI197525-01

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2030

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract. Human immunodeficiency virus type 1 (HIV-1) facilitates viral egress and ingress via the activity of the polyprotein, Gag. Gag is the sole facilitator of the identification, organization, and sequestration of the viral genome from the host cytoplasm to the plasma membrane, nucleating the a...

Research Terms

<AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advanced HIV><Amino Acid Sequence><Amino Acid Substitution><Anti-Retroviral Agents><Biochemical><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Capsid><Causality><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cell membrane><Cells><Cellular biology><Clinic><Clinical><Clinical Treatment><Code><Coding System><Codon><Codon Nucleotides><Core Assembly><Cytoplasm><Cytoplasmic Membrane><DNA Library><DNA bank><DNA mutation><Dependence><Development><Doctor of Philosophy><Drug resistance><Esteroproteases><Etiology><Event><Fellowship><Functional RNA><Genes><Genetic><Genetic Change><Genetic Determinism><Genetic Diversity><Genetic Materials><Genetic Variation><Genetic defect><Genetic mutation><Genetics-Mutagenesis><Genome><Genotype><Goals><HIV><HIV-1><HIV-I><HIV1><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Heterogeneity><Host Factor><Host Factor Protein><Human><Human Biology><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Imaging Device><Imaging Instrument><Imaging Tool><Immune><Immune system><Immunes><In Situ><Individual><Infection><Integration Host Factors><Intracellular Communication and Signaling><Investigation><Kinetics><Knowledge><LAV-HTLV-III><Laboratories><Leadership><Lentiviral Vector><Lentivirinae><Lentivirus><Lentivirus Vector><Life Cycle><Life Cycle Stages><Link><Lymphadenopathy-Associated Virus><Malignant Hematologic Neoplasm><Mentorship><Methodology><Methods><Modern Man><Modernization><Molecular><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><Mutation Detection><Noncoding RNA><Nontranslated RNA><Nuclear Pore><Nucleocapsid><Nucleotides><Nucleus><Peptidases><Peptide Hydrolases><Persons><Ph.D.><PhD><Phenotype><Physicians><Plasma Membrane><Polyproteins><Predisposition><Preventative vaccine><Preventive vaccine><Primary Protein Structure><Process><Productivity><Property><Prophylactic vaccine><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Public Health><Reporter><Reverse Transcription><Ribonucleoproteins><Role><SIV><Sampling><Scanning><Scientist><Severe HIV Disease><Signal Transduction><Signal Transduction Systems><Signaling><Simian Immunodeficiency Viruses><Specific qualifier value><Specificity><Specified><Structural Protein><Susceptibility><System><T8 Cells><T8 Lymphocytes><Technology><Temperature><Testing><Therapeutic><Time><Untranslated RNA><Variant><Variation><Viral><Viral Diseases><Viral Genetics><Viral Genome><Virion><Virus><Virus Diseases><Virus Particle><Virus-HIV><Work><anti-retroviral><antiretroviral therapy><antiretroviral treatment><biological signal transduction><career><causation><cell biology><clinical intervention><clinical therapy><comparative><deep sequencing><developmental><disease causation><drug resistant><enzyme activity><genetic determinant><genome mutation><improved><inhibitor><insight><integration site><life course><live cell image><live cell imaging><live cellular image><live cellular imaging><mutant><mutation scanning><mutation screening><next generation><noncoding><novel><particle><pharmacologic><plasmalemma><plasmid DNA><programs><protein sequence><reconstitute><reconstitution><resistance mutation><resistance to Drug><resistant mutation><resistant to Drug><social role><structural determinants><structural factors><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><trial regimen><trial treatment><viral RNA><viral fitness><viral infection><virology><virtual><virus RNA><virus genetics><virus genome><virus infection><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Carly Merritt

BOSTON UNIVERSITY MEDICAL CAMPUS, BOSTON, MA

Good lead · 48/100
Training-friendly
Very recent
Active award
$54,538
FY 2026

Project Title

Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells

Grant Number:

5F30HL170745-03

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2024

End Date:

6/30/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Alpha-1 antitrypsin deficiency (AATD) is the sole monogenic cause of emphysema. AATD is caused by a mutation in the SERPINA1 gene, which encodes for alpha-1 antitrypsin (AAT). AAT is produced mainly in hepatocytes, from which it is secreted into the bloodstream to exert its primary function of inhib...

Research Terms

<A1PI><AAT deficiency><Accounting><Activities of Daily Living><Activities of everyday life><Acute><Air><Alpha Cell><Anatomic Sites><Anatomic structures><Anatomy><Antiproteases><Apical><Biology><Blood Circulation><Blood monocyte><Bloodstream><CRISPR><CRISPR correction><CRISPR-based correction><CRISPR/Cas system><Cas9-based correction><Cas9-mediated correction><Cell Body><Cell Function><Cell Line><Cell Physiology><Cell Process><Cell surface><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Stress><Cellular Stress Response><Chronic><Clustered Regularly Interspaced Short Palindromic Repeats><Complementary DNA><DNA mutation><Data><Development><Distal><Dysfunction><Emphysema><Endopeptidase Inhibitors><Endoplasmic Reticulum><Environment><Environmental Factor><Environmental Risk Factor><Epithelial Cells><Ergastoplasm><Esteroproteases><Exposure to><Extrahepatic><Functional disorder><Gene Transcription><Genes><Genetic Change><Genetic Diseases><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic Transcription><Genetic defect><Genetic mutation><Glucagon Cell><Glucagon Secreting Cell><Goals><Granulocyte Elastase><Hepatic Cells><Hepatic Disorder><Hepatic Parenchymal Cell><Hepatocyte><Histologic><Histologically><Human><Immune infiltrates><In Vitro><Injury><Innate Immune Response><Leukocyte Elastase><Liquid substance><Liver Cells><Liver diseases><Location><Lung><Lung Alveolar Epithelia><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Lysosomal Elastase><Marrow monocyte><Measures><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Mutate><Mutation><Neutrophil Elastase><PMN Elastase><Pathogenesis><Patients><Peptidase Inhibitors><Peptidases><Peptide Hydrolase Inhibitors><Peptide Hydrolases><Peptide Peptidohydrolase Inhibitors><Persons><Physiopathology><Play><Polymorphonuclear Leukocyte Elastase><Progenitor Cells><Protease Antagonists><Protease Gene><Protease Inhibitor><Proteases><Proteinase Inhibitors><Proteinases><Proteins><Proteolytic Enzymes><Publishing><Pulmonary Emphysema><RNA Expression><Recombinant DNA Technology><Regenerative Medicine><Role><Severities><Strains Cell Lines><Structure of parenchyma of lung><Subcellular Process><Supplementation><Surface><Testing><Therapeutic><Touch><Touch sensation><Toxic effect><Toxicities><Transcription><United States><a1-antitrypsin deficiency><alpha 1 Antiprotease><alpha 1-Antiproteinase><alpha 1-Antitrypsin><alpha 1-Antitrypsin Deficiency><alpha 1-Antitrypsin Trypsin Inhibitor><alpha 1-Protease Inhibitor><alpha 1-Proteinase Inhibitor><alpha-1-anti-trypsin deficiency><alpha-cell><alpha1-antitrypsin deficiency><alveolar epithelium><cDNA><cell stress><cell type><cigarette smoke><cultured cell line><daily living function><daily living functionality><developmental><differentiation protocol><directed differentiation><disease causing variant><disease-causing allele><disease-causing mutation><emphysematous><environmental risk><epithelial progenitor><epithelial progenitor cell><epithelial stem cell><experience><fluid><functional ability><functional capacity><functional loss><gain of function><gene corrected><gene correction><genetic condition><genetic disorder><genetically engineered><genome mutation><genomic correction><hepatic disease><hepatopathy><iPS><iPSC><iPSCs><immune cell infiltrate><in vivo><induced pluripotent cell><induced pluripotent stem cell><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><inducible pluripotent cell><inducible pluripotent stem cell><injuries><injury response><liquid><liver disorder><monocyte><mouse model><murine model><novel><pathogenic allele><pathogenic variant><pathophysiology><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><proteotoxic><proteotoxicity><response><response to injury><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><stem cells><surfactant><tactile sensation><transcriptomics><treatment strategy><α-1 anti-trypsin deficiency><α-1-antitrypsin deficiency><α-cell><α1-Antitrypsin><α1-Antitrypsin Deficiency><α1-Proteinase Inhibitor>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lubna Ghanem

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 48/100
Training-friendly
Very recent
Active award
$49,538
FY 2026

Project Title

Allosteric Regulation of MKP-1 in Liver Metabolism

Grant Number:

1F31DK146635-01

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2029

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Mitogen-activated protein kinase phosphatase-1 (MKP-1) is a nuclear localized dual specificity phosphatase that dephosphorylates the regulatory tyrosine and threonine residues in the activation loop of MAPKs. MKP-1 preferentially dephosphorylates the nuclear pool of JNK1/2 and p38 MA...

Research Terms

<3T3 Cells><Active Sites><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Affinity><Allosteric Regulation><Allosteric Site><Basal Transcription Factor><Basal transcription factor genes><Binding><Binding Sites><Bioavailability><Biological Availability><C-jun Amino-Terminal Kinase><C-jun Kinase-1><C-jun N-Terminal Kinase 1><CSAID-Binding Protein 1><CSAID-Binding Protein 2><CSBP2><Catalysis><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cells><Charge><Combining Site><Cyclic AMP-Dependent Protein Kinases><Cytokine-Suppressive Antiinflammatory Drug-Binding Protein 1><Cytokine-Suppressive Antiinflammatory Drug-Binding protein 2><Cytosolic Protein Tyrosine Phosphastase><DNA mutation><Dephosphorylation><Development><Docking><ERK 1><ERK 2><ERK1><ERK1 Kinase><ERK2><ERK3 Kinase><ERT1><Exhibits><Extracellular Signal-Regulated Kinase 1><Extracellular Signal-Regulated Kinase 2><Family><Fatty Acid Metabolism Pathway><Fatty Liver><Gene Expression><General Transcription Factor Gene><General Transcription Factors><Genetic Change><Genetic defect><Genetic mutation><Goals><Hep G2><HepG2><HepG2 cell line><Hepatic><Hepatic Cells><Hepatic Disorder><Hepatic Parenchymal Cell><Hepatocyte><High Fat Diet><Human><Immune Precipitation><Immunoprecipitation><Intermediary Metabolism><Intracellular Communication and Signaling><JN Kinase><JNK><JNK Mitogen-Activated Protein Kinases><JNK1><JNK1 Kinase><JNK1 protein><JNK1A2><JNK21B1/2><JUN Family Gene><JUN Proto-oncogene Family><JUN gene><L-Serine><L-Threonine><Lead><Lipids><Liver><Liver Cells><Liver Dysfunction><Liver Fibrosis><Liver Steatosis><Liver diseases><MAP Kinase 1><MAP Kinase 2><MAP Kinase 3><MAP Kinase 6><MAP Kinase 8><MAP Kinase 8 Gene><MAP kinase><MAPK Inhibitors><MAPK1><MAPK1 Mitogen-Activated Protein Kinase><MAPK1 gene><MAPK14><MAPK14 Mitogen-Activated Protein Kinase><MAPK14 gene><MAPK2><MAPK2 Mitogen-Activated Protein Kinase><MAPK3><MAPK3 Mitogen-Activated Protein Kinase><MAPK3 gene><MAPK6 Mitogen-Activated Protein Kinase><MAPK8><MAPK8 Mitogen-Activated Protein Kinase><MAPK8 gene><Measures><Mediating><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Mitogen Activated Protein Kinase 1><Mitogen-Activated 5 Protein Kinase><Mitogen-Activated Protein Kinase 14><Mitogen-Activated Protein Kinase 2><Mitogen-Activated Protein Kinase 3><Mitogen-Activated Protein Kinase 3 Gene><Mitogen-Activated Protein Kinase 6><Mitogen-Activated Protein Kinase 8><Mitogen-Activated Protein Kinase Inhibitor><Mitogen-Activated Protein Kinases><Modeling><Modern Man><Molecular Interaction><Murine><Mus><Mutation><Mxi2><Nuclear><Nucleus><Obesity><Obesity Epidemic><Organism-Level Process><Organismal Process><P41MAPK><P42MAPK><P44ERK1><PKA><PPAR><PPAR gamma><PPAR-g><PPAR-γ><PPARgamma><PPARγ><PRKM1><PRKM2><PRKM8><PSTkinase p44mpk><PTP Family Gene><PTPase><Patients><Pb element><Peroxisome Proliferative Activated Receptor Gamma><Peroxisome Proliferator-Activated Receptor gamma><Peroxisome Proliferator-Activated Receptor γ><Peroxisome Proliferator-Activated Receptors><Phosphatases><Phosphohydrolases><Phosphomonoesterases><Phosphopeptides><Phosphoric Monoester Hydrolases><Phosphorylation><Phosphotyrosine Phosphatase><Phosphotyrosyl Protein Phosphatase><Physiologic><Physiologic Availability><Physiologic Processes><Physiological><Physiological Processes><Play><Protein Dephosphorylation><Protein Kinase A><Protein Kinase Interaction><Protein Phosphorylation><Protein Tyrosine Phosphatase><Protein Tyrosine Phosphatase Gene><Protein-Serine Kinase><Protein-Serine-Threonine Kinases><Protein-Threonine Kinase><Reactive Site><Receptor Type PTP Gene><Regulation><Role><SAP Kinase-1><SAPK/JNK><SAPK1 Mitogen-Activated Protein Kinase><SAPK1/JNK><SAPK2A><Serine><Serine Kinase><Serine-Threonine Kinases><Serine/Threonine Protein Kinase Gene><Signal Transduction><Signal Transduction Pathway><Signal Transduction Systems><Signaling><Site><Specificity><Stress><Stress-Activated Protein Kinase 2A><Stress-Activated Protein Kinase JNK1><Stress-Activated Protein Kinase gamma><Testing><Thiazolidinedione Receptor><Threonine><Threonine Kinase><Transcription Factor Proto-Oncogene><Transcription factor genes><Tyrosine><Tyrosine Phosphatase><Tyrosyl Phosphoprotein Phosphatase><adipogenesis><adiposity><biological signal transduction><c jun><c-jun Gene><c-jun N-Terminal Kinase><cAMP-Dependent Protein Kinases><corpulence><developmental><experiment><experimental research><experimental study><experiments><extracellular signal-regulated kinase 3><fat metabolism><fatty acid metabolism><fatty acid oxidation><fibrotic liver><genome mutation><heavy metal Pb><heavy metal lead><hepatic body system><hepatic disease><hepatic fibrosis><hepatic metabolism><hepatic organ system><hepatic steatosis><hepatopathy><hepatosteatosis><inhibitor><jun-NH2-Terminal Kinase><lipid biosynthesis><lipid metabolism><lipogenesis><liver development><liver disorder><liver metabolism><mutant><p38><p38 MAP Kinase><p38 MAPK Gene><p38 Mitogen Activated Protein Kinase><p38 Protein Kinase><p38 SAPK><p38-Alpha><p38Alpha><p42 MAP Kinase><p42 MAPK><p44 MAPK><p97 Extracellular Signal-Regulated Kinase><p97(MAPK) Protein><p97MAPK Protein><pharmacologic><phosphatase-1 kinase><phosphoprotein phosphatase kinase><protein tyrosine phosphate phosphohydrolase><small molecular inhibitor><small molecule inhibitor><social role><stress-activated protein kinase 1><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcription factor><treatment strategy>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gai-Linn Besing

VANDERBILT UNIVERSITY, Nashville, TN

Good lead · 48/100
Training-friendly
Very recent
Active award
$34,954
FY 2026

Project Title

Contribution of FGF21 and macronutrient composition towards Glp1r agonist-induced weight loss

Grant Number:

1F31DK145043-01A1

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2029

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/ Abstract Glucagon-like peptide-1 (Glp1) receptor (Glp1r) agonists are a promising new class of weight loss drugs for treating obesity, yet weight loss outcomes to Glp1r agonists range from 0% to over 20% of starting body weight which raises the critical question of why some individu...

Research Terms

<ACTH-beta-Lipotropin Precursor><Adult-Onset Diabetes Mellitus><Affect><Agonist><Back><Blood Plasma><Body Weight><Body Weight decreased><Brain><Brain Nervous System><Breeding><CNS Nervous System><Carbohydrates><Central Nervous System><Clinical Trials><Communication><Complex><Consumption><Corticotropin-beta-Lipotropin Precursor><D-Glucose><Data><Data Analyses><Data Analysis><Dextrose><Diet><Dietary Carbohydrates><Dorsum><Drugs><Eating><Effectiveness><Encephalon><Endocrine Gland Secretion><Endorphin-ACTH Precursor><Experimental Designs><FGF-21><Fats><Fatty acid glycerol esters><Feeds><Food Intake><Food Preferences><GLP-1><GLP-1 receptor><GLP-I receptor><Glp-1><Glucose><Goals><High Fat Diet><Hormones><Imaging Procedures><Imaging Technics><Imaging Techniques><Impairment><Individual><Intake><Intermediate Hypothalamic Region><Investigation><Investigators><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Knowledge><Learning><Liver><Macronutrients><Macronutrients Nutrition><Maintenance><Maturity-Onset Diabetes Mellitus><Medial Hypothalamus><Mediating><Medication><Mentors><Metabolic Diseases><Metabolic Disorder><Methods><Mice><Mice Mammals><Middle Hypothalamus><Modeling><Murine><Mus><NIDDM><Nerve Cells><Nerve Unit><Neural Cell><Neuraxis><Neurocyte><Neuroendocrinology><Neurons><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Null Mouse><Obesity><Oral><Outcome><Pharmaceutical Preparations><Plasma><Plasma Serum><Play><Pro-ACTH-Endorphin><Pro-Opio-Melanocortin><Pro-Opiocortin><Pro-Opiomelanocortin><Proopiocortin><Proopiomelanocortin><Publishing><R-Series Research Projects><R01 Mechanism><R01 Program><Receptor Activation><Receptor Protein><Regulation><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Reticuloendothelial System, Serum, Plasma><Rewards><Role><Saccharose><Scientist><Slow-Onset Diabetes Mellitus><Source><Stable Diabetes Mellitus><Starch><Sucrose><T2 DM><T2D><T2DM><Techniques><Testing><Therapeutic><Therapeutic Hormone><Thesaurismosis><Training><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><Weight Loss><Weight Loss Agents><Weight Reduction><Weight-Loss Drugs><Work><Writing><adiposity><adult onset diabetes><analog><behavior phenotype><behavioral phenotyping><body weight loss><career><clinical applicability><clinical application><corpulence><data interpretation><diet choice><diet preference><dietary choice><dietary preferences><diets><drug/agent><experiment><experimental research><experimental study><experiments><fibroblast growth factor 21><food choice><glucagon-like peptide 1><glucagon-like peptide-1 receptor><hepatic body system><hepatic organ system><insight><ketosis resistant diabetes><liraglutide><maturity onset diabetes><metabolic phenotype><metabolism disorder><metabotype><neuronal><novel><obesity management><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacologic><preference><receptor><response><sensor><skills><social role><sugar><training opportunity><type 2 DM><type II DM><type two diabetes><weights><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michelle Ying-Ying Chan

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 48/100
Training-friendly
Very recent
Active award
$32,536
FY 2026

Project Title

Mechanisms Driving the Kinetics of Incretin-Mediated Beta Cell Responses

Grant Number:

5F31DK136313-03

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2024

End Date:

11/30/2026

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The incretin receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), are therapeutic Type 2 Diabetes Mellitus (T2DM) targets. Incretins bind to their respective receptors on beta () cells to activate adenylyl cyclases (ACs) and generate...

Research Terms

<3'5'-cyclic ester of AMP><3,5 cyclic AMP synthetase><Address><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adenyl Cyclase><Adenylate Cyclase><Adenylyl Cyclase><Adult-Onset Diabetes Mellitus><Affect><Agonist><American><Arrestins><Automobile Driving><Beta Cell><Binding><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chemosensitization><Chemosensitization/Potentiation><Coupled><Cyclic AMP><D-Glucose><Development><Dextrose><Diabetes Mellitus><Effectiveness><Exocytosis><Food Interactions><Functional Imaging><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GIP receptor><GLP-1><GLP-1 receptor><GLP-I receptor><GPCR><Generations><Genetic><Glp-1><Glucose><Glucose-Dependent Insulinotropic Polypeptide><Humulin R><Hypoglycemia><Image><Insulin><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Intracellular Communication and Signaling><Intracellular Second Messenger><Ketosis-Resistant Diabetes Mellitus><Kinetics><Knock-out><Knockout><Knowledge><Maturity-Onset Diabetes Mellitus><Mediating><Mice><Mice Mammals><Mission><Molecular Interaction><Murine><Mus><NIDDK><NIDDM><National Institute of Diabetes and Digestive and Kidney Diseases><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Nutrient><Outcome><Pancreatic Secretion><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Perfusion><Phase><Physiologic Imaging><Potentiation><Production><Public Health><Receptor Protein><Receptor Signaling><Recycling><Regular Insulin><Research><Retinal S-Antigen><Risk><Second Messenger Systems><Second Messengers><Secretory Cell><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Stimulus><T2 DM><T2D><T2DM><Testing><Therapeutic><Transgenic Mice><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Weight><adenosine 3'5' monophosphate><adult onset diabetes><biological signal transduction><cAMP><developmental><diabetes><driving><gastric inhibitory polypeptide receptor><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose-dependent insulinotropic polypeptide receptor><hypoglycemic><hypoglycemic episodes><imaging><improved><innovate><innovation><innovative><insight><insulin resistant><insulin secretagogues><insulin secretion><insulin tolerance><islet><ketosis resistant diabetes><maturity onset diabetes><novel><nutrient interaction><pancreatic juice><patient oriented outcomes><physiological imaging><preference><receptor><recruit><response><sensor><signal transduction second messengers><synergism><tool><trafficking><type 2 DM><type II DM><type two diabetes><weights><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David Aslaner

VANDERBILT UNIVERSITY, Nashville, TN

Good lead · 48/100
Training-friendly
Very recent
Active award
$3,000
FY 2026

Project Title

Attenuation of sepsis-induced microvascular permeability and inflammation with the GLP-1R agonist liraglutide.

Grant Number:

3F31HL178162-01S1

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

5/1/2025

End Date:

5/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.
  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Abstract Sepsis is a critical problem around the world causing 20% of all global deaths. The lack of effective therapeutics leaves critically ill patients with systemic organ dysfunction often caused by damage to the vascular endothelium. The damage induces micro-vessel dysfunction and incre...

Research Terms

<ASCVD><Abdomen><Adherens Junction><Adhering Junction><Adhesion Molecule><Adhesions><Adhesive Junction><Agonist><Anchoring Junction><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatory Effect><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Attenuated><Blood Circulation><Blood Plasma><Blood Vessels><Blood leukocyte><Blood monocyte><Bloodstream><Body Tissues><Brain Vascular Disorders><CCL2><CCL2 gene><CD54 Antigens><CSAID-Binding Protein 1><CSAID-Binding Protein 2><CSBP2><Cell Adhesion Molecule Gene><Cell Adhesion Molecules><Cell Body><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cell secretion><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Secretion><Cerebrovascular Disease><Cerebrovascular Disorders><Cessation of life><Chemokine, CC Motif, Ligand 2><Critical Illness><Critically Ill><Cytokine-Suppressive Antiinflammatory Drug-Binding Protein 1><Cytokine-Suppressive Antiinflammatory Drug-Binding protein 2><Data><Death><Diabetes Mellitus><Down-Regulation><Drug Targeting><Drugs><Dysfunction><Endothelial Cells><Endothelium><Functional disorder><Funding><GLP-1 receptor><GLP-I receptor><Goals><Human><Hyperoxia><ICAM-1><Immune response><In Vitro><Infection><Inflammation><Inflammation Mediators><Inflammatory><Injury><Injury to Kidney><Injury to Liver><Intercellular Adhesion Molecules><Intercellular adhesion molecule 1><Interruption><Intracellular Communication and Signaling><Intracranial Vascular Diseases><Intracranial Vascular Disorders><Leukocyte Trafficking><Leukocytes><Leukocytes Reticuloendothelial System><Life><Lipopolysaccharides><Lung><Lung Respiratory System><Lung damage><MAP kinase><MAPK Inhibitors><MAPK14><MAPK14 Mitogen-Activated Protein Kinase><MAPK14 gene><MCAF><MCP-1><MCP1><Marrow leukocyte><Marrow monocyte><Measures><Mediating><Medication><Mice><Mice Mammals><Microvascular Permeability><Mitogen-Activated Protein Kinase 14><Mitogen-Activated Protein Kinase Inhibitor><Mitogen-Activated Protein Kinases><Modeling><Modern Man><Monocyte Chemoattractant Protein-1><Monocyte Chemotactic Protein-1><Monocyte Chemotactic and Activating Factor><Monocyte Chemotactic and Activating Protein><Monocyte Chemotactive and Activating Factor><Monocyte Secretory Protein JE><Morbidity><Murine><Mus><Mxi2><Non obese><Nonobese><Obesity><Occluding Junctions><Organ><Pathway interactions><Patients><Peripheral><Permeability><Pharmaceutical Preparations><Physiopathology><Plasma><Plasma Serum><Principal Investigator><Production><Proteins><Pulmonary Edema><Regulation><Reticuloendothelial System, Serum, Plasma><SAPK2A><SCYA2><Sepsis><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Site><Small Inducible Cytokine A2><Stress-Activated Protein Kinase 2A><Subcellular Process><Testing><Therapeutic><Tight Junctions><Tissues><Upregulation><Vascular Endothelial Cell><Vascular Endothelium><Vascular Permeabilities><White Blood Cells><White Cell><Wild Type Mouse><Zonula Occludens><adiposity><anti-inflammatory effect><antisepsis treatment><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><attenuate><attenuates><attenuation><biological signal transduction><brain vascular disease><brain vascular dysfunction><cell adhesion protein><cell type><cerebral vascular disease><cerebral vascular dysfunction><cerebrovascular dysfunction><clinical efficacy><clinical relevance><clinically relevant><corpulence><cytokine><diabetes><drug/agent><experiment><experimental research><experimental study><experiments><glucagon-like peptide-1 receptor><hepatic damage><hepatic injury><host response><hyperoxygenation><immune system response><immunoresponse><improved><in vitro Model><inflammatory mediator><inhibitor><injuries><injury to organs><intracranial vascular dysfunction><kidney injury><liraglutide><liver damage><liver injury><lung edema><lung injury><lung microvascular endothelial cells><lung vascular endothelial cells><migration><monocyte><mortality><mouse model><murine model><novel><organ injury><p38><p38 MAP Kinase><p38 MAPK Gene><p38 Mitogen Activated Protein Kinase><p38 Protein Kinase><p38 SAPK><p38-Alpha><p38Alpha><pathophysiology><pathway><preservation><protective effect><pulmonary damage><pulmonary injury><pulmonary microvascular endothelial cells><pulmonary tissue damage><pulmonary tissue injury><pulmonary vascular endothelial cells><recruit><renal injury><sepsis care><sepsis interventions><sepsis management><sepsis therapeutics><sepsis therapy><sepsis treatment><septic therapy><septic treatment><therapeutically effective><treat sepsis><treatment strategy><vascular><vascular inflammation><white blood cell><white blood corpuscle><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Angelina Dixon

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$193,075
FY 2026

Project Title

SMART-2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults with Type 2 Diabetes

Grant Number:

1K23DK146189-01

Activity Code:

K23

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/1/2026

End Date:

12/19/2030

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT: CANDIDATE: Angelina Dixon, MD, is currently Chief Medicine/Pediatric Nephrology Fellow, and will join the faculty as an Instructor in July 2025 in the Division of Renal Diseases and Hypertension at the University of Colorado Anschutz Medical Campus (UC-AMC). Dr. Dixon has t...

Research Terms

<12 year old><12 years of age><21+ years old><5-Lipoxygenase><Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Adolescent and Young Adult><Adoption><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Agonist><Albuminuria><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Aorta><Arachidonate 5-Lipoxygenase><Arachidonic Acid 5-Lipoxygenase><Asthma><Attenuated><Award><Biological Markers><Biometrics><Biometry><Biopsy><Biopsy Sample><Biopsy Specimen><Biostatistics><Blood><Blood Plasma><Blood Pressure><Blood Reticuloendothelial System><Blood Vessels><Body Tissues><Breast Microcalcification><Brittle Diabetes Mellitus><Bronchial Asthma><CCL2><CCL2 gene><Cachectin Receptors><Cardiovascular Diseases><Caring><Cell Body><Cells><Chemokine, CC Motif, Ligand 2><Childhood><Chronic><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical Research><Clinical Study><Clinical Trials><Co-Transporters><Colorado><Complications of Diabetes Mellitus><Cys-LT><D-Glucose><Data><Data Analyses><Data Analysis><Development><Development Plans><Dextrose><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Complications><Diabetic Kidney Disease><Diabetic Nephropathy><Double-blind trial><Early identification><Elasticity><Endocrinology><Environment><Enzyme Gene><Enzymes><Equipment><Exposure to><Faculty><Frequencies><Funding><Future><GLP-1 receptor><GLP-I receptor><Glomerular Filtration Rate><Glucose><Goals><Grant><Human><Hypertension><Hypertensive Nephropathy><IDDM><Incidence><Infiltration><Inflammation><Inflammation Mediators><Inflammatory><Insulin-Dependent Diabetes Mellitus><Intervention><Investigation><Investigators><Iohexol><Iohexol 350><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Diseases><Kidney Failure><Kidney Insufficiency><Kidney Urinary System><Knowledge><LTA4 Synthase><Laboratories><Lead><Leadership><Leukotriene A Synthase><Leukotriene A4 Synthase><Leukotriene A4 Synthetase><Leukotrienes><MCAF><MCP-1><MCP1><Macrophage><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Mediating><Medical><Medicine><Mentors><Mentorship><Messenger RNA><Metabolism and Endocrinology><Methods><Mice><Mice Mammals><Microcalcification><Modern Man><Monocyte Chemoattractant Protein-1><Monocyte Chemotactic Protein-1><Monocyte Chemotactic and Activating Factor><Monocyte Chemotactic and Activating Protein><Monocyte Chemotactive and Activating Factor><Monocyte Secretory Protein JE><Morbidity><Murine><Mus><Mφ><NIDDM><NIH><Na element><National Institutes of Health><Nephrology><Nephropathy><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Participant><Pathway interactions><Patients><Pb element><Phenotype><Physiologic pulse><Placebos><Plasma><Plasma Serum><Population><Position><Positioning Attribute><Postdoc><Postdoctoral Fellow><Prevalence><Production><Publications><Pulse><Randomized><Receptor Protein><Renal Disease><Renal Failure><Renal Hypertension><Renal Insufficiency><Renal Plasma Flow><Renal Vascular><Renal function><Renal vessels><Research><Research Associate><Research Methodology><Research Methods><Research Personnel><Research Resources><Research Training><Researchers><Resources><Reticuloendothelial System, Serum, Plasma><Risk><SCYA2><Safety><Scientific Publication><Sham Treatment><Slow-Onset Diabetes Mellitus><Small Inducible Cytokine A2><Sodium><Stable Diabetes Mellitus><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNFR><Techniques><Time><Tissues><Training><Translational Research><Translational Science><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><United States><United States National Institutes of Health><Universities><Urine><Vascular Endothelial Cell><Vascular Endothelium><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Vascular resistance><Writing><Youth><Youth 10-21><acute kidney injury><adult onset diabetes><adult youth><adulthood><age 12><age 12 years><arterial stiffening><arterial stiffness><artery stiffening><artery stiffness><attenuate><attenuates><bio-markers><biologic marker><biomarker><brachial artery><cardiovascular disorder><cardiovascular health><career><career development><chronic kidney disease><cost><cysteinyl-leukotriene><cytokine><damage to kidney><data interpretation><design><designing><developmental><diabetes><double-blind placebo control trial><double-blind placebo controlled trial><double-masked controlled trial><endothelial dysfunction><experience><glucagon-like peptide-1 receptor><heavy metal Pb><heavy metal lead><hemodynamics><high blood pressure><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><hypertensive kidney><improved><improved outcome><inflammatory mediator><inhibitor><instructor><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><kidney damage><kidney disorder><kidney function><kidney vascular><kidney vascular structure><lipid mediator><mRNA><maturity onset diabetes><meeting><meetings><montelukast><mortality><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathway><pediatric><post-doc><post-doctoral><post-doctoral trainee><pressure><prevent><preventing><protective effect><randomisation><randomization><randomly assigned><receptor><renal><renal damage><renal disorder><renovascular><research and methods><research associates><sham therapy><skill acquisition><skill development><skills><symporter><translation research><translational investigation><twelve year old><twelve years of age><type 1 diabetes onset><type 2 DM><type I diabetes><type II DM><type one diabetes><type two diabetes><urinary><vascular><vascular inflammation><young adult><young adult age><young adulthood><younger age><youth age>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christine Limonte

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$188,028
FY 2026

Project Title

Autophagy in Diabetic Kidney Disease

Grant Number:

5K23DK135789-04

Activity Code:

K23

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

5/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Diabetic kidney disease (DKD) is clinically and mechanistically heterogeneous. Individual patients present with variable trajectories of estimated glomerular filtration rate (eGFR) and albuminuria that may not be concordant with severity of kidney histopathological injury, r...

Research Terms

<21+ years old><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Advanced Glycation End Products><Advanced Glycosylation End Products><Affect><Agonist><Akimel O'odham><Albumins><Albuminuria><Autophagocytosis><Autophagosome><Autoregulation><Bioinformatics><Blood><Blood Plasma><Blood Reticuloendothelial System><Body Tissues><Cathepsins><Cellular injury><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Clinical Trials><Cohort Studies><Cytoplasm><Data><Development and Research><Diabetes Mellitus><Diabetic Kidney Disease><Diabetic Nephropathy><Diagnosis><Diagnostic><ESKD><ESRD><Electron Microscopy><End stage renal failure><End-Stage Kidney Disease><End-Stage Renal Disease><Enrollment><Enzyme Gene><Enzymes><Epidemiology><Epithelial Cells><Excretory function><Experimental Diabetes><Experimental Diabetes Mellitus><Experimental Models><Fellowship><Fibrosis><Foundations><Future><GLP-1 receptor><GLP-I receptor><Gene Expression><Genes><Glomerular Filtration Rate><Goals><Heterogeneity><Histopathology><Homeostasis><Human><Hyperglycemia><Hypoxia><Hypoxic><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Inflammation><Injury><Injury to Kidney><Investigation><Ketosis-Resistant Diabetes Mellitus><Kidney><Kidney Urinary System><Knowledge><LCN2><LCN2 gene><Laboratories><Lipocalin 2><Long-term cohort><Longitudinal cohort><Lysosomes><Maintenance><Maturity-Onset Diabetes Mellitus><Measures><Mediating><Mentors><Methodology><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Morbidity><Murine><Mus><NGAL><NIDDM><Neutrophil Gelatinase-Associated Lipocalin><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Oncogenic Lipocalin 24P3><Organelles><Outcome><Oxidative Stress><Oxygen Deficiency><Participant><Pathogenesis><Pathway interactions><Pattern><Persons><Physicians><Physiological Homeostasis><Pima Indian><Plasma><Plasma Serum><Play><Prediction of Response to Therapy><Predisposition><Process><Prognosis><Proteins><Proteomics><R & D><R&D><R-Series Research Projects><R01 Mechanism><R01 Program><Renal function><Research><Research Grants><Research Project Grants><Research Projects><Reticuloendothelial System, Serum, Plasma><Role><SGLT 2 inhibitor><SGLT2i><Scientist><Severities><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Stable Diabetes Mellitus><Subgroup><Susceptibility><T2 DM><T2D><T2DM><Testing><Therapeutic><Tissues><Training><Tubular><Tubular formation><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Universities><Urine><Uterocalin><Washington><Work><adult onset diabetes><adulthood><advanced glycation endproduct><advanced glycosylation endproduct><autophagy><biomarker signature><career><career development><cell damage><cell injury><cellular damage><chronic kidney disease><cohort><cohort research study><cohort survey><critical injury><damage to cells><design><designing><detection of nutrient><devastating injury><diabetes><diabetic><disease model><disease subgroups><disease subtype><disorder model><disorder subtype><enroll><epidemiologic><epidemiological><excretion><experience><glucagon-like peptide-1 receptor><hyperglycemic><hypertensive><improved><individual patient><individualized therapeutic><injuries><injury to cells><insight><ketosis resistant diabetes><kidney biopsy><kidney function><kidney injury><light microscopy><maturity onset diabetes><molecular phenotype><mortality><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><nutrient sensing><pathway><perception of nutrients><personalized diagnosis><personalized diagnostics><personalized therapeutic><precise diagnostics><precision diagnostics><precision medicine><precision-based medicine><predict therapeutic response><predict therapy response><prognostic><renal><renal biopsy><renal injury><research and development><response><scRNA sequencing><scRNA-seq><severe injury><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><therapy prediction><treatment prediction><treatment response prediction><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sokratis Apostolidis

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$172,393
FY 2026

Project Title

Single-cell dissection of CD4 T cell changes in patients with immune-related adverse events following PD-1 inhibition

Grant Number:

5K08AR081929-04

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary This application proposes a five-year research and training plan with a scientific focus on the mechanisms through which PD-1 checkpoint inhibition leads to immune-related adverse events (irAEs). The hypothesis is that de novo loss of PD-1 signaling enhances the antigen sensitivity o...

Research Terms

<Affect><Antigens><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><Autoregulation><Bioinformatics><Blood><Blood Reticuloendothelial System><Business-Friendly Atmosphere><CD28><CD28 gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancer Treatment><Cancers><Caring><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Clinical><Clinical Research><Clinical Study><Clonal Expansion><Clonality><Collaborations><Communication><Data><Development><Development Plans><Dissection><Dysfunction><Early Diagnosis><Early Intervention><Early treatment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evaluation><Event><Exhibits><Expression Signature><Faculty><Feedback><Flu vaccination><Foundations><Functional disorder><Funding><Gene Expression Profile><Gene Transcription><Generalized Growth><Genetic Transcription><Goals><Grant><Growth><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Homeostasis><Human><Immune><Immune mediated therapy><Immunes><Immunization><Immunologically Directed Therapy><Immunotherapy><Impairment><Inducer Cells><Inducer T-Lymphocytes><Inflammatory><Influenza Vaccines><Influenza immunization><Influenza vaccination><Intervention><Intracellular Communication and Signaling><Investigators><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Medical><Memory><Mentors><Modern Man><Molecular Target><Musculoskeletal Pain Disorder><NIH><National Institutes of Health><Oncology Group><PD 1><PD-1><PD-1 antibody><PD-1 antibody therapy><PD-1 checkpoint pathway><PD-1 pathway><PD-1 signaling pathway><PD-1 therapy><PD1><PD1 antibody><PD1 antibody therapy><PD1 based treatment><PD1 checkpoint pathway><PD1 pathway><PD1 signaling pathway><Pathology><Pathway interactions><Patients><Pennsylvania><Phase><Physicians><Physiological Homeostasis><Physiopathology><Population><Position><Positioning Attribute><Preparation><Prevention><Productivity><Prophylactic vaccination against influenza><Proxy><RNA Expression><Research><Research Personnel><Researchers><Resolution><Rheumatic Diseases><Rheumatism><Rheumatologic Diseases><Rheumatologic Disorder><Rheumatology><Sampling><Scientist><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Surface><T cell response><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T44><T8 Cells><T8 Lymphocytes><Testing><Time><Tissue Growth><Toxic effect><Toxicities><Training><Transcription><Transcriptional Control><Transcriptional Regulation><Translational Research><Translational Science><United States National Institutes of Health><Universities><Vaccination><Vaccines><Writing><aPD-1><aPD-1 therapy><aPD-1 treatment><aPD1><aPD1 therapy><aPD1 treatment><analytical tool><anti programmed cell death 1><anti programmed cell death protein 1 checkpoint pathway><anti programmed cell death protein 1 pathway><anti programmed cell death protein 1 signaling pathway><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 monoclonal antibodies><anti-PD-1 therapy><anti-PD-1 treatment><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 monoclonal antibodies><anti-PD1 therapy><anti-PD1 treatment><anti-cancer therapy><anti-programmed cell death 1 therapy><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed cell death protein 1 therapy><anti-programmed death-1 antibody><antiPD-1><autoimmune condition><autoimmune disorder><autoimmune reactivity><autoimmune toxicity><autoimmunity disease><autoreactivity><biological signal transduction><business-friendly environment><cancer immune therapeutics><cancer immunotherapeutics><cancer therapy><cancer-directed therapy><career><career development><cellular targeting><check point inhibition><checkpoint inhibition><cohort><collaborative atmosphere><collaborative environment><design><designing><developmental><early detection><early therapy><epigenetic regulation><epigenetically><experience><fitness><flu immunisation><flu vaccine><flu virus vaccine><gene expression pattern><gene expression signature><immune check point inhibition><immune checkpoint inhibition><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-mediated adverse events><immune-related adverse effect><immune-related adverse events><immune-related adverse reaction><immuno therapy><immunogen><immunopathology><influenza virus vaccination><influenza virus vaccine><interactive atmosphere><interactive environment><interdisciplinary atmosphere><interdisciplinary environment><malignancy><multi-modality><multimodality><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><ontogeny><pathophysiology><pathway><peer-group atmosphere><peer-group environment><permissiveness><pre-clinical><preclinical><preparations><prevent><preventing><programmed cell death 1><programmed cell death protein 1><programmed cell death protein 1 therapy><programmed death 1><programs><prospective><recruit><resolutions><response><seasonal flu><seasonal influenza><single cell analysis><single cell technology><skills><sle2><systemic autoimmune disease><systemic autoimmune disorder><systemic lupus erythematosus susceptibility 2><tenure process><tenure track><thymus derived lymphocyte><transcriptional profile><transcriptional signature><translation research><translational investigation><tumor><vaccination against influenza><vaccine against flu><vaccine against influenza><αPD-1><αPD1>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael Fang

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$157,248
FY 2026

Project Title

Disparities in the management and prognosis of type 1 diabetes

Grant Number:

5K01DK138273-03

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/12/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Michael Fang, PhD, MHS is an Assistant Professor in the Department of Epidemiology at Johns Hopkins Bloomberg School of Public Health. He seeks a K01 Mentored Research Scientist Development Award in order to obtain essential skills and mentored research experience for an independent career as a scie...

Research Terms

<0-11 years old><21+ years old><Acute><Adult><Adult Human><Affect><Apoplexy><Area><Brain Vascular Accident><Brittle Diabetes Mellitus><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Caring><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Child><Child Youth><Childhood diabetes><Children (0-21)><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinical><Collaborations><Complications of Diabetes Mellitus><Coronary Disease><Coronary heart disease><Data><Data Bases><Databases><Decrease health disparities><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Complications><Disease Progression><Disparities><Disparity><Doctor of Philosophy><Electronic Health Record><Emergencies><Emergency Situation><Epidemiology><Event><Five-Year Plans><Fostering><Goals><Health><Health Informatics><Health Policy><Health disparity mitigation><Health disparity reduction><Heart Vascular><Heart failure><Hyperglycemia><Hypoglycemia><IDDM><Insulin Infusion Systems><Insulin-Dependent Diabetes Mellitus><International><Investigators><Juvenile-Onset Diabetes Mellitus><K01 Award><K01 Mechanism><K01 Program><Ketosis-Prone Diabetes Mellitus><Life Cycle><Life Cycle Stages><Life Expectancy><Lower health disparities><Measures><Mentored Research Scientist Development Award><Mentored Training Award><Mentors><Mentorship><Metabolic><Methods><Microvascular Dysfunction><Mitigate health disparities><Modeling><Morbidity><Morbidity - disease rate><Neuropathy><Outcome><Patients><Persons><Ph.D.><PhD><Population><Population Research><Population-based research><Population-level research><Predicting Risk><Prognosis><Public Health Informatics><Public Health Schools><Publishing><Recommendation><Reduce health disparities><Research><Research Personnel><Research Proposals><Research Scientist Development Award><Researchers><Retinal Diseases><Retinal Disorder><Risk><Scientist><Stroke><Subgroup><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><Technology><Training><Translational Research><Translational Science><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Underserved Population><adulthood><brain attack><cardiac failure><career><career development><cerebral vascular accident><cerebrovascular accident><chronic kidney disease><circulatory system><clinical risk><consumer informatics><coronary disorder><data base><diabetes><diabetes control><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes management><diabetes mellitus control><diabetes mellitus management><diabetic management><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><epidemiologic><epidemiological><experience><forecasting risk><glycemic control><health care policy><hyperglycemic><hypoglycemic><hypoglycemic episodes><insulin dependent diabetes><insulin dependent type 1><insulin infusion device><insulin infusion pump><insulin pump><investigate population><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kids><life course><life-time risk><lifetime risk><metabolic rate><microvascular complications><microvascular disease><model-based simulation><models and simulation><morbidity rate><mortality><neuropathic><pediatric diabetes><population investigation><population level investigation><population specific research><predict risk><predict risks><predicted risk><predicted risks><predicting risks><predictive risk><predicts risk><professor><programs><retina disease><retina disorder><retinopathy><risk prediction><risk predictions><simulation><skills><small vessel disease><social disadvantage><social disparities><social health determinants><social inequality><socio-demographic disparity><socio-demographic inequality><socio-demographic inequity><socio-demographics><socio-economic><socio-economically><sociodemographic disparity><sociodemographic inequality><sociodemographic inequity><sociodemographics><socioeconomically><socioeconomics><stroked><strokes><studies of populations><study of the population><study population><survey population><translation research><translational investigation><trend><type I diabetes><type one diabetes><under served group><under served individual><under served people><under served population><underserved group><underserved individual><underserved people><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Samantha Fortin

UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, FARMINGTON, CT

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$150,930
FY 2026

Project Title

Examining the role of locus coeruleus glucagon-like peptide-1 receptors infeeding behavior.

Grant Number:

7K01DK133627-04

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/19/2025

End Date:

2/29/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary/Abstract The staggering prevalence of obesity presents major public health and economic consequences. Effective anti- obesity drugs are desperately needed to combat the obesity epidemic, as behavioral strategies offer limited success. Analogs of the endogenous satiety signal glucagon...

Research Terms

<Affect><Agonist><Anatomic Sites><Anatomic structures><Anatomy><Anorexia><Anti-Obesity Agents><Anti-Obesity Drugs><Axon Terminals><Behavior><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Mechanisms><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Bioinformatics><Body Weight><Body Weight decreased><Brain><Brain Nervous System><Calcium Ion Signaling><Calcium Signaling><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Common Rat Strains><Complex><Computer software><Conditioning Therapy><Data><Dedications><Development><Development Plans><Drug Therapy><Drugs><Eating><Economics><Electrophysiology><Electrophysiology (science)><Emesis><Emetic Agents><Emetic Drugs><Emetics><Encephalon><Ex4 peptide><Exendin 4><FDA approved><Feeding behaviors><Fingerprint><Food Intake><Funding><Future><GLP-1><GLP-1 receptor><GLP-I receptor><Genes><Genetic><Glp-1><Glutamates><Goals><Hind Brain><Human><Illness Behavior><In Situ Hybridization><In vivo two-photon calcium imaging><Individual><Ingestion><Ingestive Behavior><Intracellular Communication and Signaling><Investigation><Kaolin><L-Glutamate><Levarterenol><Levonorepinephrine><Ligands><Locus Coeruleus><Mechanisms of Behavior and Behavior Change><Mediating><Medication><Mice><Mice Mammals><Microinjections><Modern Man><Murine><Mus><Nature><Nausea><Nausea and Vomiting><Nerve Cells><Nerve Unit><Neural Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurons><Neurophysiology / Electrophysiology><Noradrenaline><Norepinephrine><Nucleus><Nucleus Pigmentosus Pontis><Obesity><Obesity Epidemic><Output><Pathway interactions><Pattern><Peripheral><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Physiologic><Physiological><Pica Disease><Population><Post-Transcriptional Gene Silencing><Pre-Clinical Model><Preclinical Models><Presynaptic Nerve Endings><Presynaptic Terminals><Prevalence><Proxy><Public Health><RNA Interference><RNA Silencing><RNAi><Rat><Rats Mammals><Rattus><Receptor Activation><Receptor Signaling><Regulation><Reporting><Research><Rhombencephalon><Role><Satiation><Scientist><Sequence-Specific Posttranscriptional Gene Silencing><Shrews><Sick Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single-Nucleus Sequencing><Site><Software><Source><Synaptic Boutons><Synaptic Terminals><Testing><Therapeutic><Therapeutic Effect><Time><Training><Virus><Vomiting><Weight Loss><Weight Reduction><adiposity><analog><antagonism><antagonist><anti-obesity compounds><anti-obesity medications><anti-obesity therapeutics><behavior intervention><behavior mechanism><behavioral intervention><behavioral pharmacology><biological signal transduction><blue nucleus><body weight loss><brain control><career development><clay><combat><corpulence><developmental><drug intervention><drug treatment><drug/agent><eat less><economic><electrophysiological><exenatide><experiment><experimental research><experimental study><experiments><feeding><feeding-related behaviors><global gene expression><global transcription profile><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glutamate signaling><glutamatergic><glutamatergic dendrodendritic synapses><glutamatergic signaling><hindbrain><human model><improved><in situ Hybridization Genetics><in situ Hybridization Staining Method><in vivo calcium imaging><ingest><insight><integrated circuit><integrated circuits><knock-down><knockdown><locus ceruleus structure><model of human><neural><neuronal><noradrenergic><novel><nutrient intake activity><obesity intervention><obesity therapy><obesity treatment><parabrachial nucleus><pathway><pharmaceutical intervention><pharmacobehavioral><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pica><pre-proglucagons><preproglucagons><presynaptic><professor><reduced eating><reduced food intake><response><sNuc-Seq><satiety><side effect><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><skills><snRNA sequencing><snRNA-seq><social role><success><tenure process><tenure track><transcriptome><transcriptomics><translation strategy><translational approach><translational strategy><wt-loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laura Shaw

NATIONAL JEWISH HEALTH, DENVER, CO

Exploratory lead · 42/100
Training-friendly
Active award
Career award
$114,626
FY 2026

Project Title

Transcriptional control of T cell function during type 1 diabetes

Grant Number:

5K01DK134835-03

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY T cells responding to persistent antigen during cancer and chronic infection develop a hyporesponsive phenotype, while T cells responding to self-antigen during type 1 diabetes (T1D) maintain function and eliminate pancreatic beta cells. My co-mentor previously identified a transcrip...

Research Terms

<Address><Affinity><Antigens><Autoantigens><Autoimmune Diseases><Autoimmune Responses><Autoimmune Status><Autoimmunity><Autologous Antigens><Basal Transcription Factor><Basal transcription factor genes><Brittle Diabetes Mellitus><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cancers><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Characteristics><Chronic><Chronic Disease><Chronic Illness><Clone Cells><Data><Diabetes Mellitus><Enabling Factors><Environment><Exposure to><Family><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Transcription><Human><Humulin R><IDDM><Immune response><Inbred NOD Mice><Insulin><Insulin-Dependent Diabetes Mellitus><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Link><Long-term infection><MHC Interaction><Malignant Neoplasms><Malignant Tumor><Mentors><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><NF-AT><NF-AT proteins><NFAT proteins><NFAT-1><NFATC proteins><NOD Mouse><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><Nuclear Receptors><Pancreas><Pancreatic><Pancreatic beta Cell><Pancreatic β-Cell><Pattern><Peptides><Phenotype><Proteins><RNA Expression><Receptor Protein><Regular Insulin><Risk-associated variant><Self-Antigens><Specificity><Structure of beta Cell of islet><Subcellular Process><Sudden-Onset Diabetes Mellitus><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T1 DM><T1 diabetes><T1D><T1DM><T8 Cells><T8 Lymphocytes><Testing><Thymocyte Selection><Training><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Control><Transcriptional Regulation><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Viral Diseases><Virus><Virus Diseases><antigen-specific T cells><autoimmune condition><autoimmune disorder><autoimmune reactivity><autoimmunity disease><autoreactive T cell><autoreactivity><chronic disorder><chronic infection><cytokine><cytoplasmic nuclear factor of activated T-cells><diabetes><disease control><disorder control><exhaust><exhaustion><experiment><experimental research><experimental study><experiments><host response><immune system response><immunogen><immunoresponse><insulin dependent diabetes><insulin dependent type 1><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><malignancy><mouse model><murine model><neoplasm/cancer><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><nuclear factors of activated T-cells><pancreas beta cell><pancreas β cell><pancreatic b-cell><persistent infection><programs><receptor><receptor expression><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><scRNA sequencing><scRNA-seq><self-reactive T cell><self-renew><self-renewal><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><therapeutic target><thymus derived lymphocyte><tool><transcription factor><transcription factor NF-AT><tumor><type I diabetes><type one diabetes><viral infection><virus infection><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Terry L. Bowlin

MICROBIOTIX, INC, WORCESTER, MA

Exploratory lead · 40/100
Above-average budget
Recent
Active award
$669,859
FY 2026

Project Title

Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis

Grant Number:

5R33EY036947-02

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2028

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract The long-term goal of this project, to develop filociclovir (FCV) for the safe and effective treatment of human adenovirus (HAdV) ocular infections, especially HAdV-related epidemic keratoconjunctivitis (EKC), a stated National Eye Institute (NEI) research priority. There a...

Research Terms

<2-Pyrrolidinone, 1-ethenyl-, homopolymer><Accounting><Active Follow-up><Acute><Adenoviridae><Adenoviridae Infections><Adenovirus Infections><Adenoviruses><Adverse effects><Animals><Artificial Tears><Australia><Behavioral><Blindness><CMV infection><Canine Species><Canis familiaris><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Chemistry><Chronic><Cidofovir><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Design><Common Rat Strains><Communication><Conjunctivitis><Cornea><Cytomegalic Inclusion Disease><Cytomegalovirus Infections><Data><Devices><Disease><Disorder><Dogs><Dogs Mammals><Domestic Rabbit><Dose><Drug Kinetics><Drug Therapy><Early-Stage Clinical Trials><Economic Burden><Enzyme Gene><Enzymes><Epidemic Keratoconjunctivitis><Exhibits><Eye><Eye Drops><Eye Infections><Eyeball><Eyedrops><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Formulation><Gel><Goals><HPMPC><Heart Vascular><Human><IND Filing><IND application><IND package><IND submission><Inclusion Disease><India><Infection><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Iodine><Keratitis><Keratoconjunctivitis><Medical><Modeling><Modern Man><NOAEL><NSAIDs><National Eye Institute><Neurologic><Neurological><No-Observed-Adverse-Effect Level><Non-Steroidal Anti-Inflammatory Agents><Ocular Infections><Oryctolagus cuniculus><P-30 Protein><P30 Protein><Pancreatic RNase><Pancreatic ribonuclease><Pathology><Patients><Pharmacokinetics><Pharmacological Treatment><Pharmacology><Pharmacology and Toxicology><Pharmacotherapy><Phase><Phase 1 Clinical Trials><Phase 2 Clinical Trials><Phase I Clinical Trials><Phase II Clinical Trials><Polvidone><Polyvidon><Polyvinylpyrrolidone><Position><Positioning Attribute><Povidone><Pre IND FDA meeting><Pre-IND mtg><Preclinical data><Primary Care Physician><RNase A><RNase I><Rabbits><Rabbits Mammals><Rat><Rats Mammals><Rattus><Reaction><Regimen><Research Design><Research Priority><Ribonuclease A><Ribonuclease I><Safety><Salivary Gland Virus Disease><Solid><Specific qualifier value><Specified><Study Type><Supportive Therapy><Supportive care><Topical Corticosteroids><Toxicology><United States><Viral Activity><Viral Burden><Viral Function><Viral Load><Viral Load result><Viral Physiology><Viral Shedding><Virus Shedding><Visit><Visual><Work><active followup><anti-microbial><antimicrobial><canine><carcinogenicity><circulatory system><conjunctiva><corneal><decreased income><domestic dog><drug intervention><drug treatment><effective therapy><effective treatment><effectiveness testing><efficacy study><follow up><follow-up><followed up><followup><genotoxicity><improve symptom><income loss><inhibitor><lost earning><lost income><lost wage><manufacture><meeting><meetings><meter><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-steroidal anti-inflammatory drugs><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><nucleoside analog><organ transplant patient><organ transplant recipient><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><phase 2 study><phase I protocol><phase II protocol><phase II study><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><pre-clinical><pre-clinical development><pre-clinical study><preclinical><preclinical development><preclinical findings><preclinical information><preclinical study><programs><ranpirnase><reduced income><respiratory><safety study><socio-economic><socio-economically><socioeconomically><socioeconomics><study design><symptom improvement><symptomatic improvement><translational study><vision loss><visual loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PETER MANCUSO

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 40/100
Solid budget
Very recent
Active award
$429,000
FY 2026

Project Title

Enhancing Host Defense Against Bacterial Pneumonia in Lipodystrophy: Evaluating the Therapeutic Potential of Leptin and Tirzepatide

Grant Number:

1R21AI196410-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/7/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Respiratory tract infections are a leading cause of death for lipodystrophy patients. Lipodystrophy syndromes are rare disorders characterized by selective loss of adipose tissue, hyperphagia, severe insulin resistance, type 2 diabetes, hepatic steatosis, and leptin deficiency. The life spa...

Research Terms

<Address><Adipocytes><Adipose Cell><Adipose tissue><Adult-Onset Diabetes Mellitus><Affect><Agonist><Airway infections><Alveolar Macrophages><Antibodies><Autoregulation><Bacterial Pneumonia><Blood Glucose><Blood Sugar><Cause of Death><Cell Body><Cells><Cellular Immune Function><Clinical Management><Clinical Trials><Combined Modality Therapy><Defect><Development><Diabetes Mellitus><Dose><Drug Combinations><Drugs><Exhibits><FDA approved><Fat Cells><Fatty Liver><Fatty Tissue><GLP-1><Gastric Inhibitory Polypeptide><General Population><General Public><Glp-1><Glucose-Dependent Insulin-Releasing Peptide><Glucose-Dependent Insulinotropic Peptide><Goals><HIV Lipodystrophy Syndrome><HIV-Associated Lipodystrophy><HIV-Associated Lipodystrophy Syndrome><Homeostasis><Host Defense><Hyperphagia><Impairment><Infection><Insulin Resistance><K pneumoniae><K. pneumoniae><Ketosis-Resistant Diabetes Mellitus><Klebsiella pneumoniae><Knock-out><Knockout><Lamin A><Lamin Type A><Leptin><Leptin deficiency><Leptin resistance><Life><Lipocytes><Lipodystrophy><Lipodystrophy Syndrome><Liver Steatosis><Lung><Lung Respiratory System><Malnutrition><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Medication><Metabolic><Metabolic Control><Metabolic Diseases><Metabolic Disorder><Mice><Mice Mammals><Modeling><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nutritional Deficiency><Ob Gene Product><Ob Protein><Obese Gene Product><Obese Protein><Orphan Disease><Outcome><Overeating><Patients><Phagocytosis><Pharmaceutical Preparations><Physiological Homeostasis><Pneumonia><Predisposition><Process><Production><Pulmonary Macrophages><Rare Diseases><Rare Disorder><Research><Respiratory Infections><Respiratory Tract Infections><Risk><Severity of illness><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Susceptibility><T2 DM><T2D><T2DM><Testing><Therapeutic><Therapeutic Agents><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Undernutrition><Wild Type Mouse><Work><adipose><adult onset diabetes><bacteria pneumonia><blood glucose regulation><blood lipid><combination therapy><combined modality treatment><combined treatment><developmental><diabetes><diabetic patient><dietary deficiency><disease severity><drug/agent><gastric inhibitory peptide><glucagon-like peptide 1><glucose control><glucose homeostasis><glucose regulation><hepatic steatosis><hepatosteatosis><immune function><improved><in vivo><infection risk><insight><insulin resistant><insulin tolerance><ketosis resistant diabetes><malnourished><maturity onset diabetes><metabolism disorder><multi-modal therapy><multi-modal treatment><nutrition deficiency><nutrition deficiency disorder><nutritional deficiency disorder><orphan disorder><patient population><polyphagia><pulmonary><reactive oxygen intermediate><response><risk mitigation><type 2 DM><type II DM><type two diabetes><white adipose tissue><wildtype mouse><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sebla B. Kutluay

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 40/100
Solid budget
Very recent
Active award
$427,626
FY 2026

Project Title

Identification of Host Factors that Mediate the Nuclear Retention of Unspliced and Partially Spliced HIV-1 Transcripts

Grant Number:

1R21AI198155-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Transcription of a HIV-1 provirus generates a 9-kilobase full-length transcript, that either remains unspliced or undergoes extensive alternative splicing resulting in generation of over 100 transcripts. While the completely spliced viral mRNAs can easily access the host mRNA nuclear...

Research Terms

<Adenosine><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Binding><CRISPR><CRISPR editing screen><CRISPR screen><CRISPR-based screen><CRISPR/Cas system><CRISPR/Cas9 screen><Cell Nucleus><Clustered Regularly Interspaced Short Palindromic Repeats><Code><Coding System><Codon><Codon Nucleotides><Coupled><Cytosine><Data><Dependence><Deposit><Deposition><Elements><Endogenous Interferon Beta><Engineering><Fibroblast Interferon><Fireflies><Firefly Luciferases><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Generations><Genes><Genetic Transcription><Goals><Guide RNA><HIV Genome><HIV replication><HIV viral replication><HIV-1><HIV-1 genome><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV1><HIV1 genome><Host Factor><Host Factor Protein><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><IFN-alpha D><IFN-β><IFNA1><IFNA13 gene><IFNb><IFNα1><Integration Host Factors><Interferon-β><Intervening Sequences><Introns><Knowledge><Lampyridae><Length><Luciferase Immunologic><Luciferases><Mammalia><Mammals><Maps><Mediating><Messenger RNA><Modeling><Modern Man><Molecular Interaction><Natural Interferon Beta><Natural human interferon beta><Non-Polyadenylated RNA><Nuclear><Nuclear Export><Nucleotides><Nucleus><Pathway interactions><Photinus luciferin 4 monooxygenase><Pre-mRNA><Process><Property><Protein Export><Protein Export Pathway><Proteins><Proviruses><RNA><RNA Expression><RNA Gene Products><RNA Splicing><RNA, Messenger, Precursors><Regulatory Element><Reporter><Reporter Genes><Response Elements><Ribonucleic Acid><Short interfering RNA><Small Interfering RNA><Splicing><System><Transcript><Transcription><Translating><Viral><Virus><Work><candidate identification><clustered regularly interspaced short palindromic repeats screen><empowerment><flexibility><flexible><gRNA><genome scale><genome wide screen><genome-wide><genomewide><genomic RNA><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><insight><interferon alfa D><interferon alpha-1><interferon α-1><mRNA><mRNA Export><mRNA Precursor><novel><pathway><recruit><rev Protein><siRNA><viral RNA><virology><virus RNA>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexander L Greninger

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Exploratory lead · 40/100
Solid budget
Very recent
Active award
$270,591
FY 2026

Project Title

Multiplex binding antibody assay for confirmatory HSV-1/2 serological diagnosis

Grant Number:

1R21AI190539-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Herpes simplex virus types 1 and 2 (HSV-1/2) are major human viral pathogens that cause one of the most common, debilitating, stigmatized and lifelong infections of humankind with more than 143 million new infections every year and affecting more than 4 billion people around...

Research Terms

<7S Gamma Globulin><Affect><Africa><American><Antibodies><Antigen S 100><Antigens><Assay><Authorization><Authorization documentation><Binding><Bioassay><Biological Assay><Blinded><Blood Serum><Characteristics><Chemiluminescence Measurements><Chemiluminescence assay><Chemiluminescent Assays><Chemiluminescent Measurements><Chemoluminescence Measurements><Clinical><Clinical Virology><Country><Data><Development><Enzyme Gene><Enzymes><Ethnic Origin><Ethnicity><Future><Geography><Goals><Guidelines><HHV-2><HHV2><HSV><HSV-1><HSV-2><HSV1><HSV2><Herpes Simplex><Herpes Simplex Infections><Herpes Simplex Type 1><Herpes Simplex Virus><Herpes Simplex Virus 1><Herpes Simplex Virus 2><Herpes Simplex Virus Type 1><Herpes Simplex Virus Type 2><Herpes labialis Virus><Herpes simplex disease><Herpesvirus 1><Herpesvirus 2 (alpha), Human><Herpesvirus hominis disease><Herpesvirus progenitalis><Human><Human (alpha) herpes virus 2><Human Herpesvirus 2><Human herpes simplex virus type 2><IgG><Immunoassay><Immunoblotting><Immunoglobulin G><Individual><Infection><Laboratories><Licensing><Membrane><Modern Man><Molecular Interaction><Nerve Tissue Protein S 100><Patients><Pattern><Performance><Permission><Persons><Prevention program><Process><Proteins><Public Health><Quality Control><Reagent><Recommendation><Recurrence><Recurrent><Research Specimen><Running><S-100 Protein><S100 Protein Family><S100 Proteins><Sampling><Sensitivity and Specificity><Serodiagnoses><Serological Diagnosis><Serology><Serology test><Serum><Simplexvirus><Specificity><Specimen><Stigmatization><Technology><Testing><United States><Universities><Viral><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Latency><Viral Proteins><Virus><Virus Latency><Washington><Western Blotting><Western Immunoblotting><antibody assay><antibody based test><antibody test><clinical validation><cost><cross reactivity><depository><developmental><diagnostic serology><glycoprotein G><herpes simplex i><herpes simplex ii><herpes simplex virus 1 infection><herpes simplex virus infection><herpes simplex-1><human alphaherpesvirus 2><immunogen><instrumentation><interest><membrane structure><pathogenic virus><point of care><protein blotting><repository><response><screening><screenings><serology assay><seropositive><viral pathogen><viral testing><virology><virus antigen><virus pathogen><virus protein><virus testing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anton M Sholukh

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Exploratory lead · 40/100
Solid budget
Very recent
Active award
$270,591
FY 2026

Project Title

Multiplex binding antibody assay for confirmatory HSV-1/2 serological diagnosis

Grant Number:

1R21AI190539-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Herpes simplex virus types 1 and 2 (HSV-1/2) are major human viral pathogens that cause one of the most common, debilitating, stigmatized and lifelong infections of humankind with more than 143 million new infections every year and affecting more than 4 billion people around...

Research Terms

<7S Gamma Globulin><Affect><Africa><American><Antibodies><Antigen S 100><Antigens><Assay><Authorization><Authorization documentation><Binding><Bioassay><Biological Assay><Blinded><Blood Serum><Characteristics><Chemiluminescence Measurements><Chemiluminescence assay><Chemiluminescent Assays><Chemiluminescent Measurements><Chemoluminescence Measurements><Clinical><Clinical Virology><Country><Data><Development><Enzyme Gene><Enzymes><Ethnic Origin><Ethnicity><Future><Geography><Goals><Guidelines><HHV-2><HHV2><HSV><HSV-1><HSV-2><HSV1><HSV2><Herpes Simplex><Herpes Simplex Infections><Herpes Simplex Type 1><Herpes Simplex Virus><Herpes Simplex Virus 1><Herpes Simplex Virus 2><Herpes Simplex Virus Type 1><Herpes Simplex Virus Type 2><Herpes labialis Virus><Herpes simplex disease><Herpesvirus 1><Herpesvirus 2 (alpha), Human><Herpesvirus hominis disease><Herpesvirus progenitalis><Human><Human (alpha) herpes virus 2><Human Herpesvirus 2><Human herpes simplex virus type 2><IgG><Immunoassay><Immunoblotting><Immunoglobulin G><Individual><Infection><Laboratories><Licensing><Membrane><Modern Man><Molecular Interaction><Nerve Tissue Protein S 100><Patients><Pattern><Performance><Permission><Persons><Prevention program><Process><Proteins><Public Health><Quality Control><Reagent><Recommendation><Recurrence><Recurrent><Research Specimen><Running><S-100 Protein><S100 Protein Family><S100 Proteins><Sampling><Sensitivity and Specificity><Serodiagnoses><Serological Diagnosis><Serology><Serology test><Serum><Simplexvirus><Specificity><Specimen><Stigmatization><Technology><Testing><United States><Universities><Viral><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Latency><Viral Proteins><Virus><Virus Latency><Washington><Western Blotting><Western Immunoblotting><antibody assay><antibody based test><antibody test><clinical validation><cost><cross reactivity><depository><developmental><diagnostic serology><glycoprotein G><herpes simplex i><herpes simplex ii><herpes simplex virus 1 infection><herpes simplex virus infection><herpes simplex-1><human alphaherpesvirus 2><immunogen><instrumentation><interest><membrane structure><pathogenic virus><point of care><protein blotting><repository><response><screening><screenings><serology assay><seropositive><viral pathogen><viral testing><virology><virus antigen><virus pathogen><virus protein><virus testing>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Molly Nelson

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$49,538
FY 2026

Project Title

Early-Life Microbes Prevent Autoimmune Diabetes by Upregulating PD-1 on T Cells

Grant Number:

1F31DK143738-01A1

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2029

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary: Type 1 diabetes (T1D) is a chronic autoimmune disease that affects millions globally, and the incidence of T1D is increasing. Early-life disruptions of the gut microbiome have long-lasting impacts on the risk for developing type 1 diabetes (T1D), yet how the composition of the earl...

Research Terms

<21+ years old><Activities of Daily Living><Activities of everyday life><Address><Adult><Adult Human><Affect><Animals><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Autoimmune Diabetes><Autoimmune Diseases><Autoimmune Status><Autoimmunity><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B9 endocrine pancreas><Bacteria><Brittle Diabetes Mellitus><Cell Communication and Signaling><Cell Locomotion><Cell Migration><Cell Movement><Cell Signaling><Cellular Migration><Cellular Motility><Childhood><Childhood diabetes><Children's Hospital><Communication><Communities><Complex><Computer Analysis><Data><Data Analyses><Data Analysis><Development><Diabetes Mellitus><Educational process of instructing><Endocrine Pancreas><Environmental Factor><Environmental Risk Factor><Experimental Designs><Fellowship><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Frequencies><Future><GI microbiome><Genetic><Germ-Free><Gnotobiotic><Gnotobiotics><Goals><Humulin R><IDDM><Immune><Immune response><Immune system><Immunes><Immunologic Technics><Immunologic Techniques><Immunological Technics><Immunological Techniques><Immunology><Immunomodulation><In Vitro><Inbred NOD Mice><Incidence><Institution><Insulin><Insulin-Dependent Diabetes Mellitus><Intracellular Communication and Signaling><Investigation><Investigators><Islands of Langerhans><Islet Cell><Islets of Langerhans><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Laboratories><Life><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Measures><Mediating><Mentors><Mentorship><Mice><Mice Mammals><Microbe><Miscellaneous Antibiotic><Modeling><Murine><Mus><NOD Mouse><Nesidioblasts><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><PD 1><PD-1><PD1><Pancreas><Pancreatic><Pancreatic Islets><Pars endocrina pancreatis><Pathway interactions><Patients><Pediatric Hospitals><Pennsylvania><Persons><Philadelphia><Population><Pre-DM><Prediabetes><Prediabetes syndrome><Prediabetic State><Predisposition><Receptor Protein><Regular Insulin><Research Personnel><Research Resources><Researchers><Resources><Risk><Science><Scientist><Signal Transduction><Signal Transduction Systems><Signaling><Spleen><Spleen Reticuloendothelial System><Structure><Students><Sudden-Onset Diabetes Mellitus><Susceptibility><Systems Development><T-Cells><T-Lymphocyte><T1 DM><T1 diabetes><T1D><T1DM><Teaching><Teff cell><Therapeutic><Time><Training><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Universities><Weaning><Work><Writing><adulthood><analog><autoimmune condition><autoimmune disorder><autoimmune reactivity><autoimmunity disease><autoreactive T cell><autoreactivity><biological signal transduction><career><career development><cell motility><chronic autoimmune disease><clinical relevance><clinically relevant><commensal flora><commensal microbes><commensal microbiota><commensal microflora><compare to control><comparison control><computational analyses><computational analysis><computer analyses><daily living function><daily living functionality><data interpretation><develop therapy><developmental><diabetes><diabetes during childhood><diabetes in childhood><diabetes in children><diabetes pathogenesis><digestive tract microbiome><disease risk><disorder risk><effector T cell><enteric microbiome><environmental risk><exhaust><flow cytophotometry><functional ability><functional capacity><gastrointestinal microbiome><gut microbiome><gut-associated microbiome><high dimensionality><high risk><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><improved><innovate><innovation><innovative><insulin dependent diabetes><insulin dependent type 1><intervention development><intestinal biome><intestinal microbiome><islet><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><lymph gland><lymph nodes><lymphnodes><meeting><meetings><member><microbial><microbial consortia><microbial flora><microbiome><microbiome intervention><microbiome therapeutics><microbiome therapy><microbiome treatment><microbiome-based intervention><microbiome-based therapeutic><microbiome-based therapy><microbiome-based treatment><microbiota><microflora><mouse model><multispecies consortia><murine model><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><pathway><pediatric><pediatric diabetes><pre-diabetes><pre-diabetic><prediabetic><prevent><preventing><programmed cell death 1><programmed cell death protein 1><programmed death 1><programs><receptor><restraint><scRNA sequencing><scRNA-seq><self-reactive T cell><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skills><sle2><systemic lupus erythematosus susceptibility 2><therapy development><thymus derived lymphocyte><treatment development><type I diabetes><type one diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brenna Duffy

DREXEL UNIVERSITY, PHILADELPHIA, PA

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$49,416
FY 2026

Project Title

Investigating molecular mechanisms of glutamate toxicity in HIV-1 Tat-induced cognitive impairment

Grant Number:

1F31MH139360-01A1

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/10/2026

End Date:

3/9/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary HIV-1 associated neurocognitive disorders (HAND) affect 15 to 40% of people living with HIV (PWH), despite the use of anti-retroviral therapies (ART). Persistence of HAND in the presence of ART suggests that factors outside of viral replication contribute to neurocognitive impairment...

Research Terms

<AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advanced HIV><Affect><Animal Model><Animal Models and Related Studies><Animals><Assay><Astrocytes><Astrocytus><Astroglia><Astroprotein><Attention><Automobile Driving><Behavior assessment><Bioassay><Biological Assay><Brain><Brain Nervous System><Calcium><Cell Communication and Signaling><Cell Signaling><Cerebrospinal Fluid><Co-culture><Cocultivation><Coculture><Coculture Techniques><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive Manifestations><Cognitive Symptoms><Cognitive decline><Cognitive function abnormal><Common Rat Strains><Cystine><DNA><Deoxyribonucleic Acid><Development><Disease><Disorder><Disturbance in cognition><Down-Regulation><EAAT-1><EAAT2 Neurotransmitter Transporter><EAAT2 Protein><Encephalon><Evaluation><Excitatory Amino Acid Transporter 1><Excitatory Amino Acid Transporter 2><Exposure to><Future><GFA-Protein><GFAP><GLAST-1><GLT-1 Protein><GLT-1 Transport Protein><Gene Transcription><Generations><Genetic Transcription><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Gliosis><GluT-1 Glutamate Transporter><Glutamate Aspartate Transporter 1><Glutamates><HIV><HIV 1 associated neurocognitive disorder><HIV Infections><HIV associated neurocognitive deficit><HIV associated neurocognitive impairment><HIV individuals><HIV induced neurocognitive deficit><HIV induced neurocognitive impairment><HIV infected individuals><HIV infected persons><HIV infection persistence><HIV neurocognitive impairment><HIV people><HIV persistence><HIV positive individuals><HIV positive people><HIV viral infection><HIV viral persistence><HIV virus infection><HIV-1><HIV-1 associated neurocognitive deficit><HIV-1 associated neurocognitive disorder><HIV-1 associated neurocognitive impairment><HIV-1 infection><HIV-1 persistence><HIV-I><HIV-associated neurocognitive disorder><HIV1><Hortega cell><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><IQ Deficit><Image><Immunoblotting><Impaired cognition><In Vitro><Increase lifespan><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Intracellular Communication and Signaling><L-Cystine><L-Glutamate><LAV-HTLV-III><Learning><Lentiviral Vector><Lentivirinae><Lentivirus><Lentivirus Vector><Literature><Lymphadenopathy-Associated Virus><Macaca><Macaque><Mediating><Memory><Messenger RNA><Microglia><Modeling><Molecular><N-Methyl-D-Aspartate Receptors><N-Methylaspartate Receptors><NMDA Receptor-Ionophore Complex><NMDA Receptors><Nerve Cells><Nerve Impulse Transmission><Nerve Transmission><Nerve Transmitter Substances><Nerve Unit><Neural Cell><Neurocognitive Deficit><Neurocognitive Impairment in HIV><Neurocognitive Impairment in HIV-1><Neurocyte><Neuronal Transmission><Neurons><Neuropathogenesis><Neurotransmitters><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Outcome><PLWH><PWH><Pathogenesis><Play><Population><Prefrontal Cortex><Prognosis><Proteins><RNA><RNA Expression><RNA Gene Products><RT-PCR><Rat><Rats Mammals><Rattus><Receptor Protein><Receptor Signaling><Reporting><Reverse Transcriptase Polymerase Chain Reaction><Ribonucleic Acid><Role><SIV><Severe HIV Disease><Signal Transduction><Signal Transduction Systems><Signaling><Simian Immunodeficiency Viruses><Slc1a3 GlutamateTransporter><Source><Sprague-Dawley Rats><Surgical><Surgical Interventions><Surgical Procedure><Symptoms><Synapses><Synaptic><Techniques><Testing><Therapeutic><Toxic effect><Toxicities><Trans-Acting Factors><Trans-Activators><Transactivators><Transcription><Transcription Activator><Transcription Coactivator><Transcription Factor Coactivator><Transcriptional Activator/Coactivator><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral reservoir><Virus Replication><Virus reservoir><Virus-HIV><Western Blotting><Western Immunoblotting><affective disturbance><antiporter><antiretroviral therapy><antiretroviral treatment><astrocytic glia><axon signaling><axon-glial signaling><axonal signaling><behavior test><behavioral assessment><behavioral test><biological signal transduction><boost longevity><brain tissue><cell type><cerebral spinal fluid><clinical relevance><clinically relevant><cognitive dysfunction><cognitive function><cognitive loss><developmental><disturbance in affect><driving><elongating the lifespan><enhance longevity><excitatory neuron><excitotoxic><excitotoxicity><executive control><executive function><experience><extend life span><extend lifespan><extend longevity><extracellular><flexibility><flexible><foster longevity><gitter cell><glia signaling><glial signaling><glutamatergic><human immunodeficiency virus infection><human immunodeficiency virus persistence><imaging><improve lifespan><improve longevity><in vitro Model><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><intelligence quotient deficit><lentiviral-transduced><lentivirally transduced><lentivirus transduced><lifespan extension><mRNA><mesoglia><microglial cell><microgliocyte><model of animal><mood alteration><mood and affect disturbance><mood disturbance><mood dysfunction><motor impairment><movement impairment><movement limitation><nerve signaling><neural signaling><neurocognitive decline><neurocognitive impairment><neuron toxicity><neuronal><neuronal signaling><neuronal toxicity><neuropathologic><neuropathological><neuropathology><neurotoxic><neurotoxicity><neurotransmission><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><object recognition><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><perivascular glial cell><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><prolong lifespan><prolong longevity><promote lifespan><promote longevity><promoter><promotor><protein blotting><receptor><receptor expression><receptor function><reuptake><reverse transcriptase PCR><social role><spinal fluid><success><support longevity><surgery><synapse><therapeutic target><viral multiplication><viral replication><virus multiplication><virus protein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aislinn Keane

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$49,114
FY 2026

Project Title

Investigating the role of nicotine and the NRLP3 Inflammasome in HIV-1-Associated CNS Inflammation

Grant Number:

5F31DA062536-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT People with HIV (PWH) often experience chronic systemic inflammation and are at risk for cognitive impairment due to neuroinflammation and blood-brain barrier (BBB) breakdown. Tobacco use exacerbates neuroinflammation and is associated with poor outcomes, such as increased r...

Research Terms

<3-D><3-Dimensional><3D><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Affect><Alveolar Macrophages><Assay><Beta Proprotein Interleukin 1><Binding><Bioassay><Biological Assay><Blood - brain barrier anatomy><Blood-Brain Barrier><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Death><Cell Signaling><Cells><Chronic><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Complex><Data><Development><Disturbance in cognition><Encephalon><Endothelium><Engraftment><Fluorescence Agents><Fluorescent Agents><Fluorescent Dyes><Future><HIV><HIV Infections><HIV individuals><HIV infected individuals><HIV infected persons><HIV latency><HIV people><HIV positive individuals><HIV positive people><HIV viral infection><HIV virus infection><HIV-1 infection><Hemato-Encephalic Barrier><Hortega cell><Human><Human Immunodeficiency Viruses><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune><Immunes><Impaired cognition><In Vitro><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Inflammasome><Inflammation><Inflammatory><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Intermediary Metabolism><Intracellular Communication and Signaling><LAV-HTLV-III><Laboratories><Lead><Lineage Tracing><Link><Lymphadenopathy-Associated Virus><Macrophage><Maintenance><Metabolic Processes><Metabolism><Microglia><Modeling><Modern Man><Molecular Interaction><Myeloid Cells><Mφ><Nerve Degeneration><Neuron Degeneration><Nicotine><Outcome><PLWH><PWH><Pathogenesis><Pathway interactions><Patients><Pb element><Periodicals><Permeability><Persons><Preinterleukin 1 Beta><Principal Investigator><Productivity><Proviruses><Pulmonary Macrophages><Reporting><Risk><Role><Scientist><Signal Transduction><Signal Transduction Systems><Signaling><Source><Structure><System><Technology><Testing><Tobacco><Tobacco Consumption><Tobacco use><Tonsil><Training><Viral><Viral Latency><Viral reservoir><Viremia><Virus Latency><Virus Replication><Virus reservoir><Virus-HIV><Work><antiretroviral therapy><antiretroviral treatment><asymptomatic HIV infection><biological signal transduction><blood flow imaging><blood imaging><bloodbrain barrier><career><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cellular lineage mapping><cellular lineage tracking><chronic HIV infection><clinical relevance><clinically relevant><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><comorbidity><cytokine><develop therapy><developmental><experience><exposure to nicotine><fluorescent dye/probe><gene signatures><genetic signature><gitter cell><heavy metal Pb><heavy metal lead><hematology imaging><human immunodeficiency virus infection><humanized mice><humanized mouse><iPS><iPSC><iPSCs><immunoneurology><improved><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><infected with HIV><infected with human immunodeficiency virus><insight><intervention development><latency/reactivation><latent HIV infection><medical college><medical schools><mesoglia><microglial cell><microgliocyte><migration><mortality><mouse model><multidisciplinary><murine model><necrocytosis><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neuroimmunology><neuroinflammation><neuroinflammatory><neurological degeneration><neuronal degeneration><nicotine consumption><nicotine exposure><nicotine use><novel><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><periodic><periodical><perivascular glial cell><reactivation from latency><response><scRNA sequencing><scRNA-seq><school of medicine><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><stem cell organoids><stem cell-derived organoids><substance use><substance using><systemic inflammation><systemic inflammatory response><therapeutic agent development><therapeutic development><therapy development><three dimensional><tobacco product use><tonsillar><training opportunity><treatment development><viraemia><viral multiplication><viral replication><viral sepsis><virology><virus multiplication><virusemia>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gabrielle Bais

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$42,191
FY 2026

Project Title

The roles of Fragile-X related protein 1 in cardiomyocyte and heart biology

Grant Number:

5F31HL176049-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY / ABSTRACT Cardiomyocytes (CMs) generate contractile forces to pump blood throughout the body. Contraction begins at the sarcomere and is coordinated by actin-myosin filament interactions. Coordinated CM contraction is maintained by adaptive responses to external stimuli. During post...

Research Terms

<21+ years old><ASD><Actin-Activated ATPase><Actins><Adult><Adult Human><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Autism><Autistic Disorder><Biology><Body Tissues><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cardiac><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac development><Cardiocyte><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cells><Cellular Matrix><Cellular Mechanotransduction><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><Contracting Opportunities><Contracts><Cultured Cells><Cyclicity><Cytoplasm><Cytoskeletal System><Cytoskeleton><DNA mutation><Dependence><Development><Disease><Disorder><Early Infantile Autism><Echocardiogram><Echocardiography><Endoplasmic Reticulum><Ergastoplasm><Escalante syndrome><Exclusion><Exhibits><Exons><FMR-1 Protein><FMR1 Protein><FMR1 gene><FMRP><FMRP protein><FRAXA><FXR1><FXR1 gene><FXR1P><FXR2><FXR2 gene><FXR2P><Fellowship><Fetal Tissues><Filament><Fragile X><Fragile X Mental Retardation 1 Gene><Fragile X Mental Retardation Protein><Fragile X Mental Retardation, Autosomal Homolog 1><Fragile X Mental Retardation, Autosomal Homolog 2><Fragile X Syndrome><Fragile X-Related Protein 1><Gene Expression><Gene Transcription><GeneHomolog><Genes><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Health><Heart><Heart Muscle Cells><Heart Vascular><Heart failure><Heart myocyte><Hereditary><Homolog><Homologous Gene><Homologue><Hypertrophy><Immunoblotting><Infantile Autism><Inherited><Intracellular Communication and Signaling><Investigators><Isoforms><Kanner's Syndrome><Kinesin><Link><Maintenance><Martin-Bell Syndrome><Martin-Bell-Renpenning syndrome><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mechanical Signal Transduction><Mechanics><Mechanosensory Transduction><Mediating><Messenger RNA><Mice><Mice Mammals><Micro-tubule><Microtubule Polymerization><Microtubules><Minicore disease><Minicore myopathy><Modeling><Morphology><Multi-minicore disease><Multi-minicore myopathy><Multicore disease><Multicore myopathy><Multiminicore disease><Multiminicore myopathy><Murine><Mus><Muscle><Muscle Cells><Muscle Fibers><Muscle Tissue><Mutation><Myocardium><Myocytes><Myosin ATPase><Myosin Adenosine Triphosphatase><Myosin Adenosinetriphosphatase><Myosins><Myotubes><Nature><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neuromuscular conditions><Neurons><Non-Polyadenylated RNA><North Carolina><Nuclear><Nucleus><O element><O2 element><Oxygen><Periodicity><Physiology><Production><Protein Family><Protein Isoforms><Proteins><Quantitative Microscopy><RNA><RNA Binding><RNA Expression><RNA Gene Products><RNA Processing><RNA Splicing><RNA bound><RNA-Binding Proteins><Regulation><Renpenning syndrome 2><Research><Research Personnel><Researchers><Rhabdomyocyte><Rhythmicity><Ribo-seq><Ribonucleic Acid><Ribosomes><Role><Sarcomeres><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skeletal Fiber><Skeletal Muscle><Skeletal Muscle Cell><Skeletal Muscle Fiber><Skeletal Myocytes><Splicing><Stimulus><Stretching><Striated Muscles><Synapses><Synaptic><System><Tail><Testing><Tissues><Training><Transcript><Transcription><Translating><Translational Regulation><Translations><Transmission><Transthoracic Echocardiography><Universities><Voluntary Muscle><Western Blotting><Western Immunoblotting><Wild Type Mouse><X-linked mental deficiency-megalotestes syndrome><X-linked mental retardation with fragile X syndrome><X-linked mental retardation-fragile site 1 syndrome><adulthood><autism spectral disorder><autism spectrum disorder><autism-fragile X (AFRAX) syndrome><autistic spectrum disorder><autosome><biological signal transduction><birthing individual><birthing patient><birthing people><blood pump><cardiac failure><cardiac function><cardiac muscle><cardiogenesis><cardiomyocyte><cardiovascular disease therapy><cardiovascular disorder><cardiovascular disorder therapy><circulatory system><defined contribution><develop therapy><developmental><experience><fetus tissue><fra(X) syndrome><fra(X)(28) syndrome><fra(X)(q27) syndrome><fra(X)(q27-28) syndrome><fragile X FMR1 protein><fragile X mental retardation 1><fragile X mental retardation-1 protein><fragile X-mental retardation syndrome><fragile X-related protein 2><fragile Xq syndrome><fragile site mental retardation 1><function of the heart><genome mutation><heart development><heart formation><heart function><heart muscle><heart sonography><in vivo><individual who gives birth><insight><intercalation><intervention development><intracellular skeleton><mRNA><mRNP><macro-orchidism-marker X (MOMX) syndrome><macro-orchidism-marker X syndrome><mar(X) syndrome><marker X syndrome><mechanic><mechanical><mechanical cue><mechanical force><mechanical signal><mechanical stimulus><mechanosensing><mechanotransduction><member><mental retardation-macroorchidism syndrome><messenger ribonucleoprotein><mouse model><multidisciplinary><murine model><muscular><neuronal><novel><patient who gives birth><people giving birth><people who birth><people who give birth><polarized cell><postnatal><pressure><programs><protein blotting><protein function><protein protein interaction><response><ribosome footprint profiling><ribosome profiling><social role><synapse><therapeutic candidate><therapy development><translation><transmission process><treatment development><wildtype mouse>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jennifer Lynn Powers

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$40,599
FY 2026

Project Title

The role of caspase-3 mediated cleavage of VPS4A in restricting HSV-1

Grant Number:

5F30AI188981-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/6/2025

End Date:

6/30/2029

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Caspases are critical initiators and executioners of programmed cell death (PCD) pathways. While these pathways function in antiviral defense, little is known about the mechanisms by which caspases and PCD pathways restrict virus replication. This is particularly true in muc...

Research Terms

<ATP Hydrolysis><ATP phosphohydrolase><ATPase><Adenosine Triphosphatase><Affect><Antimorphic mutation><Apopain><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 3><Apoptosis-Related Cysteine Protease Gene Caspase 8><Apoptotic Cysteine Protease Gene><Apoptotic Protease MCH-5 Gene><Aspartic Endopeptidases><Aspartic Proteinases><Aspartyl Proteases><Aspartyl Proteinases><Bioinformatics><Body Tissues><Buccal Cavity><Buccal Cavity Head and Neck><CAP4><CAP4 protease><CASP-3><CASP3><CASP3 gene><CASP8><CASP8 Protein><CASP8 gene><CPP-32><CPP32><CPP32 protein><CPP32B><CPP32beta><Cachectin Receptors><Carboxyl (Acid) Proteinases><Carboxylic Proteinases><Caspase><Caspase Gene><Caspase Inhibitor><Caspase-8 Gene><Caspase-8/Flice><Cavitas Oris><Cell Body><Cell Death><Cell Death Process><Cell Death Signaling><Cell Death Signaling Process><Cell surface><Cell-Death Protease><Cells><Cessation of life><Complex><Cysteine><Cysteine Endopeptidases><Cysteine Protease><Cysteine Protease CPP32><Cysteine Protease CPP32 Gene><Cysteine Proteinases><DNA><Death><Deoxyribonucleic Acid><Dominant Negative><Dominant-Negative Mutant><Dominant-Negative Mutation><Endosomes><Environment><Esteroproteases><Event><FADD-Homologous ICE/CED3-Like Protease Gene><FADD-Like ICE><FADD-Like ICE Gene><FADD-homologous ICE/CED3-Like Protease><FLICE><FLICE protein><Genetics-Mutagenesis><Goals><HSV-1><HSV1><Half-Cystine><Herpes Simplex><Herpes Simplex Infections><Herpes Simplex Type 1><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes simplex disease><Herpesvirus 1><Herpesvirus hominis disease><Human><ICE-Like Apoptotic Protease 5 Gene><ICE-like protease><In Vitro><Individual><Inflammatory><Investigation><Keratinocyte tumor><L-Cysteine><Ligands><MACH protein><MACH-Alpha-1/2/3 Protein Gene><MACH-Beta-1/2/3/4 Protein Gene><MCH5><MCH5 Isoform Alpha Gene><MORT1-Associated CED-3 Homolog Gene><MORT1-Associated CED3 Homolog Gene><Mch5 protease><Mediating><Mediator><Membrane><Modeling><Modern Man><Molecular><Mouth><Mucosa><Mucosal Tissue><Mucous Membrane><Mutagenesis><Mutagenesis Molecular Biology><Oral><Oral cavity><PARP Cleavage Protease><PARP Cleavage Protease Gene><Pathway interactions><Peptidases><Peptide Hydrolases><Production><Programmed Cell Death><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Receptor Protein><Receptosomes><Recycling><Role><SCA-1><SCA-1 Gene><SREBP Cleavage Activity 1><SREBP Cleavage Activity 1 Gene><Site><Sorting><System><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNFR><Testing><Tissues><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Vacuolar Protein Sorting><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Yama><Yama protein><aspartate protease><aspartic protease><caspase-3><caspase-8><cell type><cystein protease><cystein proteinase><cysteine endopeptidase><cysteine protease P32><extracellular><herpes simplex i><herpes simplex virus 1 infection><herpes simplex virus infection><herpes simplex-1><human pathogen><keratinocyte><lytic replication><lytic viral replication><lytic virus replication><membrane structure><mutant><necrocytosis><novel><oral cavity epithelium><oral epithelia><oral epithelium><pathway><protein expression><receptor><social role><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus protein><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zachary A Kipp

UNIVERSITY OF KENTUCKY, LEXINGTON, KY

Exploratory lead · 40/100
Training-friendly
Recent
Active award
$35,530
FY 2026

Project Title

Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction

Grant Number:

5F31HL170972-03

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2026

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Summary: Urobilin is formed in the intestine as a biproduct of conjugated bilirubin catabolism. Currently, the physiological function of urobilin is unknown. Human association studies have indicated a positive correlation to obesity and cardiovascular diseases (CVD). Since obesity is a major risk fa...

Research Terms

<Adipose tissue><Affect><Antioxidants><Arterial Fatty Streak><Atheroma><Atheromatous><Atheromatous degeneration><Atheromatous plaque><Bilirubin><Bilirubin IX alpha><Binding><Blood Plasma><Blood Pressure><Blood Serum><Blood Vessels><Body Weight><CVD prevention><Calories><Cardiac Diseases><Cardiac Disorders><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Catabolism><Cause of Death><Cessation of life><Cholesterol><Circulation><Clotting><Coagulation><Coagulation Process><Data><Death><Development><Diet><Environment><Enzyme Gene><Enzymes><Excretory function><Fat-Restricted Diet><Fats><Fatty Tissue><Fatty acid glycerol esters><Fellowship><Ferroprotoporphyrin><Fibrosis><Fibrosis in the heart><Fibrosis in the myocardium><Fibrosis within the heart><Fibrosis within the myocardium><Fibrotic myocardium><Financial Hardship><Foundations><Future><GI microbiota><GNT1><Gastrointestinal microbiota><Generations><Genetic Polymorphism><Gilbert Disease><Gilbert's syndrome><Glucuronic Acids><Goals><Health Care Systems><Heart Diseases><Heart Vascular><Heart failure><Heme><Hepatic><High Fat Diet><Hormonal><Human><Hydrogen Oxide><Intestinal><Intestines><KO mice><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Lead><Leanness><Link><Liver><Low-Fat Diet><Measures><Mediator><Messenger RNA><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic dysfunction><Mice><Mice Mammals><Modern Man><Molecular Interaction><Murine><Mus><Nuclear Receptors><Null Mouse><Obese Mice><Obesity><PAI-1><PAI1><PLANH1><PPAR alpha><PPAR-α><PPARalpha><PPARα><Pathway interactions><Patients><Pb element><Peroxisome Proliferator-Activated Receptor alpha><Peroxisome Proliferator-Activated Receptor α><Physiologic><Physiological><Plasma><Plasma Serum><Plasminogen Activator Inhibitor 1><Portal System><Post-Transcriptional Gene Silencing><Prevention><Production><Proteins><Protoheme><RNA Interference><RNA Seq><RNA Silencing><RNA sequencing><RNAi><RNAseq><Research><Research Proposals><Research Technics><Research Techniques><Reticuloendothelial System, Serum, Plasma><Risk><Risk Factors><Role><Scientist><Sequence-Specific Posttranscriptional Gene Silencing><Serine or Cysteine Proteinase Inhibitor Clade E Member 1><Serum><Structure><Technology><Testing><Therapeutic><Thesaurismosis><Thinness><Training><Translating><Travel><Type 1 Plasminogen Activator Inhibitor><UDP glycosyltransferase 1 family, polypeptide A1 Gene><UDP glycosyltransferase gene 1><UGT1><UGT1A><UGT1A1><UGT1A1 gene><UGT1A5><United States><Water><Woman><Work><absorption><adipose><adiposity><atherosclerosis plaque><atherosclerotic lesions><atherosclerotic plaque><bile duct><bile ductule><bowel><calorie><cardiac disease prevention><cardiac failure><cardiac fibrosis><cardioprotectant><cardioprotection><cardioprotective><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><career><circulatory system><co-morbid><co-morbidity><comorbidity><congenital nonhemolytic jaundice><coronary fibrosis><corpulence><developmental><diet-associated obesity><diet-induced obesity><diet-related obesity><diets><economic hardship><economic strain><enteric microbial community><enteric microbiota><excretion><feeding><ferroheme><fibrotic heart><financial adversity><financial burden><financial distress><financial insecurity><financial instability><financial strain><financial stress><financial worry><gastrointestinal microbial flora><global gene expression><global transcription profile><glucose tolerance><gut community><gut flora><gut microbe community><gut microbial community><gut microbial composition><gut microbial consortia><gut microbiota><gut microbiotic><gut microflora><heart disorder><heart fibrosis><heavy metal Pb><heavy metal lead><hepatic body system><hepatic organ system><hereditary nonhemolytic jaundice><improved><intestinal flora><intestinal microbiota><intestinal microflora><intestinal tract microflora><mRNA><men><metabolism disorder><mouse development><myocardial fibrosis><new drug target><new drug treatments><new druggable target><new drugs><new marker><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel biomarker><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel marker><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><ob/ob mouse><obese patients><pathway><patients with obesity><plaques in atherosclerosis><polymorphism><prevent><preventing><promoter><promotor><social role><therapeutic target><tool><transcriptome><transcriptome sequencing><transcriptomic sequencing><vascular><white adipose tissue><yellow adipose tissue>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James H Hurley

UNIVERSITY OF CALIFORNIA BERKELEY, BERKELEY, CA

Exploratory lead · 34/100
Above-average budget
Active award
$556,938
FY 2026

Project Title

Biochemical, Biophysical, and Structural Mechanisms of HIV-1 Budding and Release

Grant Number:

5R37AI112442-13

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2014

End Date:

12/31/2028

Why this may be worth a closer look

  • • Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY (See instructions): The assembly and release of HIV-1 from infected cells are essential steps in the viral replication cycle. HIV assembly is driven by the virally encoded Gag polyprotein. Bending of the plasma membrane into spherical buds, packing of the RNA genome (gRNA), and incor...

Research Terms

<AIDS Virus><ATP phosphohydrolase><ATPase><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adenosine Triphosphatase><Antimorphic mutation><Award><Biochemical><Biophysics><Capsid><Cell Body><Cell Function><Cell Physiology><Cell Process><Cell membrane><Cells><Cellular Function><Cellular Physiology><Cellular Process><Collaborations><Communication><Communities><Complex><Coupled><Cryo-electron Microscopy><Cryo-electron tomography><Cryoelectron Microscopy><Cytoplasmic Membrane><Dominant Negative><Dominant-Negative Mutant><Dominant-Negative Mutation><Drug resistance><Drugs><Electron Cryomicroscopy><Event><Evolution><GeneHomolog><Genome><Glycoproteins><Guide RNA><HIV><HIV-1><HIV-I><HIV1><Homolog><Homologous Gene><Homologue><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Image><In Situ><In Vitro><Instruction><Intercellular nanotubes><Ions><LAV-HTLV-III><Life Cycle><Life Cycle Stages><Lymphadenopathy-Associated Virus><Mediating><Medication><Membrane><Modeling><Modern Man><Neck><New World Monkeys><Non-Polyadenylated RNA><Normal Cell><Pathway interactions><Pharmaceutical Preparations><Physiology><Plasma Membrane><Platyrrhina><Platyrrhini><Position><Positioning Attribute><Process><Proteins><RNA><RNA Gene Products><Research><Resolution><Retroviral Antigen gag Protein><Retroviridae><Retroviruses><Ribonucleic Acid><Sampling><Structure><Subcellular Process><System><TOMO><Tomogram><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral gag Proteins><Virus><Virus Replication><Virus-HIV><Virus-Retrovirus><Work><animation><biophysical foundation><biophysical principles><biophysical sciences><cryo-EM><cryo-EM tomography><cryoEM><cryoEM tomography><cryoelectron tomography><cryogenic electron microscopy><drug resistant><drug/agent><electron cryo-tomography><gRNA><gag Antigens><gag Gene Products><gag Polyproteins><gag Protein><group specific antigen><imaging><laser tweezer><life course><membrane nanotubes><membrane structure><membranous nanotubes><movie><optic tweezer><optical traps><optical tweezers><particle><pathway><plasmalemma><platyrhine monkey><protein complex><reconstitute><reconstitution><recruit><resistance to Drug><resistant to Drug><resolutions><simulation><tunneling nanotubes><viral multiplication><viral replication><virus multiplication><virus protein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Gregory Lowe

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA

Exploratory lead · 34/100
Training-friendly
Active award
$79,348
FY 2026

Project Title

Understanding How Distinct Heterochromatin States Control Pioneer Factor Binding

Grant Number:

5F32GM156052-02

Activity Code:

F32

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary Precise spatiotemporal regulation of lineage-specification genes is critical not only for directing proper development in the early embryo but also for safeguarding cell fate decisions in adult tissues. Histone methyltransferases (HMTs) restrict transcription factor binding by conden...

Research Terms

<0-11 years old><21+ years old><ATAC sequencing><ATAC-seq><ATACseq><Adult><Adult Human><Affect><Assay for Transposase-Accessible Chromatin using sequencing><Basal Transcription Factor><Basal transcription factor genes><Belief><Binding><Body Tissues><C-terminal><Cell Body><Cell Differentiation><Cell Differentiation process><Cell Lineage><Cells><ChIP Sequencing><ChIP-seq><ChIPseq><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chromatin><Chromatin Structure><Chromosome 7><Complex><DNA><Data><Deoxyribonucleic Acid><Development><Developmental Gene><Differential Gene Expression><Disease><Disorder><ES cell differentiation><ESC differentiation><ESET><Embryo><Embryo Development><Embryogenesis><Embryonic><Embryonic Development><Enhancers><Feedback><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fusion Protein><G9a histone methyltransferase><Gene Down-Regulation><Gene Expression><General Transcription Factor Gene><General Transcription Factors><Genes><Germ Layers><Health><Heterochromatin><Histone H3><Histones><Human><Impairment><Junk DNA><KG1T><KIAA0067><L-Lysine><Link><Lysine><Maps><Mediating><Methods><Methylation><Modern Man><Molecular><Molecular Interaction><Mouse ES Cell><Mouse ESC><Mouse Embryonic Progenitor><Mouse Embryonic Stem Cells><Neural Stem Cell><Neurodevelopmental Disorder><Neurological Development Disorder><Nucleosomes><Oncogenesis><Pathology><Permeability><Position><Positioning Attribute><Predisposition><Process><Proteins><Regulation><Regulatory Element><Reporter><Repression><Resistance><Resolution><Role><SETDB1><SETDB1 gene><Specific qualifier value><Specified><Susceptibility><Syndrome><Testing><Time><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Tissues><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription Repressor><Transcription factor genes><Transcriptional Repressor><United States><Work><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adulthood><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><cellular differentiation><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><de novo mutation><de novo variant><derepression><developmental><developmental disease><developmental disorder><differentiation in embryonic stem cells><directed differentiation><embryonic precursor differentiation><embryonic stem cell differentiation><exome sequencing><exome-seq><flow cytophotometry><gene desert><gene repression><genetic etiology><genetic mechanism of disease><genetic repressor><genome sequencing><histone H3 methyltransferase><histone methylase><histone methyltransferase><kids><mESC><murine ES cells><murine ESC><murine embryonic progenitor><murine embryonic stem cell><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodevelopmental disease><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroprogenitor><neuropsychiatric><neuropsychiatry><new approaches><novel approaches><novel strategies><novel strategy><prevent><preventing><progenitor and neural stem cells><progenitor cell differentiation><progenitor differentiation><programs><promoter><promotor><recombinase-mediated cassette exchange><recombination-mediated cassette exchange><recruit><resistant><resolutions><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial and temporal><spatial temporal><spatiotemporal><stem and progenitor differentiation><stem cell differentiation><transcription factor><tumorigenesis><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jack Michael Moen

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 34/100
Training-friendly
Active award
$76,780
FY 2026

Project Title

Modulation of ADP-Ribosylation as a Target During HIV-1 Latency and Reactivation

Grant Number:

5F32AI176916-02

Activity Code:

F32

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

11/1/2024

End Date:

10/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Human immunodeficiency virus 1 (HIV-1) is one of the most highly infectious pathogens of the modern age, characterized by a rapid loss in CD4+ T cells, which, if left untreated, results in acquired immunodeficiency syndrome and a high likelihood of death due to complications...

Research Terms

<(TNF)-α><ADP Ribose><ADP ribosylation><AIDS><AIDS progression><Abscission><Acetylation><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose><Adenosine 5'-Diphosphoribose><Adenosine Diphosphate Ribose><Adenosine Diphosphoribose><Advanced HIV><Affect><Affinity Chromatography><Age><Agonist><Amino Acids><Anti-Retroviral Agents><Basal Transcription Factor><Basal transcription factor genes><Binding><Biochemical><Biology><C-C CKR-5><C-C CKR-5 Gene><C-C Chemokine Receptor Type 5><C-C Chemokine Receptor Type 5 Gene><CC Chemokine Receptor 5><CC-CKR-5><CC-CKR-5 Gene><CC-CKR5><CCCKR5><CCCKR5 Gene><CCR-5><CCR-5 Gene><CCR5><CCR5 Protein><CCR5 Receptors><CCR5 gene><CD195 Antigen><CD195 Antigen Gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CHEMR13><CHEMR13 Gene><CKR-5><CKR-5 Gene><CKR5><CKR5 Gene><CKR5 Receptors><CMKBR5><CMKBR5 Gene><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CXC-R4><CXCR-4><CXCR4><CXCR4 gene><Cachectin><Calcium Phospholipid-Dependent Protein Kinase><Calcium-Activated Phospholipid-Dependent Kinase><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cellular Assay><Cellular Stress><Cellular Stress Response><Cessation of life><Chemicals><Chemokine (C-C Motif) Receptor 5><Chemokine (C-C) Receptor 5><Chemokine (C-C) Receptor 5 Gene><Chromatin><Circulatory Collapse><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Communities><D2S201E><DNA Damage><DNA Injury><Death><Development><Dihydronicotinamide Adenine Dinucleotide><Diphosphopyridine Nucleotide><Disease><Disorder><Drugs><Excision><Extirpation><FB22><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genetic Code><Genetic Transcription><Global Change><Goals><HDAC><HDAC Agent><HDAC Proteins><HDAC inhibitor><HIV cure><HIV disease progression><HIV functional cure><HIV infection prevalence><HIV prevalence><HIV progression><HIV replication><HIV viral replication><HIV-1><HIV-1 Fusion Co-Receptor><HIV-1 Fusion Co-Receptor Gene><HIV-1 cure><HIV-1 disease progression><HIV-1 functional cure><HIV-1 infection prevalence><HIV-1 prevalence><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV/AIDS cure><HIV/AIDS prevalence><HIV/AIDS progression><HIV1><HM89><HSY3RR><Half-Life><Histone Deacetylase><Histone Deacetylase Inhibitor><Histone deacetylase inhibition><Histones><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Hybrids><Hydrolase><Hydrolase Family Gene><Hydrolase Gene><Immune response><Immune signaling><Immune system><Immunomodulation><Infection><Innate Immune Response><Intracellular Communication and Signaling><Invaded><Investigation><Knock-out><Knockout><Knowledge><LAP3><LCR1><LESTR><Label><Left><Link><Macrophage-Derived TNF><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mediating><Mediator><Medication><Methods><Mission><Modeling><Modernization><Molecular Interaction><Monocyte-Derived TNF><NIH><NPY3R><NPYR><NPYRL><NPYY3R><Nadide><National Institutes of Health><Nicotinamide adenine dinucleotide><Nicotinamide-Adenine Dinucleotide><Nucleosomes><PARP Polymerase><PARP protein><PARS><Pathogenesis><Pathway interactions><Patients><Persons><Pharmaceutical Preparations><Phospholipid-Sensitive Calcium-Dependent Protein Kinase><Phosphorylation><Physiologic><Physiological><Play><Poly(ADP-ribose) Polymerases><Poly(ADPribose) Polymerase><Population><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Process><Progress into acquired immunodeficiency syndrome><Progress to acquired immunodeficiency syndrome><Progression in HIV><Progression in HIV-1><Progression to AIDS><Progression towards AIDS><Protein Kinase C><Protein Modification><Protein Phosphorylation><Proteins><Proteomics><Proviruses><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Expression><Reagent><Receptor Protein><Removal><Research><Research Grants><Research Project Grants><Research Projects><Rest><Retrovirology><Role><SAHA><Scientist><Severe HIV Disease><Shock><Shotguns><Signal Transduction><Signal Transduction Systems><Signaling><Site><Stem Cell like><Strains Cell Lines><Suberoylanilide Hydroxamic Acid><Surgical Removal><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Target Populations><Techniques><Testing><Therapeutic><Time><Trans-Acting Factors><Trans-Activation of Transcription Protein><Trans-Activator of Transcription of HIV><Trans-Activators><Transactivating Regulatory Protein><Transactivators><Transcription><Transcription Activator><Transcription Coactivator><Transcription Elongation><Transcription Factor Coactivator><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Activator/Coactivator><Transcriptional Control><Transcriptional Regulation><Transferase><Transferase Gene><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><United States National Institutes of Health><Viral Pathogenesis><Virus><Vorinostat><Work><acquired immunodeficiency syndrome progression><adaptive immune response><affinity purification><ages><aminoacid><anti-retroviral><biological signal transduction><cell assay><cell stress><circulatory shock><combinatorial><crosslink><cultured cell line><developmental><drug/agent><experiment><experimental research><experimental study><experiments><host response><human immunodeficiency virus cure><human immunodeficiency virus prevalence><human immunodeficiency virus progression><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><human model><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><in vivo><inhibitor><interest><latency/reactivation><model of human><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapeutics><new therapy><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapeutics><novel therapy><novel therapy approach><novel therapy target><pathogen><pathway><poly ADP polymerase><poly ADP ribose synthetase><progenitor capacity><progenitor cell like><progenitor-like><progression to acquired immunodeficiency syndrome><prophylactic><prostratin><protein protein interaction><reactivation from latency><receptor><recruit><resection><response><shocks><shot gun><social role><stem cell characteristics><stem-like><stemness><suberanilohydroxamic acid><tat Protein><thymus derived lymphocyte><transcription factor><vector><virus pathogenesis>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gavin Edward Piester

UNIVERSITY OF ROCHESTER, ROCHESTER, NY

Exploratory lead · 34/100
Training-friendly
Active award
$55,114
FY 2026

Project Title

Sigma-1 Receptor as a modulator of Astrocyte pro-inflammatory activities in Parkinson's Disease

Grant Number:

5F30AG087521-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/2/2024

End Date:

12/1/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY The objective of this proposal is to characterize a regulatory signaling axis which promotes astrocyte-driven CNS pathology in Parkinson’s Disease (PD) and to provide the necessary training for me to become a successful physician-scientist. PD is characterized by progressive motor d...

Research Terms

<Astrocytes><Astrocytus><Astroglia><Beta Proprotein Interleukin 1><CNS Diseases><CNS Nervous System><CNS disorder><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Central Nervous System><Central Nervous System Diseases><Central Nervous System Disorders><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-culture><Cocultivation><Coculture><Coculture Techniques><Conflict><Conflict (Psychology)><Corpus Striatum><Corpus striatum structure><DA Neuron><Data><Degenerative Neurologic Disorders><Development><Disease><Disorder><Disseminated Sclerosis><Dopamine neuron><Dysfunction><EAE><ER stress><Elements><Experimental Allergic Encephalitis><Experimental Allergic Encephalomyelitis><Experimental Autoimmune Encephalitis><Experimental Autoimmune Encephalomyelitis><Functional disorder><Gene Transcription><Genetic><Genetic Transcription><Gliosis><Health><Hortega cell><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><In Vitro><Inflammation><Inflammatory><Inflammatory Response><Injections><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Intracellular Communication and Signaling><Knock-out><Knockout><Lab Findings><Laboratory Finding><Mice><Mice Mammals><Microglia><Modeling><Multiple Sclerosis><Murine><Mus><NAC precursor><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neuraxis><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurologic Disorders><Neurological Disorders><Neuron Degeneration><Neurons><PARK1 protein><PARK4 protein><Paralysis Agitans><Parkinson><Parkinson Disease><Pathogenesis><Pathogenicity><Pathology><Pathway interactions><Persons><Phosphorylation><Physicians><Physiopathology><Play><Pre-Clinical Model><Preclinical Models><Preinterleukin 1 Beta><Primary Parkinsonism><Prions><Process><Production><Protein Phosphorylation><Proteins><RNA Expression><Receptor Inhibition><Receptor Signaling><Recombinants><Regulation><Regulatory Pathway><Reporting><Research Training><Role><SNCA><SNCA protein><Scientist><Severity of illness><Signal Transduction><Signal Transduction Systems><Signaling><Stimulus><Striate Body><Striatum><Testing><Therapeutic><Training><Transcription><Transmission><Upregulation><XBP1><XBP1 gene><a-syn><a-synuclein><alpha synuclein><alpha synuclein gene><alphaSP22><antagonism><antagonist><arm><astrocytic glia><astrogliosis><asyn><autoimmune encephalomyelitis><biological signal transduction><clinical training><cytokine><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><disease model><disease severity><disorder model><dopaminergic neuron><endoplasmic reticulum stress><experiment><experimental research><experimental study><experiments><gitter cell><in vitro activity><in vivo><insular sclerosis><mesoglia><microglial cell><microgliocyte><monomer><motor deficit><motor symptom><mouse model><murine model><nerve cell death><nerve cell loss><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroinflammation><neuroinflammatory><neurological degeneration><neurological disease><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal degeneration><neuronal loss><neurotoxic><non A-beta component of AD amyloid><non A4 component of amyloid precursor><pathophysiology><pathway><perivascular glial cell><pharmacologic><pre-clinical><pre-formed fibril><preclinical><prevent><preventing><response><sigma-1 receptor><social role><striatal><therapeutic candidate><therapeutic target><translational opportunities><translational potential><transmission process><uptake><α synuclein gene><α-syn><α-synuclein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Uma Kantheti

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 34/100
Training-friendly
Active award
$55,114
FY 2026

Project Title

Programmed death ligand-1 interactions in the regulation of dendritic cell migration and T cell priming

Grant Number:

5F30AI176607-03

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/1/2023

End Date:

11/30/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT: Dendritic cells (DCs) are sentinels of the immune system that operate at interface of the innate and adaptive immune response. DC-driven responses require their migration from peripheral tissue to the draining lymph node in order prime naïve T cells. Understanding and disc...

Research Terms

<2-photon microscopy><Address><Amino Acids><Antibodies><Antigen Presentation><Antigen-Presenting Cells><Antigens><B7-1><B7-H1><BB1><Binding><Blocking Antibodies><Body Tissues><CD274><CD28><CD28 gene><CD28LG><CD28LG1><CD80><CD80 gene><CITE sequencing><CITE-seq><CITEseq><Cancers><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Interaction><Cell Locomotion><Cell Mediated Immunology><Cell Migration><Cell Movement><Cell Signaling><Cell Surface Proteins><Cell-Mediated Immunity><Cell-to-Cell Interaction><Cells><Cellular Immunity><Cellular Indexing of Transcriptomes and Epitopes by Sequencing><Cellular Migration><Cellular Motility><Chemokine Receptor Gene><Chemotactic Cytokines><Clinic><Clinical><Cross Presentation><Cytoplasmic Domain><Cytoplasmic Tail><DNA mutation><Data><Defect><Dendritic Cells><Endothelium><External Domain><Extracellular Domain><Family><Frequencies><Genetic Change><Genetic defect><Genetic mutation><Goals><Homologous Chemotactic Cytokines><Human><Image><Immune mediated therapy><Immune response><Immune system><Immunity><Immunologically Directed Therapy><Immunotherapy><Impairment><Infection><Infectious Skin Diseases><Inflammatory Response><Innate Immune Response><Intercrines><Intracellular Communication and Signaling><LAB7><Laboratories><Ligands><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Neoplasms><Malignant Tumor><Mediating><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Memory><Mentors><Mice><Mice Mammals><Mind><Modeling><Modern Man><Molecular Interaction><Murine><Mus><Mutant Strains Mice><Mutate><Mutation><Organ><PD 1><PD-1><PD-L1><PD1><PDL-1><Pathogenicity><Patients><Peripheral><Phenotype><Play><Poxvirus officinale><Process><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Family><Publishing><Receptor Protein><Receptor Signaling><Regulation><Residencies><Resolution><Role><SIS cytokines><Sentinel><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Surface Proteins><T cell response><T memory cell><T-Cell Activation><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T44><Techniques><Tissues><Vaccinia><Vaccinia virus><Veiled Cells><Viral Antigens><Viral Diseases><Virus Diseases><Work><accessory cell><activate T cells><adaptive immune response><aminoacid><biological signal transduction><cell motility><cellular indexing of transcriptomes and epitopes by single cell sequencing><check point receptors><checkpoint receptors><chemoattractant cytokine><chemokine><chemokine receptor><cutaneous infection><dendritic cell vaccination><draining lymph node><exhaust><exhaustion><extracellular><genome mutation><host response><imaging><immune check point><immune checkpoint><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><immunogen><immunoresponse><infected skin><lymph gland><lymph nodes><lymphnodes><malignancy><memory T lymphocyte><migration><mouse model><mouse mutant><murine model><neoplasm/cancer><new drug target><new druggable target><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapy approach><novel therapy target><pathogen><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><programs><protein death-ligand 1><protein protein interaction><receptor><recombinant vaccinia virus><regional lymph node><resident memory T cell><resolutions><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skin infection><sle2><social role><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tissue resident memory T cell><trafficking><tumor><two photon excitation microscopy><two photon microscopy><viral infection><virus antigen><virus infection><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ilana Rae Olin

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 34/100
Training-friendly
Active award
$54,538
FY 2026

Project Title

Characterizing IgA-microbe interactions in type 1 diabetes

Grant Number:

5F30DK142323-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2027

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY Type 1 diabetes (T1D) is a chronic autoimmune disease that often emerges during childhood due to T cell- mediated destruction of insulin-producing  cells in the pancreas. Over the last 30 years, the incidence of T1D has increased by 3-4%, a rapid change that cannot be explained by g...

Research Terms

<Address><Affect><Affinity><Agammaglobulinaemia tyrosine kinase><Anaerobic Bacteria><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Antigen-Presenting Cells><Assay><Attenuated><Autoimmune Diseases><Autoimmune Status><Autoimmunity><B blood cells><B cell><B cell progenitor kinase><B cell receptor><B cell repertoire><B cells><B-Cell Antigen Receptor><B-Cell Receptor Binding><B-Cells><B-Lymphocytes><B-cell><B-cell receptor repertoire sequencing><B-cell receptor sequencing><BCR repertoire sequencing><BCR seq><BCR sequencing><BCRseq><Bacterial RNA><Binding><Bioassay><Biological><Biological Assay><Biological Response Modifiers><Biomodulators><Blood Glucose><Blood Sugar><Brittle Diabetes Mellitus><Bruton's tyrosine kinase><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Childhood><Class Switching><Class Switchings><Clinical Treatment Moab><Development><Disease><Disorder><ELISA><Environment><Environmental Factor><Environmental Risk Factor><Enzyme-Linked Immunosorbent Assay><Exocrine IgA><Failure><Gene Expression><Generalized Growth><Genetic><Germ-Free><Goals><Goblet Cells><Growth><Housing><Human><Humulin R><Hygiene><IDDM><Ig Somatic Hypermutation><IgA><Immune><Immune Mediators><Immune Mediators/Modulators><Immune response><Immunes><Immunoglobulin A><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunoglobulin Somatic Hypermutation><Immunology><Immunomodulation><In Vitro><Inbred NOD Mice><Incidence><Insulin><Insulin-Dependent Diabetes Mellitus><Intracellular Communication and Signaling><Investigation><Isotype Switching><Isotype Switchings><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Knowledge><Light><Measurement><Mediating><Mice><Mice Mammals><Microbe><Miscellaneous Antibiotic><Modern Man><Modernization><Molecular Interaction><Monoclonal Antibodies><Mucins><Mucosa><Mucosal Immunity><Mucosal Tissue><Mucous Membrane><Mucous body substance><Mucus><Mucus Glycoprotein><Murine><Mus><NOD Mouse><Non obese><Non-Obese Diabetic Mice><Nonobese><Nonobese Diabetic Mouse><Novolin R><Occluding Junctions><Oral><Pancreas><Pancreatic><Pathogenesis><Patients><Peyer's Patches><Phenotype><Photoradiation><Play><Probiotics><Production><Proteins><RNA Seq><RNA sequencing><RNAseq><Receptor Signaling><Regular Insulin><Role><SIgA><Scientist><Secretory IgA><Secretory Immunoglobulin A><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Factor Proto-Oncogene><Signaling Pathway Gene><Signaling Protein><Site><Small Intestines><Sudden-Onset Diabetes Mellitus><Supplementation><T-Cells><T-Lymphocyte><T1 DM><T1 diabetes><T1D><T1DM><Testing><Therapeutic><Tight Junctions><Time><Tissue Growth><Training><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><Work><Zonula Occludens><accessory cell><anaerobe><anti-microbial peptide><attenuate><attenuates><autoimmune condition><autoimmune disorder><autoimmunity disease><autoreactive B cell><biologic><biological signal transduction><bpk protein><btk protein><chronic autoimmune disease><defined contribution><developmental><diabetes pathogenesis><diabetic><environmental risk><enzyme linked immunoassay><experiment><experimental research><experimental study><experiments><fitness><gut microbes><gut microbial species><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><improved><in vivo><insulin dependent diabetes><insulin dependent diabetes mellitus onset><insulin dependent type 1><intestinal microbes><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><mAbs><microbial><microbial colonization><microbial consortia><microbial flora><microbiota><microbiota composition><microflora><monoclonal Abs><mouse model><mucous><multispecies consortia><murine model><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><ontogeny><pediatric><prevent><preventing><self reactive B cell><small bowel><social role><somatic hypermutation><thymus derived lymphocyte><transcriptome sequencing><transcriptomic sequencing><type 1 diabetes onset><type I diabetes><type one diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

WILLIAM MICHAEL MCFADDEN

EMORY UNIVERSITY, ATLANTA, GA

Exploratory lead · 34/100
Training-friendly
Active award
$49,538
FY 2026

Project Title

Structural and Biochemical Effects of Capsid-targeting Molecules on HIV-1 Capsid Assembly

Grant Number:

5F31AI174951-04

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/29/2022

End Date:

12/28/2026

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Abstract HIV infection impacts over 37 million individuals, with over 2/3 of these patients receiving antiretroviral therapies (ART). ART is sustained for a patient’s life and can lead to the emergence of drug-resistant HIV-1. To combat drug-resistance, an improved and diverse set of antiretrovirals...

Research Terms

<AIDS><AIDS Virus><AIDS progression><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Adherence><Advanced HIV><Affect><Affinity><Aminoacetic Acid><Anti-Retroviral Agents><Anti-viral Agents><Anti-viral Drug Resistance><Anti-viral Drug Resistant><Anti-viral resistance><Assay><Binding><Binding Proteins><Bioassay><Bioavailability><Biochemical><Biological Assay><Biological Availability><Capsid><Capsid Proteins><Cell Body><Cells><Characteristics><Clinical><Coat Proteins><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><DNA mutation><Detection><Deuterium><Dipeptides><Dissociation><Drug Targeting><Drug Therapy><Drug resistance><Drug resistant viral><EC 2.7.7.49><Electron Cryomicroscopy><Electron Microscopy><Epidemic><Future><Genetic Change><Genetic defect><Genetic mutation><Glycine><H element><H2 isotope><HIV><HIV Infections><HIV disease progression><HIV progression><HIV replication><HIV viral infection><HIV viral replication><HIV virus infection><HIV-1><HIV-1 disease progression><HIV-1 infection><HIV-1 replication><HIV-1 viral replication><HIV-1 virus replication><HIV-I><HIV/AIDS progression><HIV1><Host Factor><Host Factor Protein><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hydrogen><Hydrophobicity><In Vitro><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Integrase><Integration Host Factors><LAV-HTLV-III><Label><Life><Ligand Binding Protein><Ligand Binding Protein Gene><Lymphadenopathy-Associated Virus><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Medicine><Molecular Interaction><Morphology><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mutation><Nature><Negative Staining><Nuclear Import><Optics><Patient Care><Patient Care Delivery><Patients><Pharmacological Treatment><Pharmacotherapy><Phenotype><Phenylalanine><Physiologic Availability><Progress into acquired immunodeficiency syndrome><Progress to acquired immunodeficiency syndrome><Progression in HIV><Progression in HIV-1><Progression to AIDS><Progression towards AIDS><Protein Binding><Proteins><RNA Transcriptase><RNA-Dependent DNA Polymerase><RNA-Directed DNA Polymerase><Reporting><Research><Research Resources><Resistance><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistant to Multiple Drug><Resistant to multi-drug><Resistant to multidrug><Resolution><Resources><Reverse Transcriptase><Revertase><Role><Scanning><Science><Severe HIV Disease><Site><Structure><Surface Plasmon Resonance><System><Therapeutic><Tube><Viral><Viral Coat Proteins><Viral Drug Resistance><Viral Genome><Viral Outer Coat Protein><Virion><Virus><Virus Particle><Virus Replication><Virus-HIV><Visualization><acquired immunodeficiency syndrome progression><analog><anti-retroviral><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral resistant><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiretroviral therapy><antiretroviral treatment><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><bound protein><care for patients><care of patients><career><caring for patients><clinical practice><combat><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><drug intervention><drug resistant><drug resistant virus><drug treatment><emergent virus><emerging virus><experiment><experimental research><experimental study><experiments><genome mutation><high risk><human immunodeficiency virus infection><human immunodeficiency virus progression><human immunodeficiency virus replication><human immunodeficiency virus-1 replication><improved><infected with HIV><infected with human immunodeficiency virus><insight><monomer><multi-drug resistant><multidrug resistant><mutant><nano-molar><nanomolar><new approaches><next generation><novel><novel approaches><novel strategies><novel strategy><optical><particle><peptide mimetic><peptide mimic><peptidomimetics><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pressure><prevent><preventing><progression to acquired immunodeficiency syndrome><resistance to Drug><resistance to anti-viral><resistance to therapy><resistant><resistant to Drug><resistant to anti-viral><resistant to therapy><resolutions><scaffold><scaffolding><skills><social role><stoichiometry><success><therapeutic resistance><therapy resistant><treatment resistance><viral emergence><viral fitness><viral multiplication><viral replication><virus genome><virus multiplication>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jesse Francis Mangold

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Exploratory lead · 34/100
Training-friendly
Active award
$49,114
FY 2026

Project Title

Probing the Role of Secondary Lymphoid Tissue Architecture in HIV-1 Associated NLRP3 Inflammasome Signaling

Grant Number:

5F30AI189255-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2028

Why this may be worth a closer look

  • • Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Human immunodeficiency virus type 1 (HIV-1) infection can lead to both acute and chronic states of inflammation in people with HIV (PWH), even in the setting of effective viral suppression with antiretroviral therapy (ART). Dysfunctional and hyperactive inflammation in PWH is associated with an acce...

Research Terms

<3-D><3-Dimensional><3D><AIDS Virus><ASCVD><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Address><Advocacy><Affect><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 1><Architecture><Area><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Atlases><Automobile Driving><Biology><Body Tissues><CASP-1><CASP1><CASP1 gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Caspase-1><Caspase-1 Gene><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Death><Cell Function><Cell Interaction><Cell Physiology><Cell Process><Cell Signaling><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chronic><Clinical><Clinical Skills><Communicable Diseases><Core Facility><Development><Disease><Disorder><Dissociation><Educational process of instructing><Endothelium><Engineering / Architecture><Environment><Epithelium><Expression Signature><Fellowship><Follicular Dendritic Cells><Foundations><Gene Activation><Gene Expression><Gene Expression Profile><Gene Transcription><Genes><Genetic Transcription><Genomics><Goals><HIV><HIV burden><HIV disease burden><HIV epidemic burden><HIV global burden><HIV health burden><HIV individuals><HIV infected individuals><HIV infected persons><HIV latency><HIV people><HIV positive individuals><HIV positive people><HIV-1><HIV-I><HIV1><Health system><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Hyperactivity><ICE Protease><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1BC><IL-1b Converting Enzyme><IL1B-Convertase><IL1BC><IL1BCE><IQ Deficit><Image><Immune><Immune Cell Activation><Immune mediated therapy><Immune signaling><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunology><Immunotherapy><In Situ><Infection><Infectious Diseases><Infectious Disorder><Inflammasome><Inflammation><Inflammatory><Institution><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Intracellular Communication and Signaling><Investigators><Knowledge><LAV-HTLV-III><Leadership><Life><Lipodystrophy><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphoid><Lymphoid Tissue><Mediating><Medicine><Mentors><Mentorship><Metabolic><Methods><Modeling><Modern Man><Molecular><Molecular Virology><Morbidity><Morphology><Myeloid Cells><Neurocognitive Deficit><Non-Polyadenylated RNA><Organ><Oxidative Phosphorylation><Oxidative Phosphorylation Pathway><PBMC><PLWH><PWH><Pathogenesis><Pathway interactions><Peripheral Blood Mononuclear Cell><Phenotype><Physicians><Production><Programmed Cell Death><Property><Public Health><QOL improvement><RNA><RNA Expression><RNA Gene Products><Regimen><Research><Research Personnel><Research Resources><Researchers><Residual><Residual state><Resolution><Resource Sharing><Resources><Ribonucleic Acid><Risk><Role><Scientist><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single cell seq><Stromal Cells><Structure><Subcellular Process><Supporting Cell><Suspension substance><Suspensions><T4 Cells><T4 Lymphocytes><Teaching><Technology><Testing><Therapeutic><Tissues><Tonsil><Training><Transcription><Viral><Virus-HIV><Work><accelerated aging><accelerated biological age><accelerated biological aging><age acceleration><aging associated><aging related><antiretroviral therapy><antiretroviral treatment><asymptomatic HIV infection><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><biological signal transduction><career><cell type><chronic HIV infection><clinical relevance><clinically relevant><co-morbid><co-morbidity><comorbidity><computational resources><computing resources><cytokine><developmental><driving><gene expression pattern><gene expression signature><high dimensional data><human immunodeficiency virus burden><human immunodeficiency virus global burden><human model><imaging><immune activation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improvements in QOL><improvements in quality of life><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><innate immune mechanisms><innovate><innovation><innovative><insight><intelligence quotient deficit><latent HIV infection><medical college><medical schools><model of human><mortality><multidimensional data><multidimensional datasets><multidisciplinary><necrocytosis><neurocognitive decline><neurocognitive impairment><novel><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><peripheral blood><preservation><programs><quality of life improvement><resolutions><response><scRNA sequencing><scRNA-seq><school of medicine><scientific computing><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell next generation sequencing><single cell sequencing><single cell transcriptomic profiling><single-cell RNA sequencing><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial molecular analysis><spatial molecular imaging><spatial molecular mapping><spatial molecular profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><supercomputer><systemic inflammation><systemic inflammatory response><three dimensional><tonsillar><tool><transcriptional profile><transcriptional signature>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JENNIFER LYNN ST SAUVER

MAYO CLINIC ROCHESTER, ROCHESTER, MN

Exploratory lead · 32/100
Solid budget
Recent
Active award
$443,850
FY 2026

Project Title

Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on older adults

Grant Number:

1R21AG097887-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/29/2028

Project Abstract

PROJECT SUMMARY Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is rapidly increasing throughout the US population, particularly in older adults (≥60 years). It has been estimated that 26.8 million adults insured by Medicare alone are eligible for a GLP-1 RA prescription. Clinical trial...

Research Terms

<1 year of age><1 year old><21+ years old><65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><Address><Adult><Adult Human><Age><Age Years><Aged 65 and Over><Aging><Agonist><Benefits and Risks><Blood Glucose><Blood Pressure><Blood Sugar><Body Weight decreased><Bowel Obstruction><Cardiac><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Centers for Medicare and Medicaid Services><Clinical><Clinical Trials><Communities><Controlled Clinical Trials><Data><Diabetes Mellitus><Drug Prescribing><Drug Prescriptions><Drugs><Electronic Health Record><Eligibility><Eligibility Determination><Epidemiology><Event><Fracture><GLP-1 receptor><GLP-I receptor><Gastric Stasis><Gastroparesis><General Practices><Health Benefit><Health Care Financing Administration><Health Care Providers><Health Insurance for Aged and Disabled, Title 18><Health Insurance for Disabled Title 18><Health Personnel><Heart Vascular><Interstitial Nephritis><Intestinal Obstruction><Link><Measures><Medical><Medicare><Medication><Midwest><Midwest U.S.><Midwest US><Midwestern United States><Monitor><Obesity><Older Population><Outcome><Pancreatitis><Patient Selection><Patients><Persons><Pharmaceutical Preparations><Population><Primary Care><Primary Prevention><Protocol Screening><R-Series Research Projects><R01 Mechanism><R01 Program><Recommendation><Research><Research Grants><Research Infrastructure><Research Project Grants><Research Projects><Risk><Risk Reduction><Sampling><System><Testing><Title 18><United States Centers for Medicare and Medicaid Services><United States Health Care Financing Administration><Weight Loss><Weight Reduction><Woman><above age 65><adiposity><adulthood><adverse consequence><adverse outcome><after age 65><age 1><age 1 year><age 65 and greater><age 65 and older><age 65 or older><age > 65><age associated difference><age based difference><age dependent difference><age dependent variation><age difference><age of 65 years onward><age related difference><age related variation><age specific difference><aged 1 year><aged 65 and greater><aged 65+><aged group><aged groups><aged individual><aged individuals><aged one year><aged people><aged person><aged persons><aged population><aged populations><aged ≥65><ages><aging population><billing data><blood glucose regulation><body weight loss><bone fracture><circulatory system><clinical practice><cohort><corpulence><delayed gastric emptying><diabetes><diabetes control><diabetes mellitus control><differ by age><difference across age><difference in age><drug/agent><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><epidemiologic><epidemiological><experience><falls><frailty><glucagon-like peptide receptor><glucagon-like peptide-1 receptor><glucose control><glucose homeostasis><glucose regulation><health care personnel><health care worker><health insurance for disabled><health provider><health staff><health workers><health workforce><healthcare employees><healthcare staff><healthcare workforce><human old age (65+)><improved><intestine obstruction><lean body mass><medical care providers><medical personnel><medication prescription><men><mid life><mid-life><middle age><middle aged><midlife><mortality><multidisciplinary><obesity intervention><obesity therapy><obesity treatment><older adult><older adulthood><older groups><older individuals><older person><one year of age><one year old><over 65 years><population aging><population based><prescribed medication><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><response><risk-reducing><sarcopenia><sarcopenic><sex><side effect><treatment provider><variation by age><wt-loss><≥65 years>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xiaomo Xiong

UNIVERSITY OF CINCINNATI, CINCINNATI, OH

Exploratory lead · 32/100
Solid budget
Recent
Active award
$324,000
FY 2026

Project Title

GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment

Grant Number:

1R03AG098738-01

Activity Code:

R03

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

1/31/2028

Project Abstract

ABSTRACT Alzheimer’s disease (AD) affects millions in the United States, with cases expected to further surge in the coming decades. There are no treatments currently available to halt or reverse AD progression, which indicates the urgent need for preventions before the onset of AD. Mild cognitive i...

Research Terms

<21+ years old><65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><AD dementia><AD prevention><AD risk><AD risk factor><Active Follow-up><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Adverse Experience><Adverse event><Affect><Aged 65 and Over><Agonist><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease prevention><Alzheimer prevention><Alzheimer risk factor><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease risk><Alzheimers Dementia><Amentia><Amyloid><Amyloid Substance><Antibody Therapy><Attention><Clinical Treatment Moab><Clinical Trials><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Control Groups><Data><Dementia><Development><Disease Progression><Disturbance in cognition><Early Intervention><Economic Burden><Effectiveness><Food and Drug Administration><Future><GLP-1><GLP-1 receptor><GLP-I receptor><Gastrointestinal Diseases><Glp-1><Goals><Health Care Costs><Health Costs><Impaired cognition><Incidence><Individual><Intervention><Ketosis-Resistant Diabetes Mellitus><Link><Literature><Maturity-Onset Diabetes Mellitus><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic dysfunction><Monoclonal Antibodies><NIDDM><Nerve Degeneration><Neuron Degeneration><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Onset of illness><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Persons><Preventative strategy><Prevention><Prevention strategy><Preventive strategy><Price><Primary Senile Degenerative Dementia><Randomized, Controlled Trials><Research><Risk><Risk Reduction><Role><Safety><Sample Size><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Structure><T2 DM><T2D><T2DM><Therapeutic><Thesaurismosis><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><USFDA><United States><United States Food and Drug Administration><above age 65><active followup><adult onset diabetes><adulthood><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age of 65 years onward><aged 65 and greater><aged 65+><aged ≥65><alzheimer risk><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><assess effectiveness><assessing cost effectiveness><clinical decision-making><cognitive benefits><cognitive disability><cognitive dysfunction><cognitive function><cognitive loss><cognitively disabled><comparative><cost><cost effective><cost effectiveness><cost-effectiveness evaluation><data collected in real world><design><designing><determine cost effectiveness><determine effectiveness><developmental><diabetes management><diabetes mellitus management><diabetic management><disability><disease onset><disorder onset><economic analysis><economic assessment><economic evaluation><effectiveness assessment><effectiveness evaluation><effectiveness outcome><effectiveness-related outcomes><evaluate cost-effectiveness><evaluate effectiveness><evidence base><examine cost effectiveness><examine effectiveness><follow up><follow-up><followed up><followup><gastrointestinal><gastrointestinal disorder><glucagon-like peptide 1><glucagon-like peptide-1 receptor><human old age (65+)><improved><improved outcome><innovate><innovation><innovative><insight><ketosis resistant diabetes><mAbs><markov model><maturity onset diabetes><metabolism disorder><mild cognitive decline><mild cognitive disorder><mild cognitive dysfunction><mild cognitive impairment><mild cognitive loss><mild neurocognitive impairment><monoclonal Abs><mortality><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neuroinflammation><neuroinflammatory><neurological degeneration><neuronal degeneration><neuroprotection><neuroprotective><new approaches><novel approaches><novel strategies><novel strategy><older adult><older adulthood><over 65 years><patient oriented outcomes><pre-clinical study><preclinical study><prevent><preventing><pricing><primary degenerative dementia><progression risk><randomized control trial><real world data><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><repurposing><risk factor for developing Alzheimer's><risk factor in Alzheimer's><risk of developing Alzheimer's><risk-reducing><safety assessment><safety outcomes><senile dementia of the Alzheimer type><social role><treatment choice><type 2 DM><type II DM><type two diabetes><≥65 years>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Leonardo D'Aiuto

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 32/100
Solid budget
Recent
Active award
$250,682
FY 2026

Project Title

Role of nuclear paraspeckles in regulating HSV-1 infection in neurons

Grant Number:

1R21AI196548-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/19/2026

End Date:

1/31/2028

Project Abstract

7. PROJECT SUMMARY/ABSTRACT Nuclear speckles and paraspeckles are dynamic subnuclear ribonucleoprotein structures that play critical roles in the regulation of gene expression and RNA processing. Increasing evidence suggests that these structures regulate HSV-1 replication in HeLa cells and mouse em...

Research Terms

<Binding><Burkitt Herpesvirus><Burkitt Lymphoma Virus><Cell Body><Cell Culture Techniques><Cell Nucleus><Cells><Chromatin><Chromatin Remodeling Complex><Chromatin Remodeling Factor><Complex><Cytoplasmic Granules><DNA copy number><Data><Degenerative Neurologic Disorders><E1A Binding Protein p300><EB virus><EBV><ENX-1><EP300><EP300 gene><EZH1><EZH2><EZH2 gene><Embryo><Embryonic><Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Epstein Barr Virus><Equilibrium><Exhibits><Fibroblasts><Foreskin><Functional RNA><Gene Action Regulation><Gene Down-Regulation><Gene Expression><Gene Expression Regulation><Gene Inactivation><Gene Regulation><Gene Regulation Process><Gene Silencing><Gene Transcription><Genes><Genetic Transcription><Genome><HHV-4><HHV4><HSV-1><HSV1><HeLa><Hela Cells><Herpes Simplex Type 1><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpesviridae><Herpesvirus 1><Herpesviruses><Histone H1><Human><Human Herpesvirus 4><Impairment><Induced pluripotent stem cell derived human neuron><Induced pluripotent stem cell derived neurons><Infection><Infectious Mononucleosis Virus><KAT3B><KMT6><KMT6A><Knowledge><Lentiviral Vector><Lentivirus Vector><Life Cycle><Life Cycle Stages><Link><Lytic><Lytic Cycle><Lytic Infection><Lytic Phase><Maintenance><Male Prepuce><Mediating><Membrane><Mice><Mice Mammals><Modeling><Modern Man><Molecular Interaction><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neuron from iPSC><Neuron from induced pluripotent stem cells><Neurons><Non-Polyadenylated RNA><Noncoding RNA><Nontranslated RNA><Nuclear><Nucleus><Play><Preputium Penis><Process><Productivity><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Processing><Recurrence><Recurrent><Ribonucleic Acid><Ribonucleoproteins><Role><SC35><SRSF2><SRSF2 gene><STAT3><STAT3 gene><Serine/Arginine-Rich Splicing Factor 2><Structure><Testing><Time><Transcription><Transcription Repression><Untranslated RNA><Viral><Viral Diseases><Viral Genes><Viral Latency><Virus Activation><Virus Diseases><Virus Induction><Virus Latency><Virus Replication><balance><balance function><biological adaptation to stress><cell culture><cell cultures><chromatin modification><chromatin modifier><clinical applicability><clinical application><compare to control><comparison control><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><epigenetically><gene repression><granule><hammerhead ribozyme><herpes simplex i><herpes simplex-1><herpes virus><hiPSC-derived neurons><histone acetyltransferase p300><histone modification><human iPSC-derived sensory neuron><human induced pluripotent stem cell derived sensory neuron><iPS neurons><iPSC derived-neurons><iPSC-derived human neuron><in vitro Model><induced pluripotent stem cell neurons><inducible pluripotent stem cell derived human neuron><inducible pluripotent stem cell derived human sensory neuron><inhibitor><insight><knock-down><knockdown><latent infection><life course><lytic gene expression><membrane structure><neurodegenerative illness><neuronal><neurons derived from induced pluripotent stem cells><neurons differentiated from human induced pluripotent stem cells><neurons differentiated from induced pluripotent stem cells><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><noncoding><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><p300><pathogen><penis foreskin><prevent><preventing><promoter><promotor><protein complex><reactioncrisis><recruit><response><scaffold><scaffolding><shRNA><short hairpin RNA><small hairpin RNA><social role><stress response><stressreaction><transcriptional silencing><viral DNA><viral activation><viral induction><viral infection><viral multiplication><viral replication><virus DNA><virus host interaction><virus infection><virus multiplication><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Roger D. Cone

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 30/100
Very recent
Active award
$231,000
FY 2026

Project Title

Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment of Obesity

Grant Number:

1R56DK141545-01A1

Activity Code:

R56

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2026

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Rates of obesity have steadily increased in the US, with about 50% of Americans projected to be obese by 2030. Recent advances include GLP-1 peptides, such as semaglutide, approved in 2021 for adult obesity, and setmelanotide, approved in 2020 for early-onset syndromic obesity due to POMC a...

Research Terms

<Acute><Agonist><American><Animal Model><Animal Models and Related Studies><Binding><Body Weight><Body Weight decreased><Brain><Brain Nervous System><Chronic><Classification><Dose><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drugs><Emesis><Encapsulated><Encephalon><Excipients><Formulation><Future><GLP-1 receptor><GLP-I receptor><Genetic><Glycolates><Grant><HuB219><Hydrogen Oxide><Hypermelanoses><Hypermelanosis><Hyperpigmentation><Injectable><Injections><LEP-R><LEPR Protein><Malaise><Medication><Melanocortin-1><Methods><Microbeads><Microspheres><Molecular Interaction><Nausea><OB Receptor><OB-R><Obesity><Patient Compliance><Patients><Peptide-based drug><Peptides><Performance><Pharmaceutical Preparations><Pharmacokinetics><Physiologic><Physiological><Polymers><Research><Specificity><Sterility><Structure-Activity Relationship><Systematics><Temperature><Testing><Toxic effect><Toxicities><Vomiting><Water><Weight Loss><Weight Reduction><Weight maintenance regimen><Work><adiposity><adult adiposity><adult obesity><adults with obesity><alpha-Melanotropin><aqueous><biodegradable polymer><bioresorbable polymer><body weight loss><chemical structure function><corpulence><cost effective><degradable polymer><dietary><drug/agent><early onset><experience><glucagon like peptide><glucagon-like peptide><glucagon-like peptide-1 receptor><glycolic acid><improved><in vivo><leptin receptor><leptin-binding protein><microsphere encapsulation><model of animal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><obesity intervention><obesity therapy><obesity treatment><patient adherence><patient cooperation><patient population><peptide drug><polymer><polymeric><side effect><sterile><structure function relationship><therapeutic peptide><weight control><weight management><wt-loss><α-MSH><α-Melanocyte stimulating hormone>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

STEVEN P. SCHWENDEMAN

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 30/100
Very recent
Active award
$231,000
FY 2026

Project Title

Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment of Obesity

Grant Number:

1R56DK141545-01A1

Activity Code:

R56

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/17/2026

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Rates of obesity have steadily increased in the US, with about 50% of Americans projected to be obese by 2030. Recent advances include GLP-1 peptides, such as semaglutide, approved in 2021 for adult obesity, and setmelanotide, approved in 2020 for early-onset syndromic obesity due to POMC a...

Research Terms

<Acute><Agonist><American><Animal Model><Animal Models and Related Studies><Binding><Body Weight><Body Weight decreased><Brain><Brain Nervous System><Chronic><Classification><Dose><Drug Delivery><Drug Delivery Systems><Drug Kinetics><Drugs><Emesis><Encapsulated><Encephalon><Excipients><Formulation><Future><GLP-1 receptor><GLP-I receptor><Genetic><Glycolates><Grant><HuB219><Hydrogen Oxide><Hypermelanoses><Hypermelanosis><Hyperpigmentation><Injectable><Injections><LEP-R><LEPR Protein><Malaise><Medication><Melanocortin-1><Methods><Microbeads><Microspheres><Molecular Interaction><Nausea><OB Receptor><OB-R><Obesity><Patient Compliance><Patients><Peptide-based drug><Peptides><Performance><Pharmaceutical Preparations><Pharmacokinetics><Physiologic><Physiological><Polymers><Research><Specificity><Sterility><Structure-Activity Relationship><Systematics><Temperature><Testing><Toxic effect><Toxicities><Vomiting><Water><Weight Loss><Weight Reduction><Weight maintenance regimen><Work><adiposity><adult adiposity><adult obesity><adults with obesity><alpha-Melanotropin><aqueous><biodegradable polymer><bioresorbable polymer><body weight loss><chemical structure function><corpulence><cost effective><degradable polymer><dietary><drug/agent><early onset><experience><glucagon like peptide><glucagon-like peptide><glucagon-like peptide-1 receptor><glycolic acid><improved><in vivo><leptin receptor><leptin-binding protein><microsphere encapsulation><model of animal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><obesity intervention><obesity therapy><obesity treatment><patient adherence><patient cooperation><patient population><peptide drug><polymer><polymeric><side effect><sterile><structure function relationship><therapeutic peptide><weight control><weight management><wt-loss><α-MSH><α-Melanocyte stimulating hormone>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Genevieve Giny Fouda Amou ou

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Exploratory lead · 30/100
Very recent
Active award
$215,844
FY 2026

Project Title

Defining and modeling HIV-1-specific antibody function in HIV-1-exposed Infants passively Infused with broadly neutralizing antibodies in the IMPAACT P1112 trial.

Grant Number:

5R21HD118592-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/9/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Despite the significant reduction in HIV-1 vertical transmission with the implementation of antiretroviral therapy (ART) to pregnant and breastfeeding parents, in 2022, 130,000 new pediatric HIV-1 infections occurred, disproportionately impacting infants who constitute 10% of new infections...

Research Terms

<0-11 years old><21+ years old><AIDS Virus><AIDS prevention><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adult><Adult Human><Affect><Anti-Retroviral Agents><Anti-viral Response><Antibodies><Assay><Binding><Binding Sites><Bioassay><Biological Assay><Biological Markers><Birth><Blood Serum><Breast Feeding><Breast Milk><Breastmilk><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Trials><Clinical Trials Design><Combining Site><Complement><Complement Proteins><Consensus><Development><Disease><Disorder><Dose><Drug Kinetics><Env trimer><Evaluation><Future><Goals><HBV disease><HIV><HIV Env><HIV Infections><HIV Prevention><HIV disease transmission><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV infection spread><HIV infection transmission><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 prevention><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS prevention><HIV/AIDS transmission><HIV1><HepB><Hepatitis B><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human Milk><Human Mother's Milk><Human immunodeficiency virus 1><IMPAACT><Immunize><In Vitro><Infant><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><International Maternal Pediatric Adolescent AIDS Clinical Trials><International Maternal Pediatric Adolescent HIV/AIDS Clinical Trials><Intervention><LAV-HTLV-III><Life><Lymphadenopathy-Associated Virus><Mammary Gland Milk><Maternal antibody><Measures><Mediating><Methodology><Modeling><Molecular Interaction><Mother's Milk><Mother-to-child HIV transmission><Mothers><Multi-center studies><Multicenter Studies><Parents><Participant><Parturition><Passive Immunization><Pharmacokinetics><Phase><Population><Prevent HIV><Preventative intervention><Prevention><Prevention trial><Public Health><Reactive Site><Regimen><Respiratory syncytial virus><Safety><Sampling><Serum><Site><Testing><Time><Transmission><Vertical HIV><Vertical HIV-1><Vertical Transmission><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Hepatitis B><Viral Physiology><Virus><Virus Diseases><Virus-HIV><adulthood><anti-retroviral><antiretroviral therapy><antiretroviral treatment><bio-markers><biologic marker><biomarker><complementation><design><designing><developmental><efficacy trial><hep B><hepatitis B virus disease><human immunodeficiency virus infection><human immunodeficiency virus transmission><improved><infected with HIV><infected with human immunodeficiency virus><intervention for prevention><kids><maternal milk><neutralizing antibody><new marker><novel biomarker><novel marker><open label><open label study><parent><passive antibodies><passive vaccination><pediatric><pharmacokinetic model><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant><prevent><prevent AIDS><prevent human immunodeficiency virus><preventing><prevention intervention><preventional intervention strategy><preventive intervention><safety study><spread of human immunodeficiency virus><subcutaneous><subdermal><transmission process><vertical transmission of HIV><viral infection><viral transmission><virus infection><virus transmission><virus-induced disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Holly Janes

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Exploratory lead · 30/100
Very recent
Active award
$215,844
FY 2026

Project Title

Defining and modeling HIV-1-specific antibody function in HIV-1-exposed Infants passively Infused with broadly neutralizing antibodies in the IMPAACT P1112 trial.

Grant Number:

5R21HD118592-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/9/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Despite the significant reduction in HIV-1 vertical transmission with the implementation of antiretroviral therapy (ART) to pregnant and breastfeeding parents, in 2022, 130,000 new pediatric HIV-1 infections occurred, disproportionately impacting infants who constitute 10% of new infections...

Research Terms

<0-11 years old><21+ years old><AIDS Virus><AIDS prevention><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adult><Adult Human><Affect><Anti-Retroviral Agents><Anti-viral Response><Antibodies><Assay><Binding><Binding Sites><Bioassay><Biological Assay><Biological Markers><Birth><Blood Serum><Breast Feeding><Breast Milk><Breastmilk><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Trials><Clinical Trials Design><Combining Site><Complement><Complement Proteins><Consensus><Development><Disease><Disorder><Dose><Drug Kinetics><Env trimer><Evaluation><Future><Goals><HBV disease><HIV><HIV Env><HIV Infections><HIV Prevention><HIV disease transmission><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV infection spread><HIV infection transmission><HIV spread><HIV transmission><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 prevention><HIV-1 spread><HIV-1 transmission><HIV-1 virus transmission><HIV-I><HIV/AIDS prevention><HIV/AIDS transmission><HIV1><HepB><Hepatitis B><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human Milk><Human Mother's Milk><Human immunodeficiency virus 1><IMPAACT><Immunize><In Vitro><Infant><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><International Maternal Pediatric Adolescent AIDS Clinical Trials><International Maternal Pediatric Adolescent HIV/AIDS Clinical Trials><Intervention><LAV-HTLV-III><Life><Lymphadenopathy-Associated Virus><Mammary Gland Milk><Maternal antibody><Measures><Mediating><Methodology><Modeling><Molecular Interaction><Mother's Milk><Mother-to-child HIV transmission><Mothers><Multi-center studies><Multicenter Studies><Parents><Participant><Parturition><Passive Immunization><Pharmacokinetics><Phase><Population><Prevent HIV><Preventative intervention><Prevention><Prevention trial><Public Health><Reactive Site><Regimen><Respiratory syncytial virus><Safety><Sampling><Serum><Site><Testing><Time><Transmission><Vertical HIV><Vertical HIV-1><Vertical Transmission><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Hepatitis B><Viral Physiology><Virus><Virus Diseases><Virus-HIV><adulthood><anti-retroviral><antiretroviral therapy><antiretroviral treatment><bio-markers><biologic marker><biomarker><complementation><design><designing><developmental><efficacy trial><hep B><hepatitis B virus disease><human immunodeficiency virus infection><human immunodeficiency virus transmission><improved><infected with HIV><infected with human immunodeficiency virus><intervention for prevention><kids><maternal milk><neutralizing antibody><new marker><novel biomarker><novel marker><open label><open label study><parent><passive antibodies><passive vaccination><pediatric><pharmacokinetic model><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><pregnant><prevent><prevent AIDS><prevent human immunodeficiency virus><preventing><prevention intervention><preventional intervention strategy><preventive intervention><safety study><spread of human immunodeficiency virus><subcutaneous><subdermal><transmission process><vertical transmission of HIV><viral infection><viral transmission><virus infection><virus transmission><virus-induced disease><youngster>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bassem Al-Sady

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 30/100
Very recent
Active award
$213,663
FY 2026

Project Title

Biochemically counteracting maladaptive functions of G9a/GLP in addiction

Grant Number:

5R21DA062828-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The development of addictive behaviors to stimulants and opiates requires changes in the reward center of the brain, in particular, the Nucleus Accumbens. Animal studies and examination of postmortem human cocaine users have indicated a decrease in some gene repressive-epigenetic modifiers,...

Research Terms

<ANK Domain><ANK Repeat><Adaptive Behaviors><Addictive Behavior><Alcohol Chemical Class><Alcohols><Animal Model><Animal Models and Related Studies><Animals><Ankyrin Repeat><Ankyrin Repeat Domain><Automobile Driving><Autopsy><Behavior><Binding><Biochemical><Biology><Body Tissues><Brain><Brain Nervous System><CNS plasticity><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Differentiation><Cell Differentiation process><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Clinical><Cocaine><Cocaine Addiction><Cocaine Dependence><Cocaine Users><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><DNA mutation><Development><Dimerization><Disease><Disorder><Drugs><EC 2.1.1><Electron Cryomicroscopy><Embryo Development><Embryogenesis><Embryonic Development><Encephalon><Enzyme Antagonist><Enzyme Gene><Enzyme Inhibitor><Enzyme Inhibitor Agent><Enzyme Inhibitor Drugs><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Experimental Models><Future><G9a histone methyltransferase><Gene Down-Regulation><Gene Expression><Gene Proteins><Genes><Genetic Change><Genetic defect><Genetic mutation><Heterodimerization><Histones><Homo><Human><Individual><Intervention><Investigation><Knock-out><Knockout><L-Lysine><Lead><Learning><Link><Literature><Lysine><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Medication><Methods><Methylation><Methyltransferase><Modeling><Modern Man><Molecular><Molecular Interaction><Mutation><Nerve Cells><Nerve Unit><Neural Cell><Neural Stem Cell><Neurocyte><Neuronal Plasticity><Neurons><Nucleosomes><Nucleus Accumbens><Opiate Addiction><Opiate Dependence><Opiates><Opioid><Outcome><Pathway interactions><Pb element><Pharmaceutical Preparations><Phenotype><Play><Position><Positioning Attribute><Process><Protein Dimerization><Protein Gene Products><Proteins><Publishing><Reaction><Reading><Rewards><Role><Stimulant><Structure><Subcellular Process><Surface><Testing><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Transcription Repression><Transferase><Transferase Gene><Work><adaptation behavior><adaptive behavior><addicted to cocaine><addiction><addiction to cocaine><addiction to psychostimulants><addiction to stimulants><addictive disorder><biochemical model><cellular differentiation><central nervous system plasticity><co-repressor><cocaine addicted><corepressor><crosslink><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><dimer><disease phenotype><driving><drug/agent><epigenetically><epigenomics><gene co-repressor><gene corepressor><gene repression><genetic co-repressor><genetic corepressor><genome mutation><heavy metal Pb><heavy metal lead><histone H3 methyltransferase><histone methylase><histone methylation><histone methyltransferase><human disease><inhibitor><insight><maladaptive behavior><methylase><model of animal><mutant><necropsy><nerve stem cell><neural plasticity><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroplastic><neuroplasticity><neuroprogenitor><next generation><opiate exposure><opioid addiction><opioid dependence><opioid dependent><opioid exposure><paralog><paralogous gene><pathway><postmortem><pre-clinical development><preclinical development><progenitor and neural stem cells><protein complex><psychostimulant addiction><psychostimulant dependence><residence><residential building><residential site><response><restoration><small molecule><social role><stimulant addiction><stimulant dependence><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcriptomics><transmethylase>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mario Halic

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 30/100
Very recent
Active award
$213,663
FY 2026

Project Title

Biochemically counteracting maladaptive functions of G9a/GLP in addiction

Grant Number:

5R21DA062828-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The development of addictive behaviors to stimulants and opiates requires changes in the reward center of the brain, in particular, the Nucleus Accumbens. Animal studies and examination of postmortem human cocaine users have indicated a decrease in some gene repressive-epigenetic modifiers,...

Research Terms

<ANK Domain><ANK Repeat><Adaptive Behaviors><Addictive Behavior><Alcohol Chemical Class><Alcohols><Animal Model><Animal Models and Related Studies><Animals><Ankyrin Repeat><Ankyrin Repeat Domain><Automobile Driving><Autopsy><Behavior><Binding><Biochemical><Biology><Body Tissues><Brain><Brain Nervous System><CNS plasticity><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cell Differentiation><Cell Differentiation process><Cell Function><Cell Physiology><Cell Process><Cellular Function><Cellular Physiology><Cellular Process><Chromatin><Clinical><Cocaine><Cocaine Addiction><Cocaine Dependence><Cocaine Users><Complex><Cryo-electron Microscopy><Cryoelectron Microscopy><DNA mutation><Development><Dimerization><Disease><Disorder><Drugs><EC 2.1.1><Electron Cryomicroscopy><Embryo Development><Embryogenesis><Embryonic Development><Encephalon><Enzyme Antagonist><Enzyme Gene><Enzyme Inhibitor><Enzyme Inhibitor Agent><Enzyme Inhibitor Drugs><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Experimental Models><Future><G9a histone methyltransferase><Gene Down-Regulation><Gene Expression><Gene Proteins><Genes><Genetic Change><Genetic defect><Genetic mutation><Heterodimerization><Histones><Homo><Human><Individual><Intervention><Investigation><Knock-out><Knockout><L-Lysine><Lead><Learning><Link><Literature><Lysine><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Medication><Methods><Methylation><Methyltransferase><Modeling><Modern Man><Molecular><Molecular Interaction><Mutation><Nerve Cells><Nerve Unit><Neural Cell><Neural Stem Cell><Neurocyte><Neuronal Plasticity><Neurons><Nucleosomes><Nucleus Accumbens><Opiate Addiction><Opiate Dependence><Opiates><Opioid><Outcome><Pathway interactions><Pb element><Pharmaceutical Preparations><Phenotype><Play><Position><Positioning Attribute><Process><Protein Dimerization><Protein Gene Products><Proteins><Publishing><Reaction><Reading><Rewards><Role><Stimulant><Structure><Subcellular Process><Surface><Testing><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Transcription Repression><Transferase><Transferase Gene><Work><adaptation behavior><adaptive behavior><addicted to cocaine><addiction><addiction to cocaine><addiction to psychostimulants><addiction to stimulants><addictive disorder><biochemical model><cellular differentiation><central nervous system plasticity><co-repressor><cocaine addicted><corepressor><crosslink><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><dimer><disease phenotype><driving><drug/agent><epigenetically><epigenomics><gene co-repressor><gene corepressor><gene repression><genetic co-repressor><genetic corepressor><genome mutation><heavy metal Pb><heavy metal lead><histone H3 methyltransferase><histone methylase><histone methylation><histone methyltransferase><human disease><inhibitor><insight><maladaptive behavior><methylase><model of animal><mutant><necropsy><nerve stem cell><neural plasticity><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroplastic><neuroplasticity><neuroprogenitor><next generation><opiate exposure><opioid addiction><opioid dependence><opioid dependent><opioid exposure><paralog><paralogous gene><pathway><postmortem><pre-clinical development><preclinical development><progenitor and neural stem cells><protein complex><psychostimulant addiction><psychostimulant dependence><residence><residential building><residential site><response><restoration><small molecule><social role><stimulant addiction><stimulant dependence><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcriptomics><transmethylase>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Deborah Persaud

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 30/100
Very recent
Active award
$194,219
FY 2026

Project Title

Virologic Determinants of Very Early Antiretroviral Treatment Responses of Infants with in utero HIV-1

Grant Number:

5R21HD118590-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/16/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Initiation of very early antiretroviral therapy (ART) in neonates with in utero HIV-1 leads to the possibility of long-term ART-free control in a small subset of neonates. In the IMPAACT P1115 clinical trial, very early ART has led to four cases of long-term, ART- free contr...

Research Terms

<0-11 years old><21+ years old><Adult><Adult Human><Assay><Binding><Bioassay><Biological Assay><Biological Markers><Blood Cells><Blood Plasma><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><Cell Body><Cell Isolation><Cell Line><Cell Segregation><Cell Separation><Cell Separation Technology><CellLine><Cells><Child><Child Youth><Children (0-21)><Clinical Trials><Cord Blood><Country><DNA><DNA Sequence><Deoxyribonucleic Acid><Development><Differences between sexes><Differs between sexes><Disease remission><Eligibility><Eligibility Determination><Exhibits><Female><Fetus><Future><Genome><HIV Infections><HIV disease transmission><HIV infection spread><HIV infection transmission><HIV replication><HIV spread><HIV transmission><HIV viral infection><HIV viral replication><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 infection><HIV-1 replication><HIV-1 spread><HIV-1 transmission><HIV-1 viral replication><HIV-1 virus replication><HIV-1 virus transmission><HIV-I><HIV/AIDS transmission><HIV1><Hour><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><IFN><IMPAACT><Immune><Immune Evasion><Immunes><Immunochemical Immunologic><Immunologic><Immunologic Factors><Immunological><Immunological Factors><Immunologically><Immunologics><Infant><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Interferon Type I><Interferons><International Maternal Pediatric Adolescent AIDS Clinical Trials><International Maternal Pediatric Adolescent HIV/AIDS Clinical Trials><Interruption><Knowledge><Length><Life><Measures><Mediating><Molecular Cloning><Molecular Interaction><Mononuclear><Outcome><PBMC><Participant><Peripheral Blood Cell><Peripheral Blood Mononuclear Cell><Phenotype><Plasma><Plasma Serum><Predisposition><Prospective cohort><Protocol Screening><Proviruses><Publishing><Remission><Reporter><Reporting><Research><Resistance><Resistance profile><Resistant profile><Rest><Reticuloendothelial System, Serum, Plasma><Role><Sex Differences><Sexual differences><South African><Spinal Column><Spine><Strains Cell Lines><Susceptibility><T4 Cells><T4 Lymphocytes><Testing><Time><Transmission><Umbilical Cord Blood><Variant><Variation><Vertebral column><Viral><Viral Burden><Viral Genetics><Viral Load><Viral Load result><Viral reservoir><Viremia><Virus reservoir><adulthood><antiretroviral therapy><antiretroviral treatment><backbone><bio-markers><biologic marker><biological sex><biomarker><biomarker identification><cell immortalization><cell sorting><cell type><clinical trial participant><cohort><cultured cell line><developmental><early biomarkers><early detection biomarkers><early detection markers><experience><fetal><fetal cell><fetal cord blood><fetus cell><genome sequencing><human immunodeficiency virus infection><human immunodeficiency virus replication><human immunodeficiency virus transmission><human immunodeficiency virus-1 replication><identification of biomarkers><identification of new biomarkers><immune evasive><immunologic substance><immunological substance><in utero><infancy><infantile><infected with HIV><infected with human immunodeficiency virus><kids><male><marker identification><memory CD4 T cell><memory CD4 T lymphocyte><neonate><postnatal><recombinant virus><resistant><response><response to therapy><response to treatment><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><social role><spread of human immunodeficiency virus><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><transmission process><treatment response><treatment responsiveness><treatment strategy><viraemia><viral rebound><viral sepsis><virus genetics><virus rebound><virusemia><youngster><♀><♂>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael S German

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 30/100
Very recent
Active award
$164,000
FY 2026

Project Title

IL17 Signaling in Monogenic Type 1 Diabetes

Grant Number:

5R21AI191139-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/25/2025

End Date:

3/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract This proposal’s objective is to determine whether genetic mutations that alter IL-17 signaling contribute to the etiology of autoimmune diabetes. Autoimmune diabetes is characterized by circulating autoantibodies and infiltrating autoreactive lymphocytes into the pancreatic ...

Research Terms

<Acceleration><Affect><Alleles><Allelomorphs><American><Assay><Autoantibodies><Autocrine Systems><Autoimmune><Autoimmune Diabetes><Autoimmune Diseases><Autoimmune Mechanism><Autoimmune Polyendocrinopathies><Autoimmune Process><Autoimmune Regulator><Autoimmune Status><Autoimmunity><B9 endocrine pancreas><Beta Cell><Binding><Bioassay><Biologic Models><Biological><Biological Assay><Biological Models><Biology><Brittle Diabetes Mellitus><CD152><CD152 Antigen><CD152 Gene><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CTLA 4><CTLA-4 Gene><CTLA-8><CTLA-8 Gene><CTLA4><CTLA4 gene><CTLA4-TM><CTLA8><CTLA8 Gene><Cas nuclease technology><Causality><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cessation of life><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><Cytokine CX2><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Antigen 8><Cytotoxic T-Lymphocyte-Associated Antigen 8 Gene><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase 8><Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 Gene><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DNA mutation><Data><Data Bases><Databases><Death><Detection><Development><Disease><Disorder><Endocrine Pancreas><Engineering><Etiology><FOXP3><FOXP3 gene><Failure><Family><Forkhead Box P3><Future><Gene Targeting><Generations><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetic study><Genetics-Mutagenesis><Genome><HeLa><Hela Cells><Human><Human Biology><Human Genetics><Human Genome><Humulin R><IDDM><IL 17 Signaling Pathway><IL-17><IL-17 Gene><IL-17A><IL-17A Gene><IL-17C><IL17><IL17 Protein><IL17 Signaling Pathway><IL17 gene><IL17A><IL17A Gene><IL17C><IL17C gene><Immune><Immune Tolerance><Immunes><Immunologic Tolerance><In Vitro><Inbred NOD Mice><Individual><Infiltration><Inflammation><Inflammation Mediators><Inflammatory><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin-Dependent Diabetes Mellitus><Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)><Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) Gene><Interleukin 17 Precursor><Interleukin 17 Precursor Gene><Interleukin-17><Intervention><Intracellular Communication and Signaling><Islands of Langerhans><Islets of Langerhans><JM2><Juvenile-Onset Diabetes Mellitus><KI mice><Ketosis-Prone Diabetes Mellitus><Knock-in Mouse><Ligands><Link><Lymphatic cell><Lymphocyte><Lymphocytic><Maps><Methods><Mice><Mice Mammals><Model System><Modeling><Modern Man><Molecular Interaction><Murine><Mus><Mutagenesis><Mutagenesis Molecular Biology><Mutation><NOD Mouse><Names><Nesidioblasts><Non-Obese Diabetic Mice><Nonobese Diabetic Mouse><Novolin R><ORFs><Open Reading Frames><Organ><Pancreatic Islets><Pancreatic beta Cell><Pancreatic β-Cell><Pars endocrina pancreatis><Pathogenicity><Pathway interactions><Patients><Phenotype><Production><Protein Coding Region><Receptor Protein><Regular Insulin><Reporter><Risk><Risk Factors><Role><SCURFIN><STAT1><STAT1 gene><STAT3><STAT3 gene><STAT91><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single Base Polymorphism><Single Nucleotide Polymorphism><Strains Cell Lines><Structure of beta Cell of islet><Sudden-Onset Diabetes Mellitus><Syndrome><T1 DM><T1 diabetes><T1D><T1DM><Techniques><Testing><Therapeutic><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Type 1 Diabetes Mellitus><Type 1 diabetes><Type I Diabetes Mellitus><aggregation database><autocrine><autoimmune antibody><autoimmune condition><autoimmune disorder><autoimmune polyendocrine syndrome><autoimmune polyglandular syndrome><autoimmune reactivity><autoimmunity disease><autoreactive antibody><autoreactivity><biologic><biological signal transduction><causation><cultured cell line><cytokine><cytotoxic T-lymphocyte antigen 4><data base><developmental><disease causation><drug detection><drug testing><exome sequencing><exome-seq><gain of function mutation><gene product><genome mutation><human model><human whole genome><immune system tolerance><immune unresponsiveness><immunological paralysis><improved><in vivo><individual patient><inflammatory mediator><insight><insulin dependent diabetes><insulin dependent type 1><interleukin-17C><islet><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><kindred><knockin mice><low-frequency mutation><lymph cell><model of human><mouse model><murine model><name><named><naming><non-obese diabetic (NOD) mice><nonobese diabetic (NOD) mice><novel><pancreas beta cell><pancreas β cell><pancreatic b-cell><pathway><patient population><patient registry><predictive tools><prevent><preventing><rare allele><rare mutation><rare variant><receptor><self reactive antibody><single nucleotide variant><social role><type I diabetes><type one diabetes><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vijaya Subramanian

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 30/100
Recent
Active award
Career award
$122,591
FY 2026

Project Title

Etiology of Impaired Counterregulation in Glucose Homeostasis: Exploring the Roles of Glucagon, Somatostatin, Cortisol, and Epinephrine through Mathematical Modeling of Oral Glucose Tolerance Tests

Grant Number:

5K25DK131328-05

Activity Code:

K25

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/16/2022

End Date:

1/31/2027

Project Abstract

PROPOSAL SUMMARY Glucose homeostasis is tightly controlled in animals with plasma glucose levels maintained in a narrow range. While insulin, secreted by the beta cell, regulates by promoting efficient glucose disposal and suppressing glucose release from the liver when glucose levels rise, glucagon...

Research Terms

<Acceleration><Acute><Adrenaline><Adult-Onset Diabetes Mellitus><Aeroseb-HC><Alpha Cell><Animals><Antidiabetic Hormone><Apoptosis><Apoptosis Pathway><Autoregulation><Behavior><Beta Cell><Blood Plasma><Carbohydrates><Causality><Cell Communication and Signaling><Cell Signaling><Cetacort><Chronic><Cort-Dome><Cortef><Cortenema><Cortisol><Cortispray><Cortril><Cyclic Somatostatin><D-Glucose><Data><Dermacort><Development><Dextrose><Diabetes Mellitus><Disease><Disease Management><Disease Progression><Disorder><Disorder Management><Drops><Dysfunction><Eldecort><Endocrine Gland Secretion><Endosomes><Epidemic><Epinephrine><Etiology><Event><Fasting><Functional disorder><GLP-1><Glp-1><Glucagon><Glucagon Cell><Glucagon Secreting Cell><Gluconeogenesis><Glucose><Glukagon><Goals><Growth Hormone><Growth Hormone 1><Growth Hormone Inhibiting Factors><Growth Hormone-Inhibiting Hormone><HG-Factor><Health Care Systems><Homeostasis><Hormones><Hour><Humulin R><Hydrocortisone><Hydrocortone><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><Hypoglycemia><Hytone><Impairment><Ingestion><Insulin><Insulin Cell><Insulin Resistance><Insulin Secreting Cell><Intracellular Communication and Signaling><Investigation><Ketosis-Resistant Diabetes Mellitus><Liver><Math Models><Maturity-Onset Diabetes Mellitus><Mediating><Modeling><NIDDM><Nature><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Novolin R><Nutracort><OGTT><Oral Glucose Tolerance Test><Pathology><Patients><Persons><Physiological Homeostasis><Physiopathology><Pituitary Growth Hormone><Plasma><Plasma Serum><Play><Polycystic Ovarian Disease><Polycystic Ovarian Syndrome><Polycystic Ovary Syndrome><Postprandial Hypoglycemia><Pre-DM><Prediabetes><Prediabetes syndrome><Prediabetic State><Proctocort><Programmed Cell Death><Reactive hypoglycemia><Receptosomes><Recovery><Regular Insulin><Regulation><Reticuloendothelial System, Serum, Plasma><Role><SRIH><SRIH-14><Sclerocystic Ovarian Degeneration><Sclerocystic Ovary Syndrome><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Somatostatin><Somatostatin-14><Somatotropin><Somatotropin Release Inhibiting Factors><Somatotropin Release-Inhibiting Hormone><Stable Diabetes Mellitus><Symptoms><T2 DM><T2D><T2DM><Therapeutic Epinephrine><Therapeutic Hormone><Type 2 Diabetes Mellitus><Type 2 diabetes><Type 2 diabetic><Type II Diabetes Mellitus><Type II diabetes><Type II diabetic><Validation><adult onset diabetes><aggressive therapy><aggressive treatment><alpha-cell><beta cell development><biological signal transduction><blood glucose regulation><causation><cell regeneration><cellular regeneration><counterregulation><data modeling><developmental><diabetes><diabetic><diabetic patient><disease causation><disease model><disorder model><endocrine pancreas development><experience><falls><fasted><fasting glucose><fasts><glucagon-like peptide 1><glucose biosynthesis><glucose control><glucose disposal><glucose homeostasis><glucose regulation><glycogenolysis><growth hormone release inhibiting factor><hepatic body system><hepatic organ system><hyperglycemic><hypoglycemic><hypoglycemic episodes><hypoglycemic reaction><ingest><inhibitor><insight><insulin resistant><insulin secretion><insulin stimulated glucose disposal><insulin tolerance><islet development><ketosis resistant diabetes><mathematic model><mathematical model><mathematical modeling><maturity onset diabetes><model of data><model the data><modeling of the data><pathophysiology><polycystic ovary><polycystic ovary disease><polycystic ovary disorder><pre-diabetes><pre-diabetic><prediabetic><response><social role><somatotropic hormone><type 2 DM><type II DM><type two diabetes><validations><α-cell><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID S DANDY

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 30/100
Very recent
Active award
$63,735
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing: SUPPLEMENT

Grant Number:

3R61AI181052-03S1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

1/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

To develop the HIV-eCaDI device we are developing for our NIAID project R61 AI181052 “Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing” we prepare, quantify and validate HIV virions for testing as well as test that our HIV sample inactivation is effective to maintain b...

Research Terms

<16 year old><16 years of age><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Administrative Supplement><Antigens><Assay><Binding><Bioassay><Biological Assay><Biosensor><Blood Sample><Blood capillaries><Blood specimen><Carbon><Cell Culture Techniques><Characteristics><Clinical><Cytology and Pathology><Cytopathology><Development><Devices><Diagnostic><ELISA><Early Diagnosis><Electrodes><Enzyme-Linked Immunosorbent Assay><Failure><Fluorescence Polarization><Goals><HIV><HIV Core Protein p24><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV gag Gene Product p24><HIV gag Protein p24><HIV infection status><HIV p24 Antigen><HIV serostatus><HIV status><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 infection><HIV-I><HIV1><HIV1 infection status><HIV1 status><HTLV-III p24><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immunoassay><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><LAV-HTLV-III><Laboratories><Language><Lymphadenopathy-Associated Virus><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Modernization><Modification><Molecular Interaction><Monitor><NIAID><National Institute of Allergy and Infectious Disease><Paper><Parents><Patients><Performance><PrEP><Preparation><Privacy><Quantitative Evaluations><Research><Sampling><Specificity><System><Testing><Validation><Viral Burden><Viral Load><Viral Load result><Virion><Virus Particle><Virus-HIV><age 16><age 16 years><antibody based detection><antibody detection><antigen based detection><antigen detection><biological sensor><capillary><cell culture><cell cultures><cell killing><cost><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><home test><home-based test><homes><human immunodeficiency virus infection><immunogen><improved><infected with HIV><infected with human immunodeficiency virus><microfluidic chip><novel><parent><pre-exposure prophylaxis><preparations><preservation><sensor><sixteen year old><sixteen years of age><user-friendly><validations><viral detection><virus detection><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brian Geiss

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 30/100
Very recent
Active award
$63,735
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing: SUPPLEMENT

Grant Number:

3R61AI181052-03S1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

1/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

To develop the HIV-eCaDI device we are developing for our NIAID project R61 AI181052 “Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing” we prepare, quantify and validate HIV virions for testing as well as test that our HIV sample inactivation is effective to maintain b...

Research Terms

<16 year old><16 years of age><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Administrative Supplement><Antigens><Assay><Binding><Bioassay><Biological Assay><Biosensor><Blood Sample><Blood capillaries><Blood specimen><Carbon><Cell Culture Techniques><Characteristics><Clinical><Cytology and Pathology><Cytopathology><Development><Devices><Diagnostic><ELISA><Early Diagnosis><Electrodes><Enzyme-Linked Immunosorbent Assay><Failure><Fluorescence Polarization><Goals><HIV><HIV Core Protein p24><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV gag Gene Product p24><HIV gag Protein p24><HIV infection status><HIV p24 Antigen><HIV serostatus><HIV status><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 infection><HIV-I><HIV1><HIV1 infection status><HIV1 status><HTLV-III p24><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immunoassay><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><LAV-HTLV-III><Laboratories><Language><Lymphadenopathy-Associated Virus><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Modernization><Modification><Molecular Interaction><Monitor><NIAID><National Institute of Allergy and Infectious Disease><Paper><Parents><Patients><Performance><PrEP><Preparation><Privacy><Quantitative Evaluations><Research><Sampling><Specificity><System><Testing><Validation><Viral Burden><Viral Load><Viral Load result><Virion><Virus Particle><Virus-HIV><age 16><age 16 years><antibody based detection><antibody detection><antigen based detection><antigen detection><biological sensor><capillary><cell culture><cell cultures><cell killing><cost><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><home test><home-based test><homes><human immunodeficiency virus infection><immunogen><improved><infected with HIV><infected with human immunodeficiency virus><microfluidic chip><novel><parent><pre-exposure prophylaxis><preparations><preservation><sensor><sixteen year old><sixteen years of age><user-friendly><validations><viral detection><virus detection><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Charles S Henry

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 30/100
Very recent
Active award
$63,735
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing: SUPPLEMENT

Grant Number:

3R61AI181052-03S1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

1/31/2027

Why this may be worth a closer look

  • • Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

To develop the HIV-eCaDI device we are developing for our NIAID project R61 AI181052 “Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing” we prepare, quantify and validate HIV virions for testing as well as test that our HIV sample inactivation is effective to maintain b...

Research Terms

<16 year old><16 years of age><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Administrative Supplement><Antigens><Assay><Binding><Bioassay><Biological Assay><Biosensor><Blood Sample><Blood capillaries><Blood specimen><Carbon><Cell Culture Techniques><Characteristics><Clinical><Cytology and Pathology><Cytopathology><Development><Devices><Diagnostic><ELISA><Early Diagnosis><Electrodes><Enzyme-Linked Immunosorbent Assay><Failure><Fluorescence Polarization><Goals><HIV><HIV Core Protein p24><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV gag Gene Product p24><HIV gag Protein p24><HIV infection status><HIV p24 Antigen><HIV serostatus><HIV status><HIV viral infection><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 infection><HIV-I><HIV1><HIV1 infection status><HIV1 status><HTLV-III p24><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immunoassay><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><LAV-HTLV-III><Laboratories><Language><Lymphadenopathy-Associated Virus><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Modernization><Modification><Molecular Interaction><Monitor><NIAID><National Institute of Allergy and Infectious Disease><Paper><Parents><Patients><Performance><PrEP><Preparation><Privacy><Quantitative Evaluations><Research><Sampling><Specificity><System><Testing><Validation><Viral Burden><Viral Load><Viral Load result><Virion><Virus Particle><Virus-HIV><age 16><age 16 years><antibody based detection><antibody detection><antigen based detection><antigen detection><biological sensor><capillary><cell culture><cell cultures><cell killing><cost><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><home test><home-based test><homes><human immunodeficiency virus infection><immunogen><improved><infected with HIV><infected with human immunodeficiency virus><microfluidic chip><novel><parent><pre-exposure prophylaxis><preparations><preservation><sensor><sixteen year old><sixteen years of age><user-friendly><validations><viral detection><virus detection><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID S DANDY

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 26/100
Solid budget
Active award
$454,761
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing

Grant Number:

5R61AI181052-03

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2027

Project Abstract

Human immunodeficiency virus (HIV) is a highly contagious global pathogen that infects millions of individuals annually. Almost 38 million individuals worldwide are living with HIV, and approximately 62% with HIV are receiving antiretroviral therapy. Rapid, sensitive, and accurate detection of HIV i...

Research Terms

<AIDS Virus><AIDS test><AIDS/HIV test><Academic Medical Centers><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Algorithms><Anti-Retroviral Agents><Antibodies><Antigen Presentation><Antigens><Assay><Automation><Binding><Bioassay><Biological Assay><Biological Markers><Biosensor><Blinded><Blood Sample><Blood Serum><Blood Volume><Blood capillaries><Blood specimen><Buffers><Carbon><Cell Phone><Cellular Phone><Cellular Telephone><Characteristics><Chemistry><Clinic><Clinical><Colorado><Communicable Diseases><Communication><Custom><DNA><Data><Deoxyribonucleic Acid><Detection><Development><Device Designs><Devices><Diagnostic><Diagnostic tests><ELISA><Early Diagnosis><Electrochemistry><Electrodes><Enzyme-Linked Immunosorbent Assay><Generations><Goals><HIV><HIV Core Protein p24><HIV Genome><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV disease transmission><HIV gag Gene Product p24><HIV gag Protein p24><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection status><HIV infection transmission><HIV intervention><HIV p24 Antigen><HIV people><HIV positive individuals><HIV positive people><HIV serostatus><HIV spread><HIV status><HIV test><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 genome><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 test><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-2 test><HIV-I><HIV/AIDS transmission><HIV1><HIV1 genome><HIV1 infection status><HIV1 status><HTLV-III p24><Health><Heart><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Human immunodeficiency virus test><Hybrids><Immunoassay><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Infrastructure><Integrated Health Care Systems><Interruption><LAV-HTLV-III><Laboratories><Letters><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><Marketing><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Mobile Phones><Modality><Molecular Interaction><Monitor><Morbidity><NIH><National Institutes of Health><New York City><Non-Polyadenylated RNA><Nucleic Acid Amplification Tests><Nucleic Acid Testing><PLWH><PWH><Paper><Patient Monitoring><Patients><Performance><Phase><Physicians><Point-of-Care Systems><PrEP><Preparation><Privacy><Proteins><Provider><Public Health><QOL><Quality of life><RNA><RNA Gene Products><Reagent><Research Specimen><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Rest><Ribonucleic Acid><Running><Sampling><Sensitivity and Specificity><Serum><Specificity><Specimen><System><Systems Integration><Technology><Telemedicine><Testing><Therapeutic><Time><Transmission><United States National Institutes of Health><Universities><University Medical Centers><Validation><Viral><Viral Antigens><Viral Burden><Viral Load><Viral Load result><Virus-HIV><acute infection><anti-retroviral><antibody based detection><antibody detection><antigen based detection><antigen detection><antiretroviral therapy><antiretroviral treatment><bio-markers><biologic marker><biological sensor><biomarker><capillary><clinical relevance><clinically relevant><cost><customs><data management><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic assay><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><experience><home test><home-based test><homes><human immunodeficiency virus infection><human immunodeficiency virus transmission><iPhone><immunogen><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><integrated health system><integrated system><integrated system of care><medical college><medical schools><microfluidic chip><mortality><novel><particle><pathogen><pathogenic virus><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><point of care><point-of-care diagnostics><portability><pre-exposure prophylaxis><preparations><prophylactic><prototype><rapid detection><rapid testing><response><sample collection><school of medicine><self testing><sensor><smart phone><smartphone><specimen collection><spread of human immunodeficiency virus><standard of care><system integration><transmission process><treat HIV><treat Human Immunodeficiency Virus><user-friendly><validations><viral RNA><viral detection><viral pathogen><virus RNA><virus antigen><virus detection><virus pathogen><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brian Geiss

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 26/100
Solid budget
Active award
$454,761
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing

Grant Number:

5R61AI181052-03

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2027

Project Abstract

Human immunodeficiency virus (HIV) is a highly contagious global pathogen that infects millions of individuals annually. Almost 38 million individuals worldwide are living with HIV, and approximately 62% with HIV are receiving antiretroviral therapy. Rapid, sensitive, and accurate detection of HIV i...

Research Terms

<AIDS Virus><AIDS test><AIDS/HIV test><Academic Medical Centers><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Algorithms><Anti-Retroviral Agents><Antibodies><Antigen Presentation><Antigens><Assay><Automation><Binding><Bioassay><Biological Assay><Biological Markers><Biosensor><Blinded><Blood Sample><Blood Serum><Blood Volume><Blood capillaries><Blood specimen><Buffers><Carbon><Cell Phone><Cellular Phone><Cellular Telephone><Characteristics><Chemistry><Clinic><Clinical><Colorado><Communicable Diseases><Communication><Custom><DNA><Data><Deoxyribonucleic Acid><Detection><Development><Device Designs><Devices><Diagnostic><Diagnostic tests><ELISA><Early Diagnosis><Electrochemistry><Electrodes><Enzyme-Linked Immunosorbent Assay><Generations><Goals><HIV><HIV Core Protein p24><HIV Genome><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV disease transmission><HIV gag Gene Product p24><HIV gag Protein p24><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection status><HIV infection transmission><HIV intervention><HIV p24 Antigen><HIV people><HIV positive individuals><HIV positive people><HIV serostatus><HIV spread><HIV status><HIV test><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 genome><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 test><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-2 test><HIV-I><HIV/AIDS transmission><HIV1><HIV1 genome><HIV1 infection status><HIV1 status><HTLV-III p24><Health><Heart><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Human immunodeficiency virus test><Hybrids><Immunoassay><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Infrastructure><Integrated Health Care Systems><Interruption><LAV-HTLV-III><Laboratories><Letters><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><Marketing><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Mobile Phones><Modality><Molecular Interaction><Monitor><Morbidity><NIH><National Institutes of Health><New York City><Non-Polyadenylated RNA><Nucleic Acid Amplification Tests><Nucleic Acid Testing><PLWH><PWH><Paper><Patient Monitoring><Patients><Performance><Phase><Physicians><Point-of-Care Systems><PrEP><Preparation><Privacy><Proteins><Provider><Public Health><QOL><Quality of life><RNA><RNA Gene Products><Reagent><Research Specimen><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Rest><Ribonucleic Acid><Running><Sampling><Sensitivity and Specificity><Serum><Specificity><Specimen><System><Systems Integration><Technology><Telemedicine><Testing><Therapeutic><Time><Transmission><United States National Institutes of Health><Universities><University Medical Centers><Validation><Viral><Viral Antigens><Viral Burden><Viral Load><Viral Load result><Virus-HIV><acute infection><anti-retroviral><antibody based detection><antibody detection><antigen based detection><antigen detection><antiretroviral therapy><antiretroviral treatment><bio-markers><biologic marker><biological sensor><biomarker><capillary><clinical relevance><clinically relevant><cost><customs><data management><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic assay><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><experience><home test><home-based test><homes><human immunodeficiency virus infection><human immunodeficiency virus transmission><iPhone><immunogen><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><integrated health system><integrated system><integrated system of care><medical college><medical schools><microfluidic chip><mortality><novel><particle><pathogen><pathogenic virus><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><point of care><point-of-care diagnostics><portability><pre-exposure prophylaxis><preparations><prophylactic><prototype><rapid detection><rapid testing><response><sample collection><school of medicine><self testing><sensor><smart phone><smartphone><specimen collection><spread of human immunodeficiency virus><standard of care><system integration><transmission process><treat HIV><treat Human Immunodeficiency Virus><user-friendly><validations><viral RNA><viral detection><viral pathogen><virus RNA><virus antigen><virus detection><virus pathogen><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Charles S Henry

COLORADO STATE UNIVERSITY, FORT COLLINS, CO

Exploratory lead · 26/100
Solid budget
Active award
$454,761
FY 2026

Project Title

Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing

Grant Number:

5R61AI181052-03

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2027

Project Abstract

Human immunodeficiency virus (HIV) is a highly contagious global pathogen that infects millions of individuals annually. Almost 38 million individuals worldwide are living with HIV, and approximately 62% with HIV are receiving antiretroviral therapy. Rapid, sensitive, and accurate detection of HIV i...

Research Terms

<AIDS Virus><AIDS test><AIDS/HIV test><Academic Medical Centers><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute><Algorithms><Anti-Retroviral Agents><Antibodies><Antigen Presentation><Antigens><Assay><Automation><Binding><Bioassay><Biological Assay><Biological Markers><Biosensor><Blinded><Blood Sample><Blood Serum><Blood Volume><Blood capillaries><Blood specimen><Buffers><Carbon><Cell Phone><Cellular Phone><Cellular Telephone><Characteristics><Chemistry><Clinic><Clinical><Colorado><Communicable Diseases><Communication><Custom><DNA><Data><Deoxyribonucleic Acid><Detection><Development><Device Designs><Devices><Diagnostic><Diagnostic tests><ELISA><Early Diagnosis><Electrochemistry><Electrodes><Enzyme-Linked Immunosorbent Assay><Generations><Goals><HIV><HIV Core Protein p24><HIV Genome><HIV Infections><HIV Major Core Protein p24><HIV Protein p24><HIV disease status><HIV disease transmission><HIV gag Gene Product p24><HIV gag Protein p24><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection spread><HIV infection status><HIV infection transmission><HIV intervention><HIV p24 Antigen><HIV people><HIV positive individuals><HIV positive people><HIV serostatus><HIV spread><HIV status><HIV test><HIV therapeutic><HIV therapy><HIV transmission><HIV treatment><HIV viral infection><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Core Protein p24><HIV-1 genome><HIV-1 infection><HIV-1 intervention><HIV-1 spread><HIV-1 test><HIV-1 therapeutic><HIV-1 therapy><HIV-1 transmission><HIV-1 treatment><HIV-1 virus transmission><HIV-2 test><HIV-I><HIV/AIDS transmission><HIV1><HIV1 genome><HIV1 infection status><HIV1 status><HTLV-III p24><Health><Heart><Home><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Human immunodeficiency virus test><Hybrids><Immunoassay><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Infrastructure><Integrated Health Care Systems><Interruption><LAV-HTLV-III><Laboratories><Letters><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><Marketing><Measurement><Methods><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Microfluidics><Mobile Phones><Modality><Molecular Interaction><Monitor><Morbidity><NIH><National Institutes of Health><New York City><Non-Polyadenylated RNA><Nucleic Acid Amplification Tests><Nucleic Acid Testing><PLWH><PWH><Paper><Patient Monitoring><Patients><Performance><Phase><Physicians><Point-of-Care Systems><PrEP><Preparation><Privacy><Proteins><Provider><Public Health><QOL><Quality of life><RNA><RNA Gene Products><Reagent><Research Specimen><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Rest><Ribonucleic Acid><Running><Sampling><Sensitivity and Specificity><Serum><Specificity><Specimen><System><Systems Integration><Technology><Telemedicine><Testing><Therapeutic><Time><Transmission><United States National Institutes of Health><Universities><University Medical Centers><Validation><Viral><Viral Antigens><Viral Burden><Viral Load><Viral Load result><Virus-HIV><acute infection><anti-retroviral><antibody based detection><antibody detection><antigen based detection><antigen detection><antiretroviral therapy><antiretroviral treatment><bio-markers><biologic marker><biological sensor><biomarker><capillary><clinical relevance><clinically relevant><cost><customs><data management><design><designing><detect antibodies><detect antigen><detection limit><detection platform><detection system><developmental><diagnostic assay><diagnostic platform><diagnostic system><early detection><enzyme linked immunoassay><experience><home test><home-based test><homes><human immunodeficiency virus infection><human immunodeficiency virus transmission><iPhone><immunogen><improved><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><integrated health system><integrated system><integrated system of care><medical college><medical schools><microfluidic chip><mortality><novel><particle><pathogen><pathogenic virus><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><point of care><point-of-care diagnostics><portability><pre-exposure prophylaxis><preparations><prophylactic><prototype><rapid detection><rapid testing><response><sample collection><school of medicine><self testing><sensor><smart phone><smartphone><specimen collection><spread of human immunodeficiency virus><standard of care><system integration><transmission process><treat HIV><treat Human Immunodeficiency Virus><user-friendly><validations><viral RNA><viral detection><viral pathogen><virus RNA><virus antigen><virus detection><virus pathogen><µfluidic>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Julio Alejandro Lamprea Montealegre

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 22/100
Recent
Active award
$236,314
FY 2026

Project Title

Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach

Grant Number:

5R00HL157721-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2027

Project Abstract

Project Summary/Abstract Individuals with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) have an extremely high risk of cardiovascular disease (CVD). However, they are not optimally prescribed evidence-based cardio-renal preventive therapies that could considerably reduce such risk...

Research Terms

<ACE Inhibitors><Accounting><Adoption><Adult-Onset Diabetes Mellitus><Affect><Agonist><Angiotensin I-Converting Enzyme Inhibitors><Angiotensin Receptor><Angiotensin-Converting Enzyme Antagonists><Angiotensin-Converting Enzyme Inhibitors><Award><Awareness><Booklets><Brochures><CVD prevention><Cardiovascular Diseases><Caring><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Clinic><Clinical><Complex><Data Set><Detection><Development><Dialysis><Dialysis procedure><Disease Progression><Drug Prescribing><Drug Prescriptions><Education><Education for Intervention><Educational Intervention><Educational Materials><Educational aspects><Endocrinologist><Endocrinology><Environment><Facility Controls><Focus Groups><GLP-1 receptor><GLP-I receptor><Geography><Health Care Systems><Health system><Individual><Instruction Intervention><Interdisciplinary Education><Interdisciplinary Learning><Intervention><Ketosis-Resistant Diabetes Mellitus><Kininase II Antagonists><Kininase II Inhibitors><Knowledge><Lead><Life><Maturity-Onset Diabetes Mellitus><Medical><Medicine><Mentors><Metabolism and Endocrinology><Methods><NIDDM><Nephrology><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Pamphlets><Patient Care><Patient Care Delivery><Patients><Pb element><Persons><Phase><Position><Positioning Attribute><Preventative care><Preventative therapy><Preventative treatment><Preventive><Preventive care><Preventive therapy><Preventive treatment><Primary Care><Provider><Quasi-experiment><Quasi-experimental analysis><Quasi-experimental approach><Quasi-experimental design><Quasi-experimental methods><Quasi-experimental research><Quasi-experimental study><Quasi-experimental technique><Recommendation><Reporting><Research><Research Methodology><Research Methods><Risk><SGLT 2 inhibitor><SGLT2i><Self Efficacy><Services><Severity of illness><Slow-Onset Diabetes Mellitus><Sodium glucose co-transporter 2 inhibitor><Specialty><Stable Diabetes Mellitus><System><T2 DM><T2D><T2DM><Training><Training Intervention><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States Department of Veterans Affairs><United States Veterans Administration><Veterans Administration><Veterans Affairs><Veterans Health Administration><Veterans Health Affairs><adult onset diabetes><burden of disease><burden of illness><cardiac disease prevention><cardiovascular disease epidemiology><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder epidemiology><cardiovascular disorder prevention><cardiovascular disorder risk><cardiovascular epidemiology><care for patients><care of patients><career><caring for patients><case-based><chronic kidney disease><conference><convention><demographics><design><designing><developmental><dialysis therapy><disease burden><disease severity><effective intervention><evidence base><experience><glucagon-like peptide-1 receptor><heavy metal Pb><heavy metal lead><high risk><implementation science><implementation strategy><improved><improved outcome><instructional intervention><intervention algorithm><ketosis resistant diabetes><maturity onset diabetes><medical specialties><medication prescription><novel><patient centered><patient oriented><posters><prescribed medication><primary care provider><programs><progression risk><providers from primary care><providers of primary care><research and methods><response><skills><strategies for implementation><summit><symposia><symposium><therapeutic algorithm><therapy algorithm><tool><treatment algorithm><trend><type 2 DM><type II DM><type two diabetes>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Linda Mac Pherson Bradley

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, LA JOLLA, CA

Exploratory lead · 22/100
Recent
Active award
$209,674
FY 2026

Project Title

Immune Checkpoint Blockade Targeting the Novel PSGL-1/VISTA Axis for Pancreatic Cancer

Grant Number:

5R21CA293150-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/10/2025

End Date:

2/28/2027

Project Abstract

Project Summary The goal of this project is to develop a novel immunotherapy to treat PDAC based on blockade of PSGL-1 (P- selectin glycoprotein ligand-1), to identify the attendant cellular and transcriptional changes in tumors comprising high vs low T cell infiltration, and to determine whether re...

Research Terms

<Address><Anti-CD40><Antitumor Response><B7-H1><Binding><Biological Markers><Bp50><CD152><CD152 Antigen><CD152 Gene><CD162 antigen><CD274><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD40><CD62P Antigens><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CDW40><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Checkpoint inhibitor><Clinical><Clinical Treatment Moab><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Data><Development><Exhibits><Failure><Frequencies><GEM model><GEMM model><GMP-140><Gene Transcription><GeneHomolog><Generalized Growth><Generations><Genetic><Genetic Transcription><Genetically Engineered Mouse><Glycoproteins><Goals><Growth><Homolog><Homologous Gene><Homologue><Human><Immune><Immune Cell Activation><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunobiology><Immunochemical Immunologic><Immunocompetent><Immunoglobulin Domain><Immunoglobulin-Like Domain><Immunologic><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunophysiology><Immunotherapy><Implant><In Vitro><Infiltration><Inflammation><Intervention><Intracellular Communication and Signaling><KPC genetically-engineered mouse><KPC model><KPC mouse><KPC murine><LECAM-3><LSL-KrasG12D/+LSL-Trp53R172H/+Pdx-1-Cre><LSL-KrasG12D/+LSL-p53R172H/+Pdx-1-Cre><Ligands><Link><MGC9013><Malignant Melanoma><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Mediating><Melanoma><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Modality><Modern Man><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Monoclonal Antibodies><Murine><Mus><Neoplasm Metastasis><Outcome><P-Selectin><P-selectin glycoprotein ligand-1><P-selectin ligand protein><PD 1><PD-1><PD-1 blockade><PD-L1><PD1><PD1 blockade><PDA model><PDAC Model><PDAC cancer cell><PDAC cell><PDL-1><PSGL-1><Pancreas Cancer><Pancreatic Cancer><Patients><Phenotype><Platelet alpha-Granule Membrane Protein><Population><Pre-Clinical Model><Preclinical Models><Prognosis><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><RNA Expression><Receptor Protein><Refractory><Resistance><Role><Sampling><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Site><Strains Cell Lines><Suppressor Cells><Suppressor-Effector T-Cells><Suppressor-Effector T-Lymphocytes><T Suppressor Cell><T cell differentiation><T cell infiltration><T cell response><T-Cell Activation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TNFRSF5><TNFRSF5 gene><Teff cell><Testing><Therapeutic><Tissue Growth><Transcription><Tumor Cell><Tumor Immunity><Tumor Necrosis Factor Receptor Superfamily Member 5 Gene><activate T cells><anti-PD-1 blockade><anti-PD1 blockade><anti-tumor immunity><anti-tumor response><antitumor immunity><bio-markers><biologic marker><biological signal transduction><biomarker><cancer immunity><cancer metastasis><cancer microenvironment><check point blockade><checkpoint blockade><chemotherapy><cultured cell line><cytotoxic T-lymphocyte antigen 4><developmental><effector T cell><exhaust><exhaustion><genetically engineered mouse model><genetically engineered murine model><host response><immune activation><immune check point blockade><immune check point inhibitor><immune checkpoint blockade><immune competent><immune microenvironment><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><implantation><improved><lung metastasis><mAbs><malignancy><metastasize to the lung><molecular profile><molecular signature><monoclonal Abs><mouse model><murine model><neoplasm/cancer><neoplastic cell><new approaches><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel approaches><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><p50><pancreatic cancer patients><pancreatic ductal adenocarcinoma cell><pancreatic ductal adenocarcinoma model><pancreatic malignancy><patients with pancreatic cancer><pharmacologic><pre-clinical study><preclinical study><progenitor-like cell><prognostic><programmed cell death 1><programmed cell death ligand 1><programmed cell death protein 1><programmed cell death protein ligand 1><programmed death 1><protein death-ligand 1><pulmonary metastasis><receptor><refractory cancer><resistant><resistant cancer><response><self-renew><self-renewal><single cell analysis><sle2><social role><stem-like cell><suppressor T lymphocyte><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><tumor><tumor cell metastasis><tumor growth><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jianguo Liu

SAINT LOUIS UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 22/100
Recent
Active award
$192,500
FY 2026

Project Title

Molecular mechanisms of MCP-1 polymorphism-mediated susceptibility to pulmonary tuberculosis infection

Grant Number:

1R21AI190812-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/13/2026

End Date:

1/31/2028

Project Abstract

Project Summary/Abstract Tuberculosis (TB) remains a leading global health problem. Though one fourth of the world’s population is infected by Mycobacterium tuberculosis (Mtb), 90% of the people infected with Mtb remain asymptomatic as latent TB infection (LTBI). The reasons why 10% of the infected...

Research Terms

<(TNF)-α><ARNTL><ARNTL gene><Affect><Africa><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BHLH Protein><BMAL1><BSF-2><BSF2><Basal Transcription Factor><Basal transcription factor genes><Basic HLH Protein><Basic Helix-Loop-Helix Protein><Basic Helix-Loop-Helix Transcription Factors><Binding><Binding Proteins><Biological Markers><Blood monocyte><Boxing><C 2a><C2a><CCL2><CCL2 gene><Cachectin><Cancers><Case-Comparison Studies><Case-Compeer Studies><Case-Referent Studies><Case-Referrent Studies><Case/Control Studies><Cell Body><Cells><Chemokine, CC Motif, Ligand 2><Chemotactic Cytokines><Consensus><Cy5><DNA Sequence><E-Box Elements><E-Box Motifs><E-Box Sequences><E-Box Sites><Edodekin Alfa><Enhancers><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genetic Carriers><Genetic Diversity><Genetic Polymorphism><Genetic Transcription><Genetic Variation><Growth><HD1><HDAC1><HDAC1 gene><HPGF><Haplotypes><Hepatocyte-Stimulating Factor><Histone Deacetylase 1><Homologous Chemotactic Cytokines><Homozygote><Host Defense><Human><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-12><IL-6><IL12><IL6 Protein><Individual><Infection><Infiltration><Inflammatory><Intercrines><Interleukin-12><Interleukin-6><Ligand Binding Protein><Ligand Binding Protein Gene><Luciferase Immunologic><Luciferases><Lung TB><Lung Tuberculosis><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MCAF><MCP-1><MCP1><MGI-2><MTB infection><Macrophage><Macrophage-Derived TNF><Malignant Neoplasms><Malignant Tumor><Marrow monocyte><Mediating><Messenger RNA><Meta-Analysis><Modern Man><Molecular><Molecular Interaction><Monocyte Chemoattractant Protein-1><Monocyte Chemotactic Protein-1><Monocyte Chemotactic and Activating Factor><Monocyte Chemotactic and Activating Protein><Monocyte Chemotactive and Activating Factor><Monocyte Secretory Protein JE><Monocyte-Derived TNF><Muscle><Muscle Tissue><Mycobacterial Infection><Mycobacterium Infections><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Myeloid Differentiation-Inducing Protein><Mφ><NKSF><Natural Killer Cell Stimulatory Factor><Nuclear><Nuclear Proteins><Nucleotides><Patients><Persons><Plasmacytoma Growth Factor><Play><Population><Predisposition><Promoter Regions><Promotor Regions><Protein Binding><Protein Family><Proteins><Pulmonary TB><Pulmonary Tuberculosis><RNA Expression><RPD3-Like 1><RPD3L1><Reduced Potassium Dependency 3, Yeast, Homolog-Like 1><Reporting><Risk><Risk Factors><Role><SCYA2><SIS cytokines><Sexual Development><Single Base Polymorphism><Single Nucleotide Polymorphism><Site><Small Inducible Cytokine A2><Susceptibility><TB immunity><TB infection><TB therapy><TB treatment><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Testing><Tissue Growth><Transcript><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Tuberculosis><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><allele carriers><aryl hydrocarbon receptor nuclear translocator-like><bio-markers><biologic marker><biomarker><bound protein><case-control survey><case-controlled studies><chemoattractant cytokine><chemokine><complement 2a><complement C2a><complement C2a fragment><cyanine dye 5><cytokine><disseminated TB><disseminated tuberculosis><genetic promoter element><genetic promoter sequence><global health><healthy volunteer><immunity against M. tuberculosis><immunity against Mtb><immunity against Mycobacterium tuberculosis><immunity against TB><immunity against tuberculosis><immunity in tuberculosis><immunity to TB><immunity to tuberculosis><infection due to Mycobacterium tuberculosis><interferon beta 2><mRNA><malignancy><migration><monocyte><mtb><muscular><mycobacterial><neoplasm/cancer><nervous system development><novel><ontogeny><peripheral blood><polymorphism><promoter><promoter sequence><promotor><sex determination><sex development><single nucleotide variant><social role><transcription factor><treat M. tuberculosis><treat Mtb><treat Mycobacterium tuberculosis><treat tb><treat tuberculosis><tuberculosis immunity><tuberculosis infection><tuberculosis therapy><tuberculosis treatment><tuberculous spondyloarthropathy><vector>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PRASHANT J DESAI

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 22/100
Recent
Active award
$77,667
FY 2026

Project Title

Functions of the largest HSV-1 virion protein, pUL36

Grant Number:

5R03AI190227-02

Activity Code:

R03

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2027

Project Abstract

Herpesviruses are major human pathogens that cause life-long persistent infections and result in clinical manifestations that range from a mild cold sore to cancer. Herpes simplex virus (HSV) is among the most frequently encountered pathogen by the general population. Infection with HSV-1 often resu...

Research Terms

<Biological><Blindness><Brain Inflammation><Cancers><Capsid><Cell Body><Cell Nucleus><Cell membrane><Cells><Clinical><Cold Sore><Collection><Cytoplasm><Cytoplasmic Membrane><DNA><DNA Packaging><DNA Replication><DNA Synthesis><DNA biosynthesis><DNA mutation><Data><Deoxyribonucleic Acid><Disease><Disorder><Drugs><Electrons><Encephalitis><Enzyme Gene><Enzymes><Eye diseases><Fever Blister><Gene Transcription><General Population><General Public><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genital Organs><Genitalia><Genome><Genomic DNA><Glycoproteins><Goals><Grant><HSV><HSV-1><HSV1><Herpes Labialis><Herpes Simplex Type 1><Herpes Simplex Virus><Herpes Simplex Virus 1><Herpes Simplex Virus Type 1><Herpes labialis Virus><Herpesviridae><Herpesvirus 1><Herpesviruses><Herpetic Stomatitis><Image><Infection><Keratitis><Labial Herpes Simplex><Life Cycle><Life Cycle Stages><Long-term infection><Malignant Neoplasms><Malignant Tumor><Maps><Medication><Membrane><Methods><Molecular Genetics><Morphogenesis><Movement><Mutation><Negative Beta Particle><Negatrons><Nuclear><Nucleus><Oral Herpes Simplex><Outcome><Peptide Domain><Pharmaceutical Preparations><Phenotype><Plasma Membrane><Process><Protein Domains><Proteins><RNA Expression><Role><Simplexvirus><Site><Tertiary Protein Structure><Transcription><Vaccines><Viral><Viral Gene Products><Viral Gene Proteins><Viral Genome><Viral Proteins><Virion><Virus><Virus Particle><Virus Replication><biologic><body movement><chronic infection><domain mapping><drug/agent><experience><experiment><experimental research><experimental study><experiments><eye disorder><gDNA><gene null><gene product><genetic selection><genome mutation><herpes febrilis><herpes simplex i><herpes simplex-1><herpes virus><human pathogen><imaging><infected neonate><infected newborn><inhibitor><intraoral herpes simplex infection><intraoral hsv infection><life course><malignancy><membrane structure><morphogenetic process><mutant><neonatal infection><neoplasm/cancer><newborn infection><null mutation><ocular disease><ocular disorder><ophthalmopathy><oral HSV><oral herpes><oral mucosal herpes><particle><pathogen><persistent infection><plasmalemma><polypeptide><prevent><preventing><protein function><social role><viral DNA><viral multiplication><viral replication><virus DNA><virus genome><virus multiplication><virus protein><vision loss><visual loss>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MICHAEL JEFFREY ROOT

THOMAS JEFFERSON UNIVERSITY, PHILADELPHIA, PA

Exploratory lead · 16/100
Active award
$195,000
FY 2026

Project Title

Function of HIV-1 Env cytoplasmic tail domain

Grant Number:

5R21AI191986-03

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2027

Project Abstract

How HIV-1 glycoprotein Env traffics through infected cells to sites of viral budding and viral synapse formation is largely unknown. This enigma presents an exciting opportunity to discover new targets for antiviral drug development, which remains a critical need as the AIDS pandemic enters its fift...

Research Terms

<AIDS><AIDS prevention><AP-1><AP-1 Enhancer-Binding Protein><AP-2><AP-2 Alpha Gene><AP1><AP1 protein><AP2 Gene><AP2TF><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Activator Protein-1><Advanced HIV><Affinity><Amino Acids><Applications Grants><Assay><Binding><Bioassay><Biological Assay><Biotinylation><C-terminal><Carrier Proteins><Cell Body><Cell Culture Techniques><Cell Line><Cell membrane><Cell surface><CellLine><Cells><Cellular biology><Code><Coding System><Codon><Codon Nucleotides><Complex><Cys-Cys><Cytoplasm><Cytoplasmic Domain><Cytoplasmic Membrane><Cytoplasmic Tail><DNA mutation><Data><Drug Therapy><Endocytosis><Endosomes><Enhancer-Binding Protein AP1><Env trimer><Frame Shift Mutation><Frameshift Mutation><Genetic Change><Genetic defect><Genetic mutation><Glycoproteins><Grant Proposals><HIV Env><HIV Infections><HIV Prevention><HIV disease transmission><HIV envelope><HIV envelope protein><HIV glycoprotein Env><HIV infection spread><HIV infection transmission><HIV replication><HIV spread><HIV transmission><HIV viral infection><HIV viral replication><HIV viral transmission><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 envelope><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 prevention><HIV-1 replication><HIV-1 spread><HIV-1 transmission><HIV-1 viral replication><HIV-1 virus replication><HIV-1 virus transmission><HIV-I><HIV/AIDS prevention><HIV/AIDS transmission><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus Type 1 transmission><Human Immunodeficiency Virus-1><Human immunodeficiency virus 1><Immune Precipitation><Immunoprecipitation><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Knowledge><Label><Length><Lipids><Lymphatic cell><Lymphocyte><Lymphocytic><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measurement><Measures><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metabolic><Methods><Molecular><Molecular Interaction><Mutation><Pathway interactions><Pharmacological Treatment><Pharmacotherapy><Plasma Membrane><Point Mutation><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Precipitation><Prevent HIV><Protein Modification><Proteins><Proteomics><Reading Frame Shift Mutation><Receptosomes><Recycling><Reporting><Research><Resistance><Route><Severe HIV Disease><Site><Strains Cell Lines><Structure><Supporting Cell><Surface Proteins><TFAP2><TFAP2A><TFAP2A gene><Techniques><Testing><Transcription Factor AP-1><Transport Protein Gene><Transport Proteins><Transporter Protein><Variant><Variation><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><aminoacid><anti-viral development><anti-viral drug development><anti-viral therapeutic development><anti-viral therapy development><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><cell biology><cell culture><cell cultures><cell type><cultured cell line><cysteinylcysteine><develop therapy><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><drug intervention><drug treatment><env Genes><experiment><experimental research><experimental study><experiments><genome mutation><human immunodeficiency virus infection><human immunodeficiency virus replication><human immunodeficiency virus transmission><human immunodeficiency virus-1 replication><infected with HIV><infected with human immunodeficiency virus><inhibitor><intervention development><knock-down><knockdown><lymph cell><mutant><neutralizing antibody><overexpress><overexpression><palmitoylation><pandemic><pandemic disease><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><plasmalemma><precipitations><prenylation><prevent AIDS><prevent human immunodeficiency virus><resistant><response><spread of human immunodeficiency virus><structural biology><synapse formation><synaptogenesis><therapeutic agent development><therapeutic development><therapy development><trafficking><treatment development><viral infection><viral multiplication><viral replication><viral transmission><virus infection><virus multiplication><virus transmission><virus-induced disease>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TERRY L. SHEPPARD

KEYSTONE SYMPOSIA, SILVERTHORNE, CO

Exploratory lead · 16/100
Active award
$18,100
FY 2026

Project Title

Cardiometabolism in Health and Disease

Grant Number:

1R13HL184864-01

Activity Code:

R13

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/21/2026

End Date:

12/31/2026

Project Abstract

Abstract Support is requested for a Keystone Symposia conference entitled “Cardiometabolism in Health and Disease,” organized by Drs. Daniel P. Kelly, Rong Tian and William C. Sessa, with scientific programming input from Keystone Symposia. The meeting will take place January 26–29, 2026 at the Keys...

Research Terms

<Abnormal Assessment of Metabolism><Academia><Adult-Onset Diabetes Mellitus><Agonist><Amaze><Area><Basic Research><Basic Science><Biology><Blood Vessels><Cardiac Diseases><Cardiac Disorders><Cardiometabolic Disease><Cardiometabolic Disorder><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular Physiology><Cardiovascular system><Career Choice><Career Path><Circadian Rhythms><Clinical><Collaborations><Colorado><Communities><Development><Development and Research><Diabetes Mellitus><Diet><Disease><Disorder><Drug Industry><Drugs><Ecological impact><Educational workshop><Energy Expenditure><Energy Metabolism><Environmental Factor><Environmental Impact><Environmental Risk Factor><Event><Feedback><Fertilization><Fostering><Foundations><GLP-1 receptor><GLP-I receptor><Goals><Health><Heart><Heart Diseases><Heart Vascular><Heart failure><Industry><Insulin Resistance><Intermediary Metabolism><International><Investigators><Joints><Ketosis-Resistant Diabetes Mellitus><Knowledge><Learning><Link><Maturity-Onset Diabetes Mellitus><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Processes><Metabolic Studies><Metabolism><Metabolism Studies><Modality><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nyctohemeral Rhythm><Obesity><Organ><Outcome><Participant><Pharmaceutic Industry><Pharmaceutical Industry><Pharmaceutical Preparations><Prevalence><Prevention><R & D><R&D><R-Series Research Projects><R01 Mechanism><R01 Program><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Resort><Scientist><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><T2 DM><T2D><T2DM><Technology><Therapeutic><Thesaurismosis><Thinking><Time><Training><Translational Research><Translational Science><Twenty-Four Hour Rhythm><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Vascular Diseases><Vascular Disorder><Work><Workshop><adiposity><adult onset diabetes><blood vessel disorder><cardiac failure><cardiometabolic><cardiometabolism><cardioprotectant><cardioprotection><cardioprotective><cardiovascular disorder><cardiovascular function><cardiovascular health><career><career aspiration><career interest><career pathway><career track><circadian process><circadian rhythmicity><circulatory system><conference><convention><corpulence><daily biorhythm><design><designing><developmental><diabetes><diets><drug/agent><effective therapy><effective treatment><environmental risk><experience><fertilizations><global health><glucagon-like peptide-1 receptor><heart disorder><inhibitor><innovative technologies><insight><insulin resistant><insulin tolerance><interdisciplinary collaboration><ketosis resistant diabetes><maturity onset diabetes><meeting><meetings><metabolic abnormality assessment><metabolism disorder><multidisciplinary><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><obese patients><obesity intervention><obesity therapy><obesity treatment><patient population><patients with obesity><posters><research and development><side effect><social><summit><symposia><symposium><synergism><therapeutic agent development><therapeutic development><thoughts><transdisciplinary collaboration><translation research><translational investigation><type 2 DM><type II DM><type two diabetes><vascular><vascular dysfunction><vasculopathy>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michelle E Kimple

WM S. MIDDLETON MEMORIAL VETERANS HOSP, MADISON, WI

Exploratory lead · 10/100
Active award
$0
FY 2026

Project Title

G protein mediated mechanisms of beta-cell compensation and failure in type 2 diabetes

Grant Number:

5I01BX005804-04

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2022

End Date:

9/30/2026

Project Abstract

Diabetes is a costly and complex chronic illness and a serious public health problem. Currently, the prevalence of diabetes in the VA patient population is approximately 25%, with many more Veterans at risk for diabetes due to obesity, aging, and poor lifestyle, as well as exposure to known diabetog...

Research Terms

<0-11 years old><3'5'-cyclic ester of AMP><3,5 cyclic AMP synthetase><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adenyl Cyclase><Adenylate Cyclase><Adenylyl Cyclase><Adult-Onset Diabetes Mellitus><Aging><Agonist><Ally><Alpha Cell><Arachidonic Acids><Autocrine Systems><Beta Cell><Blood Circulation><Blood Glucose><Blood Sugar><Bloodstream><Body Tissues><CCK><Caring><Causality><Cell Body><Cell Communication and Signaling><Cell Death><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemicals><Child><Child Youth><Children (0-21)><Cholecystokinin><Chronic Disease><Chronic Illness><Compensation><Complex><Coupled><Critical Paths><Critical Pathways><Cyclic AMP><Cytoplasm><D-Glucose><Data><Dextrose><Diabetes Mellitus><Diabetes prevention><Dinoprostone><Drugs><Dysfunction><Endocrine Gland Secretion><Etiology><Exposure to><Expression Signature><Failure><Functional disorder><G-Protein alpha Subunit><G-Protein α Subunit><G-Proteins><GLP-1><GLP-1 receptor><GLP-I receptor><GTP-Binding Protein alpha Subunits><GTP-Binding Protein α Subunits><GTP-Binding Proteins><GTP-Regulatory Proteins><Gene Expression Profile><General Population><General Public><Generalized Growth><Genes><Genetic><Glp-1><Glucagon Cell><Glucagon Secreting Cell><Glucose><Goals><Growth><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Health><Hormones><Human><Humulin R><Hyperglycemia><Immune><Immunes><Individual><Insulin><Insulin Cell><Insulin Secreting Cell><Intracellular Communication and Signaling><Intracellular Second Messenger><Islet Cell><Isoforms><KO mice><Ketosis-Resistant Diabetes Mellitus><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Life Style><Lifestyle><Link><Maturity-Onset Diabetes Mellitus><Mediating><Medication><Membrane><Metabolic><Methods><Mice><Mice Mammals><Modern Man><Molecular><Murine><Mus><NIDDM><Non obese><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nonobese><Novolin R><Null Mouse><Obesity><Organ Donor><Osmosis><PGE2><PGE2 alpha><PGE2alpha><Pancreas><Pancreatic><Pancreatic beta Cell><Pancreatic β-Cell><Pancreozymin><Paracrine Communication><Paracrine Signaling><Pathway interactions><Pharmaceutical Preparations><Physiopathology><Pre-Clinical Model><Pre-DM><Preclinical Models><Prediabetes><Prediabetes syndrome><Prediabetic State><Prevalence><Preventive><Process><Production><Prostaglandin E2><Prostaglandin E2 alpha><Prostaglandin E2alpha><Protein Isoforms><Public Health><Pump><RNA Splicing><Receptor Protein><Regular Insulin><Regulation><Research><Residual><Residual state><Resistance><Role><Second Messenger Systems><Second Messengers><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Slow-Onset Diabetes Mellitus><Splicing><Stable Diabetes Mellitus><Stimulus><Structure of beta Cell of islet><Subcellular Process><Sulfonylurea Compounds><T2 DM><T2D><T2DM><Testing><Therapeutic><Therapeutic Hormone><Tissue Growth><Tissues><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Uropancreozymin><Variant><Variation><Veterans><Work><adenosine 3'5' monophosphate><adiposity><adult onset diabetes><alpha-cell><antagonism><antagonist><autocrine><biological signal transduction><cAMP><causation><cell type><cellular targeting><chronic disorder><corpulence><cost><diabetes><diabetes mellitus therapy><diabetes risk><diabetes therapy><diabetic><diabetic patient><diabetogenic><disease causation><drug/agent><functional loss><gene expression pattern><gene expression signature><glucagon-like peptide 1><glucagon-like peptide-1 receptor><healthspan><healthy life span><hyperglycemic><improved><incretin hormone><innovate><innovation><innovative><insulin secretion><islet><ketosis resistant diabetes><kids><life-time risk><lifetime risk><maturity onset diabetes><membrane structure><metabolome><metabonome><military veteran><necrocytosis><non-diabetic><nondiabetic><novel><ontogeny><pancreas beta cell><pancreas β cell><pancreatic b-cell><paracrine><pathophysiology><pathway><patient population><pharmacologic><pre-diabetes><pre-diabetic><prediabetic><preservation><prevent><preventing><programs><receptor><resistant><signal transduction second messengers><social role><sulfonylurea><therapeutic target><transcriptional profile><transcriptional signature><type 2 DM><type II DM><type two diabetes><veteran population><youngster><α-cell><β-cell><β-cells><βCell>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Lawrence Hepokoski

VA SAN DIEGO HEALTHCARE SYSTEM, SAN DIEGO, CA

Exploratory lead · 10/100
Active award
$0
FY 2026

Project Title

Physiologic and Molecular Mechanisms of Ventilator Induced Kidney Injury

Grant Number:

5I01BX006238-02

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2024

End Date:

9/30/2028

Project Abstract

Mechanical ventilation is the most utilized form of life support in Veterans suffering from critical illnesses. While mechanical ventilation may be lifesaving, it is also associated with an increased risk of acute kidney injury (AKI). Concurrent illnesses, such as sepsis and shock, contribute to AKI...

Research Terms

<Active Biologic Transport><Active Biological Transport><Active Transport><Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Agonist><Airway failure><Apoptosis><Apoptosis Pathway><Arteries><Autoregulation><Biological Markers><Biology><Blood Vessels><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 years><Cardiac Diseases><Cardiac Disorders><Cell Death><Cellular injury><Chronic Kidney Failure><Chronic Renal Disease><Chronic Renal Failure><Circulatory Collapse><Closure by Ligation><Common Rat Strains><Critical Illness><Critically Ill><DNA Nucleases><DNase><Data><Deoxyribonucleases><Development><Disease><Disorder><Diuretics><Drug Therapy><Electrolytes><Ex4 peptide><Exendin 4><GLP-1><GLP-1 receptor><GLP-I receptor><Glomerular Filtration Rate><Glp-1><Goals><Health Care Systems><Heart Diseases><Histology><Homeostasis><Hypertension><Hypoxia><Hypoxic><Incidence><Inflammation><Inflammation Mediators><Inflammatory><Injury><Injury to Kidney><Intermediary Metabolism><Intervention><Investigators><Kidney><Kidney Urinary System><Knowledge><Life><Ligation><Liquid substance><Long-term disability><Lung><Lung Respiratory System><Lung damage><Mechanical ventilation><Mediating><Mediator><Metabolic Processes><Metabolism><Methods><Micropuncture><Microvascular Dysfunction><Mitochondria><Mitochondrial DNA><Modeling><Molecular><Na element><Natriuresis><Nephrons><Nerve><O element><O2 element><Outcome><Oxygen><Oxygen Deficiency><Pathway interactions><Patients><Pharmacological Treatment><Pharmacotherapy><Physiologic><Physiological><Physiological Homeostasis><Physiology><Pilot Projects><Pre-Clinical Model><Preclinical Models><Preventative treatment><Preventive treatment><Programmed Cell Death><Rat><Rats Mammals><Rattus><Renal Blood Flow><Renal Vascular><Renal function><Renal vessels><Renin-Angiotensin System><Research Personnel><Researchers><Respiratory Failure><Risk><Risk Factors><Rodent><Rodentia><Rodents Mammals><Role><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Sepsis><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Shock><Sodium><Structure><Sympathetic Nervous System><TLR9 gene><TLR9 protein><TLR9 receptor><Techniques><Testing><Tidal Volume><Time><Tubular><Tubular formation><Uphill Transport><Uriniferous Tube><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><Vascular resistance><Ventilator><Ventilator-induced lung injury><Veterans><Work><absorption><acute kidney injury><bio-markers><biologic marker><biomarker><cell damage><cell injury><cellular damage><chronic kidney disease><circulatory shock><clinical care><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><damage to cells><death risk><developmental><drug intervention><drug treatment><exenatide><experience><experiment><experimental research><experimental study><experiments><extracellular><fluid><glomerular function><glucagon-like peptide 1><glucagon-like peptide-1 receptor><heart disorder><hemodynamics><high blood pressure><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><improved><inflammatory mediator><injuries><injury to cells><kidney function><kidney injury><kidney metabolism><kidney vascular><kidney vascular structure><liquid><lung injury><mechanical respiratory assist><mechanically ventilated><microvascular complications><microvascular disease><military veteran><mitochondrial><mitochondrial dysfunction><mortality><mortality risk><mtDNA><multidisciplinary><necrocytosis><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutics><novel therapy><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pilot study><pressure><prevent><preventing><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><renal><renal injury><renovascular><respiratory airway volume><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><shocks><small vessel disease><social role><solute><standard care><standard treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><toll-like receptor 9><translational opportunities><translational potential><translational study><treatment effect><vascular><ventilation><ventilation induced lung injury><ventilator associated lung injury><veteran population>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MARYROSE P SULLIVAN

VA BOSTON HEALTH CARE SYSTEM, BOSTON, MA

Exploratory lead · 10/100
Active award
$0
FY 2026

Project Title

Bladder Dysfunction and Dysregulation of Neurotransmission

Grant Number:

5I01BX001790-12

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

1/1/2013

End Date:

9/30/2026

Project Abstract

Bladder dysfunction is a common, distressing finding in patients afflicted with two disorders that are increasingly prevalent in the general population but significantly over- represented in the veteran population—type 2 diabetes (T2DM) and Parkinson’s disease (PD). Currently, treatments for bladder...

Research Terms

<Acceleration><Actin-Activated ATPase><Actins><Address><Adult-Onset Diabetes Mellitus><Age><Aging><Agonist><Amyloid><Amyloid Substance><Animal Disease Models><Animal Model><Animal Models and Related Studies><Anti-diabetic Agents><Anti-diabetic Drugs><Biochemical><Biological Function><Biological Process><Bladder><Bladder Diseases><Bladder Disorder><Bladder Dysfunction><Bladder Urinary System><Brain><Brain Nervous System><Cell Communication and Signaling><Cell Signaling><Cellular Matrix><Cerebrospinal Fluid><Chronic Disease><Chronic Illness><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Cohort Studies><Complex><Complications of Diabetes Mellitus><Cytoskeletal System><Cytoskeleton><Data><Defect><Degenerative Neurologic Disorders><Deposit><Deposition><Diabetes Complications><Diabetes Mellitus><Diabetes-Related Complications><Diabetic Complications><Disease><Disease Progression><Disorder><Distress><Disturbance in cognition><Docking><Drug Therapy><Drugs><Dysfunction><Early Intervention><Early identification><Emotional><Encephalon><Epidemiology><Event><Exocytosis><Family><Foundations><Functional disorder><GLP-1><GLP-1 receptor><GLP-I receptor><GWA study><GWAS><General Population><General Public><Glp-1><Health><Hyperglycemia><Impaired cognition><Impairment><In Vitro><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Lower urinary tract><Maturity-Onset Diabetes Mellitus><Mediating><Medication><Methods><Molecular><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Motor><Myosin ATPase><Myosin Adenosine Triphosphatase><Myosin Adenosinetriphosphatase><Myosins><NAC precursor><NIDDM><Nerve><Nerve Degeneration><Nerve Fibers><Nerve Impulse Transmission><Nerve Transmission><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurogenic Bladder><Neurogenic Bladder Disorder><Neurogenic Urinary Bladder Disorder><Neurologic Degenerative Conditions><Neuron Degeneration><Neuronal Transmission><Neuropathic Bladder><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><PARK1 protein><PARK4 protein><Paralysis Agitans><Parkinson><Parkinson Disease><Pathogenesis><Pathologic><Pathology><Patients><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phosphorylation><Physiologic><Physiological><Physiopathology><Prevalence><Primary Parkinsonism><Primates><Primates Mammals><Process><Property><Protein Phosphorylation><Proteins><Psyche structure><QOL><Quality of life><Risk><Role><SNCA><SNCA protein><Series><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Symptoms><Synaptic Vesicles><T2 DM><T2D><T2DM><Techniques><Testing><Therapeutic><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Urinary Bladder Neurogenic Dysfunction><Varices><Varicose Veins><Varicosity><Veterans><a-syn><a-synuclein><adult onset diabetes><adverse consequence><adverse outcome><ages><alpha synuclein><alpha synuclein gene><alphaSP22><anti-diabetic><asyn><axon signaling><axon-glial signaling><axonal signaling><biological signal transduction><blood glucose regulation><cerebral spinal fluid><chronic disorder><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><cohort research study><cohort survey><comorbidity><conformation><conformational><conformational state><conformationally><conformations><death risk><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><diabetes><diabetic><drug intervention><drug treatment><drug/agent><effective intervention><epidemiologic><epidemiological><functional restoration><genome wide association><genome wide association scan><genome wide association study><genomewide association scan><genomewide association study><glia signaling><glial signaling><glucagon like peptide><glucagon-like peptide><glucagon-like peptide 1><glucagon-like peptide-1 receptor><glucose control><glucose homeostasis><glucose metabolism><glucose regulation><glycation><health and care delivery><health care delivery><health delivery systems><health services delivery><high risk><hyperglycemic><improved><improved motor function><innervation><insight><intracellular skeleton><ketosis resistant diabetes><loss of function><maturity onset diabetes><mental><military veteran><model of animal><mortality risk><motor function improvement><motor impairment><movement impairment><movement limitation><multidisciplinary><nerve signaling><nerve supply><neural degeneration><neural signaling><neurodegeneration><neurodegenerative><neurodegenerative illness><neurological degeneration><neuron toxicity><neuronal degeneration><neuronal signaling><neuronal toxicity><neuropathologic><neuropathological><neuropathology><neuroprotection><neuroprotective><neurotoxicity><neurotransmission><non A-beta component of AD amyloid><non A4 component of amyloid precursor><non-enzymatic glycosylation><nonenzymatic glycosylation><novel><pathophysiology><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-synaptic nerve><pre-synaptic neurons><presynaptic><presynaptic nerve><presynaptic neurons><psychologic><psychological><response><restoration><restore function><restore functionality><restore lost function><social><social role><spinal fluid><trafficking><treatment strategy><type 2 DM><type II DM><type two diabetes><urinary bladder><urinary bladder disorder><veteran population><whole genome association analysis><whole genome association study><α synuclein gene><α-syn><α-synuclein>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HUIPING Rose ZHOU

VA VETERANS ADMINISTRATION HOSPITAL, RICHMOND, VA

Exploratory lead · 10/100
Active award
$0
FY 2026

Project Title

Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)

Grant Number:

5I01BX005730-04

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2022

End Date:

9/30/2027

Project Abstract

Non-alcoholic fatty liver disease (NAFLD) is becoming a globally prevalent disease, especially among US veterans. NAFLD and non-alcoholic steatohepatitis (NASH) are recognized as hepatic manifestations of metabolic syndrome. The disease progression from simple steatosis to NASH, fibrosis, cirrhosis,...

Research Terms

<AKT><Akt protein><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Autoregulation><Bile Acids><Biological Function><Biological Process><Blood Serum><Cell Communication and Signaling><Cell Signaling><Cirrhosis><Complex><Coupled><Data><Development><Diet><Disease><Disease Progression><Disorder><Dyslipidemias><ERK 1><ERK1><ERK1 Kinase><Edg Receptors><Energy Expenditure><Energy Metabolism><Evaluation><Extracellular Signal-Regulated Kinase 1><Fatty Acid Metabolism Pathway><Fatty Liver><Fibrosis><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPBAR1><GPBAR1 gene><GPCR><Gene Expression><Genes><HD1><HDAC1><HDAC1 gene><Hepatic><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocarcinoma><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatocyte><Hepatoma><Heterogeneity><Histone Deacetylase 1><Homeostasis><Human><Hydrogen Oxide><IFN><Immune system><Incidence><Inflammation><Inflammatory Response><Innate Immune Response><Innate Immunity><Insulin Resistance><Interferons><Intracellular Communication and Signaling><KO mice><Knock-out Mice><Knockout Mice><Link><Lipids><Liver><Liver Cells><Liver Cells Carcinoma><Liver Steatosis><MAP Kinase 3><MAPK3><MAPK3 Mitogen-Activated Protein Kinase><MAPK3 gene><Macrophage><Maintenance><Mediating><Metabolic Diseases><Metabolic Disorder><Metabolic stress><Metabolic syndrome><Mice><Mice Mammals><Mission><Mitogen-Activated Protein Kinase 3><Mitogen-Activated Protein Kinase 3 Gene><Modeling><Modern Man><Molecular><Murine><Mus><Mφ><NAFLD><NASH><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Nuclear><Nuclear Receptors><Null Mouse><P44ERK1><PSTkinase p44mpk><Pathogenesis><Pathway interactions><Patients><Phosphorylation><Physiological Homeostasis><Play><Prevalence><Primary carcinoma of the liver cells><Process><Protein Kinase B><Protein Phosphorylation><Proteins><Proto-Oncogene Proteins c-akt><RAC-PK protein><RNA Seq><RNA sequencing><RNAseq><RPD3-Like 1><RPD3L1><Receptor Protein><Reduced Potassium Dependency 3, Yeast, Homolog-Like 1><Reporting><Role><S1P Receptor><Serum><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Molecule><Single-Nucleus Sequencing><Sphingolipids><Sphingosine-1-Phosphate Receptor><TGR5><Testing><Thesaurismosis><United States Department of Veterans Affairs><United States Veterans Administration><Veterans><Veterans Administration><Veterans Affairs><Water><base><bases><biological signal transduction><c-akt protein><cholangiocyte><cirrhotic><clinical significance><clinically significant><developmental><diets><dysbacteriosis><dysbiosis><dysbiotic><effective therapy><effective treatment><fat metabolism><fatty acid metabolism><fatty liver disease><glucose metabolism><hepatic body system><hepatic inflammation><hepatic organ system><hepatic steatosis><hepatosteatosis><inflamed liver><inhibitor><insulin resistant><insulin tolerance><intrahepatic><lipid metabolism><liver carcinoma><liver inflammation><metabolism disorder><microbial imbalance><mouse model><murine model><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><non-alcohol fatty liver disease><non-alcohol induced steatohepatitis><non-alcoholic fatty liver disease><non-alcoholic liver disease><non-alcoholic steato-hepatitis><non-alcoholic steatohepatitis><nonalcoholic fatty liver disease><nonalcoholic steato-hepatitis><nonalcoholic steatohepatitis><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><p44 MAPK><pathway><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><receptor><related to A and C-protein><response><sNuc-Seq><simple fatty liver><simple steatosis><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><social role><sphingosine 1-phosphate><sphingosine kinase><sugar><transcriptome sequencing><transcriptomic sequencing><western diet><western-style diet><western-type diet>
View Full Project Details on NIH Reporter
Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

How to Use PI Funding Data for Career Decisions

Finding the right principal investigator is one of the most important decisions in an academic career. Whether you are a postdoc looking for a mentor, a graduate student choosing a rotation lab, or a collaborator seeking a co-PI, NIH funding data provides objective signals about which investigators have active research programs and resources to support new team members.

A PI with a recently awarded R01 or equivalent grant is more likely to have budget for new personnel than one whose funding ended two years ago. The activity code tells you the type of grant: R01 and R35 awards typically support multiple lab members, while K-series awards are individual career development grants that may not fund additional positions. Understanding these distinctions helps you interpret search results accurately.

Look beyond the dollar amount. A $500,000 per year R01 at a high-cost institution may support fewer positions than a $300,000 award at a university with lower overhead rates. The project abstract and public health relevance statement reveal whether the PI's research direction aligns with your interests and expertise.

Understanding PI Grant Portfolios

A PI's grant portfolio reveals more than individual awards. Investigators with multiple active grants often run larger labs with more diverse projects, which can mean more opportunities for trainees. However, a PI with a single well-funded grant may offer more focused mentorship and a clearer path to publications.

Multi-PI grants (those with more than one principal investigator listed) indicate collaborative research and may involve trainees from multiple institutions. These can be excellent opportunities for interdisciplinary training but may also mean split attention from any single mentor.

Pay attention to the timing of awards. A PI who just received a new five-year R01 is in a different position than one whose grant ends next year. New awards often correspond to lab expansion and active recruiting, making them ideal targets for job seekers. The start and end dates shown in each result help you assess this timing.

Best Practices for Contacting Funded PIs

Once you identify a promising PI through this tool, the next step is outreach. NIH public records do not include email addresses, but you can usually find contact information through the PI's institutional profile page, lab website, or recent publications. Google Scholar, PubMed, and the PI's department website are reliable starting points.

When reaching out, reference the specific grant that caught your attention. Mentioning the project title and explaining how your skills relate to the funded work shows that you have done your homework. Keep your initial message concise: introduce yourself, explain your interest, attach your CV, and ask whether they anticipate openings.

Timing matters. Contacting a PI within the first year of a new award is ideal, as this is when they are most likely to be recruiting. If you find multiple promising PIs in the same field, prioritize those with the most recent award notices and activity codes that support trainee positions such as R01, U01, or P-series grants.

Frequently Asked Questions About PI Search

What does the opportunity score mean?

The opportunity score is a heuristic that combines award recency, funding amount, activity code type, and project characteristics to estimate how actionable a result might be for job seekers or collaborators. Higher scores suggest stronger signals, but always verify by reading the abstract and checking the PI's current lab page.

Why can't I find a PI I know has funding?

Name variations are the most common cause. Try searching with just the last name, or use different formats like "Smith, John" versus "John Smith." Some PIs also publish under different name variations or may have awards under a previous institutional affiliation.

Does this tool show all NIH-funded PIs?

The tool searches NIH RePORTER data for the keyword and year range you specify. It returns PIs whose funded projects match your search terms. PIs with grants in unrelated areas or whose projects use different terminology will not appear in keyword-filtered results.

What is the difference between "Likely hiring" and "Training-friendly" filters?

"Likely hiring" flags PIs with large new awards or activity codes typically associated with lab expansion. "Training-friendly" identifies awards that include training components or are at institutions known for postdoctoral programs. Both are heuristic filters to help prioritize your outreach.

How to use this well

Start broad, then narrow. Search a field first, then refine by timeframe once you understand who is currently active.

After you find a promising PI, cross-check them in Check PI Funding and review their institution, mechanism type, and project abstracts before reaching out.

What a match means

A result means the keyword appears relevant to the funded project data we searched. It does not guarantee the PI is hiring or that the grant is still active.

Use the abstract, award year, mechanism, and organization context to decide whether the record is strategically relevant.

Data limits

NIH records can lag, institutional names can vary, and some investigators publish or file awards under multiple name formats.

For details on source coverage and refresh cadence, read Data & Methodology.

Related guides

Companion guides for turning a PI search result into useful outreach or a job lead.

Career Guide8 min read

How Postdocs Can Find PIs with New NIH Funding

A tactical job-search guide for identifying recently funded labs, judging fit, and timing outreach to principal investigators.

Read guide
Career Guide7 min read

How to Contact a PI: Finding Emails and Crafting the Perfect Message

Emailing strategies, outreach examples, and a workflow for turning NIH funding signals into focused PI conversations.

Read guide
Career Guide10 min read

How to Read a New NIH Award Like a Hiring Signal

A practical framework for using newly funded NIH awards to judge whether a lab may be expanding, hiring, or worth contacting now.

Read guide
Funding Strategy16 min read

How to Find NIH Funding Opportunities: A Step-by-Step Guide for Researchers

Learn how to find NIH funding opportunities using the NIH Guide, Grants.gov, FOAs, NIH RePORTER, and program officer outreach.

Read guide

Recently Funded Labs in Trending Areas

Principal investigators who received NIH awards in the last 90 days, organized by research area. Use this as a starting point for postdoc searches, collaborator outreach, or competitor scans. Counts and labs refresh daily.

Alzheimer's disease

Neurodegeneration, biomarkers, and disease-modifying therapies.

  • Carlos Cruchaga — WASHINGTON UNIVERSITY, MO
    CONGAS: "Caribbean Omics 'N' Genomics for Alzheimer Study"
    $101,153 · awarded Feb 25, 2026 · 3U01AG084514-01A1S1
  • Carlos Cruchaga — WASHINGTON UNIVERSITY, MO
    CONGAS: "Caribbean Omics 'N' Genomics for Alzheimer Study"
    $3,086,339 · awarded Feb 19, 2026 · 1U01AG084514-01A1
  • Jonathan Haines — CASE WESTERN RESERVE UNIVERSITY, OH
    Alzheimer Disease Genetic Analysis to Identify Potential Therapeutic Targets (ADAPTT)
    $1,256,627 · awarded Feb 4, 2026 · 1R01AG096172-01
  • HARALD SONTHEIMER — UNIVERSITY OF VIRGINIA, VA
    Extracellular matrix and memory impairments in Alzheimer disease
    $709,066 · awarded Apr 7, 2026 · 5R01AG085359-03
  • Keith Josephs — MAYO CLINIC ROCHESTER, MN
    The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies
    $643,670 · awarded Apr 1, 2026 · 5R01DC014942-09
Search more PIs in Alzheimer's disease →

CRISPR & gene editing

Therapeutic gene editing, base editing, and prime editing.

  • Claire Clelland — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
    CRISPR for tauopathy
    $680,792 · awarded Jan 30, 2026 · 1R01AG092420-01
  • Changchun Liu — UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT
    Asymmetric CRISPR Approach for Nucleic Acid Quantification
    $643,849 · awarded Mar 30, 2026 · 2R01EB023607-06A1
  • William Pu — BOSTON CHILDREN'S HOSPITAL, MA
    A modular system for murine CRISPR genome and epigenome editing
    $202,920 · awarded Mar 27, 2026 · 5R21OD037909-02
  • Naama Aviram — SLOAN-KETTERING INST CAN RESEARCH, NY
    Molecular mechanisms of memory formation and tolerance in CRISPR-Cas systems
    $249,000 · awarded Apr 2, 2026 · 5R00GM148720-04
  • Mats Ljungman — UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI
    Precision targeting of bladder cancer using CRISPR
    $582,849 · awarded Feb 17, 2026 · 5R01CA285730-03
Search more PIs in CRISPR & gene editing →

Cancer immunotherapy

Checkpoint inhibitors, CAR-T, TIL therapy, and beyond.

  • TERRY SHEPPARD — KEYSTONE SYMPOSIA, CO
    Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations
    $5,000 · awarded Mar 3, 2026 · 1R13CA310704-01
  • Veronika Fedirko — UNIVERSITY OF TX MD ANDERSON CAN CTR, TX
    Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma
    $927,329 · awarded Mar 3, 2026 · 5R01CA255322-05
  • Yuwen Zhu — UNIVERSITY OF COLORADO DENVER, CO
    The GPR171 pathway in cancer immunotherapy
    $355,706 · awarded Apr 2, 2026 · 5R01CA279398-04
  • Wei Hu — YALE UNIVERSITY, CT
    Novel Treg inactivating approach for cancer immunotherapy via targeted protein degradation
    $482,312 · awarded Apr 6, 2026 · 1R01CA295942-01A1
  • Laurent Gapin — UNIVERSITY OF COLORADO DENVER, CO
    Development and Characterization of the MAIT-Boost Knock-In (MBKI) Mouse to Investigate MAIT Cell Biology and Cancer Immunotherapy
    $429,000 · awarded Jan 30, 2026 · 1R21AI195296-01
Search more PIs in Cancer immunotherapy →

GLP-1 & metabolic disease

Diabetes, obesity, and weight-loss therapeutic mechanisms.

  • Xiaomo Xiong — UNIVERSITY OF CINCINNATI, OH
    GLP-1 Agonists for Preventing Alzheimer's Disease in Mild Cognitive Impairment
    $324,000 · awarded Feb 5, 2026 · 1R03AG098738-01
  • STEVEN SCHWENDEMAN — UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI
    Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment of Obesity
    $231,000 · awarded Apr 17, 2026 · 1R56DK141545-01A1
  • JENNIFER ST SAUVER — MAYO CLINIC ROCHESTER, MN
    Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on older adults
    $443,850 · awarded Mar 13, 2026 · 1R21AG097887-01
  • Naykky Singh Ospina — UNIVERSITY OF FLORIDA, FL
    Navigating the Uncertainties of Thyroid Cancer Risk in GLP-1RA Users
    $694,122 · awarded Mar 24, 2026 · 1R01CA299220-01A1
  • Patricia Grigson — PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA
    Cocaine Addition and the Need-State Hypothesis
    $667,063 · awarded Feb 26, 2026 · 5R01DA060250-02
Search more PIs in GLP-1 & metabolic disease →

Long COVID

Post-acute sequelae and chronic infection-driven illness.

  • Alexei Tumanov — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX
    Lymphotoxin-dependent control of long COVID
    $234,715 · awarded Feb 13, 2026 · 1R21AI185790-01A1
  • E ELY — VANDERBILT UNIVERSITY MEDICAL CENTER, TN
    REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD
    $6,778,156 · awarded Feb 6, 2026 · 5R01AG085873-03
  • Amal Amer — OHIO STATE UNIVERSITY, OH
    Role of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and Coagulopathy
    $2,974,582 · awarded Apr 21, 2026 · 5P01AI175399-03
  • Alba Azola — JOHNS HOPKINS UNIVERSITY, MD
    Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequelae of Post-SARS-CoV-2 onset ME/CFS versus Pre-Pandemic ME/CFS Patients
    $633,378 · awarded Apr 17, 2026 · 1R01NS147100-01
  • DANIELLE REED — MONELL CHEMICAL SENSES CENTER, PA
    Inflammation and chemosensory loss
    $2,654,249 · awarded Feb 26, 2026 · 1P50DC022549-01A1
Search more PIs in Long COVID →